PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Laser-controlled cells	SCIENCE			English	Article																		Halfon MS, 1997, P NATL ACAD SCI USA, V94, P6255, DOI 10.1073/pnas.94.12.6255; Harris J, 1996, DEVELOPMENT, V122, P3117; STRINGHAM EG, 1993, J EXP ZOOL, V266, P227, DOI 10.1002/jez.1402660309	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					975	975						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281076				2022-12-01	WOS:A1997XQ98500047
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Selecting the needle	SCIENCE			English	Article																		KETNER G, 1994, P NATL ACAD SCI USA, V91, P6186, DOI 10.1073/pnas.91.13.6186; LARIONOV V, 1997, P NATL ACAD SCI USA, V97, P7384	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					975	975						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281076				2022-12-01	WOS:A1997XQ98500048
J	Shibata, H; Toyama, K; Shioya, H; Ito, M; Hirota, M; Hasegawa, S; Matsumoto, H; Takano, H; Akiyama, T; Toyoshima, K; Kanamaru, R; Kanegae, Y; Saito, I; Nakamura, Y; Shiba, K; Noda, H				Shibata, H; Toyama, K; Shioya, H; Ito, M; Hirota, M; Hasegawa, S; Matsumoto, H; Takano, H; Akiyama, T; Toyoshima, K; Kanamaru, R; Kanegae, Y; Saito, I; Nakamura, Y; Shiba, K; Noda, H			Rapid colorectal adenoma formation initiated by conditional targeting of the APC gene	SCIENCE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; MOUSE; MUTATION; TUMORS; CELLS; DELETION; PROTEIN; MICE; FAP	Familial adenomatous polyposis coli (FAP) is a disease characterized by the development of multiple colorectal adenomas, and affected individuals carry germline mutations in the APC gene. With the use of a conditional gene targeting system, a mouse model of FAP was created that circumvents the embryonic lethality of Apc deficiency and directs Apc inactivation specifically to the colorectal epithelium, loxP sites were inserted into the introns around Ape exon 14, and the resultant mutant allele (Apc(580S)) was introduced into the mouse germline. Mice homozygous for Apc0(580S) were normal; however, upon infection of the colorectal region with an adenovirus encoding the Cre recombinase, the mice developed adenomas within 4 weeks, The adenomas showed deletion of Apc exon 14, indicating that the loss of Apc function was caused by Cre-loxP-mediated recombination.	INST CANC RES, DEPT CELL BIOL, TOSHIMA KU, TOKYO 170, JAPAN; JAPAN SCI & TECHNOL CORP, CREST, TOKYO, JAPAN; OSAKA UNIV, INST MICROBIAL DIS, DEPT ONCOGENE RES, SUITA, OSAKA 565, JAPAN; CTR ADULT DIS, OSAKA 537, JAPAN; TOHOKU UNIV, INST DEV AGING & CANC, DEPT CLIN ONCOL, SENDAI, MIYAGI 980, JAPAN; UNIV TOKYO, INST MED SCI, MOL GENET LAB, MINATO KU, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, MOL MED LAB, MINATO KU, TOKYO 108, JAPAN	Japan Science & Technology Agency (JST); Osaka University; Tohoku University; University of Tokyo; University of Tokyo			hasegawa, sumitaka/A-4020-2012; Shiba, Kiyotaka/I-9588-2014	Shiba, Kiyotaka/0000-0001-6459-0204; Hirota, Morihisa/0000-0001-5682-0911				BRODY SL, 1994, ANN NY ACAD SCI, V716, P90, DOI 10.1111/j.1749-6632.1994.tb21705.x; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; ICHII S, 1993, ONCOGENE, V8, P2399; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; LUONGO C, 1994, CANCER RES, V54, P5947; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1995, DEV DYNAM, V203, P422, DOI 10.1002/aja.1002030405; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHIBATA H, UNPUB; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; TOYAMA K, UNPUB	21	444	454	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					120	123		10.1126/science.278.5335.120	http://dx.doi.org/10.1126/science.278.5335.120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311916				2022-12-01	WOS:A1997XZ12400052
J	Tamura, Y; Peng, P; Liu, K; Daou, M; Srivastava, PK				Tamura, Y; Peng, P; Liu, K; Daou, M; Srivastava, PK			Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations	SCIENCE			English	Article							IN-VIVO; T-CELLS; ANTIGEN; PEPTIDES; SARCOMAS; IMMUNITY; CANCER; GP96	Immunotherapy of mice with preexisting cancers with heat shock protein preparations derived from autologous cancer resulted in retarded progression of the primary cancer, a reduced metastatic load, and prolongation of life-span. Treatment with heat shock protein preparations derived from cancers other than the autologous cancer did not provide significant protection. Spontaneous cancers (lung cancer and melanoma), chemically induced cancers (fibrosarcoma and colon carcinoma), and an ultraviolet radiation-induced spindle cell cacinoma were tested, and the results support the efficacy of autologous cancer-derived heat shock protein-peptide complexes in immunotherapy of cancers without the need to identify specific tumor antigenic epitopes.	UNIV CONNECTICUT, SCH MED, CTR IMMUNOTHERAPY CANC & INFECT DIS, FARMINGTON, CT 06030 USA	University of Connecticut					NCI NIH HHS [CA44786, CA64394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA044786, R01CA064394, R01CA044786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; BASOMBRIO MA, 1970, CANCER RES, V30, P2458; BLACHERE NE, 1993, J IMMUNOTHER, V14, P351; BLACHERE NE, IN PRESS J EXP MED; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CHANDAWARKAR RY, UNPUB; DAOU M, 1996, C R I CANC VACCINES; FELDWEG AM, 1995, INT J CANCER, V63, P310, DOI 10.1002/ijc.2910630227; GLOBERSON A, 1964, J NATL CANCER I, V32, P1229, DOI 10.1093/jnci/32.6.1229; Heikema A, 1997, IMMUNOL LETT, V57, P69, DOI 10.1016/S0165-2478(97)00048-5; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; JANETZKI S, UNPUB; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; MANDELBOIM O, 1995, NAT MED, V1, P1179, DOI 10.1038/nm1195-1179; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; PALLADINO MA, 1987, CANCER RES, V47, P5074; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; Peng P, 1997, J IMMUNOL METHODS, V204, P13, DOI 10.1016/S0022-1759(97)00017-3; RAMARATHINAM L, 1995, J IMMUNOL, V155, P5323; Roman E, 1996, IMMUNOLOGY, V88, P487, DOI 10.1046/j.1365-2567.1996.d01-697.x; Skeen MJ, 1996, J IMMUNOL, V156, P1196; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; Srivastava P K, 1996, Semin Immunol, V8, P295, DOI 10.1006/smim.1996.0038; SRIVASTAVA PK, 1984, INT J CANCER, V33, P417, DOI 10.1002/ijc.2910330321; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1993, ADV CANCER RES, V62, P153, DOI 10.1016/S0065-230X(08)60318-8; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SUGIURA K, 1955, CANCER RES, V15, P38; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Yuui, UNPUB; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391	32	578	736	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					117	120		10.1126/science.278.5335.117	http://dx.doi.org/10.1126/science.278.5335.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311915				2022-12-01	WOS:A1997XZ12400051
J	Steinbach, OC; Wolffe, AP; Rupp, RAW				Steinbach, OC; Wolffe, AP; Rupp, RAW			Somatic linker histones cause loss of mesodermal competence in Xenopus	NATURE			English	Article							GENE-TRANSCRIPTION; MYOD EXPRESSION; EARLY RESPONSE; IN-VIVO; EMBRYOS; INDUCTION; LAEVIS; PROTEIN; CELLS; EMBRYOGENESIS	In Xenopus, cells from the animal hemisphere are competent to form mesodermal tissues from the morula through to the blastula stage(1). Loss of mesodermal competence at early gastrula is programmed cell-autonomously, and occurs even in single cells at the appropriate stage(2). To determine the mechanism by which this occurs, we have been investigating a concomitant, global change in expression of H1 linker histone subtypes. H1 histones are usually considered to be general repressors of transcription(3), but in Xenopus they are increasingly thought to have selective functions in transcriptional regulation(4-6). Xenopus eggs and embryos at stages before the midblastula transition(7) are deficient in histone H1 protein, but contain an oocyte-specific variant called histone B4 or H1M. After the midblastula transition, histone B4 is progressively substituted by three somatic histone H1 variants, and replacement is complete by early neurula(8,9). Here we report that accumulation of somatic H1 protein is rate limiting for the loss of mesodermal competence. This involves selective transcriptional silencing of regulatory genes required for mesodermal differentiation pathways, like muscle, by somatic, but not maternal, H1 protein.	MAX PLANCK GESELL, FRIEDRICH MIESCHER LAB, D-72076 TUBINGEN, GERMANY; NICHHD, MOL EMBRYOL LAB, NIH, BETHESDA, MD 20892 USA	Eberhard Karls University of Tubingen; Max Planck Society; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				rupp, ralph/0000-0002-8068-9957				BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DALE L, 1987, DEVELOPMENT, V99, P527; DIMITROV S, 1993, DEV BIOL, V160, P214, DOI 10.1006/dbio.1993.1299; DWORKINRASTL E, 1994, DEV BIOL, V161, P425, DOI 10.1006/dbio.1994.1042; FRANK D, 1991, DEVELOPMENT, V113, P1387; GRAINGER RM, 1989, P NATL ACAD SCI USA, V86, P1900, DOI 10.1073/pnas.86.6.1900; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JONES EA, 1987, DEVELOPMENT, V101, P557; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; Patterton D, 1996, DEV BIOL, V173, P2, DOI 10.1006/dbio.1996.0002; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SMITH JC, 1995, CURR OPIN CELL BIOL, V7, P856, DOI 10.1016/0955-0674(95)80070-0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; SYMES K, 1987, DEVELOPMENT, V101, P339; TSUDA T, 1986, FEBS LETT, V208, P39, DOI 10.1016/0014-5793(86)81527-7	29	158	163	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					395	399		10.1038/38755	http://dx.doi.org/10.1038/38755			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311783				2022-12-01	WOS:A1997XX67500056
J	Cohen, LG; Celnik, P; PascualLeone, A; Corwell, B; Faiz, L; Dambrosia, J; Honda, M; Sadato, N; Gerloff, C; Catala, MD; Hallett, M				Cohen, LG; Celnik, P; PascualLeone, A; Corwell, B; Faiz, L; Dambrosia, J; Honda, M; Sadato, N; Gerloff, C; Catala, MD; Hallett, M			Functional relevance of cross-modal plasticity in blind humans	NATURE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; VISUAL-CORTEX; OCCIPITAL CORTEX; COIL SUPPRESSION; PERCEPTION; DISCRIMINATION; ACTIVATION	Functional imaging studies of people who were blind from an early age have revealed that their primary visual cortex can be activated by Braille reading and other tactile discrimination task(1). Other studies have also shown that visual cortical areas can be activated by somatosensory input in blind subjects but not those with sight(2-7). The significance of this cross-modal plasticity is unclear, however, as it is not known whether the visual cortex can process somatosensory information in a functionally relevant way. To address this issue, we used transcranial magnetic stimulation to disrupt the function of different cortical areas in people who were blind from an early age as they identified Braille or embossed Roman letters, Transient stimulation of the occipital (visual) cortex induced errors in both tasks and distorted the tactile perceptions of blind subjects, In contrast, occipital stimu lation had no effect on tactile performance in normal-sighted subjects, whereas similar stimulation is known to disrupt their visual performance. We conclude that blindness from an early age can cause the visual cortex to be recruited to a role in somatosensory processing. We propose that this cross-modal plasticity may account in part for the superior tactile perceptual abilities of blind subjects.	NINCDS,BIOMETRY & FIELD STUDIES BRANCH,NIH,BETHESDA,MD 20892; UNIV BUENOS AIRES,DEPT NEUROL REHABIL,FDN LUCHA ENFERMEDADES NEUROL INFANTILES,RA-1053 BUENOS AIRES,DF,ARGENTINA; BETH ISRAEL DEACONESS MED CTR,LAB MAGNET BRAIN STIMULAT,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV VALENCIA,INST CAJAL,VALENCIA,SPAIN; FUKUI MED SCH,BIOMED IMAGING RES CTR,MATUOKA,FUKUI 91011,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Buenos Aires; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); University of Valencia; University of Fukui	Cohen, LG (corresponding author), NINCDS,HUMAN CORT PHYSIOL UNIT,NIH,BLDG 36,RM 4D04,BETHESDA,MD 20892, USA.		HONDA, Manabu/AAO-1202-2020; Pascual-Leone, Alvaro/AAC-5101-2019; Pascual-Leone, Alvaro/G-6566-2011	Pascual-Leone, Alvaro/0000-0001-8975-0382; Sadato, Norihiro/0000-0002-9786-3907				AMASSIAN VE, 1989, ELECTROEN CLIN NEURO, V74, P458, DOI 10.1016/0168-5597(89)90036-1; ANDERSON JA, 1972, BIOMETRIKA, V59, P19, DOI 10.1093/biomet/59.1.19; BARKER AT, 1985, LANCET, V1, P1106; BRIDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; CHEN R, IN PRESS ELECTROENCE; COHEN LG, 1990, ELECTROEN CLIN NEURO, V75, P350, DOI 10.1016/0013-4694(90)90113-X; COHEN LG, 1991, ELECTROEN CLIN NEURO, V81, P366, DOI 10.1016/0168-5597(91)90026-T; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P247, DOI 10.1097/00004691-199605000-00009; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P242, DOI 10.1097/00004691-199605000-00008; HENDERSON DC, 1979, T AM SOC ART INT ORG, V25, P367; HOMAN RW, 1987, ELECTROEN CLIN NEURO, V66, P376, DOI 10.1016/0013-4694(87)90206-9; Homser DW, 1989, APPL LOGISTIC REGRES; KUJALA T, 1995, NEUROSCI LETT, V183, P143, DOI 10.1016/0304-3940(94)11135-6; Luders H, 1987, SURG TREATMENT EPILE, P297; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; PASCUALLEONE A, 1991, NEUROLOGY, V41, P697, DOI 10.1212/WNL.41.5.697; PASCUALLEONE A, 1993, ANN NEUROL, V34, P33, DOI 10.1002/ana.410340108; PascualLeone A, 1996, EXP BRAIN RES, V107, P479; Penfield W., 1959, SPEECH BRAIN MECH; Pons T, 1996, NATURE, V380, P479; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; Rushton D. N., 1978, Frontiers in Visual Science, P574; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Schmidt EM, 1996, BRAIN, V119, P507, DOI 10.1093/brain/119.2.507; UHL F, 1993, NEUROSCI LETT, V150, P162, DOI 10.1016/0304-3940(93)90526-Q; UHL F, 1991, NEUROSCI LETT, V124, P256, DOI 10.1016/0304-3940(91)90107-5; WANETDEFALQUE MC, 1988, BRAIN RES, V446, P369, DOI 10.1016/0006-8993(88)90896-7; WASSERMANN EM, IN PRESS ELECTROENCE; [No title captured]	30	649	664	3	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					180	183		10.1038/38278	http://dx.doi.org/10.1038/38278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296495				2022-12-01	WOS:A1997XV75700048
J	Spencer, TE; Jenster, G; Burcin, MM; Allis, CD; Zhou, JX; Mizzen, CA; McKenna, NJ; Onate, SA; Tsai, SY; Tsai, MJ; OMalley, BW				Spencer, TE; Jenster, G; Burcin, MM; Allis, CD; Zhou, JX; Mizzen, CA; McKenna, NJ; Onate, SA; Tsai, SY; Tsai, MJ; OMalley, BW			Steroid receptor coactivator-1 is a histone acetyltransferase	NATURE			English	Article							THYROID-HORMONE RECEPTOR; MMTV PROMOTER; TRANSCRIPTION; ACTIVATION; GENE; CBP; DEACETYLASE; NUCLEOSOME; REGULATOR; COMPLEX	Steroid receptors and coactivator proteins are thought to stimulate gene expression by facilitating the assembly of basal transcription factors into a stable preinitiation complex(1). That is not clear, however, is how these transcription factors gain access to transcriptionally repressed chromatin to modulate the transactivation of specific gene networks in vitro. The available evidence indicates that acetylation of chromatin in vivo is coupled to transcription and that specific histone acetyltransferases (HATs) target histones bound to DNA and overcome the inhibitory effect of chromatin on gene expression(2-4). The steroid-receptor coactivator SRC-1 is a coactivator for many members of the steroid-hormone receptor superfamily of Ligand-inducible transcription factors(5), Here we show that SRC-1 possesses intrinsic histone acetyltransferase activity and that it also interacts with another HAT, p300/CBP-associate factor (PCAF). The HAT activity of SRC-1 maps to its carboxy-terminal region and is primarily specific for histones H3 and H4, Acetylation by SRC-1 and PCAF of histones bound at specific promoters may result from ligand binding to steroid receptors and could be a mechanism by which the activation functions of steroid receptors and associated coactivators enhance formation of a stable preinitiation complex, thereby increasing transcription of specific genes from transcriptionally repressed chromatin templates.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	Baylor College of Medicine; University of Rochester			Spencer, Thomas/AAD-6434-2020	McKenna, Neil/0000-0001-6689-0104; Spencer, Thomas/0000-0003-2815-766X				ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; IENSTET G, 1997, P NATL ACAD SCI USA, V94, P7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KINGSTON RE, 1996, GENE DEV, V10, P950; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; WONG J, 1997, EMBO J, V11, P3158; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	26	1030	1045	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					194	198		10.1038/38304	http://dx.doi.org/10.1038/38304			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296499				2022-12-01	WOS:A1997XV75700052
J	Richards, B; Zhang, H; Phear, G; Meuth, M				Richards, B; Zhang, H; Phear, G; Meuth, M			Conditional mutator phenotypes in hMSH2-deficient tumor cell lines	SCIENCE			English	Article							MISMATCH REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY; COLON-CANCER; COLORECTAL TUMORIGENESIS; GENETIC INSTABILITY; HPRT LOCUS; MUTATIONS; PROTEIN; ACCUMULATION; DEFECTS	Two human tumor cell lines that are deficient in the mismatch repair protein hMSH2 show little or no increase in mutation rate relative to that of a mismatch repair-proficient cell line when the cells are maintained in culture conditions allowing rapid growth. However, mutations accumulate at a high rate in these cells when they are maintained at high density. Thus the mutator phenotype of some mismatch repair-deficient cell lines is conditional and strongly depends on growth conditions. These observations have implications for tumor development because they suggest that mutations may accumulate in tumor cells when growth is limited.	UNIV UTAH,ECCLES INST HUMAN GENET,DEPT ONCOL SCI,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES INST HUMAN GENET,DEPT RADIAT ONCOL,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah				Zhang, Hong/0000-0002-3930-6731; Richards, Burt/0000-0003-1789-2335	NCI NIH HHS [R01-CA-62244, T32-CA-09602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009602, R01CA062244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; BAKER RM, 1974, CELL, V1, P9, DOI 10.1016/0092-8674(74)90149-4; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6063; BRANCH P, 1995, CANCER RES, V55, P2304; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; delaChapelle A, 1995, ANNU REV GENET, V29, P329, DOI 10.1146/annurev.ge.29.120195.001553; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FREEDMAN RS, 1978, CANCER, V42, P2352, DOI 10.1002/1097-0142(197811)42:5<2352::AID-CNCR2820420536>3.0.CO;2-#; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LOEB LA, 1991, CANCER RES, V51, P3075; Luria SE, 1943, GENETICS, V28, P491; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marra G, 1996, ONCOGENE, V13, P2189; Meyers M, 1997, CANCER RES, V57, P206; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reynolds TY, 1996, CANCER RES, V56, P5754; RICHARDS BS, UNPUB; RISINGER JI, 1995, CANCER RES, V55, P5664; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; STRAUSS BS, 1992, CANCER RES, V52, P249	38	85	91	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1523	1526		10.1126/science.277.5331.1523	http://dx.doi.org/10.1126/science.277.5331.1523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278518				2022-12-01	WOS:A1997XV42900045
J	Ruggiu, M; Speed, R; Taggart, M; McKay, SJ; Kilanowski, F; Saunders, P; Dorin, J; Cooke, HJ				Ruggiu, M; Speed, R; Taggart, M; McKay, SJ; Kilanowski, F; Saunders, P; Dorin, J; Cooke, HJ			The mouse Dazla gene encodes a cytoplasmic protein essential for gametogenesis	NATURE			English	Article							Y-CHROMOSOME; AUTOSOMAL GENE; ZONA PELLUCIDA; AZOOSPERMIA; HOMOLOG; SPERMATOGENESIS; DELETIONS; CANDIDATE; OOCYTES; HUMANS	RBM and DAZ/SPGY are two families of genes located on the Y chromosome that encode proteins containing RNA-binding motifs, and both have been described as candidate human spermatogenesis genes(1,2). Transmission of deletions from father to son has been observed in the case of DAZ(3-5), but neither gene family has been shown to be essential for spermatogenesis in human males. The DAZ/SPGY genes are particularly amenable to a knockout approach, as they are found on the Y chromosome in Old World primates and apes(6), but in other mammals, they are represented only by an autosomal gene, DAZLA(7-10), which is also present in Old World primates and apes. It has also been shown that a Dazla homologue is essential for spermatogenesis in Drosophila(11). Here we show that Dazla protein is cytoplasmic in male and female germ cells, unlike the nuclear RBM protein(12) Disruption of the Dazla gene leads to loss of germ cells and complete absence of gamete production, demonstrating that Dazla is essential for the differentiation of germ cells.	WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; MRC, REPROD BIOL UNIT, EDINBURGH EH3 9EW, MIDLOTHIAN, SCOTLAND	University of Edinburgh			Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380; Ruggiu, Matteo/0000-0002-6404-1210	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1980, P NATL ACAD SCI-BIOL, V77, P1029, DOI 10.1073/pnas.77.2.1029; Cooke HJ, 1996, HUM MOL GENET, V5, P513, DOI 10.1093/hmg/5.4.513; Eberhart CG, 1996, NATURE, V381, P783, DOI 10.1038/381783a0; Elliott DJ, 1997, P NATL ACAD SCI USA, V94, P3848, DOI 10.1073/pnas.94.8.3848; Frojdman K, 1993, SERTOLI CELL, P87; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Nakahori Y, 1996, HORM RES, V46, P20, DOI 10.1159/000185175; Niederberger C, 1997, MAMM GENOME, V8, P277, DOI 10.1007/s003359900409; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Reijo R, 1996, LANCET, V347, P1290, DOI 10.1016/S0140-6736(96)90938-1; Reijo R, 1996, GENOMICS, V35, P346, DOI 10.1006/geno.1996.0366; Saxena R, 1996, NAT GENET, V14, P292, DOI 10.1038/ng1196-292; SEARLE AG, 1974, MUTAT RES, V22, P63, DOI 10.1016/0027-5107(74)90009-8; Shan ZH, 1996, HUM MOL GENET, V5, P2005, DOI 10.1093/hmg/5.12.2005; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; Yen PH, 1996, HUM MOL GENET, V5, P2013, DOI 10.1093/hmg/5.12.2013	17	498	523	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					73	77		10.1038/37987	http://dx.doi.org/10.1038/37987			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288969				2022-12-01	WOS:A1997XU59600047
J	Egger, G; Swinburn, B				Egger, G; Swinburn, B			An ''ecological'' approach to the obesity pandemic	BRITISH MEDICAL JOURNAL			English	Article							DIETARY-FAT INTAKE; BODY-COMPOSITION; WOMEN; WEIGHT; EPIDEMIOLOGY		DEAKIN UNIV,SCH HUMAN MOVEMENT,MELBOURNE,VIC,AUSTRALIA; UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND 1,NEW ZEALAND	Deakin University; University of Auckland								BOURDIN M, 1993, EUR J APPL PHYSIOL O, V66, P439, DOI 10.1007/BF00599618; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; FLATT JP, 1988, DIABETES METAB REV, V4, P571, DOI 10.1002/dmr.5610040603; FRISCH RE, 1994, P NUTR SOC, V53, P113, DOI 10.1079/PNS19940015; GLASSER GA, 1995, SPORTS MED DIGES MAR, P5; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; HAWKS SR, 1994, J HLTH ED, V25, P147; HEITMANN BL, 1995, AM J CLIN NUTR, V61, P1213, DOI 10.1093/ajcn/61.6.1213; JAMES WPT, 1992, INT J OBESITY, V16, pS23; JAMES WPT, 1995, INT J OBESITY, V19, pS37; KATAHN M, 1990, ANN NY ACAD SCI, V602, P189, DOI 10.1111/j.1749-6632.1990.tb22739.x; Kickbusch I., 1989, HLTH PROMOTION, V4, P265, DOI DOI 10.1093/HEAPR0/4.4.265; LIEBEL RL, 1995, NEW ENGL J MED, V332, P621; LISSNER L, 1995, EUR J CLIN NUTR, V49, P79; LYON XH, 1995, INT J OBESITY, V19, P260; MAGNUS P, 1994, MED J AUSTRALIA, V161, P519; PRENTICE AM, 1991, P NUTR SOC, V50, P441, DOI 10.1079/PNS19910055; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; PREWITT TE, 1991, AM J CLIN NUTR, V54, P304, DOI 10.1093/ajcn/54.2.304; RAYUSSIN E, 1992, OBESITY THEORY THERA, P97; REBUFFESCRIVE M, 1985, J CLIN INVEST, V75, P1973, DOI 10.1172/JCI111914; Rose G., 1992, STRATEGY PREVENTIVE; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; STUBBS RJ, 1995, INT J OBESITY, V19, pS11; SWINBURN B, 1993, AM J CLIN NUTR S, V57; TUTEN C, 1995, OBES RES, V3, P313, DOI 10.1002/j.1550-8528.1995.tb00156.x; WESTSTRATE JA, 1995, INT J OBESITY, V19, pS38; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	571	573	1	44	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					477	480		10.1136/bmj.315.7106.477	http://dx.doi.org/10.1136/bmj.315.7106.477			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284671	Green Published			2022-12-01	WOS:A1997XT71400026
J	Whiteman, MC; Deary, IJ; Lee, AJ; Fowkes, FGR				Whiteman, MC; Deary, IJ; Lee, AJ; Fowkes, FGR			Submissiveness and protection from coronary heart disease in the general population: Edinburgh Artery Study	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; WESTERN-COLLABORATIVE-GROUP; A BEHAVIOR; PATTERN; PERSONALITY; HOSTILITY	Background Type A behaviour and, more specifically, hostility and anger have been associated with increased risk of coronary heart disease (CHD). But less attention has been paid to other features of personality. Our aim was to assess whether a submissiveness trait, which is independent of hostility, was related to future risk of CHD in the general population. Methods The Edinburgh Artery Study is a cohort study of a random sample of 809 men and 783 women aged 55 to 74 years, At the baseline examination in 1988, we administered the Bedford-Foulds Personality Deviance Scales. The participants were followed up for 5 years for cardiovascular events. Criteria to define events were adapted from the American Heart Association. Events were ascertained from the Information and Statistics Division of the Scottish Office Home and Health Department, general practitioners, the UK National Health Service Central Register, annual questionnaires to the participants, and the second examination at the end of follow-up. Findings During follow-up, 57 (7.0%) men and 28 (3.6%) women had non-fatal myocardial infarctions; 25 (3.1%) men and 8 (1.0%) women had fatal myocardial infarctions; and 48 (5.9%) men and 41 (5.2%) women developed angina pectoris. We found that mean submissiveness scores were significantly higher in men and women who did not have a non-fatal myocardial infarction than in those who did (18.88 [SE 0.15] vs 17.70 [0.40], p=0.023 in men; 20.76 [0.17] vs 18.18 [0.86], p=0.002 in women). In multiple logistic-regression models, submissiveness remained independently associated with risk of myocardial infarction in women only; a decreased risk of both non-fatal myocardial infarction (relative risk 0.59 [95% Cl 0.40-0.85]) and, to a lesser extent, total myocardial infarction (0.69 [0.27-0.96]), was associated with an increase of 1 SD in submissiveness. Interpretation The personality trait of submissiveness may be protective against non-fatal myocardial infarction, particularly in women. A better understanding is required of the complicated effects of personality on CHD development.	UNIV EDINBURGH,DEPT PSYCHOL,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PUBL HLTH SCI,WOLFSON UNIT PREVENT PERIPHERAL VASC DIS,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				[Anonymous], 1990, PERSONALITY ADULTHOO; BAREFOOT JC, 1995, AM J EPIDEMIOL, V142, P477, DOI 10.1093/oxfordjournals.aje.a117663; BEDFORD A, 1978, PERSONALITY DEVIANCE; BOOTHKEWLEY S, 1987, PSYCHOL BULL, V101, P343, DOI 10.1037/0033-2909.101.3.343; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; Brunner E, 1997, BMJ-BRIT MED J, V314, P1472, DOI 10.1136/bmj.314.7092.1472; CASE RB, 1985, NEW ENGL J MED, V312, P737, DOI 10.1056/NEJM198503213121201; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cook WW, 1954, J APPL PSYCHOL, V38, P414, DOI 10.1037/h0060667; DEARY IJ, 1995, PERS INDIV DIFFER, V19, P275, DOI 10.1016/0191-8869(95)00061-A; DEARY IJ, 1994, PSYCHOSOM MED, V56, P197, DOI 10.1097/00006842-199405000-00004; DEMBROSKI TM, 1987, J PERS, V55, P211, DOI 10.1111/j.1467-6494.1987.tb00435.x; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRIEDMAN M, 1996, BEHAV ITS DIAGNOSIS; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; HAYNES SG, 1980, AM J EPIDEMIOL, V111, P37, DOI 10.1093/oxfordjournals.aje.a112873; HECKER MHL, 1988, PSYCHOSOM MED, V50, P153, DOI 10.1097/00006842-198803000-00005; Houston BK, 1997, PSYCHOSOM MED, V59, P5, DOI 10.1097/00006842-199701000-00002; JOHNSTON DW, 1993, J R SOC MED, V86, P409; Kaplan JR, 1996, PSYCHOSOM MED, V58, P598, DOI 10.1097/00006842-199611000-00008; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; MATTHEWS KA, 1982, PSYCHOL BULL, V91, P293; MILLER TQ, 1991, PSYCHOL BULL, V110, P469, DOI 10.1037/0033-2909.110.3.469; Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322; Prineas R.J., 1982, MINNESOTA CODE MANUA; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; ROSENMAN RH, 1975, JAMA-J AM MED ASSOC, V233, P872, DOI 10.1001/jama.233.8.872; Sapolsky RM, 1995, ANN NY ACAD SCI, V771, P626, DOI 10.1111/j.1749-6632.1995.tb44715.x; SHEKELLE RB, 1985, AM J EPIDEMIOL, V122, P559, DOI 10.1093/oxfordjournals.aje.a114135; SHEKELLE RB, 1985, AM J CARDIOL, V56, P221; SHIVELY CA, 1994, ARTERIOSCLER THROMB, V14, P721, DOI 10.1161/01.ATV.14.5.721; Stone SV, 1990, PERSONALITY DIS, P178; Whitehead M, 1992, INEQUALITIES HLTH BL	33	42	43	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					541	545		10.1016/S0140-6736(96)03141-8	http://dx.doi.org/10.1016/S0140-6736(96)03141-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284775				2022-12-01	WOS:A1997XT22100008
J	Gore, SM				Gore, SM			Age related exposure of patients to the agent of BSE should not be downplayed - Commentary	BRITISH MEDICAL JOURNAL			English	Article											Gore, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							ALPEROVITCH A, 1996, B EPIDEMIOL HEBDOM, V48, P207; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; GORE SM, 1995, BRIT MED J, V311, P1416, DOI 10.1136/bmj.311.7017.1416a; GORE SM, 1996, SCI PARLIAMENT, V53, P2; Gregory J., 1990, DIETARY NUTR SURVEY; Will RG, 1997, LANCET, V349, P847, DOI 10.1016/S0140-6736(97)24012-2	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					395	396		10.1136/bmj.315.7105.395	http://dx.doi.org/10.1136/bmj.315.7105.395			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277602	Green Published			2022-12-01	WOS:A1997XR54900018
J	Jentsch, JD; Redmond, DE; Elsworth, JD; Taylor, JR; Youngren, KD; Roth, RH				Jentsch, JD; Redmond, DE; Elsworth, JD; Taylor, JR; Youngren, KD; Roth, RH			Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine	SCIENCE			English	Article							PREFRONTAL CORTEX; CINGULATE CORTEX; WORKING MEMORY; MOTOR DEFICITS; SCHIZOPHRENIA; CLOZAPINE; ACTIVATION; MPTP; AMPHETAMINE; DISEASE	The effects of the psychotomimetic drug phencyclidine on the neurochemistry and function of the prefrontal cortex in vervet monkeys were investigated, Monkeys treated with phencyclidine twice a day for 14 days displayed performance deficits on a task that was sensitive to prefrontal cortex function; the deficits were ameliorated by the atypical antipsychotic drug clozapine, Repeated exposure to phencyclidine caused a reduction in both basal and evoked dopamine utilization in the dorsolateral prefrontal cortex, a brain region that has long been associated with cognitive function, Behavioral deficits and decreased dopamine utilization remained after phencyclidine treatment was stopped, an indication that these effects were not simply due to direct drug effects. The data suggest that repeated administration of phencyclidine in monkeys may be useful for studying psychiatric disorders associated with cognitive dysfunction and dopamine hypofunction in the prefrontal cortex, particularly schizophrenia.	YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT USA; YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT USA; YALE UNIV, SCH MED, DEPT NEUROSURG, NEW HAVEN, CT USA; YALE UNIV, SCH MED, INTERDEPT NEUROSCI PROGRAM, NEW HAVEN, CT USA	Yale University; Yale University; Yale University; Yale University; Yale University					NIMH NIH HHS [MH14092, RSA K05-MH00643, MH44866] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH014092, R01MH014092, K05MH000643, P50MH044866] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGRIST B, 1982, PSYCHOPHARMACOLOGY, V78, P128, DOI 10.1007/BF00432248; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Bunney Blynn Garland, 1995, P1205; CARLIN AS, 1979, AM J DRUG ALCOHOL AB, V6, P273, DOI 10.3109/00952997909001717; COSGROVE J, 1991, J CLIN PSYCHOL, V47, P159, DOI 10.1002/1097-4679(199101)47:1<159::AID-JCLP2270470125>3.0.CO;2-O; Daniel D G, 1989, J Neuropsychiatry Clin Neurosci, V1, P377; DANIEL DG, 1991, J NEUROSCI, V11, P1907; DAVIS KL, 1991, AM J PSYCHIAT, V148, P11; DEUTCH AY, 1992, J NEURAL TRANSM-GEN, P61; DIAMOND A, 1989, BEHAV NEUROSCI, V103, P526, DOI 10.1037/0735-7044.103.3.526; Diamond A, 1988, THOUGHT LANGUAGE, P337; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; ELSWORTH JD, 1990, NEUROSCI LETT, V114, P316, DOI 10.1016/0304-3940(90)90583-U; FEY ET, 1951, J CONSULT PSYCHOL, V15, P311; FREEDMAN M, 1986, BEHAV NEUROSCI, V100, P337, DOI 10.1037/0735-7044.100.3.337; GOLDBERG TE, 1993, BRIT J PSYCHIAT, V162, P43, DOI 10.1192/bjp.162.1.43; GOLDBERG TE, 1994, J CLIN PSYCHIAT, V55, P88; Goldberg Terry E., 1995, P1245; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1; HERTZMAN M, 1990, AM J PSYCHIAT, V147, P255; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Jentsch JD, 1997, J NEUROSCI, V17, P1769; Jentsch JD, 1997, NEUROPSYCHOPHARMACOL, V17, P92, DOI 10.1016/S0893-133X(97)00034-1; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KARLSSON P, 1995, PSYCHOPHARMACOLOGY, V121, P309, DOI 10.1007/BF02246068; KLONOFF H, 1970, J NERV MENT DIS, V150, P291, DOI 10.1097/00005053-197004000-00004; LEE MA, 1994, J CLIN PSYCHIAT, V55, P82; LEVIN S, 1984, J PSYCHIATR RES, V18, P27, DOI 10.1016/0022-3956(84)90046-3; LEWIS JE, 1986, PHENCYCLIDINE UPDATE, P66; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; Murphy BL, 1997, NEUROPSYCHOPHARMACOL, V16, P433, DOI 10.1016/S0893-133X(97)00019-5; OWEN AM, 1993, BRAIN, V116, P1159, DOI 10.1093/brain/116.5.1159; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; RIDLEY RM, 1993, NEUROSCIENCE, V52, P595, DOI 10.1016/0306-4522(93)90409-9; ROBBINS TW, 1990, SCHIZOPHRENIA BULL, V16, P391, DOI 10.1093/schbul/16.3.391; SALETU B, 1987, PHARMACOPSYCHIATRY, V20, P12, DOI 10.1055/s-2007-1017125; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SHALLICE T, 1991, PSYCHOL MED, V21, P661, DOI 10.1017/S0033291700022303; TAYLOR JR, 1990, BEHAV NEUROSCI, V104, P564, DOI 10.1037/0735-7044.104.4.564; TAYLOR JR, 1990, BRAIN, V113, P617, DOI 10.1093/brain/113.3.617; WEINBERGER DR, 1988, ARCH GEN PSYCHIAT, V45, P609; WU JC, 1991, PSYCHOPHARMACOLOGIA, V11, P47; Young K. A., 1995, Society for Neuroscience Abstracts, V21, P1705; YOUNGREN KD, 1994, NEUROSCI LETT, V165, P41, DOI 10.1016/0304-3940(94)90704-8	45	324	345	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					953	955		10.1126/science.277.5328.953	http://dx.doi.org/10.1126/science.277.5328.953			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XQ985	9252326				2022-12-01	WOS:A1997XQ98500041
J	Martin, TG; Somberg, KA; Meng, YG; Cohen, RL; Heid, CA; deSauvage, FJ; Shuman, MA				Martin, TG; Somberg, KA; Meng, YG; Cohen, RL; Heid, CA; deSauvage, FJ; Shuman, MA			Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							C-MPL LIGAND; THROMBOCYTOPENIA	Background: Thrombocytopenia is a common manifestation of cirrhosis. Objectives: To determine plasma thrombopoietin levels in cirrhotic patients with thrombocytopenia, monitor those levels before and after orthotopic liver transplantation, and compare thrombopoietin messenger RNA (mRNA) levels in liver samples from cirrhotic patients and controls. Design: A cross-sectional study of patients with cirrhosis, including a small subset of patients who had orthotopic liver transplantation. Setting: University-affiliate hospital. Patients: 44 patients with cirrhosis, including 17 patients who had orthotopic liver transplantation. Intervention: Orthotopic liver transplantation. Measurements: Plasma thrombopoietin levels in all patients, platelet counts in all patients, and thrombopoietin mRNA levels in liver samples from nine patients with cirrhosis and eight controls. Results: Thrombopoietin levels were undetectable in 39 of 44 patients with cirrhosis. In 16 of 17 patients, the levels became detectable after liver transplantation. Thrombopoietin mRNA levels were decreased in liver samples from patients with cirrhosis compared with controls (P = 0.0103). Conclusions: The low thrombopoietin levels in cirrhotic patients with thrombocytopenia and the increased levels after orthotopic liver transplantation suggest that impaired production of thrombopoietin may contribute to thrombocytopenia associated with cirrhosis.	GENENTECH INC, BIOANALYT TECHNOL DEPT, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MOL ONCOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Martin, TG (corresponding author), UNIV CALIF SAN FRANCISCO, MED CTR, DIV HEMATOL, BOX 1270, PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584	NHLBI NIH HHS [HL54476] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054476] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alvarez OA, 1996, AM J GASTROENTEROL, V91, P134; ASTER RH, 1966, J CLIN INVEST, V45, P645, DOI 10.1172/JCI105380; CRANE C, 1962, SURG GYNECOL OBSTET, V115, P12; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; FERRARA J, 1979, SURGERY, V86, P570; HARKER LA, 1969, J CLIN INVEST, V48, P963, DOI 10.1172/JCI106077; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KAUSHANSKY K, 1995, THROMB HAEMOSTASIS, V74, P521; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; LOK S, 1994, STEM CELLS, V12, P586, DOI 10.1002/stem.5530120606; MCALLISTER E, 1995, AM SURGEON, V61, P129; Meng YG, 1996, BRIT J HAEMATOL, V95, P535, DOI 10.1046/j.1365-2141.1996.d01-1933.x; Sanyal AJ, 1996, HEPATOLOGY, V23, P32, DOI 10.1002/hep.510230105; TOGHILL PJ, 1977, J CLIN PATHOL, V30, P367, DOI 10.1136/jcp.30.4.367	15	135	136	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					285	288		10.7326/0003-4819-127-4-199708150-00005	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265428				2022-12-01	WOS:A1997XR26600007
J	Frey, M; Chomet, P; Glawischnig, E; Stettner, C; Grun, S; Winklmair, A; Eisenreich, W; Bacher, A; Meeley, RB; Briggs, SP; Simcox, K; Gierl, A				Frey, M; Chomet, P; Glawischnig, E; Stettner, C; Grun, S; Winklmair, A; Eisenreich, W; Bacher, A; Meeley, RB; Briggs, SP; Simcox, K; Gierl, A			Analysis of a chemical plant defense mechanism in grasses	SCIENCE			English	Article							TRYPTOPHAN SYNTHASE-ALPHA; ESCHERICHIA-COLI; ARABIDOPSIS-THALIANA; HYDROXAMIC ACIDS; MAIZE; EXPRESSION; GENE; BIOSYNTHESIS; SUBUNIT; MONOOXYGENASE	In the Gramineae, the cyclic hydroxamic acids 2,4-dihydroxy-1,4-benzoxazin-3-one (DIBOA) and 2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one (DIMBOA) form part of the defense against insects and microbial pathogens. Five genes, Bx1 through Bx5, are required for DIBOA biosynthesis in maize. The functions of these five genes, clustered on chromosome 4, were demonstrated in vitro. Bx1 encodes a tryptophan synthase a homolog that catalyzes the formation of indole for the production of secondary metabolites rather than tryptophan, thereby defining the branch point from primary to secondary metabolism. Bx2 through Bx5 encode cytochrome P450-dependent monooxygenases that catalyze four consecutive hydroxylations and one ring expansion to form the highly oxidized DIBOA.	TECH UNIV MUNICH, GENET INST, D-85747 GARCHING, GERMANY; DEKALB GENET CORP, MYSTIC, CT 06355 USA; TECH UNIV MUNICH, INST ORGAN CHEM & BIOCHEM, D-85747 GARCHING, GERMANY; PIONEER HI BRED INT INC, JOHNSTON, IA 50131 USA; OHIO STATE UNIV, DEPT HORT & CROP SCI, WOOSTER, OH 44691 USA	Technical University of Munich; Technical University of Munich; DuPont; Pioneer Hi-Bred International, Inc.; University System of Ohio; Ohio State University			Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279; Glawischnig, Erich/0000-0001-9280-5065				BAILEY BA, 1991, PLANT PHYSIOL, V95, P792, DOI 10.1104/pp.95.3.792; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; Chomet Paul S., 1994, P243; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; Desai SR, 1996, CHEM COMMUN, P1321, DOI 10.1039/cc9960001321; FREY M, 1995, MOL GEN GENET, V246, P100, DOI 10.1007/BF00290138; Glawischnig E, 1997, PHYTOCHEMISTRY, V45, P715, DOI 10.1016/S0031-9422(96)00832-1; HAMILTON R. H., 1964, WEEDS, V12, P27, DOI 10.2307/4040633; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KRAMER VC, 1995, PLANT MOL BIOL, V27, P1183, DOI 10.1007/BF00020891; KUMAR P, 1994, PHYTOCHEMISTRY, V36, P893, DOI 10.1016/S0031-9422(00)90458-8; KUTCHAN TM, 1995, PLANT CELL, V7, P1059, DOI 10.2307/3870057; LIM WK, 1991, J BACTERIOL, V173, P1886, DOI 10.1128/jb.173.6.1886-1893.1991; Mena M, 1996, SCIENCE, V274, P1537, DOI 10.1126/science.274.5292.1537; NIEMEYER HM, 1988, PHYTOCHEMISTRY, V27, P3349, DOI 10.1016/0031-9422(88)80731-3; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; RADWANSKI ER, 1995, MOL GEN GENET, V248, P657, DOI 10.1007/BF02191705; RADWANSKI ER, 1995, PLANT CELL, V7, P921, DOI 10.1105/tpc.7.7.921; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; TRUAN G, 1993, GENE, V125, P49, DOI 10.1016/0378-1119(93)90744-N; TSUJI J, 1993, PHYSIOL MOL PLANT P, V43, P221, DOI 10.1006/pmpp.1993.1052; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WEISCHET WO, 1976, EUR J BIOCHEM, V65, P375, DOI 10.1111/j.1432-1033.1976.tb10351.x; WOODWARD MD, 1979, PLANT PHYSIOL, V63, P9, DOI 10.1104/pp.63.1.9; WRIGHT AD, 1992, PLANT CELL, V4, P711, DOI 10.1105/tpc.4.6.711; Zhao JM, 1996, PLANT CELL, V8, P2235, DOI 10.1105/tpc.8.12.2235	28	498	547	6	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					696	699		10.1126/science.277.5326.696	http://dx.doi.org/10.1126/science.277.5326.696			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235894				2022-12-01	WOS:A1997XN90700044
J	Hamel, MB; Phillips, RS; Davis, RB; Desbiens, N; Connors, AF; Teno, JM; Wenger, N; Lynn, J; Wu, AW; Fulkerson, W; Tsevat, J				Hamel, MB; Phillips, RS; Davis, RB; Desbiens, N; Connors, AF; Teno, JM; Wenger, N; Lynn, J; Wu, AW; Fulkerson, W; Tsevat, J			Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med		outcome and process assessment (health care); dialysis; cost-benefit analysis; kidney failure, acute; decision making	ACUTE-RENAL-FAILURE; CONVENIENT APPROXIMATION; REQUIRING DIALYSIS; LIFE EXPECTANCY; RISK-FACTORS; APACHE-II; SURVIVAL; SYSTEM; PROGNOSIS; SUPPORT	Background: Renal failure requiring dialysis in the setting of hospitalization for serious illness is a poor prognostic sign, and dialysis and aggressive care are sometimes withheld. Objective: To evaluate the clinical outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care for seriously ill hospitalized patients. Design: Prospective cohort study and cost-effectiveness analysis. Setting: Five geographically diverse teaching hospitals. Patients: 490 patients (median age, 61 years; 58% women) enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT) in whom dialysis was initiated. Measurements: Survival, functional status, quality of life, and health care costs. Life expectancy was estimated by extrapolating survival data (up to 4.4 years of followup) using a declining exponential function. Utilities (quality-of-life weights) were estimated by using time-tradeoff questions. Costs were based on data from SUPPORT and published Medicare data. Results: Median duration of survival was 32 days, and only 27% of patients were alive after 6 months. Survivors reported a median of one dependency in activities of daily living, and 62% rated their quality of life as ''good'' or better. Overall, the estimated cost per quality-adjusted life-year saved by initiating dialysis and continuing aggressive care rather than withholding dialysis and allowing death to occur was $128 200. For the 103 patients in the worst prognostic category, the estimated cost per quality-adjusted life-year was $274 100; for the 94 patients in the best prognostic category, the cost per quality-adjusted life-year was $61 900. Conclusions: For the few patients who survived, clinical outcomes were fairly good. With the exception of patients with the best prognoses, however, the cost-effectiveness of initiating dialysis and continuing aggressive care far exceeded $50 000 per quality-adjusted life-year, a commonly cited threshold for cost-effective care.	UNIV TENNESSEE, CHATTANOOGA UNIV, CHATTANOOGA, TN 37403 USA; UNIV VIRGINIA, SCH MED, DEPT HLTH EVALUAT SCI, CHARLOTTESVILLE, VA 22908 USA; JOHNS HOPKINS UNIV, HLTH SERV RES CTR, BALTIMORE, MD 21205 USA; DUKE UNIV, SCH MED, DURHAM, NC 27710 USA; UNIV CINCINNATI, MED CTR, SECT OUTCOMES RES, CINCINNATI, OH 45267 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; DUKE UNIV, MED CTR, SCH MED, DURHAM, NC 27710 USA	University of Tennessee System; University of Tennessee at Chattanooga; University of Virginia; Johns Hopkins University; Duke University; University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University	Hamel, MB (corresponding author), BETH ISRAEL DEACONESS MED CTR, DIV GEN MED & PRIMARY CARE, 330 BROOKLINE AVE, LY-330, BOSTON, MA 02215 USA.		Wu, Albert/AAJ-4780-2021	Connors, Alfred F./0000-0001-7123-3360				BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; CHERTOW GM, 1995, ARCH INTERN MED, V155, P1505, DOI 10.1001/archinte.155.14.1505; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; GOLDMAN L, 1992, HEART DIS TXB CARDIO; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kuntz KM, 1996, CIRCULATION, V94, P957, DOI 10.1161/01.CIR.94.5.957; LIEN J, 1985, ARCH INTERN MED, V145, P2067, DOI 10.1001/archinte.145.11.2067; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LOHR JW, 1988, AM J KIDNEY DIS, V11, P254, DOI 10.1016/S0272-6386(88)80158-6; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; MAHER ER, 1989, Q J MED, V72, P857; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; SHUSTERMAN N, 1987, AM J MED, V83, P65, DOI 10.1016/0002-9343(87)90498-0; SPURNEY RF, 1991, CRIT CARE MED, V19, P8, DOI 10.1097/00003246-199101000-00007; Torrance G W, 1972, Health Serv Res, V7, P118; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; TSEVAT J, 1995, ANN INTERN MED, V122, P514, DOI 10.7326/0003-4819-122-7-199504010-00007; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; WHEELER DC, 1986, Q J MED, V61, P977	29	165	166	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					195	+		10.7326/0003-4819-127-3-199708010-00003	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XN129	9245224				2022-12-01	WOS:A1997XN12900003
J	Edmonson, MB; Stoddard, JJ; Owens, LM				Edmonson, MB; Stoddard, JJ; Owens, LM			Hospital readmission with feeding-related problems after early postpartum discharge of normal newborns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TERM NEWBORN	Context.-Increasingly short postpartum hospital stays in the United States precipitated a policy debate that culminated in passage of the Newborns' and Mothers' Health Protection Act of 1996. The debate occurred without population-based evidence for adverse health effects in newborns who are discharged early. Objective.-To determine whether early postpartum hospital discharge of normal newborns increases their risk for hospital readmission with feeding-related problems. Design and Setting.-Nested case-control analysis of 1991 to 1994 Wisconsin birth certificate and hospital discharge data. Subjects.-A total of 210 readmitted case patients and 630 control subjects selected from a cohort of 120 290 normal newborns who weighed at least 2500 g, were delivered vaginally of mothers with uncomplicated medical and obstetrical histories, and were discharged from the hospital either early (day of life 1 or 2) or conventionally (day 3). Outcome Measure.-Readmission at age 4 to 28 days with discharge diagnoses indicating a primary feeding problem, secondary dehydration, or inadequate weight gain. Results.-Early discharges increased 3-fold (reaching 521/1000 discharges) during the study period, but feeding-related readmissions (1.7/1000) remained stable. Most readmitted newborns (53.8%) were 4 to 7 days old, many (34.3%) had concurrent dehydration and jaundice, and 29% were admitted through emergency departments. Readmitted newborns were significantly (P<.05) more likely to have been breast-fed, firstborn, or preterm or to have mothers who were poorly educated (<12th grade), unmarried, or receiving Medicaid. Readmission was not associated with early discharge (adjusted odds ratio, 1.05; 95% confidence interval, 0.71-1.53), Conclusion.-Although several neonatal and maternal factors increase the risk that a normal newborn will be rehospitalized with a feeding-related problem, early discharge following an uncomplicated postpartum hospital stay appears to have little or no independent effect on this risk.	UNIV WISCONSIN,CTR HLTH SCI,DEPT PREVENT MED,MADISON,WI 53792; WISCONSIN DEPT HLTH & SOCIAL SERV,CTR HLTH STAT,MADISON,WI	University of Wisconsin System; University of Wisconsin Madison	Edmonson, MB (corresponding author), UNIV WISCONSIN,CTR HLTH SCI,DEPT PEDIAT,H6-440 CLIN SCI CTR,600 HIGHLAND AVE,MADISON,WI 53792, USA.							*AM AC PED COMM FE, 1995, PEDIATRICS, V96, P788; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRITTON JR, 1994, PEDIATRICS, V94, P291; Center for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P335; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P700; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; Iezzoni L I, 1990, Int J Technol Assess Health Care, V6, P272; Kini N, 1995, Wis Med J, V94, P143; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Margolis LH, 1995, CLIN PEDIATR, V34, P626, DOI 10.1177/000992289503401201; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P554, DOI 10.1001/jama.275.7.554; NEWMAN TB, 1992, PEDIATRICS, V89, P809; *OFF HLTH CAR INF, 1995, HLTH CAR DAT ANN REP; PARISI V, 1996, NEW ENGL J MED, V333, P1635; POSES RM, 1995, MED CARE, V33, pAS36; Public Health Service, 1988, INT CLASS DIS; *SAS I INC, 1990, SAS TECHN REP P 200, P175; SELBY JV, 1994, EPIDEMIOL REV, V16, P90, DOI 10.1093/oxfordjournals.epirev.a036148; Soskolne EI, 1996, ARCH PEDIAT ADOL MED, V150, P373, DOI 10.1001/archpedi.1996.02170290039006; WEN SW, 1995, JAMA-J AM MED ASSOC, V274, P1687, DOI 10.1001/jama.274.21.1687; *WI ASS PER CAR, 1993, INT C REP EARL DISCH, P1	22	93	98	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					299	303		10.1001/jama.278.4.299	http://dx.doi.org/10.1001/jama.278.4.299			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228435				2022-12-01	WOS:A1997XL05900030
J	Super, M; Postlethwaite, RJ				Super, M; Postlethwaite, RJ			Genes, familial enuresis, and clinical management	LANCET			English	Editorial Material							NOCTURNAL ENURESIS; VASOPRESSIN		ROYAL MANCHESTER CHILDRENS HOSP,DEPT PAEDIAT NEPHROL,MANCHESTER M27 4HA,LANCS,ENGLAND	Royal Manchester Children's Hospital	Super, M (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,DEPT PAEDIAT GENET,MANCHESTER M27 4HA,LANCS,ENGLAND.							Arnell H, 1997, J MED GENET, V34, P360, DOI 10.1136/jmg.34.5.360; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; EIBERG H, 1995, NAT GENET, V10, P354, DOI 10.1038/ng0795-354; FERGUSSON DM, 1986, PEDIATRICS, V78, P884; HOGG RJ, 1993, J UROLOGY, V150, P444, DOI 10.1016/S0022-5347(17)35506-4; Koff SA, 1996, PEDIATR NEPHROL, V10, P667, DOI 10.1007/s004670050186; RITTIG S, 1989, AM J PHYSIOL, V256, pF664, DOI 10.1152/ajprenal.1989.256.4.F664; Steers WD, 1997, LANCET, V349, P1604, DOI 10.1016/S0140-6736(05)61633-9; WILLE S, 1904, ACTA PAEDIAT, V93, P772	9	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					159	160		10.1016/S0140-6736(05)62347-1	http://dx.doi.org/10.1016/S0140-6736(05)62347-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250180				2022-12-01	WOS:A1997XL72200006
J	Engert, F; Bonhoeffer, T				Engert, F; Bonhoeffer, T			Synapse specificity of long-term potentiation breaks down at short distances	NATURE			English	Article							SLICE CULTURES; RAT HIPPOCAMPUS; ENHANCEMENT; PLASTICITY; TRANSMISSION; PROBABILITY; RELEASE; NEURONS	Long-term potentiation (LTP), the long-lasting increase in synaptic transmission, has been proposed to be a cellular mechanism essential for learning and memory, neuronal development, and circuit reorganization. In the original theoretical(1) and experimental(2) work it was assumed that only synapses that had experienced concurrent pre- and postsynaptic activity are subject to synaptic modification. It has since been shown, however, that LTP is also expressed in synapses on neighbouring neurons that have not undergone the induction procedure(3-5). Yet, it is still believed that this spread of LTP is limited to adjacent postsynaptic cells, and does not occur for synapses on neighbouring input fibres(2,6,7). However, for technical reasons, tests for 'input specificity' were always done for synapses relatively far apart. Here we have used a new local superfusion technique, which allowed us to assess the synaptic specificity of LTP with a spatial resolution of similar to 30 mu m. Our results indicate that there is no input specificity at a distance of less than 70 mu m. Synapses in close proximity to a site of potentiation are also potentiated regardless of their own history of activation, whereas synapses far away show no potentiation.	MAX PLANCK INST PSYCHIAT, D-82152 MUNICH, GERMANY	Max Planck Society			Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				Arancio O, 1996, CELL, V87, P1025, DOI 10.1016/S0092-8674(00)81797-3; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; Cash S, 1996, SCIENCE, V272, P998, DOI 10.1126/science.272.5264.998; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; FROTSCHER M, 1990, PROG BRAIN RES, V83, P323; GAHWILER BH, 1981, PROC R SOC SER B-BIO, V211, P287, DOI 10.1098/rspb.1981.0007; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HEBB DO, 1949, ORG BEHAVIOR; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Kossel A, 1990, Neuroreport, V1, P115, DOI 10.1097/00001756-199010000-00008; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIPSKI J, 1981, J NEUROSCI METH, V4, P1, DOI 10.1016/0165-0270(81)90015-7; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; Neveu D, 1996, J NEUROPHYSIOL, V75, P2157, DOI 10.1152/jn.1996.75.5.2157; OTANI S, 1995, LEARN MEMORY, V2, P101, DOI 10.1101/lm.2.2.101; Scanziani M, 1996, NATURE, V380, P446, DOI 10.1038/380446a0; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; Veselovsky NS, 1996, PFLUG ARCH EUR J PHY, V432, P351, DOI 10.1007/s004240050143; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WOLBURG H, 1991, J NEUROCYTOL, V20, P552, DOI 10.1007/BF01215263	25	192	195	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 17	1997	388	6639					279	284		10.1038/40870	http://dx.doi.org/10.1038/40870			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230437	Bronze			2022-12-01	WOS:A1997XL12100052
J	Song, YH				Song, YH			Why tyrosinase for treatment of melanoma	LANCET			English	Editorial Material							VITILIGO				Song, YH (corresponding author), UNIV FLORIDA, DEPT PATHOL IMMUNOL & LAB MED, GAINESVILLE, FL 32610 USA.		Song, Yao-Hua/A-2516-2011					ALBADRI AMT, 1993, J PATHOL, V170, P149, DOI 10.1002/path.1711700209; Baharav E, 1996, CLIN EXP IMMUNOL, V105, P84, DOI 10.1046/j.1365-2249.1996.d01-727.x; Becker JC, 1996, J INVEST DERMATOL, V107, P627, DOI 10.1111/1523-1747.ep12584237; Berd D, 1996, CANCER IMMUNOL IMMUN, V42, P263, DOI 10.1007/s002620050280; BOLOGNIA JL, 1988, J AM ACAD DERMATOL, V19, P217, DOI 10.1016/S0190-9622(88)70168-1; DUHRA P, 1991, CLIN EXP DERMATOL, V16, P303, DOI 10.1111/j.1365-2230.1991.tb00383.x; HARA I, 1995, J EXP MED, V182, P1609, DOI 10.1084/jem.182.5.1609; SALTER J, 1995, MELANOMA RES, V5, P267, DOI 10.1097/00008390-199508000-00010; SCHALLREUTER KU, 1991, DERMATOLOGICA, V183, P239, DOI 10.1159/000247693; SONG YH, 1994, LANCET, V344, P1049, DOI 10.1016/S0140-6736(94)91709-4; VISSEREN MJW, 1995, J IMMUNOL, V154, P3991	11	20	20	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 12	1997	350	9071					82	83		10.1016/S0140-6736(05)61810-7	http://dx.doi.org/10.1016/S0140-6736(05)61810-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228956				2022-12-01	WOS:A1997XK11400004
J	Lisman, J; Malenka, RC; Nicoll, RA; Malinow, R				Lisman, J; Malenka, RC; Nicoll, RA; Malinow, R			Neuroscience - Learning mechanisms: The case for CaM-KII	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; PROTEIN-KINASE; CALMODULIN; INDUCTION; LTP; AUTOPHOSPHORYLATION; TRANSMISSION; STORAGE; PKC		BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Brandeis University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cold Spring Harbor Laboratory	Lisman, J (corresponding author), BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254, USA.							Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; BARRIA A, 1997, SCIENCE, V276, P2022; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HVALBY O, 1994, P NATL ACAD SCI USA, V91, P4761, DOI 10.1073/pnas.91.11.4761; Lem J, 1996, CURR OPIN NEUROBIOL, V6, P453, DOI 10.1016/S0959-4388(96)80049-3; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; OTMAKHOV N, IN PRESS J NEUROSCI; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9	19	108	111	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					2001	2002		10.1126/science.276.5321.2001	http://dx.doi.org/10.1126/science.276.5321.2001			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9221509				2022-12-01	WOS:A1997XG74800050
J	McDonagh, TA; Morrison, CE; Lawrence, A; Ford, I; TunstallPedoe, H; McMurray, JJV; Dargie, HJ				McDonagh, TA; Morrison, CE; Lawrence, A; Ford, I; TunstallPedoe, H; McMurray, JJV; Dargie, HJ			Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; UNITED-STATES; PREVALENCE; HEALTH; ECHOCARDIOGRAPHY; HYPERTENSION; MORBIDITY; MORTALITY	Background In most previous epidemiological studies on the prevalence of chronic heart failure (CHF) the disorder has been defined on clinical criteria. In a cross-sectional survey of 2000 men and women aged 25-74, randomly sampled from one geographical area, we assessed left-ventricular systolic function by echocardiography. Methods 1640 (83%) of those invited took part. They completed a questionnaire on current medication, history, and symptoms of breathlessness. Blood pressure was measured and electrocardiography (ECG) and echocardiography were done. Left-ventricular ejection fraction was measurable in 1467 (89.5%) participants by the biplane Simpson's rate method. Findings The mean left-ventricular ejection fraction was 47.3%. The prevalence of definite left-ventricular systolic dysfunction (defined as a left-ventricular ejection fraction less than or equal to 30%) was 2.9% overall (43 participants); it increased with age and was higher in men than in women (4.0 vs 2.0%). The left-ventricular systolic dysfunction was symptomatic in 1.5% of participants and asymptomatic in 1.4%. 83% of participants with left-ventricular systolic dysfunction had evidence of ischaemic heart disease (IHD) from history or ECG criteria compared with 21% of those without this abnormality (p<0.001). Hypertension was also more common in those with left-ventricular systolic dysfunction (72 vs 38%, p<0.001), but there was no difference between those with and without left-ventricular systolic dysfunction in the rate of hypertension without IHD. Interpretation Left-ventricular systolic dysfunction was at least twice as common as symptomatic heart failure defined by clinical criteria. The main risk factors are IHD and hypertension in the presence of IHD; screening of such high-risk groups for left-ventricular systolic dysfunction should be considered.	UNIV GLASGOW,WESTERN INFIRM,MRC,CLIN RES INITIAT HEART FAILURE,GLASGOW G11 6NT,LANARK,SCOTLAND; GLASGOW ROYAL INFIRM,SCOTTISH MONICA PROJECT,GLASGOW G4 0SF,LANARK,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DUNDEE DD1 9SY,SCOTLAND; UNIV GLASGOW,ROBERTSON CTR BIOSTAT,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow; University of Dundee; University of Glasgow	McDonagh, TA (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT CARDIOL,GLASGOW G11 6NT,LANARK,SCOTLAND.		Ford, Ian/ABE-6145-2020; mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				BONNEUX L, 1994, AM J PUBLIC HEALTH, V84, P20, DOI 10.2105/AJPH.84.1.20; Clarke KW, 1995, J PUBLIC HEALTH MED, V17, P459; *CONSENSUS TRIAL S, 1987, NEW ENGL J MED, V316, P1429; COSTANZO MR, 1995, CIRCULATION, V92, P3593, DOI 10.1161/01.CIR.92.12.3593; ERIKSSON H, 1989, EUR HEART J, V10, P647, DOI 10.1093/oxfordjournals.eurheartj.a059542; FLETCHER CM, 1959, BMJ-BRIT MED J, V2, P257, DOI 10.1136/bmj.2.5147.257; GARDIN JM, 1995, CIRCULATION, V91, P1739, DOI 10.1161/01.CIR.91.6.1739; GHJALI JK, 1990, ARCH INTERN MED, V150, P769; GIBSON TC, 1966, J CHRON DIS, V19, P141, DOI 10.1016/0021-9681(66)90045-2; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; KOSTIS JB, 1995, AM J HYPERTENS, V8, P909, DOI 10.1016/0895-7061(95)00156-J; LAUER MS, 1992, AM J CARDIOL, V70, P1180, DOI 10.1016/0002-9149(92)90052-Z; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Mair FS, 1996, BRIT J GEN PRACT, V46, P77; MCKEE PA, 1971, NEW ENGL J MED, V285, P781; MCMURRAY J, 1993, EUR HEART J, V14, P1158, DOI 10.1093/eurheartj/14.9.1158; PARAMESHWAR J, 1992, BRIT J GEN PRACT, V42, P287; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROSE GA, WHO MONOGRAPH SERIES, V56; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; SMITH WCS, 1990, J CLIN EPIDEMIOL, V43, P637, DOI 10.1016/0895-4356(90)90033-L; *SOLVD INV, 1991, NEW ENGL J MED, V325, P293; *SOLVD INV, 1992, NEW ENGL J MED, V327, P685; *TASK FORC HEART F, 1995, EUR HEART J, V16, P741; TEERLINK JR, 1991, AM HEART J, V121, P1852, DOI 10.1016/0002-8703(91)90072-P; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Vasan RS, 1997, NEW ENGL J MED, V336, P1350, DOI 10.1056/NEJM199705083361903; WHEELDON NM, 1993, Q J MED, V86, P17	30	453	466	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					829	833		10.1016/S0140-6736(97)03033-X	http://dx.doi.org/10.1016/S0140-6736(97)03033-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310600				2022-12-01	WOS:A1997XX40100008
J	Starks, CM; Back, KW; Chappell, J; Noel, JP				Starks, CM; Back, KW; Chappell, J; Noel, JP			Structural basis for cyclic terpene biosynthesis by tobacco 5-epi-aristolochene synthase	SCIENCE			English	Article							SESQUITERPENE CYCLASE; TAXADIENE SYNTHASE; TAXOL BIOSYNTHESIS; DITERPENE CYCLASE; EXPRESSION; CATALYZES; ALGORITHM; BIOLOGY; MODELS; STEP	Terpene cyclases catalyze the synthesis of cyclic terpenes with 10-, 15-, and 20-carbon acyclic isoprenoid diphosphates as substrates. Plants have been a source of these natural products by providing a homologous set of terpene synthases. The crystal structures of 5-epi-aristolochene synthase, a sesquiterpene cyclase from tobacco, alone and complexed separately with two farnesyl diphosphate analogs were analyzed. These structures reveal an unexpected enzymatic mechanism for the synthesis of the bicyclic product, 5-epi-aristolochene, and provide a basis for understanding the stereochemical selectivity displayed by other cyclases in the biosynthesis of pharmacologically important cyclic terpenes. As such, these structures provide templates for the engineering of novel terpene cyclases.	SALK INST BIOL STUDIES,STRUCT BIOL LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV KENTUCKY,BIOCHEM & MOL BIOL PROGRAM,LEXINGTON,KY 40546	Salk Institute; University of California System; University of California San Diego; University of Kentucky			Noel, Joseph P/A-9459-2009		NIGMS NIH HHS [GM54029, GM07240] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054029] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDULLAH MI, 1990, HETEROCYCLES, V30, P317; ALESHIN AE, 1994, J MOL BIOL, V238, P575, DOI 10.1006/jmbi.1994.1316; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BACK KC, UNPUB; BACK KW, 1994, ARCH BIOCHEM BIOPHYS, V315, P527, DOI 10.1006/abbi.1994.1533; Back KW, 1996, P NATL ACAD SCI USA, V93, P6841, DOI 10.1073/pnas.93.13.6841; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BISWAS KM, 1989, J CHEM SOC P1, V11, P1981; BORMAN S, 1996, CHEM ENG NEWS   0701, P27; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P187; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; Cane DE, 1996, BIOCHEMISTRY-US, V35, P12369, DOI 10.1021/bi961344y; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CHAPPELL J, 1995, PLANT PHYSIOL, V107, P1, DOI 10.1145/224057.224059; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GUEDES MEM, 1982, PHYTOCHEMISTRY, V21, P2987, DOI 10.1016/0031-9422(80)85086-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; Lin XY, 1996, BIOCHEMISTRY-US, V35, P2968, DOI 10.1021/bi9526239; Morse MA, 1996, CANCER LETT, V104, P211, DOI 10.1016/0304-3835(96)04252-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1991, CCP4 SERC DAR LAB; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201	31	551	596	2	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1815	1820		10.1126/science.277.5333.1815	http://dx.doi.org/10.1126/science.277.5333.1815			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295271				2022-12-01	WOS:A1997XX29800045
J	Wortley, PM; Fleming, PL				Wortley, PM; Fleming, PL			AIDS in women in the United States - Recent trends	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS DRUG-USERS; CRACK COCAINE USE; NEW-YORK-CITY; HIV-INFECTION; RISK-FACTORS; SAN-FRANCISCO; CONDOM USE; EPIDEMIC; BEHAVIOR	Context.-The effect of the acquired immunodeficiency syndrome (AIDS) epidemic Objective.-To describe AIDS incidence trends in women. Design.-We analyzed national surveillance data on women 13 years of age and older with AIDS reported through June 1996. Data were adjusted for reporting delay, unreported risk, and the 1993 change in AIDS surveillance case definition to assess overall trends and examine trends by age group and birth cohort. Setting.-Surveillance conducted by the Centers for Disease Control and Prevention in collaboration with state and local health departments. Results.-In 1995, women accounted for 19% of AIDS cases in adults; AIDS incidence rates per 100 000 women were highest in black women (50.1), women in the Northeast (22.3), heterosexual contacts (5.5), and women living in metropolitan statistical areas with more than 1 million residents (15.9). Greatest increases in rates between 1991 and 1995 by region and mode of transmission were in the South and in heterosexual contacts. Greatest increases in AIDS incidence rates were observed in heterosexually infected women born between 1970 and 1974, ie, women who were 14 to 18 years old in 1988. Conclusions.-These trends predict continued growth of the number of AIDS cases in women, especially in those in the South and those infected heterosexually, and suggest that successive cohorts or young women may be at risk for human immunodeficiency virus infection as they reach adolescence and young adulthood. Prevention programs must reach young women before they initiate sexual activity and drug use.			Wortley, PM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HIV STD & TB PREVENT, DIV HIV AIDS PREVENT, ATLANTA, GA 30333 USA.							*A GUTTM I, 1994, SEX AM TEEN; BACCHETTI P, 1991, BIOMETRICS, V47, P947, DOI 10.2307/2532651; BATTJES RJ, 1994, AIDS, V8, P681, DOI 10.1097/00002030-199405000-00016; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; CDC, 1991, MMWR-MORBID MORTAL W, V40, P314; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P323; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P151; *CDCP, 1996, HIV AIDS SURV REP, P8; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P121; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; Chu SY, 1996, OBSTET GYNECOL, V87, P195, DOI 10.1016/0029-7844(95)00399-1; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DIAZ T, 1993, JAMA-J AM MED ASSOC, V269, P2845, DOI 10.1001/jama.1993.03500220031012; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; Guinan M E, 1995, J Am Med Womens Assoc (1972), V50, P74; Gwinn M, 1996, CLIN OBSTET GYNECOL, V39, P292, DOI 10.1097/00003081-199606000-00005; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HEWITT M, 1989, DEFINING RURAL AREAS, P1; HSER YI, 1987, AM J DRUG ALCOHOL AB, V13, P231, DOI 10.3109/00952998709001512; HU DJ, 1994, ARCH INTERN MED, V154, P654, DOI 10.1001/archinte.154.6.654; JARLAIS DCD, 1994, JAMA-J AM MED ASSOC, V271, P121, DOI 10.1001/jama.271.2.121; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KARON JM, 1991, J ACQ IMMUN DEF SYND, V4, P1179; KARON JM, 1993, PROJECTIONS NUMBERS; KARON JM, 1989, MATH STATISTICAL APP, P58; KARON JM, 1993, IN PRESS J ACQUIR IM; KLEVENS RM, 1996, P 11 INT C AIDS JUL; Males M, 1996, AM J PUBLIC HEALTH, V86, P565, DOI 10.2105/AJPH.86.4.565; MICHAEL RT, 1994, SEX AM DEFINITIVE SU, P42; MILLER K, IN PRESS FAM PLANN P; *NAT CTR HLTH STAT, 1994, BIRTHS TEEN MOMS AG; NOVICK DM, 1989, J MED VIROL, V29, P181, DOI 10.1002/jmv.1890290307; NWANYANWU OC, 1993, AM J DRUG ALCOHOL AB, V19, P399, DOI 10.3109/00952999309001630; OTTEN MW, 1994, AIDS, V8, P549, DOI 10.1097/00002030-199404000-00020; Paone D, 1995, J Am Med Womens Assoc (1972), V50, P109; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; SCHMID GP, 1987, JAMA-J AM MED ASSOC, V258, P3265, DOI 10.1001/jama.258.22.3265; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SINGH BK, 1993, INT J ADDICT, V28, P735, DOI 10.3109/10826089309062170; *US BUR CENS, 1990 1994 STAT POP E; *US BUR CENS, APR 1 90 JUL 1 94 CO; VANICHSENI S, 1993, AIDS, V7, P887, DOI 10.1097/00002030-199306000-00020; WATTERS JK, 1994, J ACQ IMMUN DEF SYND, V7, P1276; Webster Linda A., 1993, Morbidity and Mortality Weekly Report, V42, P13; Webster Linda A., 1993, Morbidity and Mortality Weekly Report, V42, P1	51	135	138	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					911	916		10.1001/jama.278.11.911	http://dx.doi.org/10.1001/jama.278.11.911			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302243				2022-12-01	WOS:A1997XV64000029
J	Huber, AH; Nelson, WJ; Weis, WI				Huber, AH; Nelson, WJ; Weis, WI			Three-dimensional structure of the armadillo repeat region of beta-catenin	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; CELL-ADHESION MOLECULE; E-CADHERIN; XENOPUS EMBRYOS; ALPHA-CATENIN; ANOMALOUS DIFFRACTION; NUCLEAR-LOCALIZATION; CYTOPLASMIC DOMAIN	beta-catenin is essential for cadherin-based cell adhesion and Wnt/Wingless growth factor signaling. In these roles, it binds to cadherins, Tcf-family transcription factors, and the tumor suppressor gene product Adenomatous Polyposis Coli (APC). A core region of beta-catenin, composed of 12 copies of a 42 amino acid sequence motif known as an armadillo repeat, mediates these interactions. The three-dimensional structure of a protease-resistant fragment of beta-catenin containing the armadillo repeat region has been determined. The 12 repeats form a superhelix of helices that features a long, positively charged groove. Although unrelated in sequence, the beta-catenin binding regions of cadherins, Tcfs, and APC are acidic and are proposed to interact with this groove.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, STANFORD, CA 94305 USA	Stanford University; Stanford University			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150				Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hirschl D, 1996, FEBS LETT, V383, P31, DOI 10.1016/0014-5793(96)00215-3; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNIGHT S, 1989, THESIS SWEDISH U AGR; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nicholls A., 1992, GRASP GRAPHICAL REPR; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TUNNISSEN AMW, 1994, NATURE, V467, P750; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	57	552	575	0	22	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					871	882		10.1016/S0092-8674(00)80352-9	http://dx.doi.org/10.1016/S0092-8674(00)80352-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298899	Bronze			2022-12-01	WOS:A1997XV56300008
J	Aksentijevich, I; Centola, M; Deng, ZM; Sood, R; Balow, JE; Wood, G; Zaks, N; Mansfield, E; Chen, X; Eisenberg, S; Vedula, A; Shafran, N; Raben, N; Pras, E; Pras, M; Kastner, DL; Blake, T; Baxevanis, AD; Robbins, C; Krizman, D; Collins, FS; Liu, PP; Chen, XG; Shohat, M; Hamon, M; Kahan, T; Cercek, A; Rotter, JI; FischelGhodsian, N; Richards, N; Shelton, DA; Gumucio, D; Yokoyama, Y; Mangelsdorf, M; Orsborn, A; Richards, RI; Ricke, DO; Buckingham, JM; Moyzis, RK; Deaven, LL; Doggett, NA				Aksentijevich, I; Centola, M; Deng, ZM; Sood, R; Balow, JE; Wood, G; Zaks, N; Mansfield, E; Chen, X; Eisenberg, S; Vedula, A; Shafran, N; Raben, N; Pras, E; Pras, M; Kastner, DL; Blake, T; Baxevanis, AD; Robbins, C; Krizman, D; Collins, FS; Liu, PP; Chen, XG; Shohat, M; Hamon, M; Kahan, T; Cercek, A; Rotter, JI; FischelGhodsian, N; Richards, N; Shelton, DA; Gumucio, D; Yokoyama, Y; Mangelsdorf, M; Orsborn, A; Richards, RI; Ricke, DO; Buckingham, JM; Moyzis, RK; Deaven, LL; Doggett, NA			Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN SECONDARY STRUCTURE; SHORT ARM; EXPRESSION; CLONING; FINGER; IDENTIFICATION; CHROMOSOME-16; EVOLUTIONARY; AMYLOIDOSIS	Familial Mediterranean fever (FMF) is a recessively inherited disorder characterized by dramatic episodes of fever and serosal inflammation. This report describes the cloning of the gene likely to cause FMF from a 115-kb candidate interval on chromosome 16p. Three different missense mutations were identified in affected individuals, but not in normals. Haplotype and mutational analyses disclosed ancestral relationships among carrier chromosomes in populations that have been separated for centuries. The novel gene encodes a 3.7-kb transcript that is almost exclusively expressed in granulocytes. The predicted protein, pyrin, is a member of a family of nuclear factors homologous to the Ro52 autoantigen. The cloning of the FMF gene promises to shed light on the regulation of acute inflammatory responses.	NIAMSD, ARTHRIT & RHEUMATISM BRANCH, BETHESDA, MD 20892 USA; CHAIM SHEBA MED CTR, HELLER INST MED RES, DEPT MED C, IL-52621 TEL HASHOMER, ISRAEL; NHGRI, CANC GENET LAB, BETHESDA, MD 20892 USA; NHGRI, LAB GENE TRANSFER, BETHESDA, MD 20892 USA; NHGRI, GENOME TECHNOL BRANCH, BETHESDA, MD 20892 USA; CEDARS SINAI MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90048 USA; CEDARS SINAI MED CTR, DEPT MED GENET, LOS ANGELES, CA 90048 USA; BEILINSON MED CTR, DEPT MED GENET, IL-49100 PETAH TIQWA, ISRAEL; UNIV MICHIGAN, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; ADELAIDE WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOL GENET, ADELAIDE, SA 5006, AUSTRALIA; LOS ALAMOS NATL LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Cedars Sinai Medical Center; Cedars Sinai Medical Center; Rabin Medical Center; University of Michigan System; University of Michigan; Womens & Childrens Hospital Australia; United States Department of Energy (DOE); Los Alamos National Laboratory			Hamon, Melanie/B-3501-2013; Mangelsdorf, Marie E/A-2318-2013; Aksentijevich, Ivona/AAF-1335-2019; Liu, Paul/A-7976-2012; Richards, Robert/ABE-6423-2020	Mangelsdorf, Marie E/0000-0002-7855-7701; Liu, Paul/0000-0002-6779-025X; Baxevanis, Andy/0000-0002-5370-0014; Richards, Robert Ian/0000-0002-5978-6453; Hamon, Melanie/0000-0001-5078-4083				AISEN PS, 1985, P NATL ACAD SCI USA, V82, P1232, DOI 10.1073/pnas.82.4.1232; AKSENTIJEVICH I, 1993, AM J HUM GENET, V53, P644; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BALOW JE, 1997, IN PRESS GENOMICS; BARAKAT MH, 1988, LANCET, V2, P1280; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; Dackowski WR, 1996, GENOME RES, V6, P515, DOI 10.1101/gr.6.6.515; DANIELS M, 1995, AM J MED GENET, V55, P311, DOI 10.1002/ajmg.1320550313; DOGGETT NA, 1995, NATURE, V377, P335; FRENCH FMF, 1996, AM J HUM GENET, V59, P603; GERTZ MA, 1987, MAYO CLIN PROC, V62, P1095, DOI 10.1016/S0025-6196(12)62502-6; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Henry J, 1997, BIOCHEM BIOPH RES CO, V235, P162, DOI 10.1006/bbrc.1997.6751; ITOH K, 1991, J CLIN INVEST, V87, P177, DOI 10.1172/JCI114968; JACK LJW, 1990, J BIOL CHEM, V265, P14481; KARENKO L, 1992, J INTERN MED, V232, P365, DOI 10.1111/j.1365-2796.1992.tb00600.x; KASTNER DL, 1996, RTHRITIS ALLIED COND, P1279; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Levy EN, 1996, AM J HUM GENET, V58, P523; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PRAS E, 1994, HUM GENET, V94, P576; PRAS E, 1992, NEW ENGL J MED, V326, P1509, DOI 10.1056/NEJM199206043262301; PRAS E, 1997, IN PRESS AM J MED GE; PRAS M, 1982, JOHNS HOPKINS MED J, V150, P22; PTACEK LJ, 1991, CELL, V67, P1021; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SHOHAT M, 1992, AM J HUM GENET, V51, P1349; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; Sood R, 1996, CYTOGENET CELL GENET, V72, P21; Sood R, 1997, GENOMICS, V42, P83, DOI 10.1006/geno.1997.4629; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; VERNET C, 1993, J MOL EVOL, V37, P600; WEATHERALL DJ, 1995, METABOLIC MOL BASES, P3417; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2; YUVAL Y, 1995, AM J MED GENET, V57, P455, DOI 10.1002/ajmg.1320570319	48	1135	1181	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					797	807						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288758				2022-12-01	WOS:A1997XT06600022
J	Kaghad, M; Bonnet, H; Yang, A; Creancier, L; Biscan, JC; Valent, A; Minty, A; Chalon, P; Lelias, JM; Dumont, X; Ferrara, P; McKeon, F; Caput, D				Kaghad, M; Bonnet, H; Yang, A; Creancier, L; Biscan, JC; Valent, A; Minty, A; Chalon, P; Lelias, JM; Dumont, X; Ferrara, P; McKeon, F; Caput, D			Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers	CELL			English	Article							TUMOR-SUPPRESSOR GENES; N-MYC AMPLIFICATION; WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; PROTEIN; CARCINOMA; MUTATIONS; GROWTH; RETINOBLASTOMA	We describe a gene encoding p73, a protein that shares considerable homology with the tumor suppressor p53. p73 maps to 1p36, a region frequently deleted in neuroblastoma and other tumors and thought to contain multiple tumor suppressor genes. Our analysis of neuroblastoma cell lines with Ip and p73 loss of heterozygosity failed to detect coding sequence mutations in remaining p73 alleles. However, the demonstration that p73 is monoallelically expressed supports the notion that it is a candidate gene in neuroblastoma. p73 also has the potential to activate p53 target genes and to interact with p53. We propose that the disregulation of p73 contributes to tumorigenesis and that p53-related proteins operate in a network of developmental and cell cycle controls.	SANOFI RECH,F-31676 LABEGE,FRANCE; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; INST GUSTAVE ROUSSY,URA 1967 CNRS,LAB CYTOGENET & GENET ONCOL,VILLEJUIF,FRANCE	Sanofi-Aventis; Sanofi France; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								AMBROS PF, 1995, EUR J CANCER, V31A, P510, DOI 10.1016/0959-8049(95)00044-J; AMLER LC, 1995, EUR J CANCER, V31A, P527, DOI 10.1016/0959-8049(95)00064-P; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHENG NC, 1995, ONCOGENE, V10, P291; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; GENUARDI M, 1989, AM J HUM GENET, V45, P73; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huttner WB, 1997, CURR OPIN NEUROBIOL, V7, P29, DOI 10.1016/S0959-4388(97)80117-1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAUREYS G, 1995, EUR J CANCER, V31A, P523, DOI 10.1016/0959-8049(95)00012-8; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LIN J, 1994, COLD SPRING HARB SYM, V59, P215, DOI 10.1101/SQB.1994.059.01.026; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANIATIS T, 1992, MOL CLONING; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SOZZI G, 1988, CANCER GENET CYTOGEN, V30, P151, DOI 10.1016/0165-4608(88)90104-5; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEMESS BA, 1990, SCIENCE, V248, P76; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; YEH SH, 1994, CANCER RES, V54, P4188; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	59	1474	1612	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					809	819		10.1016/S0092-8674(00)80540-1	http://dx.doi.org/10.1016/S0092-8674(00)80540-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288759	Bronze			2022-12-01	WOS:A1997XT06600023
J	Katan, MB; Grundy, SM; Willett, WC				Katan, MB; Grundy, SM; Willett, WC			Beyond low-fat diets	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RANDOMIZED TRIAL; LIPOPROTEINS; ACIDS; WOMEN; CHOLESTEROL		UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard T.H. Chan School of Public Health	Katan, MB (corresponding author), AGR UNIV WAGENINGEN, DIV HUMAN NUTR & EPIDEMIOL, BOMENWEG 2, NL-6703 HD WAGENINGEN, NETHERLANDS.							BLACK HS, 1994, NEW ENGL J MED, V330, P1272, DOI 10.1056/NEJM199405053301804; ERNST N, 1980, CIRCULATION, V62, P41; GRUNDY SM, 1986, NEW ENGL J MED, V314, P745, DOI 10.1056/NEJM198603203141204; HYEWON LH, 1988, AM J CLIN NUTR, V48, P575, DOI 10.1093/ajcn/48.3.575; JEFFERY RW, 1995, INT J OBESITY, V19, P132; KASIM SE, 1993, AM J CLIN NUTR, V57, P146, DOI 10.1093/ajcn/57.2.146; KEYS A, 1957, LANCET, V2, P959; MENSINK RP, 1987, LANCET, V1, P122, DOI 10.1016/S0140-6736(87)91965-9; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; *NAT DIET HEART ST, 1968, CIRCULATION S1, V37, P170; SACKS RM, 1994, J CARDIOVASC RISK, V1, P3; SHEPPARD L, 1991, AM J CLIN NUTR, V54, P821, DOI 10.1093/ajcn/54.5.821; Vega GL, 1996, CURR OPIN LIPIDOL, V7, P209, DOI 10.1097/00041433-199608000-00007; Willett Walter C., 1997, P559; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; WILLETT WC, IN PRESS AM J CLIN N	16	206	209	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					563	566						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262504				2022-12-01	WOS:A1997XR54800012
J	Rye, HS; Burston, SG; Fenton, WA; Beechem, JM; Xu, ZH; Sigler, PB; Horwich, AL				Rye, HS; Burston, SG; Fenton, WA; Beechem, JM; Xu, ZH; Sigler, PB; Horwich, AL			Distinct actions of cis and trans ATP within the double ring of the chaperonin GroEL	NATURE			English	Article							PROTEIN; CYCLE; CARBOXYLASE; MECHANISM; INTENSITY; RELEASE; BINDING; DOMAIN	The chaperonin GroEL is a double-ring structure with a central cavity in each ring that provides an environment for the efficient folding of proteins(1-3) when capped by the co-chaperone GroES in the presence of adenine nucleotides(4-8). Productive folding of the substrate rhodanese has been observed in cis ternary complexes, where GroES and polypeptide are bound to the same ring, formed with either ATP, ADP or non-hydrolysable ATP analogues(2,9), suggesting that the specific requirement for ATP is confined to an action in the trans ring that evicts GroES and polypeptide from the cis side(9). We show here, however, that for the folding of malate dehydrogenase and Rubisco there is also an absolute requirement for ATP in the cis ring, as ADP and AMP-PNP are unable to promote folding. We investigated the specific roles of binding and hydrolysis of ATP in the cis and trans rings using mutant forms of GroEL that bind ATP but are defective in its hydrolysis. Binding of ATP and GroES in cis initiated productive folding inside a highly stable GroEL-ATP-GroES complex. To discharge GroES and polypeptide, ATP hydrolysis in the cis ring was required to form a GroEL-ADP-GroES complex with decreased stability, priming the cis complex for release by ATP binding (without hydrolysis) in the trans ring. These observations offer an explanation of why GroEL functions as a double-ring complex.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; VANDERBILT UNIV,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Vanderbilt University				Rye, Hays/0000-0002-9420-3137; Burston, Steven/0000-0003-1848-1853				BEECHEM JM, 1995, BIOCHEMISTRY-US, V34, P13943, DOI 10.1021/bi00042a028; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ETFINK MR, 1994, BIOPHYS J, V66, P482; Fenton WA, 1997, PROTEIN SCI, V6, P743; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; PIERCE J, 1986, ARCH BIOCHEM BIOPHYS, V245, P483, DOI 10.1016/0003-9861(86)90241-9; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	24	348	350	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					792	798		10.1038/42047	http://dx.doi.org/10.1038/42047			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285593	Bronze			2022-12-01	WOS:A1997XR66700055
J	Beller, M; Ellis, A; Lee, SH; Drebot, MA; Jenkerson, SA; Funk, E; Sobsey, MD; Simmons, OD; Monroe, SS; Ando, T; Noel, J; Petric, M; Middaugh, JP; Spika, JS				Beller, M; Ellis, A; Lee, SH; Drebot, MA; Jenkerson, SA; Funk, E; Sobsey, MD; Simmons, OD; Monroe, SS; Ando, T; Noel, J; Petric, M; Middaugh, JP; Spika, JS			Outbreak of viral gastroenteritis due to a contaminated well - International consequences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ROUND STRUCTURED VIRUS; REVERSE TRANSCRIPTION-PCR; NORWALK-LIKE VIRUSES; HOSPITAL OUTBREAK; AIRBORNE TRANSMISSION; SRSV GASTROENTERITIS; WATER-SYSTEM; CRUISE SHIP; ABOARD; EPIDEMIOLOGY	Context.-Small round-structured viruses (SRSVs) are known to cause viral gastroenteritis, but until now have not been confirmed in the implicated Vehicle in outbreaks. Objective.-Investigation of a gastroenteritis outbreak. Design.-After applying epidemiologic methods to locate the outbreak source, we conducted environmental and laboratory investigations to elucidate the cause. Setting.-Tourists traveling by bus through Alaska and the Yukon Territory of Canada. Participants.-Staff of a restaurant at a business complex implicated as the outbreak source, convenience sample of persons on buses that had stopped there, and bus employees. Main Outcome Measures.-Odds ratios (ORs) for illness associated with exposures. Water samples from the restaurant and stool specimens from tourists and restaurant staff were examined by nucleic acid amplification using reverse transcription polymerase chain reaction and sequencing of viral amplification products. Results.-The itineraries of groups of tourists manifesting vomiting or diarrhea were traced back to a restaurant where buses had stopped 33 to 36 hours previously, Water consumption was associated with illness (OR, 5.3; 95% confidence interval [CI], 2.3-12.6). Eighteen of 26 employees of the business complex were ill; although not the index case, an employee ill shortly before the outbreak lived in a building connected to a septic pit, which was found to contaminate the well supplying the restaurant's water, Genotype 2/P2B SRSV was identified in stool specimens of 2 tourists and 1 restaurant employee. Stools and water samples yielded identical amplification product sequences. Conclusions.-The investigation documented SRSVs in a vehicle epidemiologically linked to a gastroenteritis outbreak. The findings demonstrate the power of molecular detection and identification and underscore the importance of fundamental public health practices such as restaurant inspection, assurance of a safe water supply, and disease surveillance.	LAB CTR DIS CONTROL,BUR DIS SURVEILLANCE & FIELD EPIDEMIOL,OTTAWA,ON K1A 0L2,CANADA; NATL CTR ENTEROVIRUSES,HALIFAX,NS,CANADA; CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,NATL CTR INFECT DIS,ATLANTA,GA; UNIV N CAROLINA,SCH PUBL HLTH,DEPT ENVIRONM SCI & ENGN,CHAPEL HILL,NC 27599; HOSP SICK CHILDREN,DEPT MICROBIOL,VIROL LAB,TORONTO,ON M5G 1X8,CANADA; LAB CTR DIS CONTROL,BUR INFECT DIS,OTTAWA,ON K1A 0L2,CANADA	Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Beller, M (corresponding author), ALASKA DEPT HLTH & SOCIAL SERV,DIV PUBL HLTH,POB 240249,ANCHORAGE,AK 99524, USA.			Monroe, Stephan/0000-0002-5424-716X				ANDO T, 1995, J MED VIROL, V47, P145, DOI 10.1002/jmv.1890470207; ANDO T, 1995, J CLIN MICROBIOL, V33, P64, DOI 10.1128/JCM.33.1.64-71.1995; CANNON RO, 1991, J INFECT DIS, V164, P860, DOI 10.1093/infdis/164.5.860; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P446; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P37; CHADWICK PR, 1994, LANCET, V343, P171, DOI 10.1016/S0140-6736(94)90959-8; CHADWICK PR, 1994, J HOSP INFECT, V26, P251, DOI 10.1016/0195-6701(94)90015-9; CHALMERS JWT, 1995, EPIDEMIOL INFECT, V115, P163, DOI 10.1017/S0950268800058222; DINGLE KE, 1995, J GEN VIROL, V76, P2349, DOI 10.1099/0022-1317-76-9-2349; DREBOT MA, 1994, J MED VIROL, V44, P340, DOI 10.1002/jmv.1890440406; DREBOT MA, IN PRESS BIOTECHNIQU; FLEISSNER ML, 1989, AM J EPIDEMIOL, V129, P165, DOI 10.1093/oxfordjournals.aje.a115105; GELLERT GA, 1990, INFECT CONT HOSP EP, V11, P459; GOODMAN RA, 1982, ARCH ENVIRON HEALTH, V37, P358, DOI 10.1080/00039896.1982.10667591; HO MS, 1989, LANCET, V2, P961; KAPIKIAN AZ, 1996, FIELDS VIROLOGY, P783; KAPLAN JE, 1982, J INFECT DIS, V146, P190, DOI 10.1093/infdis/146.2.190; KHAN AS, 1994, J CLIN MICROBIOL, V32, P318, DOI 10.1128/JCM.32.2.318-322.1994; KOBAYASHI S, 1991, EPIDEMIOL INFECT, V107, P81, DOI 10.1017/S0950268800048706; KOHN MA, 1995, JAMA-J AM MED ASSOC, V273, P466, DOI 10.1001/jama.273.6.466; LAWSON HW, 1991, LANCET, V337, P1200, DOI 10.1016/0140-6736(91)92868-3; Levett PN, 1996, J CLIN MICROBIOL, V34, P1497, DOI 10.1128/JCM.34.6.1497-1501.1996; LO SV, 1994, EPIDEMIOL INFECT, V113, P513, DOI 10.1017/S0950268800068527; MCANULTY JM, 1993, AUST J PUBLIC HEALTH, V17, P86; Morgan D, 1994, Commun Dis Rep CDR Rev, V4, pR91; NELSON M, 1992, J ENVIRON HEALTH, V54, P50; PATTERSON T, 1993, EPIDEMIOL INFECT, V111, P157, DOI 10.1017/S0950268800056776; Perrett K, 1995, Commun Dis Rep CDR Rev, V5, pR153; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; SCHWAB KJ, 1995, APPL ENVIRON MICROB, V61, P531, DOI 10.1128/AEM.61.2.531-537.1995; SHARP TW, 1995, J MED VIROL, V45, P61, DOI 10.1002/jmv.1890450112; SOBSEY MD, 1979, APPL ENVIRON MICROB, V37, P588, DOI 10.1128/AEM.37.3.588-595.1979; SOBSEY MD, 1994, RAPID METHODS AND AUTOMATION IN MICROBIOLOGY AND IMMUNOLOGY, P387; STEVENSON P, 1994, J HOSP INFECT, V26, P261, DOI 10.1016/0195-6701(94)90016-7; TREANOR J, 1995, PRINCIPLES PRACTICE, P1666; WARNER RD, 1991, ARCH INTERN MED, V151, P2419, DOI 10.1001/archinte.151.12.2419; WILSON R, 1982, AM J PUBLIC HEALTH, V72, P72, DOI 10.2105/AJPH.72.1.72; 1994, COMMUN DIS REP CDR W, V4, P43	39	140	145	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					563	568		10.1001/jama.278.7.563	http://dx.doi.org/10.1001/jama.278.7.563			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268277				2022-12-01	WOS:A1997XQ98600030
J	Mouzin, E; Mascola, L; Tormey, MP; Dassey, DE				Mouzin, E; Mascola, L; Tormey, MP; Dassey, DE			Prevention of Vibrio vulnificus infections - Assessment of regulatory educational strategies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Vibrio vulnificus-related disease caused by eating contaminated raw oysters prompted California to implement regulatory educational initiatives in 1991. Objective.-To assess California guidelines and education efforts with regard to the prevention of V vulnificus infections in Los Angeles County and to evaluate compliance with state regulations mandating posting of warning signs concerning risks of eating raw oysters. Design.-Review of epidemiologic investigations of V vulnificus infections in Los Angeles County between 1993 and 1995; telephone interviews of patients or surrogates; and a survey of restaurants serving raw oysters in Los Angeles County. Setting-General community. Main Outcome Measures.-Prior warning of patients and posting of warning signs in restaurants. Results.-Recent cases of V vulnificus infections in Los Angeles County suggest that a unique, vulnerable group (uninsured Hispanic men with viral or alcoholic liver disease) has not been reached through education efforts. Of a total of 11 cases, information regarding being warned about the hazard of eating raw shellfish was available for 8; of these, only 1 case was reported as having been warned, but he had misunderstood the preventive message. Warning signs were not posted adequately in more than 50% of restaurants surveyed and one third of these establishments had signs in English only. Warnings were never located on dining tables and rarely included in menus. Conclusion.-A more effective strategy is required to prevent V vulnificus infections in Los Angeles County.			Mouzin, E (corresponding author), LOS ANGELES CTY DEPT HLTH SERV,ACUTE COMMUNICABLE DIS CONTROL UNIT,313 N FIGUEROA ST,ROOM 212,LOS ANGELES,CA 90012, USA.							BLAKE PA, 1979, NEW ENGL J MED, V300, P1, DOI 10.1056/NEJM197901043000101; *CA STAT DEP HLTH, 1993, CALIFORNIA MORBIDITY, V31; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P405; Center for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P621; DAYAL HH, 1993, AM J PREV MED, V9, P191, DOI 10.1016/S0749-3797(18)30737-2; FELIX CW, 1995, FOOD PROTECTION REP, V11, P1; JOHNSTON JM, 1985, JAMA-J AM MED ASSOC, V253, P2850, DOI 10.1001/jama.253.19.2850; KELLY MT, 1982, APPL ENVIRON MICROB, V44, P820, DOI 10.1128/AEM.44.4.820-824.1982; OLIVER JD, 1982, MAR TECHNOL SOC J, V25, P49; TACKET CO, 1984, J INFECT DIS, V149, P558, DOI 10.1093/infdis/149.4.558; TAMPLIN M, 1982, APPL ENVIRON MICROB, V44, P1466, DOI 10.1128/AEM.44.6.1466-1470.1982; TUTTLE J, 1994, J TRANSPLANT COORDIN, V4, P60	12	34	34	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					576	578		10.1001/jama.278.7.576	http://dx.doi.org/10.1001/jama.278.7.576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268279				2022-12-01	WOS:A1997XQ98600032
J	Hendry, BM; James, AF				Hendry, BM; James, AF			Endothelin antagonists in renal disease	LANCET			English	Editorial Material											Hendry, BM (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON SE5 9PJ,ENGLAND.							Benigni A, 1996, AM J KIDNEY DIS, V27, P416, DOI 10.1016/S0272-6386(96)90366-2; FIRTH JD, 1995, AM J PHYSIOL-RENAL, V269, pF522, DOI 10.1152/ajprenal.1995.269.4.F522; GELLAI M, 1995, J PHARMACOL EXP THER, V275, P200; Kaddoura S, 1996, LANCET, V348, P418, DOI 10.1016/S0140-6736(05)64531-X; Kohan DE, 1997, AM J KIDNEY DIS, V29, P2, DOI 10.1016/S0272-6386(97)90004-4; Nabokov A, 1996, NEPHROL DIAL TRANSPL, V11, P514; ONG ACM, 1995, KIDNEY INT, V48, P390, DOI 10.1038/ki.1995.307; Parkinson NA, 1996, NEPHROL DIAL TRANSPL, V11, P1532; Weber C, 1996, CLIN PHARMACOL THER, V60, P124, DOI 10.1016/S0009-9236(96)90127-7	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					381	382		10.1016/S0140-6736(05)64131-1	http://dx.doi.org/10.1016/S0140-6736(05)64131-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259650				2022-12-01	WOS:A1997XQ24800006
J	Lovestone, S; Graham, N; Howard, R				Lovestone, S; Graham, N; Howard, R			Guidelines on drug treatments for Alzheimer's disease	LANCET			English	Editorial Material									ROYAL FREE HOSP,DEPT OLD AGE PSYCHIAT,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Lovestone, S (corresponding author), INST PSYCHIAT,OLD AGE PSYCHIAT SECT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.		Lovestone, Simon/E-8725-2010	Lovestone, Simon/0000-0003-0473-4565; Howard, Robert/0000-0002-3071-2338; Livingston, Gill/0000-0001-6741-5516				FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Kelly CA, 1997, BRIT MED J, V314, P693, DOI 10.1136/bmj.314.7082.693; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939	3	59	59	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					232	233		10.1016/S0140-6736(05)62221-0	http://dx.doi.org/10.1016/S0140-6736(05)62221-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242796				2022-12-01	WOS:A1997XM86600005
J	Regnier, CH; Song, HY; Gao, X; Goeddel, DV; Cao, ZD; Rothe, M				Regnier, CH; Song, HY; Gao, X; Goeddel, DV; Cao, ZD; Rothe, M			Identification and characterization of an I kappa B kinase	CELL			English	Article							TUMOR-NECROSIS-FACTOR; DEATH DOMAIN; CYTOPLASMIC DOMAIN; FACTOR RECEPTOR; FACTOR-ALPHA; ACTIVATION; PROTEIN; INTERACTS; FAMILY; CD40	Activation of the transcription factor NF-kappa B by tumor necrosis factor (TNF) and interleukin-1 (IL-1) requires the NF-kappa B-inducing kinase (NIK). In a yeast two-hybrid screen for NIK-interacting proteins, we have identified a protein kinase previously known as CHUK. Overexpression of CHUK activates a NF-kappa B-dependent reporter gene. A catalytically inactive mutant of CHUK is a dominant-negative inhibitor of TNF-, IL-1-, TRAF-, and NIK-induced NF-kappa B activation. CHUK associates with the NF-kappa B inhibitory protein, I kappa B-alpha, in mammalian cells. CHUK specifically phosphorylates I kappa B-alpha on both serine 32 and serine 36, modifications that are required for targeted degradation of I kappa B-alpha via the ubiquitin-proteasome pathway. This phosphorylation of I kappa B-alpha is greatly enhanced by NIK costimulation. Thus, CHUK is a NIK-activated I kappa B-alpha kinase that links TNF- and IL-1-induced kinase cascades to NF-kappa B activation.	TULARIK INC, San Francisco, CA 94080 USA					Regnier, Catherine/0000-0002-4386-1324				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHOI KY, 1994, CELL, V78, P499; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOCK BA, 1995, GENOMICS, V27, P348, DOI 10.1006/geno.1995.1054; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Orth R, 1997, J BIOL CHEM, V272, P8841; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1997, IN PRESS P NATL ACAD; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784	56	1071	1123	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					373	383		10.1016/S0092-8674(00)80344-X	http://dx.doi.org/10.1016/S0092-8674(00)80344-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244310	Bronze			2022-12-01	WOS:A1997XN24900020
J	Medzhitov, R; PrestonHurlburt, P; Janeway, CA				Medzhitov, R; PrestonHurlburt, P; Janeway, CA			A human homologue of the Drosophila Toll protein signals activation of adaptive immunity	NATURE			English	Article							IL-1 RECEPTOR; LEUCINE; DORSAL; EMBRYO; IMMUNOLOGY	Induction of the adaptive immune response depends on the expression of co-stimulatory molecules and cytokines by antigen-presenting cells. The mechanisms that control the initial induction of these signals upon infection are poorly understood. It has been proposed that their expression is controlled by the non-clonal, or innate, component of immunity that preceded in evolution the development of an adaptive immune system in vertebrates(1). We report here the cloning and characterization of a human homologue of the Drosophila toll protein (Toll) which has been shown to induce the innate immune response in adult Drosophila(2-4). Like Drosophila Toll, human Toll is a type I transmembrane protein with an extracellular domain consisting of a leucine-rich repeat (LRR) domain, and a cytoplasmic domain homologous to the cytoplasmic domain of the human interleukin (IL)-1 receptor. Both Drosophila Toll and the IL-1 receptor are known to signal through the NF-kappa B pathway(5-7). We show that a constitutively active mutant of human Toll transfected into human cell lines can induce the activation of NF-kappa B and the expression of NF-kappa B-controlled genes for the inflammatory cytokines IL-1, IL-6 and IL-8, as well as the expression of the co-stimulatory molecule B7.1, which is required for the activation of naive T cells.	HOWARD HUGHES MED INST,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Yale University								ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; INNIS MA, 1992, PCR PROTOCOLS GUIDE; IP YT, 1994, CURR OPIN GENET DEV, V4, P672, DOI 10.1016/0959-437X(94)90133-N; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Medzhitov R, 1996, RES IMMUNOL, V147, P208, DOI 10.1016/0923-2494(96)87222-1; MIYAKE K, 1995, J IMMUNOL, V154, P3333; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; ROSETTO M, 1995, BIOCHEM BIOPH RES CO, V209, P111, DOI 10.1006/bbrc.1995.1477; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WINANS KA, 1995, MOL BIOL CELL, V6, P587, DOI 10.1091/mbc.6.5.587; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	21	3906	4380	11	345	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					394	397		10.1038/41131	http://dx.doi.org/10.1038/41131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237759	Bronze			2022-12-01	WOS:A1997XM52800055
J	Pettitt, DJ; Forman, MR; Hanson, RL; Knowler, WC; Bennett, PH				Pettitt, DJ; Forman, MR; Hanson, RL; Knowler, WC; Bennett, PH			Breastfeeding and incidence of non-insulin-dependent diabetes mellitus in Pima Indians	LANCET			English	Article							FORMULA-FED INFANTS; 1ST YEAR; BREAST; MILK; LIFE	Background Early exposure to cow's milk has been implicated in the occurrence of insulin-dependent diabetes mellitus but there is little information about infant-feeding practices and subsequent non-insulin-dependent diabetes mellitus (NIDDM). We examined the association between breastfeeding and NIDDM in a population with a high prevalence of this disorder, the Pima Indians. Methods Glucose-tolerance status was obtained from a 75 g oral glucose-tolerance test. A standard questionnaire given to mothers was used to classify infant-feeding practices for the first 2 months of life into three groups; exclusively breastfed, some breastfeeding, or exclusively bottlefed. The association between the three infant-feeding groups and NIDDM was analysed by multiple logistic regression. Findings Data were available for 720 Pima Indians aged between 10 and 39 years. 325 people who were Background Early exposure to cow's milk has been implicated in the occurrence of insulin-dependent diabetes mellitus but there is little information about infant-feeding practices and subsequent non-insulin-dependent diabetes mellitus (NIDDM). We examined the association between breastfeeding and NIDDM in a population with a high prevalence of this disorder, the Pima Indians. Methods Glucose-tolerance exclusively bottlefed had significantly higher age-adjusted and sex-adjusted mean relative weights (146%) than 144 people who were exclusively breastfed (140%) or 251 people who had some breastfeeding (139%) (p=0.019), People who were exclusively breastfed had significantly lower rates of NIDDM than those who were exclusively bottlefed in ail age-groups (age 10-19, 0 of 56 vs 6 [3.6%] of 165; age 20-29, 5 [8.6%] of 58 vs 17 [14.7%] of 116]; age 30-39, 6 [20.0%] of 30 vs 13 [29.6%] of 44). The odds ratio for NIDDM in exclusively breastfed people, compared with those exclusively bottlefed, was 0.41 (95% CI 0.18-0.93) adjusted for age, sex, birthdate, parental diabetes, and birthweight. Interpretation Exclusive breastfeeding for the first 2 months of life is associated with a significantly lower rate of NIDDM in Pima Indians. The increase in prevalence of diabetes in some populations may be due to the concomitant decrease in breastfeeding.	NIDDK,PHOENIX EPIDEMIOL & CLIN RES BRANCH,PHOENIX,AZ 85014; NATL CANC INST,CANC PREVENT STUDIES BRANCH,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pettitt, DJ (corresponding author), NIDDK,DIABET & ARTHRIT EPIDEMIOL SECT,PHOENIX,AZ 85014, USA.		Hanson, Robert L/O-3238-2015; Bennett, Peter/AAH-9605-2021	Hanson, Robert L/0000-0002-4252-7068; 				AYNSLEYGREEN A, 1989, BAILLIERE CLIN ENDOC, V3, P837, DOI 10.1016/S0950-351X(89)80056-4; BENNETT PH, 1971, LANCET, V2, P125; BORCHJOHNSEN K, 1984, LANCET, V2, P1083; BROOK CGD, 1972, LANCET, V2, P624; Cavallo MG, 1996, LANCET, V348, P926, DOI 10.1016/S0140-6736(95)12065-3; DEWEY KG, 1992, PEDIATRICS, V89, P1035; DEWEY KG, 1995, J PEDIATR-US, V126, P696, DOI 10.1016/S0022-3476(95)70395-0; EVANS HE, 1979, PEDIATR ANN, V8, P110; FORMAN MR, 1984, AM J EPIDEMIOL, V119, P335, DOI 10.1093/oxfordjournals.aje.a113752; FORMAN MR, 1984, INT J EPIDEMIOL, V13, P447, DOI 10.1093/ije/13.4.447; FORMAN MR, 1982, AM J CLIN NUTR, V35, P1477, DOI 10.1093/ajcn/35.6.1477; Frederick I B, 1984, Obstet Gynecol Annu, V13, P131; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; GrummerStrawn LM, 1996, INT J EPIDEMIOL, V25, P94, DOI 10.1093/ije/25.1.94; HALL B, 1975, LANCET, V1, P779; HAMOSH M, 1988, J PEDIATR GASTR NUTR, V7, P10, DOI 10.1097/00005176-198801000-00004; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JELLIFFE DB, 1966, ASSESSMENT NUTRITION; KARGES W, 1995, MOL MECH MOL ASPECTS, P79; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; KNOWLER WC, 1979, DIABETOLOGIA, V17, P161, DOI 10.1007/BF01219743; KOVAR MG, 1984, PEDIATRICS, V74, P615; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; LUCAS A, 1980, LANCET, V1, P1267; LUCAS A, 1979, LANCET, V2, P57; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; *NAT RES COUNC, 1964, NAT AC SCI PUBL, V1146, P4; PETTITT DJ, 1988, DIABETES, V37, P622, DOI 10.2337/diabetes.37.5.622; SALMENPERA L, 1988, J PEDIATR GASTR NUTR, V7, P651, DOI 10.1097/00005176-198809000-00005; SILVERMAN BL, 1991, DIABETES, V40, P121, DOI 10.2337/diab.40.2.S121; Thorogood M, 1979, J R Coll Gen Pract, V29, P427; *WHO STUD GROUP PR, 1994, WHO TECHN REP SER, V844; Wright P, 1981, Health Bull (Edinb), V39, P197	34	190	194	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					166	168		10.1016/S0140-6736(96)12103-6	http://dx.doi.org/10.1016/S0140-6736(96)12103-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250183				2022-12-01	WOS:A1997XL72200010
J	Tichonova, L; Borisenko, K; Ward, H; Meheus, A; Gromyko, A; Renton, A				Tichonova, L; Borisenko, K; Ward, H; Meheus, A; Gromyko, A; Renton, A			Epidemics of syphilis in the Russian Federation: Trends, origins, and priorities for control	LANCET			English	Article							SEXUALLY-TRANSMITTED DISEASES; INFECTION	After continuous decline throughout the 1980s, surveillance-defined estimates of the incidence of syphilis in Russia have shown a rapid and substantial increase during the 1990s. The reasons for this epidemic are unclear, but must be sought among changes both in sexual behaviour and in the patterns of provision, use, and effectiveness of diagnostic, treatment, and contact tracing services. High incidence of sexually transmitted disease causes correspondingly high levels of morbidity and suffering as well as significant health-care and other economic costs. Our current understanding suggests that the transmissibility of HIV is increased by infection with sexually transmitted disease. The syphilis epidemic together with changes in sexual behaviour, increased travel and migration, and rapid increases in injecting drug use may create the conditions for an epidemic of sexually acquired HIV infection in Russia that substantially outstrips those encountered in most Western European countries.	MINIST HLTH RUSSIAN FEDERAT,MOSCOW,RUSSIA; RUSSIAN ASSOC AGAINST STD,SANAM,MOSCOW,RUSSIA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT EPIDEMIOL & COMMUNITY HLTH,LONDON,ENGLAND; UNIV INSTELLING ANTWERP,DEPT EPIDEMIOL & COMMUNITY HLTH,ANTWERP,BELGIUM; WHO,REG OFF EUROPE,DK-2100 COPENHAGEN,DENMARK	Ministry of Health of the Russian Federation; Imperial College London; University of Antwerp; World Health Organization			Ward, Helen/A-1836-2009	Ward, Helen/0000-0001-8238-5036				AKOVBIAN BA, 1995, SEX TRANSM DIS, V4, P15; *EC INT UN, 1995, COUNTR REP; GARNETT GP, 1993, PHILOS T R SOC B, V342, P137, DOI 10.1098/rstb.1993.0143; GASPARD M, 1993, NATO EC C EC DEV COO; GIMPELSON V, 1993, NATO EC C EC DEV COO; GROMYKO A, 1996, WHO M EP SEX TRANSM; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hardy IRB, 1996, LANCET, V347, P1739, DOI 10.1016/S0140-6736(96)90811-9; Hethcote H.W., 1984, LECT NOTES BIOMATH, V56; INGRAM M, 1995, BRIT MED J, V311, P528, DOI 10.1136/bmj.311.7004.528b; KREISS J, 1988, GENITOURIN MED, V64, P1; LINGLOF T, 1995, SEX TRANSM DIS, V22, P160, DOI 10.1097/00007435-199505000-00005; *MIN HLTH RUSS FED, 1993, 286 MIN HLTH RUSS FE; *MIN HLTH RUSS FED, 1993, TREATM PREV SYPH REC; *MIN HLTH USSR, 1986, 1570 MIN HLTH USSR; *MIN HLTH USSR, 1985, 1161 MIN HLTH USSR; *NAT AIDS PREV CON, 1994, RUSS FED ASS NAT PRO; PLUMMER FA, 1991, AIDS, V5, pS169; RENTON AM, 1994, SOC SCI MED, V38, P1153, DOI 10.1016/0277-9536(94)90230-5; TICHONOVA L, 1995, ANN M ALL RUSS ASS V; TICHONOVA LI, 1995, SEX TRANSM DIS, V4, P15	21	147	153	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					210	213		10.1016/S0140-6736(97)01382-2	http://dx.doi.org/10.1016/S0140-6736(97)01382-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250199				2022-12-01	WOS:A1997XL72200046
J	Antonsson, B; Conti, F; Ciavatta, A; Montessuit, S; Lewis, S; Martinou, I; Bernasconi, L; Bernard, A; Mermod, JJ; Mazzei, G; Maundrell, K; Gambale, F; Sadoul, R; Martinou, JC				Antonsson, B; Conti, F; Ciavatta, A; Montessuit, S; Lewis, S; Martinou, I; Bernasconi, L; Bernard, A; Mermod, JJ; Mazzei, G; Maundrell, K; Gambale, F; Sadoul, R; Martinou, JC			Inhibition of Bax channel-forming activity by Bcl-2	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; SYMPATHETIC NEURONS; PROTEIN	Proteins of the Bcl-2 family are intracellular membrane-associated proteins that regulate programmed cell death (apoptosis) either positively or negatively by as yet unknown mechanisms. Bax, a pro-apoptotic member of the Bcl-2 family, was shown to form channels in lipid membranes. Bax triggered the release of liposome-encapsulated carboxyfluorescein at both neutral and acidic pH. AS physiological pH, release could be blocked by Bcl-2, Bcl-2, in contrast, triggered carboxyfluorescein release at acidic pH only. In planar lipid bilayers, Bax formed pH- and voltage-dependent ion-conducting channels. Thus, the pro-apoptotic effects of Bax may be elicited through an intrinsic pore-forming activity that can be antagonized by Bcl-2.	IST CIBERNET & BIOFIS, I-16149 GENOA, ITALY		Antonsson, B (corresponding author), GLAXO WELLCOME RES & DEV SA, GENEVA BIOMED RES INST, CH-1288 GENEVA, SWITZERLAND.			martinou, Jean-claude/0000-0002-9847-2051; SADOUL, Remy/0000-0002-4763-0320				BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Conti F., UNPUB; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HALDAR S, 1994, ARCH BIOCHEM BIOPHYS, V315, P483, DOI 10.1006/abbi.1994.1529; HENNET T, 1993, CANCER RES, V53, P1456; KENNY B, 1994, MOL MICROBIOL, V11, P99, DOI 10.1111/j.1365-2958.1994.tb00293.x; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Montal M, 1974, Methods Enzymol, V32, P545; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113	16	900	926	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					370	372		10.1126/science.277.5324.370	http://dx.doi.org/10.1126/science.277.5324.370			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219694				2022-12-01	WOS:A1997XL35800046
J	Kliore, AJ; Hinson, DP; Flasar, FM; Nagy, AF; Cravens, TE				Kliore, AJ; Hinson, DP; Flasar, FM; Nagy, AF; Cravens, TE			The ionosphere of Europa from Galileo radio occultations	SCIENCE			English	Article							ATMOSPHERE; JUPITER	The Galileo spacecraft performed six radio occultation observations of Jupiter's Galilean satellite Europa during its tour of the jovian system, In five of the six instances, these occultations revealed the presence of a tenuous ionosphere on Europa, with an average maximum electron density of nearly 10(4) per cubic centimeter near the surface and a plasma scale height of about 240 +/- 40 kilometers from the surface to 300 kilometers and of 440 +/- 60 kilometers above 300 kilometers. Such an ionosphere could be produced by solar photoionization and jovian magnetospheric particle impact in an atmosphere having a surface density of about 10(8) electrons per cubic centimeter. If this atmosphere is composed primarily of O-2, then the principal ion is O-2(+) and the neutral atmosphere temperature implied by the 240-kilometer scale height is about 600 kelvin. If it is composed of H2O, the principal ion is H3O+ and the neutral temperature is about 340 kelvin. In either case, these temperatures are much higher than those observed on Europa's surface, and an external heating source from the jovian magnetosphere is required.	STANFORD UNIV,CTR RADAR ASTRON,STANFORD,CA 94305; NASA,GODDARD SPACE FLIGHT CTR,EXTRATERR PHYS LAB,GREENBELT,MD 20771; UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; UNIV KANSAS,DEPT PHYS & ASTRON,LAWRENCE,KS 66045	Stanford University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Michigan System; University of Michigan; University of Kansas	Kliore, AJ (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.		Flasar, F Michael/C-8509-2012	Hinson, David/0000-0002-1620-4011				BARTH CA, COMMUNICATION; BARTH CA, IN PRESS GEOPHYS RES; BROADFOOT AL, 1979, SCIENCE, V204, P979, DOI 10.1126/science.204.4396.979; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; FJELDBO G, 1971, ASTRON J, V76, P123, DOI 10.1086/111096; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HOWARD HT, 1992, SPACE SCI REV, V60, P565, DOI 10.1007/BF00216868; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; Johnson RE., 1990, ENERGETIC CHARGED PA, DOI 10.1007/978-3-642-48375-2; KLIORE A, 1974, SCIENCE, V183, P323, DOI 10.1126/science.183.4122.323; KLIORE AJ, 1972, X62150 NASA TM AM RE; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; SCHREIER R, 1993, J GEOPHYS RES-SPACE, V98, P21231, DOI 10.1029/93JA02585; TORR MR, 1985, J GEOPHYS RES-SPACE, V90, P6675, DOI 10.1029/JA090iA07p06675; WU FM, 1978, ASTROPHYS J, V325, P325; [No title captured]	16	95	95	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					355	358		10.1126/science.277.5324.355	http://dx.doi.org/10.1126/science.277.5324.355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219689				2022-12-01	WOS:A1997XL35800041
J	Scheffzek, K; Ahmadian, MR; Kabsch, W; Wiesmuller, L; Lautwein, A; Schmitz, F; Wittinghofer, A				Scheffzek, K; Ahmadian, MR; Kabsch, W; Wiesmuller, L; Lautwein, A; Schmitz, F; Wittinghofer, A			The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants	SCIENCE			English	Article							C-TERMINAL DOMAIN; TYPE-1 NF1 GENE; NEUROFIBROMATOSIS TYPE-1; TRIPHOSPHATE CONFORMATION; 3-DIMENSIONAL STRUCTURES; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; BINDING DOMAIN; PROTEIN GAP; MECHANISM	The three-dimensional structure of the complex between human H-Ras bound to guanosine diphosphate and the guanosine triphosphatase (GTPase)-activating domain of the human GTPase-activating protein p120(GAP) (GAP-334) in the presence of aluminum fluoride was solved at a resolution of 2.5 angstroms, The structure shows the partly hydrophilic and partly hydrophobic nature of the communication between the two molecules, which explains the sensitivity of the interaction toward both sails and lipids, An arginine side chain (arginine-789) of GAP-334 is supplied into the active site of Pas to neutralize developing charges in the transition state, The switch II region of Pas is stabilized by GAP-334, thus allowing glutamine-61 of Pas, mutation of which activates the oncogenic potential, to participate in catalysis, The structural arrangement in the active site is consistent with a mostly associative mechanism of phosphoryl transfer and provides an explanation for the activation of Pas by glycine-12 and glutamine-61 mutations, Glycine-12 in the transition state mimic is within van der Waals distance of both arginine-789 of GAP-334 and glutamine-61 of Pas, and even its mutation to alanine would disturb the arrangements of residues in the transition state.	MAX PLANCK INST MOL PHYSIOL, ABT STRUKT BIOL, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Max Planck Society								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; AHMADIAN MR, IN PRESS NATURE STRU; AHMADIAN MR, UNPUB; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BRUNGER AT, 1996, X PLOR VERSION 3 8; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; Morcos P, 1996, MOL CELL BIOL, V16, P2496; MORI S, 1995, J BIOL CHEM, V270, P28834, DOI 10.1074/jbc.270.48.28834; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POULLET P, 1994, MOL CELL BIOL, V14, P815, DOI 10.1128/MCB.14.1.815; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHEFFZEK K, UNPUB; SCHLICTING I, IN PRESS BIOCHEMISTR; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Sermon BA, 1996, J BIOL CHEM, V271, P1566, DOI 10.1074/jbc.271.3.1566; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; VANDOP C, 1984, J BIOL CHEM, V259, P696; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; 1997, PROTEIN-STRUCT FUNCT, V27, P315	77	1156	1201	3	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 18	1997	277	5324					333	338		10.1126/science.277.5324.333	http://dx.doi.org/10.1126/science.277.5324.333			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219684				2022-12-01	WOS:A1997XL35800036
J	Webb, JK; Carswell, RF; Lanzetta, KM; Ferlet, R; Lemoine, M; VidalMadjar, A; Bowen, DV				Webb, JK; Carswell, RF; Lanzetta, KM; Ferlet, R; Lemoine, M; VidalMadjar, A; Bowen, DV			A high deuterium abundance at redshift z=0.7	NATURE			English	Article							NUCLEOSYNTHESIS	Of the light elements, the primordial abundance of deuterium relative to hydrogen, (D/H)(p), provides the most sensitive diagnostic(1) for the cosmological mass density parameter, Omega(B). Recent high-redshift D/H measurements are highly discrepant(2-6), although this may reflect observational uncertainties(7,8). The larger primordial D/H values imply a low Omega(B) (requiring the Universe to be. dominated by non-baryonic matter), and cause problems for galactic chemical evolution models, which have difficulty in reproducing the steep decline in D/H to the present-day values, Conversely, the lower D/H values measured at high redshift imply an Omega(B) greater than that derived from Li-7 and He-4 abundance measurements, and may require a deuterium-abundance evolution that is too low to easily explain. Here we report the first measurement of D/H at intermediate redshift (z = 0.7010), in a gas cloud selected to minimize observational uncertainties, Our analysis yields a value of D/H ((2.0 +/- 0.5) x 10(-4)) which is at the upper end of the range of values measured at high redshifts. This finding, together with other independent observations, suggests that there may be inhomogeneity in (D/H)(p) of at least a factor of ten.	SUNY STONY BROOK,DEPT PHYS & ASTRON,STONY BROOK,NY 11794; UNIV SUSSEX,CTR ASTRON,BRIGHTON BN1 9QH,E SUSSEX,ENGLAND; INST ASTRON,CAMBRIDGE CB3 0HA,ENGLAND; INST ASTROPHYS,F-75014 PARIS,FRANCE; UNIV CHICAGO,ENRICO FERMI INST,DEPT ASTRON & ASTROPHYS,CHICAGO,IL 60637; ROYAL OBSERV,EDINBURGH EH9 3HJ,MIDLOTHIAN,SCOTLAND; UNIV NEW S WALES,SCH PHYS,SYDNEY,NSW 2052,AUSTRALIA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of Sussex; University of Cambridge; UDICE-French Research Universities; Sorbonne Universite; University of Chicago; University of Edinburgh; University of New South Wales Sydney			Lemoine, Martin/AAE-6416-2019; Webb, John/J-9122-2018	Lemoine, Martin/0000-0002-2395-7812; Webb, John/0000-0002-0004-9360				BURLES S, UNPUB SCIENCE; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1, DOI 10.1093/mnras/268.1.L1; Copi C.J., ASTROPH9606156; COPI CJ, 1995, SCIENCE, V267, P192, DOI 10.1126/science.7809624; EPSTEIN RI, 1976, NATURE, V263, P198, DOI 10.1038/263198a0; Hata N, 1997, PHYS REV D, V55, P540, DOI 10.1103/PhysRevD.55.540; HOGAN CJ, ASTROPH9609138; JEDAMZIK K, 1995, ASTROPHYS J, V452, P33, DOI 10.1086/176278; JEDAMZIK K, ASTROPH9609103; LANZETTA KM, 1993, ASTROPHYS J SUPPL S, V84, P109, DOI 10.1086/191749; Pagel BEJ., 1997, NUCLEOSYNTHESIS CHEM; Rugers M, 1996, ASTRON J, V111, P2135, DOI 10.1086/117949; Rugers M, 1996, ASTROPHYS J, V459, pL1, DOI 10.1086/309931; Schramm DN, 1996, NATURE, V381, P193, DOI 10.1038/381193a0; Songaila A, 1997, NATURE, V385, P137, DOI 10.1038/385137a0; Tytler D, 1996, NATURE, V381, P207, DOI 10.1038/381207a0; TYTLER D, ASTROPH9612121; VANGIONIFLAM E, 1995, ASTROPHYS J, V441, P471, DOI 10.1086/175373; VIDALMADJAR A, ASTROPH9612020; Wampler EJ, 1996, NATURE, V383, P308, DOI 10.1038/383308a0; WEBB JK, 1991, MON NOT R ASTRON SOC, V250, P657, DOI 10.1093/mnras/250.4.657; WEBB JK, 1987, THESIS CAMBRIDGE U; White M, 1996, MON NOT R ASTRON SOC, V283, P107, DOI 10.1093/mnras/283.1.107; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0	24	141	141	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					250	252		10.1038/40814	http://dx.doi.org/10.1038/40814			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230433				2022-12-01	WOS:A1997XL12100042
J	Saketkhou, BB; Conte, FJ; Noris, M; Tilkemeier, P; Miller, G; Forman, DE; Cannistra, L; Leavitt, J; Sharma, SC; Garber, C; Parisi, AF				Saketkhou, BB; Conte, FJ; Noris, M; Tilkemeier, P; Miller, G; Forman, DE; Cannistra, L; Leavitt, J; Sharma, SC; Garber, C; Parisi, AF			Emergency department use of aspirin in patients with possible acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article							UNSTABLE ANGINA; TRIAL	Background: Efforts have been made to improve the suboptimal use of aspirin af Objective: To assess the frequency and timing of aspirin administration in emergency department patients with possible myocardial infarction. Design: Retrospective record review. Setting: Emergency departments of four hospitals affiliated with the same university. Patients: All patients who were admitted to the four hospitals in 1994 for evaluation and treatment of suspected acute myocardial infarction. Measurements: The frequency and timing of aspirin administration and the definitive diagnosis established before discharge from the hospital. Results: Aspirin was not given to 253 of 463 emergency department patients (55%) who had a definitive diagnosis of acute myocardial infarction. Seventy-eight pet-cent of patients who did receive aspirin received it more than 30 minutes after arrival in the emergency department. Conclusion: Aspirin therapy is underutilized as the first intervention in patients who are admitted with suspected myocardial infarction.	MIRIAM HOSP, DEPT MED, DIV CARDIOL, PROVIDENCE, RI 02906 USA; MEM HOSP, DEPT MED, DIV CARDIOL, PAWTUCKET, RI 02860 USA; VET AFFAIRS MED CTR, DEPT MED, DIV CARDIOL, PROVIDENCE, RI 02908 USA; ROGER WILLIAMS CANC MED CTR, PROVIDENCE, RI USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	Lifespan Health Rhode Island; Miriam Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Roger Williams Medical Center; Brown University			Garber, Carol/ABD-4375-2021; Tilkemeier, Peter/AAW-4936-2020	Garber, Carol/0000-0002-1268-576X; 				[Anonymous], 1988, LANCET, V2, P349; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Gunnar R M, 1990, Circulation, V82, P664; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; KRUMHOLZ HM, 1995, CIRCULATION, V92, P2841, DOI 10.1161/01.CIR.92.10.2841; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MOHER M, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WYLLIE HR, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760a	13	23	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					126	129		10.7326/0003-4819-127-2-199707150-00005	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230001				2022-12-01	WOS:A1997XK15800007
J	James, JA; Laing, GJ; Logan, S; Rossdale, M				James, JA; Laing, GJ; Logan, S; Rossdale, M			Feasibility of screening toddlers for iron deficiency anaemia in general practice	BRITISH MEDICAL JOURNAL			English	Article									DEPT CHILD HLTH,LONDON N1 5LZ,ENGLAND; INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,LONDON WC1N 1EH,ENGLAND	University of London; University College London	James, JA (corresponding author), MONTPELIER HLTH CTR,BRISTOL BS6 5PT,AVON,ENGLAND.			Logan, Stuart/0000-0002-9279-261X				AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; HALL D, 1996, HLTH CHILDREN; IDJRADINATA P, 1993, LANCET, V341, P1, DOI 10.1016/0140-6736(93)92477-B; JAMES J, 1989, BRIT MED J, V299, P838, DOI 10.1136/bmj.299.6703.838; JAMES JA, 1995, BRIT MED J, V311, P230, DOI 10.1136/bmj.311.6999.230	5	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					102	103		10.1136/bmj.315.7100.102	http://dx.doi.org/10.1136/bmj.315.7100.102			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240051	Green Published			2022-12-01	WOS:A1997XL25200026
J	Liao, SR; Lin, JL; Do, H; Johnson, AE				Liao, SR; Lin, JL; Do, H; Johnson, AE			Both lumenal and cytosolic gating of the aqueous ER translocon pore are regulated from inside the ribosome during membrane protein integration	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; CONDUCTING CHANNEL; MESSENGER-RNA; TRANSLATION; GLYCOPROTEIN; ENVIRONMENT; BIOGENESIS; SEQUENCES; SEGMENTS; SIGNAL	Portions of the nascent chain are exposed to the lumen, the cytosol, or neither at different stages during the cotranslational integration of a protein into the ER membrane, as shown by compartment-specific collisional quenching of fluorophores incorporated into the polypeptide. The opening or closing of each end of the aqueous translocon pore is tightly controlled and occurs in a sequence that does not compromise the membrane's permeability barrier. Surprisingly, these structural changes at the membrane are effected by the transmembrane segment in the nascent protein from inside the ribosome. Thus, the ribosome, not the translocon, first recognizes the transmembrane segment and triggers long-range structural changes at the translocon that may be involved in shifting its function from translocation to integration.	TEXAS A&M UNIV,HLTH SCI CTR,DEPT CHEM,COLLEGE STN,TX 77843; TEXAS A&M UNIV,HLTH SCI CTR,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Liao, SR (corresponding author), TEXAS A&M UNIV,HLTH SCI CTR,DEPT MED BIOCHEM & GENET,COLLEGE STN,TX 77843, USA.		Johnson, Arthur E/G-3457-2012		NIGMS NIH HHS [F32 GM017828-02, F32 GM017828-01, F32 GM17828] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017828] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; CRANNEY M, 1983, BIOCHIM BIOPHYS ACTA, V735, P418, DOI 10.1016/0005-2736(83)90156-6; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HEDGE RS, 1996, CELL, V85, P217; Johnson AE, 1995, COLD SPRING HARB SYM, V60, P71, DOI 10.1101/SQB.1995.060.01.010; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cellbio.6.1.247; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SPIESS M, 1989, J BIOL CHEM, V264, P19117; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TWETEN RK, 1988, INFECT IMMUN, V56, P3228, DOI 10.1128/IAI.56.12.3228-3234.1988; WALTEWR P, 1994, ANN REV CELL BIOL, V140, P87; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519	30	211	212	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					31	41		10.1016/S0092-8674(00)80311-6	http://dx.doi.org/10.1016/S0092-8674(00)80311-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230300	Bronze			2022-12-01	WOS:A1997XL36200006
J	Quake, SR; Babcock, H; Chu, S				Quake, SR; Babcock, H; Chu, S			The dynamics of partially extended single molecules of DNA	NATURE			English	Article							STRETCHED POLYMER-CHAINS; TRANSIENT ELECTRIC BIREFRINGENCE; DIELECTRIC-RELAXATION; SCATTERING; FRAGMENTS; MODES	The behaviour of an isolated polymer floating in a solvent forms the basis of our understanding of polymer dynamics(1,2). Classical theories describe the motion of a polymer with linear equations of motion, which yield a set of 'normal modes', analogous to the fundamental frequency and the harmonics of a vibrating violin string. But hydrodynamic interactions make polymer dynamics inherently nonlinear, and the linearizing approximations required for the normal-mode picture have therefore been questioned(1). Here we test the normal-mode theory by measuring the fluctuations of single molecules of DNA held in a partially extended state with optical tweezers. We find that the motion of the DNA can be described by linearly independent normal modes, and we have experimentally determined the eigenstates of the system. Furthermore, we show that the spectrum of relaxation times obeys a power law.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305	Stanford University				Babcock, Hazen/0000-0003-4835-3692				ADAM M, 1977, MACROMOLECULES, V10, P1229, DOI 10.1021/ma60060a014; AMELAR S, 1991, MACROMOLECULES, V24, P3505, DOI 10.1021/ma00012a007; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; De Gennes P-G., 1979, SCALING CONCEPTS POL; DEGENNES PG, 1974, J CHEM PHYS, V60, P5030, DOI 10.1063/1.1681018; Doi M., 1986, THEORY POLYM DYNAMIC; HONG MK, 1992, PHYS REV LETT, V68, P1430, DOI 10.1103/PhysRevLett.68.1430; JOHNSON RM, 1970, POLYM J, V1, P742; KIRKWOOD JG, 1948, J CHEM PHYS, V16, P565, DOI 10.1063/1.1746947; LEWIS RJ, 1986, MACROMOLECULES, V19, P134, DOI 10.1021/ma00155a021; MARCIANO Y, 1995, MACROMOLECULES, V28, P985, DOI 10.1021/ma00108a028; PECORA R, 1991, SCIENCE, V251, P893, DOI 10.1126/science.2000490; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; PINCUS P, 1977, MACROMOLECULES, V10, P210, DOI 10.1021/ma60055a042; PINCUS P, 1976, MACROMOLECULES, V9, P386, DOI 10.1021/ma60051a002; Press W.H., 1994, NUMERICAL RECIPES; SAHOUANI H, 1992, MACROMOLECULES, V25, P5632, DOI 10.1021/ma00047a012; SAMMLER RL, 1990, MACROMOLECULES, V23, P2388, DOI 10.1021/ma00210a042; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; SORLIE SS, 1990, MACROMOLECULES, V23, P487, DOI 10.1021/ma00204a022; WATANABE H, 1995, MACROMOLECULES, V28, P6443, DOI 10.1021/ma00123a009; Watanabe H, 1996, MACROMOLECULES, V29, P97, DOI 10.1021/ma9510348; WATANABE H, 1993, MACROMOLECULES, V26, P5073, DOI 10.1021/ma00071a015; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462; ZIMM BH, 1956, J CHEM PHYS, V24, P279, DOI 10.1063/1.1742463	25	233	241	2	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					151	154		10.1038/40588	http://dx.doi.org/10.1038/40588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217154				2022-12-01	WOS:A1997XK10900043
J	Taddei, F; Hayakawa, H; Bouton, MF; Cirinesi, AM; Matic, I; Sekiguchi, M; Radman, M				Taddei, F; Hayakawa, H; Bouton, MF; Cirinesi, AM; Matic, I; Sekiguchi, M; Radman, M			Counteraction by MutT protein of transcriptional errors caused by oxidative damage	SCIENCE			English	Article							ESCHERICHIA-COLI; MUTAGENIC SUBSTRATE; DNA-SYNTHESIS; MUTATIONS; CLONING; CDNA; SUBSTITUTIONS; TRANSLATION; REPLICATION; ELIMINATION	Oxidized guanine (8-oxo-7,8-dihydroguanine; 8-oxo-G) is a potent mutagen because of its ambiguous pairing with cytosine and adenine. The Escherichia coli MutT protein specifically hydrolyzes both 8-oxo-deoxyguanosine triphosphate (8-oxo-dGTP) and 8-oxo-guanosine triphosphate (8-oxo-rGTP), which are otherwise incorporated in DNA and RNA opposite template A. In vivo, this cleaning of the nucleotide pools decreases both DNA replication and transcription errors. The effect of mutT mutation on transcription fidelity was shown to depend on oxidative metabolism Such control of transcriptional fidelity by the ubiquitous MutT function has implications for evolution of RNA-based life, phenotypic expression, adaptive mutagenesis, and functional maintenance of nondividing cells.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 812,JAPAN; FUKUOKA DENT COLL,DEPT BIOL,FUKUOKA 81401,JAPAN; INST JACQUES MONOD,F-75251 PARIS 05,FRANCE	Kyushu University; Fukuoka Dental College (FDC); UDICE-French Research Universities; Universite Paris Cite			Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0003-0216-3148; Radman, Miroslav/0000-0002-7034-4365				AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BLANK A, 1986, BIOCHEMISTRY-US, V25, P5920, DOI 10.1021/bi00368a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES BA, 1995, NATURE, V375, P741, DOI 10.1038/375741a0; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; CUPPLES CG, 1988, GENETICS, V120, P637; FOWLER RG, 1994, J BACTERIOL, V176, P7727, DOI 10.1128/JB.176.24.7727-7729.1994; Galitski T, 1996, GENETICS, V143, P645; GALLANT J, 1979, MECH AGEING DEV, V10, P27, DOI 10.1016/0047-6374(79)90068-X; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; HAYAKAWA H, 1997, UNPUB; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Miller JH, 1996, ANNU REV MICROBIOL, V50, P625, DOI 10.1146/annurev.micro.50.1.625; Miller JH., 1972, EXPT MOL GENETICS; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; NINIO J, 1991, BIOCHIMIE, V73, P1517, DOI 10.1016/0300-9084(91)90186-5; NINIO J, 1991, GENETICS, V129, P957; ORGEL LE, 1963, P NATL ACAD SCI USA, V49, P517, DOI 10.1073/pnas.49.4.517; RADMAN M, 1973, PHYSICOCHEMICAL PROP, V3, P161; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; TADDEI F, UNPUB; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	29	244	250	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					128	130		10.1126/science.278.5335.128	http://dx.doi.org/10.1126/science.278.5335.128			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311918				2022-12-01	WOS:A1997XZ12400054
J	Yu, SP; Yeh, CH; Sensi, SL; Gwag, BJ; Canzoniero, LMT; Farhangrazi, ZS; Ying, HS; Tian, M; Dugan, LL; Choi, DW				Yu, SP; Yeh, CH; Sensi, SL; Gwag, BJ; Canzoniero, LMT; Farhangrazi, ZS; Ying, HS; Tian, M; Dugan, LL; Choi, DW			Mediation of neuronal apoptosis by enhancement of outward potassium current	SCIENCE			English	Article							IONOPHORE-INDUCED APOPTOSIS; CEREBELLAR GRANULE CELLS; RAT CORTICAL-NEURONS; INTRACELLULAR CALCIUM; K+-CHANNELS; HIPPOCAMPAL-NEURONS; DNA FRAGMENTATION; NERVOUS-SYSTEM; LYMPHOCYTE-T; CA2+ INFLUX	Apoptosis of mouse neocortical neurons induced by serum deprivation or by staurosporine was associated with an early enhancement of delayed rectifier (I-K) current and loss of total intracellular K+. This I-K augmentation was not seen in neurons undergoing excitotoxic necrosis or in older neurons resistant to staurosporine-induced apoptosis. Attenuating outward K+ current with tetraethylammonium or elevated extracellular K+, but not blockers of Ca2+, Cl-, or other K+ channels, reduced apoptosis, even if associated increases in intracellular Ca2+ concentration were prevented. Furthermore, exposure to the K+ ionophore valinomycin or the K+-channel opener cromakalim induced apoptosis. Enhanced K+ efflux may mediate certain forms of neuronal apoptosis.	WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR STUDY NERVOUS SYST INJURY, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Sensi, Stefano L./O-1335-2019; Sensi, Stefano L./J-3164-2016	Sensi, Stefano L./0000-0002-0710-2574; Sensi, Stefano L./0000-0002-0710-2574; CANZONIERO, Lorella Maria Teresa/0000-0003-2255-5341	PHS HHS [30337] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams P R, 1986, Adv Neurol, V44, P137; ALLBRITTON NL, 1988, J EXP MED, V167, P514, DOI 10.1084/jem.167.2.514; BARBIERO G, 1995, EXP CELL RES, V217, P410, DOI 10.1006/excr.1995.1104; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851, DOI 10.1002/jlb.57.6.851; BEHRENS MI, UNPUB; BENNETT MR, 1979, BRAIN RES, V173, P549, DOI 10.1016/0006-8993(79)90250-6; CHALAZONITIS A, 1980, DEV BIOL, V78, P173, DOI 10.1016/0012-1606(80)90327-9; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; COLLINS F, 1991, J NEUROSCI, V11, P2582; CONE CD, 1976, SCIENCE, V192, P155, DOI 10.1126/science.56781; DECKERS CLP, 1993, EXP CELL RES, V208, P362, DOI 10.1006/excr.1993.1257; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; deLuca A, 1996, J NEUROSCI, V16, P4174; DEUTSCH C, 1990, PROG CLIN BIOL RES, V334, P251; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; ENOKIDO Y, 1993, NEUROSCIENCE, V57, P965, DOI 10.1016/0306-4522(93)90041-D; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FRANKLIN JL, 1995, J NEUROSCI, V15, P643; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HILLE B, 1967, J GEN PHYSIOL, V50, P1287, DOI 10.1085/jgp.50.5.1287; JOHNSON EM, 1992, EXP NEUROL, V115, P163, DOI 10.1016/0014-4886(92)90242-I; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KONISHI T, 1989, J PHYSIOL-LONDON, V411, P115, DOI 10.1113/jphysiol.1989.sp017564; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LAMPE PA, 1995, J NEUROBIOL, V26, P205, DOI 10.1002/neu.480260205; LEE SC, 1986, J CELL BIOL, V102, P1200, DOI 10.1083/jcb.102.4.1200; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCDONALD JW, IN PRESS BRAIN RES; MURRELL RD, 1993, EUR J NEUROSCI, V5, P1261, DOI 10.1111/j.1460-9568.1993.tb00911.x; NEHER E, 1972, PFLUG ARCH EUR J PHY, V336, P87, DOI 10.1007/BF00592924; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; POLITI DMT, 1989, EUR J PHARMACOL, V168, P7, DOI 10.1016/0014-2999(89)90626-2; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; Rose Kamala, 1993, P46; ROUZAIREDUBOIS B, 1991, CELL SIGNAL, V3, P333, DOI 10.1016/0898-6568(91)90062-Y; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SANCHEZ DY, 1992, J GEN PHYSIOL, V100, P217, DOI 10.1085/jgp.100.2.217; SCOTT BS, 1970, EXP NEUROL, V27, P16, DOI 10.1016/0014-4886(70)90197-4; TAKEI N, 1994, BRAIN RES, V652, P65, DOI 10.1016/0006-8993(94)90317-4; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; UCKER DS, 1991, NEW BIOL, V3, P103; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x	51	515	551	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					114	117		10.1126/science.278.5335.114	http://dx.doi.org/10.1126/science.278.5335.114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311914				2022-12-01	WOS:A1997XZ12400050
J	Valdivia, RH; Falkow, S				Valdivia, RH; Falkow, S			Fluorescence-based isolation of bacterial genes expressed within host cells	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM VIRULENCE; ESCHERICHIA-COLI; IDENTIFICATION; SELECTION; SECRETION; MACROPHAGES; AVIRULENT; PROTEINS; MUTANTS; SURVIVE	A selection strategy was devised to identify bacterial genes preferentially expressed when a bacterium associates with its host cell. Fourteen Salmonella typhimurium genes, which were under the control of at least four independent regulatory circuits, were identified to be selectively induced in host macrophages. Four genes encode virulence factors, including a component of a type III secretory apparatus. This selection methodology should be generally applicable to the identification of genes from pathogenic organisms that are induced upon association with host cells or tissues.			Valdivia, RH (corresponding author), STANFORD UNIV, SCH MED, DEPT IMMUNOL & MICROBIOL, STANFORD, CA 94305 USA.		Valdivia, Raphael/R-5377-2019	Valdivia, Raphael/0000-0003-0961-073X	NIAID NIH HHS [AI26195] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAOUI A, 1992, J BACTERIOL, V174, P7661, DOI 10.1128/JB.174.23.7661-7669.1992; ALLAOUI A, 1995, MOL MICROBIOL, V18, P343, DOI 10.1111/j.1365-2958.1995.mmi_18020343.x; ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DELPORTILLO FG, 1992, MOL MICROBIOL, V6, P3289; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GIROLOMONI G, 1995, EUR J IMMUNOL, V25, P2163, DOI 10.1002/eji.1830250807; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; GULIG PA, 1987, INFECT IMMUN, V55, P2891, DOI 10.1128/IAI.55.12.2891-2901.1987; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; GULIG PA, 1996, ESCHERICHIA COLI SAL, V2, P2774; Hensel M, 1997, MOL MICROBIOL, V24, P155, DOI 10.1046/j.1365-2958.1997.3271699.x; HORWITZ MA, 1987, J EXP MED, V166, P1310, DOI 10.1084/jem.166.5.1310; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; Mahan MJ, 1996, ESCHERICHIA COLI SAL, P2803; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; RHEN M, 1988, MICROB PATHOGENESIS, V5, P275, DOI 10.1016/0882-4010(88)90100-3; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Valdivia RH, 1996, MOL MICROBIOL, V22, P367, DOI 10.1046/j.1365-2958.1996.00120.x; VALDIVIA RH, UNPUB; Wang JY, 1996, P NATL ACAD SCI USA, V93, P10434, DOI 10.1073/pnas.93.19.10434; Wanner BL, 1996, ESCHERICHIA COLI SAL, P1357, DOI DOI 10.1007/978-3-642-75969-7_16	33	488	515	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					2007	2011		10.1126/science.277.5334.2007	http://dx.doi.org/10.1126/science.277.5334.2007			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302299				2022-12-01	WOS:A1997XX84900049
J	Seretakis, D; Lagiou, P; Lipworth, L; Signorello, LB; Rothman, KJ; Trichopoulos, D				Seretakis, D; Lagiou, P; Lipworth, L; Signorello, LB; Rothman, KJ; Trichopoulos, D			Changing seasonality of mortality from coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR MORTALITY; TEMPERATURE; DECLINE	Context.-Coronary heart disease is the major cause of mortality in the United States. Factors associated with coronary risk are important to identify, Coronary mortality is greater during the winter months. Objective.-To investigate whether declining coronary mortality has been accompanied by a change in the seasonal pattern and to investigate the hypothesis that diminishing exposures to environmental cold and heat have affected the seasonal pattern. Design.-We used published data on coronary mortality by year to evaluate the time trend in the seasonal pattern, We fit a sine curve to the monthly frequency of deaths in each year and examined the trend over time in the ratio of the peak to the trough of the curve. Setting.-We used monthly coronary deaths in the United States from 1937 through 1991. Deaths by cause and month were not available by geographic area within the United States, but we were able to examine total monthly deaths in 2 regions with contrasting climates, New England and the South. Outcome Measures.-We used the yearly peak-to-trough ratio as our primary outcome and assessed its trend over time by linear regression, We also depicted the time trends using polynomial smoothing. Results.-The peak-to-trough ratio diminished by about 2% per year until around 1970, when the trend reversed. In New England, the decline was steeper than in the South, as measured from all deaths. Conclusion.-Seasonal patterns in coronary mortality in the United States have changed with time, These changes are compatible with the gradual expansion of adequate heating and the subsequent increased use of air-conditioning. Microclimatic influences on coronary mortality could explain in part the socioeconomic gradient of cardiovascular mortality.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; BOSTON UNIV, MED CTR, DEPT EPIDEMIOL, BOSTON, MA USA; BOSTON UNIV, MED CTR, SECT PREVENT MED, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston University				Rothman, Kenneth/0000-0003-2398-1705				EDWARDS JH, 1961, ANN HUM GENET, V25, P83, DOI 10.1111/j.1469-1809.1961.tb01501.x; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HELLER RF, 1984, BRIT MED J, V288, P1409, DOI 10.1136/bmj.288.6428.1409; KATSOUYANNI K, 1988, LANCET, V2, P573; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; LLOYD OL, 1995, BRIT MED J, V310, P467, DOI 10.1136/bmj.310.6977.467; MARMOT MG, 1986, LANCET, V2, P274; *NAT CTR HLTH STAT, 1937, VIT STAT US; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; U. S. Bureau of the Census, 1996, STAT ABSTR US; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029	12	92	96	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1012	1014		10.1001/jama.278.12.1012	http://dx.doi.org/10.1001/jama.278.12.1012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307350				2022-12-01	WOS:A1997XX01200033
J	Engel, MH; Macko, SA				Engel, MH; Macko, SA			Isotopic evidence for extraterrestrial non-racemic amino acids in the Murchison meteorite	NATURE			English	Article							ORGANIC-MOLECULES; MASS-SPECTROMETRY; CARBON; LIFE; HYDROCARBONS; ENANTIOMERS; EARTH; CHIRALITY; DELIVERY; ORIGINS	Many amino acids contain an asymmetric centre, occurring as laevorotatory, L, or dextrorotatory, D, compounds. It is generally assumed that abiotic synthesis of amino acids on the early Earth resulted in racemic mixtures (L-and D-enantiomers in equal abundance). But the origin of life required, owing to conformational constraints, the almost exclusive selection of either L-or D-enantiomers(1,2), and the question of why living-systems on the Earth consist of L-enantiomers rather than D-enantiomers is unresolved(3). A substantial fraction of the organic compounds on the early Earth may have been derived from comet and meteorite impacts(4-6). It has been reported previously that amino acids in the Murchison meteorite exhibit an excess of L-enantiomers(7), raising the possibility that a similar excess was present in the initial inventory of organic compounds on the Earth. The stable carbon isotope compositions of individual amino acids in Murchison support an extraterrestrial origin(8)-rather than a terrestrial overprint of biological amino acids-although reservations have persisted (see, for example, ref. 9). Here we show that individual amino-acid enantiomers from Murchison are enriched in N-15 relative to their terrestrial counterparts, so confirming an extraterrestrial source for an L-enantiomer excess in the Solar System that may predate the origin of life on the Earth.	UNIV VIRGINIA, DEPT ENVIRONM SCI, CHARLOTTESVILLE, VA 22903 USA	University of Virginia	Engel, MH (corresponding author), UNIV OKLAHOMA, SCH GEOL & GEOPHYS, NORMAN, OK 73019 USA.		Macko, Stephen/K-4588-2015					BONNER WA, 1991, ORIGINS LIFE EVOL B, V21, P59, DOI 10.1007/BF01809580; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; CHYBA CF, 1990, SCIENCE, V249, P366, DOI 10.1126/science.11538074; COHEN J, 1995, SCIENCE, V267, P1265, DOI 10.1126/science.7871419; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; ENGEL MH, 1994, P NATL ACAD SCI USA, V91, P10475, DOI 10.1073/pnas.91.22.10475; ENGEL MH, 1982, NATURE, V296, P837, DOI 10.1038/296837a0; ENGEL MH, 1990, NATURE, V348, P47, DOI 10.1038/348047a0; ENGEL MH, 1993, ORGANIC GEOCHEMISTRY, P685; EPSTEIN S, 1987, NATURE, V326, P477, DOI 10.1038/326477a0; Fogel M.L., 1993, ORGANIC GEOCHEMISTRY, P73, DOI DOI 10.1007/978-1-4615-2890-6_3; GILMOUR I, 1992, METEORITICS, V27, P224; GOLDANSKII VI, 1991, NATURE, V352, P114, DOI 10.1038/352114a0; GRADY MM, 1988, GEOCHIM COSMOCHIM AC, V52, P2855, DOI 10.1016/0016-7037(88)90152-4; HARE PE, 1985, CHEM BIOCH AMINO ACI, P415; HOPPE P, 1995, GEOCHIM COSMOCHIM AC, V59, P4029, DOI 10.1016/0016-7037(95)00280-D; KIEFFER HH, 1992, MARS, P1; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; Macko SA, 1997, ANAL CHEM, V69, P926, DOI 10.1021/ac960956l; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MERRITT DA, 1994, J AM SOC MASS SPECTR, V5, P387, DOI 10.1016/1044-0305(94)85054-2; Mojzsis SJ, 1996, NATURE, V384, P55, DOI 10.1038/384055a0; ORO J, 1961, NATURE, V190, P389, DOI 10.1038/190389a0; PIZZARELLO S, 1994, GEOCHIM COSMOCHIM AC, V58, P5579, DOI 10.1016/0016-7037(94)90251-8; PIZZARELLO S, 1991, GEOCHIM COSMOCHIM AC, V55, P905, DOI 10.1016/0016-7037(91)90350-E; SHOCK EL, 1990, GEOCHIM COSMOCHIM AC, V54, P3159, DOI 10.1016/0016-7037(90)90131-4; SILFER JA, 1991, ANAL CHEM, V63, P370, DOI 10.1021/ac00004a014; SILFER JA, 1994, ORG GEOCHEM, V21, P603, DOI 10.1016/0146-6380(94)90006-X; SILFER JA, 1991, THESIS U OKLAHOMA; VALLENTYNE JR, 1964, GEOCHIM COSMOCHIM AC, V28, P157, DOI 10.1016/0016-7037(64)90147-4; YUEN G, 1984, NATURE, V307, P252, DOI 10.1038/307252a0	32	386	391	4	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					265	268		10.1038/38460	http://dx.doi.org/10.1038/38460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305838				2022-12-01	WOS:A1997XW77200041
J	Polyak, K; Xia, Y; Zweier, JL; Kinzler, KW; Vogelstein, B				Polyak, K; Xia, Y; Zweier, JL; Kinzler, KW; Vogelstein, B			A model for p53-induced apoptosis	NATURE			English	Article							CELL-DEATH; GENE; P53; IDENTIFICATION; EXPRESSION	The inactivation of the p53 gene in a large proportion of human cancers has inspired an intense search for the encoded protein's physiological and biological properties. Expression of p53 induces either a stable growth arrest or programmed cell death (apoptosis). In human colorectal cancers, the growth arrest is dependent on the transcriptional induction of the protein p21(WAF1/CIP1) (ref. 1), but the mechanisms underlying the development of p53-dependent apoptosis are largely unknown(2). As the most well documented biochemical property of p53 is its ability to activate transcription of genes, we examined in detail the transcripts induced by p53 expression before the onset of apoptosis. Of 7,202 transcripts identified, only 14 (0.19%) were found to be markedly increased in p53-expressing cells compared with control cells. Strikingly, many of these genes were predicted to encode proteins that could generate or respond to oxidative stress, including one that is implicated in apoptosis in plant meristems, These observations stimulated additional biochemical and pharmacological experiments suggesting that p53 results in apoptosis through a three-step process: (1) the transcriptional induction of redox-related genes; (2) the formation of reactive oxygen species; and (3) the oxidative degradation of mitochondrial components, culminating in cell death.	JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21231 USA; HOWARD HUGHES MED INST, BALTIMORE, MD 21231 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University			Pillay, Nischalan/F-9536-2012					BOREK C, 1987, British Journal of Cancer, V55, P74; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAULKNER K, 1993, FREE RADICAL BIO MED, V15, P447, DOI 10.1016/0891-5849(93)90044-U; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; HAYWARD DC, 1993, P NATL ACAD SCI USA, V90, P2979, DOI 10.1073/pnas.90.7.2979; HOLLAND PC, 1973, J BIOL CHEM, V248, P6050; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KREOMER G, 1997, IMMUNOL TODAY, V18, P45; Lehar SM, 1996, ONCOGENE, V12, P1181; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Orrenius S, 1996, BIOCHEM SOC T, V24, P1032, DOI 10.1042/bst0241032; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAO PV, 1992, J BIOL CHEM, V267, P96; RIENHOFF HY, 1990, MOL BIOL MED, V7, P287; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TAMM I, 1978, ADV VIRUS RES, V22, P188; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; WALDMAN T, 1995, CANCER RES, V55, P5187; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	29	2172	2272	4	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					300	305		10.1038/38525	http://dx.doi.org/10.1038/38525			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305847				2022-12-01	WOS:A1997XW77200052
J	Feeney, M; Clegg, A; Winwood, P; Snook, J				Feeney, M; Clegg, A; Winwood, P; Snook, J			A case-control study of measles vaccination and inflammatory bowel disease	LANCET			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; RISK FACTOR; VIRUS; INFECTION; ABSENCE	Background The cause of inflammatory bowel disease (IBD) remains to be established. Evidence has linked measles infection in early childhood with the subsequent risk of developing IBD, particularly Crohn's disease. A cohort study raised the possibility that immunisation with live attenuated measles vaccine, which induces active immunity to measles infection, might also predispose to the later development of IBD, provoking concerns about the safety of the vaccine. Method We report a case-control study of 140 patients with IBD (including 83 with Crohn's disease) born in or after 1968, and 280 controls matched for age, sex acid general practitioner (GP) area, designed to assess the influence of measles vaccination on later development of IBD. Documentary evidence of childhood vaccination history was sought from GP and community health records. Findings Crude measles vaccination rates were 56.4% in patients with IBD and 57.1% among controls. Matched odds ratios for measles vaccination were 1.08 (95% CI in patients with Crohn's disease, 0.84 in patients with ulcerative colitis, and 0.97 (0.64-1.47) in all patients with IBD. Interpretation These findings provide no support for the hypothesis that measles vaccination in childhood predisposes to the later development of either IBD overall or Crohn's disease in particular.	POOLE HOSP,DEPT GASTROENTEROL,POOLE BH15 2JB,DORSET,ENGLAND; ROYAL BOURNEMOUTH HOSP,DEPT GASTROENTEROL,BOURNEMOUTH,DORSET,ENGLAND; UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND	Poole Hospital; University of York - UK			Snook, Jonathon/AAK-3541-2020					BARTON JR, 1989, GUT, V30, P618, DOI 10.1136/gut.30.5.618; BAXTER T, 1995, LANCET, V345, P1363; BRESLOW N. E., 1980, STATISTICAL METHODS; CALMAN KC, 1995, COMMUNICATION   0428; Clayton D., 1993, STAT MODELS EPIDEMIO; Cosgrove M, 1996, ARCH DIS CHILD, V74, P460, DOI 10.1136/adc.74.5.460; *DEP HLTH STAT DIV, KORN DAT VACC IMM; Ekbom A, 1996, LANCET, V348, P515, DOI 10.1016/S0140-6736(96)04429-7; EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8; FARRINGTON P, 1995, LANCET, V345, P1362, DOI 10.1016/S0140-6736(95)92559-7; GENT AE, 1994, LANCET, V343, P766, DOI 10.1016/S0140-6736(94)91841-4; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; Haga Y, 1996, GUT, V38, P211, DOI 10.1136/gut.38.2.211; HERMONTAYLOR JM, 1995, LANCET, V345, P922, DOI 10.1016/S0140-6736(95)90033-0; IIZUKA M, 1995, LANCET, V345, P199; Jones P, 1997, LANCET, V349, P473, DOI 10.1016/S0140-6736(05)61184-1; LEWIN J, 1995, GUT, V36, P564, DOI 10.1136/gut.36.4.564; MACDONALD TT, 1995, LANCET, V345, P1363; MILLER C, 1987, BRIT MED J, V295, P22, DOI 10.1136/bmj.295.6589.22; PATRIARCA PA, 1995, LANCET, V345, P1062, DOI 10.1016/S0140-6736(95)90810-2; RIIS P, 1990, INFLAMMATORY BOWEL D; ROTHMANN K, 1986, MODERN EPIDEMIOLOGY; SALISBURY DM, 1996, IMMUNISATION INFECT, P125; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; THAYER WR, 1990, INFLAMMATORY BOWEL D; THOMPSON NP, 1995, EUR J GASTROEN HEPAT, V7, P385; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; Thompson NP, 1996, LANCET, V347, P263, DOI 10.1016/S0140-6736(96)90438-9; Wickramaratne P J, 1995, Stat Methods Med Res, V4, P311, DOI 10.1177/096228029500400404	29	83	84	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					764	766		10.1016/S0140-6736(97)03192-9	http://dx.doi.org/10.1016/S0140-6736(97)03192-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297995				2022-12-01	WOS:A1997XW28200010
J	Genbacev, O; Zhou, Y; Ludlow, JW; Fisher, SJ				Genbacev, O; Zhou, Y; Ludlow, JW; Fisher, SJ			Regulation of human placental development by oxygen tension	SCIENCE			English	Article							CYTOTROPHOBLASTS; EXPRESSION; TROPHOBLAST; INVASION; PROTEINS; TUMORS; CELLS	Cytotrophoblasts, specialized placental cells, proliferate early in pregnancy and then differentiate into tumor-like cells that establish blood flow to the placenta by invading the uterus and its vasculature. In this study, cytotrophoblasts cultured under hypoxic conditions (2 percent oxygen), mimicking the environment near the uterine surface before 10 weeks of gestation, continued proliferating and differentiated poorly. When cultured in 20 percent oxygen, mimicking the environment near uterine arterioles, the cells stopped proliferating and differentiated normally. Thus, oxygen tension determines whether cytotrophoblasts proliferate or invade, thereby regulating placental growth and cellular architecture.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV ROCHESTER,CTR CANC,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14642	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Rochester					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD030367] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56904] Funding Source: Medline; NICHD NIH HHS [HD30367] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Boyd J D, 1967, J Obstet Gynaecol Br Commonw, V74, P161; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAMSKY CH, 1994, DEVELOPMENT, V120, P3657; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; Fisher S J, 1993, Semin Cell Biol, V4, P183, DOI 10.1006/scel.1993.1022; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; GENBACEV O, 1992, PLACENTA, V13, P439, DOI 10.1016/0143-4004(92)90051-T; Genbacev O, 1996, J CLIN INVEST, V97, P540, DOI 10.1172/JCI118447; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hertig A.T., 1942, ANAT REC, V82, P420; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KURMAN RJ, 1984, INT J GYNECOL PATHOL, V3, P101, DOI 10.1097/00004347-198403010-00009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; MCMASTER MT, 1995, J IMMUNOL, V154, P3771; RODESCH F, 1992, OBSTET GYNECOL, V80, P283; SCHWARTING R, 1993, LAB INVEST, V68, P597; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; ZHOU Y, 1993, J CLIN INVEST, V91, P950, DOI 10.1172/JCI116316	22	691	738	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1669	1672		10.1126/science.277.5332.1669	http://dx.doi.org/10.1126/science.277.5332.1669			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287221				2022-12-01	WOS:A1997XV68400052
J	Chen, X; Weisberg, E; Fridmacher, V; Watanabe, M; Naco, G; Whitman, M				Chen, X; Weisberg, E; Fridmacher, V; Watanabe, M; Naco, G; Whitman, M			Smad4 and FAST-1 in the assembly of activin-responsive factor	NATURE			English	Article							MESODERM INDUCTION; MAD PROTEINS; BETA; RECEPTORS; FAMILY	Members of the TGF-beta superfamily of signalling molecules work by activating transmembrane receptors with phosphorylating activity (serine-threonine kinase receptors)(1); these in turn phosphorylate and activate(2) SMADs(3,4), a class of signal transducers. Activins are growth factors that act primarily through Smad2(5-7), possibly in partnership with Smad4, which forms heteromeric complexes with different ligand-specific SMADs after activation(8,9). In frog embryos, Smad2 participates in an activin-responsive factor (ARF), which then binds to a promoter element of the Mix.2 gene(10). The principal DNA-binding component of ARF is FAST-1 (ref. 11), a transcription factor with a novel winged-helix structure. We now report that Smad4 is present in ARF, and that FAST-1, Smad4 and Smad2 co-immunoprecipitate in a ligand-regulated fashion. We have mapped the site of interaction between FAST-1 and Smad2/Smad4 to a novel carboxyterminal domain of FAST-1, and find that overexpression of this domain specifically inhibits activin signalling. In a yeast two-hybrid assay,the FAST-1 carboxy terminus interacts with Smad2 but not Smad4. Deletion mutants of the FAST-1 carboxy terminus that still participate in ligand-regulated Smad2 binding no longer associated with Smad4 or ARF. These results indicate that Smad4 stabilizes a ligand-stimulated Smad2-FAST-1 complex as an active DNA-binding factor.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								Bartel PL, 1993, CELLULAR INTERACTION, P153; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	17	483	499	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					85	89		10.1038/38008	http://dx.doi.org/10.1038/38008			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288972				2022-12-01	WOS:A1997XU59600050
J	GomisRuth, FX; Maskos, K; Betz, M; Bergner, A; Huber, R; Suzuki, K; Yoshida, N; Nagase, H; Brew, K; Bourenkov, GP; Bartunik, H; Bode, W				GomisRuth, FX; Maskos, K; Betz, M; Bergner, A; Huber, R; Suzuki, K; Yoshida, N; Nagase, H; Brew, K; Bourenkov, GP; Bartunik, H; Bode, W			Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1	NATURE			English	Article							HUMAN-TISSUE INHIBITOR; CATALYTIC DOMAIN; TERMINAL DOMAIN; 3-DIMENSIONAL STRUCTURE; COLLAGENASES; HYDROXAMATE; SUPERFAMILY; ACTIVATION; ASTACINS; PROTEIN	Matrix metalloproteinases (MMPs) are zinc endopeptidases that are required for the degradation of extracellular matrix components during normal embryo development, morphogenesis and tissue remodelling(1). Their proteolytic activities are precisely regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs)(1-5). Disruption of this balance results in diseases such as arthritis, atherosclerosis, tumour growth and metastasis(1,2). Here we report the crystal structure of an MMP-TIMP complex formed between the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1. TIMP-1, a 184-residue protein(5), has the shape of an elongated, contiguous wedge. With its long edge, consisting of five different chain regions, it occupies the entire length of the active-site cleft of MMP-3. The central disulphide-linked segments Cys 1-Thr 2-Cys 3-Val 4 and Ser 68-Val 69 bind to either side of the catalytic zinc. Cys 1 bidentally coordinates this zinc, and the Thr-2 side chain extends into the large specificity pocket of MMP-3. This unusual architecture of the interface between MMP-3 and TIMP-1 suggests new possibilities for designing TIMP variants and synthetic MMP inhibitors with potential therapeutic applications.	MAX PLANCK INST BIOCHEM,ABT STRUKTURFORSCH,D-82152 MARTINSRIED,GERMANY; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOL BIOL,KANSAS CITY,KS 66160; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOL BIOL,MIAMI,FL 33101; DESY,AG PROT DYNAM MPG ASMB,D-22603 HAMBURG,GERMANY	Max Planck Society; University of Kansas; University of Kansas Medical Center; University of Miami; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Bourenkov, Gleb P/C-7794-2017; Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Bourenkov, Gleb P/0000-0002-2617-5920; Brew, Keith/0000-0003-1306-1032; Bergner, Andreas/0000-0002-5843-4325; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; Brunger AT, 1991, CURR OPIN STRUC BIOL, V1, P1016, DOI 10.1016/0959-440X(91)90100-8; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; COWTAN K, 1994, JOINT CCP4 ESF EACBM, V31; Dhanaraj V, 1996, STRUCTURE, V4, P375, DOI 10.1016/S0969-2126(96)00043-3; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Nagase H, 1996, ZINC METALLOPROTEASE, P153; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1996, DENZO FILM PROCESSIN; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; ROUSSEL A, 1989, TURBO FRODO SILICON; STOCKER W, 1995, PROTEIN SCI, V4, P823; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK E, 1994, AM J RESP CRIT CARE, V150, P5165; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; [No title captured]	30	480	495	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					77	81		10.1038/37995	http://dx.doi.org/10.1038/37995			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288970				2022-12-01	WOS:A1997XU59600048
J	AgerholmLarsen, B; TybjaergHansen, A; FrikkeSchmidt, R; Gronholdt, MLM; Jensen, G; Nordestgaard, BG				AgerholmLarsen, B; TybjaergHansen, A; FrikkeSchmidt, R; Gronholdt, MLM; Jensen, G; Nordestgaard, BG			ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article						polymorphism (genetics); peptidyl-dipeptidase A; cerebrovascular disorders; cerebral ischemia; cerebral ischemia, transient	ANGIOTENSIN-CONVERTING-ENZYME; INSERTION DELETION POLYMORPHISM; MYOCARDIAL-INFARCTION; STROKE; JAPANESE	Background: Researchers have suggested that the deletional allele of the ACE (angiotensin-converting enzyme) gene insertion-deletion polymorphism is a potent risk factor for myocardial infarction. This association could not be confirmed in the Copenhagen City Heart Study, in which 10 150 persons were studied. The ACE gene polymorphism has also recently been suggested as a potent risk factor for ischemic cerebrovascular disease. Objective: To investigate the association between ACE gene polymorphism and ischemic cerebrovascular disease. Design: Two case-referent studies and a cross-sectional study. Setting: University hospital in Copenhagen, Denmark. Participants: Case-referent study 1: 35 women and 38 men who developed ischemic cerebrovascular disease before 50 years of age compared with 1454 women and 1737 men from a general population sample. Case-referent study 2: 82 women and 137 men with ischemic cerebrovascular disease and carotid stenosis greater than 40% compared with 4273 women and 3091 men from the general population sample. Cross-sectional study of the general population sample: 67 women and 93 men with ischemic cerebrovascular disease compared with 4077 women and 3156 men without such disease. Measurements: Genotype; age; body mass index; smoking habits; levels of lipids, lipoproteins, apolipoproteins, and fibrinogen; and diagnosis of hypertension, diabetes mellitus, and ischemic cerebrovascular disease. Results: Odds ratios for ischemic cerebrovascular disease by ACE genotype classes were not significantly different from 1.0 in women or men in any of the three studies, separately or combined. In a logistic regression analysis that controlled for age and conventional cardiovascular risk factors, odds ratios in either sex still did not significantly differ from 1.0 in any study, separately or combined. Conclusion: In two case-referent studies, a cross-sectional study, and the three studies combined, no statistically significant difference was found in the development of ischemic cerebrovascular disease between genotype classes of the ACE gene polymorphism in women or men.	HERLEV UNIV HOSP, DEPT CLIN BIOCHEM, DK-2730 HERLEV, DENMARK; UNIV COPENHAGEN, NATL HOSP, DEPT VASC SURG, DK-2100 COPENHAGEN, DENMARK; UNIV COPENHAGEN, COPENHAGEN, DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; Rigshospitalet; University of Copenhagen; University of Copenhagen			Nordestgaard, Borge Gronne/ABF-1310-2020	Frikke-Schmidt, Ruth/0000-0003-4084-5027				AgerholmLarsen B, 1997, CIRCULATION, V95, P2358, DOI 10.1161/01.CIR.95.10.2358; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Catto A, 1996, STROKE, V27, P435, DOI 10.1161/01.STR.27.3.435; ERDOS EG, 1987, LAB INVEST, V56, P345; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; Kario K, 1996, CIRCULATION, V93, P1630, DOI 10.1161/01.CIR.93.9.1630; LACHURIE ML, 1995, CIRCULATION, V91, P2933, DOI 10.1161/01.CIR.91.12.2933; LEE EJD, 1994, BRIT J CLIN PHARMACO, V37, P212, DOI 10.1111/j.1365-2125.1994.tb04264.x; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; Margaglione M, 1996, ARTERIOSCL THROM VAS, V16, P304, DOI 10.1161/01.ATV.16.2.304; MARKUS HS, 1995, STROKE, V26, P1329, DOI 10.1161/01.STR.26.8.1329; NAKAI K, 1994, CIRCULATION, V90, P2199, DOI 10.1161/01.CIR.90.5.2199; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708; *SPSS WIND, 1993, ADV STAT, P1; *SPSS WIND, 1993, BAS SYST US GUID; TALMUD P, 1991, ATHEROSCLEROSIS, V89, P137, DOI 10.1016/0021-9150(91)90053-6; TIRET L, 1992, AM J HUM GENET, V51, P197; Winkelmann BR, 1996, ANN INTERN MED, V125, P19, DOI 10.7326/0003-4819-125-1-199607010-00004; 1989, SCAND J SOC MED S, V41, P1	22	53	54	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					346	+		10.7326/0003-4819-127-5-199709010-00002	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273825				2022-12-01	WOS:A1997XU10000002
J	BoltonMaggs, PHB; Moon, I				BoltonMaggs, PHB; Moon, I			Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines	LANCET			English	Article							LONG-TERM FOLLOW; THERAPY	Background Guidelines for management of acute immune thrombocytopenic purpura (ITP) in childhood were published in 1992. Regional audit in 1995 showed substantial variation in clinical practice not related to clinical differences in patient groups, which indicated a need for national audit. Methods Individuals aged from birth to their 16th birthday newly presenting with ITP were identified over 14 months by regular mailing of paediatricians and haematologists for case notification. Information was obtained from follow-up by a detailed questionnaire. Findings ITP was clinically mild and benign in 323 (76%) of 427 cases, including 181 (70%) of 260 cases with platelet counts below 10x10(9)/L. There were no deaths or intracranial haemorrhages. There was a substantial discrepancy between clinical practice and published guidelines: many children were admitted to hospital and received treatment unnecessarily; there was overuse of intravenous immunoglobulin (IVIg) as first-line therapy (94 children); children received steroids without marrow examination; and there was inappropriate use of platelet transfusions (41 with mild or moderate disease). Interpretation Our results indicate a need for change in practice.			BoltonMaggs, PHB (corresponding author), ALDER HEY CHILDRENS HOSP,DEPT HAEMATOL,LIVERPOOL L12 2AP,MERSEYSIDE,ENGLAND.							BLANCHERRE VS, 1985, ROYAL SOC MED INT C, V84, P71; BLANCHETTE VS, 1993, J PEDIATR-US, V123, P989, DOI 10.1016/S0022-3476(05)80400-7; BOLTONMAGGS PHB, 1995, THROMB HAEMOSTASIS, V73, P1069; BUCHANAN GR, 1987, EUR J PEDIATR, V146, P107, DOI 10.1007/BF02343213; Buchanan GR, 1997, BLOOD, V89, P1464, DOI 10.1182/blood.V89.4.1464; CHESSELLS J, 1989, ARCH DIS CHILD, V64, P1326, DOI 10.1136/adc.64.9.1326; DUHEM C, 1994, CLIN EXP IMMUNOL, V97, P79; EDEN OB, 1992, ARCH DIS CHILD, V67, P1056, DOI 10.1136/adc.67.8.1056; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; HALPERIN DS, 1988, AM J DIS CHILD, V142, P508, DOI 10.1001/archpedi.1988.02150050046027; LILLEYMAN JS, 1994, ARCH DIS CHILD, V71, P251, DOI 10.1136/adc.71.3.251; MCELFRESH AE, 1975, J PEDIATR-US, V87, P160, DOI 10.1016/S0022-3476(75)80110-7; REID MM, 1992, ACTA PAEDIATR, V81, P1052, DOI 10.1111/j.1651-2227.1992.tb12175.x; REID MM, 1995, ARCH DIS CHILD, V72, P125, DOI 10.1136/adc.72.2.125; SEKUL EA, 1994, ANN INTERN MED, V121, P259, DOI 10.7326/0003-4819-121-4-199408150-00004; TAMARY H, 1994, ACTA PAEDIATR, V83, P931, DOI 10.1111/j.1651-2227.1994.tb13175.x; WALKER RW, 1984, ARCH DIS CHILD, V59, P316, DOI 10.1136/adc.59.4.316	17	148	154	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					620	623		10.1016/S0140-6736(97)04143-3	http://dx.doi.org/10.1016/S0140-6736(97)04143-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288044				2022-12-01	WOS:A1997XU28300009
J	vantHof, AWJ; Liem, A; deBoer, MJ; Zijlstra, F				vantHof, AWJ; Liem, A; deBoer, MJ; Zijlstra, F			Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction	LANCET			English	Article							LEFT-VENTRICULAR FUNCTION; PRIMARY CORONARY ANGIOPLASTY; INTRAVENOUS STREPTOKINASE; SUCCESSFUL THROMBOLYSIS; RANDOMIZED TRIAL; ARTERY PATENCY; SIZE; PREDICTOR; ELEVATION; INTERVENTION	Background A simple clinical method to stratify risk for patients who have had successful reperfusion therapy after myocardial infarction is attractive since it facilitates the tailoring of therapy. Methods We investigated the clinical value of the 12-lead electrocardiogram (EGG), in 403 patients after successful reperfusion therapy by primary coronary angioplasty, in relation to infarct size measured by enzyme activity, left-ventricular function, and clinical outcome. ECGs were analysed to find the extent of the ST-segment-elevation resolution 1 h after reperfusion therapy. Findings A normalised ST segment was seen in 51% of patients, a partly normalised ST segment in 34%, and 15% had no ST-segment-elevation resolution. Enzymatic infarct size and ejection fraction were related to the extent of the early resolution of the ST segment. The relative risk of death among patients with no resolution compared with patients with a normalised ST segment was 8.7 (95% CI 3.7-20.1), and that among patients with partial resolution compared with patients with a normalised ST segment was 3.6 (1.6-8.3). Interpretation Our findings suggest that ECG patterns reflect the effectiveness of myocardial reperfusion. Patients for whom reperfusion therapy by primary angioplasty was successful and who had normalised ST segments had limited damage to the myocardium and an excellent outlook during follow-up. Patients with persistent ST elevation after reperfusion therapy may need additional interventions since they have more extensive myocardial damage and have a higher mortality rate.	ZIEKENHUIS WEEZENLANDEN, DEPT CARDIOL, NL-8011 JW ZWOLLE, NETHERLANDS				de Boer, M.J./H-8014-2014					BARBASH GI, 1990, BRIT HEART J, V64, P241; CALIFF RM, 1988, ANN INTERN MED, V108, P658, DOI 10.7326/0003-4819-108-5-658; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CLEMMENSEN P, 1990, AM J CARDIOL, V66, P1407, DOI 10.1016/0002-9149(90)90524-5; COX DR, 1972, J R STAT SOC B, V34, P187; DEBOER MJ, 1994, CIRCULATION, V90, P753, DOI 10.1161/01.CIR.90.2.753; DEBOER MJ, 1995, EUR HEART J, V16, P1347, DOI 10.1093/oxfordjournals.eurheartj.a060741; DEZWAAN C, 1988, BRIT HEART J, V59, P175; FERRARI R, 1995, AM J CARDIOL, V76, pB17; *FIBR THER TRIAL F, 1994, LANCET, V43, P311; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HASCHE ET, 1995, CIRCULATION, V92, P710, DOI 10.1161/01.CIR.92.4.710; Hashimoto A, 1996, AM J CARDIOL, V77, P25, DOI 10.1016/S0002-9149(97)89129-1; HERMENS WT, 1992, LANCET, V340, P1297, DOI 10.1016/0140-6736(92)93003-6; Iliceto S, 1996, AM J CARDIOL, V77, P441, DOI 10.1016/S0002-9149(97)89334-4; ITO H, 1992, CIRCULATION, V85, P1699, DOI 10.1161/01.CIR.85.5.1699; Ito H, 1996, CIRCULATION, V93, P223, DOI 10.1161/01.CIR.93.2.223; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klootwijk P, 1996, EUR HEART J, V17, P689; MAES A, 1995, CIRCULATION, V92, P2072, DOI 10.1161/01.CIR.92.8.2072; MAURI F, 1994, J AM COLL CARDIOL, V24, P600, DOI 10.1016/0735-1097(94)90003-5; OHMAN EM, 1994, CIRCULATION, V90, P792, DOI 10.1161/01.CIR.90.2.792; Raitt MH, 1996, CIRCULATION, V93, P48, DOI 10.1161/01.CIR.93.1.48; RENTROP KP, 1995, J AM COLL CARDIOL, V25, pS1; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P203; SCHRODER R, 1994, J AM COLL CARDIOL, V24, P384, DOI 10.1016/0735-1097(94)90292-5; VANDERLAARSE A, 1986, AM HEART J, V112, P672, DOI 10.1016/0002-8703(86)90460-6; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WONG PHC, 1994, CATHETER CARDIO DIAG, V33, P39, DOI 10.1002/ccd.1810330111; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	32	477	483	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					615	619		10.1016/S0140-6736(96)07120-6	http://dx.doi.org/10.1016/S0140-6736(96)07120-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288043				2022-12-01	WOS:A1997XU28300008
J	Herrada, G; Dulac, C				Herrada, G; Dulac, C			A novel family of putative pheromone receptors in mammals with a topographically organized and sexually dimorphic distribution	CELL			English	Article							ACCESSORY OLFACTORY-BULB; VOMERONASAL SYSTEM; DIFFERENTIAL LOCALIZATION; CA2+-SENSING RECEPTOR; GLUTAMATE RECEPTOR; G-PROTEINS; EXPRESSION; EPITHELIUM; RAT; BINDING	Mammals have retained two functionally and anatomically independent collections of olfactory neurons located in the main olfactory epithelium and in the vomeronasal organ (VNO). Pheromones activate the VNO in order to elicit fixed action behaviors and neuroendocrine changes involved in animal reproduction and aggression. Differential screening of cDNA libraries constructed from individual rat VNO neurons has led to the isolation of a novel family of similar to 100 genes encoding seven transmembrane receptors with sequence similarity with Ca2+-sensing and metabotropic glutamate receptors. These genes are likely to encode a novel family of pheromone receptors. Patterns of receptor gene expression suggest that the VNO is organized into discrete and sexually dimorphic functional units that may permit segregation of pheromone signals leading to specific arrays of behaviors and neuroendocrine responses.			Herrada, G (corresponding author), HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOL BIOL,CAMBRIDGE,MA 02138, USA.			Dulac, Catherine/0000-0001-5024-5418				Berghard A, 1996, J NEUROSCI, V16, P909; Berliner DL, 1996, J STEROID BIOCHEM, V58, P259, DOI 10.1016/0960-0760(96)00062-3; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; HENZEL WJ, 1988, J BIOL CHEM, V263, P16682; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; Humphrey T, 1940, J COMP NEUROL, V73, P431, DOI 10.1002/cne.900730305; ICHIKAWA M, 1994, DEV BRAIN RES, V78, P1, DOI 10.1016/0165-3806(94)90002-7; IMAMURA K, 1985, BRAIN RES, V328, P362, DOI 10.1016/0006-8993(85)91050-9; JACOBSON L, 1811, ANN MUS HIST NAT PAR, V18, P412; JIANG XC, 1990, J BIOL CHEM, V265, P8736; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LIMAN ER, 1996, NEUROBIOLOGY, V6, P487; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MELROSE DR, 1971, BRIT VET J, V127, P497, DOI 10.1016/S0007-1935(17)37337-2; MENZIES RA, 1992, PHYSIOL BEHAV, V52, P741, DOI 10.1016/0031-9384(92)90408-T; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1987, BRAIN RES, V408, P215, DOI 10.1016/0006-8993(87)90375-1; MURPHY MR, 1970, SCIENCE, V167, P302, DOI 10.1126/science.167.3916.302; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Rasmussen LEL, 1996, NATURE, V379, P684, DOI 10.1038/379684a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHELLER RH, 1982, CELL, V28, P707, DOI 10.1016/0092-8674(82)90050-2; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SHINOHARA H, 1992, ACTA ANAT, V144, P167; SINGER AG, 1986, J BIOL CHEM, V261, P3323; SORENSEN PW, 1988, BIOL REPROD, V39, P1039, DOI 10.1095/biolreprod39.5.1039; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4348; SULLIVAN SL, 1995, NEURON, V15, P779, DOI 10.1016/0896-6273(95)90170-1; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILSON E, 1963, PHEROMONES SCI AM, V5, P2; WYSOCKI CJ, 1989, NEURAL CONTROL REPRO, P545	47	559	581	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					763	773		10.1016/S0092-8674(00)80536-X	http://dx.doi.org/10.1016/S0092-8674(00)80536-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288755	Bronze			2022-12-01	WOS:A1997XT06600019
J	Seppala, H; Klaukka, T; VuopioVarkila, J; Muotiala, A; Helenius, H; Lager, K; Huovinen, P; Kontiainen, S; Eskola, J; Korpela, J; KostialaThompson, A; Sarkkinen, H; Schauman, K; Sivonen, A; Vaara, M; Eerola, E; Hiekkaniemi, H; Jarvinen, H; Klossner, ML; Lehtonen, OP; Meurman, O; Oinonen, S; Katila, ML; Karkkainen, P; Liimatainen, O; Vuento, R; Nissinen, A; Hirvonen, P; Kauppinen, M; Kirsi, O; Larinkari, U; Ahonen, E; Herva, E; Jagerroos, H; Koskela, M; Lantto, K; Ruuska, P				Seppala, H; Klaukka, T; VuopioVarkila, J; Muotiala, A; Helenius, H; Lager, K; Huovinen, P; Kontiainen, S; Eskola, J; Korpela, J; KostialaThompson, A; Sarkkinen, H; Schauman, K; Sivonen, A; Vaara, M; Eerola, E; Hiekkaniemi, H; Jarvinen, H; Klossner, ML; Lehtonen, OP; Meurman, O; Oinonen, S; Katila, ML; Karkkainen, P; Liimatainen, O; Vuento, R; Nissinen, A; Hirvonen, P; Kauppinen, M; Kirsi, O; Larinkari, U; Ahonen, E; Herva, E; Jagerroos, H; Koskela, M; Lantto, K; Ruuska, P			The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group a streptococci in Finland	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROUP-A STREPTOCOCCI; JAPAN; PYOGENES; DECLINE	Background In the early 1990s there was an increase in erythromycin resistance among group A streptococci in Finland. In response, policies regarding outpatient antibiotic therapy were changed, and nationwide recommendations were issued that called for reductions in the use of macrolide antibiotics for respiratory and skin infections in outpatients. We studied the effect of this policy on the pattern of erythromycin resistance throughout Finland. Methods From 1991 through 1996, a total of 39,247 group A streptococcal isolates from throat swabs (82 percent of the isolates) and pus samples (18 percent) and 290 isolates from blood cultures were studied in regional microbiology laboratories. The susceptibility of the isolates to erythromycin was tested by the disk-diffusion or the screening-prate method. Results Consumption of macrolide antibiotics decreased from 2.40 defined daily doses per 1000 inhabitants per day in 1991 to 1.38 in 1992 (P=0.007) and remained near the lower level during the study period. The change in consumption was followed by a steady decrease in the frequency of erythromycin resistance among group A streptococcal isolates from throat swabs and pus samples, from 16.5 percent in 1992 to 8.6 percent in 1996 (odds ratio for 1996 as compared with 1992, 0.5; 95 percent confidence interval, 0.4 to 0.5). Conclusions in Finland, after nationwide reductions in the use of macrolide antibiotics for outpatient therapy, there was a significant decline in the frequency of erythromycin resistance among group A streptococci isolated from throat swabs and pus samples. (C) 1997, Massachusetts Medical Society.	NATL PUBL HLTH INST,DEPT BACTERIOL,TURKU 20521,FINLAND; NATL PUBL HLTH INST,HELSINKI,FINLAND; SOCIAL INSURANCE INST,HELSINKI,FINLAND; UNIV TURKU,DEPT BIOSTAT,TURKU,FINLAND; AURORA HOSP,SF-00250 HELSINKI,FINLAND; CENT HOSP KANTA HAME,HAMEENLINNA,FINLAND; JORVI HOSP,SF-02740 ESPOO,FINLAND; CENT HOSP PAIJAT HAME,LAHTI,FINLAND; DEACONESS INST HELSINKI,HELSINKI,FINLAND; UNIV HELSINKI,HELSINKI,FINLAND; UNIV HELSINKI HOSP,HELSINKI,FINLAND; CENT HOSP VAASA,VAASA,FINLAND; CENT HOSP SATAKUNTA,PORI,FINLAND; UNIV TURKU,CENT HOSP,FIN-20520 TURKU,FINLAND; CENT HOSP ETELA POHJANMAA,SEINAJOKI,FINLAND; KUOPIO UNIV HOSP,SF-70210 KUOPIO,FINLAND; CENT HOSP MIKKELI,MIKKELI,FINLAND; TAMPERE UNIV HOSP,TAMPERE,FINLAND; CENT HOSP KESKI SUOMI,JYVASKYLA,FINLAND; CENT HOSP ETELA KARJALA,LAPPEENRANTA,FINLAND; CENT HOSP POHJOIS KARJALA,JOENSUU,FINLAND; CENT HOSP SAVONLINNA,SAVONLINNA,FINLAND; CENT HOSP KYMENLAAKSO,KOTKA,FINLAND; CENT HOSP KAINUU,KAJAANI,FINLAND; NATL PUBL HLTH INST,OULU,FINLAND; CENT HOSP LAPPI,ROVANIEMI,FINLAND; UNIV HOSP OULU,OULU,FINLAND; DEACONESS INST OULU,OULU,FINLAND; UNIV OULU,OULU,FINLAND	Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Turku; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Vaasa Central Hospital; Satakunta Central Hospital; University of Turku; Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University Hospital; Central Finland Central Hospital; Finland National Institute for Health & Welfare; University of Oulu	Seppala, H (corresponding author), NATL PUBL HLTH INST,ANTIMICROBIAL RES LAB,POB 57,TURKU 20521,FINLAND.		Huovinen, Pentti/C-1917-2009; Vaara, Martti S/D-1698-2013					Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BASS JW, 1994, ARCH PEDIAT ADOL MED, V148, P67, DOI 10.1001/archpedi.1994.02170010069016; Bronze MS, 1996, AM J MED SCI, V311, P41, DOI 10.1097/00000441-199601000-00008; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; FUJITA K, 1994, PEDIATR INFECT DIS J, V13, P1075, DOI 10.1097/00006454-199412000-00001; GERBER MA, 1995, PEDIATR CLIN N AM, V42, P539; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; HOUVINEN P, 1991, FINN MED J, V46, P3241; HUOVINEN P, 1992, FINN MED J, V47, P13; LEPPER MH, 1953, J LAB CLIN MED, V42, P832; MARUYAMA S, 1979, AM J DIS CHILD, V133, P1143, DOI 10.1001/archpedi.1979.02130110051007; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; MITSUHASHI S, 1982, MICROBIOLOGY 1982, P151; MOLSTAD S, 1988, SCAND J INFECT DIS, V20, P329, DOI 10.3109/00365548809032459; Muotiala A, 1997, J INFECT DIS, V175, P392, DOI 10.1093/infdis/175.2.392; *NAT AG MED, 1995, FINN STAT MED 1994; *NAT COMM CLIN LAB, 1995, PERF STAND ANT SUSC, V15, pM100; National Agency for Medicines and Social Insurance Institution, 1996, FINN STAT MED 1995; NISSINEN A, 1995, SCAND J INFECT DIS, V27, P52, DOI 10.3109/00365549509018972; RIDLEY M, 1970, LANCET, V1, P230; SAS Institute, 1990, SAS STAT US GUID VER; SEPPALA H, 1993, J ANTIMICROB CHEMOTH, V32, P885, DOI 10.1093/jac/32.6.885; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; Seppala H, 1995, CLIN INFECT DIS, V21, P1378, DOI 10.1093/clinids/21.6.1378; Tenover FC, 1996, AM J MED SCI, V311, P9, DOI 10.1097/00000441-199601000-00003	27	915	948	0	74	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					441	446		10.1056/NEJM199708143370701	http://dx.doi.org/10.1056/NEJM199708143370701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250845				2022-12-01	WOS:A1997XQ49900001
J	Gerber, JK; Gogel, E; Berger, C; Wallisch, M; Muller, F; Grummt, I; Grummt, F				Gerber, JK; Gogel, E; Berger, C; Wallisch, M; Muller, F; Grummt, I; Grummt, F			Termination of mammalian rDNA replication: Polar arrest of replication fork movement by transcription termination factor TTF-I	CELL			English	Article							RIBOSOMAL-RNA GENES; BACILLUS-SUBTILIS CHROMOSOME; SIMIAN VIRUS-40 DNA; POLYMERASE-I; 3' END; SACCHAROMYCES-CEREVISIAE; TERMINUS REGION; BINDING DOMAIN; SEQUENCES; ORGANIZATION	A replication fork barrier (RFB) al the 3' end of eukaryotic ribosomal RNA genes blocks bidirectional fork progression and limits DNA replication to the same direction as transcription. We have reproduced the RFB in vitro in HeLa cell extracts using 3' terminal murine rDNA fused to an SV40 origin-based vector. The RFB is polar and modularly organized, requiring both the Sal box transcription terminator and specific flanking sequences. Mutations within the terminator element, depletion of the RNA polymerase I-specific transcription termination factor TTF-I, or deletion of the termination domain of TTF-I abolishes RFB activity. Thus, the same factor that blocks elongating RNA polymerase I prevents head-on collision between the DNA replication apparatus and the transcription machinery.	UNIV WURZBURG,INST BIOCHEM,D-97074 WURZBURG,GERMANY; GERMAN CANC RES CTR,DIV MOL BIOL CELL 2,D-69120 HEIDELBERG,GERMANY; INST MOL BIOTECHNOL,DIV BIOCHEM,D-07745 JENA,GERMANY	University of Wurzburg; Helmholtz Association; German Cancer Research Center (DKFZ)				Wallisch, Michael/0000-0002-7133-795X				BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BARTSCH I, 1988, MOL CELL BIOL, V8, P3891, DOI 10.1128/MCB.8.9.3891; BARTSCH I, 1987, MOL CELL BIOL, V7, P2521, DOI 10.1128/MCB.7.7.2521; Bastia D., 1996, DNA REPLICATION EUKA, P177; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; Ermakova OV, 1996, J BIOL CHEM, V271, P33009, DOI 10.1074/jbc.271.51.33009; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; EVERS R, 1995, P NATL ACAD SCI USA, V92, P5827, DOI 10.1073/pnas.92.13.5827; Gogel E, 1996, CHROMOSOMA, V104, P511, DOI 10.1007/BF00352115; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; GRUMMT I, 1986, CELL, V45, P837, DOI 10.1016/0092-8674(86)90558-1; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HOSS A, 1990, J VIROL, V64, P4799; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KERMEKCHIEV MB, 1987, NUCLEIC ACIDS RES, V15, P4131, DOI 10.1093/nar/15.10.4131; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V74, P3927, DOI 10.1073/pnas.74.9.3927; KUHN A, 1988, EMBO J, V7, P1497, DOI 10.1002/j.1460-2075.1988.tb02968.x; LABHART P, 1987, MOL CELL BIOL, V7, P1900, DOI 10.1128/MCB.7.5.1900; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; LUCCHINI R, 1994, MOL CELL BIOL, V14, P318, DOI 10.1128/MCB.14.1.318; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; PFLEIDERER C, 1990, NUCLEIC ACIDS RES, V18, P4727, DOI 10.1093/nar/18.16.4727; REEDER RH, 1994, MOL MICROBIOL, V12, P11, DOI 10.1111/j.1365-2958.1994.tb00989.x; Sander EE, 1996, NUCLEIC ACIDS RES, V24, P3677, DOI 10.1093/nar/24.19.3677; SANDER EE, 1997, NUCLEIC ACIDS RES, V25, P3677; SMID A, 1992, J MOL BIOL, V227, P635, DOI 10.1016/0022-2836(92)90213-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710	43	100	103	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					559	567		10.1016/S0092-8674(00)80515-2	http://dx.doi.org/10.1016/S0092-8674(00)80515-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267035	Bronze			2022-12-01	WOS:A1997XQ06300019
J	Hanson, PI; Roth, R; Morisaki, H; Jahn, R; Heuser, JE				Hanson, PI; Roth, R; Morisaki, H; Jahn, R; Heuser, JE			Structure and conformational changes in NSF and its membrane receptor complexes visualized by quick-freeze/deep-etch electron microscopy	CELL			English	Article							SENSITIVE FUSION PROTEIN; VESICLE FUSION; VESICULAR TRANSPORT; ESCHERICHIA-COLI; CLPAP PROTEASE; GENE-PRODUCT; IN-VITRO; YEAST; MECHANISM; BINDING	Using quick-freeze/deep-etch electron microscopy of recombinant proteins adsorbed to mica, we show that NSF, the oligomeric ATPase involved in membrane fusion, is a hollow 10 x 16 nm cylinder whose conformation depends upon nucleotide binding. Depleted of nucleotide, NSF converts to a ''splayed'' protease-sensitive conformation that reveals its subunit composition. NSF's synaptic membrane substrate, the ternary SNARE complex containing syntaxin, SNAP-25, and synaptobrevin, is a 4 x 14 nm rod with a ''tail'' at one end, corresponding to the N-terminus of syntaxin. Using epitope tags, antibodies, and maltose-binding protein markers, we find that syntaxin and synaptobrevin are aligned in parallel in the complex, with their membrane anchors located at the same end of the rod. This SNARE rod binds with alpha-SNAP to one end of the NSF cylinder to form an asymmetric ''20S'' complex. Together, these images suggest how NSF could dissociate the SNARE complex and how association and dissociation of the complex could be related to membrane fusion.	HOWARD HUGHES MED INST, BOYER CTR MOL MED, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute	Hanson, PI (corresponding author), YALE UNIV, DEPT PHARMACOL, ROOM 247, 295 CONGRESS AVE, NEW HAVEN, CT 06510 USA.		Heuser, John/H-5940-2012; Hanson, Phyllis/E-9420-2012	Jahn, Reinhard/0000-0003-1542-3498	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029647] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29647] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; RAND RP, 1986, ANNU REV PHYSIOL, V48, P201; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHELLER RH, 1995, NEURON, V14, P893; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SINGH SK, 1994, J BIOL CHEM, V269, P29537; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILLIAMS RC, 1946, J APPL PHYS, V17, P23, DOI 10.1063/1.1707630; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	49	653	669	2	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					523	535		10.1016/S0092-8674(00)80512-7	http://dx.doi.org/10.1016/S0092-8674(00)80512-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267032	hybrid			2022-12-01	WOS:A1997XQ06300016
J	Dolan, RJ; Fletcher, PC				Dolan, RJ; Fletcher, PC			Dissociating prefrontal and hippocampal function in episodic memory encoding	NATURE			English	Article							AMNESIA; ACTIVATION; RETRIEVAL	Human lesion data indicate that an intact left hippocampal formation is necessary for auditory-verbal memory(1). By contrast, functional neuroimaging has highlighted the role of the left prefrontal cortex(2-4) but has generally failed to reveal the predicted left hippocampal activation. Here we describe an experiment involving learning category-exemplar word pairs (such as 'dog...boxer') in which we manipulate the novelty of either individual elements or the entire category-exemplar pairing. We demonstrate both left medial temporal (including hippocampal) and left prefrontal activation and show that these activations are dissociable with respect to encoding demands. Left prefrontal activation is maximal with a change in category-exemplar pairings, whereas medial temporal activation is sensitive to the overall degree of novelty. Thus, left prefrontal cortex is sensitive to processes required to establish meaningful connections between a category and its exemplar, a process maximized when a previously formed connection is changed. Conversely, the left medial temporal activation reflects processes that register the overall novelty of the presented material. Our results provide striking evidence of functionally dissociable roles for the prefrontal cortex and hippocampal formation during learning of auditory-verbal material.	ROYAL FREE HOSP,SCH MED,LONDON NW3,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Dolan, RJ (corresponding author), INST NEUROL,WELLCOME DEPT COGNIT NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND.		Fletcher, Paul/F-5380-2011	Fletcher, Paul/0000-0001-8257-1517; Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACK FW, 1976, J CLIN PSYCHOL, V32, P366, DOI 10.1002/1097-4679(197604)32:2<366::AID-JCLP2270320234>3.0.CO;2-F; DIMSDALE H, 1964, NEUROPSYCHOLOGIA, V1, P287, DOI 10.1016/0028-3932(64)90022-3; FAHY FL, 1993, EXP BRAIN RES, V96, P457; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V13, P1305; GRADY CL, 1994, J NEUROSCI, V14, P1450, DOI 10.1523/JNEUROSCI.14-03-01450.1994; Grafman, 1989, HDB NEUROPSYCHOLOGY, P91; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; Halgren Eric, 1995, P1137; JETTER W, 1986, CORTEX, V22, P229, DOI 10.1016/S0010-9452(86)80047-8; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; LI L, 1993, J NEUROPHYSIOL, V69, P1918, DOI 10.1152/jn.1993.69.6.1918; Martin A, 1996, NATURE, V379, P649, DOI 10.1038/379649a0; MOSCOVITCH M, 1982, MULTIPLE DISSOCIATIO, P337; NYBERG J, 1996, P NATL ACAD SCI USA, V93, P11280; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SCHACTER DL, 1987, PSYCHOBIOLOGY, V15, P21; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; SHIMAMURA AP, 1995, J COGNITIVE NEUROSCI, V7, P144, DOI 10.1162/jocn.1995.7.2.144; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; ZATORRE RJ, 1983, BRAIN COGNITION, V2, P331, DOI 10.1016/0278-2626(83)90017-9; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	29	328	329	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					582	585		10.1038/41561	http://dx.doi.org/10.1038/41561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252188	Bronze, Green Submitted			2022-12-01	WOS:A1997XP72200049
J	Dickens, M; Rogers, JS; Cavanagh, J; Raitano, A; Xia, ZG; Halpern, JR; Greenberg, ME; Sawyers, CL; Davis, RJ				Dickens, M; Rogers, JS; Cavanagh, J; Raitano, A; Xia, ZG; Halpern, JR; Greenberg, ME; Sawyers, CL; Davis, RJ			A cytoplasmic inhibitor of the JNK signal transduction pathway	SCIENCE			English	Article							PROTEIN-KINASES; ACTIVATION DOMAIN; PHOSPHORYLATION; JUN; TRANSFORMATION; INTEGRATION; ASSOCIATION; MECHANISM; ONCOGENE; CONTAINS	The c-Jun amino-terminal kinase (JNK) is a member of the stress-activated group of mitogen-activated protein (MAP) kinases that are implicated in the control of cell growth. A murine cytoplasmic protein that binds specifically to JNK [the JNK interacting protein-1 (JIP-1)] was characterized and cloned. JIP-1 caused cytoplasmic retention of JNK and inhibition of JNK-regulated gene expression. In addition, JIP-1 suppressed the effects of the JNK signaling pathway on cellular proliferation, including transformation by the Bcr-Abl oncogene. This analysis identifies JIP-1 as a specific inhibitor of the JNK signal transduction pathway and establishes protein targeting as a mechanism that regulates signaling by stress-activated MAP kinases.	UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; CHILDRENS HOSP, DEPT NEUROL, DIV NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Dickens, Martin/B-2001-2012; Sawyers, Charles/G-5327-2016		NCI NIH HHS [CA43855, CA65861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855, R01CA065861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHOI KY, 1994, CELL, V78, P499; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKENS M, UNPUB; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Rincon Mercedes, 1997, Genes and Function, V1, P51; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	37	615	646	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					693	696		10.1126/science.277.5326.693	http://dx.doi.org/10.1126/science.277.5326.693			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235893				2022-12-01	WOS:A1997XN90700043
J	Riechmann, L; Holliger, P				Riechmann, L; Holliger, P			The C-terminal domain of ToIA is the coreceptor for filamentous phage infection of E-coli	CELL			English	Article							GENE-III PROTEIN; ESCHERICHIA-COLI; ADSORPTION PROTEIN; FD; MEMBRANE; TOLA; BACTERIOPHAGES; TRANSLOCATION; ATTACHMENT; PRODUCTS	Filamentous bacteriophages infecting gram-negative bacteria display tropism for a variety of pilus structures. However, the obligatory coreceptor of phage infection, postulated from genetic studies, has remained elusive. Here we identify the C-terminal domain of the periplasmic protein TolA as the coreceptor for infection of Escherichia coli by phage fd and the N-terminal domain of the phage minor coat protein g3p as its cognate ligand. The neighboring g3p domain binds the primary receptor of phage infection, the F pilus, and blocks TolA binding in its absence. Contact with the pilus releases this blockage during infection. Our findings support a sequential two-way docking mechanism for phage infection, analogous to infection pathways proposed for a range of eukaryotic Viruses including herpes simplex, adenoviruses, and also lentiviruses like HIV-1.	MRC, CTR PROT ENGN, CAMBRIDGE CB2 2QH, ENGLAND	University of Cambridge	Riechmann, L (corresponding author), MRC, MOL BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ARMSTRONG GD, 1980, J BACTERIOL, V141, P333, DOI 10.1128/JB.141.1.333-341.1980; BAYER ME, 1975, MEMBRANE BIOGENESIS, P393; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BOEKE JD, 1982, MOL GEN GENET, V186, P185, DOI 10.1007/BF00331849; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CRISSMAN JW, 1984, VIROLOGY, V132, P445, DOI 10.1016/0042-6822(84)90049-7; Derouiche R, 1996, EMBO J, V15, P6408, DOI 10.1002/j.1460-2075.1996.tb01032.x; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUENAS M, 1994, BIO-TECHNOL, V12, P999, DOI 10.1038/nbt1094-999; ENDEMANN H, 1995, J MOL BIOL, V250, P496, DOI 10.1006/jmbi.1995.0393; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Gibson T., 1984, THESIS U CAMBRIDGE C; GLASERWUTTKE G, 1989, BIOCHIM BIOPHYS ACTA, V985, P239, DOI 10.1016/0005-2736(89)90408-2; GRAMATIKOFF K, 1994, NUCLEIC ACIDS RES, V22, P5761, DOI 10.1093/nar/22.25.5761; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; Holliger P, 1997, STRUCTURE, V5, P265, DOI 10.1016/S0969-2126(97)00184-6; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JACOBSON A, 1972, J VIROL, V10, P835, DOI 10.1128/JVI.10.4.835-843.1972; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; KREBBER K, 1995, FEBS LETT, V377, P227; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Model P., 1988, BACTERIOPHAGES, P375; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, P7; RAMPF B, 1991, FEBS LETT, V280, P27, DOI 10.1016/0014-5793(91)80196-A; RIECHMANN L, 1995, J BIOMOL NMR, V6, P141, DOI 10.1007/BF00211778; RUSSEL M, 1988, J BACTERIOL, V170, P5312, DOI 10.1128/jb.170.11.5312-5316.1988; SATTENTAU QJ, 1993, J VIROL, V67, P7383, DOI 10.1128/JVI.67.12.7383-7393.1993; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1992, CLONING FUSE VECTORS; STENGELE I, 1990, J MOL BIOL, V212, P143, DOI 10.1016/0022-2836(90)90311-9; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WEISS RA, 1995, CELL, V82, P531, DOI 10.1016/0092-8674(95)90024-1; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; ZACHER AN, 1980, GENE, V9, P127, DOI 10.1016/0378-1119(80)90171-7	46	151	178	4	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					351	360		10.1016/S0092-8674(00)80342-6	http://dx.doi.org/10.1016/S0092-8674(00)80342-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244308	Bronze			2022-12-01	WOS:A1997XN24900018
J	Zeng, ZH; Castano, AR; Segelke, BW; Stura, EA; Peterson, PA; Wilson, IA				Zeng, ZH; Castano, AR; Segelke, BW; Stura, EA; Peterson, PA; Wilson, IA			Crystal structure of mouse CD1: An MHC-like fold with a large hydrophobic binding groove	SCIENCE			English	Article							CLASS-I MOLECULES; T-CELL RECEPTOR; NEONATAL FC RECEPTOR; 3-DIMENSIONAL STRUCTURE; HISTOCOMPATIBILITY ANTIGEN; PEPTIDE ANTIGENS; VIRAL PEPTIDES; ALPHA-3 DOMAIN; COMPLEX; RECOGNITION	CD1 represents a third lineage of antigen-presenting molecules that are distantly related to major histocompatibility complex (MHC) molecules in the immune system. The crystal structure of mouse CD1d1, corresponding to human CD1d, at 2.8 Angstrom resolution shows that CD1 adopts an MHC fold that is more closely related to that of MHC class I than to that of MHC class II. The binding groove, although significantly narrower, is substantially larger because of increased depth and it has only two major pockets that are almost completely hydrophobic. The extreme hydrophobicity and shape of the binding site are consistent with observations that human CD1b and CD1c can present mycobacterial cell wall antigens, such as mycolic acid and lipoarabinomannans. However, mouse CD1d1 can present very hydrophobic peptides, but must do so in a very different way from MHC class Ia and class II molecules.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute			Castaño, A. Raul/A-5905-2012; Stura, Enrico A./A-2793-2010	Castaño, A. Raul/0000-0003-2107-8862; Stura, Enrico A./0000-0001-6718-2118; Segelke, Brent/0000-0003-3358-5028	NCI NIH HHS [CA-58896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, SCIENCE, V269, P185, DOI 10.1126/science.7542402; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; CASTANO AM, UNPUB; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; COLLINS EJ, 1995, P NATL ACAD SCI USA, V92, P1218, DOI 10.1073/pnas.92.4.1218; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; DELLABONA P, 1994, J EXP MED, V180, P1171, DOI 10.1084/jem.180.3.1171; DELLABONA P, 1993, J EXP MED, V177, P1763, DOI 10.1084/jem.177.6.1763; ERNST W, COMMUNICATION; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; Gulden PH, 1996, IMMUNITY, V5, P73, DOI 10.1016/S1074-7613(00)80311-8; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; Lenz LL, 1996, IMMUNITY, V5, P63, DOI 10.1016/S1074-7613(00)80310-6; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MCMICHAEL AJ, 1979, EUR J IMMUNOL, V9, P205, DOI 10.1002/eji.1830090307; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nataraj C, 1996, INT IMMUNOL, V8, P367, DOI 10.1093/intimm/8.3.367; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SEGELKE BW, UNPUB; SHIN DH, 1995, STRUCTURE, V3, P189, DOI 10.1016/S0969-2126(01)00149-6; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; SMITH KJ, 1996, P NATL ACAD SCI USA, V4, P203; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; Teitell M, 1997, J IMMUNOL, V158, P2143; *UCSF MGL, 1995, UCSF MID US MAN; VILLIEUX FMD, 1993, DEMON PROGRAM SUITE; VYAS NK, 1991, J BIOL CHEM, V266, P5226; VYAS NK, 1983, P NATL ACAD SCI-BIOL, V80, P1792, DOI 10.1073/pnas.80.7.1792; Wang C., COMMUNICATION; WANG CR, 1995, CELL, V82, P655, DOI 10.1016/0092-8674(95)90037-3; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	77	537	563	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					339	345		10.1126/science.277.5324.339	http://dx.doi.org/10.1126/science.277.5324.339			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219685				2022-12-01	WOS:A1997XL35800037
J	Song, HJ; Ming, GL; Poo, MM				Song, HJ; Ming, GL; Poo, MM			CAMP-induced switching in turning direction of nerve growth cones	NATURE			English	Article							ADENYLYL-CYCLASE; PROTEIN-KINASE; AXONS; GUIDANCE; RECEPTORS; NEURONS; SYSTEM; CA2+	Development of the nervous system depends on the correct pathfinding and target recognition by the growing tip of an axon, the growth cone(1-3). Diffusible or substrate-bound molecules present in the environment may serve as either attractants or repellents to influence the direction of growth-cone extension(4-11). Here we report that differences in cyclic-AMP-dependent activity in a neuron may result in opposite turning of the growth cone in response to the same guidance cue. A gradient of brain-derived neurotrophic factor normally triggers an attractive turning response of the growth cone of Xenopus spinal neurons in culture, but the same gradient induces repulsive turning of these growth cones in the presence of a competitive analogue of cAMP or of a specific inhibitor of protein kinase A. This cAMP-dependent switch of the turning response was also found for turning induced by acetylcholine, but not for the turning induced by neurotrophin-3 (NT-3). Thus, in the presence of other factors that modulate neuronal cAMP-dependent activity, the same guidance cue may trigger opposite turning behaviours of the growth cone during its pathfinding in the nervous system.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego			Ming, Guo-li/J-7880-2013	Ming, Guo-li/0000-0002-2517-6075				[Anonymous], 1996, BIOCH BASIS NEUROPHA; BIXBY JL, 1984, DEV BIOL, V106, P89, DOI 10.1016/0012-1606(84)90065-4; BONHOEFFER F, 1980, NATURE, V288, P162, DOI 10.1038/288162a0; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; Hempel CM, 1996, NATURE, V384, P166, DOI 10.1038/384166a0; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KATER SB, 1988, TRENDS NEUROSCI, V11, P317; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kim YT, 1996, J NEUROSCI, V16, P5593; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LOHOF AM, 1992, J NEUROSCI, V12, P1253; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; Stoop R, 1996, J NEUROSCI, V16, P3256; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; YOVELL Y, 1992, J NEUROCHEM, V59, P1736, DOI 10.1111/j.1471-4159.1992.tb11005.x; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	30	508	521	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					275	279		10.1038/40864	http://dx.doi.org/10.1038/40864			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230436				2022-12-01	WOS:A1997XL12100051
J	Wald, NJ; Watt, HC				Wald, NJ; Watt, HC			Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking related diseases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TOBACCO-SMOKE; EXPOSURE	Objective: To estimate the extent to which cigarette smokers who switch to cigars or pipes alter their risk of dying of three smoking related diseases-lung cancer, ischaemic heart disease, and chronic obstructive lung disease. Design: A prospective study of 21 520 men aged 35-64 years when recruited in 1975-82 with detailed history of smoking and measurement of carboxyhaemoglobin. Main outcome measures: Notification of deaths (to 1993) classified by cause. Results: Pipe and cigar smokers who had switched from cigarettes over 20 years before entry to the study smoked less tobacco than cigarette smokers (8.1 g/day v 20 g/day), but they had the same consumption as pipe and cigar smokers who had never smoked cigarettes (8.1 g) and had higher carboxyhaemoglobin saturations (1.2% v 1.0%, P < 0.001), indicating that they inhaled tobacco smoke to a greater extent They had a 51% higher risk of dying of the three smoking related diseases than pipe or cigar smokers who had never smoked cigarettes (relative risk 1.51; 95% confidence interval 0.96 to 2.38), a 68% higher risk than lifelong non-smokers (1.68; 1.16 to 2.45), a 57% higher risk than former cigarette smokers who gave up smoking over 20 years before entry (1.57; 1.04 to 2.38), and a 46% lower risk than continuing cigarette smokers (0.54; 0.38 to 0.77). Conclusion: Cigarette smokers who have difficulty in giving up smoking altogether are better off changing to cigars or pipes than continuing to smoke cigarettes. Much of the effect is due to the reduction in the quantity of tobacco smoked, and some is due to inhaling less. Men who switch do not, however, achieve the lower risk of pipe and cigar smokers who have never smoked cigarettes. All pipe and cigar smokers have a greater risk of lung cancer than lifelong non-smokers or former smokers.	ROYAL LONDON SCH MED & DENT, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London	Wald, NJ (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP MED COLL, WOLFSON INST PREVENT MED, BUPA EPIDEMIOL RES GRP, LONDON EC1M 6BQ, ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					BENSHLOMO Y, 1994, AM J PUBLIC HEALTH, V84, P1235, DOI 10.2105/AJPH.84.8.1235; CASTLEDEN CM, 1973, LANCET, V2, P21; COWIE J, 1973, LANCET, V1, P1033; GOLDMAN AL, 1977, CHEST, V72, P33, DOI 10.1378/chest.72.1.33; KAUFMAN DW, 1987, BRIT MED J, V294, P1315, DOI 10.1136/bmj.294.6583.1315; OCKENE JK, 1987, AM J PUBLIC HEALTH, V77, P1412, DOI 10.2105/AJPH.77.11.1412; PECHACEK TF, 1985, JAMA-J AM MED ASSOC, V254, P3330, DOI 10.1001/jama.254.23.3330; RODENSTEIN DO, 1985, AM REV RESPIR DIS, V132, P628; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; TURNER JAM, 1977, BMJ-BRIT MED J, V2, P1387, DOI 10.1136/bmj.2.6099.1387; WALD N, 1978, THORAX, V33, P201, DOI 10.1136/thx.33.2.201; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1	12	66	68	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	1997	314	7098					1860	1863		10.1136/bmj.314.7098.1860	http://dx.doi.org/10.1136/bmj.314.7098.1860			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224127	Green Published			2022-12-01	WOS:A1997XH73800020
J	Pan, ZZ; Tershner, SA; Fields, HL				Pan, ZZ; Tershner, SA; Fields, HL			Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor	NATURE			English	Article							MORPHINE ANALGESIA; MEDULLARY MU; DEPENDENCE; TOLERANCE; REWARD; PHARMACOLOGY; DYNORPHIN; PEPTIDES; PATHWAYS; MODULATE	The analgesic effect of clinically used exogenous opioids, such as morphine, is mediated primarily through mu-opioid receptors(1-3), but the function of the kappa-receptor in opioid analgesia is unclear. Although kappa-receptor agonists can produce analgesia(4,5), behavioural studies indicate that kappa agonists applied intravenously or locally into the spinal cord antagonize morphine analgesia (see refs 4, 6 for reviews). As morphine, a primary mu agonist(1), also binds to kappa-receptors(7) and the analgesic effectiveness of morphine decreases with repeated use (tolerance), it is important to understand the mechanism for the functional interaction between kappa- and mu-opioid receptors in the central nervous system. Here we present in vitro electrophysiological and in vivo behavioural evidence that activation of the kappa-receptor specifically antagonizes mu-receptor-mediated analgesia. We show that in slice preparations of a rat brainstem nucleus, which is critical for the action of opioids in controlling pain, functional kappa- and mu-receptors are each localized on physiologically different types of neuron. Activation of the kappa-receptor hyperpolarizes neurons that are activated indirectly by the mu-receptor. In rats, kappa-receptor activation in this brainstem nucleus significantly attenuates local mu-receptor-mediated analgesia. Our findings suggest a new cellular mechanism for the potentially ubiquitous opposing interaction between mu- and kappa-opioid receptors and may help in the design of treatments for pain.			Pan, ZZ (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK CTR INTEGRAT NEURSCI,SAN FRANCISCO,CA 94143, USA.		Fields, Howard/ABG-9073-2020					AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BHARGAVA HN, 1994, PHARMACOL REV, V46, P293; Bolanos CA, 1996, EUR J PHARMACOL, V317, P1, DOI 10.1016/S0014-2999(96)00698-X; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DICHIARA G, 1992, TRENDS PHARMACOL SCI, V13, P185; FIELDS HL, 1983, NATURE, V306, P684, DOI 10.1038/306684a0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.ne.14.030191.001251; FUNADA M, 1993, NEUROPHARMACOLOGY, V32, P1315; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GRUDT TJ, 1993, P NATL ACAD SCI USA, V90, P11429, DOI 10.1073/pnas.90.23.11429; HOOKE LP, 1995, J PHARMACOL EXP THER, V273, P292; KIEFEL JM, 1993, BRAIN RES, V624, P151, DOI 10.1016/0006-8993(93)90073-V; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; MARTIN WR, 1983, PHARMACOL REV, V35, P283; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MILLAN MJ, 1990, TRENDS PHARMACOL SCI, V11, P70, DOI 10.1016/0165-6147(90)90321-X; PAN ZZ, 1990, J PHYSIOL-LONDON, V427, P519, DOI 10.1113/jphysiol.1990.sp018185; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd ed; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Reisine T., 1996, GOODMAN GILMANS PHAR, P521; ROTHMAN RB, 1992, SYNAPSE, V12, P129, DOI 10.1002/syn.890120206; Roychowdhury SM, 1996, NEUROSCIENCE, V74, P863, DOI 10.1016/0306-4522(96)00180-7; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0	29	134	139	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					382	385		10.1038/38730	http://dx.doi.org/10.1038/38730			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311779				2022-12-01	WOS:A1997XX67500052
J	Rackoff, P; Feldman, T				Rackoff, P; Feldman, T			Total lymphoid irradiation - not for rheumatoid arthritis	LANCET			English	Editorial Material							TERM FOLLOW-UP				Rackoff, P (corresponding author), BETH ISRAEL MED CTR,DIV RHEUMATOL,NEW YORK,NY 10003, USA.			Rackoff, Paula/0000-0002-4669-2116				HUBERT G, 1985, ARTHRITIS RHEUM, V28, P1205; SODEN M, 1989, ARTHRITIS RHEUM, V32, P523, DOI 10.1002/anr.1780320503; TANAY A, 1987, ARTHRITIS RHEUM-US, V30, P1, DOI 10.1002/art.1780300101; TRENTHAM DE, 1987, ARTHRITIS RHEUM, V30, P980, DOI 10.1002/art.1780300904; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; Westhovens R, 1997, ARTHRITIS RHEUM, V40, P426, DOI 10.1002/art.1780400306	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					752	753		10.1016/S0140-6736(97)22037-4	http://dx.doi.org/10.1016/S0140-6736(97)22037-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297989				2022-12-01	WOS:A1997XW28200004
J	Matlack, KES; Plath, K; Misselwitz, B; Rapoport, TA				Matlack, KES; Plath, K; Misselwitz, B; Rapoport, TA			Protein transport by purified yeast sec complex and Kar2p without membranes	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL SEQUENCE; ER MEMBRANE; TRANSLOCATION; BIP; ENVIRONMENT; BINDING; DNAJ	Posttranslational protein translocation across the endoplasmic reticulum membrane of yeast requires a seven-component transmembrane complex (the Sec complex) in collaboration with the lumenal Kar2 protein (Kar2p). A translocation substrate was initially bound to the cytosolic face of the purified Sec complex in a signal-sequence-dependent but Kar2p- and nucleotide-independent manner. In a subsequent reaction, in which Kar2p interacted with the lumenal face of the Sec complex and hydrolyzed adenosine triphosphate, the substrate moved through a channel formed by the Sec complex and was released at the lumenal end. Movement through the channel occurred in detergent solution in the absence of a lipid bilayer.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Misselwitz, Benjamin/L-7193-2016	Misselwitz, Benjamin/0000-0002-8719-5175; Plath, Kathrin/0000-0001-7796-3372	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054238] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54238-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MATLACK KES, UNPUB; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NELSON MK, 1993, GENETICS, V134, P159; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677	20	63	63	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					938	941		10.1126/science.277.5328.938	http://dx.doi.org/10.1126/science.277.5328.938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252322				2022-12-01	WOS:A1997XQ98500037
J	Kuhl, PK; Andruski, JE; Chistovich, IA; Chistovich, LA; Kozhevnikova, EV; Ryskina, VL; Stolyarova, EI; Sundberg, U; Lacerda, F				Kuhl, PK; Andruski, JE; Chistovich, IA; Chistovich, LA; Kozhevnikova, EV; Ryskina, VL; Stolyarova, EI; Sundberg, U; Lacerda, F			Cross-language analysis of phonetic units in language addressed to infants	SCIENCE			English	Article							SPEECH; MOTHERESE; PATTERNS; PREFERENCE; PROTOTYPES; CATEGORIES; FEATURES; SUPPORT; WORDS	In the early months of life, infants acquire information about the phonetic properties of their native language simply by listening to adults speak. The acoustic properties of phonetic units in language input to young infants in the United States, Russia, and Sweden, were examined. In all three countries, mothers addressing their infants produced acoustically more extreme vowels than they did when addressing adults, resulting in a ''stretching'' of vowel space. The findings show that language input to infants provides exceptionally well-specified information about the linguistic units that form the building blocks for words.	EARLY INTERVENT INST, ST PETERSBURG 191194, RUSSIA; UNIV STOCKHOLM, INST LINGUIST, S-10691 STOCKHOLM, SWEDEN	Stockholm University	Kuhl, PK (corresponding author), UNIV WASHINGTON, DEPT SPEECH & HEARING SCI, BOX 357920, SEATTLE, WA 98195 USA.		Kozhevnikova, Elena/ABB-3431-2020	de Lacerda, Francisco/0000-0002-7980-3601	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P01DC000520] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC 00520] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Chomsky Noam, 1980, RULES REPRESENTATION; Fant G., 1973, SPEECH SOUNDS FEATUR; FERNALD A, 1987, INFANT BEHAV DEV, V10, P279, DOI 10.1016/0163-6383(87)90017-8; FERNALD A, 1985, INFANT BEHAV DEV, V8, P181, DOI 10.1016/S0163-6383(85)80005-9; FERNALD A, 1984, DEV PSYCHOL, V20, P104, DOI 10.1037/0012-1649.20.1.104; FROMKIN V, 1974, BRAIN LANG, V1, P81, DOI 10.1016/0093-934X(74)90027-3; GRIESER D, 1989, DEV PSYCHOL, V25, P577, DOI 10.1037/0012-1649.25.4.577; GRIESER DL, 1988, DEV PSYCHOL, V24, P14, DOI 10.1037/0012-1649.24.1.14; HILLENBRAND J, 1995, J ACOUST SOC AM, V97, P3099, DOI 10.1121/1.411872; IVERSON P, 1995, J ACOUST SOC AM, V97, P553, DOI 10.1121/1.412280; Jakobson R., 1969, PRELIMINARIES SPEECH; JOHNSON K, 1993, LANGUAGE, V69, P505, DOI 10.2307/416697; JUSCZYK PW, 1993, CHILD DEV, V64, P675, DOI 10.2307/1131210; JUSCZYK PW, 1993, J MEM LANG, V32, P402, DOI 10.1006/jmla.1993.1022; KENT RD, 1982, J ACOUST SOC AM, V72, P353, DOI 10.1121/1.388089; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; Kuhl PK, 1996, J ACOUST SOC AM, V100, P2425, DOI 10.1121/1.417951; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; KUHL PK, 1991, PERCEPT PSYCHOPHYS, V50, P93, DOI 10.3758/BF03212211; Lane H., 1976, WILD BOY AVEYRON; LILJENCRANTS J, 1972, LANGUAGE, V48, P839, DOI 10.2307/411991; LINDBLOM B, 1963, J ACOUST SOC AM, V35, P1773, DOI 10.1121/1.1918816; LINDBLOM B, 1990, NATO ADV SCI I D-BEH, V55, P403; LIVELY SE, 1993, J ACOUST SOC AM, V94, P1242, DOI 10.1121/1.408177; Merzenich MM, 1996, SCIENCE, V271, P77, DOI 10.1126/science.271.5245.77; Perkell J.S., 1986, INVARIANCE VARIABILI; PETERSON GE, 1952, J ACOUST SOC AM, V24, P175, DOI 10.1121/1.1906875; PETITTO LA, 1993, NATO ADV SCI INST SE, V69, P365; RATNER NB, 1984, J CHILD LANG, V11, P557, DOI 10.1017/S030500090000595X; Saffran JR, 1996, SCIENCE, V274, P1926, DOI 10.1126/science.274.5294.1926; Snow C.E., 1977, TALKING CHILDREN LAN, P31; Stevens KN, 1994, INTRO COMMUNICATION, P399; Stevens SS, 1937, J ACOUST SOC AM, V8, P185, DOI 10.1121/1.1915893; StuddertKennedy M, 1995, PSYCHON B REV, V2, P508, DOI 10.3758/BF03210986; SWOBODA PJ, 1978, CHILD DEV, V49, P332, DOI 10.1111/j.1467-8624.1978.tb02320.x; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81	36	529	534	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 1	1997	277	5326					684	686		10.1126/science.277.5326.684	http://dx.doi.org/10.1126/science.277.5326.684			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XN907	9235890				2022-12-01	WOS:A1997XN90700040
J	Grawunder, U; Wilm, M; Wu, XT; Kulesza, P; Wilson, TE; Mann, M; Lieber, MR				Grawunder, U; Wilm, M; Wu, XT; Kulesza, P; Wilson, TE; Mann, M; Lieber, MR			Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells	NATURE			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; MOLECULAR-CLONING; ATAXIA-TELANGIECTASIA; CATALYTIC SUBUNIT; EXPRESSION; HAMSTER; GENE; DEFICIENCY; MUTATION	Mutation of the XRCC4 gene in mammalian cells(1,2) prevents the formation of the signal and coding joints in the V(D)J recombination reaction(3), which is necessary for production of a functional immunoglobulin gene, and renders the cells highly sensitive to ionizing radiation(4). However, XRCC4 shares no sequence homology with other proteins, nor does it have a biochemical activity to indicate what its function might be(2). Here we show that DNA ligase IV (ref. 5) co-immunoprecipitates with XRCC4 and that these two proteins specifically interact with one another in a yeast two-hybrid system. Ligation of DNA double-strand breaks in a cell-free system by DNA ligase IV is increased fivefold by purified XRCC4 and seven- to eightfold when XRCC4 is co-expressed with DNA ligase IV. We conclude that the biological consequences of mutating XRCC4 are primarily due to the loss of its stimulatory effect on DNA ligase IV: the function of the XRCC4-DNA ligase IV complex may be to carry out the final steps of V(D)J recombination and joining of DNA ends.	EUROPEAN MOL BIOL LAB,PROT & PEPTIDE GRP,D-69012 HEIDELBERG,GERMANY; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV MOL ONCOL,ST LOUIS,MO 63110	European Molecular Biology Laboratory (EMBL); Washington University (WUSTL)			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345; Wilm, Matthias/0000-0002-5461-6834				BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CHEN JW, 1995, MOL CELL BIOL, V15, P5412; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GERSTEIN RM, 1993, NATURE, V363, P625, DOI 10.1038/363625a0; GIACCIA AJ, 1989, SOMAT CELL MOLEC GEN, V15, P71, DOI 10.1007/BF01534671; Grawunder U, 1996, J EXP MED, V183, P1731, DOI 10.1084/jem.183.4.1731; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MILLER RD, 1995, P NATL ACAD SCI USA, V92, P10792, DOI 10.1073/pnas.92.23.10792; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; REEVES WH, 1989, J BIOL CHEM, V264, P5047; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wu XT, 1996, MOL CELL BIOL, V16, P5186; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	517	528	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					492	495		10.1038/41358	http://dx.doi.org/10.1038/41358			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242410	Bronze			2022-12-01	WOS:A1997XN55300053
J	Goldstein, FW; Garau, J				Goldstein, FW; Garau, J			30 years of penicillin-resistant S pneumoniae: Myth or reality?	LANCET			English	Editorial Material							PNEUMOCOCCI; MENINGITIS		UNIV BARCELONA,HOSP MUTUA TERRASSA,DEPT MED,BARCELONA,SPAIN	Hospital Universitario Mutua Terrassa; University of Barcelona	Goldstein, FW (corresponding author), FDN HOP ST JOSEPH,LAB MICROBIOL MED,F-75674 PARIS 14,FRANCE.							Baquero F, 1995, MICROB DRUG RESIST, V1, P115, DOI 10.1089/mdr.1995.1.115; Bradley JS, 1997, CLIN INFECT DIS, V24, pS213, DOI 10.1093/clinids/24.Supplement_2.S213; Goldstein FW, 1996, J ANTIMICROB CHEMOTH, V38, P71, DOI 10.1093/jac/38.suppl_A.71; HANSMAN D, 1974, MED J AUSTRALIA, V2, P353, DOI 10.5694/j.1326-5377.1974.tb70836.x; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; Jacobs RF, 1996, ANTIMICROB AGENTS CH, V40, P895, DOI 10.1128/AAC.40.4.895; Keefer CS, 1943, JAMA-J AM MED ASSOC, V122, P1217; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; PARIS MM, 1995, ANTIMICROB AGENTS CH, V39, P2171, DOI 10.1128/AAC.39.10.2171	9	28	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					233	234		10.1016/S0140-6736(05)62222-2	http://dx.doi.org/10.1016/S0140-6736(05)62222-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242797				2022-12-01	WOS:A1997XM86600006
J	Sisson, JC; Ho, KS; Suyama, K; Scott, MP				Sisson, JC; Ho, KS; Suyama, K; Scott, MP			Costal2, a novel kinesin-related protein in the Hedgehog signaling pathway	CELL			English	Article							POLARITY GENE COSTAL-2; DROSOPHILA-MELANOGASTER; KINASE-A; ENGRAILED LOCUS; HOMEOTIC GENES; IMAGINAL DISKS; SEGMENT; PATTERN; TRANSDUCTION; EXPRESSION	The Hedgehog (HH) signaling proteins control cell fates and patterning during animal development. In Drosophila, HH protein induces the transcription of target genes encoding secondary signals such as DPP and WG proteins by opposing a repressor system. The repressors include Costal2, protein kinase A, and the HH receptor Patched. Like HH, the kinase Fused and the transcription factor Cubitus interruptus (CI) act positively upon targets. Here we show that costal2 encodes a kinesin-related protein that accumulates preferentially in cells capable of responding to HH. COS2 is cytoplasmic and binds microtubules. We find that CI associates with COS2 in a large protein complex, suggesting that COS2 directly controls the activity of CI.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University								Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Ashburner M., 1989, DROSOPHILA LAB HDB; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COLE DG, 1994, J BIOL CHEM, V269, P22913; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; Foe Victoria E., 1993, P149; FORBES AJ, 1993, DEVELOPMENT S, V119, P115; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRAU Y, 1987, DEV BIOL, V122, P186, DOI 10.1016/0012-1606(87)90344-7; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HEITZLER P, 1993, GENETICS, V135, P105; Hepker J, 1997, DEVELOPMENT, V124, P549; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; LILLIE SH, 1992, NATURE, V356, P358, DOI 10.1038/356358a0; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; MATHIES LD, 1994, DEVELOPMENT, V120, P2799; MILLER KG, 1989, J CELL BIOL, V109, P2963, DOI 10.1083/jcb.109.6.2963; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARDUE ML, 1994, METHOD CELL BIOL, V44, P333, DOI 10.1016/S0091-679X(08)60922-X; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1993, GENETICS, V135, P1047; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sambrook J., 1989, MOL CLONING LAB MANU; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SAXTON WM, 1994, METHOD CELL BIOL, V44, P279, DOI 10.1016/S0091-679X(08)60919-X; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1987, DEV BIOL, V122, P201, DOI 10.1016/0012-1606(87)90345-9; SLUSARSKI DC, 1995, GENETICS, V139, P229; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; THEURKAUF WE, 1992, DEV BIOL, V154, P205, DOI 10.1016/0012-1606(92)90060-T; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; WHITTLE JRS, 1976, DEV BIOL, V51, P257, DOI 10.1016/0012-1606(76)90142-1; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; XU T, 1994, PRACTICAL USES CELL, V44, P655; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	68	286	301	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					235	245		10.1016/S0092-8674(00)80332-3	http://dx.doi.org/10.1016/S0092-8674(00)80332-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244298	Bronze			2022-12-01	WOS:A1997XN24900008
J	Straight, AF; Marshall, WF; Sedat, JW; Murray, AW				Straight, AF; Marshall, WF; Sedat, JW; Murray, AW			Mitosis in living budding yeast: Anaphase a but no metaphase plate	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; MITOTIC SPINDLE; SEGREGATION; KINETOCHORES; CHECKPOINT; DYNAMICS; FORCES; CELLS	Chromosome movements and spindle dynamics were visualized in living cells of the budding yeast Saccharomyces cerevisiae. Individual chromosomal loci were detected by expression of a protein fusion between green fluorescent protein (GFP) and the Lac repressor, which bound to an array of Lac operator binding sites integrated into the chromosome. Spindle microtubules were detected by expression of a protein fusion between GFP and Tub1, the major alpha tubulin. Spindle elongation and chromosome separation exhibited biphasic kinetics, and centromeres separated before telomeres. Budding yeast did not exhibit a conventional metaphase chromosome alignment but did show anaphase A, movement of the chromosomes to the poles.	UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Straight, AF (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.			Straight, Aaron/0000-0001-5885-7881				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; BAJER AS, 1986, J CELL BIOL, V102, P263, DOI 10.1083/jcb.102.1.263; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Guacci V, 1997, MOL BIOL CELL, V8, P957, DOI 10.1091/mbc.8.6.957; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cb.04.110188.002523; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1992, J CELL SCI, V102, P681; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; PAGE BD, 1993, ANNU REV MICROBIOL, V47, P231, DOI 10.1146/annurev.micro.47.1.231; PETERSON JB, 1976, J CELL SCI, V22, P219; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687	23	313	318	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 25	1997	277	5325					574	578		10.1126/science.277.5325.574	http://dx.doi.org/10.1126/science.277.5325.574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228009				2022-12-01	WOS:A1997XM86700054
J	Kim, U; SanchezVives, MV; McCormick, DA				Kim, U; SanchezVives, MV; McCormick, DA			Functional dynamics of GABAergic inhibition in the thalamus	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; CENTRAL-NERVOUS-SYSTEM; UNDERLYING SYNCHRONIZED OSCILLATIONS; IN-VITRO; POSTSYNAPTIC POTENTIALS; PERIGENICULATE NUCLEUS; ABSENCE SEIZURES; PYRAMIDAL CELLS; ELECTROPHYSIOLOGICAL PROPERTIES; THALAMOCORTICAL OSCILLATIONS	The inhibitory gamma-aminobutyric acid-containing (GABAergic) neurons of the thalamic reticular and perigeniculate nuclei are involved in the generation of normal and abnormal synchronized activity in thalamocortical networks. An important factor controlling the generation of activity in this system is the amplitude and duration of inhibitory postsynaptic potentials (IPSPs) in thalamocortical cells, which depend on the pattern of activity generated in thalamic reticular and perigeniculate cells. Activation of single ferret perigeniculate neurons generated three distinct patterns of GABAergic IPSPs in thalamocortical neurons of the dorsal lateral geniculate nucleus: Low-frequency tonic discharge resulted in small-amplitude IPSPs mediated by GABA(A) receptors, burst firing resulted in large-amplitude GABA(A) IPSPs, and prolonged burst firing activated IPSPs mediated by GABA(A) and GABA(B) receptors. These functional properties of GABAergic inhibition can reconfigure the operations of thalamocortical networks into patterns of activity associated with waking, slow-wave sleep, and generalized seizures.	YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06510 USA	Yale University			Kobelt, Liza/F-5926-2011; Sanchez-Vives, Maria/J-8526-2014; McCormick, David A/J-2649-2015	Sanchez-Vives, Maria/0000-0002-8437-9083; McCormick, David A/0000-0002-9803-8335				AVOLI M, 1983, J NEUROPHYSIOL, V50, P819, DOI 10.1152/jn.1983.50.4.819; Bal T, 1996, NEURON, V17, P297, DOI 10.1016/S0896-6273(00)80161-0; BAL T, 1995, J PHYSIOL-LONDON, V483, P641, DOI 10.1113/jphysiol.1995.sp020612; BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; BENARDO LS, 1994, J PHYSIOL-LONDON, V476, P203, DOI 10.1113/jphysiol.1994.sp020124; BERMAN NJ, 1992, PROG BRAIN RES, V90, P443; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUSCH C, 1990, COLD SPRING HARB SYM, V55, P69; BUZSAKI G, 1991, NEUROSCIENCE, V41, P351, DOI 10.1016/0306-4522(91)90332-I; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; CONTRERAS D, 1993, J PHYSIOL-LONDON, V470, P273, DOI 10.1113/jphysiol.1993.sp019858; Cox C. L., 1996, Society for Neuroscience Abstracts, V22, P97; CRUNELLI V, 1991, TRENDS NEUROSCI, V14, P16, DOI 10.1016/0166-2236(91)90178-W; CUCCHIARO JB, 1991, J COMP NEUROL, V310, P316, DOI 10.1002/cne.903100304; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282, DOI 10.1152/jn.1995.73.3.1282; DESTEXHE A, 1995, P NATL ACAD SCI USA, V92, P9515, DOI 10.1073/pnas.92.21.9515; Destexhe A, 1996, J NEUROPHYSIOL, V76, P2049, DOI 10.1152/jn.1996.76.3.2049; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; Golomb D, 1996, J NEUROPHYSIOL, V75, P750, DOI 10.1152/jn.1996.75.2.750; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; HUGUENARD JR, 1994, J NEUROSCI, V14, P5485; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; Jones EG., 2003, THALAMUS, V1st; KAWAGUCHI Y, 1995, J NEUROSCI, V15, P2638; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; LIU Z, 1992, NEUROSCIENCE, V48, P87, DOI 10.1016/0306-4522(92)90340-8; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MILES R, 1990, J PHYSIOL-LONDON, V431, P659, DOI 10.1113/jphysiol.1990.sp018353; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OTIS TS, 1992, J NEUROPHYSIOL, V67, P227, DOI 10.1152/jn.1992.67.1.227; Peters A.J, 1985, CEREBRAL CORTEX CELL, V1, DOI [10.1086/414271, DOI 10.1086/414271]; SANCHEZVIVES MV, IN PRESS NEUROSCIENC; SNEAD OC, 1992, EUR J PHARMACOL, V213, P343, DOI 10.1016/0014-2999(92)90623-C; Sodickson DL, 1996, J NEUROSCI, V16, P6374; SOLTESZ I, 1992, PROG BRAIN RES, V90, P151; STERIADE M, 1986, J NEUROSCI, V6, P68; STERIADE M, 1985, J NEUROPHYSIOL, V54, P1473, DOI 10.1152/jn.1985.54.6.1473; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; SUGITA S, 1992, NEUROSCI LETT, V134, P207, DOI 10.1016/0304-3940(92)90518-C; THOMPSON SM, 1992, J PHYSIOL-LONDON, V451, P329, DOI 10.1113/jphysiol.1992.sp019167; THOMSON AM, 1988, NEUROSCIENCE, V25, P491, DOI 10.1016/0306-4522(88)90253-9; Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667; UHLRICH DJ, 1991, J NEUROPHYSIOL, V65, P1528, DOI 10.1152/jn.1991.65.6.1528; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; WARREN RA, 1994, J NEUROPHYSIOL, V72, P1993, DOI 10.1152/jn.1994.72.4.1993	50	259	263	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					130	134		10.1126/science.278.5335.130	http://dx.doi.org/10.1126/science.278.5335.130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311919				2022-12-01	WOS:A1997XZ12400055
J	Hoganson, CW; Babcock, GT				Hoganson, CW; Babcock, GT			A metalloradical mechanism for the generation of oxygen from water in photosynthesis	SCIENCE			English	Article							AMINO-ACID-RESIDUES; TYROSINE Y-Z; PHOTOSYSTEM-II; EVOLVING COMPLEX; MANGANESE CLUSTER; D1 POLYPEPTIDE; REDUCED DERIVATIVES; PROTON RELEASE; ACTIVE-SITE; MN CLUSTER	In plants and algae, photosystem II uses light energy to oxidize water to oxygen at a metalloradical site that comprises a tetranuclear manganese cluster and a tyrosyl radical, A model is proposed whereby the tyrosyl radical functions by abstracting hydrogen atoms from substrate water bound as terminal ligands to two of the four manganese ions. Molecular oxygen is produced in the final step in which hydrogen atom transfer and oxygen-oxygen bond formation occur together in a concerted reaction. This mechanism establishes clear analogies between photosynthetic water oxidation and amino acid radical function in other enzymatic reactions.	MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824	Michigan State University					NIGMS NIH HHS [GM-37300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babcock G. T., 1995, PHOTOSYNTHESIS LIGHT, V2, P209; Babcock GT, 1997, ACTA CHEM SCAND, V51, P533, DOI 10.3891/acta.chem.scand.51-0533; BABCOCK GT, 1976, FEBS LETT, V61, P286; BABCOCK GT, 1989, BIOCHEMISTRY-US, V28, P9557, DOI 10.1021/bi00451a001; Baldwin MJ, 1996, J AM CHEM SOC, V118, P11325, DOI 10.1021/ja9626906; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BLOMBERG MRA, IN PRESS J AM CHEM S; Bogershausen O, 1996, BER BUNSEN PHYS CHEM, V100, P1987; BOUSSAC A, 1992, BIOCHEMISTRY-US, V31, P1224, DOI 10.1021/bi00119a036; Britt R.D, 1996, ADV PHOTOSYNTHESIS O; BRUDVIG GW, 1986, P NATL ACAD SCI USA, V83, P4586, DOI 10.1073/pnas.83.13.4586; Caudle MT, 1997, J AM CHEM SOC, V119, P3415, DOI 10.1021/ja9641158; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5859, DOI 10.1021/bi00017a017; CHU HA, 1995, BIOCHEMISTRY-US, V34, P5839, DOI 10.1021/bi00017a016; COLLINS TJ, 1990, J AM CHEM SOC, V112, P899, DOI 10.1021/ja00158a077; Cotton F. A., 1988, ADV INORG CHEM, P707; DAU H, 1995, BIOCHEMISTRY-US, V34, P5274, DOI 10.1021/bi00015a043; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0167-4838(92)90520-N; DEKKER JP, 1984, BIOCHIM BIOPHYS ACTA, V767, P1, DOI 10.1016/0005-2728(84)90073-2; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; GARDNER KA, 1995, SCIENCE, V269, P1849, DOI 10.1126/science.7569922; GILBERT JA, 1985, J AM CHEM SOC, V107, P3855, DOI 10.1021/ja00299a017; GILCHRIST ML, 1995, P NATL ACAD SCI USA, V92, P9545, DOI 10.1073/pnas.92.21.9545; GIRERD JJ, 1995, PHOTOSYNTHESIS LIGHT, V2, P217; GREENWOOD NN, 1984, CHEM ELEMENTS, P1228; HADDY A, 1992, BIOCHIM BIOPHYS ACTA, V1099, P25, DOI 10.1016/0167-4838(92)90448-M; HAUMANN M, 1994, BIOCHEMISTRY-US, V33, P864, DOI 10.1021/bi00170a003; Haumann M, 1996, BBA-BIOENERGETICS, V1273, P237, DOI 10.1016/0005-2728(95)00152-2; HAUMANN M, 1996, OXYGENIC PHOTOSYNTHE, P165; HOGANSON CW, 1994, MET IONS BIOL SYST, V30, P77; Hoganson CW, 1995, PHOTOSYNTH RES, V46, P177, DOI 10.1007/BF00020428; Ingold C. K., 1969, STRUCTURE MECHANISM, P457; Karge M, 1997, BIOCHEMISTRY-US, V36, P8904, DOI 10.1021/bi962342g; Karge M, 1996, FEBS LETT, V378, P140, DOI 10.1016/0014-5793(95)01433-0; KERR JA, 1996, HDB CHEM PHYSICS, P9; KHANGULOV S, 1993, BIOCHEMISTRY-US, V32, P4912, DOI 10.1021/bi00069a028; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KOIKE H, 1987, BIOCHIM BIOPHYS ACTA, V893, P524, DOI 10.1016/0005-2728(87)90104-6; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; KRAMARZ KW, 1994, PROG INORG CHEM, V42, P1, DOI 10.1002/9780470166437.ch1; Kretschmann H, 1996, BBA-BIOENERGETICS, V1274, P1, DOI 10.1016/0005-2728(95)00150-6; KRISHTALIK LI, 1990, BIOELECTROCH BIOENER, V23, P249, DOI 10.1016/0302-4598(90)80014-A; LAVERGNE J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P175, DOI 10.1016/S0005-2728(09)91005-2; LIND J, 1990, J AM CHEM SOC, V112, P479, DOI 10.1021/ja00158a002; LINDBERG K, 1993, PHOTOSYNTH RES, V38, P401, DOI 10.1007/BF00046767; LYDAKISSIMANTIR.N, IN PRESS BIOCH BIOPH; LYDAKISSIMANTIR.N, 1995, PHOTOSYNTHESIS LIGHT, V2, P279; MANCHANDA R, 1995, COORDIN CHEM REV, V144, P1, DOI 10.1016/0010-8545(95)01147-H; MESSINGER J, 1995, P NATL ACAD SCI USA, V92, P3209, DOI 10.1073/pnas.92.8.3209; MESSINGER J, 1995, PHOTOSYNTHESIS LIGHT, V2, P283; MESSINGER J, IN PRESS BIOCHEMISTR; NARUTA Y, 1994, ANGEW CHEM INT EDIT, V33, P1839, DOI 10.1002/anie.199418391; ONO T, 1992, SCIENCE, V258, P1335, DOI 10.1126/science.258.5086.1335; PECORARO VL, 1988, PHOTOCHEM PHOTOBIOL, V48, P249; PECORARO VL, 1992, MANGANESE REDOX ENZY, P197; PROSS A, 1995, THEORETICAL PHYSICAL; RANDALL DW, 1995, J AM CHEM SOC, V117, P11780, DOI 10.1021/ja00152a021; Razeghifard MR, 1997, BIOCHEMISTRY-US, V36, P86, DOI 10.1021/bi9614287; RENGER G, 1992, FEBS LETT, V299, P28, DOI 10.1016/0014-5793(92)80092-U; RIGGS PJ, 1992, J AM CHEM SOC, V114, P10650, DOI 10.1021/ja00052a079; RiggsGelasco PJ, 1996, J AM CHEM SOC, V118, P2387, DOI 10.1021/ja9504496; Roelofs TA, 1996, P NATL ACAD SCI USA, V93, P3335, DOI 10.1073/pnas.93.8.3335; ROTZINGER FP, 1987, J AM CHEM SOC, V109, P6619, DOI 10.1021/ja00256a010; Sawyer D. T., 1991, OXYGEN CHEM; SHANK M, 1994, BIOCHEMISTRY-US, V33, P15433, DOI 10.1021/bi00255a025; STERN MK, 1992, MANGANESE REDOX ENZY, P233; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; Tang XS, 1996, J AM CHEM SOC, V118, P7638, DOI 10.1021/ja9610592; TANG XS, 1994, P NATL ACAD SCI USA, V91, P704, DOI 10.1073/pnas.91.2.704; TIAN GC, 1994, BIOCHEMISTRY-US, V33, P226, DOI 10.1021/bi00167a030; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; TOMMOS C, IN PRESS ACCT CHEM R; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; VINCENT JB, 1987, INORG CHIM A-BIOINOR, V136, pL41, DOI 10.1016/S0020-1693(00)81142-1; Wachter RM, 1996, J AM CHEM SOC, V118, P2782, DOI 10.1021/ja9519896; WALDO GS, 1992, J AM CHEM SOC, V114, P5869, DOI 10.1021/ja00040a064; Wincencjusz H, 1997, BIOCHEMISTRY-US, V36, P3663, DOI 10.1021/bi9626719; Witt HT, 1996, BER BUNSEN PHYS CHEM, V100, P1923, DOI 10.1002/bbpc.19961001202; Yachandra VK, 1996, CHEM REV, V96, P2927, DOI 10.1021/cr950052k; YACHANDRA VK, 1993, SCIENCE, V260, P675, DOI 10.1126/science.8480177; YOCUM CF, 1991, BIOCHIM BIOPHYS ACTA, V1059, P1, DOI 10.1016/S0005-2728(05)80182-3; [No title captured]	84	498	505	1	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1953	1956		10.1126/science.277.5334.1953	http://dx.doi.org/10.1126/science.277.5334.1953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302282				2022-12-01	WOS:A1997XX84900032
J	Kamohara, S; Burcelin, R; Halaas, JL; Friedman, JM; Charron, MJ				Kamohara, S; Burcelin, R; Halaas, JL; Friedman, JM; Charron, MJ			Acute stimulation of glucose metabolism in mice by leptin treatment	NATURE			English	Article							OBESE GENE; RAT HYPOTHALAMUS; MESSENGER-RNA; FOOD-INTAKE; OB PROTEIN; OB/OB MICE; EXPRESSION; INSULIN; RECEPTOR; IDENTIFICATION	Leptin is an adipocyte hormone that functions as an afferent signal in a negative feedback loop regulating body weight(1-4), and acts by interacting with a receptor in the hypothalamus and other tissues(5,6), Leptin treatment has potent effects on lipid metabolism, and leads to a large, specific reduction of adipose tissue mass after several days(1,4). Here we show that leptin also acts acutely to increase glucose metabolism, although studies of leptin's effect on glucose metabolism have typically been confounded by the weight-reducing actions of leptin treatment, which by itself could affect glucose homoeostasis(1-3). We have demonstrated acute in vivo effects of intravenous and intracerebroventricular administrations of leptin on glucose metabolism, A five-hour intravenous infusion of leptin into wild-type mice increased glucose turnover and glucose uptake, but decreased hepatic glycogen content, The plasma levels of insulin and glucose did not change. Similar effects were observed after both intravenous and intracerebroventricular infusion of leptin, suggesting that effects of leptin on glucose metabolism are mediated by the central nervous system (CNS), These data indicate that leptin induces a complex metabolic response with effects on glucose as well as lipid metabolism, This response is unique to leptin, which suggests that new efferent signals emanate from the CNS after leptin treatment.	ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10021	Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine				Kamohara, Seika/0000-0002-2482-6611				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Golden PL, 1997, J CLIN INVEST, V99, P14, DOI 10.1172/JCI119125; GosteliPeter MA, 1996, BIOCHEM BIOPH RES CO, V221, P521, DOI 10.1006/bbrc.1996.0629; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; LAUTALA P, 1981, ACTA ENDOCRINOL-COP, V98, P481, DOI 10.1530/acta.0.0980481; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEONG SF, 1984, BIOCHEM J, V218, P131, DOI 10.1042/bj2180131; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; Massillon D, 1995, AM J PHYSIOL-ENDOC M, V269, pE1037, DOI 10.1152/ajpendo.1995.269.6.E1037; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; MILES PDG, 1991, P NATL ACAD SCI USA, V88, P1296, DOI 10.1073/pnas.88.4.1296; NAGAI K, 1988, HORM METAB RES, V20, P37, DOI 10.1055/s-2007-1010743; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Satoh N, 1997, ENDOCRINOLOGY, V138, P947, DOI 10.1210/en.138.3.947; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VRANIC M, 1976, J CLIN INVEST, V57, P245, DOI 10.1172/JCI108275; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185	29	591	613	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					374	377		10.1038/38717	http://dx.doi.org/10.1038/38717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311777				2022-12-01	WOS:A1997XX67500050
J	Fertleman, CR; Gallagher, A; Rossiter, MA				Fertleman, CR; Gallagher, A; Rossiter, MA			Evaluation of fast track admission policy for children with sickle cell crises: questionnaire survey of parents' preferences	BRITISH MEDICAL JOURNAL			English	Article									N MIDDLESEX HOSP,LONDON N18 1QX,ENGLAND									BLACK J, 1986, LIVING SICKLE CELL D, P112; FRANCEDAWSON M, 1994, NURS STAND, V45, P25; Oppenheim, 2000, QUESTIONNAIRE DESIGN	3	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					650	650		10.1136/bmj.315.7109.650	http://dx.doi.org/10.1136/bmj.315.7109.650			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310567	Green Published			2022-12-01	WOS:A1997XW69400020
J	Neilson, JP				Neilson, JP			Assessment of fetal nuchal translucency test for Down's syndrome	LANCET			English	Editorial Material							FIRST-TRIMESTER; GENERAL-POPULATION; MATERNAL AGE; TRISOMY-21; THICKNESS; GESTATION; FETUSES				Neilson, JP (corresponding author), UNIV LIVERPOOL,DEPT OBSTET & GYNAECOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							ALFIREVIC Z, 1997, PREGNANCY CHILDBIRTH; Braithwaite JM, 1996, BRIT J OBSTET GYNAEC, V103, P1201, DOI 10.1111/j.1471-0528.1996.tb09629.x; Chaban FK, 1996, PRENATAL DIAG, V16, P537, DOI 10.1002/(SICI)1097-0223(199606)16:6<537::AID-PD911>3.0.CO;2-4; Hyett JA, 1996, ULTRASOUND OBST GYN, V7, P101, DOI 10.1046/j.1469-0705.1996.07020101.x; HYETT JA, 1995, AM J OBSTET GYNECOL, V172, P1411, DOI 10.1016/0002-9378(95)90470-0; Kornman LH, 1996, PRENATAL DIAG, V16, P797, DOI 10.1002/(SICI)1097-0223(199609)16:9<797::AID-PD948>3.3.CO;2-D; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; ROBERTS LJ, 1995, BRIT J OBSTET GYNAEC, V102, P381, DOI 10.1111/j.1471-0528.1995.tb11289.x; Sebire NJ, 1996, BRIT J OBSTET GYNAEC, V103, P999, DOI 10.1111/j.1471-0528.1996.tb09550.x; SZABO J, 1990, LANCET, V336, P1133, DOI 10.1016/0140-6736(90)92614-N	10	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					754	755		10.1016/S0140-6736(05)62562-7	http://dx.doi.org/10.1016/S0140-6736(05)62562-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297991				2022-12-01	WOS:A1997XW28200006
J	Yu, SJM; Conticello, VP; Zhang, GH; Kayser, C; Fournier, MJ; Mason, TL; Tirrell, DA				Yu, SJM; Conticello, VP; Zhang, GH; Kayser, C; Fournier, MJ; Mason, TL; Tirrell, DA			Smectic ordering in solutions and films of a rod-like polymer owing to monodispersity of chain length	NATURE			English	Article							SYSTEM; PHASES	Solutions and melts of stiff ('rod-like') macromolecules often exhibit nematic liquid crystalline phases characterized by orientational, but not positional, molecular order(1,2). Smectic phases, in which macromolecular rods are organized into layers roughly perpendicular to the direction of molecular orientation, are rare, owing at least in part to the polydisperse nature (distribution of chain lengths) of polymers prepared by conventional polymerization processes. Bacterial methods for polypeptide synthesis(3), in which artificial genes encoding the polymer are expressed in bacterial vectors, offer the opportunity to make macromolecules with very well defined chain lengths. Here we show that a monodisperse derivative of poly(gamma-benzyl alpha,L-glutamate) prepared in this way shows smectic ordering in solution and in films. This result suggests that methods for preparing monodisperse polymers might provide access to new smectic phases with layer spacings that are susceptible to precise control on the scale of tens of nanometres.	UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003; UNIV MASSACHUSETTS,DEPT BIOCHEM & MOL BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst			Yu, Michael S/A-3332-2010	Conticello, Vincent/0000-0001-6940-6947				ALBRECHT C, 1993, PROG COLL POL SCI S, V92, P111; BLOCK H, 1993, POLY GAMMA BENZYL L, P135; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; Chen JT, 1996, SCIENCE, V273, P343, DOI 10.1126/science.273.5273.343; Demus D., 1978, TEXTURES LIQUID CRYS; DUKE RW, 1976, J AM CHEM SOC, V98, P3094, DOI 10.1021/ja00427a006; DUPRE DB, 1979, LIQUID CRYSTALS 4TH, P203; FLORY PJ, 1956, PROC R SOC LON SER-A, V234, P73, DOI 10.1098/rspa.1956.0016; KRICHELDORF HR, 1987, ALPHA AMINOACID N CA, P170; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIVOLANT F, 1986, J PHYS-PARIS, V47, P1813, DOI 10.1051/jphys:0198600470100181300; PAPKOV SP, 1984, ADV POLYM SCI, V59, P75; PRESTON J, 1978, LIQUID CRYSTALLINE O, P141; RADZILOWSKI LH, 1994, MACROMOLECULES, V27, P7747, DOI 10.1021/ma00104a033; ROBINSON C, 1957, NATURE, V180, P1183, DOI 10.1038/1801183a0; SAMULSKI ET, 1967, NATURE, V216, P997, DOI 10.1038/216997a0; STROOBANTS A, 1987, PHYS REV A, V36, P2929, DOI 10.1103/PhysRevA.36.2929; STUPP SI, 1993, SCIENCE, V259, P59, DOI 10.1126/science.259.5091.59; WATANABE J, 1993, ORDERING MACROMOLECU, P99; WEE EL, 1990, NATURE, V346, P44; WEN X, 1989, PHYS REV LETT, V63, P2760, DOI 10.1103/PhysRevLett.63.2760; WULFMAN DS, 1988, SYNTHETIC COMMUN, V18, P2349, DOI 10.1080/00397918808082380; ZHANG GH, 1992, MACROMOLECULES, V25, P3601, DOI 10.1021/ma00039a048	23	187	195	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					167	170		10.1038/38254	http://dx.doi.org/10.1038/38254			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296493				2022-12-01	WOS:A1997XV75700044
J	Otis, TS; Kavanaugh, MP; Jahr, CE				Otis, TS; Kavanaugh, MP; Jahr, CE			Postsynaptic glutamate transport at the climbing fiber Purkinje cell synapse	SCIENCE			English	Article							GATED CHLORIDE CHANNEL; GLIAL-CELLS; RAT-BRAIN; CONDUCTANCE; TRANSMITTER; SALAMANDER; TRANSMISSION; RECEPTOR; RELEASE; NEURONS	The role of postsynaptic, neuronal glutamate transporters in terminating signals at central excitatory synapses is not known. Stimulation of a climbing fiber input to cerebellar Purkinje cells was shown to generate an anionic current mediated by glutamate transporters. The kinetics of transporter currents were resolved by pulses of glutamate to outside-out membrane patches from Purkinje cells. Comparison of synaptic transporter currents to transporter currents expressed in Xenopus oocytes suggests that postsynaptic uptake at the climbing fiber synapse removes at least 22 percent of released glutamate. These neuronal transporter currents arise from synchronous activation of transporters that greatly outnumber activated AMPA receptors.			Otis, TS (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,L 474,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.				NINDS NIH HHS [NS33270, NS21419] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033270, R01NS021419] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; Billups B, 1996, J NEUROSCI, V16, P6722; BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; Diamond JS, 1997, J NEUROSCI, V17, P4672; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; GRANT GB, 1995, J NEUROSCI, V15, P3852; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; Kataoka Y, 1996, J NEUROPHYSIOL, V76, P1870, DOI 10.1152/jn.1996.76.3.1870; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2262; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Muller T, 1995, INT REV NEUROBIOL, V38, P341, DOI 10.1016/S0074-7742(08)60530-9; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PICAUD SA, 1995, J NEUROPHYSIOL, V74, P1760, DOI 10.1152/jn.1995.74.4.1760; RIVAROS N, 1986, BRAIN RES, V386, P405; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; Takahashi M, 1996, J PHYSIOL-LONDON, V497, P523, DOI 10.1113/jphysiol.1996.sp021785; TAKAHASHI M, 1995, J NEUROSCI, V15, P5693; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; TRAYNELIS SF, 1993, NEURON, V11, P279, DOI 10.1016/0896-6273(93)90184-S; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WYLLIE DJA, 1993, J PHYSIOL-LONDON, V463, P193, DOI 10.1113/jphysiol.1993.sp019591; Yamada K, 1996, NEUROREPORT, V7, P2013, DOI 10.1097/00001756-199608120-00032; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	34	153	156	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1515	1518		10.1126/science.277.5331.1515	http://dx.doi.org/10.1126/science.277.5331.1515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278516				2022-12-01	WOS:A1997XV42900043
J	Zipkin, ID; Kindt, RM; Kenyon, CJ				Zipkin, ID; Kindt, RM; Kenyon, CJ			Role of a new Rho family member in cell migration and axon guidance in C-elegans	CELL			English	Article							GTP-BINDING PROTEIN; ACTIN STRESS FIBERS; CAENORHABDITIS-ELEGANS; SMALL GTPASES; GENE; CDC42; RAC; SEQUENCE; PATHWAY; HOMOLOG	Rho family GTPases are thought to regulate actin-dependent processes, but their functions in vivo are still poorly understood. We have investigated the function of a new, widely expressed Rho family member in C. elegans by analyzing mutations in the endogenous gene. Activated and null alleles all inhibit cell migration, demonstrating that this protein is required for cell migration in vivo. Only a small subset of the migrations inhibited by activating mutations are inhibited by null mutations, suggesting that considerable functional redundancy exists within this system. Our findings support this conclusion and show that mig-2 functions redundantly with another pathway to regulate nuclear migration. Surprisingly, activated alleles also cause misguided axon growth, suggesting that Rho family GTPases may couple guidance cues to process outgrowth.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017924, R01GM037053] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01GM37053, 5F32GM17924-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHEN WI, 1993, J BIOL CHEM, V268, P320; CHEN WN, 1993, J BIOL CHEM, V268, P13280; Chen WN, 1996, GENE, V180, P217, DOI 10.1016/S0378-1119(96)00414-3; CHEN WN, 1994, J BIOL CHEM, V269, P32394; CLARK DV, 1995, MOL GEN GENET, V247, P367, DOI 10.1007/BF00293205; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; Forrester WC, 1997, DEVELOPMENT, V124, P1831; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Run JQ, 1996, GENETICS, V143, P225; RUVKUN G, 1989, GENETICS, V121, P501; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WILLIAMS BD, 1992, GENETICS, V131, P609	38	212	217	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					883	894		10.1016/S0092-8674(00)80353-0	http://dx.doi.org/10.1016/S0092-8674(00)80353-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298900	Bronze			2022-12-01	WOS:A1997XV56300009
J	Presley, JF; Cole, NB; Schroer, TA; Hirschberg, K; Zaal, KJM; LippincottSchwartz, J				Presley, JF; Cole, NB; Schroer, TA; Hirschberg, K; Zaal, KJM; LippincottSchwartz, J			ER-to-Golgi transport visualized in living cells	NATURE			English	Article							GREEN-FLUORESCENT PROTEIN; ENDOPLASMIC-RETICULUM; VIRAL GLYCOPROTEIN; BETA-COP; COMPLEX; COMPARTMENT; VIRUS; ORGANIZATION; MEMBRANES; SURFACE	Newly synthesized proteins that leave the endoplasmic reticulum (ER) are funnelled through the Golgi complex before being sorted for transport to their different final destinations. Traditional approaches have elucidated the biochemical requirements for such transport(1-3) and have established a role for transport intermediates(4-8). New techniques for tagging proteins fluorescently(9,10) have made it possible to follow the complete life history of single transport intermediates in living cells, including their formation, path and velocity en route to the Golgi complex. We have now visualized ER-to-Golgi transport using the viral. glycoprotein ts045 VSVG tagged with green fluorescent protein (VSVG-GFP). Upon export from the ER, VSVG-GFP became concentrated in many differently shaped, rapidly forming pre-Golgi structures, which translocated inwards towards the Golgi complex along microtubules by using the microtubule minus-end-directed motor complex of dynein/dynactin. No loss of fluorescent material from pre-Golgi structures occurred during their translocation to the Golgi complex and they frequently stretched into tubular shapes. Together, our results indicate that these pre-Golgi carrier structures moving unidirectionally along microtubule tracks are responsible for transporting VSVG-GFP through the cytoplasm to the Golgi complex. This contrasts with the traditional focus on small vesicles as the primary vehicles for ER-to-Golgi transport.	NICHHD, CELL BIOL & METAB BRANCH, NICHHD, NIH, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Johns Hopkins University			Hirschberg, Koret/AAF-4566-2019	Schroer, Trina/0000-0002-5065-1835	NIGMS NIH HHS [R01 GM044589] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Burkhardt J. K., 1995, Molecular Biology of the Cell, V6, p266A; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; SARASTE J, 1991, J CELL SCI, V100, P415; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429	31	939	959	1	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					81	85		10.1038/38001	http://dx.doi.org/10.1038/38001			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288971				2022-12-01	WOS:A1997XU59600049
J	Nightingale, SL				Nightingale, SL			Public health advisory on protease inhibitors for HIV treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-01	WOS:A1997XN51800009
J	Hawthorne, G; Robson, S; Ryall, EA; Sen, D; Roberts, SH; Platt, MPW				Hawthorne, G; Robson, S; Ryall, EA; Sen, D; Roberts, SH; Platt, MPW			Prospective population based survey of outcome of pregnancy in diabetic women: results of the northern diabetic pregnancy audit, 1994	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-ANOMALIES; PRECONCEPTION CARE	Objective: To determine whether the St Vincent declaration (1989) target of diabetic pregnancy outcome approximating non-diabetic pregnancy outcome is near to being achieved. Design: Prospective collection of population based information on pregnancies in women with diabetes from all participating hospitals. Setting: District general and teaching hospitals of the former Northern region. Subjects: 111 diabetic women booking with pregnancy during 1 January to 31 December 1994. Main outcome measures: Diabetic control, perinatal mortality rate, fetal abnormality rate. Results: The perinatal mortality rate was 48/1000 for diabetic pregnancies compared with 8.9/1000 for the background population (odds ratio 5.38; 95% confidence interval 2.27 to 12.70) and the neonatal mortality rate was 59/1000 compared with 3.9/1000 (15.0; 6.77 to 33.10). Two late neonatal deaths were due to congenital heart defects. Six per cent of all fetal losses (6/109 cases) were due to major malformations. The congenital malformation rate was 83/1000 compared with 21.3/1000 (3.76; 2.00 to 7.06) in the background population. Conclusion: Diabetic pregnancy remains a high risk state with perinatal mortality and fetal malformation rates much higher than in the background population.	UNIV NEWCASTLE UPON TYNE, ROYAL VICTORIA INFIRM, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; N TEES GEN HOSP, STOCKTON ON TEES TS19 8PE, ENGLAND; N TYNESIDE HOSP, DIABET RESOURCE CTR, N SHIELDS NE29 8NH, TYNE & WEAR, ENGLAND	Newcastle University - UK; University Hospital of North Tees	Hawthorne, G (corresponding author), HARTLEPOOL GEN HOSP, HARTLEPOOL TS24 9AH, CLEVELAND, ENGLAND.		Platt, Martin Ward/D-4008-2014	Platt, Martin Ward/0000-0003-0536-5749				Diabetes care and research in Europe, 1990, DIABETIC MED, V7, P360; ELIXHAUSER A, 1993, DIABETES CARE, V16, P1146, DOI 10.2337/diacare.16.8.1146; GREGORY R, 1992, J ROY COLL PHYS LOND, V26, P162; KITZMILLER JL, 1991, JAMA-J AM MED ASSOC, V265, P731, DOI 10.1001/jama.265.6.731; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MORRIS JA, 1989, STAT CONFIDENCE, P50; *N REG HLTH AUTH, 1995, REG FET ABN SURV PRO; *NO REG HLTH AUTH, 1995, COLL SURV PER LAT NE; RENWICK M, 1992, ARCH DIS CHILD-FETAL, V67, P770; ROSENN B, 1991, OBSTET GYNECOL, V77, P846; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; TIN W, IN PRESS BR J OBSTET; TRAUB AI, 1987, BRIT J OBSTET GYNAEC, V94, P957, DOI 10.1111/j.1471-0528.1987.tb02269.x	14	157	160	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					279	281		10.1136/bmj.315.7103.279	http://dx.doi.org/10.1136/bmj.315.7103.279			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274546	Green Published			2022-12-01	WOS:A1997XP75000020
J	Annas, GJ				Annas, GJ			Patients' rights in managed care - Exit, voice, and choice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS G, 1989, RIGHTS PATIENTS; ANNAS GJ, 1974, VANDERBILT LAW REV, V27, P243; [Anonymous], 1970, EXIT VOICE LOYALTY R, DOI DOI 10.3917/RCE.002.0244; *BNA, 1996, BNAS HLTH LAW R 1107, P1631; Bodenheimer T, 1996, NEW ENGL J MED, V335, P1601, DOI 10.1056/NEJM199611213352112; CHASE M, 1997, WALL ST J       0929, pB1; GAYNOR P, 1997, PITTSBURGH POST 0202, pC21; *HCFA, 1996, BNAS MANAGED CA 1211, P1159; HILTZIK MA, 1995, LOS ANGELES TIM 0827, pA1; Kinney ED, 1996, AM J LAW MED, V22, P301; Mariner WK, 1996, NEW ENGL J MED, V335, P1986, DOI 10.1056/NEJM199612263352610; RODWIN MA, 1996, HOUSTON LAW REV, V32, P1319; 1997, CHASREG, V62, P23368	13	38	39	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					210	215		10.1056/NEJM199707173370323	http://dx.doi.org/10.1056/NEJM199707173370323			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219710	Green Published			2022-12-01	WOS:A1997XK81800030
J	Corazza, GR; Biagi, F; Volta, U; Andreani, ML; DeFranceschi, L; Gasbarrini, G				Corazza, GR; Biagi, F; Volta, U; Andreani, ML; DeFranceschi, L; Gasbarrini, G			Autoimmune enteropathy and villous atrophy in adults	LANCET			English	Article							EPITHELIAL-CELL AUTOANTIBODIES; SMALL-INTESTINE; CELIAC-DISEASE; PROTRACTED DIARRHEA; SPRUE; ANTIBODY; PATHOGENESIS; JEJUNUM; INFANCY	Background Autoimmune enteropathy is a condition described in children and characterised by villous atrophy, which is unresponsive to any dietary restrictions, and by the presence of enterocyte autoantibodies. We report two adult patients who fulfilled all the criteria for the diagnosis of this disorder. Methods Over the past 5 years we have seen four adult patients (all women, median age 51.5 [range 38-64] years) with subtotal villous atrophy, which was unresponsive to a gluten-free diet. The patients were HLA-DQ2 positive. IgA antigliadin and antiendomysial antibodies were not found in any of the patients. We did an indirect immunofluorescence search for enterocyte autoantibodies on monkey jejunum and for other autoantibodies for all four patients. Findings Of the four patients, two were positive for enterocyte autoantibodies and one of these two patients was positive for antiactin, antiparietal cell, and antithyroid microsomal autoantibodies. Interpretation To the best of our knowledge the two patients affected by severe enteropathy, who had never responded to any exclusion diet, and who were positive for enterocyte autoantibodies are the first cases of autoimmune enteropathy described in adults. We propose that adult patients whose disorders are unresponsive to a gluten-free diet should be tested for enterocyte autoantibodies.	UNIV BOLOGNA, DEPT INTERNAL MED, BOLOGNA, ITALY; CATHOLIC UNIV ROME, DEPT INTERNAL MED, ROME, ITALY	University of Bologna; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Corazza, GR (corresponding author), UNIV AQUILA, DEPT INTERNAL MED, VIA S SISTO 22E, I-67100 LAQUILA, ITALY.		Corazza, Gino Roberto/K-8500-2016; Biagi, Federico/G-2812-2011	Corazza, Gino Roberto/0000-0001-9532-0573; Biagi, Federico/0000-0002-2227-4622; De Franceschi, Lucia/0000-0003-1257-8101; Volta, Umberto/0000-0003-3405-3808				BOTTAZZO GF, 1986, IMMUNOL REV, V94, P137, DOI 10.1111/j.1600-065X.1986.tb01168.x; CATASSI C, 1988, J PEDIATR GASTR NUTR, V7, P608, DOI 10.1097/00005176-198807000-00022; CHORZELSKI TP, 1984, BRIT J DERMATOL, V111, P395, DOI 10.1111/j.1365-2133.1984.tb06601.x; CORAZZA GR, 1995, SCAND J GASTROENTERO, V30, P153, DOI 10.3109/00365529509093254; CORAZZA GR, 1985, J CLIN PATHOL, V38, P765, DOI 10.1136/jcp.38.7.765; CUENOD B, 1990, GASTROENTEROLOGY, V99, P1037, DOI 10.1016/0016-5085(90)90624-A; FERGUSON A, 1977, GUT, V18, P921, DOI 10.1136/gut.18.11.921; KATZ AJ, 1979, GASTROENTEROLOGY, V76, P375; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MARTINVILLA JM, 1991, GASTROENTEROLOGY, V101, P390, DOI 10.1016/0016-5085(91)90016-E; MARTINVILLA JM, 1993, LANCET, V342, P380, DOI 10.1016/0140-6736(93)91531-P; MCCARTHY DM, 1978, J IMMUNOL, V120, P932; MIRAKIAN R, 1986, BRIT MED J, V293, P1132, DOI 10.1136/bmj.293.6555.1132; MIRAKIAN R, 1988, J AUTOIMMUN, V1, P263, DOI 10.1016/0896-8411(88)90032-7; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; RUBIN CE, 1970, GASTROENTEROLOGY, V58, P409; SAVILAHTI E, 1985, ACTA PAEDIATR SCAND, V74, P472, DOI 10.1111/j.1651-2227.1985.tb11011.x; TRIER JS, 1978, GASTROENTEROLOGY, V75, P307; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; UNSWORTH DJ, 1985, J PEDIATR GASTR NUTR, V4, P375, DOI 10.1097/00005176-198506000-00009; VOLTA U, 1985, GUT, V26, P667, DOI 10.1136/gut.26.7.667; WALKERSMITH JA, 1982, LANCET, V1, P566; WALKERSMITH JA, 1991, DEV GASTRO, V13, P131; WALL AJ, 1970, GUT, V11, P7, DOI 10.1136/gut.11.1.7	24	105	111	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					106	109		10.1016/S0140-6736(97)01042-8	http://dx.doi.org/10.1016/S0140-6736(97)01042-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228963				2022-12-01	WOS:A1997XK11400011
J	Vignes, M; Collingridge, GL				Vignes, M; Collingridge, GL			The synaptic activation of kainate receptors	NATURE			English	Article							LONG-TERM POTENTIATION; GLUTAMATE RECEPTORS; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; EXPRESSION; SUBUNIT; CLONING; CELLS; AMPA; CYCLOTHIAZIDE	L-Glutamate, the principal excitatory neurotransmitter in the vertebrate central nervous system, acts on three classes of ionotropic glutamate receptors, named after the agonists AMPA, NMDA and kainate(1). AMPA receptors are known to mediate fast synaptic responses and NMDA receptors to mediate slow synaptic responses at most excitatory synapses in the brain(2). Kainate receptors are formed from a separate set of genes (GluR5-7, KA-1 and KA-2) and are widely distributed throughout the brain(3-8). They are implicated in epileptogenesis and cell death(9). However, the physiological functions of kainate receptors are not known. The development of 2,3-benzodiazepine antagonists that are selective for AMPA receptors(10) enables kainate receptors to be specifically activated by exogenous ligands, such as kainate(11-16). Here we demonstrate that high-frequency stimulation of messy fibres in rat hippocampal slices, in the presence of the highly selective AMPA receptor antagonist GYKI 53655 (refs 13-15) plus NMDA- and GABA-receptor antagonists, activates an inward current in CA3 neurons that has a pharmacology typical of kainate receptors. The finding that kainate receptors can be activated synaptically adds to the diversity of information transfer at glutamatergic synapses.	UNIV BRISTOL, SCH MED SCI, DEPT ANAT, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol			collingridge, graham/AAI-8362-2020; Collingridge, Graham L/C-4605-2015; Vignes, Michel/AAA-7693-2019	Collingridge, Graham L/0000-0002-9572-5359; Vignes, Michel/0000-0003-0969-2966				BAHN S, 1994, J NEUROSCI, V14, P5525; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FELDMEYER D, 1994, CURR BIOL, V4, P82, DOI 10.1016/S0960-9822(00)00021-X; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Miller LDP, 1995, J NEUROSCI, V15, P8320; MONAGHAN DT, 1985, BRAIN RES, V340, P378, DOI 10.1016/0006-8993(85)90936-9; PALMER AJ, 1993, EUR J PHARM-MOLEC PH, V244, P193, DOI 10.1016/0922-4106(93)90027-7; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; Rammes G, 1996, BRIT J PHARMACOL, V117, P1209, DOI 10.1111/j.1476-5381.1996.tb16718.x; RENARD A, 1995, NEUROPHARMACOLOGY, V34, P335, DOI 10.1016/0028-3908(94)00165-O; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; ROCHE KW, 1995, NEUROSCIENCE, V69, P383, DOI 10.1016/0306-4522(95)00253-F; RUANO D, 1995, NEURON, V14, P1009, DOI 10.1016/0896-6273(95)90339-9; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; TARNAWA I, 1990, AMINO ACIDS CHEM BIO, P538; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WESTBROOK GL, 1983, BRAIN RES, V273, P97, DOI 10.1016/0006-8993(83)91098-3; WILDING TJ, 1995, MOL PHARMACOL, V47, P582; WONG LA, 1993, MOL PHARMACOL, V44, P504; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	30	353	358	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 10	1997	388	6638					179	182		10.1038/40639	http://dx.doi.org/10.1038/40639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217158	Bronze			2022-12-01	WOS:A1997XK10900051
J	Varnum, MD; Zagotta, WN				Varnum, MD; Zagotta, WN			Interdomain interactions underlying activation of cyclic nucleotide-gated channels	SCIENCE			English	Article							CATION CHANNEL; FUNCTIONAL EXPRESSION; SUBUNIT INTERACTIONS; MOLECULAR MECHANISM; POTASSIUM CHANNEL; COMPLEMENTARY-DNA; MODULATION; SHAKER; GENE; CALMODULIN	Cyclic nucleotide-gated (CNG) ion channels are multimeric proteins that activate in response to the binding of cyclic nucleotide to intracellular domains. Here, an intramolecular protein-protein interaction between the amino-terminal domain and the carboxylterminal ligand-binding domain of the rat olfactory CNG channel was shown to exert an autoexcitatory effect on channel activation. Calcium-calmodulin, which modulates CNG channel activity during odorant adaptation, blocked this interaction. A specific deletion within the amino-terminal domain disrupted the interdomain interaction in vitro and altered the gating properties and calmodulin sensitivity of expressed channels. Thus, the amino-terminal domain may promote channel opening by directly interacting with the carboxyl-terminal gating machinery; calmodulin regulates channel activity by targeting this interaction.	UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle					NATIONAL EYE INSTITUTE [R01EY010329] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010329, EY 10329] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Finn J. T., 1995, Biophysical Journal, V68, pA253; Fodor AA, 1997, J GEN PHYSIOL, V109, P3, DOI 10.1085/jgp.109.1.3; GORDON SE, 1995, J PHYSIOL-LONDON, V486, P533, DOI 10.1113/jphysiol.1995.sp020832; GORDON SE, 1995, P NATL ACAD SCI USA, V92, P10222, DOI 10.1073/pnas.92.22.10222; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; Gordon SE, 1996, BIOCHEMISTRY-US, V35, P3994, DOI 10.1021/bi952607b; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GORDON SE, 1995, NEURON, V14, P177; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; Grunwald M. E., 1997, Biophysical Journal, V72, pA335; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; SHEN NV, 1993, NEURON, V11, P67; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; VARNUM MD, 1995, NEURON, V15, P619, DOI 10.1016/0896-6273(95)90150-7; VARNUM MD, UNPUB; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; ZAGOTT AWN, 1996, ANN REV NEUROSCI, V19, P235; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	35	125	128	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					110	113		10.1126/science.278.5335.110	http://dx.doi.org/10.1126/science.278.5335.110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311913				2022-12-01	WOS:A1997XZ12400049
J	Hautamaki, RD; Kobayashi, DK; Senior, RM; Shapiro, SD				Hautamaki, RD; Kobayashi, DK; Senior, RM; Shapiro, SD			Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice	SCIENCE			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; 1ST 2 CENTURIES; FUTURE-RESEARCH; METALLOPROTEINASES; METALLOELASTASE; EXPRESSION; LOCALIZATION; SUGGESTIONS; HAMSTERS; CLONING	To determine which proteinases are responsible for the lung destruction characteristic of pulmonary emphysema, macrophage elastase-deficient (MME-/-) mice were subjected to cigarette smoke. In contrast to wild-type mice, MME-/- mice did not have increased numbers of macrophages in their lungs and did not develop emphysema in response to long-term exposure to cigarette smoke. Smoke-exposed MME-/- mice that received monthly intratracheal instillations of monocyte chemoattractant protein-1 showed accumulation of alveolar macrophages but did not develop air space enlargement. Thus, macrophage elastase is probably sufficient for the development of emphysema that results from chronic inhalation of cigarette smoke.	WASHINGTON UNIV, SCH MED, BAMES JEWISH HOSP, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, BAMES JEWISH HOSP, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)								BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CHAPMAN HA, 1994, AM J RESP CRIT CARE, V150, pS155, DOI 10.1164/ajrccm/150.6_Pt_2.S155; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DUNNILL M. S., 1962, THORAX, V17, P320, DOI 10.1136/thx.17.4.320; FEINLEIB M, 1989, AM REV RESPIR DIS, V140, pS9, DOI 10.1164/ajrccm/140.3_Pt_2.S9; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666, DOI 10.1164/ajrccm.152.5.7582312; HAUTAMAKI RD, UNPUB; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; KAO RC, 1988, J CLIN INVEST, V82, P1963, DOI 10.1172/JCI113816; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; MACKENZIE TD, 1994, NEW ENGL J MED, V330, P975, DOI 10.1056/NEJM199404073301406; MERCHANT RK, 1992, AM REV RESPIR DIS, V146, P448, DOI 10.1164/ajrccm/146.2.448; NAGAI A, 1994, AM J RESP CRIT CARE, V150, P1411, DOI 10.1164/ajrccm.150.5.7952569; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SIRES UI, 1994, BIOCHEM BIOPH RES CO, V204, P613, DOI 10.1006/bbrc.1994.2503; SNIDER GL, 1992, AM REV RESPIR DIS, V146, P1334, DOI 10.1164/ajrccm/146.5_Pt_1.1334; SNIDER GL, 1984, AM REV RESPIR DIS, V129, P155; SNIDER GL, 1992, AM REV RESPIR DIS, V146, P1615, DOI 10.1164/ajrccm/146.6.1615; *US CDC, 1996, US NATL CENT HLTH ST, V44, P1; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WERB Z, 1975, J EXP MED, V142, P361, DOI 10.1084/jem.142.2.361; WRIGHT JL, 1990, AM REV RESPIR DIS, V142, P1422, DOI 10.1164/ajrccm/142.6_Pt_1.1422	29	1101	1158	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					2002	2004		10.1126/science.277.5334.2002	http://dx.doi.org/10.1126/science.277.5334.2002			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302297				2022-12-01	WOS:A1997XX84900047
J	Stark, H; Rodnina, MV; RinkeAppel, J; Brimacombe, R; Wintermeyer, W; vanHeel, M				Stark, H; Rodnina, MV; RinkeAppel, J; Brimacombe, R; Wintermeyer, W; vanHeel, M			Visualization of elongation factor Tu on the Escherichia coli ribosome	NATURE			English	Article							AMINOACYL-TRANSFER-RNA; FACTOR EF-TU; CRYSTAL-STRUCTURE; PROTEIN-SYNTHESIS; TERNARY COMPLEX; GTP HYDROLYSIS; CROSS-LINKING; BINDING; REGION; SITE	The delivery of a specific amino acid to the translating ribosome is fundamental to protein synthesis. The binding of aminoacyl-transfer RNA to the ribosome is catalysed by the elongation factor Tu (EF-Tu). The elongation factor the aminoacyl-tRNA and GTP form a stable 'ternary' complex that binds to the ribosome. We have used electron cryomicroscopy and angular reconstitution(1) to visualize directly the kirromycin-stalled ternary complex in the A site of the 70S ribosome of Escherichia coli. Electron cryomicroscopy had previously given detailed ribosomal structures at 25 and 23 Angstrom (refs 2, 3) resolution, and was used to determine the position of tRNAs on the ribosome(4,5). In particular, the structures' of pre-translocational (tRNAs in A and P sites) and post-translocational ribosomes (P and E sites occupied) were both visualized at a resolution of similar to 20 Angstrom. Our three-dimensional reconstruction at 18 Angstrom resolution shows the ternary complex spanning the inter-subunit space with the acceptor domain of the tRNA reaching into the decoding centre. Domain I (the G domain) of the EF-Tu is bound both to the L7/L12 stalk and to the 50S body underneath the stalk, whereas domain 2 is oriented towards the S12 region on the 30S subunit.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; MAX PLANCK GESELL,FRITZ HABER INST,D-14195 BERLIN,GERMANY; UNIV WITTEN HERDECKE,INST MOL BIOL,D-58448 WITTEN,GERMANY; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY	Imperial College London; Max Planck Society; Fritz Haber Institute of the Max Planck Society; Witten Herdecke University; Max Planck Society			Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Holger, Stark/0000-0002-6161-1118				Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; Dey D, 1995, BIOCHIMIE, V77, P925, DOI 10.1016/0300-9084(95)80003-4; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LANGER JA, 1986, J MOL BIOL, V187, P617, DOI 10.1016/0022-2836(86)90339-6; MESTERS JR, 1994, EMBO J, V13, P4877, DOI 10.1002/j.1460-2075.1994.tb06815.x; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MUELLER F, IN PRESS J MOL BIOL; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; POWERS T, 1993, P NATL ACAD SCI USA, V90, P1364, DOI 10.1073/pnas.90.4.1364; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; SANTER UV, 1995, RNA, V1, P89; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; TAPPRICH WE, 1990, EMBO J, V9, P2649, DOI 10.1002/j.1460-2075.1990.tb07447.x; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VANRYK DI, 1995, NUCLEIC ACIDS RES, V23, P3563, DOI 10.1093/nar/23.17.3563; WOLF H, 1977, EUR J BIOCHEM, V75, P67, DOI 10.1111/j.1432-1033.1977.tb11504.x	31	313	317	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					403	406		10.1038/38770	http://dx.doi.org/10.1038/38770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311785				2022-12-01	WOS:A1997XX67500058
J	Yew, PR; Kirschner, MW				Yew, PR; Kirschner, MW			Proteolysis and DNA replication: The CDC34 requirement in the Xenopus egg cell cycle	SCIENCE			English	Article							UBIQUITIN-CONJUGATING ENZYME; LICENSING FACTOR; YEAST; TRANSITION; INITIATION; EXTRACTS; PROTEIN; COMPONENT; CLONING; EMBRYOS	The cell division cycle gene, CDC34, is required for ubiquitin-mediated degradation of G(1) regulators and cell cycle progression through the transition from G(1) to S phase in budding yeast. A CDC34 requirement for S phase onset in higher eukaryotes has not been established, Studies of the simple embryonic cell cycle of Xenopus laevis eggs demonstrated that Cdc34p in a large molecular size complex was required in the initiation of DNA replication, Cdc34p appears to regulate the initiation function of Cdk2-cyclin E, perhaps through the degradation of the Xenopus cdk inhibitor, Xic1.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Mathias N, 1996, MOL CELL BIOL, V16, P6634; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; SATOH N, 1977, DEV GROWTH DIFFER, V19, P111; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; YEW PR, UNPUB	29	61	63	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1672	1676		10.1126/science.277.5332.1672	http://dx.doi.org/10.1126/science.277.5332.1672			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287222				2022-12-01	WOS:A1997XV68400053
J	Adams, MA; Dolan, P				Adams, MA; Dolan, P			Could sudden increases in physical activity cause degeneration of intervertebral discs?	LANCET			English	Article							LUMBAR SPINE; EXERCISE; STRENGTH; PAIN	Epidemiological studies link high repetitive loading of the lower back with degeneration of intervertebral discs, and experiments on cadaver spines confirm that repetitive mechanical loading can disrupt the lumbar discs in a manner characteristic of ''degeneration''. But why do living discs not just strengthen in response to this stimulus, as other musculo-skeletal tissues do? Our hypothesis proposes that the low metabolic rate of lumbar discs (the largest avascular structures in the body) prevents them from keeping pace with adaptive remodelling changes in adjacent tissues, so that large and abrupt increases in a person's level of physical activity may leave the lumbar discs the weak link in a strengthening and heavily loaded spine. Recent laboratory investigations support the hypothesis, but clinical evidence Is required to relate recent disc degeneration with recent increases in physical activity, and so test the hypothesis.			Adams, MA (corresponding author), UNIV BRISTOL, DEPT ANAT, SOUTHWELL ST, BRISTOL BS2 8EJ, AVON, ENGLAND.		Adams, Michael A/C-9875-2009	Adams, Michael A/0000-0003-0435-8651; Dolan, Patricia/0000-0001-8561-675X				ADAMS MA, 1982, SPINE, V7, P184, DOI 10.1097/00007632-198205000-00002; ADAMS MA, 1985, SPINE, V10, P524, DOI 10.1097/00007632-198507000-00006; ADAMS MA, 1994, CLIN BIOMECH, V9, P5, DOI 10.1016/0268-0033(94)90052-3; ADAMS MA, 1995, INT SOC STUD LUMB SP; Battie MC, 1995, SPINE, V20, P2601, DOI 10.1097/00007632-199512150-00001; BAYLISS MT, 1988, SPINE, V13, P972, DOI 10.1097/00007632-198809000-00003; Boos N, 1995, SPINE, V20, P2613, DOI 10.1097/00007632-199512150-00002; DOLAN P, 1994, J BIOMECH, V27, P1237, DOI 10.1016/0021-9290(94)90277-1; GRANHED H, 1987, SPINE, V12, P146, DOI 10.1097/00007632-198703000-00010; Green T P, 1993, Eur Spine J, V2, P209, DOI 10.1007/BF00299448; Ishihara H, 1996, J APPL PHYSIOL, V80, P839, DOI 10.1152/jappl.1996.80.3.839; JONES HH, 1977, J BONE JOINT SURG AM, V59, P204, DOI 10.2106/00004623-197759020-00012; KELSEY J L, 1984, Journal of Orthopaedic Research, V2, P61, DOI 10.1002/jor.1100020110; LANYON LE, 1982, J BIOMECH, V15, P141, DOI 10.1016/0021-9290(82)90246-9; MAROUDAS A, 1975, J ANAT, V120, P113; McNally D.S., 1996, BONE JOINT SURG BR, V78, P965, DOI [10.1302/0301-620X.78B6.0780965, DOI 10.1302/0301-620X.78B6.0780965]; MOFFETT JAK, 1993, INT J NURS STUD, V30, P197, DOI 10.1016/0020-7489(93)90031-O; MONETA GB, 1994, SPINE, V19, P1968, DOI 10.1097/00007632-199409000-00018; NEUMANN P, 1993, SPINE, V18, P637, DOI 10.1097/00007632-199304000-00017; OSTI OL, 1990, SPINE, V15, P762, DOI 10.1097/00007632-199008000-00005; PORTER RW, 1989, SPINE, V14, P201, DOI 10.1097/00007632-198902000-00009; VASCONCELOS D, 1973, EPILEPSIA, V14, P323, DOI 10.1111/j.1528-1157.1973.tb03967.x; VIDEMAN T, 1995, SPINE, V20, P699, DOI 10.1097/00007632-199503150-00011	23	35	37	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	1997	350	9079					734	735		10.1016/S0140-6736(97)03021-3	http://dx.doi.org/10.1016/S0140-6736(97)03021-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291918				2022-12-01	WOS:A1997XU97700045
J	Lo, HJ; Kohler, JR; DiDomenico, B; Loebenberg, D; Cacciapuoti, A; Fink, GR				Lo, HJ; Kohler, JR; DiDomenico, B; Loebenberg, D; Cacciapuoti, A; Fink, GR			Nonfilamentous C-albicans mutants are avirulent	CELL			English	Article							CANDIDA-ALBICANS; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; FILAMENTOUS GROWTH; HYPHAL FORMATION; GENE; PROTEIN; YEAST; HOMOLOG; MORPHOGENESIS	Candida albicans and Saccharomyces cerevisiae switch from a yeast to a filamentous form. In Saccharomyces, this switch is controlled by two regulatory proteins, Ste12p and Phd1p. Single-mutant strains, ste 12/ste12 or phd1/phd1, are partially defective, whereas the sfe12/ste12 phd1/phd1 double mutant is completely defective in filamentous growth and is noninvasive. The equivalent cph1/cph1 efg1/efg1 double mutant in Candida (Cph1p is the Ste12p homolog and Efg1p is the Phd1p homolog) is also defective in filamentous growth, unable to form hyphae or pseudohyphae in response to many stimuli, including serum or macrophages. This Candida cph1/cph1 efg1/efg1 double mutant, locked in the yeast form, is avirulent in a mouse model.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; CHILDRENS HOSP, DIV INFECT DIS, BOSTON, MA 02115 USA; SCHERING PLOUGH RES INST, KENILWORTH, NJ 07033 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Merck & Company; Schering-Plough Research Institute			Lo, Hsiu-Jung/B-2658-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040266, R01GM035010, R37GM035010] Funding Source: NIH RePORTER; NIAID NIH HHS [F32 AI009236] Funding Source: Medline; NIGMS NIH HHS [GM35010, GM40266] Funding Source: Medline; PHS HHS [F32A109236] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIRSE CE, 1993, INFECT IMMUN, V61, P3648, DOI 10.1128/IAI.61.9.3648-3655.1993; BOONE C, 1991, J BACTERIOL, V173, P6859, DOI 10.1128/jb.173.21.6859-6864.1991; BULLOCK WE, 1990, PRINCIPLES PRACTICE, P2340; CACCIAPUOTI A, 1992, ANTIMICROB AGENTS CH, V36, P64, DOI 10.1128/AAC.36.1.64; CANNON RD, 1992, MOL GEN GENET, V235, P453, DOI 10.1007/BF00279393; CHAPMAN SW, 1990, PRINCIPLES PRACTICE, P2353; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DABROWA N, 1981, J GEN MICROBIOL, V127, P391; DIAMOND RD, 1990, PRINCIPLES PRACTICE, P2331; Diener AC, 1996, GENETICS, V143, P769; EDWARDS JE, 1990, PRINCIPLES PRACTICE, P1943; FONZI WA, 1993, GENETICS, V134, P717; GIMENO CJ, 1994, MOL CELL BIOL, V14, P2100, DOI 10.1128/MCB.14.3.2100; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; KIRKMANCORREIA C, 1993, MOL CELL BIOL, V13, P3765, DOI 10.1128/MCB.13.6.3765; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; LIU HP, 1995, SCIENCE, V267, P17; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; ODDS FC, 1985, CRC CR REV MICROBIOL, V12, P45, DOI 10.3109/10408418509104425; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; SHEPHERD MG, 1980, CAN J MICROBIOL, V26, P21, DOI 10.1139/m80-004; Sherman F., 1986, METHODS YEAST GENETI; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982	29	1416	1469	0	61	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					939	949		10.1016/S0092-8674(00)80358-X	http://dx.doi.org/10.1016/S0092-8674(00)80358-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298905	Bronze			2022-12-01	WOS:A1997XV56300014
J	Peng, CY; Graves, PR; Thoma, RS; Wu, ZQ; Shaw, AS; PiwnicaWorms, H				Peng, CY; Graves, PR; Thoma, RS; Wu, ZQ; Shaw, AS; PiwnicaWorms, H			Mitotic and G(2) checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216	SCIENCE			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE CONTROL; FISSION YEAST; KINASE; IDENTIFICATION; PATHWAY; ROLES	Human Cdc25C is a dual-specificity protein phosphatase that controls entry into mitosis by dephosphorylating the protein kinase Cdc2. Throughout interphase, but not in mitosis, Cdc25C was phosphorylated on serine-216 and bound to members of the highly conserved and ubiquitously expressed family of 14-3-3 proteins. A mutation preventing phosphorylation of serine-216 abrogated 14-3-3 binding. Conditional overexpression of this mutant perturbed mitotic timing and allowed cells to escape the G(2) checkpoint arrest induced by either unreplicated DNA or radiation-induced damage. Chk1, a fission yeast kinase involved in the DNA damage checkpoint response, phosphorylated Cdc25C in vitro on serine-216. These results indicate that serine-216 phosphorylation and 14-3-3 binding negatively regulate Cdc25C and identify Cdc25C as a potential target of checkpoint control in human cells.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; HARVARD UNIV,SCH MED,COMM VIROL,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)			Piwnica-Worms, Helen/C-5214-2012		NIAID NIH HHS [AI34094] Funding Source: Medline; NIGMS NIH HHS [GM18428, GM47017] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018428, R01GM047017] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITLEN A, 1996, TRENDS CELL BIOL, V6, P341; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAVES PR, UNPUB; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng C., UNPUB; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; THOMA R, UNPUB; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	23	1184	1245	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1501	1505		10.1126/science.277.5331.1501	http://dx.doi.org/10.1126/science.277.5331.1501			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278512				2022-12-01	WOS:A1997XV42900039
J	Henningsen, U; Schliwa, M				Henningsen, U; Schliwa, M			Reversal in the direction of movement of a molecular motor	NATURE			English	Article							MICROTUBULE MOTOR; CRYSTAL-STRUCTURE; NCD PROTEIN; KINESIN; DROSOPHILA; DOMAINS; SEGREGATION	Kinesin and non-claret disjunctional (ncd) are molecular motors of the kinesin superfamily that move in opposite directions along microtubules. The molecular basis underlying the direction of movement is unclear, although it is thought to be an intrinsic property of the motor domain, a conserved region about 330 amino acids in length(1-3). The motor domain is found at the amino terminus in conventional kinesins, but at the carboxy terminus in ncd(4,5). Here we report on a chimaera composed of the motor domain of the minus-end-directed kinesin of Neurospora crassa(6). The bacterially expressed fusion protein was tested in motility assays using polarity-marked microtubules(7). Surprisingly, the chimaera moved towards the plus end, demonstrating that the polarity of force generation of the ncd motor domain has been reversed. This finding indicates that the domain organization, particularly the position of the motor domain, is of fundamental importance for the polarity of force production. It also demonstrates that the direction of microtubule movement is not controlled solely by the motor domain(8).	UNIV MUNICH, ADOLF BUTENANDT INST ZELLBIOL, D-80336 MUNICH, GERMANY	University of Munich								AMAL I, 1996, CURR BIOL, V6, P1265; Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HYMAN AA, 1991, J CELL SCI, P125; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MARKS DL, 1994, J CELL SCI, V107, P2417; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; STEINBERG G, 1995, MOL BIOL CELL, V6, P1605, DOI 10.1091/mbc.6.11.1605; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TABOR S, 1990, CURRENT PROTOCOLS MO; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0	22	182	184	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					93	96		10.1038/38022	http://dx.doi.org/10.1038/38022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288974				2022-12-01	WOS:A1997XU59600052
J	Liu, RH; Orgel, LE				Liu, RH; Orgel, LE			Oxidative acylation using thioacids	NATURE			English	Article							CONDENSATION	Several important prebiotic reactions, including the coupling of amino acids into polypeptides by the formation of amide linkages, involve acylation. Theae reactions present a challenge to the understanding of prebiotic synthesis. Condensation reactions relying on dehydrating agents are either inefficient in aqueous solution(1,2) or require strongly acidic conditions and high temperatures(3). Activated amino acids such as thioester derivatives have therefore been suggested as likely substrates for prebiotic peptide synthesis(4-7). Here we propose a closely related route to amide bond formation involving oxidative acylation by thioacids. We find that phenylalanine, leucine and phenylphosphate are acylated efficiently in aqueous solution by thioacetic acid and oxidizing agent, From a prebiotic point of view, oxidative acylation has the advantage of proceeding efficiently in solution and under mild conditions. We anticipate that oxidative acylation should prove to be a general method for activating carboxylic acids, including amino acids.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	Salk Institute								BRATERMAN PS, 1983, NATURE, V303, P163, DOI 10.1038/303163a0; BUTLER EA, 1958, ANAL CHEM, V30, P1379, DOI 10.1021/ac60140a027; Cefola M., 1962, TALANTA, V9, P537, DOI DOI 10.1016/0039-9140(62)80125-8; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; de Duve C, 1991, BLUEPRINT CELL NATUR; FERRIS J P, 1987, P29; HAWKER JR, 1981, J MOL EVOL, V17, P285, DOI 10.1007/BF01795750; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; HULSHOF J, 1976, ORIGINS LIFE EVOL B, V7, P197, DOI 10.1007/BF00926938; KELLER M, 1994, NATURE, V368, P836, DOI 10.1038/368836a0; Liu CF, 1996, TETRAHEDRON LETT, V37, P933, DOI 10.1016/0040-4039(95)02394-1; ROSENTHAL D, 1957, J AM CHEM SOC, V79, P2684, DOI 10.1021/ja01568a007; SHEEHAN JC, 1952, J AM CHEM SOC, V74, P4726, DOI 10.1021/ja01138a528; SMITH PAS, 1965, CHEM OPEN CHAIN ORGA, P165; WEBER AL, 1981, J MOL EVOL, V18, P24, DOI 10.1007/BF01733208; WEBER AL, 1979, J MOL EVOL, V13, P193, DOI 10.1007/BF01739479; Whittet DCB, 1997, ORIGINS LIFE EVOL B, V27, P249, DOI 10.1023/A:1006534500363; WIELAND T, 1988, ROOTS OF MODERN BIOCHEMISTRY, P213	18	71	73	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					52	54		10.1038/37944	http://dx.doi.org/10.1038/37944			3	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288964				2022-12-01	WOS:A1997XU59600040
J	Smith, CAD; Harrison, DJ				Smith, CAD; Harrison, DJ			Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema	LANCET			English	Article							ALPHA-1-ANTITRYPSIN DEFICIENCY; CIGARETTE-SMOKING; LUNG-DISEASE; EXPRESSION; INHIBITOR; ELASTASE; CANCER; MODEL; LIVER	Background The first-pass metabolism of foreign compounds in the lung is an mechanism against whether polymorphisms in the gene for microsomal epoxide hydrolase (mEPHX), an enzyme involved in this protective process, had any bearing on individual susceptibility to the development of chronic obstructive pulmonary disease (COPD) and emphysema. Methods We designed PCR-based genotyping assays to detect variant forms of mEPHX that confer slow and fast activity. We used these assays to screen 203 blood-donor controls and groups of patients with asthma (n=57), lung cancer (n=50), COPD (n=68), and emphysema (n=94), who were attending specialised clinics in Edinburgh, UK. Findings The proportion of individuals with innate slow mEPHX activity (homozygotes) was significantly higher in both the COPD group and the emphysema group than in the control group (COPD 13 [19%] vs control 13 [6%]; emphysema 21 [22%] vs 13 [6%]). The odds ratios for homozygous slow activity versus all other phenotypes were 4.1 (95% CI 1.8-9.7) for COPD and 5.0 (2.3-10.9) for emphysema. Interpretation Genetic polymorphisms in xenobiotic enzymes may have a role in individual susceptibility to oxidant-related lung disease. Epoxide derivatives of cigarette-smoke components may be the cause of some of the lung damage characteristic of these diseases.	UNIV EDINBURGH, DEPT PATHOL, EDINBURGH, MIDLOTHIAN, SCOTLAND	University of Edinburgh								AARON J, 1985, AM REV RESPIR DIS, V132, P417; BARTSCH H, 1992, ENVIRON HEALTH PERSP, V98, P119, DOI 10.2307/3431257; CANTLAY AM, 1994, THORAX, V49, P1010, DOI 10.1136/thx.49.10.1010; CANTLAY AM, 1995, J CLIN PATHOL-CL MOL, V48, pM210; CARP H, 1982, P NATL ACAD SCI-BIOL, V79, P2041, DOI 10.1073/pnas.79.6.2041; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; COX DW, 1988, AM REV RESPIR DIS, V137, P371, DOI 10.1164/ajrccm/137.2.371; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; EVANS MD, 1994, AM J PHYSIOL, V266, pL593, DOI 10.1152/ajplung.1994.266.6.L593; FARBER JL, 1994, ENVIRON HEALTH PERSP, V102, P17, DOI 10.2307/3432207; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; GARVER RI, 1986, NEW ENGL J MED, V314, P762, DOI 10.1056/NEJM198603203141207; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; Hoffmann D., 1990, CHEM CARCINOGENESIS, P63, DOI [10.1007/978-3-642-74775-5_3, DOI 10.1007/978-3-642-74775-5_3]; KALSHEKER NA, 1987, BRIT MED J, V294, P1511, DOI 10.1136/bmj.294.6586.1511; MARTORANA PA, 1993, LAB INVEST, V68, P233; MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384; MORGAN K, 1992, EUR J CLIN INVEST, V22, P134, DOI 10.1111/j.1365-2362.1992.tb01946.x; OGUSHI F, 1991, J CLIN INVEST, V87, P1060, DOI 10.1172/JCI115066; OMIECINSKI CJ, 1993, PHARMACOGENETICS, V3, P150, DOI 10.1097/00008571-199306000-00005; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; SMITH CAD, 1994, EUR J CANCER, V30A, P1921, DOI 10.1016/0959-8049(94)00382-F; TETLEY TD, 1993, THORAX, V48, P560, DOI 10.1136/thx.48.5.560; TINGLE MD, 1993, BIOCHEM PHARMACOL, V46, P1529, DOI 10.1016/0006-2952(93)90319-R	24	335	360	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					630	633		10.1016/S0140-6736(96)08061-0	http://dx.doi.org/10.1016/S0140-6736(96)08061-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288046				2022-12-01	WOS:A1997XU28300011
J	Wilcken, DEL				Wilcken, DEL			MTHFR 677C->T mutation, folate intake, neural-tube defect, and risk of cardiovascular disease	LANCET			English	Editorial Material							METHYLENETETRAHYDROFOLATE REDUCTASE; VASCULAR-DISEASE; HOMOCYSTEINE				Wilcken, DEL (corresponding author), UNIV NEW S WALES,DEPT CARDIOVASC MED,SYDNEY,NSW 2036,AUSTRALIA.							BOCKXMEER FM, 1997, CIRCULATION, V95, P21; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Fowler B, 1997, J INHERIT METAB DIS, V20, P270, DOI 10.1023/A:1005369109055; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; KANG SS, 1991, AM J HUM GENET, V48, P536; Ma J, 1996, CIRCULATION, V94, P2410, DOI 10.1161/01.CIR.94.10.2410; Molloy AM, 1997, LANCET, V349, P1591, DOI 10.1016/S0140-6736(96)12049-3; SMITHELLS RW, 1980, LANCET, V1, P339; vanderPut NMJ, 1997, QJM-MON J ASSOC PHYS, V90, P111, DOI 10.1093/qjmed/90.2.111; Wilcken DEL, 1996, ARTERIOSCL THROM VAS, V16, P878, DOI 10.1161/01.ATV.16.7.878	10	47	48	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					603	604		10.1016/S0140-6736(05)63320-X	http://dx.doi.org/10.1016/S0140-6736(05)63320-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288038				2022-12-01	WOS:A1997XU28300003
J	Grady, RM; Teng, HB; Nichol, MC; Cunningham, JC; Wilkinson, RS; Sanes, JR				Grady, RM; Teng, HB; Nichol, MC; Cunningham, JC; Wilkinson, RS; Sanes, JR			Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy	CELL			English	Article							MDX MOUSE MUSCLE; NEUROMUSCULAR-JUNCTION; GLYCOPROTEIN COMPLEX; AGRIN RECEPTOR; PROTEIN; FIBERS; CELLS; REGENERATION; LOCALIZATION; ASSOCIATION	Dystrophin is a cytoskeletal protein of muscle fibers; its toss in humans leads to Duchenne muscular dystrophy, an inevitably fatal wasting of skeletal and cardiac muscle. mdx mice also lack dystrophin, but are only mildly dystrophic. Utrophin, a homolog of dystrophin, is confined to the postsynaptic membrane at skeletal neuromuscular junctions and has been implicated in synaptic development. However, mice lacking utrophin show only subtle neuromuscular defects. Here, we asked whether the mild phenotypes of the two single mutants reflect compensation between the two proteins. Synaptic development was qualitatively normal in double mutants, but dystrophy was severe and closely resembled that seen in Duchenne. Thus, utrophin attenuates the effects of dystrophin deficiency, and the double mutant may provide a useful model for studies of pathogenesis and therapy.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	Grady, RM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110, USA.		Wilkinson, Robert/F-5408-2012					AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Amalfitano A, 1996, MUSCLE NERVE, V19, P1549, DOI 10.1002/(SICI)1097-4598(199612)19:12<1549::AID-MUS4>3.0.CO;2-A; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BELL CD, 1968, J NEUROL SCI, V7, P529, DOI 10.1016/0022-510X(68)90058-0; Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRIDGES LR, 1986, J NEUROL SCI, V72, P147, DOI 10.1016/0022-510X(86)90003-1; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; DANGAIN J, 1984, MUSCLE NERVE, V7, P700, DOI 10.1002/mus.880070903; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; DECONINCK AE, 1997, IN PRESS CELL, V90, P717; Deconinck N, 1996, P NATL ACAD SCI USA, V93, P3570, DOI 10.1073/pnas.93.8.3570; DIMARIO JX, 1991, DEV BIOL, V148, P314, DOI 10.1016/0012-1606(91)90340-9; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; Engel AG, 1994, MYOLOGY, P1769; Engel AG, 1994, MYOLOGY, pP1133; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FRANKEL KA, 1976, HUM PATHOL, V7, P375, DOI 10.1016/S0046-8177(76)80053-6; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Gillis JM, 1996, ACTA PHYSIOL SCAND, V156, P397, DOI 10.1046/j.1365-201X.1996.201000.x; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; KARPATI G, 1988, MUSCLE NERVE, V11, P795, DOI 10.1002/mus.880110802; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; LICHTMAN JW, 1987, J PHYSIOL-LONDON, V393, P355, DOI 10.1113/jphysiol.1987.sp016827; LYONS PR, 1991, J NEUROCYTOL, V20, P969, DOI 10.1007/BF01187915; MASTAGLIA FL, 1975, J NEUROL SCI, V25, P227, DOI 10.1016/0022-510X(75)90143-4; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCGEACHIE JK, 1993, J NEUROL SCI, V119, P169, DOI 10.1016/0022-510X(93)90130-Q; MENKE A, 1995, J CELL SCI, V108, P727; Mora M, 1996, DEV BRAIN RES, V91, P70, DOI 10.1016/0165-3806(95)00169-7; MUKOYAMA M, 1987, J NEUROL SCI, V81, P155, DOI 10.1016/0022-510X(87)90092-X; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; ODA T, 1993, J PEDIATR ORTHOPED, V13, P478, DOI 10.1097/01241398-199307000-00012; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PETROF BJ, 1993, AM J PHYSIOL, V265, pC834; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; Quinlivan RM, 1996, NEUROMUSCULAR DISORD, V6, P237, DOI 10.1016/0960-8966(96)00007-7; REISER PJ, 1988, DEV BIOL, V129, P400, DOI 10.1016/0012-1606(88)90387-9; REZVANI M, 1995, J APPL PHYSIOL, V78, P961, DOI 10.1152/jappl.1995.78.3.961; SANES JR, 1995, DEV BIOL, V6, P163; SARTORE S, 1982, NATURE, V298, P294, DOI 10.1038/298294a0; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; THIMAN N, 1991, J CELL BIOL, V115, P1695; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; WAKAI S, 1988, J NEUROL SCI, V84, P167, DOI 10.1016/0022-510X(88)90122-0; WILKINSON RS, 1992, J PHYSIOL-LONDON, V448, P413, DOI 10.1113/jphysiol.1992.sp019049	63	516	530	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					729	738		10.1016/S0092-8674(00)80533-4	http://dx.doi.org/10.1016/S0092-8674(00)80533-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288752	Bronze			2022-12-01	WOS:A1997XT06600016
J	Ichikawa, A; Kinoshita, T; Watanabe, T; Kato, H; Nagai, H; Tsushita, K; Saito, H; Hotta, T				Ichikawa, A; Kinoshita, T; Watanabe, T; Kato, H; Nagai, H; Tsushita, K; Saito, H; Hotta, T			Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; TUMOR SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; COMBINATION CHEMOTHERAPY; DISEASE PROGRESSION; MALIGNANT-LYMPHOMA; DELETIONS; REGIMEN; MARKER; CARCINOMAS	Background Mutations of the p53 gene are associated with a poor prognosis in several types of cancer. We investigated the prognostic importance of p53 mutations in patients with aggressive B-cell lymphoma. Methods We examined the relation between the presence or absence of a detectable p53 mutation in lymphoma cells and the response to chemotherapy and overall survival in 102 previously untreated patients with aggressive B-cell lymphoma. Mutations of the p53 gene were identified by polymerase-chain-reaction-mediated analysis of single-strand conformation polymorphisms and by direct sequencing. Results Of 102 cases of aggressive B-cell lymphoma, 22 (22 percent) involved p53 mutations. The rate of complete remission was significantly lower in patients with a tumor carrying a p53 mutation (6 of 22 patients, 27 percent) than in those with the wild-type p53 gene (61 of 80 patients, 76 percent) (P<0.001). Overall survival was significantly lower among patients with p53 mutations than among those with the wild-type p53 gene; the Kaplan-Meier estimates of survival at five years were 16 percent and 64 percent, respectively (P<0.001). Multivariate analysis incorporating prognostic factors from the international prognostic index demonstrated that p53 mutations had independent effects on the rates of complete remission and survival. When we categorized patients according to the international prognostic index, we found no effect of p53 mutations in patients in the groups at high-intermediate and high risk. However, these mutations were significantly associated (P<0.001) with low rates of complete remission (33 percent vs. 91 percent) and survival (27 percent vs. 81 percent at five years) in the groups at low and low-intermediate risk. Conclusions Mutations of the p53 gene are associated with a poor prognosis in patients with aggressive B-cell lymphoma. (C) 1997, Massachusetts Medical Society.	NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 1, NAGOYA, AICHI 466, JAPAN	Nagoya University	Ichikawa, A (corresponding author), GIFU PREFECTURAL TAJIMI HOSP, DEPT HEMATOL ONCOL, MAEHATA CHO, TAJIMI, JAPAN.			Watanabe, Takashi/0000-0002-9015-5246				Armitage P, 1994, STAT METHODS MED RES; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CARBONE PP, 1971, CANCER RES, V31, P1860; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COIFFIER B, 1991, J CLIN ONCOL, V9, P211, DOI 10.1200/JCO.1991.9.2.211; COIFFIER B, 1989, BLOOD, V74, P558; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR, 2018, ANAL BINARY DATA; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FISHER RI, 1981, BLOOD, V58, P45; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; ICHIKAWA A, 1992, BLOOD, V79, P2701; JAGANNATH S, 1986, J CLIN ONCOL, V4, P859, DOI 10.1200/JCO.1986.4.6.859; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; LAURENCE J, 1982, ANN INTERN MED, V97, P190, DOI 10.7326/0003-4819-97-2-190; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LISTER, 1990, J CLIN ONCOL, V8, P1602; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCKELVEY EM, 1976, CANCER, V38, P1484, DOI 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PUI CH, 1987, BLOOD, V70, P624; RODRIGUEZ V, 1977, BLOOD, V49, P325; ROSENBERG SA, 1982, CANCER, V49, P2112; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; SCHOUTEN HC, 1990, BLOOD, V75, P1841; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P128, DOI 10.1200/JCO.1988.6.1.128; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SOUSSI T, 1990, ONCOGENE, V5, P945; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VOSE JM, 1988, J CLIN ONCOL, V6, P1838, DOI 10.1200/JCO.1988.6.12.1838; Wilson WH, 1997, BLOOD, V89, P601, DOI 10.1182/blood.V89.2.601	48	231	237	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					529	534		10.1056/NEJM199708213370804	http://dx.doi.org/10.1056/NEJM199708213370804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262496				2022-12-01	WOS:A1997XR54800004
J	Rainville, P; Duncan, GH; Price, DD; Carrier, B; Bushnell, MC				Rainville, P; Duncan, GH; Price, DD; Carrier, B; Bushnell, MC			Pain affect encoded in human anterior cingulate but not somatosensory cortex	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; CORTICAL AFFERENTS; MONKEY; RESPONSES	Recent evidence demonstrating multiple regions of human cerebral cortex activated by pain has prompted speculation about their individual contributions to this complex experience. To differentiate cortical areas involved in pain affect, hypnotic suggestions were used to alter selectively the unpleasantness of noxious stimuli, without changing the perceived intensity. Positron emission tomography revealed significant changes in pain-evoked activity within anterior cingulate cortex, consistent with the encoding of perceived unpleasantness, whereas primary somatosensory cortex activation was unaltered. These findings provide direct experimental evidence in humans linking frontal-lobe limbic activity with pain affect, as originally suggested by early clinical lesion studies.	UNIV MONTREAL, CTR RECH SCI NEUROL, MONTREAL, PQ H3C 3J7, CANADA; MONTREAL NEUROL INST, MCCONNELL BRAIN IMAGING CTR, MONTREAL, PQ, CANADA; MCGILL UNIV, DEPT ANESTHESIOL, MONTREAL, PQ H3A 1A1, CANADA	Universite de Montreal; McGill University; McGill University			Rainville, Pierre/M-5480-2015; Price, Donald D./A-3094-2008	Rainville, Pierre/0000-0001-9801-757X; Price, Donald D./0000-0002-8971-7184				BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; COGHILL RC, 1994, J NEUROSCI, V14, P4095; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; CORBETTA M, 1991, J NEUROSCI, V11, P2383; Craig A. D., 1996, Society for Neuroscience Abstracts, V22, P111; Dostrovsky J. O., 1996, Society for Neuroscience Abstracts, V22, P111; Fields H. L., 1987, PAIN; FOLTZ EL, 1962, J NEUROSURG, V19, P89, DOI 10.3171/jns.1962.19.2.0089; FOLTZ EL, 1968, INT J NEUROL, V6, P353; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P323, DOI 10.1002/cne.902520304; GINGOLD SI, 1991, J COMP NEUROL, V308, P467, DOI 10.1002/cne.903080312; Hurt R W, 1974, Clin Neurosurg, V21, P334; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; KENSHALO DR, 1988, BRAIN RES, V454, P378, DOI 10.1016/0006-8993(88)90841-4; KIERNAN BD, 1995, PAIN, V60, P39, DOI 10.1016/0304-3959(94)00134-Z; MELZACK R, 1968, P423; Morin C., 1994, Society for Neuroscience Abstracts, V20, P127; MUFSON EJ, 1982, J COMP NEUROL, V212, P23, DOI 10.1002/cne.902120103; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; Paus T, 1996, CEREB CORTEX, V6, P207, DOI 10.1093/cercor/6.2.207; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; Price DD, 1988, PSYCHOL NEURAL MECH; RAINVILLE P, 1992, SOMATOSENS MOT RES, V9, P265, DOI 10.3109/08990229209144776; Rainville P., 1996, Society for Neuroscience Abstracts, V22, P117; RAUSELL E, 1991, J NEUROSCI, V11, P226; SIKES RW, 1992, J NEUROPHYSIOL, V68, P1720, DOI 10.1152/jn.1992.68.5.1720; STEVENS RT, 1993, BRAIN RES, V631, P241, DOI 10.1016/0006-8993(93)91541-Y; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; VOGT BA, 1979, SCIENCE, V204, P205, DOI 10.1126/science.107587; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; [No title captured]; [No title captured]; [No title captured]	38	1767	1811	0	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	1997	277	5328					968	971		10.1126/science.277.5328.968	http://dx.doi.org/10.1126/science.277.5328.968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252330				2022-12-01	WOS:A1997XQ98500045
J	Chen, HW; Lin, RJ; Schiltz, RL; Chakravarti, D; Nash, A; Nagy, L; Privalsky, ML; Nakatani, Y; Evans, RM				Chen, HW; Lin, RJ; Schiltz, RL; Chakravarti, D; Nash, A; Nagy, L; Privalsky, ML; Nakatani, Y; Evans, RM			Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300	CELL			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTION FACTOR TFIIB; DEPENDENT TRANSACTIVATION; CO-REPRESSOR; PROTEIN CBP; DOMAIN; SUPERFAMILY; NUCLEOSOME; MEDIATE; BINDING	We report here the identification of a novel cofactor, ACTR, that directly binds nuclear receptors and stimulates their transcriptional activities in a hormone-dependent fashion. ACTR also recruits two other nuclear factors, CBP and P/CAF, and thus plays a central role in creating a multisubunit coactivator complex. In addition, and unexpectedly, we show that purified ACTR is a potent histone acetyltransferase and appears to define a distinct evolutionary branch to this recently described family. Thus, hormonal activation by nuclear receptors involves the mutual recruitment of at least three classes of histone acetyltransferases that may act cooperatively as an enzymatic unit to reverse the effects of histone cleacetylase shown to be part of the nuclear receptor corepressor complex.	HOWARD HUGHES MED INST,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,SCH MED,GRAD PROGRAM MOL PATHOL,LA JOLLA,CA 92037; NICHHD,LAB MOL GROWTH REGULAT,NATL INST HLTH,BETHESDA,MD 20892; UNIV CALIF DAVIS,MICROBIOL SECT,DIV BIOL SCI,DAVIS,CA 95616	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California Davis			Nagy, Laszlo/A-3814-2008; Evans, Ronald/AAF-4001-2019	Nagy, Laszlo/0000-0001-6653-2155; Evans, Ronald/0000-0002-9986-5965; Lin, Richard/0000-0002-0834-7880; Chakravarti, Debabrata/0000-0001-8446-8599	NICHD NIH HHS [HD27183] Funding Source: Medline; NIGMS NIH HHS [GM26444] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026444, R37GM026444] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; ING NH, 1992, J BIOL CHEM, V267, P17617; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANKNECHT R, 1996, CURR BIOL, V6, P951; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; SOEL W, 1995, MOL ENDOCRINOL, V9, P72; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	59	1238	1267	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					569	580		10.1016/S0092-8674(00)80516-4	http://dx.doi.org/10.1016/S0092-8674(00)80516-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267036	Bronze			2022-12-01	WOS:A1997XQ06300020
J	Pan, GH; Ni, J; Wei, YF; Yu, GL; Gentz, R; Dixit, VM				Pan, GH; Ni, J; Wei, YF; Yu, GL; Gentz, R; Dixit, VM			An antagonist decoy receptor and a death domain-containing receptor for TRAIL	SCIENCE			English	Article							APOPTOSIS; FAS	TRAIL, also called Apo2L, is a cytotoxic protein that induces apoptosis of many transformed cell fines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types. An antagonist decoy receptor (designated as TRID for TRAIL receptor without an intracellular domain) that may explain the resistant phenotype of normal tissues was identified. TRID is a distinct gene product with an extracellular TRAIL-binding domain and a transmembrane domain but no intracellular signaling domain. TRID transcripts were detected in many normal human tissues but not in most cancer cell lines examined. Ectopic expression of TRID protected mammalian cells from TRAIL-induced apoptosis, which is consistent with a protective role. Another death domain-containing receptor for TRAIL (designated as death receptor-5), which preferentially engaged a FLICE (caspase-8)-related death protease, was also identified.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; HUMAN GENOME SCI,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; GlaxoSmithKline; Human Genome Sciences Inc			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NIEHS NIH HHS [ES08111] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Baker SJ, 1996, ONCOGENE, V12, P1; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BROJATSH J, 1996, CELL, V87, P1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	27	1350	1527	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					815	818		10.1126/science.277.5327.815	http://dx.doi.org/10.1126/science.277.5327.815			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242610				2022-12-01	WOS:A1997XQ24700043
J	Tang, AH; Neufeld, TP; Kwan, E; Rubin, GM				Tang, AH; Neufeld, TP; Kwan, E; Rubin, GM			PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-dependent mechanism	CELL			English	Article							DROSOPHILA EYE DEVELOPMENT; ETS DOMAIN PROTEIN; TYROSINE KINASE; EXPRESSION PATTERN; ECTOPIC EXPRESSION; SEGMENTATION GENE; FUSHI-TARAZU; TRAMTRACK; SEVENLESS; UBIQUITIN	We show that Tramtrack (TTK88) expression represses neuronal fate determination in the developing Drosophila eye. Phyllopod (PHYL) acts to antagonize this repression by a mechanism that requires Seven In Absentia (SINA) and is associated with decreased TTK88 protein levels, but not reduced ttk88 gene transcription or mRNA stability. We present evidence that SINA, PHYL, and TTK88 physically interact and that SINA interacts genetically and physically with UBCD1, a component of the ubiquitin-dependent protein degradation pathway. Our results suggest a model in which activation of the Sevenless receptor tyrosine kinase induces PHYL expression, which then acts with SINA to target the transcriptional repressor TTK88 for degradation, thereby promoting R7 cell fate specification.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley			; Tang, Amy/L-3226-2016	Rubin, Gerald/0000-0001-8762-8703; Tang, Amy/0000-0002-5772-2878; Neufeld, Thomas/0000-0001-5659-4811				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BROWN JL, 1993, DEVELOPMENT, V117, P45; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTHEW RW, 1994, P NATL ACAD SCI USA, V91, P11689, DOI 10.1073/pnas.91.24.11689; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson Barry, 1993, P1327; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Huang YZ, 1996, DEVELOPMENT, V122, P3207; Kauffmann RC, 1996, GENE DEV, V10, P2167, DOI 10.1101/gad.10.17.2167; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; READ D, 1992, MECH DEVELOP, V38, P183, DOI 10.1016/0925-4773(92)90052-L; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/0968-0004(96)10036-0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREIER M, 1992, EMBO J, V11, P367, DOI 10.1002/j.1460-2075.1992.tb05059.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wolff Tanya, 1993, P1277; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; XU T, 1993, DEVELOPMENT, V117, P1223; Yamamoto D, 1996, ROUX ARCH DEV BIOL, V205, P215, DOI 10.1007/BF00365799; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	65	198	201	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					459	467		10.1016/S0092-8674(00)80506-1	http://dx.doi.org/10.1016/S0092-8674(00)80506-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267026	Bronze			2022-12-01	WOS:A1997XQ06300010
J	Shaffer, LG; Phillips, MD				Shaffer, LG; Phillips, MD			Successful treatment of acquired hemophilia with oral immunosuppressive therapy	ANNALS OF INTERNAL MEDICINE			English	Article							FACTOR-VIII; CYCLOPHOSPHAMIDE; INHIBITORS; COMBINATION; PREDNISONE	Background: Acquired autoantibodies to factor VIII in patients without hemophilia are rare, but they cause severe illness and death if not eradicated. Objective: To examine daily therapy with oral cyclophosphamide and prednisone for acquired hemophilia. Design: Case series. Setting: Academic medical center. Patients: Nine consecutive patients without hemophilia who had severe hemorrhage caused by high titers of factor VIII inhibitors. Interventions: Daily oral cyclophosphamide and prednisone. Coagulation factors were used only for bleeding. Measurements: Plasma titers of factor VIII inhibitor, factor VIII activity, and clinical evidence of bleeding. Results: All patients achieved complete remission, which was defined as loss of residual inhibitor activity and return to a normal titer of factor VIII. Therapy lasted a median of 12 weeks (range, 3 to 37 weeks), Bleeding resolved in a median of 3 weeks (range, 2 to 10 weeks). Median follow-up after discontinuation of therapy was 91 weeks (range, 61 to 164 weeks). Conclusion: Daily administration of oral cyclophosphamide and prednisone without empirical factor VIII therapy seems to be an effective and well-tolerated treatment for acquired hemophilia.	UNIV TEXAS, SCH MED, DIV HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	University of Texas System; University of Texas System; UTMD Anderson Cancer Center								GREEN D, 1993, THROMB HAEMOSTASIS, V70, P753; GREEN D, 1981, THROMB HAEMOSTASIS, V45, P200; GREEN D, 1971, BLOOD-J HEMATOL, V37, P381, DOI 10.1182/blood.V37.4.381.381; HERBST KD, 1981, ANN INTERN MED, V95, P575, DOI 10.7326/0003-4819-95-5-575; Hoyer LW, 1995, ADV EXP MED BIOL, V386, P35; HULTIN MB, 1991, AM J MED, V91, pS9, DOI 10.1016/S0002-9343(91)80141-8; LIAN ECY, 1989, ANN INTERN MED, V110, P774, DOI 10.7326/0003-4819-110-10-774; LOTTENBERG R, 1987, ARCH INTERN MED, V147, P1077, DOI 10.1001/archinte.147.6.1077; MORRISON AE, 1993, BLOOD, V81, P1513	9	73	74	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					206	209		10.7326/0003-4819-127-3-199708010-00005	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245226				2022-12-01	WOS:A1997XN12900005
J	Sugimoto, Y; Yamasaki, A; Segi, E; Tsuboi, K; Aze, Y; Nishimura, T; Oida, H; Yoshida, N; Tanaka, T; Katsuyama, M; Hasumoto, K; Murata, T; Hirata, M; Ushikubi, F; Negishi, M; Ichikawa, A; Narumiya, S				Sugimoto, Y; Yamasaki, A; Segi, E; Tsuboi, K; Aze, Y; Nishimura, T; Oida, H; Yoshida, N; Tanaka, T; Katsuyama, M; Hasumoto, K; Murata, T; Hirata, M; Ushikubi, F; Negishi, M; Ichikawa, A; Narumiya, S			Failure of parturition in mice lacking the prostaglandin F receptor	SCIENCE			English	Article							OXYTOCIN RECEPTOR; LUTEOLYTIC HORMONE; RAT MYOMETRIUM; EXPRESSION	Mice lacking the gene encoding the receptor for prostaglandin F-2 alpha (FP) developed normally but were unable to deliver normal fetuses at term. Although these FP-deficient mice showed no abnormality in the estrous cycle, ovulation, fertilization, or implantation, they did not respond to exogenous oxytocin because of the lack of induction of oxytocin receptor (a proposed triggering event in parturition), and they did not show the normal decline of serum progesterone concentrations that precedes parturition. Ovariectomy at day 19 of pregnancy restored induction of the oxytocin receptor and permitted successful delivery in the FP-deficient mice. These results indicate that parturition is initiated when prostaglandin F-2 alpha interacts with FP in ovarian luteal cells of the pregnant mice to induce luteolysis.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; ONO PHARMACEUT CO LTD,FUKUI RES INST,FUKUI 913,JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH,RES INST,DIV MOL & CELLULAR IMMUNOL,OSAKA 59002,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University; Ono Pharmaceutical Co Ltd; Kyoto University			Sugimoto, Yukihiko/AAV-6470-2021; Tanaka, Takashi/O-8254-2015	Sugimoto, Yukihiko/0000-0001-6973-932X; Segi-Nishida, Eri/0000-0002-0803-6513; Murata, Takahiko/0000-0003-0132-5424				ALEXANDROVA M, 1980, ENDOCRINOLOGY, V106, P739, DOI 10.1210/endo-106-3-739; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; FUCHS AR, 1983, ENDOCRINOLOGY, V113, P742, DOI 10.1210/endo-113-2-742; Hasumoto K, 1997, J REPROD FERTIL, V109, P45, DOI 10.1530/jrf.0.1090045; HORTON EW, 1976, PHYSIOL REV, V56, P595, DOI 10.1152/physrev.1976.56.4.595; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; LEFEBVRE DL, 1992, SCIENCE, V256, P1553, DOI 10.1126/science.1598587; LEWIS RB, 1973, LANCET, V2, P1159; MATSUMOTO K, 1981, FOLIA PHARMACOL JPN, V78, P231, DOI 10.1254/fpj.78.231; MCCRACKEN JA, 1972, NATURE-NEW BIOL, V238, P129, DOI 10.1038/newbio238129a0; MOELJONO MP, 1976, PROSTAGLANDINS, V14, P543; MONCADA S, 1985, PHARMACOL BASIS THER, P660; MURDOCH WJ, 1993, PROSTAG OTH LIPID M, V46, P85, DOI 10.1016/0090-6980(93)90037-8; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; SOLOFF MS, 1988, ONSET LABOR CELLULAR, P87; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; THORBURN GD, 1979, PHYSIOL REV, V59, P863, DOI 10.1152/physrev.1979.59.4.863; Young WS, 1996, J NEUROENDOCRINOL, V8, P847, DOI 10.1046/j.1365-2826.1996.05266.x	19	484	497	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					681	683		10.1126/science.277.5326.681	http://dx.doi.org/10.1126/science.277.5326.681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235889				2022-12-01	WOS:A1997XN90700039
J	Ryan, TA; Reuter, H; Smith, SJ				Ryan, TA; Reuter, H; Smith, SJ			Optical detection of a quantal presynaptic membrane turnover	NATURE			English	Article							EXCITATORY SYNAPSES; NERVE-TERMINALS; RAT HIPPOCAMPUS; SINGLE; MICROSCOPY; MOLECULES; NEURONS	Exploration of the mechanisms and plasticity of synaptic transmission has been hindered by the lack of a method to measure single vesicle turnover directly in individual presynaptic boutons at isolated nerve terminals. Although postsynaptic electrical recordings have provided a wealth of invaluable basic information about quantal presynaptic processes(1), this approach has often proved difficult to apply at most central nervous system synapses(2-6). Here we describe the direct optical detection of single quantal events in individual presynaptic boutons of cultured hippocampal neurons. Using the fluorescent dye FM 1-43 as a tracer for presynaptic endocytosis(7-10), we have characterized both evoked and spontaneous components of presynaptic function at the level of individual quanta. Our results are consistent with quantal interpretations of previous electrophysiological analyses(1-6) and provide new information about the unitary membrane recycling event and its coupling to individual action potential stimuli, about spontaneous vesicle turnover at individual boutons, and about the numbers of vesicles recycling at individual boutons.	STANFORD UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,STANFORD,CA 94305; UNIV BERN,DEPT PHARMACOL,CH-3010 BERN,SWITZERLAND	Stanford University; University of Bern			Ryan, Timothy/AAO-8286-2020	Smith, Stephen/0000-0002-2290-8701; Ryan, Timothy/0000-0003-2533-9548				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; DEHANNE D, 1996, J PHYSL, V491, P163; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1995, PHYSIOL REV, V75, P759, DOI 10.1152/physrev.1995.75.4.759; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HARRIS KM, 1989, J NEUROSCI, V9, P2982; Katz B., 1969, RELEASE NEURAL TRANS; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1992, J NEUROSCI METH, V44, P47, DOI 10.1016/0165-0270(92)90113-R; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; Malgaroli Antonio, 1994, Seminars in Cell Biology, V5, P231, DOI 10.1006/scel.1994.1029; Mertz J, 1995, OPT LETT, V20, P2532, DOI 10.1364/OL.20.002532; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; REUTER H, 1995, NEURON, V14, P773, DOI 10.1016/0896-6273(95)90221-X; Ryan TA, 1996, P NATL ACAD SCI USA, V93, P5567, DOI 10.1073/pnas.93.11.5567; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STEVENS CF, 1993, NEURON S, V10, P55; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1	25	136	137	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					478	482		10.1038/41335	http://dx.doi.org/10.1038/41335			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242407	Bronze			2022-12-01	WOS:A1997XN55300050
J	Kolykhalov, AA; Agapov, EV; Blight, KJ; Mihalik, K; Feinstone, SM; Rice, CM				Kolykhalov, AA; Agapov, EV; Blight, KJ; Mihalik, K; Feinstone, SM; Rice, CM			Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA	SCIENCE			English	Article							NON-B HEPATITIS; NON-A; VIRAL-HEPATITIS; HIGH-FIDELITY; CDNA CLONE; VIRUS; IDENTIFICATION; AMPLIFICATION; CHIMPANZEES; MARMOSETS	More than 1% of the world's population is chronically infected with hepatitis C virus (HCV). HCV infection can result in acute hepatitis, chronic hepatitis, and cirrhosis, which is strongly associated with development of hepatocellular carcinoma. Genetic studies of HCV replication have been hampered by lack of a bona fide infectious molecular clone. Full-length functional clones of HCV complementary DNA were constructed. RNA transcripts from the clones were found to be infectious and to cause disease in chimpanzees after direct intrahepatic inoculation. This work defines the structure of a functional HCV genome RNA and proves that HCV alone is sufficient to cause disease.	WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; US FDA,DIV VIROL,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	Washington University (WUSTL); US Food & Drug Administration (FDA)					NCI NIH HHS [CA57973] Funding Source: Medline; NIAID NIH HHS [AI40034] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTER HJ, 1978, LANCET, V1, P459; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; EMERSON SU, 1992, J VIROL, V66, P6649, DOI 10.1128/JVI.66.11.6649-6654.1992; FALKOW S, 1988, REV INFECT DIS, V10, pS274; FARCI P, 1992, J INFECT DIS, V165, P1006, DOI 10.1093/infdis/165.6.1006; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HOUGHTON M, 1996, FIELDS VIROLOGY, V1, P1035; INCHAUSPE G, 1991, P NATL ACAD SCI USA, V88, P10292, DOI 10.1073/pnas.88.22.10292; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; KOLYKHALOV AA, IN PRESS HEPATITIS C; KOLYKHALOV AA, UNPUB; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MAJOR ME, 1997, HEPATOLOGY, V25, P527; Nakajima N, 1996, J VIROL, V70, P3325, DOI 10.1128/JVI.70.5.3325-3329.1996; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OHLINGER VF, 1990, J VIROL, V64, P3331, DOI 10.1128/JVI.64.7.3331-3336.1990; POPPER H, 1980, VIRCHOWS ARCH A, V387, P91, DOI 10.1007/BF00428432; REED KE, 1997, HEPATITIS C VIRUS, V61; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; SHIMIZU YK, 1993, P NATL ACAD SCI USA, V90, P6037, DOI 10.1073/pnas.90.13.6037; SHINDO M, 1992, J INFECT DIS, V166, P424, DOI 10.1093/infdis/166.2.424; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; Yamada N, 1996, VIROLOGY, V223, P255, DOI 10.1006/viro.1996.0476	26	579	646	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					570	574		10.1126/science.277.5325.570	http://dx.doi.org/10.1126/science.277.5325.570			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228008				2022-12-01	WOS:A1997XM86700053
J	Nishimura, N; Balch, WE				Nishimura, N; Balch, WE			A di-acidic signal required for selective export from the endoplasmic reticulum	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; G-PROTEIN; MDCK CELLS; CYTOPLASMIC TAIL; TRANSPORT; SEQUENCE; ER; GLYCOPROTEIN; DEGRADATION; ENDOCYTOSIS	Transport of membrane proteins between intracellular compartments requires specific sequences in the protein cytoplasmic domain to direct packaging into vesicle shuttles. A sequence that mediates export from the endoplasmic reticulum (ER) has proved elusive. A di-acidic signal (Asp-X-Glu, where X represents any amino acid) on the cytoplasmic tail of vesicular stomatitis virus glycoprotein (VSV-G) and other cargo molecules was required for efficient recruitment to vesicles mediating export from the ER in baby hamster kidney cells. The existence of such a signal provides evidence that export from the ER occurs through a selective mechanism.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NIGMS NIH HHS [GM 42336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRUAN M, 1989, EMBO J, V8, P3633; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; KLAUSNER R D, 1989, New Biologist, V1, P3; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LAFAY F, 1974, J VIROL, V14, P1220, DOI 10.1128/JVI.14.5.1220-1228.1974; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NISHIMURA N, UNPUB; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schekman R, 1995, COLD SPRING HARB SYM, V60, P11, DOI 10.1101/SQB.1995.060.01.004; SCHMID SL, IN PRESS ANN REV BIO; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749	35	392	397	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					556	558		10.1126/science.277.5325.556	http://dx.doi.org/10.1126/science.277.5325.556			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228004				2022-12-01	WOS:A1997XM86700049
J	Inouye, C; Dhillon, N; Thorner, J				Inouye, C; Dhillon, N; Thorner, J			Ste5 RING-H2 domain: Role in Ste4-promoted oligomerization for yeast pheromone signaling	SCIENCE			English	Article							GLUTATHIONE-S-TRANSFERASE; PROTEIN-PROTEIN INTERACTIONS; MAP KINASE CASCADE; SACCHAROMYCES-CEREVISIAE; RESPONSE PATHWAY; SCHISTOSOMA-JAPONICUM; 2-HYBRID SYSTEM; FINGER DOMAIN; DIMERIZATION; BRCA1	Ste5 is a scaffold for the mitogen-activated protein kinase (MAPK) cascade components in a yeast pheromone response pathway. Ste5 also associates with Ste4, the beta subunit of a heterotrimeric guanine nucleotide-binding protein, potentially linking receptor activation to stimulation of the MAPK cascade, A RING-H2 motif at the Ste5 amino terminus is apparently essential for function because Ste5(C177S) and Ste5(C177A C180A) mutants did not rescue the mating defect of a ste5 Delta cell. In vitro Ste5(C177A C180A) bound each component of the MAPK cascade, but not Ste4, Unlike wild-type Ste5, the mutant did not appear to oligomerize; however, when fused to a heterologous dimerization domain (glutathione S-transferase), the chimeric protein restored mating in an ste5 Delta cell and an ste4 Delta ste5 Delta double mutant. Thus, the RING-H2 domain mediates Ste4-Ste5 interaction, which is a prerequisite for Ste5-Ste5 self-association and signaling.	UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NCI NIH HHS [CA09041] Funding Source: Medline; NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R37GM021841] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BENTON BM, 1990, MOL CELL BIOL, V10, P353, DOI 10.1128/MCB.10.1.353; Bienstock RJ, 1996, CANCER RES, V56, P2539; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CHOI KY, 1994, CELL, V78, P499; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Evangelista C, 1996, TRENDS CELL BIOL, V6, P196, DOI 10.1016/0962-8924(96)40002-2; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; INOUYE C, IN PRESS GENETICS; INOUYE C, UNPUB; Johannsson O, 1996, AM J HUM GENET, V58, P441; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Maru Y, 1996, J BIOL CHEM, V271, P15353, DOI 10.1074/jbc.271.26.15353; MCTIGUE MA, 1995, PROTEINS, V22, P55, DOI 10.1002/prot.340220108; OEHLEN B, 1994, CURR OPIN CELL BIOL, V6, P836, DOI 10.1016/0955-0674(94)90053-1; PRINTEN JA, 1994, GENETICS, V138, P609; Riley LG, 1996, PROTEIN ENG, V9, P223, DOI 10.1093/protein/9.2.223; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sherman F., 1986, METHODS YEAST GENETI; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864	37	139	144	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					103	106		10.1126/science.278.5335.103	http://dx.doi.org/10.1126/science.278.5335.103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311911				2022-12-01	WOS:A1997XZ12400047
J	Chan, L; Koepsell, TD; Deyo, RA; Esselman, PC; Haselkorn, JK; Lowery, JK; Stolov, WC				Chan, L; Koepsell, TD; Deyo, RA; Esselman, PC; Haselkorn, JK; Lowery, JK; Stolov, WC			The effect of Medicare's payment system for rehabilitation hospitals on length of stay, charges, and total payments	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Medicare's system for the payment of rehabilitation hospitals is based on limits derived from a hospital's average allowable charges per patient discharged during a base year. Thereafter, payments are capped, but hospitals receive incentive payments if charges per patient are reduced in succeeding years. We hypothesized that per-patient charges would increase during the base year and then decrease in subsequent years. Hospitals would thus have higher reimbursement limits and receive incentive payments for reducing their charges. Methods We analyzed Medicare claims data for 190,921 discharges from 69 rehabilitation hospitals from 1987 through 1994. We compared total charges, length of stay, and interim payments before, during, and alter each hospital's base year. Results After we controlled for inflation and temporal and seasonal trends, mean charges per patient discharged increased from $25,131 for patients discharged before the base year to $32,167 for patients discharged in the base year (a 28 percent increase, P<0.001) and the mean length of stay increased from 22.1 to 26.7 days (a 21 percent increase, P<0.001). After the base year, mean charges decreased to $29,307 (a 9 percent decrease) and the mean length of stay decreased to 24.0 days (a 10 percent decrease) (P<0.001 for both comparisons). Analysis of data on patients according to diagnosis-for example, spinal cord injury, brain injury, stroke, amputation or deformity, hip fracture, and arthritis or other joint disorders-showed similar findings for each, with increases in charges and length of stay in the base year, followed by small reductions thereafter For-profit hospitals had greater increases than nonprofit hospitals in their per-patient charges (mean increase, $7,434 vs. $2,929; P<0.001) and length of slay (mean increase, 4.6 vs. 2.3 days, P<0.001) during the base year. Conclusions Although Medicare's reimbursement system far rehabilitation hospitals put an upper limit on total payments, its design was associated with substantial extra costs, including significantly increased payments to hospitals and doctors and increased numbers of hospital days for the average patient. (C) 1997, Massachusetts Medical Society.	UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chan, L (corresponding author), HLTH CARE FINANCING ADM,DIV CLIN STAND & QUAL,REG 10,MS-RX 40,2201 6TH AVE,SEATTLE,WA 98121, USA.							ALTMAN DG, 1991, PRACTICAL STAT MED R, P194; ARNOLD S, 1992, C9205 PROSP PAYM ASS, P16; *BUR LAB STAT, 1996, CPI DET REP DAT MARC; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CROMWELL J, 1990, TEFRA PSYCH HOSP UNI; Davis L M, 1993, Adv Health Econ Health Serv Res, V14, P87; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FEDER J, 1987, NEW ENGL J MED, V317, P867, DOI 10.1056/NEJM198710013171405; Guterman S, 1988, Health Care Financ Rev, V9, P67; HARADA N, 1993, INQUIRY-J HEALTH CAR, V30, P54; HARROW B, 1990, IMPACT ANAL TEFRA SY; *HLTH CAR FIN ADM, 1994, MED PROV REIMB MAN 1, P30; *HLTH CAR FIN ADM, 1995, REG OFF MAN MED, pI25; HOSEK S, 1986, R3424HCFA RAND, P1; HSIA DC, 1990, NEW ENGL J MED, V322, P1540; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Langenbrunner J C, 1989, Health Care Financ Rev, V10, P91; *PROSP PAYM ASS CO, 1996, REP REC C MARCH 1 19; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; Searle S.R., 1992, VARIANCE COMPONENTS, P168; 1993, FED REGISTER, V58, P63820	21	71	71	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					978	985		10.1056/NEJM199710023371406	http://dx.doi.org/10.1056/NEJM199710023371406			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9309104				2022-12-01	WOS:A1997XY42300006
J	Poland, GA				Poland, GA			Lessons from the influenza vaccine recall of 1996-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ELDERLY PEOPLE; COST-EFFECTIVENESS; IMMUNIZATION; EFFICACY				Poland, GA (corresponding author), MAYO CLIN & MAYO FDN, MAYO VACCINE RES GRP, 601 B GUGGENHEIM BLDG, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							[Anonymous], 1997, MMWR Recomm Rep, V46, P1; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P1100; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P601; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; GOVAERT TME, 1994, VACCINE, V12, P1185, DOI 10.1016/0264-410X(94)90241-0; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; GROSS PA, 1987, J CLIN MICROBIOL, V25, P1763, DOI 10.1128/JCM.25.9.1763-1765.1987; Gross PA, 1996, CLIN DIAGN LAB IMMUN, V3, P361, DOI 10.1128/CDLI.3.3.361-362.1996; GROSS PA, 1988, J AM GERIATR SOC, V36, P209, DOI 10.1111/j.1532-5415.1988.tb01802.x; Hilleman MR, 1996, JAMA-J AM MED ASSOC, V275, P241, DOI 10.1001/jama.275.3.241; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; KILBOURNE ED, 1994, VACCINES, P565; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; *NAT VACC ADV COMM, 1994, AD IMM; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; U.S. Department of Health and Human Services Office of Disease Pre- vention and Health Promotion, 1990, HLTH PEOPL 2000	17	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					1022	1023		10.1001/jama.278.12.1022	http://dx.doi.org/10.1001/jama.278.12.1022			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307353				2022-12-01	WOS:A1997XX01200036
J	Fass, D; Davey, RA; Hamson, CA; Kim, PS; Cunningham, JM; Berger, JM				Fass, D; Davey, RA; Hamson, CA; Kim, PS; Cunningham, JM; Berger, JM			Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 angstrom resolution	SCIENCE			English	Article							ECOTROPIC RETROVIRUS RECEPTOR; ENVELOPE GLYCOPROTEINS; PROTEIN; GENE; CLASSIFICATION; DETERMINANTS; ALIGNMENT; SEQUENCE; VECTORS; DOMAIN	An essential step in retrovirus infection is the binding of the virus to its receptor on a target cell. The structure of the receptor-binding domain of the envelope glycoprotein from Friend murine leukemia virus was determined to 2.0 angstrom resolution by x-ray crystallography. The core of the domain is an antiparallel beta sandwich, with two interstrand loops forming a helical subdomain atop the sandwich, The residues in the helical region, but not in the beta sandwich, are highly variable among mammalian C-type retroviruses with distinct tropisms, indicating that the helical subdomain determines the receptor specificity of the virus.	MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, DEPT BIOL, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, SCH MED,BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST,DIV HEMATOL, DEPT MED, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute				Davey, Robert/0000-0001-9168-2892				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BATTINI JL, 1995, J VIROL, V69, P713, DOI 10.1128/JVI.69.2.713-719.1995; BATTINI JL, 1992, J VIROL, V66, P1468, DOI 10.1128/JVI.66.3.1468-1475.1992; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DAVEY RA, IN PRESS J VIROL; FASS D, 1997, THESIS MIT CAMBRIDGE; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; HEARD JM, 1991, J VIROL, V65, P4026, DOI 10.1128/JVI.65.8.4026-4032.1991; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; JONES TA, 1992, O MANUAL; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOCH W, 1983, J VIROL, V45, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINDER M, 1992, EUR J BIOCHEM, V203, P65, DOI 10.1111/j.1432-1033.1992.tb19828.x; MacKrell AJ, 1996, J VIROL, V70, P1768, DOI 10.1128/JVI.70.3.1768-1774.1996; MORGAN RA, 1993, J VIROL, V67, P4712, DOI 10.1128/JVI.67.8.4712-4721.1993; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTT D, 1992, J VIROL, V66, P4632, DOI 10.1128/JVI.66.8.4632-4638.1992; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Peredo C, 1996, J VIROL, V70, P3142, DOI 10.1128/JVI.70.5.3142-3152.1996; PINTER A, 1982, VIROLOGY, V116, P499, DOI 10.1016/0042-6822(82)90143-X; SMITH AE, 1995, ANNU REV MICROBIOL, V49, P807; ValsesiaWittmann S, 1996, J VIROL, V70, P2059, DOI 10.1128/JVI.70.3.2059-2064.1996; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; ZHANG KYJ, 1994, PROTEIN SCI, V3, P687; 1992, NATURE, V355, P472	37	173	178	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1662	1666		10.1126/science.277.5332.1662	http://dx.doi.org/10.1126/science.277.5332.1662			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287219				2022-12-01	WOS:A1997XV68400050
J	Compston, JE				Compston, JE			Designer oestrogens: fact or fantasy?	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ESTROGEN; RISK; RALOXIFENE				Compston, JE (corresponding author), UNIV CAMBRIDGE,SCH CLIN MED,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.							Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Compston JE, 1997, DRUGS, V53, P727, DOI 10.2165/00003495-199753050-00001; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DELMAS PD, IN PRESS P ENDOCR SO; Draper MW, 1996, J BONE MINER RES, V11, P835; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	11	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					676	677		10.1016/S0140-6736(97)22036-2	http://dx.doi.org/10.1016/S0140-6736(97)22036-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291896				2022-12-01	WOS:A1997XU97700002
J	Sigrist, SJ; Lehner, CF				Sigrist, SJ; Lehner, CF			Drosophila fizzy-related down-regulates mitotic cyclins and is required for cell proliferation arrest and entry into endocycles	CELL			English	Article							S-PHASE; SACCHAROMYCES-CEREVISIAE; REPLICATION ORIGINS; DNA-REPLICATION; PROTEIN-KINASE; B-CYCLIN; MITOSIS; GENE; EMBRYOGENESIS; YEAST	We demonstrate that fizzy-related (fir), a conserved eukaryotic gene, negatively regulates the levers of cyclins A, B, and B3. These mitotic cyclins that bind and activate cdk1(cdc2) are rapidly degraded during exit from M and during G1. While Drosophila fizzy has previously been shown to be required for cyclin destruction during M phase, fir is required for cyclin removal during G1 when the embryonic epidermal cell proliferation stops and during G2 preceding salivary gland endoreduplication. Loss of fzr causes progression through an extra division cycle in the epidermis and inhibition of endoreduplication in the salivary gland, in addition to failure of cyclin removal. Conversely, premature fir overexpression down-regulates mitotic cyclins, inhibits mitosis, and transforms mitotic cycles into endoreduplication cycles.			Sigrist, SJ (corresponding author), UNIV BAYREUTH,DEPT GENET,D-95440 BAYREUTH,GERMANY.							AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; Frank LH, 1996, DEVELOPMENT, V122, P1343; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hayashi S, 1996, DEVELOPMENT, V122, P1051; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IMIGER S, 1995, CELL, V81, P269; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SMITH AV, 1991, DEVELOPMENT, V112, P997; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thomas BJ, 1997, GENE DEV, V11, P1289, DOI 10.1101/gad.11.10.1289; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; WIESCHAUS E, 1983, ROUX ARCH DEVEL BIOL, V193, P296; Wuarin J, 1996, CELL, V85, P785, DOI 10.1016/S0092-8674(00)81261-1; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	53	365	369	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					671	681		10.1016/S0092-8674(00)80528-0	http://dx.doi.org/10.1016/S0092-8674(00)80528-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288747	hybrid			2022-12-01	WOS:A1997XT06600011
J	Anto, JM				Anto, JM			Health effects due to inhalation of oilseed rape emissions	LANCET			English	Editorial Material							POTENT ANTIGEN				Anto, JM (corresponding author), INST MUNICIPAL INVEST MED,RESP & ENVIRONM HLTH RES UNIT,E-08003 BARCELONA,SPAIN.		Anto, J M/H-2676-2014	Anto, J M/0000-0002-4736-8529				BUTCHER RD, 1995, CLIN EXP ALLERGY, V25, P985, DOI 10.1111/j.1365-2222.1995.tb00401.x; COLBORN T, 1995, ENVIRON HEALTH PERSP, V103, P81, DOI 10.2307/3432353; FELL PJ, 1992, CLIN EXP ALLERGY, V22, P501, DOI 10.1111/j.1365-2222.1992.tb00154.x; Hemmer W, 1997, CLIN EXP ALLERGY, V27, P156; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; *MED RES COUNC I E, 1997, IEH ASS OILS RAP ALL; NINAN TK, 1990, LANCET, V336, P808, DOI 10.1016/0140-6736(90)93266-R; PARRATT D, 1990, LANCET, V335, P121, DOI 10.1016/0140-6736(90)90599-Z; SOUTAR A, 1994, THORAX, V49, P352, DOI 10.1136/thx.49.4.352; SOUTAR A, 1995, OCCUP ENVIRON MED, V52, P575, DOI 10.1136/oem.52.9.575	10	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					458	459		10.1016/S0140-6736(05)63076-0	http://dx.doi.org/10.1016/S0140-6736(05)63076-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274579				2022-12-01	WOS:A1997XR13500005
J	Tokunaga, M; Larrow, JF; Kakiuchi, F; Jacobsen, EN				Tokunaga, M; Larrow, JF; Kakiuchi, F; Jacobsen, EN			Asymmetric catalysis with water: Efficient kinetic resolution of terminal epoxides by means of catalytic hydrolysis	SCIENCE			English	Article								Epoxides are versatile building blocks for organic synthesis. However, terminal epoxides are arguably the most important subclass of these compounds, and no general and practical method exists for their production in enantiomerically pure form. Terminal epoxides are available very inexpensively as racemic mixtures, and kinetic resolution is an attractive strategy for the production of optically active epoxides, given an economical and operationally simple method. Readily accessible synthetic catalysts (chiral cobalt-based salen complexes) have been used for the efficient asymmetric hydrolysis of terminal epoxides. This process uses water as the only reagent, no added solvent, and low loadings of a recyclable catalyst (<0.5 mole percent), and it affords highly valuable terminal epoxides and 1,2-diols in high yield with high enantiomeric enrichment.			Tokunaga, M (corresponding author), HARVARD UNIV,DEPT CHEM & CHEM BIOL,CAMBRIDGE,MA 02138, USA.				NIGMS NIH HHS [GM-43214] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043214, R37GM043214] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal VK, 1996, J AM CHEM SOC, V118, P7004, DOI 10.1021/ja961144+; CUMMINS J, COMMUNICATION; ELIEL EL, 1994, STEREOCHEMISTRY ORGA, P95; FABER K, 1992, BIOTRANSFORMATIONS O; Hansen KB, 1996, J AM CHEM SOC, V118, P10924, DOI 10.1021/ja962600x; Jacobsen EN, 1997, TETRAHEDRON LETT, V38, P773, DOI 10.1016/S0040-4039(96)02414-8; JACOBSEN EN, 1995, COMPRENHENSIVE ORGAN, V12; KAGAN HB, 1987, TOP STEREOCHEM, V14, P249; KOLB HC, 1994, CHEM REV, V94, P2483, DOI 10.1021/cr00032a009; Larrow JF, 1996, J AM CHEM SOC, V118, P7420, DOI 10.1021/ja961708+; Sato K, 1996, J ORG CHEM, V61, P8310, DOI 10.1021/jo961287e; SINIGALIA R, 1987, ORGANOMETALLICS, V6, P728, DOI 10.1021/om00147a009; Vanhessche KPM, 1997, CHEM-EUR J, V3, P517, DOI 10.1002/chem.19970030406; Weijers CAGM, 1997, TETRAHEDRON-ASYMMETR, V8, P639, DOI 10.1016/S0957-4166(97)00012-8	14	1237	1288	8	288	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					936	938		10.1126/science.277.5328.936	http://dx.doi.org/10.1126/science.277.5328.936			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252321				2022-12-01	WOS:A1997XQ98500036
J	Hull, HF; Aylward, RB				Hull, HF; Aylward, RB			Ending polio immunization	SCIENCE			English	Article											Hull, HF (corresponding author), WHO, EXPANDED PROGRAMME IMMUNIZAT, CH-1211 GENEVA 27, SWITZERLAND.							Banerjee K, 1997, LANCET, V349, P1630, DOI 10.1016/S0140-6736(05)61675-3; COCKBURN TA, 1961, SCIENCE, V133, P1050, DOI 10.1126/science.133.3458.1050; DOMOK I, 1982, BRIT MED J, V1, P743; Dove AW, 1997, SCIENCE, V277, P779, DOI 10.1126/science.277.5327.779; Dowdle WR, 1997, J INFECT DIS, V175, pS286, DOI 10.1093/infdis/175.Supplement_1.S286; EVANS AS, 1984, REV INFECT DIS, V6, pS571; FOX JP, 1961, 5 INT POL C, P368; Hull HF, 1997, SCIENCE, V275, P40, DOI 10.1126/science.275.5296.40; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; Kew OM, 1995, SEMIN VIROL, V6, P401, DOI 10.1016/S1044-5773(05)80017-4; LEE JW, 1997, NEW GENERATION VACCI, P79; MULDERS MN, 1997, IN PRESS J INFECT DI, V175; OCHOA E G, 1987, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V31, P381; ROBINSON D, 1984, REV INFECT DIS, V6, pS586; 1997, WEEKLY EPIDEMIOL REC, V72, P189; 1997, MMWR-MORBID MORTAL W, V46, P641	16	17	17	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					780	780		10.1126/science.277.5327.780	http://dx.doi.org/10.1126/science.277.5327.780			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9273701				2022-12-01	WOS:A1997XQ24700032
J	Calder, JAM				Calder, JAM			Listeria meningitis in adults	LANCET			English	Editorial Material							BACTERIAL-MENINGITIS; UNITED-STATES				Calder, JAM (corresponding author), NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013, USA.		Calder, Jennifer/F-4508-2015	Calder, Jennifer/0000-0003-4758-611X				BUCHNER LH, 1968, AM J MED, V45, P904, DOI 10.1016/0002-9343(68)90189-7; CHERUBIN CE, 1981, AM J MED, V71, P199, DOI 10.1016/0002-9343(81)90106-6; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; JENSEN A, 1994, SCAND J INFECT DIS, V26, P171, DOI 10.3109/00365549409011781; LAVETTER A, 1971, NEW ENGL J MED, V285, P598, DOI 10.1056/NEJM197109092851103; MICHES LI, 1994, CRIT CARE NURSE  AUG, P22; Sigurdardottir B, 1997, ARCH INTERN MED, V157, P425, DOI 10.1001/archinte.157.4.425; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; *WHO, 1993, B WORLD HEALTH ORGAN, V71, P259	10	16	17	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					307	308		10.1016/S0140-6736(05)63384-3	http://dx.doi.org/10.1016/S0140-6736(05)63384-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251632				2022-12-01	WOS:A1997XP24200005
J	Freemont, AJ; Peacock, TE; Goupille, P; Hoyland, JA; OBrien, J; Jayson, MIV				Freemont, AJ; Peacock, TE; Goupille, P; Hoyland, JA; OBrien, J; Jayson, MIV			Nerve ingrowth into diseased intervertebral disc in chronic back pain	LANCET			English	Article							SUBSTANCE-P; INNERVATION; FIBERS; RAT	Background In the healthy back only the outer third of the annulus fibrosus of the intervertebral disc is innervated. Nerve ingrowth deeper into diseased intervertebral disc has been reported, but how common this feature is and whether it is associated with chronic pain are unknown. We examined nerve growth into the intervertebral disc in the pathogenesis of chronic low back pain. Methods We collected 46 samples of intervertebral discs from 38 patients during spinal fusion for chronic back pain. 30 samples were from pain levels clinically established by discography and 16 samples were from adjacent vertebral levels with no pain. We obtained 34 control samples of intervertebral disc from previously healthy individuals with normal histology within 8 h of recorded death. We used standard immunohistochemical techniques to test for a general nerve marker, a nociceptive neurotransmitter (substance P), and a protein expressed during axonogenesis (growth-associated protein 43 [GAP43]). Findings We identified nerve fibres in the outer third of the annulus fibrosus in 48 (60%) of the 80 samples of intervertebral discs. Nerves were restricted to the outer or middle third of the annulus fibrosus in the 34 control samples. Among the patients with chronic low back pain, nerves extended into the inner third of the annulus fibrosus and into the nucleus pulposus in 21 (46%) and ten (22%) samples, respectively. Nerves usually accompanied blood vessels, but in 14 of the samples from back-pain patients, isolated nerve fibres were seen in the discal matrix. Both types of nerve fibres expressed substance P, but only non-vessel-associated fibres expressed GAP43, Deep nerve ingrowth into the inner third of the annulus fibrosus, the nucleus pulposus, or both was seen in four (25%) of 16 biopsy samples from non-pain levels and in 17 (57%) samples from pain levels. Of the 16 paired samples from both pain and non-pain levels, five pain-level samples and one non-pain-level sample showed deep nerve ingrowth. Interpretation Our finding of isolated nerve fibres that express substance P deep within diseased intervertebral discs and their association with pain suggests an important role for nerve growth into the intervertebral disc in the pathogenesis of chronic low back pain.	UNIV MANCHESTER, DEPT PATHOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; CTR HOSP UNIV, TOURS, FRANCE; LONDON CLIN, LONDON, ENGLAND	University of Manchester; CHU Tours; University of London; University College London	Freemont, AJ (corresponding author), UNIV MANCHESTER, DEPT RHEUMATOL, MANCHESTER M13 9PT, LANCS, ENGLAND.		Hoyland, Judith A/P-5168-2014; Freemont, Tony J/A-9000-2015	Hoyland, Judith A/0000-0003-4876-5208; Freemont, Tony J/0000-0002-9780-208X				AHMED M, 1993, SPINE, V18, P268, DOI 10.1097/00007632-199302000-00016; AHMED M, 1991, NEURO ORTHOP, V12, P19; ASHTON IK, 1994, ACTA ORTHOP SCAND, V65, P635, DOI 10.3109/17453679408994620; ASHTON IK, 1994, J ORTHOP RES, V12, P186, DOI 10.1002/jor.1100120206; BOGDUK N, 1981, J ANAT, V132, P39; COLLINS DH, 1949, PATHOLOGY ARTICULAR, P256; COPPES MH, 1990, LANCET, V336, P189, DOI 10.1016/0140-6736(90)91723-N; DAVIS DV, 1967, GRAYS ANATOMY DESCRI, P498; FAIRBANK JCT, 1996, INT SOC BACK PAIN RE, P86; GARDNER DL, 1992, PATHOLOGICAL BASIS C, P126; GRONBLAD M, 1991, ACTA ORTHOP SCAND, V62, P614; GRONBLAD M, 1991, CLIN ORTHOP RELAT R, P291; GRONBLAD M, 1990, ACTA ORTHOP SCA S235, V61, P40; HENRY JL, 1982, CIBA F SYMP, V91, P206; HIRSCH C., 1953, ACTA ORTHOPAED SCAND, V22, P184; JACKSON HC, 1966, J BONE JOINT SURG AM, VA 48, P1272, DOI 10.2106/00004623-196648070-00002; JESSELL TM, 1982, LANCET, V2, P1084; KANG JD, 1995, SPINE, V20, P2373, DOI 10.1097/00007632-199511001-00001; KAUPPILA LI, 1995, J BONE JOINT SURG AM, V77A, P26, DOI 10.2106/00004623-199501000-00004; KONTTINEN YT, 1990, SPINE, V15, P383, DOI 10.1097/00007632-199005000-00008; MALINSKY JII, 1959, ACTA ANAT, V38, P96; MCCARTHY PW, 1991, SPINE, V16, P653, DOI 10.1097/00007632-199106000-00010; Olmarker K, 1997, SPINE, V22, P471, DOI 10.1097/00007632-199703010-00001; Palmgren T, 1996, SPINE, V21, P1301, DOI 10.1097/00007632-199606010-00004; ROBERTS S, 1995, LUMBAR SPINE DISORDE, P73; TOLONEN J, 1995, SPINE, V20, P271, DOI 10.1097/00007632-199502000-00003; VERNONROBERTS B, 1992, LUMBAR SPINE BACK PA, P24; Virri J, 1994, Eur Spine J, V3, P336, DOI 10.1007/BF02200147; WEINSTEIN J, 1988, SPINE, V13, P1344, DOI 10.1097/00007632-198812000-00002	29	611	677	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 19	1997	350	9072					178	181		10.1016/S0140-6736(97)02135-1	http://dx.doi.org/10.1016/S0140-6736(97)02135-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250186				2022-12-01	WOS:A1997XL72200013
J	Deveraux, QL; Takahashi, R; Salvesen, GS; Reed, JC				Deveraux, QL; Takahashi, R; Salvesen, GS; Reed, JC			X-linked IAP is a direct inhibitor of cell-death proteases	NATURE			English	Article							APOPTOSIS	The inhibitor-of-apoptosis (IAP) family of genes has an evolutionarily conserved role in regulating programmed cell death in animals ranging from insects to humans(1-6). Ectopic expression of human IAP proteins can suppress cell death induced by a variety of stimuli, but the mechanism of this inhibition was previously unknown. Here we show that human X-chromosome-linked IAP directly inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. As the caspases are highly conserved throughout the animal kingdom and are the principal effectors of apoptosis(7), our findings suggest how IAPs might inhibit cell death, providing evidence for a mechanism of action for these mammalian cell-death suppressors.	BURNHAM INST,PROGRAM APOPTOSIS & CELL DEATH RES,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, IN PRESS BLOOD; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YAMAKAWA T, 1995, J BIOL CHEM, V270, P25328; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	27	1636	1732	1	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					300	304		10.1038/40901	http://dx.doi.org/10.1038/40901			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230442	Bronze, Green Submitted			2022-12-01	WOS:A1997XL12100057
J	Williams, LA; Evans, SF; Newnham, JP				Williams, LA; Evans, SF; Newnham, JP			Prospective cohort study of factors influencing the relative weights of the placenta and the newborn infant	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC HEART-DISEASE; ADULT LIFE; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; FETAL WEIGHT; MORTALITY; DEATH; CHILDHOOD; PREGNANCY; ENGLAND	Objectives: To determine the demographic, environmental, and medical factors that influence the relative weights of the newborn infant and the placenta and compare this ratio with other factors known to predispose to adult ill health. Design: Prospective cohort study. Setting: The tertiary referral centre for perinatal care in Perth, Western Australia. Subjects: 2507 pregnant women who delivered a single live infant at term. Main outcome measures: Placental weight, birth weight, and the ratio of placental weight to birth weight. Results: By multiple regression analysis the placental weight to birthweight ratio was significantly and positively associated with gestational age, female sex, Asian parentage, increasing maternal body mass index, increased maternal weight at booking, lower socioeconomic status, maternal anaemia, and increasing number of cigarettes smoked daily. There were no consistent relations between the placental weight to birthweight ratio and measures of newborn size. Conclusions: The ratio of placental weight to birth weight is not an accurate marker of fetal growth. In its role as a predictor of adult disease the ratio may be acting as a surrogate for other factors which are already known to influence health and may act before or after birth. Determining the role that relative growth rates of the fetus and placenta have in predisposing to adult disease requires prospective study to account for the many confounding variables which complicate this hypothesis.	UNIV WESTERN AUSTRALIA,KING EDWARD MEM HOSP,WOMEN & INFANTS RES FDN,SUBIACO,WA 6008,AUSTRALIA	King Edward Memorial Hospital; University of Western Australia			Study, Raine/K-4517-2013	Newnham, John/0000-0001-9983-7457				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1987, BMJ-BRIT MED J, V295, P83, DOI 10.1136/bmj.295.6590.83; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEISCHER N A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P398; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Evans S, 1996, EARLY HUM DEV, V45, P203, DOI 10.1016/0378-3782(96)01728-8; Garn S.M., 1971, HUMAN RACES; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; MCCRABB GJ, 1992, J AGR SCI, V118, P127, DOI 10.1017/S002185960006809X; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PERRY IJ, 1995, BMJ-BRIT MED J, V310, P436, DOI 10.1136/bmj.310.6977.436	16	149	149	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1864	1868		10.1136/bmj.314.7098.1864	http://dx.doi.org/10.1136/bmj.314.7098.1864			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224128	Green Published			2022-12-01	WOS:A1997XH73800022
J	Pfrieger, FW; Barres, BA				Pfrieger, FW; Barres, BA			Synaptic efficacy enhanced by glial cells in vitro	SCIENCE			English	Article							RETINAL GANGLION-CELLS; NEURONS; TRANSMISSION; POTENTIALS; SURVIVAL; CULTURE; GROWTH; SWITCH	In the developing nervous system, glial cells guide axons to their target areas, but it is unknown whether they help neurons to establish functional synaptic connections, The role of glial cells in synapse formation and function was studied in cultures of purified neurons from the rat central nervous system, In glia-free cultures, retinal ganglion cells formed synapses with normal ultrastructure but displayed little spontaneous synaptic activity and high failure rates in evoked synaptic transmission, In cocultures with neuroglia, the frequency and amplitude of spontaneous postsynaptic currents were potentiated by 70-fold and 5-fold, respectively, and fewer transmission failures occurred, Glial cells increased the action potential-independent guantal release by 12-fold without affecting neuronal survival, Thus, developing neurons in culture form inefficient synapses that require glial signals to become fully functional.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Pfrieger, Frank/AAX-3208-2020	Pfrieger, Frank/0000-0001-7085-1431				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; JONES BW, 1995, CELL, V82, P1013, DOI 10.1016/0092-8674(95)90280-5; Kaplan MR, 1997, NATURE, V386, P724, DOI 10.1038/386724a0; KUWADA JY, 1986, SCIENCE, V233, P740, DOI 10.1126/science.3738507; MacKenzie PJ, 1996, NEURON, V16, P783, DOI 10.1016/S0896-6273(00)80098-7; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McLachlan E M, 1978, Int Rev Physiol, V17, P49; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; PFRIEGER FW, 1994, NEURON, V12, P97, DOI 10.1016/0896-6273(94)90155-4; PFRIEGER FW, 1995, CELL, V83, P671, DOI 10.1016/0092-8674(95)90178-7; Pfrieger FW, 1996, CURR OPIN NEUROBIOL, V6, P615, DOI 10.1016/S0959-4388(96)80093-6; PFRIEGER FW, UNPUB; POMEROY SL, 1988, J CELL BIOL, V107, P1167, DOI 10.1083/jcb.107.3.1167; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; Ramon y Cajal S., 1897, HISTOLOGY NERVOUS SY, V1; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; Tsacopoulos M, 1996, J NEUROSCI, V16, P877	23	568	611	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1684	1687		10.1126/science.277.5332.1684	http://dx.doi.org/10.1126/science.277.5332.1684			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287225	Green Submitted			2022-12-01	WOS:A1997XV68400056
J	Connor, WE; Connor, SL				Connor, WE; Connor, SL			Should a low-fat, high-carbohydrate diet be recommended for everyone?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHOLESTEROL				Connor, WE (corresponding author), OREGON HLTH SCI UNIV,DEPT MED,L465,PORTLAND,OR 97201, USA.							*AM CANC SOC 1996, 1996, CA CANC J CLIN, V43, P325; Anitschkow N.N., 1933, ARTERIOSCLEROSIS, P271; [Anonymous], 1988, CIRCULATION, V77, p721A; ARMSTRONG ML, 1970, CIRC RES, V27, P59, DOI 10.1161/01.RES.27.1.59; Bang HO, 1980, ADV NUTR RES, P1, DOI [DOI 10.1007/978-1-4757-4448-4_1, 10.1007/978-1-4757-4448-4_1]; CONNOR WE, 1961, GERIATRICS, V16, P407; DE LANGEN C. D., 1922, Geneeskundig Tijdschrift voor Nederlandsche-Indie, V62, P1; *DEP AGR, 1995, IN PRESS STAT B; *DEP AGR AGR RES S, 1995, DAT TABL RES USDAS 1; *EXP PAN DET EV TR, 1993, JAMA-J AM MED ASSOC, V269, P3015; Kennedy E, 1996, J AM DIET ASSOC, V96, P234, DOI 10.1016/S0002-8223(96)00072-7; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; SCHAEFER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1450, DOI 10.1001/jama.274.18.1450; SPADY DK, 1988, J CLIN INVEST, V81, P300, DOI 10.1172/JCI113321; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	15	122	125	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					562	563						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262503				2022-12-01	WOS:A1997XR54800011
J	Rittinger, K; Walker, PA; Eccleston, JF; Nurmahomed, K; Owen, D; Laue, E; Gamblin, SJ; Smerdon, SJ				Rittinger, K; Walker, PA; Eccleston, JF; Nurmahomed, K; Owen, D; Laue, E; Gamblin, SJ; Smerdon, SJ			Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP	NATURE			English	Article							H-RAS P21; BINDING PROTEINS; MECHANISM; HYDROLYSIS	Small G proteins transduce signals from plasma-membrane receptors to control a wide range of cellular functions(1,2). These proteins are clustered into distinct families but all act as molecular switches, active in their GTP-bound form but inactive when GDP-bound. The Rho family of G proteins, which includes Cdc42Hs, activate effecters involved in the regulation of cytoskeleton formation, cell proliferation and the JNK signalling pathway(3-9). G proteins generally have a low intrinsic GTPase hydrolytic activity but there are family-specific groups of GTPase-activating proteins (GAPs) that enhance the rate of GTP hydrolysis by up to 10(5) times(10,11). We report here the crystal structure of Cdc42Hs, with the non-hydrolysable GTP analogue GMPPNP, in complex with the GAP domain of p50rhoGAP at 2.7 Angstrom resolution. In the complex Cdc42Hs interacts, mainly through its switch I and II regions, with a shallow pocket on rhoGAP which is lined with conserved residues. Arg 85 of rhoGAP interacts with the P-loop of Cdc42Hs, but from biochemical data and by analogy with the G-protein subunit G(i alpha 1) (ref. 12), we propose that it adopts a different conformation during the catalytic cycle which enables it to stabilize the transition state of the GTP-hydrolysis reaction.	NATL INST MED RES,RIDGEWAY,LONDON NW7 1AA,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge			Rittinger, Katrin/N-3344-2019; Rittinger, Katrin/D-2586-2014	Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Laue, Ernest/0000-0002-7476-4148; Smerdon, Stephen/0000-0001-5688-8465	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4	29	223	235	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					693	697		10.1038/41805	http://dx.doi.org/10.1038/41805			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262406	Bronze			2022-12-01	WOS:A1997XQ86300054
J	Dove, AW; Racaniello, VR				Dove, AW; Racaniello, VR			The polio eradication effort: Should vaccine eradication be next?	SCIENCE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University								BEALE AJ, 1991, PEDIATR INFECT DIS J, V10, P970, DOI 10.1097/00006454-199112000-00029; ConynvanSpaendonck MAE, 1996, AM J EPIDEMIOL, V143, P929, DOI 10.1093/oxfordjournals.aje.a008836; HURST CJ, 1989, CAN J MICROBIOL, V35, P474, DOI 10.1139/m89-073; KEW O, 1996, LECT AM SOC VIR ANN; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; Knolle H, 1995, Gesundheitswesen, V57, P351; MELNICK PD, 1996, BIOLOGICALS, V6, P1; MINOR PD, 1993, BIOLOGICALS, V21, P357, DOI 10.1006/biol.1993.1096; NAKAJIMA K, 1978, NATURE, V274, P334, DOI 10.1038/274334a0; RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; ROBERTSON SE, 1994, B WORLD HEALTH ORGAN, V72, P907; SWARTZ TA, 1994, PUBLIC HLTH REV, V21, P157; Van Wijngaarden JK, 1993, PUBLIC HLTH REV, V21, P107; WHO, 1996, GLOB POL ER YEAR 200; YATES MV, 1985, APPL ENVIRON MICROB, V49, P778, DOI 10.1128/AEM.49.4.778-781.1985; [No title captured]	17	38	38	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					779	780		10.1126/science.277.5327.779	http://dx.doi.org/10.1126/science.277.5327.779			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9273700				2022-12-01	WOS:A1997XQ24700031
J	Kostic, V; JacksonLewis, V; deBilbao, F; DuboisDauphin, M; Przedborski, S				Kostic, V; JacksonLewis, V; deBilbao, F; DuboisDauphin, M; Przedborski, S			Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis	SCIENCE			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; CELL-DEATH; NEURAL CELLS; MUTATIONS; GENE; DEGENERATION; DISEASE; MICE; SUPEROXIDE-DISMUTASE-1; OVEREXPRESSION	Mutations in the gene encoding copper/zinc superoxide dismutase enzyme produce an animal model of familial amyotrophic lateral sclerosis (FALS), a fatal disorder characterized by paralysis. Overexpression of the proto-oncogene bcl-2 delayed onset of motor neuron disease and prolonged survival in transgenic mice expressing the FALS-linked mutation in which glycine is substituted by alanine at position 93. it did not, however, alter the duration of the disease. Overexpression of bcl-2 also attenuated the magnitude of spinal cord motor neuron degeneration in the FALS-transgenic mice.	COLUMBIA UNIV,DEPT NEUROL,NEW YORK,NY 10032; HOP CANTONAL UNIV GENEVA,DIV NEUROPSYCHIAT,CH-1225 GENEVA,SWITZERLAND	Columbia University; University of Geneva					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001724] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01724] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Brown RH, 1995, CURR OPIN NEUROBIOL, V5, P841, DOI 10.1016/0959-4388(95)80114-6; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHIU AY, 1995, MOL CELL NEUROSCI, V6, P349, DOI 10.1006/mcne.1995.1027; COSLULICH SC, 1996, CURR BIOL, V6, P997; deBilbao F, 1996, NEUROREPORT, V7, P3051, DOI 10.1097/00001756-199611250-00051; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P2459; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; GURNEY ME, UNPUB; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kostic V, 1997, ANN NEUROL, V41, P497, DOI 10.1002/ana.410410413; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mena MA, 1997, J NEUROCHEM, V69, P21; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Miller Robert G., 1997, Neurology, V48, pS28; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 1996, ANN NEUROL, V39, P158, DOI 10.1002/ana.410390204; Przedborski S, 1996, NEURODEGENERATION, V5, P57; Przedborski S, 1996, J NEUROCHEM, V67, P1383; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1995, ADV NEUROL, V68, P7; Rowland L. P., 1995, MERRITTS TXB NEUROLO, P742; SAGOT Y, 1995, J NEUROSCI, V15, P7727; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, J NEUROSCI, V16, P5654; Troost D, 1995, NEUROPATH APPL NEURO, V21, P498, DOI 10.1111/j.1365-2990.1995.tb01096.x; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; VIRGO L, 1995, BRAIN RES, V676, P196, DOI 10.1016/0006-8993(95)00052-R; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; YOSHIYAMA Y, 1994, ACTA NEUROPATHOL, V88, P207; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	46	390	397	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					559	562		10.1126/science.277.5325.559	http://dx.doi.org/10.1126/science.277.5325.559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228005				2022-12-01	WOS:A1997XM86700050
J	Pan, DJ; Rubin, GM				Pan, DJ; Rubin, GM			Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis	CELL			English	Article							XENOPUS-EMBRYOS; GENE-EXPRESSION; CELL FATE; PROTEIN; MELANOGASTER; SPECIFICITY; DISINTEGRIN; PHENOTYPES; HOMOLOG; FUSION	Notch and the disintegrin metalloprotease encoded by the kuzbanian (kuz) gene are both required for a lateral inhibition process during Drosophila neurogenesis. We show that a mutant KUZ protein lacking protease activity acts as a dominant-negative form in Drosophila. Expression of such a dominant-negative KUZ protein can perturb lateral inhibition in Xenopus, leading to the overproduction of primary neurons. This suggests an evolutionarily conserved role for KUZ. The Notch family of receptors are known to be processed into smaller forms under normal physiological conditions. We provide genetic and biochemical evidence that Notch is an in vivo substrate for the KUZ protease, and that this cleavage may be part of the normal biosynthesis of functional Notch proteins.			Pan, DJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Campos-Ortega Jose A., 1993, P1091; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEBERLEIN U, 1994, MECH DEVELOP, V48, P35, DOI 10.1016/0925-4773(94)90004-3; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; HUANG F, 1991, DEVELOPMENT, V111, P1087; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; Karim FD, 1996, GENETICS, V143, P315; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMPSON P, 1990, DEVELOPMENT, V109, P509; STAEHLINGHAMPTON K, 1994, CELL GROWTH DIFFER, V5, P585; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Wolff Tanya, 1993, P1277; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	36	433	451	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					271	280		10.1016/S0092-8674(00)80335-9	http://dx.doi.org/10.1016/S0092-8674(00)80335-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244301	Bronze			2022-12-01	WOS:A1997XN24900011
J	Netzer, WJ; Hartl, FU				Netzer, WJ; Hartl, FU			Recombination of protein domains facilitated by co-translational folding in eukaryotes	NATURE			English	Article							ESCHERICHIA-COLI; EXON THEORY; IN-VIVO; EXPRESSION; BINDING; CHAPERONIN; COMPLEX; CHAINS; GENES; GROEL	The evolution of complex genomes requires that new combinations of pre-existing protein domains successfully fold into modular polypeptides. During eukaryotic translation model two-domain polypeptides fold efficiently by sequential and co-translational folding of their domains. In contrast, folding of the same proteins in Escherichia coli is post-translational, and leads to intramolecular misfolding of concurrently folding domains. Sequential domain folding in eukaryotes may have been critical in the evolution of modular polypeptides, by increasing the probability that random gene-fusion events resulted in immediately foldable protein structures.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Max Planck Society			Hartl, F. Ulrich/Y-8206-2019					Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; Bremer H, 1996, ESCHERICHIA COLI SAL, P1553; CAMEAU DE, 1985, J BACTERIOL, V164, P578; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GESTELAND RF, 1966, J MOL BIOL, V18, P356, DOI 10.1016/S0022-2836(66)80253-X; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAWKINS AR, 1995, EUR J BIOCHEM, V232, P7, DOI 10.1111/j.1432-1033.1995.tb20775.x; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; LAVALLIE ER, 1995, CURR OPIN BIOTECH, V6, P501, DOI 10.1016/0958-1669(95)80083-2; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; SHARROCKS AD, 1994, GENE, V138, P105, DOI 10.1016/0378-1119(94)90789-7; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; STOLTZFUS A, 1994, SCIENCE, V265, P202, DOI 10.1126/science.8023140; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U	39	329	339	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					343	349		10.1038/41024	http://dx.doi.org/10.1038/41024			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237751	Bronze			2022-12-01	WOS:A1997XM52800040
J	Everett, C				Everett, C			Incidence and outcome of bleeding before the 20th week of pregnancy: Prospective study from general practice	BRITISH MEDICAL JOURNAL			English	Article							SPONTANEOUS-ABORTION	Objective: To estimate the miscarriage rate in a cohort of pregnant women and the final outcome of pregnancy. Design: Two year prospective community study. Setting: Women registered with four semirural practices at one health centre. Subjects: 626 pregnant women from a population 21 448. 5140 of whom were women aged 15-44 years. Main outcome measures: Vaginal bleeding and outcome of pregnancy. Results: 76 of the 89 women with an unwanted pregnancy requested a termination. In the 550 ongoing pregnancies bleeding occurred before the 20th week in 117 (21%), and 67 (12%) ended in miscarriage. The risk of miscarriage was not significantly increased after a miscarriage in the previous pregnancy (11 (15%) women had miscarriage v 55 (12%) women who had not had miscarriage who had previously had a live birth). Of the 117 women with bleeding, 64 were not admitted to hospital by the general practitioner; 42 of these women had an ultrasound examination at the heatlh centre and 19 subsequently miscarried at home. In hospital 41 of 46 women who miscarried had evacuation of the uterus. Conclusions: Bleeding occurred in one fifth of recognised pregnancies before the 20th week and over half of these miscarried. Treatment of women with miscarriage at home means current statistics on miscarriage in Britain are missing many cases.	CHURCH COTTAGE,ALTON GU34 4HD,HANTS,ENGLAND		Everett, C (corresponding author), ALTON HLTH CTR,ALTON GU34 2QX,HANTS,ENGLAND.							COHENOVERBEEK TE, 1990, LANCET, V336, P27, DOI 10.1016/0140-6736(90)91528-I; *DEP HLTH, 1993, STAT PUBL HLTH; Everett CB, 1996, BRIT J GEN PRACT, V46, P7; EVERETT CB, 1988, BRIT MED J, V295, P583; FRENCH FE, 1962, PUBLIC HEALTH REP, V77, P835, DOI 10.2307/4591645; *HOSP EP STAT HES, 1994, HOSP EP STAT HES FIN; Huisjes H. J., 1984, SPONTANEOUS ABORTION, P6; James WH, 1996, HUM REPROD, V11, P2333; KNUDSEN UB, 1991, EUR J OBSTET GYN R B, V39, P31, DOI 10.1016/0028-2243(91)90138-B; NAYLOR AF, 1979, FERTIL STERIL, V31, P282; Oakley Ann, 1984, MISCARRIAGE; *OFF POP CENS SURV, 1995, POP TRENDS, P79; RAI R, 1994, DIPLOMATE, V1, P269; REGAN L, 1989, BRIT MED J, V299, P541, DOI 10.1136/bmj.299.6698.541; REGAN L, 1991, BMJ-BRIT MED J, V302, P543, DOI 10.1136/bmj.302.6776.543; Stabile I., 1992, SPONTANEOUS ABORTION; WEINBERG CR, 1994, ANN NY ACAD SCI, V709, P280, DOI 10.1111/j.1749-6632.1994.tb30416.x; WHITTAKER PG, 1983, LANCET, V1, P1126; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	19	217	226	1	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					32	34		10.1136/bmj.315.7099.32	http://dx.doi.org/10.1136/bmj.315.7099.32			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233324	Green Published			2022-12-01	WOS:A1997XJ94700027
J	Gilbert, C; Rahi, J; Eckstein, M; OSullivan, J; Foster, A				Gilbert, C; Rahi, J; Eckstein, M; OSullivan, J; Foster, A			Retinopathy of prematurity in middle-income countries	LANCET			English	Article							CHILDHOOD BLINDNESS; VISUAL IMPAIRMENT; CHILDREN; SCHOOL; EPIDEMIOLOGY; INDIA; BIRTH	Background In the 1940s and 1950s retinopathy of prematurity (ROP) was the single commonest cause of blindness in children in many industrialised countries; it now accounts for only 6-18% of blindness registrations. It is not known what proportion of blindness is due to ROP in countries that do not have blindness registers. Information on blindness in children in these countries can be obtained by examining children in schools for the blind. Methods Between 1991 and 1996, 4121 children in 23 countries with a visual acuity in the better eye of less than 6/60 were examined with a standard method. Findings The proportion of severe visual impairment or blindness due to ROP ranged from 0% in most African countries to 38.6% in Cuba. Interpretation These data suggest that ROP is becoming a major cause of potentially preventable blindness among children in middle-income countries that have introduced neonatal intensive-care services for preterm and low-birthweight babies.	INST CHILD HLTH,DEPT EPIDEMIOL,LONDON,ENGLAND; MOORFIELDS EYE HOSP,LONDON,ENGLAND	University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Gilbert, C (corresponding author), INST OPHTHALMOL,DEPT PREVENT OPHTHALMOL,LONDON EC1V 9EL,ENGLAND.			Foster, Allen/0000-0003-2368-4436; Rahi, Jugnoo/0000-0002-5718-9209				Adekeye M., 1996, THESIS I OPHTHALMOLO; BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; *CRYOTH RET PREM C, 1996, ARCH OPHTHALMOL-CHIC, V114, P417; CUNNINGHAM S, 1995, LANCET, V346, P1464, DOI 10.1016/S0140-6736(95)92475-2; Czeizel A, 1991, Acta Paediatr Hung, V31, P365; DARLOW BA, 1988, ARCH DIS CHILD, V63, P1083, DOI 10.1136/adc.63.9.1083; DOYLE LW, 1995, MED J AUSTRALIA, V163, P11, DOI 10.5694/j.1326-5377.1995.tb126079.x; ECKSTEIN MB, 1995, BRIT J OPHTHALMOL, V79, P633, DOI 10.1136/bjo.79.7.633; FAUNDES A, 1993, HEALTH POLICY PLANN, V8, P33, DOI 10.1093/heapol/8.1.33; Fielder AR, 1997, CLIN RISK, V3, P47; FLYNN JT, 1995, PEDIATRICS, V95, P755; GILBERT C, 1993, INT OPHTHALMOL, V17, P229, DOI 10.1007/BF01007745; GILBERT C, 1993, B WORLD HEALTH ORGAN, V71, P485; GILBERT C, IN PRESS OPHTHAL EPI; Gilbert C E, 1995, Ophthalmic Epidemiol, V2, P77, DOI 10.3109/09286589509057086; GILBERT CE, 1993, EYE, V7, P184, DOI 10.1038/eye.1993.39; GILBERT CE, 1994, DEV MED CHILD NEUROL, V36, P334; GOGGIN M, 1991, BRIT J OPHTHALMOL, V75, P425, DOI 10.1136/bjo.75.7.425; HANSEN E, 1992, ACTA OPHTHALMOL, V70, P597; LUMLEY J, 1993, BAILLIERE CLIN OB GY, V7, P477, DOI 10.1016/S0950-3552(05)80445-6; MASOOD SS, 1995, THESIS I OPHTHALMOLO; NG YK, 1988, LANCET, V2, P1235; OSULLIVAN J, IN PRESS S AFR MED J; RAHI JS, 1995, EYE, V9, P545, DOI 10.1038/eye.1995.137; SAUNDERS RA, 1995, J PEDIATR OPHTHALMOL, V32, P302; Sorsby A., 1966, REPORTS PUBLIC HLTH, V114; TSUKAHARA S, 1985, JPN J OPHTHALMOL, V29, P315; *UK DEP HLTH, 1991, STAT B UK DEP HLTH, V3; VANDERPOL BAE, 1986, DOC OPHTHALMOL, V61, P223, DOI 10.1007/BF00142346	29	293	329	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					12	14		10.1016/S0140-6736(97)01107-0	http://dx.doi.org/10.1016/S0140-6736(97)01107-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217713				2022-12-01	WOS:A1997XH86900009
J	Shiff, SJ; Rigas, B				Shiff, SJ; Rigas, B			Colon adenomatous polyps - Do they grow inward?	LANCET			English	Editorial Material							CELL				Shiff, SJ (corresponding author), ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA.							GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALL PA, 1994, J CELL SCI, V107, P3569; Itzkowitz SH, 1993, GASTROINTESTINAL DIS, P1402; LIGHTDALE C, 1982, CANCER RES, V42, P4280; LIPKIN M, 1992, J CELL BIOCHEM, P1; Moss SF, 1996, GASTROENTEROLOGY, V111, P1425, DOI 10.1016/S0016-5085(96)70003-3; Sinicrope FA, 1996, CLIN CANCER RES, V2, P1999	7	15	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 28	1997	349	9069					1853	1854		10.1016/S0140-6736(05)63870-6	http://dx.doi.org/10.1016/S0140-6736(05)63870-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217752				2022-12-01	WOS:A1997XG41700003
J	Denzin, LK; SantAngelo, DB; Hammond, C; Surman, MJ; Cresswell, P				Denzin, LK; SantAngelo, DB; Hammond, C; Surman, MJ; Cresswell, P			Negative regulation by HLA-DO of MHC class II-restricted antigen processing	SCIENCE			English	Article							INVARIANT CHAIN PEPTIDES; BARE LYMPHOCYTE SYNDROME; T-CELL; INTRACELLULAR-TRANSPORT; DR MOLECULES; DM; GENES; EXPRESSION; COMPARTMENTS; COMPLEX	HLA-DM is a major histocompatibility complex (MHC) class II-like molecule that facilitates antigen processing by catalyzing the exchange of invariant chain-derived peptides (CLIP) from class II molecules for antigenic peptides. HLA-DO is a second class II-like molecule that physically associates with HLA-DM in B cells. HLA-DO was shown to block HLA-DM function. Purified HLA-DM-DO complexes could not promote peptide exchange in vitro. Expression of HLA-DO in a class II+ and DM+, DO- human T cell line caused the accumulation of class II-CLIP complexes, indicating that HLA-DO blocked DM function in two and suggesting that HLA-DO is an important modulator of class II-restricted antigen processing.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014579, R37AI014579, R37AI023081, R01AI023081] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23081, AI14579] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; AVVA RR, 1994, IMMUNITY, V1, P63; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; CHANG CH, 1995, INT IMMUNOL, V7, P1515, DOI 10.1093/intimm/7.9.1515; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; DENZIN LK, UNPUB; Douek DC, 1997, INT IMMUNOL, V9, P355, DOI 10.1093/intimm/9.3.355; ECKELS DD, 1984, IMMUNOGENETICS, V19, P409, DOI 10.1007/BF00364644; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND CI, UNPUB; KARLSSON L, 1991, NATURE, V351, P485, DOI 10.1038/351485a0; Katz JF, 1996, J EXP MED, V184, P1747, DOI 10.1084/jem.184.5.1747; KERN I, 1995, INT IMMUNOL, V7, P1295, DOI 10.1093/intimm/7.8.1295; Kropshofer H, 1997, IMMUNITY, V6, P293, DOI 10.1016/S1074-7613(00)80332-5; LAMPSON LA, 1980, J IMMUNOL, V125, P293; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.iy.11.040193.001555; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PONZONI M, 1993, INT J CANCER, V55, P817, DOI 10.1002/ijc.2910550521; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; REITH W, 1995, IMMUNOL TODAY, V16, P539, DOI 10.1016/0167-5699(95)80048-4; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; Robbins NF, 1996, HUM IMMUNOL, V45, P13, DOI 10.1016/0198-8859(95)00152-2; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; SANTANGELO DB, UNPUB; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/S0092-8674(05)80090-X; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, EMBO J, V4, P2231, DOI 10.1002/j.1460-2075.1985.tb03919.x; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WAKE CT, 1985, CELL, V42, P623, DOI 10.1016/0092-8674(85)90119-9; Weber DA, 1996, SCIENCE, V274, P618, DOI 10.1126/science.274.5287.618; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411	47	194	195	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 3	1997	278	5335					106	109		10.1126/science.278.5335.106	http://dx.doi.org/10.1126/science.278.5335.106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311912				2022-12-01	WOS:A1997XZ12400048
J	Gonzales, R; Steiner, JF; Sande, MA				Gonzales, R; Steiner, JF; Sande, MA			Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; COMMON-COLD; ERYTHROMYCIN; CHILDREN; COMMUNITY; CARRIAGE; BACTERIA; DISEASE; HEALTH; TRIAL	Contex.-Antibiotic use is associated with increased rates of antibiotic-resistant organisms. A previous study has shown that colds, upper respiratory tract infections, and bronchitis account for nearly one third of all antibiotic prescribing by ambulatory care physicians. How frequently antibiotics are prescribed for these conditions and for and by whom is not known. Objectives.-To measure antibiotic prescription rates and to identify predictors of antibiotic use for adults diagnosed as having colds, upper respiratory tract infections, and bronchitis in the United States. Design.-Sample survey of practicing physicians participating in the National Ambulatory Medical Care Survey, 1992. Setting.-Office-based physician practices. Subjects.-Physicians (n=1529) completing patient record forms for adult office visits (n=28787). Main Outcome Measures.-Antibiotic prescriptions for colds, upper respiratory tract infections, and bronchitis. Results.-Office visits for colds, upper respiratory tract infections, and bronchitis resulted in approximately 12 million antibiotic prescriptions, accounting for 21% of all antibiotic prescriptions to adults in 1992. A total of 51% of patients diagnosed as having colds, 52% of patients diagnosed as having upper respiratory tract infections, and 66% of patients diagnosed as having bronchitis were treated with antibiotics. Female sex (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.05-2.62) and rural practice location (OR, 2.25; 95% CI, 1.33-3.80) were associated with greater antibiotic prescription rates, whereas black race (OR, 0.44; 95% CI, 0.21-0.93) was associated with lower antibiotic prescription rates. Patient age, Hispanic ethnicity, geographic region, physician specialty, and payment sources were not associated with antibiotic prescription rates in the bivariate analysis. Multivariate logistic regression analysis identified only rural practice location (adjusted OR, 2.58; 95% CI, 1.39-4.76) to be independently associated with more frequent antibiotic prescriptions for colds, upper respiratory tract infections, and bronchitis. Conclusion.-Although antibiotics have little or no benefit for colds, upper respiratory tract infections, or bronchitis, these conditions account for a sizable proportion of total antibiotic prescriptions for adults by office-based physicians in the United States.; Overuse of antibiotics is widespread across geographical areas, medical specialties, and payment sources. Therefore, effective strategies for changing prescribing behavior for these conditions will need to be broad based.	UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOMETR, DENVER, CO 80262 USA; UNIV UTAH, DEPT MED, SALT LAKE CITY, UT 84112 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah	Gonzales, R (corresponding author), UNIV COLORADO, HLTH SCI CTR, DIV GEN INTERNAL MED, BOX B-180, 4200 E 9TH AVE, DENVER, CO 80262 USA.				BHP HRSA HHS [5 T32 PE10006-04] Funding Source: Medline	BHP HRSA HHS		Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; BOLDY DAR, 1990, RESP MED, V84, P377, DOI 10.1016/S0954-6111(08)80072-8; BRICKFIELD FX, 1986, J FAM PRACTICE, V23, P119; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DEFRIESE GH, 1989, HEALTH SERV RES, V23, P931; DUNLAY J, 1987, J FAM PRACTICE, V25, P137; *FOOD DRUG ADM, 1986, NAT DRUG COD DIR 198; FRANKS P, 1984, J FAM PRACTICE, V19, P185; HEIKKINEN T, 1995, J PEDIATR-US, V126, P313, DOI 10.1016/S0022-3476(95)70569-4; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; HOWIE JGR, 1970, LANCET, V2, P1099; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Kaiser L, 1996, LANCET, V347, P1507, DOI 10.1016/S0140-6736(96)90670-4; King DE, 1996, J FAM PRACTICE, V42, P601; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Lederberg J, 1996, JAMA-J AM MED ASSOC, V276, P417, DOI 10.1001/jama.276.5.417; Mainous AG, 1996, ARCH FAM MED, V5, P79, DOI 10.1001/archfami.5.2.79; Mainous AG, 1996, J FAM PRACTICE, V42, P357; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; Meza R A, 1994, Aust Fam Physician, V23, P1550; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; POTTHOFF RF, 1992, J AM STAT ASSOC, V87, P383, DOI 10.2307/2290269; PRAYER OL, 1996, AM MED NEWS, V39, P42; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHAPPERT SM, 1994, ADV DAT VIT HLTH STA, V253; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; *US DEP HHS, 1988, INT CLASS DIS 9 REV; VERHEIJ TJM, 1990, FAM PRACT, V7, P175, DOI 10.1093/fampra/7.3.175; VERJEIJ TJM, 1994, BR J GEN PRACT, V44, P400; WEINER J, 1995, ANN INTERN MED, V122, P380; WILLIAMSON HA, 1984, J FAM PRACTICE, V19, P481; 1994, MMWR-MORBID MORTAL W, V43, P23; 1994, MMWR-MORBID MORTAL W, V43, P31	35	549	563	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					901	904		10.1001/jama.278.11.901	http://dx.doi.org/10.1001/jama.278.11.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302241				2022-12-01	WOS:A1997XV64000027
J	Teasdale, TW; Engberg, A				Teasdale, TW; Engberg, A			Duration of cognitive dysfunction after concussion, and cognitive dysfunction as a risk factor: a population study of young men	BRITISH MEDICAL JOURNAL			English	Article							MINOR HEAD-INJURY; SECULAR TRENDS; INTELLIGENCE; SYMPTOMS; SEQUELAE; RECOVERY	Objectives: To establish how long cognitive dysfunction lasts after concussion, and the extent to which it may be a predisposing risk factor for concussion, by examining the prevalence of cognitive dysfunction among young men who have sustained concussion. Design: Observational study. Setting: Denmark. Subjects: 1220 young men who had been admitted to hospital for concussion between the ages of 16 and 24 (identified in a national register of admissions) and who had also been cognitively tested by the Danish conscription draft board. Main outcome measure: Score on the draft board's cognitive screening test, dichotomised as dysfunctional or non-dysfunctional (20.4% of the general population of Danish men appearing before the draft board had a dysfunctional score). Results: 700 of the 1220 men had been tested after sustaining concussion; 520 had been tested before concussion. Four (50%) of the eight men who were tested less than seven days after the injury had a dysfunctional score. Among groups of the remaining 692 men who were tested at later time points after injury, the rates were only marginally raised (range 21.4% to 26.5%) above the population level. Among men tested before injury, the rate of dysfunctional scores was higher (30.4% (158/520)). Apart from suggesting cognitive dysfunction as a risk factor for concussion, this higher proportion seems to relate to the fact that they were typically injured as young adults, whereas those men who were tested after concussion had more often been injured as adolescents. The relative risk for concussion in the presence of cognitive dysfunction is estimated to be 1.57 (95% confidence interval 1.32 to 1.86). Conclusions: Cognitive dysfunction is not only a short term consequence of concussion but also a predisposing risk factor for concussion, more so for young adults than for adolescents.	ODENSE UNIV HOSP,DEPT NEUROL,DK-5000 ODENSE C,DENMARK	University of Southern Denmark; Odense University Hospital	Teasdale, TW (corresponding author), UNIV COPENHAGEN,PSYCHOL LAB,NJALSGADE 88,DK-2300 COPENHAGEN S,DENMARK.							BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Duus B R, 1991, Ugeskr Laeger, V153, P2111; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; GRONWALL D, 1974, LANCET, V2, P605; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1989, MANAGEMENT HEAD INJU; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1989, MILD HEAD INJURY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MORTENSEN EL, 1989, SCAND J PSYCHOL, V30, P315, DOI 10.1111/j.1467-9450.1989.tb01094.x; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; TEASDALE TW, 1994, SCAND J PSYCHOL, V35, P328, DOI 10.1111/j.1467-9450.1994.tb00957.x; TEASDALE TW, 1987, NATURE, V325, P119, DOI 10.1038/325119a0	19	30	30	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					569	572						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV717	9302952				2022-12-01	WOS:A1997XV71700022
J	Basso, MA; Wurtz, RH				Basso, MA; Wurtz, RH			Modulation of neuronal activity by target uncertainty	NATURE			English	Article							FRONTAL EYE FIELD; SUPERIOR COLLICULUS; VISUAL-SEARCH; ATTENTION; SELECTION; MONKEY; CORTEX	Visual scenes are composed of many elements and although we can appreciate a scene as a whole, we can only move our eyes to one element of the scene at a time. As visual scenes become more complex, the number of potential targets in the scene increases, and the uncertainty that any particular one will be selected for an eye movement also increases. How motor systems accommodate this target uncertainty remains unknown. The activities of neurons in both the cerebral cortex(1-5) and superior colliculus(6-8) are modulated by this selection process. We reasoned that activity associated with target uncertainty should be evident in the saccadic motor system at the final stages of neural processing, in the superior colliculus(9,10). By systematically changing the number of stimuli from which a selection must be made and recording from superior colliculus neurons, we found that as the target uncertainty increased,the neural activity preceding target selection decreased. These results indicate that neurons within the final common pathway for movement generation are active well in advance of the selection of a particular movement. This early activity varies with the probability that a particular movement will be selected.			Basso, MA (corresponding author), NEI,SENSORIMOTOR RES LAB,BETHESDA,MD 20892, USA.							BRAVO MJ, 1992, PERCEPT PSYCHOPHYS, V51, P465, DOI 10.3758/BF03211642; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; GOLDBERG ME, 1972, J NEUROPHYSIOL, V35, P560, DOI 10.1152/jn.1972.35.4.560; Kustov AA, 1996, NATURE, V384, P74, DOI 10.1038/384074a0; KUSTOV AA, 1995, SOC NEUR ABSTR, V21, P665; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; Miyashita N, 1996, EXP BRAIN RES, V112, P187; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; MUNOZ DP, 1995, J NEUROPHYSIOL, V73, P2313, DOI 10.1152/jn.1995.73.6.2313; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; SCHALL JD, 1995, J NEUROSCI, V15, P6905; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; SPARKS DL, 1989, NEUROBIOLOGY SACCADI, V3, P213; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0	16	261	263	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					66	69		10.1038/37975	http://dx.doi.org/10.1038/37975			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288967				2022-12-01	WOS:A1997XU59600045
J	Vinos, J; Jalink, K; Hardy, RW; Britt, SG; Zuker, CS				Vinos, J; Jalink, K; Hardy, RW; Britt, SG; Zuker, CS			A G protein-coupled receptor phosphatase required for rhodopsin function	SCIENCE			English	Article							ROD OUTER SEGMENTS; RETINAL-DEGENERATION; IN-VIVO; 48-KDA PROTEIN; PHOSPHODIESTERASE ACTIVATION; DROSOPHILA-MELANOGASTER; PHOTOEXCITED RHODOPSIN; ADRENERGIC-RECEPTOR; VISUAL TRANSDUCTION; PHOTORECEPTOR CELL	Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors are phosphorylated by kinases that mediate agonist-dependent receptor deactivation. Although many receptor kinases have been isolated, the corresponding phosphatases, necessary for restoring the ground state of the receptor, have not been identified. Drosophila RDGC (retinal degeneration C) is a phosphatase required for rhodopsin dephosphorylation in vivo. Loss of RDGC caused severe defects in the termination of the light response as well as extensive light-dependent retinal degeneration. These phenotypes resulted from the hyperphosphorylation of rhodopsin because expression of a truncated rhodopsin lacking the phosphorylation sites restored normal photoreceptor function. These results suggest the existence of a family of receptor phosphatases involved in the regulation of G protein-coupled signaling cascades.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Britt, Steven/GVT-1340-2022	Jalink, Kees/0000-0001-7019-3440; Britt, Steven/0000-0001-7656-7984				BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Fong TM, 1996, CELL SIGNAL, V8, P217; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARRIS WA, 1977, J GEN PHYSIOL, V69, P261, DOI 10.1085/jgp.69.3.261; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Hurley James B., 1994, Current Opinion in Neurobiology, V4, P481, DOI 10.1016/0959-4388(94)90047-7; KEEN TJ, 1991, GENOMICS, V11, P199, DOI 10.1016/0888-7543(91)90119-Y; KING AJ, 1994, EUR J BIOCHEM, V225, P383, DOI 10.1111/j.1432-1033.1994.00383.x; KUNH H, 1972, FEBS LETT, V20, P1; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; Kutuzov MA, 1996, EUR J BIOCHEM, V238, P613, DOI 10.1111/j.1432-1033.1996.0613w.x; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; Langlois G, 1996, P NATL ACAD SCI USA, V93, P4677, DOI 10.1073/pnas.93.10.4677; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEFKOWITZ RJ, 1993, ADV SEC MESS PHOSPH, V28, P1; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; Montini E, 1997, HUM MOL GENET, V6, P1137, DOI 10.1093/hmg/6.7.1137; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN RS, UNPUB; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SMITH WC, 1994, J BIOL CHEM, V269, P15407; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; VINOS J, UNPUB; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; YANG SD, 1988, J BIOL CHEM, V263, P8856; YANG SD, 1991, BIOCHEM BIOPH RES CO, V178, P1306, DOI 10.1016/0006-291X(91)91036-C; ZHAO XY, 1995, BIOPHYS CHEM, V56, P183, DOI 10.1016/0301-4622(95)00031-R; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	54	99	101	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					687	690		10.1126/science.277.5326.687	http://dx.doi.org/10.1126/science.277.5326.687			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235891				2022-12-01	WOS:A1997XN90700041
J	Morgan, D; Maude, GH; Malamba, SS; Okongo, MJ; Wagner, HU; Mulder, DW; Whitworth, JA				Morgan, D; Maude, GH; Malamba, SS; Okongo, MJ; Wagner, HU; Mulder, DW; Whitworth, JA			HIV-1 disease progression and AIDS-defining disorders in rural Uganda	LANCET			English	Article							SUB-SAHARAN AFRICA; STAGING SYSTEM; NATURAL-HISTORY; HOMOSEXUAL MEN; SLIM DISEASE; DRUG-USERS; INFECTION; COHORT; MORTALITY; WOMEN	Background The majority of people infected with HIV-1 live in Africa, yet little is known about the natural history of the disease in that continent. We studied survival times, disease progression, and AIDS-defining disorders, according to the proposed WHO staging system, in a population-based, rural cohort in Uganda. Methods In 1990 we recruited a random sample of people already infected with HIV-1 (as prevalent cases) detected during the initial survey round of a general-population study to form a natural-history cohort. Individuals from the general-population cohort who seroconverted between 1990 and 1995 (incident cases) were also invited to enrol. Participants were seen routinely every 3 months and when they were ill. Findings By the end of 1995, 93 prevalent cases and 86 incident cases had been enrolled. Four patients in the prevalent group were in stage 4 (AIDS) at the initial visit. During the next 5 years, 37 prevalent cases progressed to AIDS. Seven incident cases progressed to AIDS and the cumulative progression to AIDS at 1, 3, and 5 years after seroconversion was 2%, 6%, and 22%, respectively. The cumulative probability of AIDS at 4 years from entering stages 1, 2, and 3 was 11%, 33%, and 58%, respectively. There were 47 deaths among prevalent cases and seven among incident cases during follow-up. The cumulative mortality 4 years after patients entered stages 1, 2, 3, and 4 was 9%, 33%, 56%, and 86%, respectively. The median survival after the onset of AIDS was 9.3 months. Interpretation Our results are important for the setting of priorities and rationalisation of treatment availability in countries with poor resources. We found that progression rates to AIDS are similar to those in developed countries for homosexual cohorts and greater than for cohorts infected by other modes of transmission. However, we have found that the rates of all-cause mortality are much higher and the progression times to death are shorter than in developed countries.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Morgan, D (corresponding author), UGANDA VIRUS RES INST,MED RES COUNCIL PROGRAMME AIDS,POB 49,ENTEBBE,UGANDA.							ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; AYLWARD RB, 1994, AIDS, V8, P1129, DOI 10.1097/00002030-199408000-00015; BRETTLE RP, 1995, QJM-INT J MED, V88, P479; Brettle RP, 1996, AIDS, V10, P419, DOI 10.1097/00002030-199604000-00011; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; CHEQUER P, 1992, AIDS, V6, P483, DOI 10.1097/00002030-199205000-00007; COLEBUNDERS RL, 1991, AIDS, V5, pS103; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DelAmo J, 1996, INT J STD AIDS, V7, P44, DOI 10.1258/0956462961917041; FLEGG PJ, 1994, J INFECTION, V29, P311, DOI 10.1016/S0163-4453(94)91266-1; Hendriks JCM, 1996, AIDS, V10, P649, DOI 10.1097/00002030-199606000-00011; *HIV AIDS SURV REP, 1996, STD AIDS CONTR PROGR; HU DJ, 1995, J ACQ IMMUN DEF SYND, V10, P374; KAPLAN JE, 1988, JAMA-J AM MED ASSOC, V269, P2694; Kitayaporn D, 1996, J ACQ IMMUN DEF SYND, V11, P77, DOI 10.1097/00042560-199601010-00010; Kumarasamy N, 1995, INT J STD AIDS, V6, P447, DOI 10.1177/095646249500600615; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LEPRI AC, 1994, BRIT MED J, V309, P1537, DOI 10.1136/bmj.309.6968.1537; LEROY V, 1995, J ACQ IMMUN DEF SYND, V9, P415; LIFSON AR, 1995, ANN INTERN MED, V122, P262, DOI 10.7326/0003-4819-122-4-199502150-00004; Low N, 1996, GENITOURIN MED, V72, P12; LUCAS S, 1989, AIDS, V3, P47, DOI 10.1097/00002030-198903010-00012; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; MALIN AS, 1995, LANCET, V346, P1258, DOI 10.1016/S0140-6736(95)91862-0; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; Morgan D, 1997, AIDS, V11, P633, DOI 10.1097/00002030-199705000-00011; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; OFARRELL N, 1995, GENITOURIN MED, V71, P358; SEELEY J, 1991, AIDS Care, V3, P207, DOI 10.1080/09540129108253064; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; TEMBO G, 1994, AIDS, V8, P1169, DOI 10.1097/00002030-199408000-00021; VEUGELERS PJ, 1994, AM J EPIDEMIOL, V140, P747, DOI 10.1093/oxfordjournals.aje.a117322; WHITMOREOVERTON SE, 1993, AIDS, V7, P415, DOI 10.1097/00002030-199303000-00017; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221; *WHO, 1994, WHOGPATCOSEP944; 1996, AIDS CARE, V8, P249	38	105	106	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					245	250		10.1016/S0140-6736(97)01474-8	http://dx.doi.org/10.1016/S0140-6736(97)01474-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242801				2022-12-01	WOS:A1997XM86600011
J	Rothman, N; Cantor, KP; Blair, A; Bush, D; Brook, JW; Helzlsouer, K; Zahm, SH; Needham, LL; Pearson, GR; Hoover, RN; Comstock, GW; Strickland, PT				Rothman, N; Cantor, KP; Blair, A; Bush, D; Brook, JW; Helzlsouer, K; Zahm, SH; Needham, LL; Pearson, GR; Hoover, RN; Comstock, GW; Strickland, PT			A nested case-control study of non-Hodgkin lymphoma and serum organochlorine residues	LANCET			English	Article							POLYCHLORINATED-BIPHENYLS; CANCER MORTALITY; DIETARY FACTORS; WORKERS; CONSUMPTION; EXPOSURE	Background The steady worldwide increase in the incidence of non-Hodgkin lymphoma during the past few decades remains mostly unexplained. Several studies suggest that there may be an association between the agricultural use of the organochlorine 1,1,1-trichloro-2,2'bis(p-chlorophenyl)ethane (DDT) and increased. risk of non-Hodgkin lymphoma. We have investigated the association between risk of non-Hodgkin lymphoma and body burden of selected organochlorines in the general population in a nested case-control study. Methods We measured prediagnostic serum concentrations of DDT, its metabolites, and other organochlorines, including polychlorinated biphenyls (PCBs), in 74 cases of non-Hodgkin lymphoma and 147 matched controls identified from a prospective cohort of 25 802 adults, established in 1974 in Washington County, Maryland, USA. We report results for total lipid-corrected serum concentrations of DDT and total PCBs. Findings There was a strong dose-response relation between quartiles of total lipid-corrected serum PCB concentrations and risk of non-Hodgkin lymphoma overall (odds ratios by quartile: 1.0; 1.3 [95% CI 0.5-3.3]; 2-8 [1.1-7.6]); and 4.5 [1.7-12.0]; p for trend=0.0008) and separately in men and in women. There was also evidence suggesting that seropositivity for the Epstein-Barr virus early antigen potentiated the effects of serum PCBs. By contrast, total lipid-corrected serum concentrations of DDT were not associated with risk of non-Hodgkin lymphoma. Interpretation These results should be regarded as hypothesis-generating. Before causal inferences can be made about exposure to PCBs and increased risk of non-Hodgkin lymphoma, our findings require replication and the biological plausibility of the association needs further investigation.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,ATLANTA,GA; GEORGETOWN UNIV,SCH MED,WASHINGTON,DC	Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA; Georgetown University	Rothman, N (corresponding author), NCI,DIV CANC EPIDEMIOL & GENET,BETHESDA,MD 20892, USA.		Zahm, Shelia H/B-5025-2015; Needham, Larry/E-4930-2011		NATIONAL CANCER INSTITUTE [R01CA060754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NCI NIH HHS [CA60754] Funding Source: Medline; NHLBI NIH HHS [HL21670] Funding Source: Medline; NIEHS NIH HHS [ES03819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERTAZZI PA, 1987, AM J IND MED, V11, P165, DOI 10.1002/ajim.4700110206; Brock JW, 1996, J ANAL TOXICOL, V20, P528, DOI 10.1093/jat/20.7.528; BROWN DP, 1987, ARCH ENVIRON HEALTH, V42, P333, DOI 10.1080/00039896.1987.9934355; BUSH DM, 1995, THESIS J HOPKINS U S; CANTOR KP, 1992, CANCER RES, V52, P2447; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; Chiu BCH, 1996, JAMA-J AM MED ASSOC, V275, P1315, DOI 10.1001/jama.275.17.1315; CUNNINGHAM AS, 1976, LANCET, V2, P1184; DEVESA SS, 1992, CANCER RES, V52, pS5432; Dewailly E, 1996, AM J PUBLIC HEALTH, V86, P1241, DOI 10.2105/AJPH.86.9.1241; DUGGAN RE, 1983, PESTICIDE RESIDUE LE; FRANCESCHI S, 1989, NUTR CANCER, V12, P333, DOI 10.1080/01635588909514034; Hardell L, 1996, INT J ONCOL, V9, P603; HARTGE P, 1992, CANCER RES, V52, pS5566; HOOVER RN, 1992, CANCER RES, V52, pS5477; International Agency for Research on Cancer, 1987, IARC MON EV CARC S7, V7, P1; KREISS K, 1985, ENVIRON HEALTH PERSP, V60, P193, DOI 10.2307/3429961; LUKA J, 1984, J IMMUNOL METHODS, V67, P145, DOI 10.1016/0022-1759(84)90093-0; MUELLER NE, 1992, CANCER RES, V52, pS5479; Nanni O, 1996, OCCUP ENVIRON MED, V53, P652, DOI 10.1136/oem.53.10.652; PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015; SILBERHORN EM, 1990, CRIT REV TOXICOL, V20, P439, DOI 10.3109/10408449009029331; SINKS T, 1992, AM J EPIDEMIOL, V136, P389, DOI 10.1093/oxfordjournals.aje.a116511; SVENSSON BG, 1994, INT ARCH OCC ENV HEA, V65, P351, DOI 10.1007/BF00383243; SVENSSON BG, 1995, SCAND J WORK ENV HEA, V21, P106, DOI 10.5271/sjweh.17; TRYPHONAS H, 1994, EXP CLIN IMMUNOGENET, V11, P149; WARD MH, 1994, CANCER CAUSE CONTROL, V5, P422, DOI 10.1007/BF01694756; WEISGLASKUPERUS N, 1995, PEDIATR RES, V38, P404, DOI 10.1203/00006450-199509000-00022; WOODS JS, 1987, J NATL CANCER I, V78, P899; YASSI A, 1994, AM J IND MED, V25, P425, DOI 10.1002/ajim.4700250310; ZAHM SH, 1993, ARCH ENVIRON HEALTH, V48, P353, DOI 10.1080/00039896.1993.9936725; [No title captured]	32	145	151	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 26	1997	350	9073					240	244		10.1016/S0140-6736(97)02088-6	http://dx.doi.org/10.1016/S0140-6736(97)02088-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242800	hybrid			2022-12-01	WOS:A1997XM86600010
J	Ono, M; Okada, H; Bolland, S; Yanagi, S; Kurosaki, T; Ravetch, JV				Ono, M; Okada, H; Bolland, S; Yanagi, S; Kurosaki, T; Ravetch, JV			Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; B-CELL ACTIVATION; CLASS-I MOLECULES; FC-GAMMA-RIIB; LYMPHOCYTES-B; IMMUNOGLOBULIN-SUPERFAMILY; CYTOPLASMIC DOMAIN; NEGATIVE SELECTION; SELF-TOLERANCE; CROSS-LINKING	Two signaling molecules have been implicated in the modulation of immune receptor activation by inhibitory coreceptors: an inositol polyphosphate 5'-phosphatase, SHIP, and a tyrosine phosphatase, SHP-1. To address the necessity, interaction, or redundancy of these signaling molecules, we have generated SHP-1-or SHIP-deficient B cell lines and determined their ability to mediate inhibitory signaling. Two distinct classes of inhibitory responses are defined, mediated by the selective recruitment of SHP-1 or SHIP. The Fc gamma RIIB class of inhibitory signaling is dependent on SHIP and not SHP-1; conversely, the KIR class requires SHP-1 and not SHIP. The consequence of this selective recruitment by inhibitory receptor engagement is seen in BCR-triggered apoptosis. SHP-1-mediated inhibitory signaling blocks apoptosis, while SHIP recruitment attenuates a proapoptotic signal initiated by Fc gamma RIIB.	KANSAI MED UNIV,INST LIVER RES,DEPT MOL GENET,MORIGUCHI,OSAKA 570,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE,HYOGO 650,JAPAN	Kansai Medical University; Kobe University	Ono, M (corresponding author), ROCKEFELLER UNIV,LAB MOL GENET & IMMUNOL,1230 YORK AVE,NEW YORK,NY 10021, USA.		okada, hidetaka/C-6990-2011; Okada, Hidetaka/AAP-7775-2020; Ravetch, Jeffrey/Z-1596-2019; Kurosaki, Tomohiro/D-1306-2009	Ravetch, Jeffrey/0000-0003-2024-9041; Kurosaki, Tomohiro/0000-0002-6352-304X				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Ashman RF, 1996, J IMMUNOL, V157, P5; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1997, J BIOL CHEM, V272, P8989; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CASTELLS MC, 1994, J BIOL CHEM, V269, P8393; CHEN CLH, 1982, J IMMUNOL, V129, P2580; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAndrea A, 1996, J EXP MED, V184, P789, DOI 10.1084/jem.184.2.789; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Law CL, 1996, J EXP MED, V183, P547, DOI 10.1084/jem.183.2.547; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Olcese L, 1996, J IMMUNOL, V156, P4531; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; PHILLIPS JH, 1995, SCIENCE, V268, P1173; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; VITALE M, 1995, P NATL ACAD SCI USA, V92, P3536, DOI 10.1073/pnas.92.8.3536; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Yamashita Y, 1996, J EXP MED, V184, P113, DOI 10.1084/jem.184.1.113; YI TL, 1992, GENOMICS, V14, P793, DOI 10.1016/S0888-7543(05)80189-2	59	422	440	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					293	301		10.1016/S0092-8674(00)80337-2	http://dx.doi.org/10.1016/S0092-8674(00)80337-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244303	Bronze			2022-12-01	WOS:A1997XN24900013
J	Nygard, O; Nordrehaug, JE; Refsum, H; Ueland, PM; Farstad, M; Vollset, SE				Nygard, O; Nordrehaug, JE; Refsum, H; Ueland, PM; Farstad, M; Vollset, SE			Plasma homocysteine levels and mortality in patients with coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM TOTAL HOMOCYSTEINE; MYOCARDIAL-INFARCTION; PYRIDOXAL-PHOSPHATE; RISK FACTOR; HOMOCYST(E)INE; ATHEROSCLEROSIS; MECHANISMS; STROKE; FOLATE	Background Elevated plasma homocysteine levels are a risk factor for coronary heart disease, but the prognostic value of homocysteine levels in patients with established coronary artery disease has not been defined. Methods We prospectively investigated the relation between plasma total homocysteine levels and mortality among 587 patients with angiographically confirmed coronary artery disease. At the time of angiography in 1991 or 1992, risk factors for coronary disease, including homocysteine levels, were evaluated. The majority of the patients subsequently underwent coronary-artery bypass grafting (318 patients) or percutaneous transluminal coronary angioplasty (120 patients); the remaining 149 were treated medically. Results After a median follow-up of 4.6 years, 64 patients (10.9 percent) had died. We found a strong, graded relation between plasma homocysteine levels and overall mortality. After four years, 3.8 percent of patients with homocysteine levels below 9 mu mol per liter had died, as compared with 24.7 percent of those with homocysteine levels of 15 mu mol per liter or higher. Homocysteine levels were only weakly related to the extent of coronary artery disease but were strongly related to the history with respect to myocardial infarction, the left ventricular ejection fraction, and the serum creatinine level. The relation of homocysteine levels to mortality remained strong after adjustment for these and other potential confounders. In an analysis in which the patients with homocysteine levels below 9 mu mol per liter were used as the reference group, the mortality ratios were 1.9 for patients with homocysteine levels of 9.0 to 14.9 mu mol per liter, 2.8 for those with levels of 15.0 to 19.9 mu mol per liter, and 4.5 for those with levels of 20.0 mu mol per liter or higher (P for trend = 0.02). When death due to cardiovascular disease (which occurred in 50 patients) was used as the end point in the analysis, the relation between homocysteine levels and mortality was slightly strengthened. Conclusions Plasma total homocysteine levels are a strong predictor of mortality in patients with angiographically confirmed coronary artery disease. (C)1997, Massachusetts Medical Society.	UNIV BERGEN, DEPT PUBL HLTH & PRIMARY HLTH CARE, DIV MED STAT, BERGEN, NORWAY; UNIV BERGEN, DEPT PHARMACOL, BERGEN, NORWAY; UNIV BERGEN, DEPT BIOL CLIN, DIV BIOCHEM, BERGEN, NORWAY	University of Bergen; University of Bergen; University of Bergen	Nygard, O (corresponding author), HAUKELAND UNIV HOSP, DEPT HEART DIS, N-5021 BERGEN, NORWAY.		Ueland, Per M/C-7340-2013; Refsum, Helga/A-4073-2010	Ueland, Per Magne/0000-0002-1903-0571				ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ALTMAN DG, 1995, BRIT J CANCER, V72, P511, DOI 10.1038/bjc.1995.364; [Anonymous], 1990, MONOGRAPHS STAT APPL; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOSTOM AG, IN PRESS KIDNEY INT; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1996, J NUTR, V126, pS1276, DOI 10.1093/jn/126.suppl_4.1276S; CARSON NAJ, 1962, ARCH DIS CHILD, V37, P505, DOI 10.1136/adc.37.195.505; DALERY K, 1995, AM J CARDIOL, V75, P1107, DOI 10.1016/S0002-9149(99)80739-5; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; DIXON WJ, 1992, BMDP STATISTICAL SOF; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; FUSTER V, 1995, CIRCULATION, V91, P256; GERRITSEN T, 1962, BIOCHEM BIOPH RES CO, V9, P493, DOI 10.1016/0006-291X(62)90114-6; GLUECK CJ, 1995, AM J CARDIOL, V75, P132, DOI 10.1016/S0002-9149(00)80061-2; Malinow MR, 1996, J NUTR, V126, pS1238, DOI 10.1093/jn/126.suppl_4.1238S; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MALINOW MR, 1994, J INTERN MED, V236, P603, DOI 10.1111/j.1365-2796.1994.tb00854.x; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MEADE TW, 1988, AM J OBSTET GYNECOL, V158, P1646, DOI 10.1016/0002-9378(88)90203-7; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUDD SH, 1985, AM J HUM GENET, V37, P1; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; PEDERSEN TR, 1994, LANCET, V344, P1383; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; REFSUM H, 1989, CLIN CHEM, V35, P1921; ROBINSON K, 1995, CIRCULATION, V92, P2825, DOI 10.1161/01.CIR.92.10.2825; SCHIMKE RN, 1965, J AMER MED ASSOC, V193, P711, DOI 10.1001/jama.1965.03090090017003; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Stamler JS, 1996, NUTR REV, V54, P1; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; *STAT SCI, 1995, S PLUS US MAN VERS 3; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; VERHOEF P, 1995, NUTR REV, V53, P283, DOI 10.1111/j.1753-4887.1995.tb01478.x; 1995, CIRCULATION, V92, P3172	41	1424	1508	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 24	1997	337	4					230	236		10.1056/NEJM199707243370403	http://dx.doi.org/10.1056/NEJM199707243370403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL994	9227928				2022-12-01	WOS:A1997XL99400003
J	Parazzini, F; LaVecchia, C; Negri, E; Franceschi, S; Moroni, S; Chatenoud, L; Bolis, G				Parazzini, F; LaVecchia, C; Negri, E; Franceschi, S; Moroni, S; Chatenoud, L; Bolis, G			Case-control study of oestrogen replacement therapy and risk of cervical cancer	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUSES; ORAL-CONTRACEPTIVES; ONCOGENIC TRANSFORMATION; GENITAL-TRACT; PROGESTERONE; NEOPLASIA; ESTROGEN; TYPE-16; WOMEN	Objective : To examine the relation between use of oestrogen replacement therapy and risk of cervical cancer. Design : Case-control study. Setting : Northern Italy. Subjects : 645 women aged 40-75 years with cervical cancer admitted between 1981 and 1993 to university and general hospitals. The control group consisted of 749 women aged 40-75 years admitted to the same hospitals with acute conditions judged to be unrelated to any of the known or suspected risk factors for cervical cancer. Main outcome measures : Use of oestrogen replacement therapy and risk of cervical cancer. Results : 40 cases versus 86 controls had ever used oestrogens, and the corresponding multivariate odds ratio was 0.5 (95% confidence interval 0.3 to 0.8). The odds ratios of cervical cancer decreased with duration of use, being 0.6 (0.4 to 1.1) for less than 12 months' use and 0.5 (0.2 to 1.0) for use for 12 months or more compared with never users. The protection tended to be somewhat stronger for women reporting first oestrogen use before age 50. The odds ratio was 0.9 (0.5 to 1.7) for women who had taken oestrogens within the past 10 years and 0.4 (0.2 to 0.7) for those who had taken them 10 or more years ago. Conclusion :These findings suggest that exogenous oestrogens do not increase the risk of cervical cancer and may decrease the risk.	MARIO NEGRI INST PHARMACOL RES,UNIT EPIDEMIOL METHODOL,I-20157 MILAN,ITALY; UNIV MILAN,IST STAT MED & BIOMETRIA,I-20133 MILAN,ITALY; CTR RIFERIMENTO ONCOL,DIV EPIDEMIOL,I-33081 AVIANO,PN,ITALY; UNIV MILAN,IST CLIN OSTETR GINECOL,I-20129 MILAN,ITALY; IST NAZL TUMORI,DIV GYNECOL ONCOL,I-20133 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; IRCCS Aviano (CRO); University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Parazzini, F (corresponding author), MARIO NEGRI INST PHARMACOL RES,ANALYT EPIDEMIOL UNIT,VIA ERITREA 62,I-20157 MILAN,ITALY.		franceschi, silvia/M-2452-2014; Negri, Eva Vanna Lorenza/AAC-5698-2019; Chatenoud, Liliane/AAA-6377-2020; Negri, Eva/B-7244-2013	franceschi, silvia/0000-0003-4181-8071; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; Chatenoud, Liliane/0000-0001-9599-8229; Negri, Eva/0000-0001-9712-8526; Bolis, Giorgio/0000-0001-8216-0080; La Vecchia, Carlo/0000-0003-1441-897X; parazzini, fabio/0000-0001-5624-4854				ADAMI HO, 1989, INT J CANCER, V44, P833, DOI 10.1002/ijc.2910440515; BAKER RJ, 1978, GLIM SYSTEM; BERRY G, 1993, INT J CANCER, V55, P228; BRINTON LA, 1987, J NATL CANCER I, V79, P23; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA, P3; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; HILDESHEIM A, 1990, INT J CANCER, V45, P860, DOI 10.1002/ijc.2910450513; LAVECCHIA C, 1986, BRIT J CANCER, V54, P311, DOI 10.1038/bjc.1986.178; MANTEL N, 1959, J NATL CANCER I, V22, P719; MONSONEGO J, 1991, INT J CANCER, V48, P533, DOI 10.1002/ijc.2910480410; PAGANINIHILL A, 1982, AM J EPIDEMIOL, V116, P114; PARAZZINI F, 1993, REV EPIDEMIOL SANTE, V41, P53; PARAZZINI F, 1991, GYNECOL ONCOL, V41, P1, DOI 10.1016/0090-8258(91)90246-2; PARAZZINI F, 1989, BRIT J CANCER, V59, P805, DOI 10.1038/bjc.1989.168; PARAZZINI F, 1992, CANCER-AM CANCER SOC, V69, P2276, DOI 10.1002/1097-0142(19920501)69:9<2276::AID-CNCR2820690912>3.0.CO;2-Q; PATER A, 1990, AM J OBSTET GYNECOL, V162, P1099, DOI 10.1016/0002-9378(90)91323-5; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; SCHNEIDER A, 1987, INT J CANCER, V40, P198, DOI 10.1002/ijc.2910400212; SERRA GB, 1992, TERAPIA ORMONALE NEL	19	42	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					85	88		10.1136/bmj.315.7100.85	http://dx.doi.org/10.1136/bmj.315.7100.85			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240046	Green Published			2022-12-01	WOS:A1997XL25200019
J	Chui, D; OhEda, M; Liao, YF; Panneerselvam, K; Lal, A; Marek, KW; Freeze, HH; Moremen, KW; Fukuda, MN; Marth, JD				Chui, D; OhEda, M; Liao, YF; Panneerselvam, K; Lal, A; Marek, KW; Freeze, HH; Moremen, KW; Fukuda, MN; Marth, JD			Alpha-mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis	CELL			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ANEMIA TYPE-II; N-ACETYLGLUCOSAMINYLTRANSFERASE-II; BROAD-SPECIFICITY ALPHA-1->2; RAT-LIVER; ERYTHROCYTE-MEMBRANE; STRUCTURAL DETERMINANTS; CONCANAVALIN-A; SWAINSONINE; HEMPAS	Alpha-mannosidase-II (alpha M-II) catalyzes the first committed step in the biosynthesis of complex asparagine-linked (N-linked) oligosaccharides (N-glycans). Genetic deficiency of alpha M-II should abolish complex N-glycan production as reportedly does inhibition of alpha M-II by swainsonine. We find that mice lacking a functional alpha M-II gene develop a dyserythropoietic anemia concurrent with loss of erythrocyte complex N-glycans. Unexpectedly, nonerythroid cell types continued to produce complex N-glycans by an alternate pathway comprising a distinct alpha-mannosidase. These studies reveal cell-type-specific variations in N-linked oligosaccharide biosynthesis and an essential role for alpha M-II in the formation of erythroid complex N-glycans. alpha M-II deficiency elicits a phenotype in mice that correlates with human congenital dyserythropoietic anemia type II.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; BURNHAM INST, LA JOLLA, CA 92037 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute; University System of Georgia; University of Georgia			Moremen, Kelley/AAD-4661-2019; Liao, Yung-Feng/A-9761-2011	Freeze, Hudson/0000-0001-6316-0501	NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032485] Funding Source: NIH RePORTER; NCI NIH HHS [CA71932] Funding Source: Medline; NIDDK NIH HHS [DK48247] Funding Source: Medline; NIGMS NIH HHS [GM32485] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL AS, 1991, ARCH BIOCHEM BIOPHYS, V291, P76, DOI 10.1016/0003-9861(91)90107-T; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BAINES AJ, 1982, BRIT J HAEMATOL, V50, P563, DOI 10.1111/j.1365-2141.1982.tb01956.x; BEUTLER E, 1995, WILLIAMS HEMATOLOGY, P467; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BONAY P, 1992, EUR J BIOCHEM, V205, P399, DOI 10.1111/j.1432-1033.1992.tb16793.x; CAMPBELL RM, 1995, GLYCOBIOLOGY, V5, P535, DOI 10.1093/glycob/5.5.535; CHARUK JHM, 1995, EUR J BIOCHEM, V230, P797; COLEGATE SM, 1979, AUST J CHEM, V32, P2257, DOI 10.1071/CH9792257; CROOKSTON JH, 1969, BRIT J HAEMATOL, V17, P11, DOI 10.1111/j.1365-2141.1969.tb05660.x; DORLING PR, 1978, NEUROPATH APPL NEURO, V4, P285, DOI 10.1111/j.1365-2990.1978.tb00547.x; DORLING PR, 1980, BIOCHEM J, V191, P649, DOI 10.1042/bj1910649; ELBEIN AD, 1981, P NATL ACAD SCI-BIOL, V78, P7393, DOI 10.1073/pnas.78.12.7393; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FUKUDA MN, 1992, BRIT J HAEMATOL, V82, P745, DOI 10.1111/j.1365-2141.1992.tb06953.x; FUKUDA MN, 1984, BRIT J HAEMATOL, V56, P55, DOI 10.1111/j.1365-2141.1984.tb01271.x; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; FUKUDA MN, 1993, BAILLIERE CLIN HAEM, V6, P493, DOI 10.1016/S0950-3536(05)80156-8; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; FUKUDA MN, 1989, BLOOD, V73, P1331; HAKOMORI S, 1981, SEMIN HEMATOL, V82, P745; HARPAZ N, 1980, J BIOL CHEM, V255, P4894; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; HUGHES RC, 1986, EUR J BIOCHEM, V158, P227, DOI 10.1111/j.1432-1033.1986.tb09742.x; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; KOBATA A, 1992, J CHROMATOGR, V597, P111, DOI 10.1016/0021-9673(92)80101-Y; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MERKLE RK, 1997, IN PRESS BIOCH BIOPH; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; MISAGO M, 1995, P NATL ACAD SCI USA, V92, P11766, DOI 10.1073/pnas.92.25.11766; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NARASIMHAN S, 1979, CAN J BIOCHEM CELL B, V57, P83, DOI 10.1139/o79-011; PALEK J, 1995, WILLIAMS HEMATOLOGY, P406; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCARTEZZINI P, 1982, BRIT J HAEMATOL, V51, P569, DOI 10.1111/j.1365-2141.1982.tb02820.x; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; Tan J, 1996, AM J HUM GENET, V59, P810; TULSIANI DRP, 1988, ARCH BIOCHEM BIOPHYS, V264, P607, DOI 10.1016/0003-9861(88)90327-X; TULSIANI DRP, 1987, J BIOL CHEM, V262, P6506; TULSIANI DRP, 1984, ARCH BIOCHEM BIOPHYS, V232, P76, DOI 10.1016/0003-9861(84)90522-8; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753	56	156	167	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 11	1997	90	1					157	167		10.1016/S0092-8674(00)80322-0	http://dx.doi.org/10.1016/S0092-8674(00)80322-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230311	Bronze			2022-12-01	WOS:A1997XL36200017
J	Hurme, R; Berndt, KD; Normark, SJ; Rhen, M				Hurme, R; Berndt, KD; Normark, SJ; Rhen, M			A proteinaceous gene regulatory thermometer in Salmonella	CELL			English	Article							HELICAL COILED-COILS; SHOCK TRANSCRIPTION FACTOR-1; SMOOTH-MUSCLE TROPOMYOSIN; HEAT-SHOCK; ESCHERICHIA-COLI; DNA-BINDING; ENVIRONMENTAL-REGULATION; TEMPERATURE REGULATION; PATHOGENIC BACTERIA; SHIGELLA-FLEXNERI	Novel utilization of the coiled-coil motif is presented that enables TlpA, an autoregulatory repressor protein in Salmonella, to sense temperature shifts directly and thereby to modulate the extent of transcription repression. Salmonella cells shifted to higher temperatures, such as those encountered at host entry, showed derepressed tlpA activity. tlpA::lacZ fusions indicated that the promoter itself is insensitive to thermal shifts and that transcription control was exerted by the autorepressor TlpA only. In vitro studies with highly purified TlpA showed concentration and temperature dependence for both fully folded conformation and function, indicating that the thermosensing in TlpA is based on monomer-to-coiled-coil equilibrium.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,MED NOBEL INST BIOCHEM,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet			Berndt, Kurt/J-8574-2015	Berndt, Kurt/0000-0002-3049-967X				Ausubel FM, 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAIRD GD, 1985, J GEN MICROBIOL, V131, P1815; BENSON NR, 1992, J BACTERIOL, V174, P1673, DOI 10.1128/jb.174.5.1673-1681.1992; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CORNELIS GR, 1991, MOL MICROBIOL, V5, P1023, DOI 10.1111/j.1365-2958.1991.tb01875.x; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DORMAN CJ, 1991, INFECT IMMUN, V59, P745, DOI 10.1128/IAI.59.3.745-749.1991; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; FOSTER JW, 1995, ANNU REV MICROBIOL, V49, P145, DOI 10.1146/annurev.micro.49.1.145; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Groisman EA, 1996, TRENDS MICROBIOL, V4, P127, DOI 10.1016/0966-842X(96)30013-9; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HOE NP, 1993, J BACTERIOL, V175, P7901, DOI 10.1128/JB.175.24.7901-7909.1993; HOLTZER ME, 1992, BIOPOLYMERS, V32, P1675, DOI 10.1002/bip.360321209; HROMOCKYJ AE, 1992, MOL MICROBIOL, V6, P2113, DOI 10.1111/j.1365-2958.1992.tb01385.x; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; HURME R, 1994, J BIOL CHEM, V269, P10675; Hurme R, 1996, J BIOL CHEM, V271, P12626, DOI 10.1074/jbc.271.21.12626; JAGURA-BURDZY G, 1992, J MOL BIOL, V225, P651, DOI 10.1016/0022-2836(92)90392-W; JANCSO A, 1991, J BIOL CHEM, V266, P5891; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; LARSON JS, 1995, BIOCHEMISTRY-US, V34, P1902, DOI 10.1021/bi00006a011; LEHRER SS, 1991, BIOCHEMISTRY-US, V30, P5682, DOI 10.1021/bi00237a007; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)10052-9; MAURELLI AT, 1989, MICROB PATHOGENESIS, V7, P1, DOI 10.1016/0882-4010(89)90106-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MIKULSKIS AV, 1994, MOL MICROBIOL, V11, P77, DOI 10.1111/j.1365-2958.1994.tb00291.x; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; Miller JH., 1972, EXPT MOL GENETICS; MORA R, 1988, ANAL BIOCHEM, V172, P368, DOI 10.1016/0003-2697(88)90457-5; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; OSHEA EK, 1989, SCIENCE, V243, P536; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAULING L, 1953, NATURE, V171, P59, DOI 10.1038/171059a0; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; QI SY, 1995, MOL MICROBIOL, V17, P523, DOI 10.1111/j.1365-2958.1995.mmi_17030523.x; RHEN M, 1993, MOL MICROBIOL, V10, P45, DOI 10.1111/j.1365-2958.1993.tb00902.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIEGER H, 1972, MOL GEN GENET, V119, P75, DOI 10.1007/BF00270447; TOBE T, 1993, J BACTERIOL, V175, P6142, DOI 10.1128/JB.175.19.6142-6149.1993; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; Wang X, 1996, DNA CELL BIOL, V15, P209, DOI 10.1089/dna.1996.15.209; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.micro.47.1.321; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	63	103	121	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					55	64		10.1016/S0092-8674(00)80313-X	http://dx.doi.org/10.1016/S0092-8674(00)80313-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230302	Bronze			2022-12-01	WOS:A1997XL36200008
J	Castillo, PE; Malenka, RC; Nicoll, RA				Castillo, PE; Malenka, RC; Nicoll, RA			Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons	NATURE			English	Article							GLUTAMATE-RECEPTOR; AMPA RECEPTORS; BINDING-SITES; SUBUNITS; LOCALIZATION; RESPONSES; DESENSITIZATION; DEPOLARIZATIONS; ANTAGONIST; CLONING	Glutamate, the neurotransmitter at most excitatory synapses in the brain, activates a variety of receptor subtypes that can broadly be divided into ionotropic (ligand-gated ion channels) and metabotropic (G-protein-coupled) receptors. Ionotropic receptors mediate fast excitatory synaptic transmission, and based on pharmacological and molecular biological studies are divided into NMDA and non-NMDA subtypes. The non-NMDA receptor group is further divided into AMPA and kainate subtypes(1). Virtually all fast excitatory postsynaptic currents studied so far in the central nervous system are mediated by the AMPA and NMDA subtypes of receptors. Surprisingly, despite extensive analysis of their structural biophysical properties and anatomical distribution, a synaptic role for kainate receptors in the brain has not been found(2). Here we report that repetitive activation of the hippocampal messy fibre pathway, which is associated with high-affinity kainate binding(3) and many of the kainate receptor subtypes(4-8), generates a slow excitatory synaptic current with all of the properties expected of a kainate receptor. This activity-dependent synaptic current greatly augments the excitatory drive of CA3 pyramidal cells.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL & PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Castillo, Pablo/0000-0002-9834-1801				BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Burnashev N, 1996, J PHYSIOL-LONDON, V496, P165, DOI 10.1113/jphysiol.1996.sp021674; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; DONEVAN SD, 1993, NEURON, V10, P51, DOI 10.1016/0896-6273(93)90241-I; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FOSTER AC, 1981, NATURE, V289, P73, DOI 10.1038/289073a0; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HUNTLEY GW, 1993, J NEUROSCI, V13, P2965; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; LERMA J, 1993, P NATL ACAD SCI USA, V90, P11688, DOI 10.1073/pnas.90.24.11688; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; MALVA JO, 1995, NEUROSCI LETT, V185, P83, DOI 10.1016/0304-3940(94)11230-G; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PETRALIA RS, 1994, J COMP NEUROL, V349, P85, DOI 10.1002/cne.903490107; REPRESA A, 1987, NEUROSCIENCE, V20, P739, DOI 10.1016/0306-4522(87)90237-5; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; SAWADA S, 1988, EXP BRAIN RES, V72, P135, DOI 10.1007/BF00248508; SAWADA S, 1985, EXP BRAIN RES, V60, P323; SCANZIANI JH, 1997, NATURE, V385, P630; SIEGEL SJ, 1995, J NEUROSCI, V15, P2707; Swanson GT, 1996, J PHYSIOL-LONDON, V492, P129, DOI 10.1113/jphysiol.1996.sp021295; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; VERDOORN TA, 1994, EUR J PHARM-MOLEC PH, V269, P43, DOI 10.1016/0922-4106(94)90024-8; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WILDING TJ, 1995, MOL PHARMACOL, V47, P582; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J	31	415	421	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					182	186		10.1038/40645	http://dx.doi.org/10.1038/40645			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217159	Bronze			2022-12-01	WOS:A1997XK10900052
J	Reppas, JB; Niyogi, S; Dale, AM; Sereno, MI; Tootell, RBH				Reppas, JB; Niyogi, S; Dale, AM; Sereno, MI; Tootell, RBH			Representation of motion boundaries in retinotopic human visual cortical areas	NATURE			English	Article							SENSORY STIMULATION; MACAQUE MONKEY; HUMAN BRAIN; MT; NEURONS; CORTEX; SEGREGATION; PERCEPTION; LESIONS; FMRI	Edges are important in the interpretation of the retinal image. Although luminance edges have been studied extensively, much less is known about how or where the primate visual system detects boundaries defined by differences in surface properties such as texture, motion or binocular disparity. Here we use functional magnetic resonance imaging (fMRI) to localize human visual cortical activity related to the processing of one such higher-order edge type: motion boundaries. We describe a robust fMRI signal that is selective for motion segmentation. This boundary-specific signal is present, and retinotopically organized, within early visual areas, beginning in the primary visual cortex (area V1). Surprisingly, it is largely absent from the motion-selective area MT/V5 and far extrastriate visual areas. Changes in the surface velocity defining the motion boundaries affect the strength of the fMRI signal. In parallel psychophysical experiments, the perceptual salience of the boundaries shows a similar dependence on surface velocity. These results demonstrate that information for segmenting scenes by relative motion is represented as early as V1.	MASSACHUSETTS GEN HOSP,NUCL MAGNET RESONANCE CTR,CHARLESTOWN,MA 02129; MIT,DEPT BRAIN & COGNIT SCI,PERCEPTUAL SCI GRP,CAMBRIDGE,MA 02139; UNIV CALIF SAN DIEGO,DEPT COGNIT SCI,LA JOLLA,CA 92093	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego	Reppas, JB (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.		Sereno, Martin I/F-7657-2012; Dale, Anders M/A-5180-2010	Sereno, Martin I/0000-0002-7598-7829; 				BANTON T, 1993, PERCEPTION, V22, P1195, DOI 10.1068/p221195; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; BRADDICK O, 1974, VISION RES, V14, P519, DOI 10.1016/0042-6989(74)90041-8; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRITTEN KH, 1993, VISUAL NEUROSCI, V10, P1157, DOI 10.1017/S0952523800010269; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; DICK M, 1987, SCIENCE, V237, P400, DOI 10.1126/science.3603025; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LAGAE L, 1989, BRAIN RES, V496, P361, DOI 10.1016/0006-8993(89)91089-5; LAMME VAF, 1993, NATURE, V363, P541, DOI 10.1038/363541a0; MARCAR VL, 1995, J NEUROPHYSIOL, V74, P1258, DOI 10.1152/jn.1995.74.3.1258; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2436; MURAKAMI I, 1995, VISION RES, V35, P1835, DOI 10.1016/0042-6989(94)00269-R; NAKAYAMA K, 1974, PERCEPTION, V3, P63, DOI 10.1068/p030063; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; ORBAN GA, 1995, P NATL ACAD SCI USA, V92, P993, DOI 10.1073/pnas.92.4.993; PATZWAHL DR, 1994, VISUAL NEUROSCI, V11, P1135, DOI 10.1017/S0952523800006945; REGAN D, 1992, J NEUROSCI, V12, P2198; REPPAS JB, 1996, RECHERCHE, V289, P52; SACHTLER WL, 1995, VISION RES, V35, P807, DOI 10.1016/0042-6989(94)00160-N; SCHILLER PH, 1993, VISUAL NEUROSCI, V10, P717, DOI 10.1017/S0952523800005423; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; VAINA LM, 1994, NEUROREPORT, V5, P2289, DOI 10.1097/00001756-199411000-00021; VANDOORN AJ, 1982, EXP BRAIN RES, V45, P189, DOI 10.1007/BF00235778	30	97	97	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					175	179		10.1038/40633	http://dx.doi.org/10.1038/40633			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217157	Bronze			2022-12-01	WOS:A1997XK10900050
J	Mason, D; Birmingham, L; Grubin, D				Mason, D; Birmingham, L; Grubin, D			Substance use in remand prisoners: A consecutive case study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To determine the prevalence of drug and alcohol use among newly remanded prisoners, assess the effectiveness of prison reception screening, and examine the clinical management of substance misusers among remand prisoners. Design: A consecutive case study of remand prisoners screened at reception for substance misuse and treatment needs and comparison of findings with those of prison reception screening and treatment provision. Setting: A large adult male remand prison (Durham). Subjects: 548 men aged 21 and over awaiting trial. Main outcome measures: Prevalence of substance misuse; treatment needs of substance misusers; effectiveness of prison reception screening for substance misuse; provision of detoxification programmes. Results: Before remand 312 (57%) men were using illicit drugs and 181 (33%) met DSM-IV drug misuse or dependence criteria: 177 (32%) men met misuse or dependence criteria for alcohol. 391 (71%) men were judged to require help directed at their drug or alcohol use and 197 (36%) were judged to require a detoxification programme. The prison reception screen identified recent illicit drug use in 131 (24%) of 536 men and problem drinking in 103 (19%). Drug use was more likely to be identified by prison screening if an inmate was using multiple substances. using opiates, or had a diagnosis of abuse or dependence. 47 (9%) of 536 inmates were prescribed treatment to ease the symptoms of substance withdrawal. Conclusions: The prevalence of substance misuse in newly remanded prisoners is high. Prison reception health screening consistently underestimates drug and alcohol use. In many cases in which substance use is identified the quantities and numbers of different substances being used are underestimated. Initial management of inmates identified by prison screening as having problems with dependence producing substances is poor. Few receive a detoxification programme, so that many are left with the option of continuing to use drugs in prison or facing untreated withdrawal.	UNIV NEWCASTLE UPON TYNE,ST NICHOLAS HOSP,DEPT FORENS PSYCHIAT,NEWCASTLE TYNE NE3 3XT,TYNE & WEAR,ENGLAND	Newcastle University - UK								Birmingham L, 1996, BRIT MED J, V313, P1521, DOI 10.1136/bmj.313.7071.1521; BLUGLASS R, 1990, BRIT MED J, V301, P249, DOI 10.1136/bmj.301.6746.249; Brooke D, 1996, BRIT MED J, V313, P1524, DOI 10.1136/bmj.313.7071.1524; Gore SM, 1996, LANCET, V348, P1124, DOI 10.1016/S0140-6736(96)06318-0; Joyce L, 1996, PRISON SER J, V107, P16; MAXWELL AE, 1977, BRIT J PSYCHIAT, V130, P79, DOI 10.1192/bjp.130.1.79; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P121; PHILLIPS GT, 1987, BRIT J ADDICT, V82, P691; ROSS M, 1994, BRIT MED J, V308, P1092, DOI 10.1136/bmj.308.6936.1092; SMITH R, 1992, BRIT MED J, V304, P134, DOI 10.1136/bmj.304.6820.134	10	51	51	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					18	21		10.1136/bmj.315.7099.18	http://dx.doi.org/10.1136/bmj.315.7099.18			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XJ947	9233320	Green Published			2022-12-01	WOS:A1997XJ94700021
J	Campbell, RWF				Campbell, RWF			Whither digitalis?	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; SURVIVAL; DIGOXIN				Campbell, RWF (corresponding author), FREEMAN RD HOSP,ACAD DEPT CARDIOL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND.							Banerjee AK, 1996, INT J CARDIOL, V55, P9, DOI 10.1016/0167-5273(96)02580-6; BIGGER JT, 1985, AM J CARDIOL, V55, P623, DOI 10.1016/0002-9149(85)90125-0; *DIG INV GROUP, 1997, NEW ENGL J MED, V336, P525; LEOR J, 1995, CARDIOVASC DRUG THER, V9, P723, DOI 10.1007/BF00878556; PUGH SE, 1989, BRIT HEART J, V61, P529; RYAN TJ, 1983, CIRCULATION, V67, P735, DOI 10.1161/01.CIR.67.4.735; Saunders KB, 1997, LANCET, V349, P833, DOI 10.1016/S0140-6736(96)09057-5	7	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1854	1855		10.1016/S0140-6736(05)63871-8	http://dx.doi.org/10.1016/S0140-6736(05)63871-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217753				2022-12-01	WOS:A1997XG41700004
J	Shale, DJ				Shale, DJ			Could diuretics in hypoxic states be bad for the pulmonary circulation?	LANCET			English	Editorial Material							DISEASE				Shale, DJ (corresponding author), LLANDOUGH HOSP,ACAD CTR,DEPT MED,CARDIFF CF64 2XX,S GLAM,WALES.							FARBER MO, 1982, ARCH INTERN MED, V142, P1326, DOI 10.1001/archinte.142.7.1326; FISHMAN AP, 1976, CIRC RES, V38, P221, DOI 10.1161/01.RES.38.4.221; KEILY DG, 1997, BR J CLIN PHARM, V43, P309; KLINGER JR, 1991, CHEST, V99, P715, DOI 10.1378/chest.99.3.715; LIPWORTH BJ, 1994, CHEST, V105, P1360, DOI 10.1378/chest.105.5.1360	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1856	1856		10.1016/S0140-6736(05)63873-1	http://dx.doi.org/10.1016/S0140-6736(05)63873-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217755				2022-12-01	WOS:A1997XG41700006
J	Ruiz, M; Karpen, JW				Ruiz, M; Karpen, JW			Single cyclic nucleotide-gated channels locked in different ligand-bound states	NATURE			English	Article							GMP-ACTIVATED CHANNEL; ROD OUTER SEGMENT; RETINAL RODS; ION CHANNELS; TIGER SALAMANDER; CONDUCTANCE; MEMBRANE; PATCHES; PROTONS; SITES	Cyclic nucleotide-gated (CNG) channels are directly activated by the binding of several ligands(1-6). For these channels as well as for other allosteric proteins, the functional effects of each ligand-binding event have been difficult to assess because ligands continuously bind and unbind at each site. Furthermore, in retinal rod photoreceptors the low cytoplasmic concentration of cyclic GMP(7) means that channels exist primarily in partially liganded states, so it is important to determine how such channels behave. Previous studies of single channels have suggested that they occasionally open to subconducting states at low cGMP(2,3,8-10), but the significance of these states and how they arise is poorly understood. Here we combine the high resolution of single-channel recording with the use of a photoaffinity analogue of cGMP(11,12) that tethers cGMP moieties covalently to their binding sites to show single retinal CNG channels can be effectively locked in four distinct ligand-bound states. Our results indicate that channels open more than they would spontaneously when two ligands are bound (similar to 1% of the maximum current), significantly more with three ligands bound (similar to 33%), and open maximally with four ligands bound. In each ligand-bound state, channels opened to two or three different conductance states, These findings place strong constraints on the activation mechanism of CNG channels.	UNIV COLORADO,SCH MED,DEPT PHYSIOL,DEPT PHYSIOL & BIOPHYS,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BROWN RL, 1993, P NATL ACAD SCI USA, V90, P5369, DOI 10.1073/pnas.90.11.5369; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HANKE W, 1988, P NATL ACAD SCI USA, V85, P94, DOI 10.1073/pnas.85.1.94; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; ILDEFONSE M, 1991, J MEMBRANE BIOL, V123, P133, DOI 10.1007/BF01998084; Karpen JW, 1996, J GEN PHYSIOL, V107, P169, DOI 10.1085/jgp.107.2.169; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P731, DOI 10.1113/jphysiol.1988.sp016943; NIZZARI M, 1993, P ROY SOC B-BIOL SCI, V254, P69, DOI 10.1098/rspb.1993.0128; Picco C, 1996, J GEN PHYSIOL, V108, P265, DOI 10.1085/jgp.108.4.265; PICONES A, 1995, J PHYSIOL-LONDON, V485, P699, DOI 10.1113/jphysiol.1995.sp020763; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; TANAKA JC, 1993, BIOPHYS J, V65, P2517, DOI 10.1016/S0006-3495(93)81294-3; TAYLOR WR, 1995, J PHYSIOL-LONDON, V483, P567, DOI 10.1113/jphysiol.1995.sp020607; Tibbs GR, 1997, NATURE, V386, P612, DOI 10.1038/386612a0; TORRE V, 1992, P ROY SOC B-BIOL SCI, V250, P209, DOI 10.1098/rspb.1992.0151; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; ZIMMERMAN AL, 1992, J PHYSIOL-LONDON, V449, P759, DOI 10.1113/jphysiol.1992.sp019112; ZIMMERMAN AL, 1995, CURR OPIN NEUROBIOL, V5, P296, DOI 10.1016/0959-4388(95)80041-7; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	27	120	120	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					389	392		10.1038/38744	http://dx.doi.org/10.1038/38744			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311781				2022-12-01	WOS:A1997XX67500054
J	Petticrew, M; Kennedy, SC				Petticrew, M; Kennedy, SC			Detecting the effects of thromboprophylaxis: the case of the rogue reviews	BRITISH MEDICAL JOURNAL			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; TOTAL HIP-REPLACEMENT; VENOUS THROMBOEMBOLISM; STANDARD HEPARIN; PERIOPERATIVE THROMBOSIS; PULMONARY-EMBOLISM; RANDOMIZED TRIALS; CLINICAL-TRIALS; PREVENTION				Petticrew, M (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Petticrew, Mark/AAY-6274-2021					ANDAZ S, 1994, PHLEBOLOGY, V9, P2, DOI 10.1177/026835559400900102; ANDERSON DR, 1993, ANN INTERN MED, V119, P1105, DOI 10.7326/0003-4819-119-11-199312010-00008; BEYTH RJ, 1995, DRUG AGING, V6, P45, DOI 10.2165/00002512-199506010-00004; BORRIS LC, 1995, DRUG SAFETY, V12, P26, DOI 10.2165/00002018-199512010-00002; BORRIS LC, 1994, INT J CLIN PHARM TH, V32, P262; Campling EA, 1995, REPORT NATL CONFIDEN; CHERINGTON M, 1987, NEUROLOGY, V37, P824, DOI 10.1212/WNL.37.5.824; CLAGETT GP, 1992, CHEST S, V102, P391; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Craig P C, 1972, Trans Pa Acad Ophthalmol Otolaryngol, V25, P42; DAURES JP, 1989, REV EPIDEMIOL SANTE, V37, P363; Dirckx J H, 1979, J Dermatol Surg Oncol, V5, P191; DOYLE AC, 1928, SHERLOCK HOLMES; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; GALLUS AS, 1992, THROMB HAEMOSTASIS, V68, P238; GENT M, 1986, CHEST, V89, P396; GOLDHABER SZ, 1992, JAMA-J AM MED ASSOC, V268, P1727, DOI 10.1001/jama.268.13.1727; GREEN D, 1994, PHARMACOL REV, V46, P89; GREYER HG, 1991, SEMIN THROMB HEMOST, V17, P336; HAAS S, 1993, BLOOD COAGUL FIBRIN, V4, pS5; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; JONES DR, 1991, ANN ROY COLL SURG, V73, P219; JORGENSEN LN, 1993, BRIT J SURG, V80, P689, DOI 10.1002/bjs.1800800607; KEARON C, 1995, ARCH INTERN MED, V155, P366, DOI 10.1001/archinte.155.4.366; Koch A, 1997, BRIT J SURG, V84, P750, DOI 10.1002/bjs.1800840605; LASSEN MR, 1991, SEMIN THROMB HEMOST, V17, P284; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LOWRY JC, 1995, BRIT J ORAL MAX SURG, V33, P101, DOI 10.1016/0266-4356(95)90209-0; MALTBY JR, 1988, CAN J ANAESTH, V35, P58, DOI 10.1007/BF03010546; MOHR DN, 1993, ARCH INTERN MED, V153, P2221, DOI 10.1001/archinte.153.19.2221; Murray DW, 1996, J BONE JOINT SURG BR, V78B, P863, DOI 10.1302/0301-620X78B6.6714; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OBRIEN BJ, 1994, CAN MED ASSOC J, V150, P1083; SIMONNEAU G, 1992, ANN FR ANESTH, V11, P354, DOI 10.1016/S0750-7658(05)80376-4; SKRABANEK P, 1990, LANCET, V335, P1446, DOI 10.1016/0140-6736(90)91460-R; *THROMB RISK FACT, 1992, BRIT MED J, V305, P567; WELLS PS, 1994, ARCH INTERN MED, V154, P67, DOI 10.1001/archinte.154.1.67	38	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					665	668		10.1136/bmj.315.7109.665	http://dx.doi.org/10.1136/bmj.315.7109.665			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310572	Green Published			2022-12-01	WOS:A1997XW69400026
J	DeMaria, R; Lenti, L; Malisan, F; dAgostino, F; Tomassini, B; Zeuner, A; Rippo, MR; Testi, R				DeMaria, R; Lenti, L; Malisan, F; dAgostino, F; Tomassini, B; Zeuner, A; Rippo, MR; Testi, R			Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis	SCIENCE			English	Article							FAS-MEDIATED APOPTOSIS; ACIDIC SPHINGOMYELINASE; EXPRESSION CLONING; G(D3) SYNTHASE; CELL-DEATH; PROTEASE; INVOLVEMENT; RECEPTOR; SIGNAL; MEMBRANE	Gangliosides participate in development and tissue differentiation, Cross-linking of the apoptosis-inducing CD95 protein (also called Fas or APO-1) in lymphoid and myeloid tumor cells triggered GD3 ganglioside synthesis and transient accumulation. CD95-induced GD3 accumulation depended on integral receptor ''death domains'' and on activation of a family of cysteine proteases called caspases. Cell-permeating ceramides, which are potent inducers of apoptosis, also triggered GD3 synthesis, GD3 disrupted mitochondrial transmembrane potential (Delta psi(m),), and induced apoptosis, in a caspase-independent fashion. Transient overexpression of the GD3 synthase gene directly triggered apoptosis, Pharmacological inhibition of GD3 synthesis and exposure to GD3 synthase antisense oligodeoxynucleotides prevented CD95-induced apoptosis. Thus, GD3 ganglioside mediates the propagation of CD95-generated apoptotic signals in hematopoietic cells.	UNIV ROMA TOR VERGATA,DEPT EXPT MED & BIOCHEM SCI,I-00133 ROME,ITALY; UNIV ROMA LA SAPIENZA,DEPT EXPT MED & PATHOL,I-00161 ROME,ITALY	University of Rome Tor Vergata; Sapienza University Rome			Zeuner, Ann/K-8607-2016; De Maria, Ruggero/S-6385-2019; Zeuner, Ann/A-8529-2010	De Maria, Ruggero/0000-0003-2255-0583; MALISAN, FLORENCE/0000-0002-0213-9407; Zeuner, Ann/0000-0002-8295-3715; RIPPO, Maria Rita/0000-0003-3024-3495				ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cascino I, 1996, J IMMUNOL, V156, P13; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; DEMARIA R, UNPUB; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MATHIAS S, 1993, ADV LIPID RES, V25, P65; MATYAS GR, 1987, BIOCHIM BIOPHYS ACTA, V921, P599, DOI 10.1016/0005-2760(87)90089-0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Radin N S, 1981, Methods Enzymol, V72, P673; RADIN NS, 1993, ADV LIPID RES, V26, P183; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SARTI P, 1990, BIOCHEM J, V267, P413, DOI 10.1042/bj2670413; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670	30	327	337	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1652	1655		10.1126/science.277.5332.1652	http://dx.doi.org/10.1126/science.277.5332.1652			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287216	Green Published			2022-12-01	WOS:A1997XV68400047
J	Makgoba, MW				Makgoba, MW			Molecular basis of resistance and susceptibility to malaria	LANCET			English	Editorial Material							ADHESION; SEQUESTRATION				Makgoba, MW (corresponding author), UNIV WITWATERSRAND,DEPT MOL IMMUNOL,ZA-2000 JOHANNESBURG,SOUTH AFRICA.							BERENDT AR, 1994, PARASITOLOGY, V108, pS19, DOI 10.1017/S0031182000075685; Bunn HF, 1991, HARRISONS PRINCIPLES, P1543; FERNANDEZREYESD, 1997, HUM MOL GENET, V6, P1357; MAKGOBA MW, 1992, EUR J CLIN INVEST, V22, P443, DOI 10.1111/j.1365-2362.1992.tb01489.x; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TURNER GDH, 1994, AM J PATHOL, V145, P1057	8	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 6	1997	350	9079					678	679		10.1016/S0140-6736(05)63507-6	http://dx.doi.org/10.1016/S0140-6736(05)63507-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU977	9291898				2022-12-01	WOS:A1997XU97700004
J	Sanchez, Y; Wong, C; Thoma, RS; Richman, R; Wu, RQ; PiwnicaWorms, H; Elledge, SJ				Sanchez, Y; Wong, C; Thoma, RS; Richman, R; Wu, RQ; PiwnicaWorms, H; Elledge, SJ			Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25	SCIENCE			English	Article							CELL-CYCLE CONTROL; FISSION YEAST; KINASE; PHOSPHORYLATION; IDENTIFICATION; ARREST; MUTATION; MITOSIS; CANCER; P21	In response to DNA damage, mammalian cells prevent cell cycle progression through the control of critical cell cycle regulators. A human gene was identified that encodes the protein Chk1, a homolog of the Schizosaccharomyces pombe Chk1 protein kinase, which is required for the DNA damage checkpoint. Human Chk1 protein was modified in response to DNA damage. In vitro Chk1 bound to and phosphorylated the dual-specificity protein phosphatases Cdc25A, Cdc25B, and Cdc25C, which control cell cycle transitions by dephosphorylating cyclin-dependent kinases. Chk1 phosphorylates Cdc25C on serine-216. As shown in an accompanying paper by Peng et al. in this issue, serine-216 phosphorylation creates a binding site for 14-3-3 protein and inhibits function of the phosphatase. These results suggest a model whereby in response to DNA damage, Chk1 phosphorylates and inhibits Cdc25C, thus preventing activation of the Cdc2-cyclin B complex and mitotic entry.	BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT MOL & HUMAN GENET,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Washington University (WUSTL); Baylor College of Medicine; Howard Hughes Medical Institute			Piwnica-Worms, Helen/C-5214-2012; Wu, R.Q./AAD-1067-2021	Wu, R.Q./0000-0002-6156-7874	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017763, R01GM044664, R37GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664, GM17763] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; DENG C, 1995, CELL, V82, P67; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; Gabra H, 1996, CANCER RES, V56, P950; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; Lakin ND, 1996, ONCOGENE, V13, P2707; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; SANCHEZ Y, UNPUB; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Vorechovsky I, 1996, CANCER RES, V56, P2726; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353	26	1119	1177	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1497	1501		10.1126/science.277.5331.1497	http://dx.doi.org/10.1126/science.277.5331.1497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278511				2022-12-01	WOS:A1997XV42900038
J	Rocheleau, CE; Downs, WD; Lin, RL; Wittmann, C; Bei, YX; Cha, YH; Ali, M; Priess, JR; Mello, CC				Rocheleau, CE; Downs, WD; Lin, RL; Wittmann, C; Bei, YX; Cha, YH; Ali, M; Priess, JR; Mello, CC			Wnt signaling and an APC-related gene specify endoderm in early C-elegans embryos	CELL			English	Article							CAENORHABDITIS-ELEGANS; TISSUE POLARITY; ARMADILLO CONNECTION; CELL-INTERACTIONS; DROSOPHILA; WINGLESS; PROTEIN; ENCODES; INDUCTION; GUT	In a 4-cell stage C. elegans embryo, signaling by the P-2 blastomere induces anterior-posterior polarity in the adjacent EMS blastomere, leading to endoderm formation. We have taken genetic and reverse genetic approaches toward understanding the molecular basis for this induction. These studies have identified a set of genes with sequence similarity to genes that have been shown to be, or are implicated in, Wnt/Wingless signaling pathways in other systems. The C. elegans genes described here are related to wnt/wingless,porcupine, frizzled, beta-catenin/armadillo, and the human adenomatous polyposis coil gene, APC. We present evidence that there may be partially redundant inputs into endoderm specification and that a subset of these genes appear also to function in determining cytoskeletal polarity in certain early blastomeres.	UNIV MASSACHUSETTS, CTR CANC, DEPT CELL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; FRED HUTCHINSON CANC RES CTR, HOWARD HUGHES MED INST, SEATTLE, WA 98109 USA; UNIV WASHINGTON, DEPT ZOOL, SEATTLE, WA 98195 USA	University of Massachusetts System; University of Massachusetts Worcester; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle				Rocheleau, Christian/0000-0001-6738-5636				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; ADLER PN, 1990, GENETICS, V126, P401; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; BRENNER S, 1974, GENETICS, V77, P71; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; EDGAR LG, 1994, DEVELOPMENT, V120, P443; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; Goldstein B, 1996, DEVELOPMENT, V122, P1467; GOLDSTEIN B, 1993, DEVELOPMENT, P279; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUBB D, 1993, DEVELOPMENT, P269; Guedes S, 1997, DEVELOPMENT, V124, P731; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; HUTTER H, 1995, DEVELOPMENT, V121, P1559; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; KEMPHUES KJ, 1996, NEMATODE C ELEGANS, P335; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; Orsulic S, 1996, CURR BIOL, V6, P1363, DOI 10.1016/S0960-9822(96)00731-2; Peifer M, 1996, SCIENCE, V272, P974, DOI 10.1126/science.272.5264.974; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; PowellCoffman JA, 1996, DEV BIOL, V178, P472, DOI 10.1006/dbio.1996.0232; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; SCHNABEL R, 1995, DEVELOPMENT, V121, P2219; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; THEISEN H, 1994, DEVELOPMENT, V120, P347; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	54	525	554	2	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					707	716		10.1016/S0092-8674(00)80531-0	http://dx.doi.org/10.1016/S0092-8674(00)80531-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288750	Bronze			2022-12-01	WOS:A1997XT06600014
J	Wan, Q; Xiong, ZG; Man, YH; Ackerley, CA; Braunton, J; Lu, WY; Becker, LE; MacDonald, JF; Wang, YT				Wan, Q; Xiong, ZG; Man, YH; Ackerley, CA; Braunton, J; Lu, WY; Becker, LE; MacDonald, JF; Wang, YT			Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin	NATURE			English	Article							LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; INHIBITION; SYNAPSES; RAT; CELLS; EXPRESSION; CHANNELS; RELEASE; LTP	Modification of synaptic strength in the mammalian central nervous system (CNS) occurs at both pre- and postsynaptic sites(1,2). However, because postsynaptic receptors are likely to be saturated by released transmitter, an increase in the number of active postsynaptic receptors may be a more efficient way of strengthening synaptic efficacy(3-7). But there has been no evidence for a rapid recruitment of neurotransmitter receptors to the postsynaptic membrane in the CNS, Here we report that insulin causes the type A gamma-aminobutyric acid (GABA(A)) receptor, the principal receptor that mediates synaptic inhibition in the CNS8, to translocate rapidly from the intracellular compartment to the plasma membrane in transfected HEK 293 cells, and that this relocation requires the beta 2 subunit of the GABA(A) receptor. In CNS neurons, insulin increases the expression of GABA(A) receptors on the postsynaptic and dendritic membranes. We found that insulin increases the number of functional postsynaptic GABA(A) receptors, thereby increasing the amplitude of the GABA(A)-receptor-mediated miniature inhibitory postsynaptic currents (mIPSCs) without altering their time course. These results provide evidence for a rapid recruitment of functional receptors to the postsynaptic plasmamembrane, suggesting a fundamental mechanism for the generation of synaptic plasticity.	UNIV TORONTO,HOSP SICK CHILDREN,DIV PATHOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,DIV NEUROSCI,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto			Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015; Lu, Wei-Yang/K-4404-2013					BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Benson DL, 1996, J NEUROSCI, V16, P6424; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BUSCH C, 1990, COLD SPRING HARB SYM, V55, P69; COHEN GA, 1992, NEURON, V9, P325, DOI 10.1016/0896-6273(92)90171-9; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1995, PHYSIOL REV, V75, P759, DOI 10.1152/physrev.1995.75.4.759; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; GARRY DJ, 1986, DIABETES, V35, P1090, DOI 10.2337/diabetes.35.10.1090; HAMILTON BJ, 1993, NEUROSCI LETT, V153, P206, DOI 10.1016/0304-3940(93)90323-D; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JESSELL TM, 1993, NEURON S, V10, P1; KAMATCHI GL, 1984, LIFE SCI, V34, P2297; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; NUSSER Z, 1995, J NEUROSCI, V15, P2948; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; THOMPSON SM, 1993, TRENDS NEUROSCI, V16, P222, DOI 10.1016/0166-2236(93)90160-N; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; Ueno S, 1996, MOL PHARMACOL, V50, P931; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WANG YT, 1991, NEUROSCIENCE, V40, P759, DOI 10.1016/0306-4522(91)90010-L; WOZNIAK M, 1995, NEUROCHEM INT, V22, P1	30	438	453	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					686	690		10.1038/41792	http://dx.doi.org/10.1038/41792			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262404	Bronze			2022-12-01	WOS:A1997XQ86300052
J	Fraser, J; Mok, Q; Tasker, R				Fraser, J; Mok, Q; Tasker, R			Survey of occupancy of paediatric intensive care units by children who are dependent on ventilators	BRITISH MEDICAL JOURNAL			English	Article											Fraser, J (corresponding author), HOSP SICK CHILDREN,PAEDIAT INTENS CARE UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Tasker, Robert C/R-5837-2019; Mok, Quen/AAA-2648-2019	Mok, Quen/0000-0003-4807-9275; Tasker, Robert/0000-0003-3647-8113				British Paediatric Association, 1993, REP MULT WORK PART P; DEWITT PK, 1993, CHEST, V103, P1560, DOI 10.1378/chest.103.5.1560; James I, 1996, BRIT MED J, V312, P1476, DOI 10.1136/bmj.312.7044.1476b	3	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					347	348						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270456				2022-12-01	WOS:A1997XQ86400021
J	Castillo, PE; Janz, R; Sudhof, TC; Tzounopoulos, T; Malenka, RC; Nicoll, RA				Castillo, PE; Janz, R; Sudhof, TC; Tzounopoulos, T; Malenka, RC; Nicoll, RA			Rab3A is essential for mossy fibre long-term potentiation in the hippocampus	NATURE			English	Article							FIBER LTP; 2 FORMS; PROTEIN; RABPHILIN-3A; FACILITATION; SYNAPSINS; NEURONS	Repetitive activation of excitatory synapses in the central nervous system results in a long-lasting increase in synaptic transmission called long-term potentiation (LTP). It is generally believed that this synaptic plasticity may underlie certain forms of learning and memory. LTP at most synapses involves the activation of the NMDA (N-methyl-D-aspartate) subtype of glutamate receptor, but LTP at hippocampal messy fibre synapses is independent of NMDA receptors and has a component that is induced and expressed presynaptically(1). It appears to be triggered by a rise in presynaptic Ca2+ (refs 2, 3), and requires the activation of protein kinase A(4-6), which leads to an increased release of glutamate(3,7-10). A great deal is known about the biochemical steps involved in the vesicular release of transmitter(11-13), but none of these steps has been directly implicated in long-term synaptic plasticity. Here we show that, although a variety of short-term plasticities are normal, LTP at messy fibre synapses is abolished in mice lacking the synaptic vesicle protein Rab3A.	UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Janz, Roger/0000-0002-9872-0596; Castillo, Pablo/0000-0002-9834-1801				BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DIXON D, 1989, J NEUROSCI, V9, P4246; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LopezGarcia JC, 1996, P NATL ACAD SCI USA, V93, P4712, DOI 10.1073/pnas.93.10.4712; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; REGEHR WG, 1994, J NEUROSCI, V14, P523; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SPILLANE DM, 1995, NEUROPHARMACOLOGY, V34, P1573, DOI 10.1016/0028-3908(95)00107-H; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tong G, 1996, NEURON, V16, P1147, DOI 10.1016/S0896-6273(00)80141-5; WANG Y, 1997, NATURE, V387; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WEISSKOPF MG, 1995, NATURE, V376, P256, DOI 10.1038/376256a0; XIANG ZX, 1994, J NEUROPHYSIOL, V71, P2552, DOI 10.1152/jn.1994.71.6.2552; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	281	288	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					590	593		10.1038/41574	http://dx.doi.org/10.1038/41574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252190	Bronze			2022-12-01	WOS:A1997XP72200051
J	Sosa, H; Dias, DP; Hoenger, A; Whittaker, M; WilsonKubalek, E; Sablin, E; Fletterick, RJ; Vale, RD; Milligan, RA				Sosa, H; Dias, DP; Hoenger, A; Whittaker, M; WilsonKubalek, E; Sablin, E; Fletterick, RJ; Vale, RD; Milligan, RA			A model for the microtubule-Ncd motor protein complex obtained by cryo-electron microscopy and image analysis	CELL			English	Article							KINESIN HEAVY-CHAIN; 3-DIMENSIONAL STRUCTURE; DROSOPHILA; RECONSTRUCTION; MICROGRAPHS; MOTILITY; MOVEMENT; TUBULIN; DOMAINS; INVITRO	Kinesin motors convert chemical energy from ATP hydrolysis into unidirectional movement. To understand how kinesin motors bind to and move along microtubules, we fit the atomic structure of the motor domain of Ncd (a kinesin motor involved in meiosis and mitosis) into three-dimensional density maps of Ncd-microtubule complexes calculated by cryo-electron microscopy and image analysis. The model reveals that Ncd shares an extensive interaction surface with the microtubule, and that a portion of the binding site involves loops that contain conserved residues. In the Ncd dimer, the microtubule-bound motor domain makes intimate contact with its partner head, which is dissociated from the microtubule. This head-head interaction may be important in positioning the dissociated head to take a step to the next binding site on the microtubule protofilament.	SCRIPPS RES INST, DEPT CELL BIOL MB25, LA JOLLA, CA 92037 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOL PHARMACOL, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hoenger, Andreas/0000-0001-9176-6658	NIAMS NIH HHS [AR42895] Funding Source: Medline; NIGMS NIH HHS [GM52468] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052468, R37GM052468] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; AMOS LA, 1974, J CELL SCI, V14, P523; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Carragher B, 1996, J STRUCT BIOL, V116, P107, DOI 10.1006/jsbi.1996.0018; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Hoenger A, 1996, J MOL BIOL, V263, P114, DOI 10.1006/jmbi.1996.0561; Hoenger A, 1997, J MOL BIOL, V265, P553, DOI 10.1006/jmbi.1996.0757; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; MANDELKOW EM, 1985, J MOL BIOL, V181, P123, DOI 10.1016/0022-2836(85)90330-4; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MORGAN D, 1993, BIOPHYS J, V64, pA243; RAY S, 1995, CELL MOTIL CYTOSKEL, V30, P146, DOI 10.1002/cm.970300206; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; Sosa H, 1996, J MOL BIOL, V260, P743, DOI 10.1006/jmbi.1996.0434; Sosa H, 1997, J STRUCT BIOL, V118, P149, DOI 10.1006/jsbi.1997.3851; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Tucker C, 1997, J BIOL CHEM, V272, P9481; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; Wade RH, 1995, PROTEINS, V23, P502, DOI 10.1002/prot.340230405; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	42	142	143	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					217	224		10.1016/S0092-8674(00)80330-X	http://dx.doi.org/10.1016/S0092-8674(00)80330-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244296	Bronze			2022-12-01	WOS:A1997XN24900006
J	Liu, LL; Clemens, CJ; Shay, DK; Davis, RL; Novack, AH				Liu, LL; Clemens, CJ; Shay, DK; Davis, RL; Novack, AH			The safety of newborn early discharge - The Washington State experience	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL DISCHARGE; MOTHERS; POPULATION; INFANTS	Context.-While early discharge of newborns following routine vaginal delivery has become common practice, its safety has not been firmly established. Objective.-To assess the risk for rehospitalization following newborn early discharge. Design.-Population-based, case-control study. Setting.-Washington State linked birth certificate and hospital discharge abstracts covering 310 578 live births from 1991 through 1994. Patients.-Case patients were 2029 newborns rehospitalized in the first month of life. Control subjects were 8657 randomly selected newborns not rehospitalized and frequency matched to case patients on year of birth. Cesarean deliveries, multiple births, and births at less than 36 weeks' gestation were not included. Main Outcome Measure.-Stratified analyses and logistic regression were performed to assess the risk for rehospitalization within a month of birth after early discharge (<30 hours after birth) compared with later discharge (30-78 hours after birth). Results.-Seventeen percent of newborns were discharged early. Newborns discharged early were more likely to be rehospitalized within 7 days (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.11-1.47), 14 days (OR, 1.16; 95% CI, 1.03-1.32), and 28 days (OR, 1.12; 95% CI, 1.00-1.25) of discharge than newborns sent home later. Subgroups at increased risk for rehospitalization following early discharge included newborns born to primigravidas (OR,1.25; 95% CI, 1.07-1.45), mothers younger than 18 years (OR, 1.22; 95% CI, 0.79-1.91), and mothers with premature rupture of membranes (OR, 1.41;95% CI, 0.85-2.36). Early discharge was also associated with an increased risk of readmission for jaundice, dehydration, and sepsis. Conclusion.-Newborns discharged home early (<30 hours after birth) are at increased risk for rehospitalization during the first month of life.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; University of North Carolina; University of North Carolina Chapel Hill			Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X; Shay, David/0000-0001-9619-4820	BHP HRSA HHS [5-T32-PE10002] Funding Source: Medline	BHP HRSA HHS		ANNAS GJ, 1995, NEW ENGL J MED, V333, P1647, DOI 10.1056/NEJM199512143332420; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRESLOW NE, 1980, STATISTICAL METHODS, P1; BRITTON JR, 1994, PEDIATRICS, V94, P291; CARTY EM, 1990, BIRTH-ISS PERINAT C, V17, P199, DOI 10.1111/j.1523-536X.1990.tb00021.x; CLARK G, 1996, AAP NEWS, V12, P1; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; FROST F, 1984, AM J PUBLIC HEALTH, V74, P505, DOI 10.2105/AJPH.74.5.505; Gauda EB, 1996, JAMA-J AM MED ASSOC, V275, P1823, DOI 10.1001/jama.275.23.1823; HELLMAN LM, 1962, LANCET, V1, P227; JANSSON P, 1985, AM J NURS, V85, P547, DOI 10.2307/3425241; KEMPER KJ, 1990, AM J DIS CHILD, V144, P238, DOI 10.1001/archpedi.1990.02150260118043; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Norr K F, 1989, J Obstet Gynecol Neonatal Nurs, V18, P133, DOI 10.1111/j.1552-6909.1989.tb00476.x; PARISI VM, 1995, NEW ENGL J MED, V333, P1635, DOI 10.1056/NEJM199512143332412; PARRISH KM, 1993, AM J EPIDEMIOL, V138, P119, DOI 10.1093/oxfordjournals.aje.a116834; PITTARD WB, 1988, J PEDIATR-US, V112, P257, DOI 10.1016/S0022-3476(88)80066-0; RHODES MK, 1994, MIL MED, V159, P227, DOI 10.1093/milmed/159.3.227; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SCUPHOLME A, 1981, J NURSE-MIDWIFERY, V26, P19, DOI 10.1016/0091-2182(81)90171-3; SOLA A, 1996, SOC PED RES ANN M, V39, pA113; WALDENSTROM U, 1987, UPSALA J MED SCI, V92, P301, DOI 10.3109/03009738709178701; *WASH STAT DEP HLT, 1996, BIRA18M1 WASH STAT D; WELT SI, 1993, AM J PERINAT, V10, P384, DOI 10.1055/s-2007-994768; YANOVER MJ, 1976, NEW ENGL J MED, V294, P702, DOI 10.1056/NEJM197603252941306; 1995, NY TIMES        1011, pC18; 1995, VITAL HLTH STAT, V13	29	129	134	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					293	298		10.1001/jama.278.4.293	http://dx.doi.org/10.1001/jama.278.4.293			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XL059	9228434				2022-12-01	WOS:A1997XL05900029
J	Li, Y; Field, PM; Raisman, G				Li, Y; Field, PM; Raisman, G			Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells	SCIENCE			English	Article							SCHWANN-CELLS; SPINAL-CORD; AXONAL REGENERATION; SENSORY NEURONS; BULB; SYSTEM; GROWTH; MOTOR; MOUSE	The upper cervical corticospinal tract was transected on one side in adult rats. A suspension of ensheathing cells cultured from adult rat olfactory bulb was injected into the lesion site, This induced unbranched, elongative growth of the cut corticospinal axons, The axons grew through the transplant and continued to regenerate into the denervated caudal host tract, Rats with complete transections and no transplanted cells did not use the forepaw on the lesioned side for directed reaching, Rats in which the transplanted cells had formed a continuous bridge across the lesion exhibited directed forepaw reaching on the lesioned side.*			Li, Y (corresponding author), NATL INST MED RES,MRC,NORMAN & SADIE LEE RES CTR,DIV NEUROBIOL,LONDON NW7 1AA,ENGLAND.		Raisman, Geoffrey/B-3215-2009					BARBER PC, 1982, NEUROSCIENCE, V7, P3077, DOI 10.1016/0306-4522(82)90231-7; BARBER PC, 1978, BRAIN RES, V141, P57, DOI 10.1016/0006-8993(78)90616-9; DEVON R, 1992, BRAIN RES, V589, P175; Franceschini IA, 1996, DEV BIOL, V173, P327, DOI 10.1006/dbio.1996.0027; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; KUHLENGEL KR, 1990, J COMP NEUROL, V293, P74, DOI 10.1002/cne.902930107; LI Y, 1995, EXP NEUROL, V134, P102, DOI 10.1006/exnr.1995.1041; LI Y, 1994, J NEUROSCI, V14, P4050; MONTEROMENEI CN, 1992, BRAIN RES, V570, P198, DOI 10.1016/0006-8993(92)90582-T; MOULTON DG, 1974, ANN NY ACAD SCI, V237, P52, DOI 10.1111/j.1749-6632.1974.tb49843.x; NEUBERGER TJ, 1992, J COMP NEUROL, V315, P16, DOI 10.1002/cne.903150103; RAISMAN G, 1985, NEUROSCIENCE, V14, P237, DOI 10.1016/0306-4522(85)90176-9; RAMONCUETO A, 1995, GLIA, V14, P163, DOI 10.1002/glia.440140302; RAMONCUETO A, 1992, NEUROSCIENCE, V47, P213, DOI 10.1016/0306-4522(92)90134-N; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; WILSON KCP, 1981, BRAIN RES, V205, P245, DOI 10.1016/0006-8993(81)90336-X; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309	18	720	832	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					2000	2002		10.1126/science.277.5334.2000	http://dx.doi.org/10.1126/science.277.5334.2000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302296				2022-12-01	WOS:A1997XX84900046
J	Allikmets, R; Shroyer, NF; Singh, N; Seddon, JM; Lewis, RA; Bernstein, PS; Peiffer, A; Zabriskie, NA; Li, YX; Hutchinson, A; Dean, M; Lupski, JR; Leppert, M				Allikmets, R; Shroyer, NF; Singh, N; Seddon, JM; Lewis, RA; Bernstein, PS; Peiffer, A; Zabriskie, NA; Li, YX; Hutchinson, A; Dean, M; Lupski, JR; Leppert, M			Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration	SCIENCE			English	Article							BEAVER DAM EYE; FUNDUS FLAVIMACULATUS; MACULOPATHY; DYSTROPHY; FROG	Age-related macular degeneration (AMD) is the leading cause of severe central visual impairment among the elderly and is associated both with environmental factors such as smoking and with genetic factors. Here, 167 unrelated AMD patients were screened for alterations in ABCR, a gene that encodes a retinal rod photoreceptor protein and is defective in Stargardt disease, a common hereditary form of macular dystrophy. Thirteen different AMD-associated alterations, both deletions and amino acid substitutions, were found in one allele of ABCR in 26 patients (16%). Identification of ABCR alterations will permit presymptomatic testing of high-risk individuals and may lead to earlier diagnosis of AMD and to new strategies for prevention and therapy.	NCI, LAB GENOM DIVERS, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; NCI, INTRAMURAL RES SUPPORT PROGRAM, SAIC FREDERICK, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; UNIV UTAH, DEPT HUMAN GENET, ECCLED INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA; HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, DEPT OPHTHALMOL, BOSTON, MA 02114 USA; BAYLOR COLL MED, DEPT OPHTHALMOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; UNIV UTAH, MORAN EYE CTR, DEPT OPHTHALMOL, SALT LAKE CITY, UT 84132 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Baylor College of Medicine; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Utah System of Higher Education; University of Utah			Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Allikmets, Rando/ABD-4533-2021	Dean, Michael C/0000-0003-2234-0631; 				Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ALLIKMETS R, UNPUB; ANDERSON KL, 1995, AM J HUM GENET, V57, P1351; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060; EGAN KM, 1993, PRINCIPLES PRACTICES, P109; Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054; FISHMAN GA, 1976, ARCH OPHTHALMOL-CHIC, V94, P2061, DOI 10.1001/archopht.1976.03910040721003; GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206; GERBER S, 1995, AM J HUM GENET, V56, P396; HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; MartinezMir A, 1997, GENOMICS, V40, P142, DOI 10.1006/geno.1996.4528; *NAT EYE I, 1992, AG REL EYE DIS STUD; National Advisory Eye Council (U.S.), 1993, NIH PUBL; PAPERMASTER DS, 1976, EXP EYE RES, V23, P105, DOI 10.1016/0014-4835(76)90194-9; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0; SHUSTER TA, 1988, EXP EYE RES, V46, P475, DOI 10.1016/S0014-4835(88)80005-8; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SZUTS EZ, 1985, BIOCHEMISTRY-US, V24, P4176, DOI 10.1021/bi00336a054; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352	25	699	735	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1805	1807		10.1126/science.277.5333.1805	http://dx.doi.org/10.1126/science.277.5333.1805			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295268	Green Submitted			2022-12-01	WOS:A1997XX29800042
J	Nelson, JC; Saven, JG; Moore, JS; Wolynes, PG				Nelson, JC; Saven, JG; Moore, JS; Wolynes, PG			Solvophobically driven folding of nonbiological oligomers	SCIENCE			English	Article							SECONDARY STRUCTURE; PHENYLACETYLENE MACROCYCLES; MOLECULAR MECHANICS; HELIX-COIL; PRINCIPLES; ALANINE; CRYSTAL; DESIGN	In solution, biopolymers commonly fold into well-defined three-dimensional structures, but only recently has analogous behavior been explored in synthetic chain molecules. An aromatic hydrocarbon backbone is described that spontaneously acquires a stable helical conformation having a large cavity. The chain does not form intramolecular hydrogen bonds, and solvophobic interactions drive the folding transition, which is sensitive to chain length, solvent quality, and temperature.	UNIV ILLINOIS,DEPT CHEM,URBANA,IL 61801; UNIV ILLINOIS,DEPT MAT SCI & ENGN,URBANA,IL 61801; UNIV ILLINOIS,BECKMAN INST ADV SCI & TECHNOL,URBANA,IL 61801; UNIV ILLINOIS,SCH CHEM SCI,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NCRR NIH HHS [PHS 1 S10 RR10444-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Appella DH, 1996, J AM CHEM SOC, V118, P13071, DOI 10.1021/ja963290l; BIXON M, 1963, BIOPOLYMERS, V1, P419, DOI 10.1002/bip.360010503; BLOOMFIELD VA, 1974, PHYSICAL CHEM NUCLEI; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; Creighton T.E., 1993, PROTEINS; DADO GP, 1994, J AM CHEM SOC, V116, P1054, DOI 10.1021/ja00082a029; DILL KA, 1995, PROTEIN SCI, V4, P561; DOLGIKH DA, 1996, MOL BIOL, V30, P1149; GO N, 1968, P NATL ACAD SCI USA, V59, P1030, DOI 10.1073/pnas.59.4.1030; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6568, DOI 10.1021/ja00042a052; Hamuro Y, 1996, J AM CHEM SOC, V118, P7529, DOI 10.1021/ja9539857; Honig B, 1996, FOLD DES, V1, pR17, DOI 10.1016/S1359-0278(96)00005-3; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LAWRENCE DS, 1995, CHEM REV, V95, P2229, DOI 10.1021/cr00038a018; LEHN JM, 1990, ANGEW CHEM INT EDIT, V29, P1304, DOI 10.1002/anie.199013041; LOKEY RS, 1995, NATURE, V375, P303; LUTHEYSCHULTEN Z, 1995, J PHYS CHEM-US, V99, P2177, DOI 10.1021/j100007a057; MIRNY LA, 1996, FOLDING DESIGN, V1, P221; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Nelson JC, 1996, J ORG CHEM, V61, P8160, DOI 10.1021/jo961250u; OKUYAMA K, 1984, J PHYS CHEM-US, V88, P1711, DOI 10.1021/j150653a010; PADMANABHAN S, 1994, J MOL BIOL, V241, P706, DOI 10.1006/jmbi.1994.1545; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; Perkins S. J., 1982, BIOL MAGN RESON, V4, P193; POLAND D, 1970, THEORY HELIXCOLL TRA; Privalov Peter L., 1992, P83; Saven JG, 1996, J MOL BIOL, V257, P199, DOI 10.1006/jmbi.1996.0156; Schimmel P. R., 1980, BIOPHYSICAL CHEM; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; Seebach D, 1996, HELV CHIM ACTA, V79, P2043, DOI 10.1002/hlca.19960790802; Shetty AS, 1996, J AM CHEM SOC, V118, P1019, DOI 10.1021/ja9528893; SMITH AB, 1994, J AM CHEM SOC, V116, P9947, DOI 10.1021/ja00101a017; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; STILL WC, 1996, MACROMODEL, V5; VENKATAC.CM, 1969, ANNU REV BIOCHEM, V38, P45, DOI 10.1146/annurev.bi.38.070169.000401; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; YANG AS, 1995, J MOL BIOL, V252, P351, DOI 10.1006/jmbi.1995.0502; ZHANG JS, 1994, J AM CHEM SOC, V116, P4227, DOI 10.1021/ja00089a012	41	733	739	1	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1793	1796		10.1126/science.277.5333.1793	http://dx.doi.org/10.1126/science.277.5333.1793			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295264				2022-12-01	WOS:A1997XX29800038
J	Sleat, DE; Donnelly, RJ; Lackland, H; Liu, CG; Sohar, I; Pullarkat, RK; Lobel, P				Sleat, DE; Donnelly, RJ; Lackland, H; Liu, CG; Sohar, I; Pullarkat, RK; Lobel, P			Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis	SCIENCE			English	Article							MITOCHONDRIAL ATP SYNTHASE; SUBUNIT-C; GENE; GLYCOPROTEINS; THIOESTERASE; INHIBITORS; EXPRESSION; SEQUENCE; ENZYMES; DISEASE	Classical late-infantile neuronal ceroid lipofuscinosis (LINCL) is a fatal neurodegenerative disease whose defective gene has remained elusive. A molecular basis for LINCL was determined with an approach applicable to other lysosomal storage diseases. When the mannose 6-phosphate modification of newly synthesized lysosomal enzymes was used as an affinity marker, a single protein was identified that is absent in LINCL. Sequence comparisons suggest that this protein is a pepstatin-insensitive lysosomal peptidase, and a corresponding enzymatic activity was deficient in LINCL autopsy specimens. Mutations in the gene encoding this protein were identified in LINCL patients but not in normal controls.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT LAB MED & PATHOL,NEWARK,NJ 07103; NEW YORK STATE INST BASIC RES DEV DISABIL,STATEN ISL,NY 10314	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Institute for Basic Research in Developmental Disabilities					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030147] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45992] Funding Source: Medline; NINDS NIH HHS [NS30147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOUSTANY RM, 1996, HDB CLIN NEUROLOGY, V66, P671; DE BERNARDO S, 1974, ARCH BIOCHEM BIOPHYS, V163, P390, DOI 10.1016/0003-9861(74)90490-1; Ezaki J, 1996, J NEUROCHEM, V67, P1677, DOI 10.1046/j.1471-4159.1996.67041677.x; *INT BATT DIS CONS, 1995, CELL, V82, P949; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; IVY GO, 1992, AM J MED GENET, V42, P555, DOI 10.1002/ajmg.1320420427; KORNFELD S, 1995, METABOLIC MOL BASES, V2; Oda K, 1996, J BIOCHEM, V120, P564; ODA K, 1994, J BIOL CHEM, V269, P26518; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; PALMER DN, 1989, J BIOL CHEM, V264, P5736; RIDER JA, 1992, AM J MED GENET, V42, P519, DOI 10.1002/ajmg.1320420419; SCHEER E, 1995, GENOMICS, V29, P269, DOI 10.1006/geno.1995.1243; Sharp JD, 1997, HUM MOL GENET, V6, P591, DOI 10.1093/hmg/6.4.591; Sleat DE, 1997, BIOCHEM J, V324, P33, DOI 10.1042/bj3240033; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; SLEAT DE, UNPUB; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0	19	452	465	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1802	1805		10.1126/science.277.5333.1802	http://dx.doi.org/10.1126/science.277.5333.1802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295267				2022-12-01	WOS:A1997XX29800041
J	Kraaijeveld, AR; Godfray, HCJ				Kraaijeveld, AR; Godfray, HCJ			Trade-off between parasitoid resistance and larval competitive ability in Drosophila melanogaster	NATURE			English	Article							ENCAPSULATION ABILITY; ASOBARA-TABIDA; SELECTION; WASP	The extent to which an organism is selected to invest in defences against pathogens and parasites depends on the advantages that ensue should infection occur, but also on the, costs of maintaining defences in the absence of infection. the presence of heritable variation in resistance suggests that costs exist, but we know very little about the nature or magnitude of these costs in natural populations of animals(1). A powerful technique for identifying trade-offs between fitness components is the study of correlated responses to artificial selection(2,3). We have selected Drosophila melanogaster for improved resistance against an endoparasitoid, Asobara tabida. Endoparasitoids are insects whose larvae develop internally within the body of other insects, eventually killing them, although their hosts can sometimes survive attack by mounting a cellular immune response(4-6). We found that reduced larval competitive ability in unparasitized D. melanogaster is a correlated response to artificial selection for improved resistance against A. tabida. The strength of selection for competitive ability and parasitoid resistance is likely to vary temporally and spatially, which may explain the observed heritable variation in resistance.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,NERC,CTR POPULAT BIOL,ASCOT SL5 7PY,BERKS,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOL,ASCOT SL5 7PY,BERKS,ENGLAND	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); Imperial College London								ATKINSON WD, 1979, J ANIM ECOL, V48, P91, DOI 10.2307/4102; CARTON Y, 1991, ACTA OECOL, V12, P89; CARTON Y, 1985, DEV COMP IMMUNOL, V9, P211, DOI 10.1016/0145-305X(85)90112-0; Godfray HCJ, 1994, PARASITOIDS BEHAV EV, DOI [DOI 10.1038/nrg2612, 10.1515/9780691207025, DOI 10.1515/9780691207025]; Gupta AP, 1985, COMPREHENSIVE INSECT, P85; HENTER HJ, 1995, EVOLUTION, V49, P427, DOI [10.1111/j.1558-5646.1995.tb02275.x, 10.2307/2410267]; Hughes K, 1996, J INSECT BEHAV, V9, P477, DOI 10.1007/BF02214024; KRAAIJEVELD AR, 1995, EVOL ECOL, V9, P10, DOI 10.1007/BF01237692; KRAAIJEVELD AR, 1994, ECOL ENTOMOL, V19, P221, DOI 10.1111/j.1365-2311.1994.tb00413.x; LEWONTIN RC, 1955, EVOLUTION, V9, P27, DOI 10.2307/2405355; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; PARTRIDGE L, 1992, EVOLUTION, V46, P76, DOI [10.2307/2409806, 10.1111/j.1558-5646.1992.tb01986.x]; Read A. F., 1995, P450, DOI 10.1017/CBO9780511629396.018; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; Salt G., 1970, CELLULAR DEFENCE REA; SANTOS M, 1992, HEREDITY, V69, P489, DOI 10.1038/hdy.1992.163; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335	17	562	571	1	216	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					278	280		10.1038/38483	http://dx.doi.org/10.1038/38483			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305840				2022-12-01	WOS:A1997XW77200045
J	Lurie, P; Wolfe, SM				Lurie, P; Wolfe, SM			Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ZIDOVUDINE TREATMENT; CLINICAL RESEARCH; HIV-INFECTION; INFANT; TYPE-1; ETHICS				Lurie, P (corresponding author), PUBL CITIZENS HLTH RES GRP,WASHINGTON,DC 20009, USA.							ANGELL M, 1988, NEW ENGL J MED, V319, P1081, DOI 10.1056/NEJM198810203191608; ANNAS G, 1997, BOSTON GLOBE    0518, pC1; Bishop WP, 1996, S AFR MED J, V86, P458; BRENNAN TA, 1994, COMMUNICATION   1228; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper E., 1996, P57; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; HALSEY NA, 1997, COMMUNICATION   0506; HEIMLICH HJ, 1996, 11 INT C AIDS VANC J; LALLEMANT M, 1995, ZDV COURSE PREVENT P; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; MACHIN D, 1987, STAT TABLES DESIGN C, P35; *NIH, 1997, DRAFT TALK POINTS RE; ROUZIOUX C, 1993, AIDS, V7, pS49, DOI 10.1097/00002030-199311002-00011; Scarlatti G, 1996, LANCET, V348, P863, DOI 10.1016/S0140-6736(95)11030-5; SIMONDS RJ, 1996, 11 INT C AIDS VANC C; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; US Public Health Service, 1994, MMWR-MORBID MORTAL W, V43, P1; VARMUS H, 1997, TESTIMONY SUBCOMMITT; VARMUS H, 1996, M ADV COMM DIR NIH D; *WHO, 1994, REC M MOTH INF TRANS; WIKTOR SZ, RANDOMIZED PLACEBO B; World Health Organization, 1993, INT ETH GUID BIOM RE	25	457	474	1	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 18	1997	337	12					853	856		10.1056/NEJM199709183371212	http://dx.doi.org/10.1056/NEJM199709183371212			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW283	9295246				2022-12-01	WOS:A1997XW28300012
J	Hanna, FWF; Scanlon, MF				Hanna, FWF; Scanlon, MF			Hyponatraemia, hypothyroidism, and role of arginine-vasopressin	LANCET			English	Editorial Material							MYXEDEMA; HYPONATREMIA				Hanna, FWF (corresponding author), UNIV WALES HOSP,DEPT DIABET ENDOCRINOL & METAB,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.			hanna, fahmy/0000-0001-5800-1442				ALLON M, 1990, J AM SOC NEPHROL, V1, P205; ARCHAMBEAUDMOUVEROUX F, 1987, ANN MED INTERNE, V138, P114; GILLUM DM, 1997, AM J PHYSIOL, V253, pF170; HOCHBERG Z, 1983, HORM RES, V17, P128, DOI 10.1159/000179687; IWASAKI Y, 1990, J CLIN ENDOCR METAB, V70, P534, DOI 10.1210/jcem-70-2-534; KINSELLA J, 1985, P NATL ACAD SCI USA, V82, P3606, DOI 10.1073/pnas.82.11.3606; KOIDE Y, 1982, ENDOCRINOL JAPON, V29, P363; MCDONOUGH AA, 1988, AM J PHYSIOL, V254, pC323, DOI 10.1152/ajpcell.1988.254.2.C323; Montenegro J, 1996, AM J KIDNEY DIS, V27, P195, DOI 10.1016/S0272-6386(96)90539-9; OJAMAA K, 1993, ANN THORAC SURG, V56, pS61, DOI 10.1016/0003-4975(93)90556-W; Saito T, 1997, J CLIN ENDOCR METAB, V82, P1054, DOI 10.1210/jc.82.4.1054; SKOWSKY WR, 1978, AM J MED, V64, P613, DOI 10.1016/0002-9343(78)90581-8	12	74	80	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					755	756		10.1016/S0140-6736(05)62563-9	http://dx.doi.org/10.1016/S0140-6736(05)62563-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9297992				2022-12-01	WOS:A1997XW28200007
J	Conte, JE				Conte, JE			A novel approach to preventing insect-borne diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTHROPOD VECTOR COMPETENCE				Conte, JE (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							BEARD CB, 1993, PARASITOL TODAY, V9, P179, DOI 10.1016/0169-4758(93)90142-3; BEARD CB, 1992, AM J TROP MED HYG, V46, P195, DOI 10.4269/ajtmh.1992.46.195; Durvasula RV, 1997, P NATL ACAD SCI USA, V94, P3274, DOI 10.1073/pnas.94.7.3274; Richards F. F., 1993, ASM News (Washington), V59, P509; Ward E S, 1993, Adv Pharmacol, V24, P1, DOI 10.1016/S1054-3589(08)60931-X	5	11	11	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					785	786		10.1056/NEJM199709113371112	http://dx.doi.org/10.1056/NEJM199709113371112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287238				2022-12-01	WOS:A1997XV17400012
J	Blattner, FR; Plunkett, G; Bloch, CA; Perna, NT; Burland, V; Riley, M; ColladoVides, J; Glasner, JD; Rode, CK; Mayhew, GF; Gregor, J; Davis, NW; Kirkpatrick, HA; Goeden, MA; Rose, DJ; Mau, B; Shao, Y				Blattner, FR; Plunkett, G; Bloch, CA; Perna, NT; Burland, V; Riley, M; ColladoVides, J; Glasner, JD; Rode, CK; Mayhew, GF; Gregor, J; Davis, NW; Kirkpatrick, HA; Goeden, MA; Rose, DJ; Mau, B; Shao, Y			The complete genome sequence of Escherichia coli K-12	SCIENCE			English	Review							SINGLE-STRANDED-DNA; CODON USAGE; SALMONELLA-TYPHIMURIUM; MYCOPLASMA-GENITALIUM; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; BINDING-PROTEIN; FLAGELLAR HOOK; REGION; REPLICATION	The 4,639,221-base pair sequence of Escherichia coli K-12 is presented. Of 4288 protein-coding genes annotated, 38 percent have no attributed function. Comparison with five other sequenced microbes reveals ubiquitous as well as narrowly distributed gene families; many families of similar genes within E. coli are also evident. The largest family of paralogous proteins contains 80 ABC transporters. The genome as a whole is strikingly organized with respect to the local direction of replication; guanines, oigonucleotides possibly related to replication and recombination, and most genes are so oriented. The genome also contains insertion sequence (IS) elements, phage remnants, and many other patches of unusual composition indicating genome plasticity through horizontal transfer.	UNIV MICHIGAN, SCH MED, DEPT PEDIAT, ANN ARBOR, MI 48105 USA; FMC BIOPROD, ROCKLAND, ME 04841 USA; MARINE BIOL LABS, WOODS HOLE, MA 02543 USA; UNIV NACL AUTONOMA MEXICO, CTR INVEST FIJAC NITROGENO, CUERNAVACA 62100, MORELOS, MEXICO	University of Michigan System; University of Michigan; Marine Biological Laboratory - Woods Hole; Universidad Nacional Autonoma de Mexico	Blattner, FR (corresponding author), UNIV WISCONSIN, GENET LAB, 445 HENRY MALL, MADISON, WI 53706 USA.		Riley, Monica/E-1427-2011; Plunkett, Guy/B-8058-2009; Mayhew, George F/B-4042-2016; Riley, Andrew/F-3526-2013	Plunkett, Guy/0000-0003-1422-469X; Mayhew, George F/0000-0003-0609-6018; Perna, Nicole/0000-0001-8208-0929; Riley, Andrew/0000-0001-9003-3540; Collado-Vides, Julio/0000-0001-8780-7664	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010379] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG001428] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR10379] Funding Source: Medline; NHGRI NIH HHS [P01 HG01428] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ABDULLAH KM, 1991, J BACTERIOL, V173, P5597, DOI 10.1128/jb.173.18.5597-5603.1991; Aiba H, 1996, DNA Res, V3, P363, DOI 10.1093/dnares/3.6.363; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bachellier S, 1996, CELLULAR MOL BIOL, VII, P2012; BACHMANN BJ, 1996, CELLULAR MOL BIOL, V2, P2460; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; BHAGWAT AS, 1992, NUCLEIC ACIDS RES, V20, P1663, DOI 10.1093/nar/20.7.1663; BLAISDELL BE, 1993, J MOL BIOL, V229, P833, DOI 10.1006/jmbi.1993.1090; BLATTNER FR, 1983, SCIENCE, V222, P719, DOI 10.1126/science.222.4625.719; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; Bloch CA, 1996, BIOCHEM BIOPH RES CO, V223, P104, DOI 10.1006/bbrc.1996.0853; BLOCH CA, UNPUB; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BREWER BJ, 1990, BACTERIAL CHROMOSOME, P61; BUGG TDH, 1993, BIOCHIM BIOPHYS ACTA, V1202, P258, DOI 10.1016/0167-4838(93)90013-H; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; BURLAND V, 1993, NUCLEIC ACIDS RES, V21, P3385, DOI 10.1093/nar/21.15.3385; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; BURLAND V, 1995, NUCLEIC ACIDS RES, V23, P2105, DOI 10.1093/nar/23.12.2105; Burland V, 1996, BIOTECHNIQUES, V21, P142; BURLINGAME RP, 1986, J BACTERIOL, V168, P55, DOI 10.1128/jb.168.1.55-64.1986; CAMPBELL AM, 1996, CELLULAR MOL BIOL, V2, P2041; CARDON LR, 1993, NUCLEIC ACIDS RES, V21, P3875, DOI 10.1093/nar/21.16.3875; CHUANG SE, 1993, J BACTERIOL, V175, P2026, DOI 10.1128/JB.175.7.2026-2036.1993; DANIELS DL, 1990, BACTERIAL CHROMOSOME, P43; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DANIELS DL, 1982, COLD SPRING HARB SYM, V47, P1009; DEONIER RC, 1996, CELLULAR MOL BIOL, V2, P2000; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRANCOIS V, 1989, MOL MICROBIOL, V3, P995, DOI 10.1111/j.1365-2958.1989.tb00250.x; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GRALLA JD, 1996, CELLULAR MOL BIOL, V1, P1232; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HILL TM, 1996, CELLULAR MOL BIOL, V2, P1602; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HLASA H, 1989, GENE, V84, P9; HOMMA M, 1990, J MOL BIOL, V213, P819, DOI 10.1016/S0022-2836(05)80266-9; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; Itoh T, 1996, DNA Res, V3, P379, DOI 10.1093/dnares/3.6.379; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; Kaneko T, 1996, DNA Res, V3, P109; KARLIN S, 1994, ANNU REV MICROBIOL, V48, P619, DOI 10.1146/annurev.mi.48.100194.003155; Karp PD, 1997, NUCLEIC ACIDS RES, V25, P43, DOI 10.1093/nar/25.1.43; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOFOID E, COMMUNICATION; KUTSUKAKE K, 1994, GENE, V143, P49; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LABEDAN B, 1995, MOL BIOL EVOL, V12, P980; LAWTHER RP, 1982, J BACTERIOL, V149, P294, DOI 10.1128/JB.149.1.294-298.1982; LIM DB, 1992, MOL MICROBIOL, V6, P3531, DOI 10.1111/j.1365-2958.1992.tb01788.x; LINDSEY DF, 1992, J BACTERIOL, V174, P3834, DOI 10.1128/JB.174.11.3834-3835.1992; LIU D, 1994, MICROBIOL-UK, V140, P49, DOI 10.1099/13500872-140-1-49; Lobry JR, 1996, SCIENCE, V272, P745, DOI 10.1126/science.272.5262.745; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LU Y, 1992, J BIOL CHEM, V267, P24848; MACNAB RM, 1996, CELLULAR MOL BIOL, V2, P123; MATSUTANI S, 1993, GENE, V127, P111; MCCLELLAND M, 1992, NATURE, V355, P595; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; MEDIGUE C, 1991, MOL MICROBIOL, V5, P2629, DOI 10.1111/j.1365-2958.1991.tb01972.x; MERKL R, 1992, NUCLEIC ACIDS RES, V20, P1657, DOI 10.1093/nar/20.7.1657; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; NAKATA A, 1989, J BACTERIOL, V171, P3553, DOI 10.1128/jb.171.6.3553-3556.1989; NEIDHARDT FC, 1996, CELLULAR MOL BIOL, V2, P1; NEIDHARDT FC, 1996, CELLULAR MOL BIOL; OHNISHI K, 1994, J BACTERIOL, V176, P2272, DOI 10.1128/JB.176.8.2272-2281.1994; Ohno S., 1970, EVOLUTION GENE DUPLI, DOI [DOI 10.1007/978-3-642-86659-3, 10.1007/978-3-642-86659-3_11]; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; Oshima T, 1996, DNA Res, V3, P137, DOI 10.1093/dnares/3.3.137; PERNA NT, 1995, J MOL EVOL, V41, P353, DOI 10.1007/BF01215182; PERRIN A, 1993, EMBO J, V12, P2939, DOI 10.1002/j.1460-2075.1993.tb05956.x; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; POSFAI G, 1994, NUCLEIC ACIDS RES, V22, P2392, DOI 10.1093/nar/22.12.2392; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; Riley M, 1997, NUCLEIC ACIDS RES, V25, P51, DOI 10.1093/nar/25.1.51; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; RILEY M, 1997, J MOL BIOL, V269, P1; RILEY M, 1996, CELLULAR MOL BIOL, V2, P2118; RODE CK, 1995, GENE, V166, P1, DOI 10.1016/0378-1119(95)00630-5; Rosenblueth DA, 1996, COMPUT APPL BIOSCI, V12, P415; SACERDOT C, 1982, EMBO J, V1, P311, DOI 10.1002/j.1460-2075.1982.tb01166.x; SALYERS AA, 1994, BACTERIOL PATHOGENES; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SCHULTZ DW, 1981, J MOL BIOL, V146, P275, DOI 10.1016/0022-2836(81)90388-0; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; Spence EL, 1996, J BACTERIOL, V178, P5249, DOI 10.1128/jb.178.17.5249-5256.1996; STAHL F, 1995, J HERED, V86, P327, DOI 10.1093/oxfordjournals.jhered.a111599; SWART JR, 1993, J BIOL CHEM, V268, P12970; TAN HM, 1993, GENE, V130, P33, DOI 10.1016/0378-1119(93)90343-2; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; VANVLIET F, 1988, ANN INST PASTEUR MIC, V139, P493, DOI 10.1016/0769-2609(88)90111-1; WANG TCV, 1994, BIOCHEM BIOPH RES CO, V198, P844, DOI 10.1006/bbrc.1994.1120; WANG TCV, 1992, BIOCHEM BIOPH RES CO, V184, P1496, DOI 10.1016/S0006-291X(05)80052-X; WU CI, 1987, NATURE, V327, P169, DOI 10.1038/327169a0; YODA K, 1991, MOL GEN GENET, V227, P1, DOI 10.1007/BF00260698; YODA KY, 1988, NUCLEIC ACIDS RES, V16, P6531, DOI 10.1093/nar/16.14.6531; YURA T, 1992, NUCLEIC ACIDS RES, V20, P3305, DOI 10.1093/nar/20.13.3305	105	5755	10582	21	776	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	1997	277	5331					1453	+		10.1126/science.277.5331.1453	http://dx.doi.org/10.1126/science.277.5331.1453			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278503				2022-12-01	WOS:A1997XV42900030
J	Furnari, B; Rhind, N; Russell, P				Furnari, B; Rhind, N; Russell, P			Cdc25 mitotic inducer targeted by Chk1 DNA damage checkpoint kinase	SCIENCE			English	Article							WEE1 PROTEIN-KINASE; FISSION YEAST; NEGATIVE REGULATION; FEEDBACK CONTROLS; MITOSIS; PHOSPHORYLATION; PATHWAY; ARREST	Arrest of the cell cycle at the G(2) checkpoint, induced by DNA damage, requires inhibitory phosphorylation of the kinase Cdc2 in both fission yeast and human cells. The kinase Wee1 and the phosphatase Cdc25, which regulate Cdc2 phosphorylation, were evaluated as targets of Chk1, a kinase essential for the checkpoint. Fission yeast cdc2-3w Delta cdc25 cells, which express activated Cdc2 and lack Cdc25, were responsive to Wee1 but insensitive to Chk1 and irradiation. Expression of large amounts of Chk1 produced the same phenotype as did loss of the cdc25 gene in cdc2-3w cells. Cdc25 associated with Chk1 in vivo and was phosphorylated when copurified in Chk1 complexes. These findings identify Cdc25, but not Wee1, as a target of the DNA damage checkpoint.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute				Rhind, Nicholas/0000-0003-1758-7736				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FEILOTTER H, 1991, GENETICS, V127, P309; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FUMARI B, UNPUB; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHELDRICK KS, 1993, BIOESSAYS, V15, P775, DOI 10.1002/bies.950151202; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0	29	467	479	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	1997	277	5331					1495	1497		10.1126/science.277.5331.1495	http://dx.doi.org/10.1126/science.277.5331.1495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278510				2022-12-01	WOS:A1997XV42900037
J	Jones, GRN				Jones, GRN			Are CS sprays safe?	LANCET			English	Editorial Material																		ABDO K, 1990, NIH PUBL; BHATTACHARYA ST, 1993, ANAESTHESIA, V48, P896, DOI 10.1111/j.1365-2044.1993.tb07424.x; GIBBONS S, 1996, POLICE REV      0216, P4; HELLREICH A, 1967, 4075 EDGW ARS; HIMSWORTH H, 1971, CMND4775; Himsworth H., 1969, CMND4173; PARNEIXSPAKE A, 1993, ARCH DERMATOL, V129, P913, DOI 10.1001/archderm.1993.01680280103029	7	6	6	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					605	606		10.1016/S0140-6736(05)63322-3	http://dx.doi.org/10.1016/S0140-6736(05)63322-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288040				2022-12-01	WOS:A1997XU28300005
J	Tanaka, TU; Knapp, D; Nasmyth, K				Tanaka, TU; Knapp, D; Nasmyth, K			Loading of an Mcm protein onto DNA replication origins is regulated by Cdc6p and CDKs	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; RECOGNITION COMPLEX; S-PHASE; XENOPUS; INITIATION; CHROMATIN; BINDING; KINASE; PHOSPHORYLATION	In eukaryotic cells, firing of DNA replication origins normally does not recur until after M phase. This characteristic is thought to be due to the properties of ''initiation'' proteins like Ore, Cdc6, and Mcms. Using formaldehyde cross-linking, we show that Cdc6p and Mcm7p associate specifically with replication origins during G1 but not during G2 in S. cerevisiae. Mcm7p's association with origins depends on Cdc6p. Ectopic expression of Cdc6p enables it to associate with origins during G2, but this fails to recruit Mcm7p. Our data suggest that the loading of Mcm proteins onto origins is regulated by two mechanisms: first, by Cdc6p occupancy, and second, by S-and M-CDKs, whose activity during S, G2, and M phases prevents Mcm loading.			Tanaka, TU (corresponding author), RES INST MOL PATHOL, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.		Knapp, Dunja/N-2180-2017; Tanaka, Tomoyuki U/A-4775-2008	Knapp, Dunja/0000-0002-7533-2208; Nasmyth, Kim/0000-0001-7030-4403; Tanaka, Tomoyuki/0000-0002-9886-5947				BLOW JJ, 1996, EUKARYOTIC DNA REPLI, P143; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; Lei M, 1996, MOL CELL BIOL, V16, P5081; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; NASMYTH K, 1996, DNA REPLICATION EUKA, P331; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TOYN JH, 1995, MOL CELL BIOL, V15, P5312; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	36	431	437	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					649	660		10.1016/S0092-8674(00)80526-7	http://dx.doi.org/10.1016/S0092-8674(00)80526-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288745	Bronze			2022-12-01	WOS:A1997XT06600009
J	Tomioka, N; Fujino, K				Tomioka, N; Fujino, K			Natural (Mg,Fe)SiO3-ilmenite and -perovskite in the Tenham meteorite	SCIENCE			English	Article							PHASES; MGSIO3	The minerals (Mg, Fe)SiO3-ilmenite and -perovskite were identified in the shock-induced veins in the Tenham chondritic meteorite. Both phases are inferred to have transformed from pyroxene at high pressures and temperatures by shock metamorphism. Columnar-shaped ilmenite grains, one of two types of morphologies, have a topotaxial relationship with neighboring pyroxene grains, indicating shear transformation. Granular-shaped perovskite grains showed a diffraction pattern consistent with orthorhombic perovskite, but these grains were not stable under the electron beam irradiation and became amorphous. The higher iron concentration in both phases compared with those experimentally reported may suggest their metastable transition from enstatite because of shock compression.			Tomioka, N (corresponding author), HOKKAIDO UNIV,GRAD SCH SCI,DIV EARTH & PLANETARY SCI,SAPPORO,HOKKAIDO 060,JAPAN.		Tomioka, Naotaka/AID-3472-2022; Tomioka, Naotaka/B-1888-2011	Tomioka, Naotaka/0000-0001-5725-9513				BINNS RA, 1969, NATURE, V221, P943, DOI 10.1038/221943a0; Chen M, 1996, SCIENCE, V271, P1570, DOI 10.1126/science.271.5255.1570; Coleman LC, 1977, CAN MINERAL, V15, P97; Fei YW, 1996, J GEOPHYS RES-SOL EA, V101, P11525, DOI 10.1029/96JB00408; FUJINO K, 1996, P US JAP SEM MAU HI; ITO E, 1989, J GEOPHYS RES-SOLID, V94, P10637, DOI 10.1029/JB094iB08p10637; Ito E., 1977, HIGH PRESSURE RES, P193; Ito E., 1982, HIGH PRESSURE RES GE, P405; KATO T, 1985, NATURE, V316, P803, DOI 10.1038/316803a0; LIU L, 1975, GEOPHYS RES LETT, V2, P417, DOI 10.1029/GL002i010p00417; LIU LG, 1976, EARTH PLANET SC LETT, V31, P200, DOI 10.1016/0012-821X(76)90212-0; MASON B, 1968, SCIENCE, V160, P66, DOI 10.1126/science.160.3823.66; MORI H, 1985, LUNAR PLANET SCI, V16, P579; PRICE GD, 1979, CONTRIB MINERAL PETR, V71, P211, DOI 10.1007/BF00375437; PRICE GD, 1983, CAN MINERAL, V21, P29; PUTNIS A, 1979, NATURE, V280, P217, DOI 10.1038/280217a0; Sawamoto H., 1987, HIGH PRESSURE RES MI, P209; Stu┬ffler D., 1972, FORTSCHRITTE MINERAL, V49, P50; VANSCHMUS WR, 1967, GEOCHIM COSMOCHIM AC, V31, P747, DOI 10.1016/S0016-7037(67)80030-9	19	112	117	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1084	1086		10.1126/science.277.5329.1084	http://dx.doi.org/10.1126/science.277.5329.1084			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262473				2022-12-01	WOS:A1997XT03300030
J	Fraser, FC				Fraser, FC			Trinucleotide repeats not the only cause of anticipation	LANCET			English	Editorial Material											Fraser, FC (corresponding author), MCGILL UNIV,CTR HUMAN GENET,MONTREAL,PQ H3A 1B1,CANADA.							CROW TJ, 1991, EUR ARCH PSY CLIN N, V240, P314, DOI 10.1007/BF02279759; Horwitz M, 1996, AM J HUM GENET, V59, P990; McInnis MG, 1996, AM J HUM GENET, V59, P973; Paterson AD, 1996, AM J HUM GENET, V59, P264; PENROSE LS, 1948, ANN EUGENIC, V14, P125; Petronis A., 1996, American Journal of Human Genetics, V59, pA186; Polito JMII, 1996, LANCET, V347, P798, DOI 10.1016/S0140-6736(96)90870-3; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636	8	44	45	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					459	460		10.1016/S0140-6736(05)63077-2	http://dx.doi.org/10.1016/S0140-6736(05)63077-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274580				2022-12-01	WOS:A1997XR13500006
J	Gore, SM; Bingham, S; Day, NE				Gore, SM; Bingham, S; Day, NE			Age related dietary exposure to meat products from British dietary surveys of teenagers and adults in the 1980s and 1990s	BRITISH MEDICAL JOURNAL			English	Article									MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB2 2SR,ENGLAND		Gore, SM (corresponding author), MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; *COUNC ROYAL SOC, 1997, UPD BSE, P1; Gregory J., 1990, DIETARY NUTR SURVEY; Ministry of Agriculture Fisheries and Food, 1991, 50 YEARS NAT FOOD SU; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					404	405		10.1136/bmj.315.7105.404	http://dx.doi.org/10.1136/bmj.315.7105.404			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277606	Green Published			2022-12-01	WOS:A1997XR54900022
J	Maggiorini, M; Bartsch, P; Oelz, O				Maggiorini, M; Bartsch, P; Oelz, O			Association between raised body temperature and acute mountain sickness: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							PULMONARY-EDEMA; HIGH-ALTITUDE		UNIV CLIN MED,HEIDELBERG,GERMANY; STADTSPITAL TRIEMLI,DEPT MED,ZURICH,SWITZERLAND	Triemli Hospital	Maggiorini, M (corresponding author), UNIV ZURICH HOSP,DEPT MED,CH-8091 ZURICH,SWITZERLAND.			Maggiorini, Marco/0000-0001-8180-2117				HOUSTON CS, 1987, GOING HIGHER STORY M; Kleger GR, 1996, J APPL PHYSIOL, V81, P1917, DOI 10.1152/jappl.1996.81.5.1917; MAGGIORINI M, 1990, BRIT MED J, V301, P853, DOI 10.1136/bmj.301.6756.853; SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605, DOI 10.1152/jappl.1988.64.6.2605; VOCK P, 1989, RADIOLOGY, V170, P661, DOI 10.1148/radiology.170.3.2916019	5	19	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					403	404		10.1136/bmj.315.7105.403	http://dx.doi.org/10.1136/bmj.315.7105.403			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277605	Green Published			2022-12-01	WOS:A1997XR54900021
J	Ewalt, KL; Hendrick, JP; Houry, WA; Hartl, FU				Ewalt, KL; Hendrick, JP; Houry, WA; Hartl, FU			In vivo observation of polypeptide flux through the bacterial chaperonin system	CELL			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; REACTION CYCLE; ATPASE CYCLE; IN-VIVO; GROEL; EXPRESSION; RHODANESE; BINDING	The quantitative contribution of chaperonin GroEL to protein folding in E. coli was analyzed. A diverse set of newly synthesized polypeptides, predominantly between 10-55 kDa, interacts with GroEL, accounting for 10%-15% of all cytoplasmic protein under normal growth conditions, and for 30% or more upon exposure to heat stress. Most proteins leave GroEL rapidly within 10-30 s. We distinguish three classes of substrate proteins: (I) proteins with a chaperonin-independent folding pathway; (II) proteins, more than 50% of total, with an intermediate chaperonin dependence for which normally only a small fraction transits GroEL; and (III) a set of highly chaperonin-dependent proteins, many of which dissociate slowly from GroEL and probably require sequestration of aggregation-sensitive intermediates within the GroEL cavity for successful folding.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MAX PLANCK INST BIOCHEM,DEPT CELLULAR BIOCHEM,D-82152 MARTINSRIED,GERMANY	Memorial Sloan Kettering Cancer Center; Max Planck Society	Ewalt, KL (corresponding author), MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021, USA.		Hartl, F. Ulrich/Y-8206-2019					Ausubel FM, 1992, CURRENT PROTOCOLS MO; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FLANAGAN JM, 1992, P NATL ACAD SCI USA, V89, P748, DOI 10.1073/pnas.89.2.748; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; GAITANARIS GA, 1994, MOL MICROBIOL, V14, P861, DOI 10.1111/j.1365-2958.1994.tb01322.x; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cellbio.9.1.601; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hagenmaier S, 1997, J BACTERIOL, V179, P2073, DOI 10.1128/jb.179.6.2073-2076.1997; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOHFELD J, 1995, CELL, V83, P589; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KIM HB, 1991, BIOCHEM INT, V25, P381; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MARTIN J, 1997, P NATL ACAD SCI USA, V94, P14107; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	49	279	285	0	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					491	500		10.1016/S0092-8674(00)80509-7	http://dx.doi.org/10.1016/S0092-8674(00)80509-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267029	Bronze			2022-12-01	WOS:A1997XQ06300013
J	Casson, IF; Clarke, CA; Howard, CV; McKendrick, O; Pennycook, S; Pharoah, POD; Platt, MJ; Stanisstreet, M; vanVelszen, D; Walkinshaw, S				Casson, IF; Clarke, CA; Howard, CV; McKendrick, O; Pennycook, S; Pharoah, POD; Platt, MJ; Stanisstreet, M; vanVelszen, D; Walkinshaw, S			Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-ANOMALIES; SPONTANEOUS-ABORTION; MELLITUS; CARE	Objective: To monitor pregnancies in women with pre-existent insulin dependent diabetes for pregnancy loss, congenital malformations, and fetal growth in a geographically defined area of north west England. Design: Population cohort study. Setting: 10 maternity units in Cheshire, Lancashire, and Merseyside which had no regional guidelines for the management of pregnancy in diabetic women. Subjects: 462 pregnancies in 355 women with insulin dependent diabetes from the 10 centres over five years (1990-4 inclusive). Main outcome measures: Numbers and rates of miscarriages, stillbirths, and neonatal and postneonatal deaths; prevalence of congenital malformations; birth weight in relation to gestational age. Results: Among 462 pregnancies, 351 (76%) resulted in a liveborn infant, 78 (17%) aborted spontaneously, nine (2%) resulted in stillbirth, and 24 (5%) were terminated. Of the terminations, nine were for congenital malformation. The stillbirth rate was 25.0/1000 total births (95% confidence interval 8.9 to 41.1) compared with a population rate of 5.0/1000, and infant mortality was 19.9/1000 live births (5.3 to 34.6) compared with 6.8/1000. The prevalence of congenital malformations was 94.0/1000 live births (63.5 to 124.5) compared with 9.7/1000 in the general population. When corrected for gestational age, mean birth weight in the sample was 1.3 standard deviations greater than that of infants of non-diabetic mothers. Infants with congenital malformations weighed less than those without. Conclusion: In an unselected population the infants of women with pre-existent insulin dependent diabetes mellitus have a 10-fold greater risk of a congenital malformation and a fivefold greater risk of being stillborn than infants in the general population. Further improvements in the management of pregnancy in diabetic women are needed if target of die St Vincent declaration of 1989 is to be met.	BROADGREEN HOSP,LIVERPOOL L14 3LD,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,SCH BIOL SCI,LIVERPOOL L69 38X,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; LIVERPOOL WOMENS HOSP,LIVERPOOL L8 7SS,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3GB,MERSEYSIDE,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool			Platt, MJ/K-4588-2012	Platt, MJ/0000-0002-9372-9575; Howard, Charles Vyvyan/0000-0002-6151-3446				Albert TJ, 1996, AM J OBSTET GYNECOL, V174, P1424, DOI 10.1016/S0002-9378(96)70583-5; CORDERO L, 1993, CLIN PERINATOL, V20, P635, DOI 10.1016/S0095-5108(18)30390-7; Diabet Control Complications Trial Res Grp, 1996, AM J OBSTET GYNECOL, V174, P1343; DOLK H, 1991, DESCRIPTIVE EUROCAT; DUNLOP DC, 1996, DIABETIC MED, V13, pS44; HAWTHORNE GC, 1996, DIABET MED S3, V13, pS44; KITZMILLER JL, 1991, JAMA-J AM MED ASSOC, V265, P731, DOI 10.1001/jama.265.6.731; LANDON MB, 1987, AM J OBSTET GYNECOL, V156, P1089, DOI 10.1016/0002-9378(87)90116-5; Landon MB, 1995, MED DISORDERS PREGNA, P63; LOWRY C, 1986, DIABETIC MED, V3, P458; MILLER E, 1981, NEW ENGL J MED, V304, P1331, DOI 10.1056/NEJM198105283042204; MILLS JL, 1988, NEW ENGL J MED, V319, P1617, DOI 10.1056/NEJM198812223192501; *N W REG HLTH AUTH, 1995, HLTH N W ENGL COMM D; *NW REG HLTH AUTH, 1995, N W REG 1994 PUBL HL; OATS JN, 1995, BAILLIERE CLIN OB GY, V9, P481, DOI 10.1016/S0950-3552(05)80376-1; *OFF NAT STAT, 1996, POP TRENDS 84; *OFF POP CENS SURV, 1982, INF PER MORT SOC BIO; *OFF POP CENS SURV, 1992, INF PER MORT SOC BIO; *OFF POP CENS SURV, 1992, BRITH STAT; *OFF POP CENS SURV, 1992, CONG MALF STAT; ROSENN B, 1994, OBSTET GYNECOL, V84, P515; *SCOTT HLTH SERV C, 1991, BIRTHW HEAD CIRC LEN; STEEL JM, 1990, BRIT MED J, V301, P1070, DOI 10.1136/bmj.301.6760.1070; WEATHERALL JAC, 1978, POPUL TRENDS, V11, P27; WHO/IDF Europe, 1990, DIABETIC MED, V7, P360; ZAR JH, 1984, BIOSTAT ANAL, P386	26	367	373	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					275	278		10.1136/bmj.315.7103.275	http://dx.doi.org/10.1136/bmj.315.7103.275			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274545	Green Published			2022-12-01	WOS:A1997XP75000019
J	Swerlick, RA; Lawley, TJ				Swerlick, RA; Lawley, TJ			Hypersensitivity vasculitis - not always benign?	LANCET			English	Editorial Material											Swerlick, RA (corresponding author), EMORY UNIV,SCH MED,DEPT DERMATOL,ATLANTA,GA 30345, USA.		Swerlick, Robert/AAY-1998-2020	Swerlick, Robert/0000-0002-9802-4144				EKENSTAM AE, 1984, ARCH DERMATOL, V120, P484; MartinezTaboada VM, 1997, AM J MED, V102, P186; TancredeBohin E, 1997, ARCH DERMATOL, V133, P438, DOI 10.1001/archderm.133.4.438; WINKELMANN RK, 1964, MEDICINE, V43, P59, DOI 10.1097/00005792-196401000-00003; WISNIESKI JJ, 1995, MEDICINE, V74, P24, DOI 10.1097/00005792-199501000-00003	5	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					306	307		10.1016/S0140-6736(05)63383-1	http://dx.doi.org/10.1016/S0140-6736(05)63383-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251631				2022-12-01	WOS:A1997XP24200004
J	Gewirtz, JC; Davis, M				Gewirtz, JC; Davis, M			Second-order fear conditioning prevented by blocking NMDA receptors in amygdala	NATURE			English	Article							LONG-TERM POTENTIATION; LATERAL NUCLEUS; INTRAAMYGDALA INFUSION; BASOLATERAL AMYGDALA; IMPAIRS ACQUISITION; STARTLE; ANTAGONIST; EXPRESSION; MEMORY; BLOCKADE	Antagonists of NMDA (N-methyl-D-aspartate)-type glutamate receptors disrupt several forms of learning(1-8). Although this might indicate that NMDA-receptor-mediated processes are critical for synaptic plasticity, there may be other mechanisms by which NMDA-receptor antagonism could interfere with learning(1,9-12). For instance, fear conditioning would be blocked by microinfusion of the NMDA-receptor antagonist AP5 (D,L-2-amino-5-phosphonovalerate) into the basolateral amygdala(6,13,14) if AP5 inhibited routine synaptic transmission, thereby reducing the ability of stimuli to activate amygdala neurons(15,16). In second-order fear conditioning(17,18), the reinforcer is a fear-eliciting conditioned stimulus rather than an unconditioned stimulus. Expression of conditioned fear is amygdala-dependent(19,20) and so provides a behavioural assessment of the ability of the reinforcer to activate amygdala neurons in the presence of AP5. We report here that intra-amygdala AP5 actually enhances expression of conditioned fear to the conditioned stimulus that provides the reinforcement signal for second-order conditioning. Nevertheless, acquisition of second-order fear conditioning is completely blocked. Our findings strongly support the view that NMDA receptors are critically involved in synaptic plasticity.	YALE UNIV,RIBICOFF RES FACIL,CONNECTICUT MENTAL HLTH CTR,DEPT PSYCHIAT,NEW HAVEN,CT 06508	Yale University	Gewirtz, JC (corresponding author), YALE UNIV,RIBICOFF RES FACIL,CONNECTICUT MENTAL HLTH CTR,DEPT PSYCHOL,34 PK ST,NEW HAVEN,CT 06508, USA.							BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BURNS LH, 1994, BEHAV NEURAL BIOL, V61, P242, DOI 10.1016/S0163-1047(05)80007-X; CAMPEAU S, 1995, J NEUROSCI, V15, P2312, DOI 10.1523/JNEUROSCI.15-03-02312.1995; CAMPEAU S, 1995, J NEUROSCI, V15, P2301, DOI 10.1523/JNEUROSCI.15-03-02301.1995; CAMPEAU S, 1991, BRAIN RES, V565, P349, DOI 10.1016/0006-8993(91)91669-R; CAMPEAU S, 1992, BEHAV NEUROSCI, V106, P569, DOI 10.1037/0735-7044.106.3.569; CARAMANOS Z, 1994, BEHAV NEUROSCI, V108, P30, DOI 10.1037/0735-7044.108.1.30; CASSELLA JV, 1986, PHYSIOL BEHAV, V36, P377, DOI 10.1016/0031-9384(86)90032-6; EVERITT B J, 1992, P401; FALLS WA, 1992, J NEUROSCI, V12, P854; FANSELOW MS, 1994, BEHAV NEUROSCI, V108, P210, DOI 10.1037/0735-7044.108.1.210; HATFIELD T, 1995, BEHAV NEUROSCI, V109, P663, DOI 10.1037/0735-7044.109.4.663; Hatfield T, 1996, J NEUROSCI, V16, P5256; IZQUIERDO I, 1995, NEUROBIOL LEARN MEM, V63, P19, DOI 10.1006/nlme.1995.1002; KEITH JR, 1990, PSYCHOBIOLOGY, V18, P251; KIM JJ, 1991, BEHAV NEUROSCI, V105, P125; KIM M, 1993, BEHAV NEURAL BIOL, V59, P5, DOI 10.1016/0163-1047(93)91075-X; KIM M, 1992, BRAIN RES, V585, P35, DOI 10.1016/0006-8993(92)91188-K; LI XF, 1995, EXP BRAIN RES, V105, P87; Li XF, 1996, LEARN MEMORY, V3, P229, DOI 10.1101/lm.3.2-3.229; Maren S, 1996, BEHAV NEUROSCI, V110, P1365, DOI 10.1037/0735-7044.110.6.1365; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; Pavlov IP, 1927, CONDITIONED REFLEXES; Rescorla RA., 1980, PAVLOVIAN 2 ORDER CO; ROMANSKI LM, 1992, J NEUROSCI, V12, P4501; ROMANSKI LM, 1993, BEHAV NEUROSCI, V107, P444, DOI 10.1037/0735-7044.107.3.444; SAUCIER D, 1995, NATURE, V378, P186, DOI 10.1038/378186a0; Servatius RJ, 1996, BEHAV NEUROSCI, V110, P1040; STAUBLI U, 1989, BEHAV NEUROSCI, V103, P54, DOI 10.1037/0735-7044.103.1.54; WILLICK ML, 1995, BEHAV NEUROSCI, V109, P929, DOI 10.1037/0735-7044.109.5.929	30	168	170	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					471	474		10.1038/41325	http://dx.doi.org/10.1038/41325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242405	Bronze			2022-12-01	WOS:A1997XN55300048
J	Ido, Y; Vindigni, A; Chang, K; Stramm, L; Chance, R; Heath, WF; DiMarchi, RD; DiCera, E; Williamson, JR				Ido, Y; Vindigni, A; Chang, K; Stramm, L; Chance, R; Heath, WF; DiMarchi, RD; DiCera, E; Williamson, JR			Prevention of vascular and neural dysfunction in diabetic rats by C-peptide	SCIENCE			English	Article							ELEVATED GLUCOSE-LEVELS; RENAL-FUNCTION; PROTEIN; POLYPEPTIDE; SORBITOL; CONFORMATION; TYPE-1	C-peptide, a cleavage product from the processing of proinsulin to insulin, has been considered to possess little if any biological activity other than its participation in insulin synthesis, Injection of human C-peptide prevented or attenuated vascular and neural (electrophysiological) dysfunction and impaired Na+- and K+-dependent adenosine triphosphate activity in tissues of diabetic rats. Nonpolar amino acids in the midportion of the peptide were required for these biological effects. Synthetic reverse sequence (retro) and all-D-amino acid (enantio) C-peptides were equipotent to native C-peptide, which indicates that the effects of C-peptide on diabetic vascular and neural dysfunction were mediated by nonchiral interactions instead of stereospecific receptors or binding sites.	WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOL BIOPHYS, ST LOUIS, MO 63110 USA; ELI LILLY & CO, LILLY CORP CTR, LILLY RES LABS, DIV ENDOCRINE, INDIANAPOLIS, IN 46285 USA; ELI LILLY & CO, LILLY CORP CTR, LILLY RES LABS, RES TECHNOL & PROT, INDIANAPOLIS, IN 46285 USA	Washington University (WUSTL); Washington University (WUSTL); Eli Lilly; Eli Lilly				Ido, Yasuo/0000-0002-3036-9971	NEI NIH HHS [EY 06600] Funding Source: Medline; NHLBI NIH HHS [HL 58141, HL 39934] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058141, R01HL039934] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, DIABETES, V44, P968; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; CHANCE RE, 1971, DIABETES, P292; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; DRYBURGH JR, 1980, DIABETOLOGIA, V19, P397, DOI 10.1007/BF00280527; EADES DM, 1989, J CHROMATOGR-BIOMED, V490, P1, DOI 10.1016/S0378-4347(00)82755-3; FRANK BH, 1983, MUNCH MED WSCHR S1, V125, pS14; Frank BH, 1981, PEPTIDES SYNTHESIS S, P729; GORKA J, 1989, Peptide Research, V2, P376; IDO Y, 1994, DIABETES, V43, P1469, DOI 10.2337/diabetes.43.12.1469; IDO Y, UNPUB; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JOHANSSON BL, 1992, DIABETOLOGIA, V35, P121, DOI 10.1007/BF00402543; JOHANSSON BL, 1993, J CLIN ENDOCR METAB, V77, P976, DOI 10.1210/jc.77.4.976; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KITABCHI AE, 1977, METABOLISM, V26, P547, DOI 10.1016/0026-0495(77)90099-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEHMANN EL, 1975, NONPARAMETRICS; LEWIS PN, 1971, P NATL ACAD SCI USA, V68, P2293, DOI 10.1073/pnas.68.9.2293; MARKUSSEN J, 1973, INT J PEPT PROT RES, V5, P69; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; PUGLIESE G, 1990, DIABETES, V39, P323, DOI 10.2337/diabetes.39.3.323; ROGERS D, 1988, DIABETES, V37, P1689, DOI 10.2337/diabetes.37.12.1689; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scheffe H, 1999, ANAL VARIANCE, V72; SNELL CR, 1975, J BIOL CHEM, V250, P6291; SRINIVASAN R, 1995, PROTEINS, V22, P81, DOI 10.1002/prot.340220202; STEINER DF, 1978, DIABETES, V27, P145, DOI 10.2337/diab.27.1.S145; STEINER DF, 1995, ENDOCRINOLOGY, V2, P1296; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TILTON RG, 1995, DIABETES, V44, P234, DOI 10.2337/diabetes.44.2.234; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; TOYOTA T, 1975, TOHOKU J EXP MED, V117, P79, DOI 10.1620/tjem.117.79; VANDENENDEN MK, 1995, INVEST OPHTH VIS SCI, V36, P1675; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; WILLIAMSON JR, 1990, J CLIN INVEST, V85, P1167, DOI 10.1172/JCI114549; WOJCIKOWSKI C, 1983, DIABETOLOGIA, V25, P288, DOI 10.1007/BF00279945; WOLF BA, 1991, J CLIN INVEST, V87, P31, DOI 10.1172/JCI114988; Zierath JR, 1996, DIABETOLOGIA, V39, P306	42	299	340	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 25	1997	277	5325					563	566		10.1126/science.277.5325.563	http://dx.doi.org/10.1126/science.277.5325.563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228006				2022-12-01	WOS:A1997XM86700051
J	Neubuser, A; Peters, H; Balling, R; Martin, GR				Neubuser, A; Peters, H; Balling, R; Martin, GR			Antagonistic interactions between FGF and BMP signaling pathways: A mechanism for positioning the sites of tooth formation	CELL			English	Article							APICAL ECTODERMAL RIDGE; LIMB DEVELOPMENT; MOUSE; EXPRESSION; GROWTH; OUTGROWTH; INDUCTION; CHICK; GENE; DIFFERENTIATION	Vertebrate organogenesis is initiated at sites that are often morphologically indistinguishable from the surrounding region. Here we have identified Pax9 as a marker for prospective tooth mesenchyme prior to the first morphological manifestation of odontogenesis. We provide evidence that the sites of Pax9 expression in the mandibular arch are positioned by the combined activity of two signals, one (FGF8) that induces Pax9 expression and the other (BMP2 and BMP4) that prevents this induction. Thus it appears that the position of the teeth is determined by a combination of two different types of signaling molecules produced in wide but overlapping domains rather than by a single localized inducer. We suggest that a similar mechanism may be used for specifying the sites of development of other organs.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST SAUGETIERGENET,D-85764 NEUHERBERG,GERMANY	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Balling, Rudi/E-9680-2010	Balling, Rudi/0000-0003-2902-5650	NICHD NIH HHS [R01 HD34380] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034380] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Chen YP, 1996, DEVELOPMENT, V122, P3035; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; GAUNT WA, 1964, ACTA ANAT, V57, P115; Grobstein C, 1967, Natl Cancer Inst Monogr, V26, P279; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; JONES CM, 1991, DEVELOPMENT, V111, P531; Kaufman MH, 1994, ATLAS MOUSE DEV; KOLLAR EJ, 1970, J EMBRYOL EXP MORPH, V24, P173; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lough J, 1996, DEV BIOL, V178, P198, DOI 10.1006/dbio.1996.0211; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; LUMSDEN AGS, 1986, ARCH ORAL BIOL, V31, P301, DOI 10.1016/0003-9969(86)90044-0; LYONS KM, 1990, DEVELOPMENT, V109, P833; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; Means AL, 1996, CELL GROWTH DIFFER, V7, P989; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MINA M, 1987, ARCH ORAL BIOL, V32, P123, DOI 10.1016/0003-9969(87)90055-0; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NISWANDER L, 1993, DEVELOPMENT, V119, P287; NORTHROP J, 1995, DEV BIOL, V172, P242, DOI 10.1006/dbio.1995.0019; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; RUCH JV, 1984, DENTIN DENTINOGENESI, P47; SCHULTEMERKER S, 1995, CURR BIOL, V5, P62, DOI 10.1016/S0960-9822(95)00017-0; Spemann H., 1938, EMBRYONIC DEV INDUCT; Thesleff I, 1996, ANAT REC, V245, P151; Thesleff I, 1996, SEMIN CELL DEV BIOL, V7, P185, DOI 10.1006/scdb.1996.0025; Thesleff I, 1996, CURR OPIN CELL BIOL, V8, P844, DOI 10.1016/S0955-0674(96)80086-X; THESLEFF I, 1977, DEV BIOL, V58, P197, DOI 10.1016/0012-1606(77)90085-9; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/0092-8674(93)90678-J; Vogel A, 1996, DEVELOPMENT, V122, P1737; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; Wehr R, 1996, INT J DEV BIOL, V40, P369; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	43	483	498	2	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					247	255		10.1016/S0092-8674(00)80333-5	http://dx.doi.org/10.1016/S0092-8674(00)80333-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244299	Bronze			2022-12-01	WOS:A1997XN24900009
J	Schnitzer, MJ; Block, SM				Schnitzer, MJ; Block, SM			Kinesin hydrolyses one ATP per 8-nm step	NATURE			English	Article							HEAD DOMAINS; MICROTUBULE; MOVEMENT; MOLECULES; MOTILITY; KINETICS; PROTEIN; FORCE; ASSAY; SIZE	Kinesin is a two-headed, ATP-dependent motor protein(1,2) that moves along microtubules in discrete steps(3) of 8 nm. In vitro, single molecules produce processive movement(4,5); motors typically take similar to 100 steps before releasing from a microtubule(5-7). A central question relates to mechanochemical coupling in this enzyme: how many molecules of ATP are consumed per step? For the actomyosin system, experimental approaches to this issue have generated considerable controversy(8,9). Here we take advantage of the processivity of kinesin to determine the coupling ratio without recourse to direct measurements of ATPase activity, which are subject to large experimental uncertainties(8,10-12). Beads carrying single molecules of kinesin moving on microtubules were tracked with high spatial and temporal resolution by interferometry(3,13). Statistical analysis of the intervals between steps at limiting ATP, and studies of fluctuations in motor speed as a function of ATP concentration(14,15), allow the coupling ratio to be determined. At near-zero load, kinesin molecules hydrolyse a single ATP molecule per 8-nm advance. This finding excludes various one-to-many and many-to-one coupling schemes, analogous to those advanced for myosin, and places severe constraints on models for movement.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,PRINCETON MAT INST,PRINCETON,NJ 08544	Princeton University; Princeton University	Schnitzer, MJ (corresponding author), PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544, USA.							BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X; BLOCK SM, 1995, BIOPHYS J, V68, pS230; BURTON K, 1992, J MUSCLE RES CELL M, V13, P590, DOI 10.1007/BF01738249; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; Derenyi I, 1996, P NATL ACAD SCI USA, V93, P6775, DOI 10.1073/pnas.93.13.6775; Duke T, 1996, BIOPHYS J, V71, P1235, DOI 10.1016/S0006-3495(96)79323-2; GELLES J, 1995, BIOPHYS J, V68, pS276; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Kreis T., 1993, GUIDEBOOK CYTOSKELET; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; PESKIN CS, 1995, BIOPHYS J, V68, pS202; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; SOWERBY AJ, 1993, J MOL BIOL, V234, P114, DOI 10.1006/jmbi.1993.1567; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; TOYOSHIMA YY, 1990, P NATL ACAD SCI USA, V87, P7130, DOI 10.1073/pnas.87.18.7130; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	30	601	615	2	95	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					386	390		10.1038/41111	http://dx.doi.org/10.1038/41111			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237757				2022-12-01	WOS:A1997XM52800053
J	Anderson, DG; Kowalczykowski, SC				Anderson, DG; Kowalczykowski, SC			The translocating RecBCD enzyme stimulates recombination by directing RecA protein onto ssDNA in a chi-regulated manner	CELL			English	Article							SINGLE-STRANDED-DNA; HOT SPOT ACTIVITY; COLI SSB PROTEIN; ESCHERICHIA-COLI; PHAGE-LAMBDA; BINDING-PROTEIN; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; BACTERIOPHAGE-LAMBDA; SERRATIA-MARCESCENS	Double-stranded DNA break repair and homologous recombination in E. coli are initiated by the RecBCD enzyme, which unwinds and simultaneously degrades DNA from a double-stranded DNA end. This process is stimulated by cis-acting DNA elements, known as chi sites. Using both in vitro pairing and nuclease protection assays, we demonstrate that the translocating RecBCD enzyme, which has been activated by chi, coordinates the preferential loading of the homologous pairing protein, RecA, onto the resultant single-stranded DNA downstream of chi. This facilitated loading of RecA protein results in a substantial increase in both the efficiency and rate of in vitro recombination reactions and offers an explanation for stimulation of recombination and repair in vivo by chi.	UNIV CALIF DAVIS,GENET GRAD GRP,DAVIS,CA 95616; UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis					NIGMS NIH HHS [GM-41347] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Anderson DG, 1997, GENES CELLS, V2, P117, DOI 10.1046/j.1365-2443.1997.1130311.x; BIANCO PR, 1997, IN PRESS P NATL ACAD; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; CHENG KC, 1989, GENETICS, V123, P5; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; DEVRIES J, 1992, J GEN MICROBIOL, V138, P31, DOI 10.1099/00221287-138-1-31; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1995, J BIOL CHEM, V270, P16360, DOI 10.1074/jbc.270.27.16360; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; EMMERSON PT, 1968, GENETICS, V60, P19; ENNIS DG, 1987, GENETICS, V115, P11; FRIEDBERG EC, 1995, DNA REPAIR; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KOWALCZYKOWSKI SC, 1994, J MOL BIOL, V63, P991; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; KUZMINOV A, 1996, MOL BIOL INTELLIGENC, P135; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; MOLINEUX IJ, 1975, J MOL BIOL, V98, P811, DOI 10.1016/S0022-2836(75)80012-X; MYERS RS, 1995, GENETICS, V141, P805; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; RINKEN R, 1991, BIOCHIMIE, V73, P375, DOI 10.1016/0300-9084(91)90104-9; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1990, P NATL ACAD SCI USA, V88, P3367; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; Sambrook J., 1989, MOL CLONING LAB MANU; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1980, GENETICS, V94, P235; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNSHINE MG, 1971, J BACTERIOL, V108, P695, DOI 10.1128/JB.108.2.695-704.1971; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; Telander-Muskavitch K.M, 1981, ENZYMES, P233; TELANDERMUSKAVI.KM, 1980, MECHANISTIC STUDIES, P901; TRACY KRB, 1996, GENE DEV, V10, P1890; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005	61	244	253	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					77	86		10.1016/S0092-8674(00)80315-3	http://dx.doi.org/10.1016/S0092-8674(00)80315-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230304	Bronze			2022-12-01	WOS:A1997XL36200010
J	Zeng, L; Fagotto, F; Zhang, T; Hsu, W; Vasicek, TJ; Perry, WL; Lee, JJ; Tilghman, SM; Gumbiner, BM; Costantini, F				Zeng, L; Fagotto, F; Zhang, T; Hsu, W; Vasicek, TJ; Perry, WL; Lee, JJ; Tilghman, SM; Gumbiner, BM; Costantini, F			The mouse fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation	CELL			English	Article							PRIMITIVE STREAK FORMATION; BETA-CATENIN; SPEMANN ORGANIZER; XENOPUS-EMBRYOS; INDUCTION; PROTEIN; GENE; DROSOPHILA; LOCALIZATION; GASTRULATION	Mutations at the mouse Fused locus have pleiotropic developmental effects, including the formation of axial duplications in homozygous embryos. The product of the Fused locus, Axin, displays similarities to RGS (Regulators of G-Protein Signaling) and Dishevelled proteins. Mutant Fused alleles that cause axial duplications disrupt the major mRNA, suggesting that Axin negatively regulates the response to an axis-inducing signal. Injection of Axin mRNA into Xenopus embryos inhibits dorsal axis formation by interfering with signaling through the Wnt pathway. Furthermore, ventral injection of an Axin mRNA lacking the RGS domain induces an ectopic axis, apparently through a dominant-negative mechanism. Thus, Axin is a novel inhibitor of Wnt signaling and regulates an early step in embryonic axis formation in mammals and amphibians.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; PRINCETON UNIV,HOWARD HUGHES MED INST,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Columbia University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Princeton University; Princeton University			Hsu, Wei/ABG-6856-2021; Fagotto, Francois/AAA-9983-2021	Hsu, Wei/0000-0001-6738-6030; Fagotto, Francois/0000-0002-1495-2112	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037432, R01GM037432] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08784] Funding Source: Medline; NIDDK NIH HHS [DK-46934] Funding Source: Medline; NIGMS NIH HHS [GM37432] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHVAROVA RF, 1996, ADV DEV BIO, V4, P147; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHENCHIK A, 1995, CLONTECHNIQUES, V10, P5; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; Conlon Frank, 1995, Seminars in Developmental Biology, V6, P249, DOI 10.1016/S1044-5781(06)80050-2; COOKE J, 1972, J EMBRYOL EXP MORPH, V28, P27; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; FAGOTTO F, 1994, DEVELOPMENT, V120, P3667; Fagotto F, 1997, DEVELOPMENT, V124, P453; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GARDNER RL, 1992, J EXP ZOOL, V264, P437, DOI 10.1002/jez.1402640409; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; GREENSPAN RJ, 1986, P NATL ACAD SCI USA, V83, P4413, DOI 10.1073/pnas.83.12.4413; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; HUME CR, 1993, DEVELOPMENT, V119, P1147; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JACOBSCOHEN RJ, 1984, GENET RES, V43, P43, DOI 10.1017/S0016672300025702; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KHANER O, 1989, DEV BIOL, V134, P206, DOI 10.1016/0012-1606(89)90090-0; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LYON MF, 1996, GENETIC VARIANTS STR; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PERRY WL, 1995, GENETICS, V141, P321; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; StJacques B, 1996, CURR OPIN GENET DEV, V6, P439, DOI 10.1016/S0959-437X(96)80065-7; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TLIGHMAN SM, 1996, GENOME RES, V6, P773; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Wylie C, 1996, DEVELOPMENT, V122, P2987; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZIV T, 1992, DEVELOPMENT, V115, P689	56	750	783	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					181	192		10.1016/S0092-8674(00)80324-4	http://dx.doi.org/10.1016/S0092-8674(00)80324-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230313	hybrid			2022-12-01	WOS:A1997XL36200019
J	Irmler, M; Thome, M; Hahne, M; Schneider, P; Hofmann, B; Steiner, V; Bodmer, JL; Schroter, M; Burns, K; Mattmann, C; Rimoldi, D; French, LE; Tschopp, J				Irmler, M; Thome, M; Hahne, M; Schneider, P; Hofmann, B; Steiner, V; Bodmer, JL; Schroter, M; Burns, K; Mattmann, C; Rimoldi, D; French, LE; Tschopp, J			Inhibition of death receptor signals by cellular FLIP	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROTEIN; FAS; CYTOTOXICITY; INTERACTS; DOMAIN; SITE; P35	The widely expressed protein Fas is a member of the tumour necrosis factor receptor family which fan trigger apoptosis(1). However, Fas surface expression does not necessarily render cells susceptible to Fas ligand-induced death signals(1,2), indicating that inhibitors of the apoptosis-signalling pathway must exist. Here we report the characterization of an inhibitor of apoptosis, designated FLIP (for FLICE-inhibitory protein), which is predominantly expressed in muscle and lymphoid tissues. The short form, FLIPS, contains two death effector domains and is structurally related to the viral FLIP inhibitors of apoptosis(3), whereas the long form, FLIPL, contains in addition a caspase-like domain in which the active-centre cysteine residue is substituted by a tyrosine residue. FLIPS and FLIPL interact with the adaptor protein FADD(4,5) and the protease FLICE6,7, and potently inhibit apoptosis induced by all known human death receptors(1). FLIPL is expressed during the early stage of T-cell activation, but disappears when T cells become susceptible to Fas ligand-mediated apoptosis. High levels of FLIPL protein are also detectable in melanoma cell lines and malignant melanoma tumours. Thus FLIP may be implicated in tissue homeostasis as an important regulator of apoptosis.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND; UNIV LAUSANNE,LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND; SWISS INST EXPT CANC RES,BIL BIOMED RES CTR,CH-1066 EPALINGES,SWITZERLAND; UNIV GENEVA,SCH MED,DEPT DERMATOL,CH-1211 GENEVA 4,SWITZERLAND	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; Swiss Institute Experimental Cancer Research; University of Geneva			Irmler, Martin/B-3317-2013; French, Lars/AAL-5977-2020; Thome, Margot/F-8167-2011; Hofmann, Kay/D-6714-2011	Irmler, Martin/0000-0003-3169-479X; French, Lars/0000-0002-4629-1486; Thome, Margot/0000-0002-5656-2139; Hofmann, Kay/0000-0002-2289-9083; Schneider, Pascal/0000-0003-0677-9409				Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BODNER JL, 1997, IMMUNITY, V6, P79; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FRANCIS MJ, 1991, IMMUNOLOGY, V73, P249; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YU GL, 1996, SCIENCE, V274, P990	30	2072	2172	0	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					190	195		10.1038/40657	http://dx.doi.org/10.1038/40657			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217161	Green Submitted, Bronze			2022-12-01	WOS:A1997XK10900054
J	Boussiotis, VA; Freeman, GJ; Berezovskaya, A; Barber, DL; Nadler, LM				Boussiotis, VA; Freeman, GJ; Berezovskaya, A; Barber, DL; Nadler, LM			Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; CBL PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; C-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; SUPPRESSOR ACTIVITY; INSULIN-RECEPTOR; MAMMALIAN-CELLS	In the absence of costimulation, T cells activated through their antigen receptor become unresponsive (anergic) and do not transcribe the gene encoding interleukin-2 (IL-2) when restimulated with antigen. Anergic alloantigen-specific human T cells contained phosphorylated Cbl that coimmunoprecipitated with Fyn. The adapter protein CrkL was associated with both phosphorylated Cbl and the guanidine nucleotide-releasing factor G3G, which catalyzes guanosine triphosphate (GTP) exchange on Rap1. Active Rap1 (GTP-bound form) was present in anergic cells, Forced expression of low amounts of Rap1-GTP in Jurkat T cells recapitulated the anergic defect and blocked T cell antigen receptor (TCR)- and CD28-mediated IL-2 gene transcription. Therefore, Rap1 functions as a negative regulator of TCR-mediated IL-2 gene transcription and may be responsible for the specific defect in IL-2 production in T cell anergy.	HARVARD UNIV, SCH MED, BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; ONTARIO CANC INST, DIV CELLULAR & MOL BIOL, TORONTO, ON M5G 2M9, CANADA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Boussiotis, VA (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT ADULT ONCOL, BOSTON, MA 02115 USA.		Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Barber, Dwayne/0000-0001-5528-8150	NHLBI NIH HHS [HL 54785] Funding Source: Medline; NIAID NIH HHS [AI39671, AI 35225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039671] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH G, 1993, GTPASES BIOL 1, V108, P377; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; BOUSSIOTIS VA, UNPUB; Brownell HL, 1996, DNA CELL BIOL, V15, P443, DOI 10.1089/dna.1996.15.443; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JONGEWARD GD, 1995, GENETICS, V139, P1553; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; MIGITA K, 1995, J IMMUNOL, V155, P5083; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAHL HL, 1991, EXP HEMATOL, V19, P1038; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PIZON V, 1988, ONCOGENE, V3, P201; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; QIAN DP, 1993, J BIOL CHEM, V268, P4488; QUILL H, 1987, J IMMUNOL, V138, P3704; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SREEDQUIST KA, 1996, J BIOL CHEM, V271, P8453; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	77	388	395	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	1997	278	5335					124	128		10.1126/science.278.5335.124	http://dx.doi.org/10.1126/science.278.5335.124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XZ124	9311917				2022-12-01	WOS:A1997XZ12400053
J	Dantonel, JC; Murthy, KGK; Manley, JL; Tora, L				Dantonel, JC; Murthy, KGK; Manley, JL; Tora, L			Transcription factor TFIID recruits factor CPSF for formation of 3' end of mRNA	NATURE			English	Article							RNA-POLYMERASE-II; POLYADENYLATION SPECIFICITY FACTOR; ESTROGEN-RECEPTOR; GLOBIN GENE; ACTIVATION; TERMINATION; CLEAVAGE; SUBUNIT; COMPLEX; PROTEIN	Initiation of transcription by RNA polymerase II from a promoter region on DNA requires the assembly of several initiation factors to form a preinitiation complex, Assembly of this complex(1,2) is initiated by the binding of the transcription factor TFIID, composed of the TATA-box binding protein (TBP) and TBP-associated factors (TAF(II)s), to the promoter, We have now characterized an immunopurified TFIID complex which we unexpectedly find contains the cleavage-polyadenylation specificity factor (CPSF), one of the factors required for formation of the 3' end of messenger RNA(3,4). CPSF is brought to the preinitiation complex by TFIID, but after transcription starts, CPSF dissociates from TFIID and becomes associated with the elongating polymerase, We also show that overexpression of recombinant TBP in HeLa cells decreases polyadenylation without affecting the correct initiation of transcription of the reporter gene, This indicates that, owing to incomplete assembly of TFIID on recombinant TBP, CPSF is not brought to the promoter and therefore polyadenylation becomes less efficient. Our observations have thus revealed a link between transcription initiation and elongation by RNA polymerase II and processing of the 3' end of mRNA.	ULP,COLL FRANCE,INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 STRASBOURG,FRANCE; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Columbia University			Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Besse Sylvie, 1995, Gene Expression, V4, P143; BIENROTH S, 1991, J BIOL CHEM, V266, P768; BOAM DS, 1995, J BIOL CHEM, V270, P487; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; GERARD M, 1991, J BIOL CHEM, V266, P20940; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; LAVIGNE AC, 1996, J BIOL CHEM, V271, P774; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	30	249	250	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					399	402		10.1038/38763	http://dx.doi.org/10.1038/38763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311784				2022-12-01	WOS:A1997XX67500057
J	Cumming, BG; Parker, AJ				Cumming, BG; Parker, AJ			Responses of primary visual cortical neurons to binocular disparity without depth perception	NATURE			English	Article							HUMAN STEREO VISION; CORTEX; MONKEY	The identification of brain regions that are associated with the conscious perception of visual stimuli is a major goal in neuroscience(1). Here we present a test of whether the signals on neurons in cortical area V1 correspond directly to our conscious perception of binocular stereoscopic depth. Depth perception requires that image features on one retina are first matched with appropriate features on the other retina. The mechanisms that perform this matching can be examined by using random-dot stereograms(2), in which the left and right eyes view randomly positioned but binocularly correlated dots. We exploit the fact that anticorrelated random-dot stereograms (in which dots in one eye are matched geometrically to dots of the opposite contrast in the other eye) do not give rise to the perception of depth(3) because the matching process does not find a consistent solution. Anticorrelated random-dot stereograms contain binocular features that could excite neurons that have not solved the correspondence problem. We demonstrate that disparity-selective neurons in V1 signal the disparity of anticorrelated random-dot stereograms, indicating that they do not unambiguously signal stereoscopic depth. Hence single V1 neurons cannot account for the conscious perception of stereopsis, although combining the outputs of many V1 neurons could solve the matching problem. The accompanying paper(4) suggests an additional function for disparity signals from V1: they may be important for the rapid involuntary control of vergence eye movements (eye movements that bring the images on the two foveae into register).			Cumming, BG (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Parker, Andrew J/I-7867-2013	Parker, Andrew J/0000-0001-5800-0407	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; COGAN AI, 1993, VISION RES, V33, P1959, DOI 10.1016/0042-6989(93)90021-N; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; GRIMSON WEL, 1981, PHILOS T ROY SOC B, V292, P217, DOI 10.1098/rstb.1981.0031; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; Masson GS, 1997, NATURE, V389, P283, DOI 10.1038/38496; NIKARA T, 1968, EXP BRAIN RES, V6, P353; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; POGGIO GF, 1984, ANNU REV NEUROSCI, V7, P379, DOI 10.1146/annurev.ne.07.030184.002115; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; POGGIO GF, 1985, VISION RES, V25, P397, DOI 10.1016/0042-6989(85)90065-3; POGGIO GF, 1995, CEREB CORTEX, V3, P193; QIAN N, 1994, NEURAL COMPUT, V6, P390, DOI 10.1162/neco.1994.6.3.390; SKOTTUN BC, 1991, VISION RES, V31, P1079, DOI 10.1016/0042-6989(91)90033-2	17	310	315	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					280	283		10.1038/38487	http://dx.doi.org/10.1038/38487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305841				2022-12-01	WOS:A1997XW77200046
J	Luger, K; Mader, AW; Richmond, RK; Sargent, DF; Richmond, TJ				Luger, K; Mader, AW; Richmond, RK; Sargent, DF; Richmond, TJ			Crystal structure of the nucleosome core particle at 2.8 angstrom resolution	NATURE			English	Article							X-RAY-DIFFRACTION; CHROMATIN; DNA; TRANSCRIPTION; HISTONE; PROTEIN; MODEL; BINDING; YEAST; INTEGRATION	The X-ray crystal structure of the nucleosome cave particle of chromatin shows in atomic detail how the histone protein octamer is assembled and how 146 base pairs of DNA are organized into a superhelix around it. Both histone/histone and histone/DNA interactions depend on the histone fold domains and additional, well ordered structure elements extending from this motif. Histone amino-terminal tails pass over and between the gyres of the DNA superhelix to contact neighbouring particles. The lack of uniformity between multiple histone/DNA-binding sites causes the DNA to deviate from ideal superhelix geometry.	ETH HONGGERBERG, ETHZ, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich				SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331				ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Blank TA, 1996, J MOL BIOL, V260, P1, DOI 10.1006/jmbi.1996.0377; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BRUNGER A, 1992, X PLOR V3 1 MANUAL; CAMERINIOTERO RD, 1977, P NATL ACAD SCI USA, V74, P5519, DOI 10.1073/pnas.74.12.5519; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; FINCH JT, 1979, FEBS P M, V51, P193; Flaus A, 1996, P NATL ACAD SCI USA, V93, P1370, DOI 10.1073/pnas.93.4.1370; FLAUS A, IN PRESS J MOL BIOL; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GRAZIANO V, 1994, NATURE, V368, P351, DOI 10.1038/368351a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Harp JM, 1996, ACTA CRYSTALLOGR D, V52, P283, DOI 10.1107/S0907444995009139; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LUGER K, IN PRESS J MOL BIOL; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHALLORAN TV, 1987, J MOL BIOL, V194, P705, DOI 10.1016/0022-2836(87)90248-8; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RHODES D, 1989, METHOD ENZYMOL, V170, P420; RHODES D, 1981, NATURE, V292, P378, DOI 10.1038/292378a0; RICHMOND TJ, 1988, J MOL BIOL, V199, P161, DOI 10.1016/0022-2836(88)90386-5; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Starich MR, 1996, J MOL BIOL, V255, P187, DOI 10.1006/jmbi.1996.0016; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; van Holde K E, 1988, CHROMATIN; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YANG TP, 1982, P NATL ACAD SCI-BIOL, V79, P6593, DOI 10.1073/pnas.79.21.6593	51	6507	6720	14	638	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					251	260		10.1038/38444	http://dx.doi.org/10.1038/38444			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305837				2022-12-01	WOS:A1997XW77200038
J	Yeh, KC; Wu, SH; Murphy, JT; Lagarias, JC				Yeh, KC; Wu, SH; Murphy, JT; Lagarias, JC			A cyanobacterial phytochrome two-component light sensory system	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; AVENA PHYTOCHROME; GENE; PROTEINS; SIMILARITY; MECHANISM; ETR1	The biliprotein phytochrome regulates plant growth and developmental responses to the ambient light environment through an unknown mechanism. Biochemical analyses demonstrate that phytochrome is an ancient molecule that evolved from a more compact light sensor in cyanobacteria. The cyanobacterial phytochrome Cph1 is a light-regulated histidine kinase that mediates red, far-red reversible phosphorylation of a small response regulator, Rcp1 (response regulator for cyanobacterial phytochrome), encoded by the adjacent gene, thus implicating protein phosphorylation-dephosphorylation in the initial step of light signal transduction by phytochrome.	UNIV CALIF DAVIS, SECT MOL & CELLULAR BIOL, DAVIS, CA 95616 USA	University of California System; University of California Davis			Yeh, Kuo-Chen/AAG-4485-2021; Wu, Shu-Hsing/B-4317-2009; Lagarias, John Clark/L-3139-2013	Yeh, Kuo-Chen/0000-0002-3791-3423; Wu, Shu-Hsing/0000-0002-7179-3138; Lagarias, John Clark/0000-0002-2093-0403	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NCRR NIH HHS [1 P41 RR06009] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Allen JF, 1997, TRENDS PLANT SCI, V2, P41, DOI 10.1016/S1360-1385(97)82554-X; BORTHWICK HA, 1960, SCIENCE, V132, P1223, DOI 10.1126/science.132.3435.1223; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jones Alan M., 1994, Seminars in Cell Biology, V5, P295, DOI 10.1006/scel.1994.1036; Kakimoto T, 1996, SCIENCE, V274, P982, DOI 10.1126/science.274.5289.982; Kaneko T, 1996, DNA Res, V3, P109; Kehoe DM, 1997, J BACTERIOL, V179, P3914, DOI 10.1128/jb.179.12.3914-3921.1997; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; LI LM, 1992, J BIOL CHEM, V267, P19204; LINO M, 1997, PHOTOCHEM PHOTOBIOL, V65, P1032; LITTS JC, 1983, J BIOL CHEM, V258, P1025; Murphy JT, 1997, PHOTOCHEM PHOTOBIOL, V65, P750, DOI 10.1111/j.1751-1097.1997.tb01920.x; MUTCH N, 1986, J BACTERIOL, V165, P161; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; PRATT LH, 1995, PHOTOCHEM PHOTOBIOL, V61, P10, DOI 10.1111/j.1751-1097.1995.tb09238.x; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SCHMIDT TGM, 1994, J CHROMATOGR A, V676, P337, DOI 10.1016/0021-9673(94)80434-6; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; WONG YS, 1989, PLANT PHYSIOL, V91, P709, DOI 10.1104/pp.91.2.709; WONG YS, 1986, J BIOL CHEM, V261, P2089	33	436	462	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	1997	277	5331					1505	1508		10.1126/science.277.5331.1505	http://dx.doi.org/10.1126/science.277.5331.1505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278513				2022-12-01	WOS:A1997XV42900040
J	Gale, JE; Ashmore, JF				Gale, JE; Ashmore, JF			An intrinsic frequency limit to the cochlear amplifier	NATURE			English	Article							OUTER HAIR-CELLS; MEMBRANE CAPACITANCE; NA,K PUMP; CHANNEL; MOTILITY; TRANSITIONS	Hearing in mammals depends on a feedback process within the inner ear termed the 'cochlear amplifier'(1). The essential components of this amplifier are sensorimotor cells, the outer hair cells, which transduce motion of the basilar membrane induced by sound and generate forces to cancel the viscous damping of the cochlear partition(2,3). Outer hair cells alter the passive mechanics of the cochlea, enhancing both the sensitivity and the frequency selectivity of the auditory system. The molecular basis of the mechanism is thought to be a voltage-sensitive 'motor' protein, as yet unidentified, embedded in the basolateral membrane of the outer hair cell(4). The cochlear amplifier operates up to at least 22 kHz (ref. 5), but by measuring both the charge and mechanical movements associated with the motor(6,7) in isolated membrane patches under voltage damp, we show here that the limiting frequency at which the motor operates lies near 25 kHz. This value therefore sets an upper limit to the range of hearing in mammalian cochleas using this mechanism. The fast charge movement, arising from charge displacement within the presumed motor molecule, further suggests that the protein is more likely to be related to a transporter than to a modified ion channel.	UCL, DEPT PHYSIOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London	Gale, JE (corresponding author), UNIV BRISTOL, SCH MED SCI, DEPT PHYSIOL, UNIV WALK, BRISTOL BS8 1TD, AVON, ENGLAND.		Gale, Jonathan/AAG-6874-2019	Gale, Jonathan/0000-0003-4678-4878	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASHMORE JF, 1988, Q J EXP PHYSIOL CMS, V73, P143, DOI 10.1113/expphysiol.1988.sp003114; ASHMORE JF, 1990, NEUROSCI RES       S, V12, P39; CONTI F, 1989, EUR BIOPHYS J BIOPHY, V17, P53, DOI 10.1007/BF00257102; DALLOS P, 1995, SCIENCE, V267, P2006, DOI 10.1126/science.7701325; Dallos P., 1996, COCHLEA, P1; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; FORGE A, 1991, CELL TISSUE RES, V265, P473, DOI 10.1007/BF00340870; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GALE JE, 1997, EUR J PHYSL, V434, P267; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; IWASA KH, 1994, J ACOUST SOC AM, V96, P2216, DOI 10.1121/1.410094; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; MACONOCHIE DJ, 1995, BIOPHYS J, V68, P483, DOI 10.1016/S0006-3495(95)80209-2; MAMMANO F, 1993, J ACOUST SOC AM, V93, P3320, DOI 10.1121/1.405716; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; SANTOS-SACCHI J, 1989, J NEUROSCI, V9, P2954; SANTOS-SACCHI J, 1992, J NEUROSCI, V12, P1906; SIGG D, 1994, SCIENCE, V264, P578, DOI 10.1126/science.8160016; TUNSTALL MJ, 1995, J PHYSIOL-LONDON, V485, P739, DOI 10.1113/jphysiol.1995.sp020765; VATER M, 1992, J COMP NEUROL, V318, P367, DOI 10.1002/cne.903180403; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	24	107	107	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					63	66		10.1038/37968	http://dx.doi.org/10.1038/37968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288966				2022-12-01	WOS:A1997XU59600044
J	Uesugi, M; Nyanguile, O; Lu, H; Levine, AJ; Verdine, GL				Uesugi, M; Nyanguile, O; Lu, H; Levine, AJ; Verdine, GL			Induced alpha helix in the VP16 activation domain upon binding to a human TAF	SCIENCE			English	Article							TRANSCRIPTION FACTOR-TFIIB; TRANSACTIVATION DOMAIN; NMR-SPECTROSCOPY; PROTEINS; GAL4; C-13; H-1; EXPRESSION; TAF(II)40; SPECTRA	Activation domains are functional modules that enable sequence-specific DNA binding proteins to stimulate transcription. The structural basis for the function of activation domains is poorly understood. A combination of nuclear magnetic resonance (NMR) and biochemical experiments revealed that the minimal acidic activation domain of the herpes simplex virus VP16 protein undergoes an induced transition from random coil to or helix upon binding to its target protein, hTAF(parallel to)31 (a human TFIID TATA box-binding protein-associated factor). Identification of the two hydrophobic residues that make nonpolar contacts suggests a general recognition motif of acidic activation domains for hTAF(parallel to)31.	HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Harvard University; Princeton University			Uesugi, Motonari/AAM-9777-2020					BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; HAMPSEY M, 1997, CURR BIOL, V7, P44; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACFERRIN KD, 1993, METHOD ENZYMOL, V217, P79; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MORIUCHI H, 1995, P NATL ACAD SCI USA, V92, P9333, DOI 10.1073/pnas.92.20.9333; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4827; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016	38	272	278	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 29	1997	277	5330					1310	1313		10.1126/science.277.5330.1310	http://dx.doi.org/10.1126/science.277.5330.1310			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271577				2022-12-01	WOS:A1997XT82700056
J	Elghanian, R; Storhoff, JJ; Mucic, RC; Letsinger, RL; Mirkin, CA				Elghanian, R; Storhoff, JJ; Mucic, RC; Letsinger, RL; Mirkin, CA			Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles	SCIENCE			English	Article							PARTICLES; PROBES	A highly selective, colorimetric polynucleotide detection method based on mercaptoal-kyloligonucleotide-modified gold nanoparticle probes is reported. Introduction of a single-stranded target oligonucleotide (30 bases) into a solution containing the appropriate probes resulted in the formation of a polymeric network of nanoparticles with a concomitant red-to-pinkish/purple color change. Hybridization was facilitated by freezing and thawing of the solutions, and the denaturation of these hybrid materials showed transition temperatures over a narrow range that allowed differentiation of a variety of imperfect targets. Transfer of the hybridization mixture to a reverse-phase silica plate resulted in a blue color upon drying that could be detected visually. The unoptimized system can detect about 10 femtomoles of an oligonucleotide.	NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208	Northwestern University			Mirkin, Chad A/E-3911-2010	Mirkin, Chad/0000-0002-6634-7627	NIGMS NIH HHS [GM 10265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010265, R37GM010265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; BRUST M, 1995, ADV MATER, V7, P795, DOI 10.1002/adma.19950070907; DUSEMUND B, 1991, Z PHYS D ATOM MOL CL, V20, P305, DOI 10.1007/BF01543997; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; Grabar KC, 1996, J AM CHEM SOC, V118, P1148, DOI 10.1021/ja952233+; GRABAR KC, 1995, ANAL CHEM, V67, P735, DOI 10.1021/ac00100a008; GRYAZNOV SM, 1993, J AM CHEM SOC, V115, P3808, DOI 10.1021/ja00062a070; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HAMES BD, 1995, GENES PROBES, V1; KREIBIG U, 1985, SURF SCI, V156, P678, DOI 10.1016/0039-6028(85)90239-0; Kricka L. J., 1992, NONISOTOPIC DNA PROB; MANSFIELD ES, 1995, MOL CELL PROBE, V9, P145, DOI 10.1006/mcpr.1995.0023; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; RAZIN S, 1994, MOL CELL PROBE, V8, P497, DOI 10.1006/mcpr.1994.1071; Storhoff J. J., 1997, J CLUST SCI, V8, P179; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; URDEA MS, 1988, NUCLEIC ACIDS RES, V16, P4937, DOI 10.1093/nar/16.11.4937; Wang J, 1996, J AM CHEM SOC, V118, P7667, DOI 10.1021/ja9608050; Weisbecker CS, 1996, LANGMUIR, V12, P3763, DOI 10.1021/la950776r; YANG WH, 1995, J CHEM PHYS, V103, P869, DOI 10.1063/1.469787	20	3827	4148	27	1702	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1078	1081		10.1126/science.277.5329.1078	http://dx.doi.org/10.1126/science.277.5329.1078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262471				2022-12-01	WOS:A1997XT03300028
J	Gabay, L; Seger, R; Shilo, BZ				Gabay, L; Seger, R; Shilo, BZ			In situ activation pattern of Drosophila EGF receptor pathway during development	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; SIGNALING PATHWAY; RHOMBOID GENE; CELL FATE; ECTODERM; HOMOLOG; ENCODES; KINASE; ESTABLISHMENT; MELANOGASTER	Signaling cascades triggered by receptor tyrosine kinases (RTKs) participate in diverse developmental processes. The active state of these signaling pathways was monitored by examination of the in situ distribution of the active, dual phosphorylated form of mitogen-activated protein kinase (ERK) with a specific monoclonal antibody. Detection of the active state of the Drosophila epidermal growth factor receptor (DER) pathway allowed the visualization of gradients and boundaries of receptor activation, assessment of the distribution of activating ligands, and analysis of interplay with the inhibitory ligand Argos. This in situ approach can be used to monitor other receptor-triggered pathways in a wide range of organisms.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science				Shilo, Ben Zion/0000-0003-4903-8889				BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; DIAZBENJUMEA FJ, 1990, P ROY SOC B-BIOL SCI, V242, P36, DOI 10.1098/rspb.1990.0100; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gabay L, 1997, DEVELOPMENT, V124, P3535; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; Golembo M, 1996, DEVELOPMENT, V122, P3363; Golembo M, 1996, DEVELOPMENT, V122, P223; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KOLODKIN AL, 1994, DEVELOPMENT, V120, P1731; NOLL R, 1994, DEVELOPMENT, V120, P2329; Okabe M, 1997, DEVELOPMENT, V124, P1045; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RAZ E, 1992, DEVELOPMENT, V114, P113; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Schnepp B, 1996, GENE DEV, V10, P2302, DOI 10.1101/gad.10.18.2302; Scholz H, 1997, MECH DEVELOP, V62, P79, DOI 10.1016/S0925-4773(96)00652-1; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Simcox AA, 1996, DEV BIOL, V177, P475, DOI 10.1006/dbio.1996.0179; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; Tio M, 1997, DEVELOPMENT, V124, P343; Xiao H, 1996, MECH DEVELOP, V58, P65, DOI 10.1016/S0925-4773(96)00559-X; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; zurLage P, 1997, CURR BIOL, V7, P166, DOI 10.1016/S0960-9822(97)70087-3	34	326	326	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1103	1106		10.1126/science.277.5329.1103	http://dx.doi.org/10.1126/science.277.5329.1103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262480				2022-12-01	WOS:A1997XT03300037
J	Jacobsen, SE; Meyerowitz, EM				Jacobsen, SE; Meyerowitz, EM			Hypermethylated SUPERMAN epigenetic alleles in Arabidopsis	SCIENCE			English	Article							HOMEOTIC GENES; THALIANA	Mutations in the SUPERMAN gene affect flower development in Arabidopsis. Seven heritable but unstable sup epi-alleles (the clark kent alleles) are associated with nearly identical patterns of excess cytosine methylation within the SUP gene and a decreased level of SUP RNA. Revertants of these alleles are largely demethylated at the SUP locus and have restored levels of SUP RNA. A transgenic Arabidopsis line carrying an antisense methyltransferase gene, which shows an overall decrease in genomic cytosine methylation, also contains a hypermethylated sup allele. Thus, disruption of methylation systems may yield more complex outcomes than expected and can result in methylation defects at known genes. The clark kent alleles differ from the antisense line because they do not show a general decrease in genomic methylation.	CALTECH,DIV BIOL 156 29,PASADENA,CA 91125	California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009					BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; FEIL R, 1994, NUCLEIC ACIDS RES, V22, P695, DOI 10.1093/nar/22.4.695; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; GAISER JC, 1995, PLANT CELL, V7, P333, DOI 10.1105/tpc.7.3.333; Huang H, 1997, PLANT CELL, V9, P115; Kakutani T, 1996, P NATL ACAD SCI USA, V93, P12406, DOI 10.1073/pnas.93.22.12406; KOORNNEEF M, 1982, MUTAT RES, V93, P109, DOI 10.1016/0027-5107(82)90129-4; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SAKAI H, COMMUNICATION; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832	17	348	370	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1100	1103		10.1126/science.277.5329.1100	http://dx.doi.org/10.1126/science.277.5329.1100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262479				2022-12-01	WOS:A1997XT03300036
J	RichEdwards, JW; Stampfer, MJ; Manson, JE; Rosner, B; Hankinson, SE; Colditz, GA; Willett, WC; Hennekens, CH				RichEdwards, JW; Stampfer, MJ; Manson, JE; Rosner, B; Hankinson, SE; Colditz, GA; Willett, WC; Hennekens, CH			Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; ADULT LIFE; BLOOD-PRESSURE; INFANT GROWTH; FETAL; DEATH; HYPERTENSION; CHILDHOOD; INUTERO	Objective: To examine the association between birth weight and non-fatal adult cardiovascular disease while controlling for potential confounders such as socioeconomic group and adult lifestyle. Design: Retrospective self report of birth weight in an ongoing longitudinal cohort of nurses followed up by postal questionnaire every two years. Setting: Nurses' health study, a cohort of 121 700 women followed up since 1976. Main outcome measures: Non-fatal cardiovascular disease, including myocardial infarction, coronary revascularisation, and stroke. Results: Among the 70 297 women free of cardiovascular disease at baseline who reported birth weight in the 1992 questionnaire there were 1309 first cases of non-fatal cardiovascular disease. Increasing birth weight was associated with decreasing risk of non-fatal cardiovascular disease. There were 1216 first cases of non-fatal cardiovascular disease among women who were singletons and had been born full term; their relative risks adjusted for several cardiovascular risk factors were 1.49 (95% confidence interval 1.05 to 2.10) for birth weight < 2268 g (< 5 lb 0 oz); 1.25 (0.98 to 1.61) for birth weight 2268-2495 g (5 lb 0 oz to 5 lb 8 oz); 1.12 (0.98 to 1.27) for birth weight > 2495-3175 g (> 5 lb 8 oz to 7 lb 0 oz); 1.00 (referent) for birth weight >3175-3856 g(>7 lb 0 oz to 8 lb 8 oz); 0.96 (0.80 to 1.15) for birth weight > 3856-4536 g (> 8 lb 8 oz to 10 lb 0 oz); and 0.68 (0.46 to 1.00) for birth weight > 4536 g (> 10 lb 0 oz) (P value for trend = 0.0004). The inverse trend was apparent for both coronary heart disease and stroke. Conclusions: These data Provide strong evidence of an association between birth weight and adult coronary heart disease and stroke.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02215; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL-07575, HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; COX DR, 1972, J R STAT SOC B, V34, P187; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HENNEKENS CH, 1979, LANCET, V1, P1301; HOLLAND FJ, 1993, J EPIDEMIOL COMMUN H, V47, P432, DOI 10.1136/jech.47.6.432; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P336; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Rich-Edwards J. W., 1996, American Journal of Epidemiology, V143, pS39; Rose GA., 1982, WHO MONOGRAPH SERIES, V58; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; US Census Bureau, 1994, STAT ABSTR US; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/BF00403383; Walker AE, 1981, STROKE S1, V12, pI13	23	574	590	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					396	400		10.1136/bmj.315.7105.396	http://dx.doi.org/10.1136/bmj.315.7105.396			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277603	Green Published			2022-12-01	WOS:A1997XR54900019
J	King, RW; Lustig, KD; Stukenberg, PT; McGarry, TJ; Kirschner, MW				King, RW; Lustig, KD; Stukenberg, PT; McGarry, TJ; Kirschner, MW			Expression cloning in the test tube	SCIENCE			English	Article									TULARIK INC,DEPT BIOL,S SAN FRANCISCO,CA 94080		King, RW (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.			Stukenberg, Todd/0000-0002-6788-2111				CRYNS V, COMMUNICATION; KING RW, 1997, Patent No. 5654150; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; MCGARRY T, UNPUB; MEAD P, COMMUNICATION; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; XUE D, COMMUNICATION	7	41	45	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					973	974		10.1126/science.277.5328.973	http://dx.doi.org/10.1126/science.277.5328.973			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9281074				2022-12-01	WOS:A1997XQ98500046
J	Steyer, JA; Horstmann, H; Almers, W				Steyer, JA; Horstmann, H; Almers, W			Transport, docking and exocytosis of single secretory granules in live chromaffin cells	NATURE			English	Article							NEUROTRANSMITTER RELEASE; VESICLE; ACTIN; SYNAPTOBREVIN; MICROSCOPY; CULTURE; QUANTA; POOL	Neurons maintain a limited pool of synaptic vesicles which are docked at active zones and are awaiting exocytosis(1-4). By contrast, endocrine cells releasing large, dense-core secretory granules have no active zones, and there is disagreement about the size(5) and even the existence(6) of the docked pool. It is not known how, and how rapidly, secretory vesicles are replaced at exocytic sites in either neurons or endocrine cells. By using electron microscopy, we have now been able to identify a pool of docked granules in chromaffin cells that is selectively depleted when cells secrete. With evanescent-wave fluorescence microscopy(7), we observed single granules undergoing exocytosis and leaving behind patches of bare plasmalemma. Fresh granules travelled to the plasmalemma at a top speed of 114 nm s(-1), taking an average of 6 min to arrive. On arrival, their motility diminished 4-food, probably as a result of docking. Some granules detached and returned to the cytosol. We conclude that a large pool of docked granules turns over slowly, that granules move actively to their docking sites, that docking is reversible, and that the 'rapidly releasable pool' measured electrophysiologically represents a small subset of docked granules.	MAX PLANCK INST MED RES,D-69120 HEIDELBERG,GERMANY	Max Planck Society								BETZ WJ, 1995, CURR BIOL, V5, P1098, DOI 10.1016/S0960-9822(95)00220-X; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; Chow Robert H., 1995, P245; EVANS LL, 1995, P NATL ACAD SCI USA, V92, P10954, DOI 10.1073/pnas.92.24.10954; GHOSH RN, 1994, BIOPHYS J, V66, P1301, DOI 10.1016/S0006-3495(94)80939-7; GILLIS KD, IN PRESS SEM CELL DE; GINGELL D, 1979, BIOPHYS J, V26, P507, DOI 10.1016/S0006-3495(79)85268-6; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; LEE RWH, 1981, NEUROSCIENCE, V6, P2087, DOI 10.1016/0306-4522(81)90048-8; Moser T, 1997, J NEUROSCI, V17, P2314; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; SCHROEDER TJ, 1994, J BIOL CHEM, V269, P17215; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; STOUT AL, 1989, APPL OPTICS, V28, P5237, DOI 10.1364/AO.28.005237; TERAKAWA S, 1991, NEUROSCI LETT, V123, P82, DOI 10.1016/0304-3940(91)90163-N; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754	24	349	354	2	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					474	478		10.1038/41329	http://dx.doi.org/10.1038/41329			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242406	Green Submitted, Bronze			2022-12-01	WOS:A1997XN55300049
J	Stager, CL; Werker, JF				Stager, CL; Werker, JF			Infants listen for more phonetic detail in speech perception than in word-learning tasks	NATURE			English	Article								Infants aged 4-6 months discriminate the fine phonetic differences that distinguish syllables in both their native and unfamiliar languages(1-3), but by 10-12 months their perceptual sensitivities are reorganized so that they discriminate only the phonetic variations that are used to distinguish meaning in their native language(12). It would seem, then, that infants apply their well honed phonetic sensitivities as they advance and begin to associate words with objects, but the question of how speech perception sensitivities are used in early word learning has not yet been answered. Here we use a recently developed technique to show that when they are required to pair words with objects, infants of 14 months fail to use the fine phonetic detail they detect in syllable discrimination tasks. In contrast, infants of 8 months-who are not yet readily learning words-successfully discriminate phonetic detail in the same task in which infants aged 14 months fail. Taken together, these results suggest a second reorganization in infants's use of phonetic detail as they move from listening to syllables to learning words.			Stager, CL (corresponding author), UNIV BRITISH COLUMBIA,DEPT PSYCHOL,2136 W MALL,VANCOUVER,BC V6T 1Z4,CANADA.			Werker, Janet F./0000-0002-1168-9013				Barton D., 1978, DEV COMMUNICATION, P255; BENEDICT H, 1979, J CHILD LANG, V6, P183, DOI 10.1017/S0305000900002245; CharlesLuce J, 1995, J CHILD LANG, V22, P727, DOI 10.1017/S0305000900010023; JUSCZYK PW, 1995, HDB PERCEPTION COGNI, V11, P263; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; OVIATT SL, 1980, CHILD DEV, V51, P97, DOI 10.1111/j.1467-8624.1980.tb02514.x; SPELKE ES, 1994, COGNITIVE NEUROSCIEN, P165; TURKEWITZ G, 1982, DEV PSYCHOBIOL, V15, P357, DOI 10.1002/dev.420150408; WERKER JF, 1984, INFANT BEHAV DEV, V7, P49, DOI 10.1016/S0163-6383(84)80022-3; WERKER JF, 1995, INVITATION COGNITIVE, P87; WOODWARD A, 1993, 24 ANN CHILD LANGUAG, P35; [No title captured]	12	479	483	3	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					381	382		10.1038/41102	http://dx.doi.org/10.1038/41102			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM528	9237755	Bronze			2022-12-01	WOS:A1997XM52800051
J	Barnes, CA; Suster, MS; Shen, JM; McNaughton, BL				Barnes, CA; Suster, MS; Shen, JM; McNaughton, BL			Multistability of cognitive maps in the hippocampus of old rats	NATURE			English	Article							MEMORY DYSFUNCTION; PLACE CELLS; WATER MAZE; PERFORMANCE; STABILITY	Hippocampal neurons provide a population code for location(1). In young rats, environments are reliably 'mapped' by groups of neurons that have firing locations ('place fields'(2)) that can be stable for several months(3). Old animals exhibit deficits in spatial memory, raising the question of whether the quality or stability of their hippocampal 'cognitive maps'(4) is altered. By recording from large groups of neurons, we observed the hippocampal spatial code to be multistable. In young rats, the place field maps were reliable both within and between episodes in a familiar environment. In old rats, place field maps were accurate and stable during an episode, but frequently exhibited complete rearrangements between episodes. In a spatial memory task, both young and old rats exhibited bimodal performance, consistent with map multistability early in training. However, the performance of young rats became almost unimodal with further training, whereas that of old rats remained markedly bimodal. The multistability of the hippocampal map provides an insight into the dynamics of neural coding in high-level cortical structures and their changes during ageing, and may provide an explanation for the frequent failure of place recognition in elderly humans.	UNIV ARIZONA,DEPT NEUROL,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PHYSIOL,TUCSON,AZ 85724; UNIV ARIZONA,DIV NEURAL SYST MEMORY & AGING,ARIZONA RES LABS,TUCSON,AZ 85724	University of Arizona; University of Arizona; University of Arizona	Barnes, CA (corresponding author), UNIV ARIZONA,DEPT PSYCHOL,LIFE SCI N BLDG,ROOM 384,TUCSON,AZ 85724, USA.							BARNES CA, 1983, NEUROBIOL AGING, V4, P113, DOI 10.1016/0197-4580(83)90034-9; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BARNES CA, 1994, TRENDS NEUROSCI, V17, P13, DOI 10.1016/0166-2236(94)90029-9; DETOLEDOMORRELL L, 1988, NEUROBIOL AGING, V9, P581, DOI 10.1016/S0197-4580(88)80117-9; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GEINISMAN Y, 1995, PROG NEUROBIOL, V45, P223, DOI 10.1016/0301-0082(94)00047-L; GOTHARD M, 1996, J NEUROSCI, V16, P8027; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; Kubie J. L., 1983, NEUROBIOLOGY HIPPOCA, P433; LANDFIELD PW, 1988, NEUROBIOL AGING, V9, P571, DOI 10.1016/S0197-4580(88)80116-7; MARKUS EJ, 1994, HIPPOCAMPUS, V4, P410, DOI 10.1002/hipo.450040404; McNaughton BL, 1996, J EXP BIOL, V199, P173; MCNAUGHTON BL, 1989, PSYCHOBIOLOGY, V17, P230; Mizumori SJY, 1996, BEHAV NEUROSCI, V110, P1006; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Muller R U, 1991, Hippocampus, V1, P243, DOI 10.1002/hipo.450010306; Nadel L., 1985, CONTEXT LEARNING, P385; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; QUIRK GJ, 1990, J NEUROSCI, V10, P2008; Rapp P. R., 1995, Society for Neuroscience Abstracts, V21, P1710; Samsonovich A. V., 1997, THESIS U ARIZONA; SHAPIRO ML, 1993, BEHAV NEUROSCI, V107, P34, DOI 10.1037/0735-7044.107.1.34; SHEN J, 1996, THESIS U ARIZONA; Skaggs W., 1993, ADV NEURAL INFORM PR, V5, P1030; SPENCER RL, 1995, BEHAV BRAIN RES, V68, P139, DOI 10.1016/0166-4328(94)00167-E; THOMPSON LT, 1990, BRAIN RES, V509, P299, DOI 10.1016/0006-8993(90)90555-P; Tsodyks M, 1995, INT J NEURAL SYS S, V6, P81; UTTL B, 1993, PSYCHOL AGING, V8, P257, DOI 10.1037/0882-7974.8.2.257; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	30	265	271	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					272	275		10.1038/40859	http://dx.doi.org/10.1038/40859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230435				2022-12-01	WOS:A1997XL12100050
J	Tsunoda, S; Sierralta, J; Sun, YM; Bodner, R; Suzuki, E; Becker, A; Socolich, M; Zuker, CS				Tsunoda, S; Sierralta, J; Sun, YM; Bodner, R; Suzuki, E; Becker, A; Socolich, M; Zuker, CS			A multivalent PDZ-domain protein assembles signalling complexes in a g-protein-coupled cascade	NATURE			English	Article							SIGNALING PROTEINS; PTB DOMAIN; DROSOPHILA; TRANSDUCTION; JUNCTIONS; HOMOLOG; SEPTATE; KINASES; MODULE; GENE	How are signalling molecules organized into different pathways within the same cell? In Drosophila, the inaD gene encodes a protein consisting of five PDZ domains which serves as a scaffold to assemble different components of the phototransduction cascade, including the principal fight-activated ion channels, the effector phospholipase C-beta and protein kinase C, Null inaD mutants have a dramatically reorganized subcellular distribution of signalling molecules, and a total loss of transduction complexes. Also, mutants defective in a single PDZ domain produce signalling complexes that lack the target protein and display corresponding defects in their physiology. A picture emerges of a highly organized unit of signalling, a 'transducisome', with PDZ domains functioning as key elements in the organization of transduction complexes in vivo.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV TOKYO,INST MED SCI,TOKYO,JAPAN	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Tokyo			Sierralta, Jimena Alejandra/AAG-8877-2021; Sierralta, Jimena/A-7591-2008	Sierralta, Jimena/0000-0002-0257-146X; Socolich, Michael/0000-0002-0702-1061; Suzuki, Emiko/0000-0002-4005-0542				BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI KY, 1994, CELL, V78, P499; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HUALING D, 1997, NATURE, V386, P279; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; JOHNSON EC, 1986, J GEN PHYSIOL, V88, P651, DOI 10.1085/jgp.88.5.651; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINKE B, 1994, COMMENTS THEOR BIOL, V3, P229; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Niethammer M, 1996, J NEUROSCI, V16, P2157; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; PAK WL, 1975, MUTANTS AFFECTING VI; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PRINTEN JA, 1994, GENETICS, V138, P309; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUZUKI E, 1993, J ELECTRON MICROSC, V42, P178; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; YEANDLE S, 1957, THESIS J HOPKINS U	50	538	549	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					243	249		10.1038/40805	http://dx.doi.org/10.1038/40805			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230432	Bronze			2022-12-01	WOS:A1997XL12100041
J	RochetteEgly, C; Adam, S; Rossignol, M; Egly, JM; Chambon, P				RochetteEgly, C; Adam, S; Rossignol, M; Egly, JM; Chambon, P			Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7	CELL			English	Article							RETINOIC ACID RECEPTOR; PROTEIN-KINASE; CELL-CYCLE; RESPONSE ELEMENT; IMMUNODETECTION	The activity of the N-terminal activation function AF-1 of RAR alpha 1 is abrogated upon mutation of a phosphorylatable serine residue (Ser-77). Recombinant RAR alpha was phosphorylated by a variety of proline-directed protein kinases in vitro. However, only the coexpression of cdk7 stimulated Ser-77 phosphorylation in vivo and enhanced transactivation by RAR alpha, but not by a S77A RAR mutant. Both free CAK (cdk7, cyclin H, MAT1) and the CAK-containing general transcription factor TFIIH phosphorylated Ser-77 in vitro. Furthermore RAR alpha bound free CAK and purified TFIIH in vitro, and RAR alpha-TFIIH complexes could be isolated from HeLa nuclear extracts. These findings represent the first example of activation of a transactivator through binding to and phosphorylation by a general transcription factor.			RochetteEgly, C (corresponding author), UNIV STRASBOURG 1,COLL FRANCE,INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,BP 163,F-67404 ILLKIRCH GRAFFENS,FRANCE.							Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DRAPKIN R, 1996, P NATL ACAD SCI UYS, V93, P6468; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; GRONEMEYER H, 1995, TRANSCRIPTION FACTOR, V3; HOELJMAKERS JHJ, 1996, CURR OPIN GENE DEV, V6, P26; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; READON JT, 1996, P NATL ACAD SCI USA, V93, P6482; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Warbrick E, 1996, CURR BIOL, V6, P1057, DOI 10.1016/S0960-9822(02)70663-5; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638	44	255	267	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					97	107		10.1016/S0092-8674(00)80317-7	http://dx.doi.org/10.1016/S0092-8674(00)80317-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230306	Bronze			2022-12-01	WOS:A1997XL36200012
J	Tsang, AP; Visvader, JE; Turner, CA; Fujiwara, Y; Yu, CN; Weiss, MJ; Crossley, M; Orkin, SH				Tsang, AP; Visvader, JE; Turner, CA; Fujiwara, Y; Yu, CN; Weiss, MJ; Crossley, M; Orkin, SH			FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation	CELL			English	Article							DNA-BINDING PROTEIN; HEMATOPOIETIC-CELLS; MAMMALIAN-CELLS; EXPRESSION; GENE; ASSOCIATION; NF-E2; MICE; LINEAGES; CLONING	The hematopoietic transcription factor GATA-1 is essential for development of the erythroid and megakaryocytic lineages. Using the conserved zinc finger DNA-binding domain of GATA-1 in the yeast two-hybrid system, we have identified a novel, multitype zinc finger protein, friend of GATA-1 (FOG), which binds GATA-1 but not a functionally inactive mutant lacking the amino (N) finger. FOG is coexpressed with GATA-1 during embryonic development and in erythroid and megakaryocytic cells. Furthermore, FOG and GATA-1 synergistically activate transcription from a hematopoietic-specific regulatory region and cooperate during both erythroid and megakaryocytic cell differentiation. These findings indicate that FOG acts as a cofactor for GATA-1 and provide a paradigm for the regulation of cell type-specific gene expression by GATA transcription factors.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute			Weiss, Mitchell J/W-9814-2018; Weiss, Mitchell J/A-1245-2013; Crossley, Merlin/D-7888-2011	Weiss, Mitchell J/0000-0003-2460-3036; Crossley, Merlin/0000-0003-2057-3642; Yu, Channing/0000-0002-3231-2565	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07753-18, T32 GM007753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Basson M, 1996, GENE DEV, V10, P1953, DOI 10.1101/gad.10.15.1953; Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Sambrook J., 1989, MOL CLONING LAB MANU; SHIVDASANI RA, 1997, IN PRESS EMBO J; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; TING KCN, 1996, NATURE, V384, P474; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; VISVADER JE, 1995, MOL CELL BIOL, V15, P634; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	51	588	604	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					109	119		10.1016/S0092-8674(00)80318-9	http://dx.doi.org/10.1016/S0092-8674(00)80318-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230307	Bronze			2022-12-01	WOS:A1997XL36200013
J	deGennes, PG				deGennes, PG			Polymer physics - Molecular individualism	SCIENCE			English	Editorial Material											deGennes, PG (corresponding author), ECOLE SUPER PHYS & CHIM IND VILLE PARIS,10 RUE VAUQUELIN,F-75231 PARIS 05,FRANCE.							BrochardWyart F, 1997, MRS BULL, V22, P48, DOI 10.1557/S0883769400032346; Ferry J. D., 1961, VISCOELASTIC PROPERT; KELLER A, 1985, COLLOID POLYM SCI, V263, P181, DOI 10.1007/BF01415506; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; STOCKMAYER WH, 1976, MOL FLUIDS, P107; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462	6	97	98	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 27	1997	276	5321					1999	1999		10.1126/science.276.5321.1999	http://dx.doi.org/10.1126/science.276.5321.1999			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XG748	9221507				2022-12-01	WOS:A1997XG74800048
J	Williams, PA; Fulop, V; Garman, EF; Saunders, NFW; Ferguson, SJ; Hajdu, J				Williams, PA; Fulop, V; Garman, EF; Saunders, NFW; Ferguson, SJ; Hajdu, J			Haem-ligand switching during catalysis in crystals of a nitrogen-cycle enzyme	NATURE			English	Article							NITRIC-OXIDE; THIOSPHAERA-PANTOTROPHA; ELECTRON-TRANSFER; CYTOCHROME CD(1); HEME-PROTEINS; REDUCTASE; PSEUDOAZURIN; BINDING; PROGRAM	Cytochrome cd(1) nitrite reductase catalyses the conversion of nitrite to nitric oxide in the nitrogen cycle(1,2). The crystal structure of the oxidized enzyme(3,4) shows that the d(1) haem iron of the active site is ligated by His/Tyr side chains, and the c haem iron is ligated by a His/His ligand pair. Here we show that both haems undergo re-ligation during catalysis, Upon reduction, the tyrosine ligand of the d(1) haem is released to allow substrate binding, Concomitantly, a refolding of the cytochrome c domain takes place, resulting in an unexpected change of the c haem iron coordination from His17/His69 to Met106/His69. This step is similar to the last steps in the folding of cytochrome c(5-8). The changes must affect the redox potential of the haems, and suggest a mechanism by which internal electron transfer is regulated, Structures of reaction intermediates show how nitric oxide is formed and expelled from the active-site iron, as well as how both haems return to their starting coordination. These results show how redox energy can be switched into conformational energy within a haem protein.	UNIV OXFORD,MOL BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QT,ENGLAND; UNIV UPPSALA,DEPT BIOCHEM,S-75123 UPPSALA,SWEDEN	University of Oxford; University of Oxford; University of Oxford; Uppsala University			Fulop, Vilmos/AAZ-7720-2021; Saunders, Neil/B-5325-2010	Saunders, Neil/0000-0003-2139-6107; Williams, Pamela/0000-0002-1257-2351; Garman, Elspeth/0000-0001-8329-5665	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADMAN ET, 1995, J BIOL CHEM, V270, P27458, DOI 10.1074/jbc.270.46.27458; Averill BA, 1996, CHEM REV, V96, P2951, DOI 10.1021/cr950056p; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; BERGER H, 1980, BIOCHIM BIOPHYS ACTA, V622, P355, DOI 10.1016/0005-2795(80)90047-1; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Colon W, 1996, BIOCHEMISTRY-US, V35, P5538, DOI 10.1021/bi960052u; EDWARDS SL, 1988, BIOCHEMISTRY-US, V27, P8074, DOI 10.1021/bi00421a016; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; Harutyunyan EH, 1996, J MOL BIOL, V264, P152, DOI 10.1006/jmbi.1996.0630; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Moore G., 1990, CYTOCHROMES C EVOLUT; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Pascher T, 1996, SCIENCE, V271, P1558, DOI 10.1126/science.271.5255.1558; PETTIGREW GW, 1987, CYTOCHROMES C BIOL A; PETTIGREW GW, 1987, CYTOCHROMES C EVOLUT; Poulos TL, 1996, NAT STRUCT BIOL, V3, P401, DOI 10.1038/nsb0596-401; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SILVESTRINI MC, 1982, BIOCHEM J, V203, P445, DOI 10.1042/bj2030445; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; Takahashi S, 1997, NAT STRUCT BIOL, V4, P44, DOI 10.1038/nsb0197-44; WILLIAMS PA, 1995, NAT STRUCT BIOL, V2, P975, DOI 10.1038/nsb1195-975; WILLIAMS PA, 1996, THESIS OXFORD U; Wittung P, 1996, FEBS LETT, V388, P47, DOI 10.1016/0014-5793(96)00513-3; Yeh SR, 1997, NAT STRUCT BIOL, V4, P51, DOI 10.1038/nsb0197-51	31	257	261	0	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					406	412		10.1038/38775	http://dx.doi.org/10.1038/38775			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311786				2022-12-01	WOS:A1997XX67500059
J	Bjorge, T; Dillner, J; Anttila, T; Engeland, A; Hakulinen, T; Jellum, E; Lehtinen, M; Luostarinen, T; Paavonen, J; Pukkala, E; Sapp, M; Schiller, J; Youngman, L; Thoresen, S				Bjorge, T; Dillner, J; Anttila, T; Engeland, A; Hakulinen, T; Jellum, E; Lehtinen, M; Luostarinen, T; Paavonen, J; Pukkala, E; Sapp, M; Schiller, J; Youngman, L; Thoresen, S			Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers	BRITISH MEDICAL JOURNAL			English	Article							ANAL EPIDERMOID CARCINOMA; SQUAMOUS-CELL CARCINOMA; INTRAEPITHELIAL NEOPLASIA; SERUM ANTIBODIES; UTERINE CERVIX; HPV DNA; TYPE-16; VULVA; INFECTION; EXPERIENCE	Objective: To evaluate the association between infection with the major oncogenic types of human papillomavirus and the risk of developing non-cervical anogenital cancers in a cohort followed up prospectively. Design: Data from two large serum banks to which about 700 000 people had donated serum samples were followed up for a mean of 8 years. People who developed non-cervical anogenital cancers during follow up were identified by registry linkage with the nationwide cancer registries in Finland and Norway Within this cohort a nested case-control study was conducted based on the serological diagnosis of infection with human papillomavirus types 16, 18, and 33. Subjects: 81 cases and 240 controls matched for sex, age, and storage time of serum samples. Main outcome measures: Odds ratios of developing non-cervical anogenital cancers in presence of IgG antibodies to specific micro-organisms. Results: Subjects seropositive far human. papillomavirus type 16 had an increased risk of developing non-cervical anogenital cancers (odds ratio 3.1 (95% confidence interval 1.4 to 6.9)). Subjects seropositive for type 33 also had an increased risk (odds ratio 2.8 (1.0 to 8.3)) but not significantly after adjustment for infection with type 16. Seropositivity for human papillomavirus type 16 was associated with an increased risk of developing vulvar and vaginal. cancers (odds ratio 4.5 (1.1 to 22)) and a strongly increased risk of developing preinvasive vulvar and vaginal lesions (odds ratio infinity (3.8 to infinity)). Seropositivity for human papillomavirus type 18 increased the risk of developing preinvasive lesions (odds ratio 12 (1.2 to 590)). High, but non-significant odds ratios for types 16 and 33 were seen for penile cancers. Conclusions: This study provides prospective seroepidemiological evidence that infection with human papillomavirus type 16 confers an increased risk of developing non-cervical genital cancers, particularly vulvar and vaginal cancers.	KAROLINSKA INST,MICROBIOL & TUMORBIOL CTR,S-17177 STOCKHOLM,SWEDEN; NATL PUBL HLTH INST,FIN-90101 OULU,FINLAND; KAROLINSKA INST,DEPT CANC EPIDEMIOL,S-17177 STOCKHOLM,SWEDEN; NORWEGIAN CANC SOC,JANUS COMM,N-0369 OSLO,NORWAY; NATL PUBL HLTH INST,DEPT INFECT DIS EPIDEMIOL,FIN-00300 HELSINKI,FINLAND; FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,FIN-00170 HELSINKI,FINLAND; UNIV HELSINKI HOSP,DEPT OBSTET & GYNECOL,FIN-00290 HELSINKI,FINLAND; UNIV TAMPERE,TAMPERE SCH PUBL HLTH,FIN-33101 TAMPERE,FINLAND; UNIV MAINZ,DEPT MED MICROBIOL,D-55101 MAINZ,GERMANY; NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; UNIV OXFORD,CLIN TRIALS SERV UNIT,OXFORD OX2 6HE,ENGLAND	Karolinska Institutet; Finland National Institute for Health & Welfare; Karolinska Institutet; Finland National Institute for Health & Welfare; Finnish Cancer Registry; University of Helsinki; Helsinki University Central Hospital; Tampere University; Johannes Gutenberg University of Mainz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oxford	Bjorge, T (corresponding author), CANC REGISTRY NORWAY,INST EPIDEMIOL CANC RES,N-0310 OSLO,NORWAY.		Schiller, John/ABK-8287-2022; Engeland, Anders/AAG-7437-2021	lehtinen, matti/0000-0002-9481-0535; Bjorge, Tone/0000-0002-9096-5257; van Tinteren, Harm/0000-0002-4626-8702; Paavonen, Jorma/0000-0003-4775-606X; Luostarinen, Tapio/0000-0003-3231-8550				AnderssonEllstrom A, 1996, SEX TRANSM DIS, V23, P234, DOI 10.1097/00007435-199605000-00013; ANDERSSONELLSTROM A, 1994, LANCET, V344, P1435, DOI 10.1016/S0140-6736(94)90601-7; ANSINK AC, 1994, GYNECOL ONCOL, V52, P180, DOI 10.1006/gyno.1994.1028; AYNAUD O, 1994, CANCER, V74, P1762, DOI 10.1002/1097-0142(19940915)74:6<1762::AID-CNCR2820740619>3.0.CO;2-1; BJORGE T, 1995, INT J CANCER, V62, P29, DOI 10.1002/ijc.2910620108; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1990, OBSTET GYNECOL, V75, P859; BRINTON LA, 1990, GYNECOL ONCOL, V38, P49, DOI 10.1016/0090-8258(90)90010-I; Cannistra SA, 1996, NEW ENGL J MED, V334, P1030, DOI 10.1056/NEJM199604183341606; CHENG G, 1995, J INFECT DIS, V172, P1584, DOI 10.1093/infdis/172.6.1584; Chua KL, 1996, INT J CANCER, V68, P54, DOI 10.1002/(SICI)1097-0215(19960927)68:1<54::AID-IJC11>3.0.CO;2-6; *CYT SOFTW CORP, 1993, LOGX TURB VERS 1 1, V1; Daling J R, 1992, IARC Sci Publ, P223; DILLNER J, 1995, CANCER J - FRANCE, V8, P264; Dillner J, 1996, J INFECT DIS, V173, P1394, DOI 10.1093/infdis/173.6.1394; DILLNER J, 1995, INT J CANCER, V60, P377; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; GRAHAM S, 1979, CANCER, V44, P1870, DOI 10.1002/1097-0142(197911)44:5<1870::AID-CNCR2820440546>3.0.CO;2-E; HEINO P, 1995, J NATL CANCER I, V87, P437, DOI 10.1093/jnci/87.6.437; HORDING U, 1994, GYNECOL ONCOL, V52, P241, DOI 10.1006/gyno.1994.1039; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; JELLUM E, 1995, ENVIRON HEALTH PERSP, V103, P85, DOI 10.2307/3432566; KIRNBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494, DOI 10.1093/jnci/86.7.494; Lehtinen M, 1996, BMJ-BRIT MED J, V312, P537, DOI 10.1136/bmj.312.7030.537; LI JY, 1982, JNCI-J NATL CANCER I, V69, P1063; MEHTA CR, 1995, STAT MED, V14, P2143, DOI 10.1002/sim.4780141908; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MESSING MJ, 1995, OBSTET GYNECOL, V86, P51, DOI 10.1016/0029-7844(95)00101-V; MILDELANGOSCH K, 1995, INT J CANCER, V63, P639, DOI 10.1002/ijc.2910630507; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; Trimble CL, 1996, OBSTET GYNECOL, V87, P59, DOI 10.1016/0029-7844(95)00351-7; WANG SP, 1970, AM J OPHTHALMOL, V70, P367, DOI 10.1016/0002-9394(70)90096-6; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	35	53	56	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					646	649		10.1136/bmj.315.7109.646	http://dx.doi.org/10.1136/bmj.315.7109.646			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310566	Green Published			2022-12-01	WOS:A1997XW69400019
J	Tramer, MR; Reynolds, DJM; Moore, RA; McQuay, HJ				Tramer, MR; Reynolds, DJM; Moore, RA; McQuay, HJ			Impact of covert duplicate publication on meta-analysis: a case study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTOPERATIVE NAUSEA; INTRAVENOUS ONDANSETRON; REDUNDANT PUBLICATION; MULTIPLE PUBLICATION; CONTROLLED TRIALS; PREVENTION; SURGERY; DROPERIDOL; PLACEBO; QUALITY	Objective: To quantify the impact of duplicate data on estimates of efficacy. Design: Systematic search for published full reports of randomised controlled trials investigating ondansetron's effect on postoperative emesis. Abstracts were not considered. Data sources: Eighty four-trials (11 980 patients receiving ondansetron) published between 1991 and September 1996. Main outcome measures: Percentage of duplicated trials and patient data. Estimation of antiemetic efficacy (prevention of emesis) of the most duplicated ondansetron regimen. Comparison between the efficacy of non-duplicated and duplicated data. Results: Data from nine trials had been published in 14 further reports, duplicating data from 3335 patients receiving ondansetron; none used a clear cross reference. Intravenous ondansetron 4 mg versus placebo was investigated in 16 reports not subject to duplicate publication three reports subject to duplicate publication, and six duplicates of those three reports. The number needed to treat to prevent vomiting within 24 hours was 9.5 (95% confidence interval 6.9 to 15) in the 16 non-duplicated reports and 3.9 (3.3 to 4.8) in the three reports which were duplicated (P < 0.00001). When these 19 were combined the number needed to treat was 6.4 (5.3 to 7.9). When all original and duplicate reports were combined (n = 25) the apparent number needed to treat improved to 4.9 (4.4 to 5.6). Conclusions: By searching systematically we found 17% of published full reports of randomised trials and 28% of the patient data were duplicated. Trials reporting greater treatment effect were significant more likely to be duplicated. Inclusion of duplicated data in meta-analysis led to a 23% overestimation of ondansetron's antiemetic efficacy.	JOHN RADCLIFFE HOSP, OXFORD OX3 9DU, ENGLAND	University of Oxford	Tramer, MR (corresponding author), CHURCHILL HOSP, NUFFIELD DEPT ANAESTHET, OXFORD OX3 7LJ, ENGLAND.							ANGELL M, 1989, NEW ENGL J MED, V320, P1212, DOI 10.1056/NEJM198905043201812; [Anonymous], 1979, BMJ-BRIT MED J, V1, P532; ASPINALL RL, 1995, BRIT MED J, V311, P844, DOI 10.1136/bmj.311.7009.844; Calamandrei M, 1994, Cah Anesthesiol, V42, P19; CALAMANDREI M, 1994, MINERVA ANESTESIO S1, V60, P37; Campbell C, 1995, AM J ANESTHESIOL, V22, P81; CLAYBON L, 1994, ANAESTHESIA, V49, P24, DOI 10.1111/j.1365-2044.1994.tb03579.x; Collini S., 1995, Acta Anaesthesiologica Italica, V46, P49; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DAVIS A, 1995, ANAESTH INTENS CARE, V23, P438, DOI 10.1177/0310057X9502300404; DERSHWITZ M, 1992, CLIN PHARMACOL THER, V52, P96, DOI 10.1038/clpt.1992.107; DERSHWITZ M, 1997, AMBULATORY ANESTHESI, P441; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIDONATO A, 1994, MINERVA ANESTHESI S1, V60, P61; Du Pen S, 1992, Eur J Anaesthesiol Suppl, V6, P55; DUPEYRON JP, 1993, ANAESTHESIA, V48, P214, DOI 10.1111/j.1365-2044.1993.tb06904.x; GIORGI L, 1994, MINERVA ANESTESIO S1, V60, P73; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; HELMERS JH, 1992, EUROPEAN J ANAEST S6, V9, P49; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; KENNY GNC, 1992, BRIT J ANAESTH, V68, P466, DOI 10.1093/bja/68.5.466; KHALIL SN, 1994, ANESTH ANALG, V79, P845; Kovac A, 1992, Eur J Anaesthesiol Suppl, V6, P37; Kovac AL, 1996, J CLIN ANESTH, V8, P644, DOI 10.1016/S0952-8180(96)00173-0; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEIZOROVICZ A, 1992, LANCET, V340, P1102, DOI 10.1016/0140-6736(92)93126-8; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V270, P2495, DOI 10.1001/jama.1993.03510200101040; MARKHAM A, 1993, DRUGS, V45, P931, DOI 10.2165/00003495-199345060-00006; MCKENZIE R, 1993, J CLIN ANESTH, V5, P30, DOI 10.1016/0952-8180(93)90084-R; MCKENZIE R, 1993, ANESTHESIOLOGY, V78, P21, DOI 10.1097/00000542-199301000-00005; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Melani A. M., 1995, Acta Anaesthesiologica Italica, V46, P37; PAECH MJ, 1995, ANAESTH INTENS CARE, V23, P548, DOI 10.1177/0310057X9502300503; PAXTON LD, 1995, ANAESTHESIA, V50, P403, DOI 10.1111/j.1365-2044.1995.tb05993.x; PEARMAN MH, 1994, ANAESTHESIA, V49, P11, DOI 10.1111/j.1365-2044.1994.tb03577.x; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCUDERI P, 1993, ANESTHESIOLOGY, V78, P15, DOI 10.1097/00000542-199301000-00004; Taddei F., 1995, Acta Anaesthesiologica Italica, V46, P43; Tramer M, 1997, BRIT J ANAESTH, V78, P247, DOI 10.1093/bja/78.3.247; Tramer MR, 1997, BRIT MED J, V314, P1088, DOI 10.1136/bmj.314.7087.1088; TRAMER MR, IN PRESS ANESTHESIOL; VOLPE N, 1994, DRUG INVEST, V8, P67, DOI 10.1007/BF03257429; VOLPE N, 1994, MINERVA ANESTESIO S1, V60, P121; WATCHA MF, 1995, EUR J ANAESTH, V12, P18; Zideman DA, 1996, MONATSSCHR KINDERH, V144, P727; ZIDEMAN DA, 1994, BRIT MED J, V308, P1349	47	451	455	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	1997	315	7109					635	640		10.1136/bmj.315.7109.635	http://dx.doi.org/10.1136/bmj.315.7109.635			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310564	Green Published			2022-12-01	WOS:A1997XW69400017
J	Unger, VM; Hargrave, PA; Baldwin, JM; Schertler, GFX				Unger, VM; Hargrave, PA; Baldwin, JM; Schertler, GFX			Arrangement of rhodopsin transmembrane alpha-helices	NATURE			English	Article							PROJECTION STRUCTURE; BOVINE RHODOPSIN; ACTIVATION; RESOLUTION; RECEPTORS; PROTEIN; TRANSDUCIN; DOMAIN	Rhodopsins(1), the photoreceptors in rod cells, are G-protein-coupled receptors with seven hydrophobic segments containing characteristic conserved sequence patterns that define a large family(2,3). Members of the family are expected to share a conserved transmembrane structure. Direct evidence for the arrangement of seven alpha-helices was obtained from a 9 Angstrom projection map of bovine rhodopsin(4). Structural constraints inferred from a comparison of G-protein-coupled receptor sequences were used to assign the seven hydrophobic stretches in the sequence to features in the projection map(5), A low-resolution three-dimensional structure of bovine rhodopsin(6) and two projection structures of frog rhodopsin(7) confirmed the position of the three least tilted helices, 4, 6 and 7, A more elongated peak of density for helix 5 indicated that it is tilted or bent(6,7), but helices 1, 2 and 3 were not resolved, Here we have used electron micrographs of frozen-hydrated two-dimensional frog rhodopsin crystals to determine the structure of frog rhodopsin, Seven rods of density in the map are used to estimate tilt angles for the seven helices. Density visible on the extracellular side of the membrane suggests a folded domain, Density extends from helix 6 on the intracellular side, and a short connection between helices 1 and 2, and possibly a part of the carboxy terminus, are visible.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV FLORIDA,DEPT OPHTHALMOL,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT BIOCHEM & MOL BIOL,GAINESVILLE,FL 32610	MRC Laboratory Molecular Biology; State University System of Florida; University of Florida; State University System of Florida; University of Florida			Schertler, Gebhard/M-9512-2014	Schertler, Gebhard F.X./0000-0002-5846-6810				Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; HAN M, 1995, BIOPHYS CHEM, V56, P23, DOI 10.1016/0301-4622(95)00011-L; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HARGRAVE PA, 1993, INT REV CYTOL B, V137, P49; HAVELKA WA, 1995, J MOL BIOL, V247, P726, DOI 10.1006/jmbi.1995.0176; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; THURMOND RL, 1997, P NATL ACAD SCI USA, V94, P1713; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YEAGLE PL, 1995, NAT STRUCT BIOL, V2, P832, DOI 10.1038/nsb1095-832; ZHANG HZ, 1994, J AM CHEM SOC, V116, P10165, DOI 10.1021/ja00101a040	26	446	452	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					203	206		10.1038/38316	http://dx.doi.org/10.1038/38316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296501				2022-12-01	WOS:A1997XV75700054
J	Villard, J; LisowskaGrospierre, B; vandenElsen, P; Fischer, A; Reith, W; Mach, B				Villard, J; LisowskaGrospierre, B; vandenElsen, P; Fischer, A; Reith, W; Mach, B			Mutation of RFXAP, a regulator of MHC class II genes, in primary MHC class II deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BARE LYMPHOCYTE SYNDROME; BINDING-PROTEIN; COOPERATIVE BINDING; X-BOX; COMPLEMENTATION; EXPRESSION; IMMUNODEFICIENCY; INDUCTION; PROMOTERS; REQUIRES	Background Major-histocompatibility - complex (MHC) class II deficiency is an autosomal recessive primary immunodeficiency disease in which MHC class II molecules are absent, It is a genetically heterogeneous disease of gene regulation resulting from defects in several transactivating genes that regulate the expression of MHC class II genes, The mutations responsible for MHC class II deficiency are classified according to complementation group (a group in which the phenotype remains uncorrected in pairwise fusions of cells), There are three known complementation groups (A, B, and C). Methods To elucidate the genetic defect in patients with MHC class II deficiency that was not classified genetically, we performed direct complementation assays with the three genes known to regulate the expression of MHC class II genes, CIITA, RFX5, and RFXAP, and the relevant mutations were identified in each patient. Results Mutations in the RFXAP gene were found in three patients from unrelated families, and the resulting defect was classified as belonging to a novel complementation group (D), Transfection with the wild-type RFXAP gene restored the expression of MHC class II molecules in the patients' cells. Conclusions Mutations in a novel MHC class II transactivating factor, RFXAP, can cause MHC class II deficiency. These mutations abolish the expression of MHC class II genes and lead to the same clinical picture of immunodeficiency as in patients with mutations in the other two MHC class II regulatory genes. (C) 1997, Massachusetts Medical Society.	UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,LOUIS JEANTET LAB MOL GENET,CH-1211 GENEVA 4,SWITZERLAND; HOP NECKER ENFANTS MALAD,INSERM,U429,PARIS,FRANCE; LEIDEN UNIV HOSP,DEPT IMMMUNOHEMATOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,BLOOD BANK,LEIDEN,NETHERLANDS	University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)								AMALDI I, 1989, J IMMUNOL, V142, P999; BENICHOU B, 1991, P NATL ACAD SCI USA, V88, P4285, DOI 10.1073/pnas.88.10.4285; CHENG YSE, 1986, J INTERFERON RES, V6, P417, DOI 10.1089/jir.1986.6.417; DEPREVAL C, 1985, NATURE, V318, P291, DOI 10.1038/318291a0; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GRISCELLI C, 1993, NEW CONCEPTS IMMUNOD, P177; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HAUBER I, 1995, J EXP MED, V181, P1411, DOI 10.1084/jem.181.4.1411; KLEIN C, 1995, BLOOD, V85, P580; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LISOWSKAGROSPIERRE B, 1994, HUM MOL GENET, V3, P953, DOI 10.1093/hmg/3.6.953; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; PEIJNENBURG A, 1995, IMMUNOGENETICS, V41, P287, DOI 10.1007/BF00172153; REITH W, 1994, J BIOL CHEM, V269, P20020; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; SEIDL C, 1992, J IMMUNOL, V148, P1576; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/S0092-8674(05)80090-X; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TOURAINE JL, 1981, HUM IMMUNOL, V2, P147, DOI 10.1016/0198-8859(81)90061-6; TOURAINE JL, 1978, J PEDIATR-US, V93, P47, DOI 10.1016/S0022-3476(78)80598-8; VILLARD J, IN PRESS HUM MUTAT; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10934, DOI 10.1093/nar/16.22.10934; WOLF HM, 1995, NEW ENGL J MED, V332, P86, DOI 10.1056/NEJM199501123320204	30	57	59	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	1997	337	11					748	753		10.1056/NEJM199709113371104	http://dx.doi.org/10.1056/NEJM199709113371104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV174	9287230				2022-12-01	WOS:A1997XV17400004
J	Hickman, M; Sutcliffe, H; Sondhi, A; Stimson, GV				Hickman, M; Sutcliffe, H; Sondhi, A; Stimson, GV			Validation of a regional drug misuse database: implications for policy and surveillance of problem drug use in the UK	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Hickman, M (corresponding author), IMPERIAL COLL SCH MED, DEPT SOCIAL SCI & MED, CTR RES DRUGS & HLTH BEHAV, LONDON SW6 1RQ, ENGLAND.		Hickman, Matthew/Y-2400-2019	Hickman, Matthew/0000-0001-9864-459X; Sondhi, Arun/0000-0002-4748-5522				CRABBE T, 1995, INT J DRUG POLICY, V6, P31; DONMALL M, 1990, DRUG MISUSE DATABASE; Home Office, 1995, TACKLING DRUGS TOGET; STIMSON GV, 1995, SOC SCI MED, V41, P699, DOI 10.1016/0277-9536(94)00435-V; SUTTON M, 1993, ADDICTION, V88, P455, DOI 10.1111/j.1360-0443.1993.tb02051.x	5	12	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	1997	315	7108					581	581						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV717	9302956				2022-12-01	WOS:A1997XV71700026
J	Cooper, GW; Thiemens, MH; Jackson, TL; Chang, S				Cooper, GW; Thiemens, MH; Jackson, TL; Chang, S			Sulfur and hydrogen isotope anomalies in meteorite sulfonic acids	SCIENCE			English	Article							MURCHISON METEORITE; CARBONACEOUS CHONDRITES; HYDROCARBONS; MONOSULFIDE; CHEMISTRY; OZONE	Intramolecular carbon, hydrogen, and sulfur isotope ratios were measured on a homologous series of organic sulfonic acids discovered in the Murchison meteorite. Mass independent sulfur isotope fractionations were observed along with high deuterium/hydrogen ratios. The deuterium enrichments indicate formation of the hydrocarbon portion of these compounds in a low-temperature environment that is consistent with that of interstellar clouds. Sulfur-33 enrichments observed in methanesulfonic acid could have resulted from gas-phase ultraviolet irradiation of a precursor, carbon disulfide, The source of the sulfonic acid precursors may have been the reactive interstellar molecule carbon monosulfide.	NASA, AMES RES CTR, MOFFETT FIELD, CA 94035 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of California System; University of California San Diego	Cooper, GW (corresponding author), SETI INST, MS 239-4, MOFFETT FIELD, CA 94035 USA.							BOHN RB, 1992, J AM CHEM SOC, V114, P6452, DOI 10.1021/ja00042a024; BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; COLEMAN ML, 1978, ANAL CHEM, V50, P1594, DOI 10.1021/ac50033a056; Colman JJ, 1996, SCIENCE, V273, P774, DOI 10.1126/science.273.5276.774; Cooper G. W., 1995, LPS, VXXVI, P281; COOPER GW, 1995, GEOCHIM COSMOCHIM AC, V59, P1003, DOI 10.1016/0016-7037(95)00018-6; COOPER GW, 1992, GEOCHIM COSMOCHIM AC, V56, P4109, DOI 10.1016/0016-7037(92)90023-C; COOPER GW, 1995, METEORITICS, V30, P500; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; DESORGO M, 1965, CAN J CHEMISTRY, V43, P1886; EPSTEIN S, 1987, NATURE, V326, P477, DOI 10.1038/326477a0; GAO X, 1993, GEOCHIM COSMOCHIM AC, V57, P3159, DOI 10.1016/0016-7037(93)90300-L; Gao X., 1991, GEOCHIM COSMOCHIM AC, V55, P2671, DOI DOI 10.1016/0016-7037(91)90381-E; HAYES JM, 1968, GEOCHIM COSMOCHIM AC, V32, P239, DOI 10.1016/S0016-7037(68)80006-7; HEIDENREICH JE, 1986, J CHEM PHYS, V84, P2129, DOI 10.1063/1.450373; HOGG MAP, 1958, J CHEM SOC, P4196; KLABUNDE KJ, 1989, PHOSPHORUS SULFUR, V43, P47, DOI 10.1080/10426508908040278; MAUERSBERGER K, 1993, GEOPHYS RES LETT, V20, P1031, DOI 10.1029/93GL01080; MOLTZEN EK, 1988, CHEM REV, V88, P391, DOI 10.1021/cr00084a003; STEUDEL R, 1966, Z NATURFORSCH B, V218, P1106; STUDIER MH, 1972, GEOCHIM COSMOCHIM AC, V36, P189; THIEMENS MH, 1994, METEORITICS, V29, P540; THIEMENS MH, 1995, LUNAR PLANET SCI, V26, P1405; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WHITE CM, 1974, THESIS U N DAKOTA GR; Xu X., UNPUB; YUEN G, 1984, NATURE, V307, P252, DOI 10.1038/307252a0	27	69	70	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1072	1074		10.1126/science.277.5329.1072	http://dx.doi.org/10.1126/science.277.5329.1072			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262469	Green Submitted			2022-12-01	WOS:A1997XT03300026
J	Korolev, S; Hsieh, J; Gauss, GH; Lohman, TM; Waksman, G				Korolev, S; Hsieh, J; Gauss, GH; Lohman, TM; Waksman, G			Major domain swiveling revealed by the crystal structures of complexes of E-coli Rep helicase bound to single-stranded DNA and ADP	CELL			English	Article							ADENINE-NUCLEOTIDE BINDING; XERODERMA-PIGMENTOSUM; INDUCED DIMERIZATION; KINETIC MECHANISM; EXCISION-REPAIR; UVRD PROTEINS; SEQUENCE; MONOMER; HYDROLYSIS; PROGRAM	Crystal structures of binary and ternary complexes of the E. coli Rep helicase bound to single-stranded (ss) DNA or ssDNA and ADP were determined to a resolution of 3.0 Angstrom and 3.2 Angstrom, respectively. The asymmetric unit in the crystals contains two Rep monomers differing from each other by a large reorientation of one of the domains, corresponding to a swiveling of 130 degrees about a hinge region. Such domain movements are sufficiently large to suggest that these may be coupled to translocation of the Rep dimer along DNA. The ssDNA binding site involves the helicase motifs la, Iii, and V, whereas the ADP binding site involves helicase motifs I and IV. Residues in motifs II and VI may function to transduce the allosteric effects of nucleotides on DNA binding. These structures represent the first view of a DNA helicase bound to DNA.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOL BIOPHYS, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Korolev, Sergey/ABA-7517-2020	Korolev, Sergey/0000-0001-9313-7126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054033, R01GM045948] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045948, GM54033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Bjornson KP, 1996, BIOCHEMISTRY-US, V35, P2268, DOI 10.1021/bi9522763; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; Brunger A.T., 1992, X PLOR VERSION 3 1 M; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHAO KL, 1990, J BIOL CHEM, V265, P1067; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GILCHRIST CA, 1987, NUCLEIC ACIDS RES, V15, P465, DOI 10.1093/nar/15.2.465; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1996, NATURE, V379, P621; LANE HED, 1974, J BACTERIOL, V120, P805, DOI 10.1128/JB.120.2.805-814.1974; LANE HED, 1975, J MOL BIOL, V97, P99; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; WONG I, 1992, J BIOL CHEM, V267, P7596; WONG I, 1993, J BIOL CHEM, V268, P20386; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Wong I, 1997, BIOCHEMISTRY-US, V36, P3115, DOI 10.1021/bi9621977; Wong I, 1996, P NATL ACAD SCI USA, V93, P10051, DOI 10.1073/pnas.93.19.10051; Wong I, 1996, BIOCHEMISTRY-US, V35, P5726, DOI 10.1021/bi952959i; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	49	431	450	2	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					635	647		10.1016/S0092-8674(00)80525-5	http://dx.doi.org/10.1016/S0092-8674(00)80525-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288744	Bronze			2022-12-01	WOS:A1997XT06600008
J	Luo, JM; Sladek, R; Bader, JA; Matthyssen, A; Rossant, J; Giguere, V				Luo, JM; Sladek, R; Bader, JA; Matthyssen, A; Rossant, J; Giguere, V			Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta	NATURE			English	Article							STEM-CELLS; MICE; IDENTIFICATION; TROPHOBLAST; PROTEIN; GENES	Classical endocrine studies have shown that steroid hormones are required for the maintenance of pregnancy and placental viability. The oestrogen-receptor-related receptor beta (ERR-beta) is an orphan member of the superfamily of nuclear hormone receptors(1) Although ERR-beta is homologous to the oestrogen receptor and binds the oestrogen response element(2), it is not activated by oestrogens'. Expression of ERR-beta during embryogenesis defines a subset of extra-embryonic ectoderm that subsequently forms the dome of the chorion, suggesting that ERR-beta may be involved in early placental development. Homozygous mutant embryos generated by targeted disruption of the Estrrb gene have severely impaired placental formation, and die at 10.5 days post-coitum. The mutants display abnormal chorion development associated with an overabundance of trophoblast giant cells and a severe deficiency of diploid trophoblast. The phenotype can be rescued by aggregation of Estrrb mutant embryos with tetraploid wildtype cells, which contribute exclusively to extra-embryonic tissues. Our results indicate that ERR-beta has an important role in early placentation, and suggest that an inductive signal originating from or modified by the chorion is required for normal trophoblast proliferation and differentiation.	ROYAL VICTORIA HOSP,MOL ONCOL GRP,MONTREAL,PQ H3A 1A1,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1A8,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; Royal Victoria Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; McGill University; McGill University			Sladek, Robert/R-2391-2019	Sladek, Robert/0000-0002-2730-1204; Giguere, Vincent/0000-0001-9567-3694				COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; FINNERTY H, 1993, ONCOGENE, V8, P2293; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; ILGREN EB, 1983, PLACENTA, V4, P307, DOI 10.1016/S0143-4004(83)80010-1; ILGREN EB, 1981, J EMBRYOL EXP MORPH, V62, P183; Kaufman M.H., 1992, ATLAS MOUSE DEV; LESCISIN KR, 1988, GENE DEV, V2, P1639, DOI 10.1101/gad.2.12a.1639; LINZER DIH, 1985, P NATL ACAD SCI USA, V82, P4356, DOI 10.1073/pnas.82.13.4356; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 1993, Gene targeting: a practical approach., P147; PARAMITHIOTIS E, 1994, EUR J IMMUNOL, V24, P458, DOI 10.1002/eji.1830240229; Pettersson K, 1996, MECH DEVELOP, V54, P211, DOI 10.1016/0925-4773(95)00479-3; ROSSANT J, 1981, J EMBRYOL EXP MORPH, V62, P217; ROSSANT J, 1977, J EMBRYOL EXP MORPH, V39, P183; Speroff L, 1994, CLIN GYNECOLOGIC END, V5th; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Yen S. S. C., 1991, REPROD ENDOCRINOLOGY	23	321	333	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					778	782		10.1038/42022	http://dx.doi.org/10.1038/42022			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285590	Bronze			2022-12-01	WOS:A1997XR66700052
J	Palsboll, PJ; Allen, J; Berube, M; Clapham, PJ; Feddersen, TP; Hammond, PS; Hudson, RR; Jorgensen, H; Katona, S; Larsen, AH; Larsen, F; Lien, J; Mattila, DK; Sigurjonsson, J; Sears, R; Smith, T; Sponer, R; Stevick, P; Oien, N				Palsboll, PJ; Allen, J; Berube, M; Clapham, PJ; Feddersen, TP; Hammond, PS; Hudson, RR; Jorgensen, H; Katona, S; Larsen, AH; Larsen, F; Lien, J; Mattila, DK; Sigurjonsson, J; Sears, R; Smith, T; Sponer, R; Stevick, P; Oien, N			Genetic tagging of humpback whales	NATURE			English	Article							MEGAPTERA-NOVAEANGLIAE; SIMPLE SEQUENCES; DNA; POPULATION; MAINE; GULF	The ability to recognize individual animals has substantially increased our knowledge of the biology and behaviour of many taxa(1). However, not all species lend themselves to this approach, either because of insufficient phenotypic variation or because tag attachment is not feasible. The use of genetic markers ('tags') represents a viable alternative to traditional methods of individual recognition, as they are permanent and exist in all individuals. We tested the use of genetic markers as the primary means of identifying individuals in a study of humpback whales in the North Atlantic Ocean. Analysis of six microsatellite loci(2,3) among 3,060 skin samples collected throughout this ocean allowed the unequivocal identification of individuals. Analysis of 692 'recaptures', identified by their genotype, revealed individual local and migratory movements of up to 10,000 km, limited exchange among summer feeding grounds, and mixing in winter breeding areas, and also allowed the first estimates of animal abundance based solely on genotypic data. Our study demonstrates that genetic tagging is not only feasible, but generates data (for example, on sex) that can be valuable when interpreting-the results of tagging experiments.	COLL ATLANTIC,BAR HARBOR,ME 04609; DEPT NAT RESOURCES SCI,ST ANNE BELLEVUE,PQ H9X 3V9,CANADA; CTR COASTAL STUDIES,PROVINCETOWN,MA 02657; UNIV ST ANDREWS,SEA MAMMAL RES UNIT,ST ANDREWS KY16 9LB,FIFE,SCOTLAND; UNIV CALIF IRVINE,DEPT ECOL & EVOLUTIONARY BIOL,IRVINE,CA 92697; GREENLAND INST NAT RESOURCES,NUUK 3900,GREENLAND; MEM UNIV NEWFOUNDLAND,WHALE RES GRP,ST JOHNS,NF A1B 3X9,CANADA; MARINE RES INST,IS-121 REYKJAVIK,ICELAND; MINGAN ISL CETACEAN STUDY INC,ST LAMBERT,PQ J4P 1T3,CANADA; NATL MARINE FISHERIES SERV,NE FISHERIES SCI CTR,WOODS HOLE,MA 02543; INST MARINE RES,N-5024 BERGEN,NORWAY	University of St Andrews; University of California System; University of California Irvine; Greenland Institute of Natural Resources; Memorial University Newfoundland; Marine & Freshwater Research Institute (MFRI); National Oceanic Atmospheric Admin (NOAA) - USA; Institute of Marine Research - Norway	Palsboll, PJ (corresponding author), DEPT POPULAT BIOL,UNIV PK 15,DK-2100 COPENHAGEN,DENMARK.		Palsbøll, Per J/L-3494-2013; Palsboll, Per J/G-6988-2011	Palsbøll, Per J/0000-0002-4198-7599; Palsboll, Per J/0000-0002-4198-7599; Berube, Martine/0000-0002-1831-2657; Larsen, Finn/0000-0001-6498-9012				AMOS B, 1993, SCIENCE, V260, P670, DOI 10.1126/science.8480176; Barlow J, 1997, ECOLOGY, V78, P535; Berube M, 1996, MOL ECOL, V5, P283; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P1065, DOI 10.1139/z93-142; CLAPHAM PJ, 1993, MAR MAMMAL SCI, V9, P213, DOI 10.1111/j.1748-7692.1993.tb00448.x; Clapham PJ, 1997, P ROY SOC B-BIOL SCI, V264, P95, DOI 10.1098/rspb.1997.0014; CLAPHAM PJ, 1995, MAR MAMMAL SCI, V11, P227, DOI 10.1111/j.1748-7692.1995.tb00520.x; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P440, DOI 10.1139/z93-063; CONSTABLE JJ, 1995, NATURE, V373, P393, DOI 10.1038/373393a0; GERLOFF U, 1995, MOL ECOL, V4, P515, DOI 10.1111/j.1365-294X.1995.tb00247.x; Hammond PS, 1990, REPORT INT WHALING C, P440; Katona, 1990, REPORT INT WHALING C, V12, P295; Katona S.K., 1981, Polar Record, V20, P439; LAMBERTSEN RH, 1987, J MAMMAL, V68, P443, DOI 10.2307/1381495; LARSEN AH, 1996, P R SOC LOND B, V263, P611; Maniatis T., 1982, MOL CLONING; MATTILA DK, 1989, CAN J ZOOL, V67, P281, DOI 10.1139/z89-041; MORIN PA, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P63; PAETKAU D, 1994, MOL ECOL, V3, P489, DOI 10.1111/j.1365-294X.1994.tb00127.x; Palsboll P.J., 1991, Reports of the International Whaling Commission Special Issue, P71; PALSBOLL PJ, 1995, MAR ECOL PROG SER, V116, P1, DOI 10.3354/meps116001; PALSBOLL PJ, IN PRESS MOL ECOL; ROY MS, 1994, MOL BIOL EVOL, V11, P553; Seber GAF, 1982, ESTIMATION ANIMAL AB, V2; STEVICK PT, IN PRESS MAR MAMM SC; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEBER JL, 1989, AM J HUM GENET, V44, P388	28	209	227	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					767	769		10.1038/42005	http://dx.doi.org/10.1038/42005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285587	Green Submitted, Bronze			2022-12-01	WOS:A1997XR66700049
J	Ledent, C; Vaugeois, JM; Schiffmann, SN; Pedrazzini, T; ElYacoubi, M; Vanderhaeghen, JJ; Costentin, J; Heath, JK; Vassart, G; Parmentier, M				Ledent, C; Vaugeois, JM; Schiffmann, SN; Pedrazzini, T; ElYacoubi, M; Vanderhaeghen, JJ; Costentin, J; Heath, JK; Vassart, G; Parmentier, M			Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A(2a) receptor	NATURE			English	Article							GENE-EXPRESSION; CAFFEINE; RAT; STRIATUM; AGONISTS; CLONING; NEURONS; BRAIN	Adenosine is released from metabolically active cells by facilitated diffusion, and is generated extracellularly by degradation of released ATP. It is a potent biological mediator that modulates the activity of numerous cell types, including various neuronal populations, platelets, neutrophils and mast cells, and smooth muscle cells in bronchi and vasculatue. Most of these effects help to protect cells and tissues during stress conditions such as ischaemia. Adenosine mediates its effects through four receptor subtypes: the A(1), A(2a), A(2b) and A(3) receptors(1). The A(2a) receptor (A(2a)R)(2,3) is abundant in basal ganglia, vasculature and platelets, and stimulates adenylyl cyclase. It is a major target of caffeine, the most widely used psychoactive drug(4). Here we investigate the role of the A(2a) receptor by disrupting the gene in mice. Here found that A(2a)R-knockout (A(2a)R(-/-)) mice were viable and bred normally. Their exploratory activity was reduced, whereas caffeine, which normally stimulates exploratory behaviour, became a depressant of exploratory activity. Knockout animals scored higher in anxiety tests, and male mice were much more aggressive towards intruders. The response of A(2a)R(-/-) mice to acute pain stimuli was slower. Blood pressure and heart rate were increased, as well as platelet aggregation. The specific A(2a) agonist CGS 21680 lost its biological activity in all systems tested.	FREE UNIV BRUSSELS, IRIBHN, LAB RECH NEUROPEPTIDES, B-1070 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, SERV GENET MED, B-1070 BRUSSELS, BELGIUM; FAC MED & PHARM, IFRMP,UNITE NEUROPSYCHOPHARMACOL EXPT,CNRS, UPRESA 6036, F-76803 ST ETIENNE DU ROUVRAY, FRANCE; UNIV LAUSANNE, SCH MED, DIV HYPERTENS, CH-1011 LAUSANNE, SWITZERLAND; UNIV OXFORD, DEPT BIOCHEM, CRC GROWTH FACTORS, OXFORD OX1 3QU, ENGLAND	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); University of Lausanne; University of Oxford				Schiffmann, Serge/0000-0002-0118-9816; Parmentier, Marc/0000-0001-8081-4685; EL YACOUBI, Malika/0000-0002-1010-9179; Vaugeois, Jean-Marie/0000-0001-8296-672X				BALK JH, 1995, NATURE, V377, P424; COSTENTIN J, 1986, EUR J PHARMACOL, V123, P37, DOI 10.1016/0014-2999(86)90684-9; CRISTALLI G, 1994, N-S ARCH PHARMACOL, V349, P644, DOI 10.1007/PL00004904; DELANDER GE, 1994, J PHARMACOL EXP THER, V268, P943; DIONISOTTI S, 1992, N-S ARCH PHARMACOL, V346, P673; FILE SE, 1988, PHARMACOL BIOCHEM BE, V30, P809, DOI 10.1016/0091-3057(88)90104-9; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; FREDHOLM BB, 1995, PHARMACOL TOXICOL, V76, P93, DOI 10.1111/j.1600-0773.1995.tb00111.x; FURLONG TJ, 1992, MOL BRAIN RES, V15, P62, DOI 10.1016/0169-328X(92)90152-2; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; HOPKER VH, 1995, NEUROREPORT, V6, P1153; JAIN N, 1995, BRIT J PHARMACOL, V116, P2127, DOI 10.1111/j.1476-5381.1995.tb16421.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MCQUEEN DS, 1986, BRIT J PHARMACOL, V88, P615, DOI 10.1111/j.1476-5381.1986.tb10242.x; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIKODIJEVIC O, 1993, PHARMACOL BIOCHEM BE, V44, P199, DOI 10.1016/0091-3057(93)90299-9; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6; PALMOUR RM, 1989, LIFE SCI, V44, P1293, DOI 10.1016/0024-3205(89)90367-6; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SAWYNOK J, 1993, PHARMACOL REV, V45, P43; SCHIFFMANN SN, 1992, J COMP NEUROL, V317, P117, DOI 10.1002/cne.903170202; SCHIFFMANN SN, 1993, J NEUROSCI, V13, P1080; SWEENEY MI, 1987, EUR J PHARMACOL, V141, P169, DOI 10.1016/0014-2999(87)90428-6; Varani K, 1996, BRIT J PHARMACOL, V117, P1693, DOI 10.1111/j.1476-5381.1996.tb15341.x; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WORST W, 1993, GENE TARGETING PRACT, P33	28	720	747	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	1997	388	6643					674	678		10.1038/41771	http://dx.doi.org/10.1038/41771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262401	Bronze			2022-12-01	WOS:A1997XQ86300049
J	Davies, SW; Turmaine, M; Cozens, BA; DiFiglia, M; Sharp, AH; Ross, CA; Scherzinger, E; Wanker, EE; Mangiarini, L; Bates, GP				Davies, SW; Turmaine, M; Cozens, BA; DiFiglia, M; Sharp, AH; Ross, CA; Scherzinger, E; Wanker, EE; Mangiarini, L; Bates, GP			Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation	CELL			English	Article							DISEASE GENE HOMOLOG; IT15 PROTEIN PRODUCT; HUNTINGTONS-DISEASE; EMBRYONIC LETHALITY; CAUDATE-NUCLEUS; BRAIN; EXPRESSION; LOCALIZATION; REPEAT; EXPANSION	Huntington's disease (HD) is one of an increasing number of human neurodegenerative disorders caused by a CAG/polyglutamine-repeat expansion. The mutation occurs in a gene of unknown function that is expressed in a wide range of tissues. The molecular mechanism responsible for the delayed onset, selective pattern of neuropathology, and cell death observed in HD has not been described. We have observed that mice transgenic for exon 1 of the human Ho gene carrying (GAG)(115) to (CAG)(156) repeat expansions develop pronounced neuronal intranuclear inclusions, containing the proteins huntingtin and ubiquitin, prior to developing a neurological phenotype. The appearance in transgenic mice of these inclusions, followed by characteristic morphological change within neuronal nuclei, is strikingly similar to nuclear abnormalities observed in biopsy material from HD patients.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114; JOHNS HOPKINS UNIV,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOL GENET,LONDON SE1 9RT,ENGLAND; MAX PLANCK INST MOL GENET,BERLIN,DAHLEM,GERMANY	Harvard University; Harvard Medical School; Massachusetts General Hospital; Johns Hopkins University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Max Planck Society	Davies, SW (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Ross, Christopher A/H-8395-2013; Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305; Wanker, Erich/0000-0001-8072-1630	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALZHEIMER A, 1911, Z GES NEUROL PSYCH, V3, P566; [Anonymous], ADV NEUROL; ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; BATES GP, 1997, IN PRESS HUM MOL GEN; Bhide PG, 1996, J NEUROSCI, V16, P5523; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruyn GW, 1987, ACTA NEUROPATHOL, V5, P21; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; DELAMONTE SM, 1988, J NEUROPATH EXP NEUR, V47, P516, DOI 10.1097/00005072-198809000-00003; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Ebling FJP, 1996, BRAIN RES BULL, V41, P257, DOI 10.1016/S0361-9230(96)00192-X; FORNO LS, 1979, ADV NEUROL, V23, P95; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HADREEN JC, 1995, J NEUROPATHOL EXP NE, V54, P105; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22; Hollen KM, 1997, MOL BRAIN RES, V47, P31, DOI 10.1016/S0169-328X(97)00034-X; *HUNT DIS COLL RES, 1993, CELL, V72, P971; IDE K, 1995, BIOCHEM BIOPH RES CO, V209, P1119, DOI 10.1006/bbrc.1995.1613; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; KEMP JM, 1971, PHILOS T R SOC B, V262, P383, DOI 10.1098/rstb.1971.0102; KOSINSKI CM, 1997, IN PRESS EXP NEUROL; KOWALL NW, 1987, TRENDS NEUROSCI, V10, P24, DOI 10.1016/0166-2236(87)90120-2; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; LOWE J, 1989, NEUROSCI LETT, V105, P7, DOI 10.1016/0304-3940(89)90003-7; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MYERS RH, 1991, J NEUROPATH EXP NEUR, V50, P729, DOI 10.1097/00005072-199111000-00005; MYERS RH, 1988, NEUROLOGY, V38, P341, DOI 10.1212/WNL.38.3.341; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; ROOS RAC, 1983, J NEUROL SCI, V61, P37, DOI 10.1016/0022-510X(83)90053-9; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHILLING G, 1995, HUM MOL GENET, V4, P1365, DOI 10.1093/hmg/4.8.1365; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3952, DOI 10.1073/pnas.87.10.3952; TELLEZNAGEL I, 1974, J NEUROCYTOL, V3, P308; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155	55	1809	1868	2	68	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					537	548		10.1016/S0092-8674(00)80513-9	http://dx.doi.org/10.1016/S0092-8674(00)80513-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267033	hybrid			2022-12-01	WOS:A1997XQ06300017
J	Blaumueller, CM; Qi, HL; Zagouras, P; ArtavanisTsakonas, S				Blaumueller, CM; Qi, HL; Zagouras, P; ArtavanisTsakonas, S			Intracellular cleavage of notch leads to a heterodimeric receptor on the plasma membrane	CELL			English	Article							DROSOPHILA-NOTCH; GENE-PRODUCT; MAMMALIAN NOTCH; HUMAN HOMOLOG; CELL-FATE; PROTEIN; LOCUS; EXPRESSION; NEUROGENESIS; MELANOGASTER	Previous models for signal transduction via the Notch pathway have depicted the full-length Notch receptor expressed at the cell surface. We present evidence demonstrating that the Notch receptor on the plasma membrane is cleaved. This cleavage is an evolutionarily conserved, general property of Notch and occurs in the trans-Golgi network as the receptor traffics toward the plasma membrane. Although full-length Notch is detectable in the cell, it does not reach the surface. Cleavage results in a C-terminal fragment, N(TM), that appears to be cleaved N-terminal to the transmembrane domain, and an N-terminal fragment, N-EC, that contains most of the extracellular region. We provide evidence that these fragments are tethered together on the plasma membrane by a link that is sensitive to reducing conditions, forming a heterodimeric receptor.	YALE UNIV, HOWARD HUGHES MED INST, DEPT CELL BIOL & BIOL, BOYER CTR MOL MED, NEW HAVEN, CT 06536 USA	Howard Hughes Medical Institute; Yale University				Blaumueller, Christine/0000-0002-1236-9353	NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS026084] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Baker R, 1996, DEVELOPMENT, V122, P617; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Blaumueller CM, 1997, PERSPECT DEV NEUROBI, V4, P325; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FOSTER GG, 1975, GENETICS, V81, P99; GEHRING WJ, 1973, GENETIC MECHANISMS D, P103; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOPPE PE, 1990, DEVELOPMENT, V109, P875; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MARKOPOULOU K, 1990, J EXP ZOOL, V27, P23; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, THESIS YALE U NEW HA; STERN C, 1968, P NATL ACAD SCI USA, V60, P1252, DOI 10.1073/pnas.60.4.1252; STERNBERG PW, 1993, CURR BIOL, V3, P763, DOI 10.1016/0960-9822(93)90025-J; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Sun X, 1996, DEVELOPMENT, V122, P2465; TECHNAU GM, 1987, P NATL ACAD SCI USA, V84, P4500, DOI 10.1073/pnas.84.13.4500; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	49	475	496	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					281	291		10.1016/S0092-8674(00)80336-0	http://dx.doi.org/10.1016/S0092-8674(00)80336-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244302	hybrid			2022-12-01	WOS:A1997XN24900012
J	Raymond, GJ; Hope, J; Kocisko, DA; Priola, SA; Raymond, LD; Bossers, A; Ironside, J; Will, RG; Chen, SG; Petersen, RB; Gambetti, P; Rubenstein, R; Smits, MA; Lansbury, PT; Caughey, B				Raymond, GJ; Hope, J; Kocisko, DA; Priola, SA; Raymond, LD; Bossers, A; Ironside, J; Will, RG; Chen, SG; Petersen, RB; Gambetti, P; Rubenstein, R; Smits, MA; Lansbury, PT; Caughey, B			Molecular assessment of the potential transmissibilities of BSE and scrapie to humans	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; PRION PROTEIN; SHEEP; GENOTYPE; FIBRILS; DISEASE; CATTLE; MICE; PRP	More than a million cattle infected with bovine spongiform encephalopathy (BSE) may have entered the human food chain(1). Fears that BSE might transmit to man were raised when atypical cases of Creutzfeldt-Jakob disease (CJD), a human transmissible spongiform encephalopathy (TSE), emerged in the UK2,3. I, BSE and other TSE diseases, the conversion of the protease-sensitive host prion protein (PrP-sen) to a protease-resistant isoform (PrP-res) is an important event in pathogenesis(4-7). Biological aspects of TSE diseases are reflected in the specificities of in vitro PrP conversion reactions(8-12). Here we show that there is a correlation between in vitro conversion efficiencies and known transmissibilities of BSE, sheep scrapie and CJD. On this basis, we used an in vitro system to gauge the potential transmissibility of scrapie and BSE to humans. We found Limited conversion of human PrP-sen to PrP-res driven by PrP-res associated with both scrapie (PrPSc) and BSE (prp(BSE)). The efficiencies of these heterologous conversion reactions were similar but much lower than those of relevant homologous conversions. Thus the inherent ability of these infectious agents of BSE and scrapie to affect humans following equivalent exposure may be finite but similarly low.	BBSRC,INST ANIM HLTH,COMPTON LAB,NEWBURY RG20 7NN,BERKS,ENGLAND; NIAID,ROCKY MT LABS,NIH,HAMILTON,MT 59840; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; DLO,INST ANIM SCI & HLTH,DEPT BACTERIOL,NL-8200 AB LELYSTAD,NETHERLANDS; WESTERN GEN HOSP,CJD SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; NEW YORK STATE INST BASIC RES DEV DISABIL,NEW YORK,NY 10314; HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Massachusetts Institute of Technology (MIT); University of Edinburgh; Case Western Reserve University; Institute for Basic Research in Developmental Disabilities; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Hope, James/C-4966-2011; Chen, Shu/Z-2943-2019; Chen, Shu G./AAK-7301-2021; Chen, Shu G./O-4750-2014; Petersen, Robert/B-5075-2011; Bossers, Alex/F-7757-2019; smits, mari/J-4892-2013; Bossers, Alex/AAA-6025-2021	Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; Petersen, Robert/0000-0002-3154-0072; Bossers, Alex/0000-0002-6586-717X; smits, mari/0000-0002-3493-291X; Bossers, Alex/0000-0002-6586-717X; Ironside, James/0000-0001-5869-2108				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; Bessen RA, 1997, J BIOL CHEM, V272, P15227, DOI 10.1074/jbc.272.24.15227; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CAUGHEY B, 1996, PRION DIS, P285; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; DAWSON M, 1990, VET REC, V126, P112; FOSTER JD, 1993, VET REC, V133, P339, DOI 10.1136/vr.133.14.339; FRASER H, 1988, VET REC, V123, P472, DOI 10.1136/vr.123.18.472; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; HOPE J, 1988, NATURE, V336, P390, DOI 10.1038/336390a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; RICK R, 1996, NATURE, V382, P180; VANKEULEN LJM, 1995, VET PATHOL, V32, P299, DOI 10.1177/030098589503200312; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	26	221	234	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					285	288		10.1038/40876	http://dx.doi.org/10.1038/40876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230438				2022-12-01	WOS:A1997XL12100053
J	Nowak, MA; Boerlijst, MC; Cooke, J; Smith, JM				Nowak, MA; Boerlijst, MC; Cooke, J; Smith, JM			Evolution of genetic redundancy	NATURE			English	Article							PROTEIN-TYROSINE KINASES; DUPLICATE LOCI; MICE; TENASCIN; DEVELOP	Genetic redundancy means that two or more genes are performing the same function and that inactivation of one of these genes has little or no effect on the biological phenotype. Redundancy seems to be widespread in genomes of higher organisms(1-9). Examples of apparently redundant genes come from numerous studies of developmental biology(10-15), immunology(16,17), neurobiology(18,19) and the cell cycle(20,21). Yet there is a problem: genes encoding functional proteins must be under selection pressure, If a gene was truly redundant then it would not be protected against the accumulation of deleterious mutations. A widespread view is therefore that such redundancy cannot be evolutionarily stable. Here we develop a simple genetic model to analyse selection pressures acting on redundant genes. We present four cases that can explain why genetic redundancy is common, In three cases, redundancy is even evolutionarily stable. Our theory provides a framework for exploring the evolution of genetic organization.	NATL INST MED RES,RIDGEWAY,LONDON NW7 1AA,ENGLAND; UNIV SUSSEX,SCH BIOL SCI,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND	University of Sussex	Nowak, MA (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.		Nowak, Martin A/A-6977-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLENDORF FW, 1978, NATURE, V272, P76, DOI 10.1038/272076a0; BAILEY GS, 1978, P NATL ACAD SCI USA, V75, P5575, DOI 10.1073/pnas.75.11.5575; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Brookfield JFY, 1997, ADV GENET, V36, P137, DOI 10.1016/S0065-2660(08)60308-9; Brookfield John, 1992, Current Biology, V2, P553, DOI 10.1016/0960-9822(92)90036-A; CHRISTIANSEN FB, 1977, AM J HUM GENET, V29, P195; DOVER GA, 1993, CURR OPIN GENET DEV, V3, P902, DOI 10.1016/0959-437X(93)90012-E; Fisher RA, 1935, AM NAT, V69, P446, DOI 10.1086/280618; GOLDSTEIN DB, 1992, EVOLUTION, V46, P412, DOI [10.2307/2409861, 10.1111/j.1558-5646.1992.tb02048.x]; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KIMURA M, 1979, P NATL ACAD SCI USA, V76, P2858, DOI 10.1073/pnas.76.6.2858; Krakauer DC, 1996, PHILOS T ROY SOC B, V351, P647, DOI 10.1098/rstb.1996.0062; Laney JD, 1996, DEVELOPMENT, V122, P2303; LI WH, 1980, GENETICS, V95, P237; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; OBRIEN SJ, 1973, NATURE-NEW BIOL, V242, P52, DOI 10.1038/newbio242052a0; OHTA T, 1989, GENETICS, V123, P579; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; PICKETT FB, 1995, PLANT CELL, V7, P1347, DOI 10.1105/tpc.7.9.1347; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; STEINDLER DA, 1995, J NEUROSCI, V15, P1971, DOI 10.1523/JNEUROSCI.15-03-01971.1995; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAUTZ D, 1992, BIOESSAYS, V14, P263, DOI 10.1002/bies.950140410; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; YANG Y, 1996, NATURE, V379, P823	30	495	508	0	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					167	171		10.1038/40618	http://dx.doi.org/10.1038/40618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217155	Bronze			2022-12-01	WOS:A1997XK10900048
J	Iyo, M; Namba, H; Fukushi, K; Shinotoh, H; Nagatsuka, S; Suhara, T; Sudo, Y; Suzuki, K; Irie, T				Iyo, M; Namba, H; Fukushi, K; Shinotoh, H; Nagatsuka, S; Suhara, T; Sudo, Y; Suzuki, K; Irie, T			Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease	LANCET			English	Article							COMPUTED-TOMOGRAPHY; IN-VIVO; DEMENTIA; DEFICITS; RECEPTORS; SEVERITY	Background Acetylcholinesterase activity, a marker for degeneration of the central cholinergic system, has consistently been reported, in necropsy brain studies, to be reduced in the cerebral cortex of patients with Alzheimer's disease. We have shown regional acetylcholinesterase activity in vivo in rodent and primate brains with radioactive acetylcholine analogues. In the present study, we used one of the analogues to map acetylcholinesterase activity in the brains of living people. Methods Positron emission tomography (PET) and a radiolabelled acetylcholine analogue with high hydrolytic specificity to acetylcholinesterase [C-11]N-methyl-4-piperidyl acetate (MP4A), was used in eight elderly healthy controls and five patients with Alzheimer's disease who had mild dementia. All participants were given an intravenous injection of [C-11]MP4A and then sequential patterns of radioactivity in various brain regions were obtained by PET. Time courses of [C-11]MP4A concentration in arterial blood were also measured to obtain an input function. A three-compartment model was used to estimate regional acetylcholinesterase activity in the brain. Findings The estimated acetylcholinesterase distribution in the brain of the control participants agreed with the acetylcholinesterase distribution at necropsy. All patients with Alzheimer's disease had multiple cortical regions with a reduced estimated acetylcholinesterase activity in comparison with control participants. The reduction was more pronounced in the parietotemporal cortex, with an average reduction rate of 31% in temporal and 38% in parietal cortex, and less pronounced in other cortical lesions (19% in frontal, 24% in occipital, and 20% in sensorimotor cortex), Each patient was found to have at least two cortical regions with significantly reduced acetylcholinesterase activity. Interpretation The method we describe for non-invasive in-vivo detection of regional acetylcholinesterase changes in the living human brain that is feasible for biochemical assessment of Alzheimer's disease.	NATL INST RADIOL SCI,DIV CLIN RES,INAGE KU,CHIBA 263,JAPAN; NATL CTR NEUROL & PSYCHIAT,NATL INST MENTAL HLTH,CHIBA,JAPAN; CHIBA CANC CTR HOSP,DIV NEUROL SURG,CHIBA,JAPAN; CHIBA UNIV,SCH MED,DEPT NEUROL,CHIBA 280,JAPAN; DAIICHI PURE CHEM CO LTD,TOKAI RES LABS,IBARAKI,OSAKA,JAPAN	National Institutes for Quantum Science & Technology; National Center for Neurology & Psychiatry - Japan; Chiba Cancer Center; Chiba University; Sekisui Chemical Co Ltd								Arai H, 1984, Rinsho Shinkeigaku, V24, P1128; ATACK JR, 1986, J NEUROCHEM, V47, P263; BIERER LM, 1995, J NEUROCHEM, V64, P749; CARLSSON A, 1987, GERONTOLOGY, V33, P159, DOI 10.1159/000212870; DAVIES P, 1976, LANCET, V2, P1403; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEWEY SL, 1990, SYNAPSE, V5, P213, DOI 10.1002/syn.890050307; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOTTFRIES CG, 1985, PSYCHOPHARMACOLOGY, V86, P245, DOI 10.1007/BF00432208; HAMBA H, 1996, ANN NUCL MED, V10, P161; HANSEN LA, 1988, NEUROLOGY, V38, P48, DOI 10.1212/WNL.38.1.48; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Irie T, 1996, J NUCL MED, V37, P649; IRIE T, 1994, NUCL MED BIOL, V21, P801, DOI 10.1016/0969-8051(94)90159-7; JAGUST WJ, 1987, ARCH NEUROL-CHICAGO, V44, P258, DOI 10.1001/archneur.1987.00520150014011; JOHNSON KA, 1987, ARCH NEUROL-CHICAGO, V44, P165, DOI 10.1001/archneur.1987.00520140035014; LASSEN NA, 1988, J CEREBR BLOOD F MET, V8, pS13, DOI 10.1038/jcbfm.1988.28; MARTIN EM, 1987, NEUROLOGY, V37, P1201, DOI 10.1212/WNL.37.7.1201; MCKHANN G, 1984, NEUROLOGY, V35, P939; NAMBA H, 1994, BRAIN RES, V667, P278, DOI 10.1016/0006-8993(94)91507-5; Pappata S, 1996, J NEUROCHEM, V67, P876; PERRY EK, 1978, BRIT MED J, V2, P1427; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; SIMS NR, 1983, J NEUROCHEM, V40, P503, DOI 10.1111/j.1471-4159.1983.tb11311.x; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; WALDEMAR G, 1994, J NEUROL NEUROSUR PS, V57, P285, DOI 10.1136/jnnp.57.3.285; WEINBERGER DR, 1991, ARCH NEUROL-CHICAGO, V48, P169, DOI 10.1001/archneur.1991.00530140061018; WILCOCK GK, 1982, J NEUROL SCI, V57, P407, DOI 10.1016/0022-510X(82)90045-4	28	201	207	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1805	1809		10.1016/S0140-6736(96)09124-6	http://dx.doi.org/10.1016/S0140-6736(96)09124-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269216				2022-12-01	WOS:A1997XF73500012
J	Varmus, H; Satcher, D				Varmus, H; Satcher, D			Ethical complexities of conducting research in developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									CTR DIS CONTROL & PREVENT,ATLANTA,GA 30329	Centers for Disease Control & Prevention - USA	Varmus, H (corresponding author), NIH,BETHESDA,MD 20892, USA.							Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; *NAT COMM PROT HUM, 1988, 887809 GPO; *US DEP HHS, 1997, COND CLIN TRIALS MAT; *WHO, 1994, REC M MOTH TO INF TR; *WORLD MED ASS DEC, 1996, 18 WORLD MED ASS HEL	6	243	250	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					1003	1005		10.1056/NEJM199710023371411	http://dx.doi.org/10.1056/NEJM199710023371411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9309109				2022-12-01	WOS:A1997XY42300011
J	Mihic, SJ; Ye, Q; Wick, MJ; Koltchine, VV; Krasowski, MD; Finn, SE; Mascia, MP; Valenzuela, CF; Hanson, KK; Greenblatt, EP; Harris, RA; Harrison, NL				Mihic, SJ; Ye, Q; Wick, MJ; Koltchine, VV; Krasowski, MD; Finn, SE; Mascia, MP; Valenzuela, CF; Hanson, KK; Greenblatt, EP; Harris, RA; Harrison, NL			Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors	NATURE			English	Article							ACID TYPE-A; LONG-CHAIN ALCOHOLS; GENERAL-ANESTHETICS; CURRENTS; PROPOFOL; INHIBITION; MODULATION	Volatile anaesthetics have historically been considered to act in a nonspecific manner on the central nervous system(1,2). More recent studies, however, have revealed that the receptors for inhibitory neurotransmitters such as gamma-aminobutyric acid (GABA) and glycine are sensitive to clinically relevant concentrations of inhaled anaesthetics(3). The function of GABAA and glycine receptors is enhanced by a number of anaesthetics(4-9) and alcohols(10-12), whereas activity of the related(13) GABA rho 1 receptor is reduced(14). We have used this difference in pharmacology to investigate the molecular basis for modulation of these receptors by anaesthetics and alcohols. By using chimaeric receptor constructs, we have identified a region of 45 amino-acid residues that is both necessary and sufficient for the enhancement of receptor function. Within this region, two specific amino-acid residues in transmembrane domains 2 and 3 are critical for allosteric modulation of both GABA(A) and glycine receptors by alcohols and two volatile anaesthetics. These observations support the idea that anaesthetics exert a specific effect on these ion-channel proteins, and allow fbr the future testing of specific hypotheses of the action of anaesthetics.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Alcohol Res Ctr, Denver, CO 80262 USA; Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Denver Veteran Adm Med Ctr, Alcoholism Res Ctr, Denver, CO 80220 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Chicago; University of Chicago; University of Pennsylvania	Mihic, SJ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.		Krasowski, Matthew D/ABA-8590-2020	Krasowski, Matthew D/0000-0003-0856-8402; Hanson, Kirsten/0000-0002-0154-0979				DildyMayfield JE, 1996, BRIT J PHARMACOL, V118, P378, DOI 10.1111/j.1476-5381.1996.tb15413.x; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; JANOFF AS, 1981, BIOCHIM BIOPHYS ACTA, V649, P125, DOI 10.1016/0005-2736(81)90017-1; JONES MV, 1995, J PHARMACOL EXP THER, V274, P962; JONES MV, 1993, J NEUROPHYSIOL, V70, P1339, DOI 10.1152/jn.1993.70.4.1339; Koltchine VV, 1996, NEUROPHARMACOLOGY, V35, P1445, DOI 10.1016/S0028-3908(96)00088-3; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LYON RC, 1981, J PHARMACOL EXP THER, V218, P669; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1996, MOL PHARMACOL, V50, P402; Mihic SJ, 1996, J PHARMACOL EXP THER, V277, P411; MIHIC SJ, 1994, EUR J PHARM-MOLEC PH, V268, P209; MIHIC SJ, 1994, MOL PHARMACOL, V46, P851; MOORE KR, 1994, BIOTECHNIQUES, V17, P130; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SANNA E, 1995, MOL PHARMACOL, V47, P213; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SHOENBORN BP, 1967, NATURE, V214, P1120; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Yu DH, 1996, MOL PHARMACOL, V50, P1010; Zhang L, 1997, BRIT J PHARMACOL, V120, P353, DOI 10.1038/sj.bjp.0700934	27	1034	1056	3	79	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 25	1997	389	6649					385	389		10.1038/38738	http://dx.doi.org/10.1038/38738			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311780				2022-12-01	WOS:A1997XX67500053
J	Moore, M; Onorato, IM; McCray, E; Castro, KG				Moore, M; Onorato, IM; McCray, E; Castro, KG			Trends in drug-resistant tuberculosis in the United States, 1993-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MYCOBACTERIUM-TUBERCULOSIS; EXOGENOUS REINFECTION	Context.-With the resurgence of tuberculosis (TB) disease in the late 1980s and early 1990s in the United States, multidrug-resistant (MDR) TB emerged as a serious challenge to TB control. In response, the Centers for Disease Control and Prevention in 1993 added drug susceptibility test results to the information collected for the national surveillance system to monitor trends in drug resistance. Objective.-To determine the extent of drug-resistant tuberculosis (TB) in the United States. Design.-Descriptive analysis or TB surveillance data. Study Population.-Patients reported to the national TB surveillance system as confirmed TB cases with culture-positive disease from 1993 through 1996 by the 50 states, New York City, and the District of Columbia (DC). Main Outcome Measure.-Percentage of case patients with culture-positive disease whose isolates are resistant to specific anti-TB drugs. Results.-Overall resistance to at least isoniazid was 8.4%; rifampin, 3.0%; both isoniazid and rifampin (ie, MDR TB), 2.2%; pyrazinamide, 3.0%; streptomycin, 6.2%; and ethambutol hydrochloride, 2.2%. Rates of resistance were significantly higher for case patients with a prior TB episode. Among those without prior TB, isoniazid resistance of 4% or more was found in 41 states, New York City, and DC. A total of 1457 MDR TB cases were reported from 42 states, New York City, and DC; however, 38% were reported from New York City. Rates of isoniazid and streptomycin resistance were higher for cases among US-born compared with foreign-born patients, but rates of rifampin resistance and MDR TB were similar. Among US-born patients, resistance to first-line drugs, particularly rifampin mono-resistance, was significantly higher among those with human immunodeficiency virus (HIV) infection. Conclusions.-Compared with recent US surveys in 1991 and 1992, isoniazid resistance has remained relatively stable. In addition, the percentage of MDR TB has decreased, although the national trend was significantly influenced by the marked decrease in New York City. Foreign-born and HIV-positive patients and those with prior TB have higher rates of resistance. The widespread extent of isoniazid resistance confirms the need for drug susceptibility testing to guide optimal treatment of patients with culture-positive disease.			Moore, M (corresponding author), CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,NATL CTR HIV STD & TB PREVENT,MAILSTOP E-10,ATLANTA,GA 30333, USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				*AM THOR SOC, 1994, AM J RESP CRIT CARE, V149, P1359; Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P1; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; Bloch AB, 1996, PUBLIC HEALTH REP, V111, P26; BLOCH AB, 1994, AM LUNG ASS AM THOR; Bradford WZ, 1996, LANCET, V348, P928, DOI 10.1016/S0140-6736(96)03027-9; BURWEN DR, 1995, ARCH INTERN MED, V155, P1281, DOI 10.1001/archinte.155.12.1281; *CDC, 1983, MMWR-MORBID MORTAL W, V32, P521; *CDC, 1981, MMWR-MORBID MORTAL W, V30, P273; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P587; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Chaulet P, 1995, TUBERCLE LUNG DIS, V76, P487, DOI 10.1016/0962-8479(95)90523-5; Cohn DL, 1997, CLIN INFECT DIS, V24, pS121, DOI 10.1093/clinids/24.Supplement_1.S121; DOSTER B, 1976, AM REV RESPIR DIS, V113, P419; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FRIEDEN TB, 1993, NEW ENGL J MED, V528, P521; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; KOPANOFF DE, 1978, AM REV RESPIR DIS, V118, P835; LASZLO A, 1994, B WORLD HEALTH ORGAN, V72, P603; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1995, AM J RESP CRIT CARE, V152, P1067, DOI 10.1164/ajrccm.152.3.7663785; RIDZON R, 1996, AM J RESP CRIT CARE, V153, pA493; RILEY LW, 1989, AM REV RESPIR DIS, V139, P1282, DOI 10.1164/ajrccm/139.5.1282; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; WHITNEY CG, 1996, AM J RESP CRIT CARE, V153, pA492	28	129	132	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					833	837		10.1001/jama.278.10.833	http://dx.doi.org/10.1001/jama.278.10.833			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU552	9293991				2022-12-01	WOS:A1997XU55200038
J	Minkoff, H; Bauer, T; Joyce, T				Minkoff, H; Bauer, T; Joyce, T			Welfare reform and the obstetrical care of immigrants and their newborns	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMPACT		NATL BUR ECON RES,NEW YORK,NY 10017	National Bureau of Economic Research	Minkoff, H (corresponding author), SUNY HLTH SCI CTR,BOX 24,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							*ASS AM MED COLL, 1997, AAMC FACT SHEET, V1; BATES AS, 1994, JAMA-J AM MED ASSOC, V272, P1105, DOI 10.1001/jama.272.14.1105; BUESCHER PA, 1991, AM J PUBLIC HEALTH, V81, P1625, DOI 10.2105/AJPH.81.12.1625; CHAVEZ LR, 1986, WOMEN HEALTH, V11, P3, DOI 10.1300/J013v11n02_02; *DEP HLTH SERV, 1997, MED CAL FUND DEL 199; Halfon N, 1997, JAMA-J AM MED ASSOC, V277, P636, DOI 10.1001/jama.277.8.636; *MARCH DIM BIRTH D, 1995, FACTS MED PREGN WOM; Minkoff H, 1997, NEW ENGL J MED, V336, P1392, DOI 10.1056/NEJM199705083361916; *NAT GOV ASS, 1996, STAT MED COV PREGN W; Reichman NE, 1996, J HEALTH ECON, V15, P455, DOI 10.1016/S0167-6296(96)00491-2; SINGH S, 1994, FAM PLANN PERSPECT, V26, P31, DOI 10.2307/2136094	11	12	12	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	1997	337	10					705	707		10.1056/NEJM199709043371011	http://dx.doi.org/10.1056/NEJM199709043371011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU349	9278471				2022-12-01	WOS:A1997XU34900011
J	Beltramo, M; Stella, N; Calignano, A; Lin, SY; Makriyannis, A; Piomelli, D				Beltramo, M; Stella, N; Calignano, A; Lin, SY; Makriyannis, A; Piomelli, D			Functional role of high-affinity anandamide transport, as revealed by selective inhibition	SCIENCE			English	Article							CANNABINOID RECEPTOR AGONIST; PHARMACOLOGICAL ACTIVITY; BRAIN CONSTITUENT; RAT-BRAIN; INVOLVEMENT; NEURONS; IDENTIFICATION; LOCALIZATION; PROTEIN; BINDING	Anandamide, an endogenous ligand for central cannabinoid receptors, is released from neurons on depolarization and rapidly inactivated. Anandamide inactivation is not completely understood, but it may occur by transport into cells or by enzymatic hydrolysis. The compound N-(4-hydroxyphenyl)arachidonylamide (AM404) was shown to inhibit high-affinity anandamide accumulation in rat neurons and astrocytes in vitro, an indication that this accumulation resulted from carrier-mediated transport. Although AM404 did not activate cannabinoid receptors or inhibit anandamide hydrolysis, it enhanced receptor-mediated anandamide responses in vitro and in vivo, The data indicate that carrier-mediated transport may be essential for termination of,the biological effects of anandamide, and may represent a potential drug target.	INST NEUROSCI,SAN DIEGO,CA 92121; UNIV NAPLES,SCH PHARM,I-80131 NAPLES,ITALY; UNIV CONNECTICUT,SCH PHARM,STORRS,CT 06269	University of Naples Federico II; University of Connecticut				CALIGNANO, Antonio/0000-0002-1742-3179				Barker Eric L., 1995, P321; Beltramo M, 1997, FEBS LETT, V403, P263, DOI 10.1016/S0014-5793(97)00061-6; BELTRAMO M, UNPUB; BITO LZ, 1976, J PHYSIOL-LONDON, V256, P257, DOI 10.1113/jphysiol.1976.sp011324; BITO LZ, 1975, NATURE, V256, P1234; Bojesen IN, 1996, ACTA PHYSIOL SCAND, V156, P501, DOI 10.1046/j.1365-201X.1996.456173000.x; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEWEY WL, 1986, PHARMACOL REV, V38, P151; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; Jung M, 1997, J NEUROCHEM, V68, P402; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Khanolkar AD, 1996, J MED CHEM, V39, P4515, DOI 10.1021/jm960152y; KOUTEK B, 1994, J BIOL CHEM, V269, P22937; KUSTER JE, 1993, J PHARMACOL EXP THER, V264, P1352; MAKI R, 1994, J NEUROSCI, V14, P6754; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MECHOULAM R, 1994, BIOCHEM PHARMACOL, V48, P1537, DOI 10.1016/0006-2952(94)90197-X; PORRECA F, 1984, J PHARMACOL EXP THER, V230, P341; PREZEAU L, 1992, P NATL ACAD SCI USA, V89, P8040, DOI 10.1073/pnas.89.17.8040; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; STEIN WD, 1990, CHANNELS PUMPS INTRO, P53; STELLA N, 1995, J NEUROSCI, V15, P3307; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823	35	649	685	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1094	1097		10.1126/science.277.5329.1094	http://dx.doi.org/10.1126/science.277.5329.1094			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262477	Green Submitted			2022-12-01	WOS:A1997XT03300034
J	Matsunami, H; Buck, LB				Matsunami, H; Buck, LB			A multigene family encoding a diverse array of putative pheromone receptors in mammals	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; OLFACTORY EPITHELIUM; VOMERONASAL SYSTEM; ODORANT RECEPTORS; GENE-EXPRESSION; NEURONS; ORGANIZATION; TRANSDUCTION; INFORMATION; PROTEINS	The vomeronasal organ of mammals is an olfactory sensory structure that detects pheromones. It contains two subsets of sensory neurons that differentially express G alpha(o) and G alpha(i2). By comparing gene expression in single neurons, we identified a novel multigene family that codes for a diverse array of candidate pheromone receptors (VRs) expressed by the G alpha(o)(+) subset. Different VRs are expressed by different neurons, but those neurons are interspersed, suggesting a distributed mode of sensory coding. Chromosome mapping experiments suggest an evolutionary connection between genes encoding VRs and receptors for volatile odorants. However, a dramatically different structure for VRs and the existence of variant VR mRNA forms indicate that there are diverse strategies to detect functionally distinct sensory stimuli.			Matsunami, H (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROBIOL,BOSTON,MA 02115, USA.							Ausubel FM., 1988, CURRENT PROTOCOLS MO; AXEL R, 1995, SCI AM, V273, P154, DOI 10.1038/scientificamerican1095-154; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Berghard A, 1996, P NATL ACAD SCI USA, V93, P2365, DOI 10.1073/pnas.93.6.2365; Berghard A, 1996, J NEUROSCI, V16, P909; BRADY G, 1993, METHOD ENZYMOL, V225, P611; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; BUCK LB, 1987, CELL, V51, P127, DOI 10.1016/0092-8674(87)90017-1; BUCK LB, 1995, CELL, V83, P349, DOI 10.1016/0092-8674(95)90110-8; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Firestein S, 1992, Curr Opin Neurobiol, V2, P444, DOI 10.1016/0959-4388(92)90178-N; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Hildebrand JG, 1997, ANNU REV NEUROSCI, V20, P595, DOI 10.1146/annurev.neuro.20.1.595; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; Jia CP, 1996, BRAIN RES, V719, P117, DOI 10.1016/0006-8993(96)00110-2; KARLSON P, 1959, NATURE, V183, P55, DOI 10.1038/183055a0; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; NOVOTNY M, 1990, CHEM SIGNAL, V5, P1; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RONNETT GV, 1992, TRENDS NEUROSCI, V15, P508, DOI 10.1016/0166-2236(92)90104-G; Sambrook J., 1989, MOL CLONING LAB MANU; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; Segaloff D L, 1992, Oxf Rev Reprod Biol, V14, P141; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; SINGER AG, 1991, J STEROID BIOCHEM, V39, P627, DOI 10.1016/0960-0760(91)90261-3; Sorensen PW, 1996, CHEM SENSES, V21, P245, DOI 10.1093/chemse/21.2.245; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Vogt R.G., 1987, P385; WILSON EO, 1963, SCI AM, V208, P100, DOI 10.1038/scientificamerican0563-100; Wu YM, 1996, BIOCHEM BIOPH RES CO, V220, P900, DOI 10.1006/bbrc.1996.0503; Wysocki C.J., 1987, P125	55	550	569	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					775	784		10.1016/S0092-8674(00)80537-1	http://dx.doi.org/10.1016/S0092-8674(00)80537-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288756	Bronze			2022-12-01	WOS:A1997XT06600020
J	Spitzer, NC; Sejnowski, TJ				Spitzer, NC; Sejnowski, TJ			Computational biology - Biological information processing: Bits of progress	SCIENCE			English	Editorial Material							MECHANISM		UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	University of California System; University of California San Diego; Howard Hughes Medical Institute; Salk Institute	Spitzer, NC (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Sejnowski, Terrence/AAV-5558-2021	Spitzer, Nicholas/0000-0002-3523-1103				ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERRIDGE MJ, 1979, J EXP BIOL, V81, P217; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Bezrukov SM, 1997, NATURE, V385, P319, DOI 10.1038/385319a0; BRABANT G, 1997, INT C BIOL INF PROC; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hartwell L, 1997, NATURE, V387, P855, DOI 10.1038/43072; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Prank K, 1996, BIOPHYS J, V70, P2540, DOI 10.1016/S0006-3495(96)79825-9; REINITZ J, 1995, MECH DEVELOP, V49, P133, DOI 10.1016/0925-4773(94)00310-J; Rieke F., 1997, SPIKES EXPLORING NEU	15	16	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1060	1061		10.1126/science.277.5329.1060	http://dx.doi.org/10.1126/science.277.5329.1060			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9289851	Green Submitted			2022-12-01	WOS:A1997XT03300023
J	Xu, ZH; Horwich, AL; Sigler, PB				Xu, ZH; Horwich, AL; Sigler, PB			The crystal structure of the asymmetric GroEL-GroES-(ADP)(7) chaperonin complex	NATURE			English	Article							ESCHERICHIA-COLI; GROEL; PROTEIN; BINDING; RELEASE; COOPERATIVITY; POLYPEPTIDE; AGGREGATION; HYDROLYSIS; MICROSCOPY	Chaperonins assist protein folding with the consumption of ATP. They exist as multi-subunit protein assemblies comprising rings of subunits stacked back to back. in Escherichia coli, asymmetric Intermediates of GroEL are formed with the co-chaperonin GroES and nucleotides bound only to one of the seven-subunit rings (the cis ring) and not to the opposing ring (the trans ring). The structure of the GroEL-GroES-(ADP), complex reveals how large en bloc movements of the cis ring's intermediate and apical domains enable bound GroES to stabilize a foiling chamber with ADP confined to the cis ring. Elevation and twist of the apical domains double the volume of the central cavity anal bury hydrophobic peptide-binding residues in the interface with GroES, as well as between GroEL subunits, leaving a hydrophilic cavity lining that is conducive to protein folding. An inward tilt of the cis equatorial domain causes an outward tilt in the trans ring that opposes the binding of a second GroES. When combined with new functional results, this negative allosteric mechanism suggests a model for an ATP-driven folding cycle that requires a double toroid.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR MOL MED,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University; Yale University								Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; ELLIS RJ, 1996, CHAPERONINS; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GRAY TE, 1992, FEBS LETT, V310, P99; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; LAMBRIGHT DG, 1994, NATURE, V369, P921; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LIN S, 1995, J BIOL CHEM, V270, P1011; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; Thiyagarajan P, 1996, STRUCTURE, V4, P79, DOI 10.1016/S0969-2126(96)00011-1; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; TRUNGER AT, 1993, X PLOR VERSION 3 1 M; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; ZEILSTRARYALLS J, 1994, J BACTERIOL, V176, P6558, DOI 10.1128/JB.176.21.6558-6565.1994	59	988	1017	3	115	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					741	750		10.1038/41944	http://dx.doi.org/10.1038/41944			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285585				2022-12-01	WOS:A1997XR66700042
J	Pusey, A; Williams, J; Goodall, J				Pusey, A; Williams, J; Goodall, J			The influence of dominance rank on the reproductive success of female chimpanzees	SCIENCE			English	Article							BABOONS	Female chimpanzees often forage alone and do not display obvious linear dominance hierarchies; consequently, it has been suggested that dominance is not of great importance to them. However, with the use of data from a 35-year field study of chimpanzees, high-ranking females were shown to have significantly higher infant survival, faster maturing daughters, and more rapid production of young, Given the foraging behavior of chimpanzees, high rank probably influences reproductive success by helping females establish and maintain access to good foraging areas rather than by sparing them stress from aggression.	JANE GOODALL INST,RIDGEFIELD,CT 06877		Pusey, A (corresponding author), UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,JANE GOODALL INST CTR PRIMATE STUDIES,ST PAUL,MN 55108, USA.		Klein, Richard G/B-5910-2009	Pusey, Anne/0000-0002-2280-8954				[Anonymous], 1993, DESIGN ANAL ECOLOGIC; Baker Kate C., 1994, P227; Bygott J. D., 1979, GREAT APES, P405; Chapais Bernard, 1992, P29; CLUTTONBROCK TH, 1979, AFR J ECOL, V17, P131, DOI 10.1111/j.1365-2028.1979.tb00250.x; COLLINS DA, 1988, J HUM EVOL, V17, P553, DOI 10.1016/0047-2484(88)90084-X; DEWAAL F, 1982, CHIMPANZEE POLITICS; DEWAAL FBM, 1984, ETHOL SOCIOBIOL, V5, P239, DOI 10.1016/0162-3095(84)90004-9; ELLIS L, 1995, ETHOL SOCIOBIOL, V16, P357; Frank Laurence, 1995, SERENGETI, P364; GOODALL J, 1977, FOLIA PRIMATOL, V28, P259, DOI 10.1159/000155817; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; HARCOURT AH, 1987, J ZOOL, V213, P471, DOI 10.1111/j.1469-7998.1987.tb03721.x; MOSES LE, 1992, AM J PRIMATOL, V28, P49, DOI 10.1002/ajp.1350280105; NISHIDA T, 1987, PRIMATE SOC, P318; NISHIDA T, 1990, UNDERSTANDING CHIMPA, P68; PACKER C, 1995, NATURE, V373, P60, DOI 10.1038/373060a0; Pusey A, 1979, GREAT APES, P465; Pusey A.E., 1987, P250; PUSEY AE, 1990, BEHAVIOUR, V115, P203, DOI 10.1163/156853990X00581; PUSEY AE, 1980, ANIM BEHAV, V28, P543, DOI 10.1016/S0003-3472(80)80063-7; PUSEY AE, 1983, ANIM BEHAV, V31, P363, DOI 10.1016/S0003-3472(83)80055-4; Silk J.B., 1987, P318; SMUTS B, 1989, AM J PRIMATOL, V19, P229, DOI 10.1002/ajp.1350190405; van Schaik CP., 1989, COMP SOCIOECOLOGY BE, P195; Wallis J, 1997, J REPROD FERTIL, V109, P297; Walters J.R., 1987, P306; Wrangham R W, 1980, J Reprod Fertil Suppl, VSuppl 28, P13; WRANGHAM RW, 1980, BEHAVIOUR, V75, P262, DOI 10.1163/156853980X00447; WRANGHAM RW, 1974, ANIM BEHAV, V22, P83, DOI 10.1016/S0003-3472(74)80056-4; WRANGHAM RW, 1992, HUMAN ORIGINS, P81	31	360	367	0	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					828	831		10.1126/science.277.5327.828	http://dx.doi.org/10.1126/science.277.5327.828			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242614				2022-12-01	WOS:A1997XQ24700047
J	Woehlke, G; Ruby, AK; Hart, CL; Ly, B; HomBooher, N; Vale, RD				Woehlke, G; Ruby, AK; Hart, CL; Ly, B; HomBooher, N; Vale, RD			Microtubule interaction site of the kinesin motor	CELL			English	Article							MONOMERIC MOTOR; ATP HYDROLYSIS; PROTEIN; MYOSIN; DOMAIN; DROSOPHILA; ACTIN; MOLECULES; TRANSPORT; MOVEMENT	Kinesin and myosin are motor proteins that share a common structural core and bind to microtubules and actin filaments, respectively. While the actomyosin interface has been well studied, the location of the microtubule-binding site on kinesin has not been identified. Using alanine-scanning mutagenesis, we have found that microtubule-interacting kinesin residues are located in three loops that cluster in a patch on the motor surface. The critical residues are primarily positively charged, which is consistent with a primarily electrostatic interaction with the negatively charged tubulin molecule. The core of the microtubule-binding interface resides in a highly conserved loop and helix (L12/alpha 5) that corresponds topologically to the major actin-binding domain of myosin. Thus, kinesin and myosin have developed distinct polymer-binding domains in a similar region with respect to their common catalytic cores.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Woehlke, G (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.			Woehlke, Gunther/0000-0001-8462-9962	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42895] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOSREMEDIOS CG, 1995, BBA-BIOENERGETICS, V1228, P99, DOI 10.1016/0005-2728(94)00169-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOYT MA, 1993, GENETICS, V135, P35; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Moore JD, 1996, EMBO J, V15, P3306, DOI 10.1002/j.1460-2075.1996.tb00695.x; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Pearce KH, 1996, BIOCHEMISTRY-US, V35, P10300, DOI 10.1021/bi960513b; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Tucker C, 1997, J BIOL CHEM, V272, P9481; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VALE RD, 1997, IN PRESS ANN REV CEL; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	56	305	311	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					207	216		10.1016/S0092-8674(00)80329-3	http://dx.doi.org/10.1016/S0092-8674(00)80329-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244295	Bronze, Green Published			2022-12-01	WOS:A1997XN24900005
J	Lauretta, DS; Lodders, K; Fegley, B				Lauretta, DS; Lodders, K; Fegley, B			Experimental simulations of sulfide formation in the solar nebula	SCIENCE			English	Article							IRON-NICKEL ALLOY; FE-NI; CHONDRITES; METEORITES; ORIGIN; SYSTEM; SULFUR	Sulfurization of meteoritic metal in H2S-H-2 gas produced three different sulfides: monosulfide solid solution [(Fe,Ni)(1-x)S], pentlandite [(Fe,Ni)(9-x)S-8], and a phosphorus-rich sulfide. The composition of the remnant metal was unchanged. These results are contrary ta theoretical predictions that sulfide formation in the solar nebula produced troilite (FeS) and enriched the remaining metal in nickel. The experimental sulfides are chemically and morphologically similar to sulfide grains in the matrix of the Alais (class Cl) carbonaceous chondrite, suggesting that these meteoritic sulfides may be condensates from the solar nebula.			Lauretta, DS (corresponding author), WASHINGTON UNIV,PLANETARY CHEM LAB,DEPT EARTH & PLANETARY SCI,CAMPUS BOX 1169,1 BROOKINGS DR,ST LOUIS,MO 63130, USA.			Lodders, Katharina/0000-0001-7531-626X				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BASTOW BD, 1985, CORROS SCI, V25, P253, DOI 10.1016/0010-938X(85)90080-0; CLARK JB, 1963, T METALL SOC AIME, V227, P1250; CONDIT RH, 1974, OXID MET, V8, P409, DOI 10.1007/BF00603390; DEAN DC, 1986, METALL TRANS A, V17, P1131, DOI 10.1007/BF02665311; DEVOUARD B, UNPUB METEORIT PLANE; DREIBUS G, 1995, METEORITICS, V30, P439, DOI 10.1111/j.1945-5100.1995.tb01150.x; Folinsbee R.E., 1967, GEOCHIM COSMOCHIM AC, V31, P1625; HANOWSKI NP, 1996, METEORIT PLANET SC S, V31, pA57; HUSS GR, 1981, GEOCHIM COSMOCHIM AC, V45, P33, DOI 10.1016/0016-7037(81)90262-3; KERRIDGE JF, 1979, EARTH PLANET SC LETT, V43, P359, DOI 10.1016/0012-821X(79)90091-8; KERRIDGE JF, 1979, EARTH PLANET SC LETT, V43, P1, DOI 10.1016/0012-821X(79)90149-3; LARIMER JW, 1967, GEOCHIM COSMOCHIM AC, V31, P1215, DOI 10.1016/S0016-7037(67)80013-9; Lauretta D.S., 1996, P NIPR S ANT MET, V9, P97; Lauretta D.S., 1996, P NIPR S ANT MET, V9, P111; Lauretta DS, 1996, ICARUS, V122, P288, DOI 10.1006/icar.1996.0126; LAURETTA DS, 1995, LUNAR PLANET SCI, V26, P831; LAURETTA DS, UNPUB METEORIT PLANE; LEWIS JS, 1972, EARTH PLANET SC LETT, V15, P286, DOI 10.1016/0012-821X(72)90174-4; LEWIS RS, 1975, P NATL ACAD SCI USA, V72, P268, DOI 10.1073/pnas.72.1.268; MILLION B, 1981, MATER SCI ENG, V50, P43, DOI 10.1016/0025-5416(81)90084-7; NARITA T, 1975, DENKI KAGAKU, V43, P443; Nazarov M. F., 1996, LUNAR PLANET SCI, V27, P939; ORCHARD JP, 1989, OXID MET, V31, P105, DOI 10.1007/BF00665489; ORCHARD JP, 1989, J ELECTROCHEM SOC, V136, P545, DOI 10.1149/1.2096679; RAMDOHR P, 1963, J GEOPHYS RES, V68, P2011, DOI 10.1029/JZ068i007p02011; SHEWMAN RW, 1970, CAN J EARTH SCI, V7, P67, DOI 10.1139/e70-005; UREY HC, 1952, PLANETS	28	65	68	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					358	360		10.1126/science.277.5324.358	http://dx.doi.org/10.1126/science.277.5324.358			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219690				2022-12-01	WOS:A1997XL35800042
J	Deng, HK; Unutmaz, D; KewalRamani, VN; Littman, DR				Deng, HK; Unutmaz, D; KewalRamani, VN; Littman, DR			Expression cloning of new receptors used by simian and human immunodeficiency viruses	NATURE			English	Article							INFECTION; IDENTIFICATION; DETERMINANT; TYPE-1; STRAIN; HIV-1	Several members of the chemokine-receptor family serve, in conjunction with CD4, as receptors for the entry of human immunodeficiency virus type I (HIV-1) into cells(1-6). The principal receptor for entry of macrophage-tropic (M-tropic) HIV-1 strains is CCR5, whereas that for T-cell-line-tropic (T-tropic) strains is CXCR4. Unlike HlV-1, infection with either M-tropic or T-tropic strains of simian immunodeficiency virus (SIV) can be mediated by CCR5, but not CXCR4 (refs 7-10). SIV strains will also infect CD4(+) cells that lack CCR5, which suggests that these strains use as yet unidentified receptors(7,9,10). Here we use an expression-cloning strategy to identify SIV receptors and have isolated genes encoding two members of the seven-transmembrane G-protein-coupled receptor family that are used not only by SIVs, but also by strains of HIV-2 and M-tropic HIV-1. Both receptors are closely related to the chemokine-receptor family and are expressed in lymphoid tissues. One of the receptors is also expressed in colon and may therefore be important in viral transmission. Usage of these new receptors following experimental infection of non-human primates with SIV strains may provide important insight into viral transmission and the mechanisms of SIV- and HIV-induced acquired immune-deficiency syndrome.	NYU,MED CTR,HOWARD HUGHES MED INST,SKIRBALL INST BIOMOL MED,DIV MOL PATHOGENESIS,NEW YORK,NY 10016	Howard Hughes Medical Institute; New York University			KewalRamani, Vineet/V-5084-2019					Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BARNETT SW, 1993, J VIROL, V67, P1006, DOI 10.1128/JVI.67.2.1006-1014.1993; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FUKASAWA M, 1988, NATURE, V333, P457, DOI 10.1038/333457a0; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Heiber M, 1996, GENOMICS, V32, P462, DOI 10.1006/geno.1996.0143; HILL CM, IN PRESS J VIROL; HWANG SS, 1992, SCIENCE, V257, P535, DOI 10.1126/science.1636088; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KONG LI, 1988, SCIENCE, V240, P1525, DOI 10.1126/science.3375832; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LIAO S, 1997, J EXP MED, V185, P2015; MARCON J, 1997, J VIROL, V71, P2522; MARTHAS ML, 1989, J MED PRIMATOL, V18, P311; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; STEFANO KA, 1993, J VIROL, V67, P6707, DOI 10.1128/JVI.67.11.6707-6715.1993; THEODOROU J, 1997, LANCET, V349, P1219; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097	31	590	615	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					296	300		10.1038/40894	http://dx.doi.org/10.1038/40894			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230441	Bronze			2022-12-01	WOS:A1997XL12100056
J	Ginsburg, J				Ginsburg, J			Unanswered questions in carcinoma of the testis	LANCET			English	Editorial Material									UCL, SCH MED, LONDON NW3 2QG, ENGLAND	University of London; University College London; UCL Medical School	Ginsburg, J (corresponding author), ROYAL FREE HOSP, JOINT UNIV DEPT MED, POND ST, LONDON NW3 2QG, ENGLAND.							BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298	1	7	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1785	1786		10.1016/S0140-6736(05)61688-1	http://dx.doi.org/10.1016/S0140-6736(05)61688-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269209				2022-12-01	WOS:A1997XF73500005
J	Kimura, Y; Vassylyev, DG; Miyazawa, A; Kidera, A; Matsushima, M; Mitsuoka, K; Murata, K; Hirai, T; Fujiyoshi, Y				Kimura, Y; Vassylyev, DG; Miyazawa, A; Kidera, A; Matsushima, M; Mitsuoka, K; Murata, K; Hirai, T; Fujiyoshi, Y			Surface of bacteriorhodopsin revealed by high-resolution electron crystallography	NATURE			English	Article							PROTON TRANSLOCATION; PURPLE MEMBRANE; HALOBACTERIUM-HALOBIUM; DIFFRACTION PATTERNS; SCHIFF-BASE; LIGHT; PROTEIN	Bacteriorhodopsin is a transmembrane protein that uses light energy, absorbed by its chromophore retinal, to pump protons from the cytoplasm of bacteria such as Halobacterium salinarium into the extracellular space(1,2.) It is made up of seven alpha-helices, and in the bacterium forms natural, two-dimensional crystals called purple membranes. We have analysed these crystals by electron cryo-microscopy to obtain images of bacteriorhodopsin at 3.0 Angstrom resolution. The structure covers nearly all 248 amino acids, including loops outside the membrane, and reveals the distribution of charged residues on both sides of the membrane surface. In addition, analysis of the electron-potential map produced by this method allows the determination of the charge status of these residues. On the extracellular side, four glutamate residues surround the entrance to the proton channel, whereas on the cytoplasmic side, four aspartic acids occur in a plane at the boundary of the hydrophobic-hydrophilic interface. The negative charges produced by these aspartate residues is encircled by areas of positive charge that may facilitate accumulation and lateral movement of protons on this surface.	RAT DRUG DESIGN LAB, MATSUKAWA, FUKUSHIMA 96012, JAPAN; MATSUSHITA ELECT IND CO LTD, INT INST ADV RES, SORAKU, KYOTO 61902, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYOU KU, KYOTO 60601, JAPAN	Kyoto University	Kimura, Y (corresponding author), BIOMOL ENGN RES INST, 6-2-3 FUREUDAI, SUITA, OSAKA 565, JAPAN.		Fujiyoshi, Yoshinori/E-5989-2012; Hirai, Teruhisa/G-2105-2015; Vassylyev, Dmitry/A-9005-2008	Fujiyoshi, Yoshinori/0000-0002-8070-1493; Hirai, Teruhisa/0000-0002-2114-8149; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN J, 1984, ULTRAMICROSCOPY, V14, P319, DOI 10.1016/0304-3991(84)90217-1; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; CESKA TA, 1990, J MOL BIOL, V213, P539, DOI 10.1016/S0022-2836(05)80214-1; FUJIYOSHI Y, 1991, ULTRAMICROSCOPY, V38, P241, DOI 10.1016/0304-3991(91)90159-4; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KIMURA Y, 1985, J MEMBRANE BIOL, V85, P225, DOI 10.1007/BF01871517; KUSHWAHA SC, 1976, BIOCHIM BIOPHYS ACTA, V426, P703, DOI 10.1016/0005-2736(76)90135-8; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; Oesterhelt D, 1974, Methods Enzymol, V31, P667; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; Riesle J, 1996, BIOCHEMISTRY-US, V35, P6635, DOI 10.1021/bi9600456; SAKATA K, 1992, ULTRAMICROSCOPY, V45, P253, DOI 10.1016/0304-3991(92)90513-J; SEIFF F, 1985, P NATL ACAD SCI USA, V82, P3227, DOI 10.1073/pnas.82.10.3227; SUBRAMANIAM S, 1992, J BIOL CHEM, V267, P25730; WILSON AJC, 1995, INT TABLE CRYSTALLOG, VC	23	402	410	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	1997	389	6647					206	211		10.1038/38323	http://dx.doi.org/10.1038/38323			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296502				2022-12-01	WOS:A1997XV75700055
J	Deconinck, AE; Rafael, JA; Skinner, JA; Brown, SC; Potter, AC; Metzinger, L; Watt, DJ; Dickson, JG; Tinsley, JM; Davies, KE				Deconinck, AE; Rafael, JA; Skinner, JA; Brown, SC; Potter, AC; Metzinger, L; Watt, DJ; Dickson, JG; Tinsley, JM; Davies, KE			Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy	CELL			English	Article							SKELETAL-MUSCLE FIBERS; MDX MOUSE; NEUROMUSCULAR-JUNCTION; ACETYLCHOLINE-RECEPTOR; PROTEIN; EXPRESSION; LOCALIZATION; ISOFORMS; MUTATION; BINDING	The absence of dystrophin at the muscle membrane leads to Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease that is inevitably fatal in early adulthood. In contrast, dystrophin-deficient mdx mice appear physically normal despite their underlying muscle pathology. We describe mice deficient for both dystrophin and the dystrophin-related protein utrophin. These mice show many signs typical of DMD in humans: they show severe progressive muscular dystrophy that results in premature death, they have ultrastructural neuromuscular and myotendinous junction abnormalities, and they aberrantly coexpress myosin heavy chain isoforms within a fiber. The data suggest that utrophin and dystrophin have complementing roles in normal functional or developmental pathways in muscle. Detailed study of these mice should provide novel insights into the pathogenesis of DMD and provide an improved model for rapid evaluation of gene therapy strategies.	UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND; UNIV LONDON,SCH BIOL SCI,SURREY TW20 0EX,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND	University of Oxford; University of London; Royal Holloway University London; Imperial College London			Rafael-Fortney, Jill/E-3909-2011; Metzinger, Laurent/B-1426-2016; metzinger, laurent/AAY-4634-2021	Metzinger, Laurent/0000-0002-7636-8480; metzinger, laurent/0000-0002-7636-8480; Brown, Sue/0000-0001-8112-933X				Amalfitano A, 1996, MUSCLE NERVE, V19, P1549, DOI 10.1002/(SICI)1097-4598(199612)19:12<1549::AID-MUS4>3.0.CO;2-A; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; Blake DJ, 1996, BRAIN PATHOL, V6, P37, DOI 10.1111/j.1750-3639.1996.tb00781.x; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHO M, 1993, J CELL BIOL, V121, P795, DOI 10.1083/jcb.121.4.795; CLERK A, 1993, HISTOCHEM J, V25, P554; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; CULLEN MJ, 1988, ACTA NEUROPATHOL, V77, P69, DOI 10.1007/BF00688245; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Deconinck AE, 1997, J CELL BIOL, V136, P883, DOI 10.1083/jcb.136.4.883; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Grady RM, 1997, J CELL BIOL, V136, P871, DOI 10.1083/jcb.136.4.871; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; JERUSALEM F, 1974, BRAIN, V97, P123, DOI 10.1093/brain/97.1.123; JOLESZ F, 1981, ANNU REV PHYSIOL, V43, P531, DOI 10.1146/annurev.ph.43.030181.002531; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; LAW DJ, 1994, J CELL SCI, V107, P1477; LAW DJ, 1995, MUSCLE NERVE, V18, P216, DOI 10.1002/mus.880180211; LYONS PR, 1991, J NEUROCYTOL, V20, P969, DOI 10.1007/BF01187915; Marini J F, 1991, Neuromuscul Disord, V1, P397, DOI 10.1016/0960-8966(91)90003-B; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; NAGEL A, 1990, MUSCLE NERVE, V13, P742, DOI 10.1002/mus.880130813; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; PONS F, 1994, CIRCULATION, V90, P369, DOI 10.1161/01.CIR.90.1.369; PONS F, 1994, J NEUROL SCI, V122, P162, DOI 10.1016/0022-510X(94)90295-X; Prakash YS, 1996, J NEUROCYTOL, V25, P88, DOI 10.1007/BF02284788; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHIAFFINO S, 1994, J APPL PHYSIOL, V77, P493, DOI 10.1152/jappl.1994.77.2.493; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SEWRY CA, 1994, NEUROMUSCULAR DISORD, V4, P401, DOI 10.1016/0960-8966(94)90079-5; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Vincent A, 1997, TRENDS NEUROSCI, V20, P15, DOI 10.1016/S0166-2236(96)10066-7; WINDER SJ, 1995, J CELL SCI, V108, P63; YELLIN H, 1967, EXP NEUROL, V19, P92, DOI 10.1016/0014-4886(67)90009-X; [No title captured]	45	572	595	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					717	727		10.1016/S0092-8674(00)80532-2	http://dx.doi.org/10.1016/S0092-8674(00)80532-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288751	Bronze			2022-12-01	WOS:A1997XT06600015
J	Kendrick, KM; GuevaraGuzman, R; Zorrilla, J; Hinton, MR; Broad, KD; Mimmack, M; Ohkura, S				Kendrick, KM; GuevaraGuzman, R; Zorrilla, J; Hinton, MR; Broad, KD; Mimmack, M; Ohkura, S			Formation of olfactory memories mediated by nitric oxide	NATURE			English	Article							LONG-TERM POTENTIATION; ASPARTATE RECEPTOR ANTAGONIST; SOLUBLE GUANYLYL CYCLASE; SYNTHASE MESSENGER-RNA; SELECTIVE IMPAIRMENT; CARBON-MONOXIDE; RAT-BRAIN; HIPPOCAMPUS; INHIBITION; SYSTEM	Sheep learn to recognize the odours of their lambs within two hours of giving birth, and this learning involves synaptic changes within the olfactory bulb(1,2). Specifically, mitral cells become increasingly responsive to the learned odour, which stimulates release of both glutamate and GABA (gamma-aminobutyric acid) neurotransmitters from the reciprocal synapses between the excitatory mitral cells and inhibitory granule cells(1). Nitric oxide (NO) has been implicated in synaptic plasticity in other regions of the brain as a result of its modulation of cyclic GMP levels(3-7). Here we investigate the possible role of NO in olfactory learning. We find that the neuronal enzyme nitric oxide synthase (nNOS) is expressed in both mitral and granule cells, whereas the guanylyl cyclase subunits that are required for NO stimulation of cGMP formation(8) are expressed only in mitral cells. Immediately after birth, glutamate levels rise, inducing formation of NO and cGMP, which potentiate glutamate release at the mitral-to-granule cell synapses. Inhibition of nNOS or guanylyl cyclase activity prevents both the potentiation of glutamate release and formation of the olfactory memory. The effects of nNOS inhibition can be reversed by infusion of NO into the olfactory bulb, Once memory has formed, however, inhibition of nNOS or guanylyl cyclase activity cannot impair either its recall or the neurochemical release evoked by the learned lamb odour. Nitric oxide therefore seems to act as a retrograde and/or intracellular messenger, being released from both mitral and granule cells to potentiate glutamate release from mitral cells by modulating cGMP concentrations. We propose that the resulting changes in the functional circuitry of the olfactory bulb underlie the formation of olfactory memories.			Kendrick, KM (corresponding author), BABRAHAM INST,DEPT NEUROBIOL,CAMBRIDGE CB2 4AT,ENGLAND.		Guevara-Guzman, Rosalinda/GXV-2779-2022	Kendrick, Keith/0000-0002-0371-5904				Arancio O, 1996, CELL, V87, P1025, DOI 10.1016/S0092-8674(00)81797-3; BANNERMAN DM, 1994, J NEUROSCI, V14, P7404; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTON CL, 1995, NEUROSCIENCE, V69, P699, DOI 10.1016/0306-4522(95)00349-N; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENNAN PA, 1989, NEUROSCIENCE, V33, P463, DOI 10.1016/0306-4522(89)90398-9; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DOZE VA, 1991, NEURON, V6, P889, DOI 10.1016/0896-6273(91)90229-S; FUJISAWA H, 1994, J NEUROCHEM, V63, P140; FURUYAMA T, 1993, MOL BRAIN RES, V20, P335, DOI 10.1016/0169-328X(93)90060-3; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766; Kendrick KM, 1996, EUR J NEUROSCI, V8, P2619, DOI 10.1111/j.1460-9568.1996.tb01557.x; KENDRICK KM, 1994, BEHAV PROCESS, V33, P89, DOI 10.1016/0376-6357(94)90061-2; KISHIMOTO J, 1993, EUR J NEUROSCI, V5, P1684, DOI 10.1111/j.1460-9568.1993.tb00236.x; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; LEVY F, 1990, BEHAV NEUROSCI, V104, P464, DOI 10.1037/0735-7044.104.3.464; LEVY F, 1995, PHYSIOL BEHAV, V57, P97, DOI 10.1016/0031-9384(94)00200-O; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; SALTER M, 1995, NEUROPHARMACOLOGY, V34, P327, DOI 10.1016/0028-3908(94)00162-L; VANDENPOL AN, 1995, J COMP NEUROL, V359, P253, DOI 10.1002/cne.903590206; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	28	221	225	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					670	674		10.1038/41765	http://dx.doi.org/10.1038/41765			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262400				2022-12-01	WOS:A1997XQ86300048
J	Ohno, T; Stribley, JA; Wu, G; Hinirichs, SH; Weisenburger, DD; Chan, WC				Ohno, T; Stribley, JA; Wu, G; Hinirichs, SH; Weisenburger, DD; Chan, WC			Clonality in nodular lymphocyte-predominant Hodgkin's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	38th Annual Meeting of the American-Society-of-Hematology	DEC 06-10, 1996	ORLANDO, FL	Amer Soc Hematol, US Dept Vet Affairs Merit Res Funds, NIH			REED-STERNBERG CELLS; POLYMERASE CHAIN-REACTION; V-H GENES; B-CELL; HISTOLOGICAL SECTIONS; GERMINAL CENTER; IMMUNOGLOBULIN; LINEAGE; REARRANGEMENTS; VARIANTS	Background There is general agreement that lymphocytic and histiocytic (L&H) cells, the variants of Reed-Sternberg cells in nodular lymphocyte-predominant Hodgkin's disease, belong to the B-cell lineage. However, the clonality of L&H cells remains controversial. Methods We used complementarity-determining region 3 (CDR3) of the immunoglobulin heavy-chain gene as a clonal marker to study individual L&H cells isolated by micromanipulation from tissue sections of five patients with nodular lymphocyte-predominant Hodgkin's disease. The heavy-chain CDR3 of each cell was amplified by the polymerase chain reaction, The products were analyzed by gel electrophoresis, and representative amplification products from each patient were sequenced. Results L&H cells whose heavy-chain CDR3 was related, indicating the presence of a clonal population, were detected in all five patients and were the dominant population in three. In four of the five patients, members of the clone were found in different nodules in the tissue section, different tissue blocks from the same tumor, or different lymph nodes from the same patient. The CDR3 sequences in each clone frequently contained nucleotide substitutions indicative of intraclonal mutation. Conclusions Clonal populations of L&H cells occur in nodular lymphocyte-predominant Hodgkin's disease. Intraclonal variation in nucleotide sequences suggests that hypermutation of the heavy-chain CDR3 continues to occur among the clonal progeny. (C) 1997, Massachusetts Medical Society.	UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [R01 CA61453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALAVAIKKO MJ, 1991, AM J CLIN PATHOL, V95, P194, DOI 10.1093/ajcp/95.2.194; ANGEL CA, 1987, J PATHOL, V153, P21, DOI 10.1002/path.1711530104; ANGEL CA, 1993, J CLIN PATHOL, V46, P337, DOI 10.1136/jcp.46.4.337; ANGEL CA, 1993, J CLIN PATHOL, V46, P940, DOI 10.1136/jcp.46.10.940; BEREK C, 1992, IMMUNOL REV, V126, P5, DOI 10.1111/j.1600-065X.1992.tb00628.x; BORGGRECH A, 1989, J CLIN ONCOL, V71, P303; CHANG B, 1994, IMMUNOL TODAY, V15, P367, DOI 10.1016/0167-5699(94)90175-9; dAmore F, 1997, LAB INVEST, V76, P219; DELABIE J, 1994, BLOOD, V84, P3291; Greiner TC, 1996, BLOOD, V88, P657, DOI 10.1182/blood.V88.2.657.bloodjournal882657; HELL K, 1993, J PATHOL, V171, P137, DOI 10.1002/path.1711710211; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KNOWLES DM, 1986, P NATL ACAD SCI USA, V83, P7942, DOI 10.1073/pnas.83.20.7942; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; KUZU I, 1993, HISTOPATHOLOGY, V22, P141, DOI 10.1111/j.1365-2559.1993.tb00092.x; LINDEN MD, 1988, HUM PATHOL, V19, P591, DOI 10.1016/S0046-8177(88)80210-7; LUKES RJ, 1966, CANCER RES, V26, P1063; MANZANAL A, 1995, HISTOPATHOLOGY, V27, P21, DOI 10.1111/j.1365-2559.1995.tb00286.x; Pan LX, 1996, BLOOD, V87, P2428, DOI 10.1182/blood.V87.6.2428.bloodjournal8762428; PINKUS GS, 1988, AM J PATHOL, V133, P211; POPPEMA S, 1989, AM J PATHOL, V135, P351; POPPEMA S, 1980, J HISTOCHEM CYTOCHEM, V28, P788, DOI 10.1177/28.8.6777426; REGULA DP, 1988, NEW ENGL J MED, V318, P214, DOI 10.1056/NEJM198801283180404; SAID JW, 1991, AM J PATHOL, V138, P261; STEIN H, 1986, AM J CLIN PATHOL, V86, P292, DOI 10.1093/ajcp/86.3.292; STOLER MH, 1995, AM J PATHOL, V146, P812; TAMARU J, 1994, BLOOD, V84, P708; TIMENS W, 1986, LAB INVEST, V54, P457; WICKERT RS, 1995, BLOOD, V86, P2312, DOI 10.1182/blood.V86.6.2312.bloodjournal8662312; WU G, IN PRESS DIAGN MOL P; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123	33	119	121	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					459	465		10.1056/NEJM199708143370704	http://dx.doi.org/10.1056/NEJM199708143370704			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250848				2022-12-01	WOS:A1997XQ49900004
J	Orci, L; Stamnes, M; Ravazzola, M; Amherdt, M; Perrelet, A; Sollner, TH; Rothman, JE				Orci, L; Stamnes, M; Ravazzola, M; Amherdt, M; Perrelet, A; Sollner, TH; Rothman, JE			Bidirectional transport by distinct populations of COPI-coated vesicles	CELL			English	Article							ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; BREFELDIN-A; BETA-COP; PROTEIN-TRANSPORT; MONOCLONAL-ANTIBODIES; VESICULAR TRANSPORT; GUANINE-NUCLEOTIDE; MEDIATED RETRIEVAL	Electron microscope immunocytochemistry reveals that both anterograde-directed (proinsulin and VSV G protein) and retrograde-directed (the KDEL receptor) cargo are present in coPI-coated vesicles budding from every level of the Golgi stack in whole cells; however, they comprise two distinct populations that together can account for at least 80% of the vesicles budding from Golgi cisternae. Segregation of antero-grade- from retrograde-directed cargo into distinct sets of COPI-coated vesicles is faithfully reproduced in the cell-free Golgi transport system, in which VSV G protein and KDEL receptor are packaged into separable vesicles, even when budding is driven by highly purified coatomer and a recombinant ARF protein.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Orci, L (corresponding author), UNIV GENEVA,CTR MED,FAC MED,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND.			Stamnes, Mark/0000-0002-5869-7985				ALLEN VJ, 1986, J CELL BIOL, V103, P2229; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUDEN R, 1994, J BIOL CHEM, V269, P24486; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GERICH B, 1995, P NATL ACAD SCI USA, V92, P8532; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MADSEN OD, 1983, ENDOCRINOLOGY, V113, P2135, DOI 10.1210/endo-113-6-2135; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELKONIAN M, 1991, J ELECTRON MICR TECH, V17, P165, DOI 10.1002/jemt.1060170205; MORRE DJ, 1977, INT REV CYTOL      S, V5, P61; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1973, J ULTRA MOL STRUCT R, V43, P270, DOI 10.1016/S0022-5320(73)80039-5; ORCI L, 1994, P NATL ACAD SCI USA, V91, P11924, DOI 10.1073/pnas.91.25.11924; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; ORCI L, 1986, Diabetes Metabolism Reviews, V2, P71; ORCI L, 1974, DIABETOLOGIA, V10, P163, DOI 10.1007/BF00423031; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; STORCH MJ, 1985, DIABETES, V34, P808, DOI 10.2337/diabetes.34.8.808; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	73	342	351	0	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					335	349		10.1016/S0092-8674(00)80341-4	http://dx.doi.org/10.1016/S0092-8674(00)80341-4			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244307	Bronze			2022-12-01	WOS:A1997XN24900017
J	Blomley, M; Cosgrove, D				Blomley, M; Cosgrove, D			Microbubble echo-enhancers: A new direction for ultrasound?	LANCET			English	Editorial Material											Blomley, M (corresponding author), HAMMERSMITH HOSP,DEPT IMAGING,LONDON W12 0HS,ENGLAND.							FLEISCHER AC, 1997, ULTRASOUND CONTRAST, P137; KEDAR PP, 1996, RADIOLOGY, V198, P679; Killam A, 1997, ULTRASOUND CONTRAST, P43; Nihoyannopoulos P, 1996, CLIN RADIOL, V51, P28; Schlief R., 1997, ULTRASOUND CONTRAST, P75	5	42	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1855	1856		10.1016/S0140-6736(05)63872-X	http://dx.doi.org/10.1016/S0140-6736(05)63872-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217754				2022-12-01	WOS:A1997XG41700005
J	Muhe, L; Lulseged, S; Mason, KE; Simoes, EAF				Muhe, L; Lulseged, S; Mason, KE; Simoes, EAF			Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children	LANCET			English	Article							COMMUNITY	Background Pneumonia is the most important cause of morbidity and mortality in children aged under 5 years worldwide. Studies in developing countries have suggested an association between nutritional rickets and pneumonia. Since both nutritional rickets and pneumonia are common in Ethiopia, we did a case-control study to determine the role of nutritional rickets in the development of pneumonia. Methods Cases were children younger than 5 years admitted to the Ethio-Swedish Children's Hospital during a 5-year period with a diagnosis of pnuemonia (n=521), but data were incomplete for 21 of these and they were not included. Controls (n=500) were matched for admission within 3 months of cases and age within 3 months and had no evidence of pneumonia. Nutritional, demographic, and clinical and radiographic data for rickets and pneumonia were collected. Matched odd ratios and logistic regression were used to test the significance of the association of richets and pneumonia. Findings Rickets was present in 210 of 500 cases compared with 20 of 500 controls (odds ratio 22.11). There were significant differences between cases and controls for family size, birth order, crowding, and months of exclusive breastfeeding (p<0.05). After correction for these confounding factors by logistic regression, there was still a 13-fold higher incidence of rickets among children with pneumonia than among controls (13.37 [95% CI 8.08-24.22], p<0.001). Interpretation Vitamin D or calcium deficiency may be important predisposing factors for pneumonia in children aged under 5 years in developing countries. Efforts to prevent vitamin D deficiency or calcium supplementation may result in significant reductions in morbidity and mortality from pneumonia in these children.	CHILDRENS HOSP,DIV INFECT DIS,DENVER,CO 80218; UNIV ADDIS ABABA,FAC MED,DEPT PEDIAT & CHILD HLTH,ADDIS ABABA,ETHIOPIA; WHO,DIV CHILD HLTH & DEV,CH-1211 GENEVA,SWITZERLAND; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DIV INFECT DIS,DENVER,CO 80262	Children's Hospital Colorado; Addis Ababa University; World Health Organization; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AUST-KETTIS A., 1965, Ethiopian Medical Journal, V3, P109; DRIDZ TA, 1979, AM J CLIN NUTR, V32, P607; *ETH SWED CHILDR H, 1994, ANN REP ETH SWED CHI; Gupta S K, 1971, J Indian Med Assoc, V57, P141; HORTAL M, 1990, REV INFECT DIS, V12, pS966; Kirkwood BR, 1995, B WORLD HEALTH ORGAN, V73, P793; LAWSON DEM, 1987, HUM NUTR-CLIN NUTR, V41C, P199; LEMIRE JM, 1985, J IMMUNOL, V134, P3032; LUBANI MM, 1989, ANN TROP PAEDIATR, V3, P134; LULSEGED S, 1990, ETHIOPIAN MED J, V28, P175; MA XC, 1986, J PRAC PEDIAT, V1, P323; MUHE L, 1995, PUBLIC HEALTH, V109, P99, DOI 10.1016/S0033-3506(05)80003-4; Oginni LM, 1996, J PEDIATR-US, V128, P692, DOI 10.1016/S0022-3476(96)80137-5; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; ROOK GAW, 1986, IMMUNOLOGY, V57, P159; SALIMPOUR R, 1975, ARCH DIS CHILD, V50, P63, DOI 10.1136/adc.50.1.63; STRODER J, 1970, ACTA PAEDIATR SCAND, V59, P288, DOI 10.1111/j.1651-2227.1970.tb09005.x; VAHLQUIST B, 1975, ACTA PAEDIATR SCAND, V64, P161; Wellcome Trust Working Party, 1970, LANCET, V2, P302; *WHO, 1994, WHOARL9433; WOLDEMARIAM T, 1973, J PAEDIAT, V82, P876; *WORLD BANK, 1993, WORLD DEV REP	22	238	247	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1801	1804		10.1016/S0140-6736(96)12098-5	http://dx.doi.org/10.1016/S0140-6736(96)12098-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269215				2022-12-01	WOS:A1997XF73500011
J	He, SG; Masland, RH				He, SG; Masland, RH			Retinal direction selectivity after targeted laser ablation of starburst amacrine cells	NATURE			English	Article							GANGLION-CELLS; RABBIT RETINA; CAENORHABDITIS-ELEGANS; MAMMALIAN RETINA; RECEPTIVE-FIELDS; CAT RETINA; ACETYLCHOLINE; IDENTIFICATION; RESPONSES; MECHANISM	Directionally selective retinal ganglion cells respond strongly when a stimulus moves in their preferred direction, but respond little or not at all when it moves in the opposite direction(1,2). This selectivity represents a classic paradigm of computation by neural microcircuits, but its cellular mechanism remains obscure. The directionally selective ganglion cells receive many synapses from a type of amacrine cell termed 'starburst' because of its regularly spaced, evenly radiating dendrites(3,4). Starburst amacrine cells have a synaptic asymmetry that has been proposed as the source of the directional response in the ganglion cells(5,6). Here we report experiments that make this unlikely, and offer an alternative concept of the function of starburst cells. We labelled starburst cells in living retinas, then killed them by targeted laser ablation while recording from individual directionally selective ganglion cells. Ablating starburst cells revealed no asymmetric contribution to the ganglion cell response. Instead of being direction discriminators, the starburst cells appear to potentiate generically the responses of ganglion cells to moving stimuli. The origin of direction selectivity probably lies with another type of amacrine cell.	MASSACHUSETTS GEN HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute								AMES AI, 1996, J NEUROCHEM, V37, P867; AMTHOR FR, 1993, VISUAL MOTION ITS RO; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P161, DOI 10.1113/jphysiol.1982.sp014105; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P135, DOI 10.1113/jphysiol.1982.sp014104; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; Borg-Graham L.J., 1992, SINGLE NEURON COMPUT, P347; BRECHA N, 1988, P NATL ACAD SCI USA, V85, P6187, DOI 10.1073/pnas.85.16.6187; CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P277, DOI 10.1113/jphysiol.1978.sp012233; COHEN ED, 1995, P NATL ACAD SCI USA, V92, P1127, DOI 10.1073/pnas.92.4.1127; FAMIGLIETTI EV, 1991, J COMP NEUROL, V309, P40, DOI 10.1002/cne.903090105; GRZYWACZ NM, 1993, J NEUROPHYSIOL, V69, P2188, DOI 10.1152/jn.1993.69.6.2188; HUBA R, 1992, BRAIN RES, V577, P10, DOI 10.1016/0006-8993(92)90531-D; JACOBS GA, 1986, J NEUROSCI, V6, P2298; Kittila CA, 1997, J NEUROPHYSIOL, V77, P675, DOI 10.1152/jn.1997.77.2.675; MARCHIAFAVA PL, 1979, VISION RES, V19, P1203, DOI 10.1016/0042-6989(79)90185-8; MASLAND RH, 1976, J NEUROPHYSIOL, V39, P1220, DOI 10.1152/jn.1976.39.6.1220; MASLAND RH, 1979, J CELL BIOL, V83, P159, DOI 10.1083/jcb.83.1.159; MASLAND RH, 1986, TRENDS NEUROSCI, V9, P218, DOI 10.1016/0166-2236(86)90062-7; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P79, DOI 10.1098/rspb.1984.0084; OMALLEY DM, 1992, J NEUROSCI, V12, P1394; SCHMIDT M, 1987, J NEUROPHYSIOL, V58, P997, DOI 10.1152/jn.1987.58.5.997; Strettoi E, 1996, P NATL ACAD SCI USA, V93, P14906, DOI 10.1073/pnas.93.25.14906; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TAUCHI M, 1984, PROC R SOC SER B-BIO, V223, P101, DOI 10.1098/rspb.1984.0085; TORRE V, 1978, PROC R SOC SER B-BIO, V202, P409, DOI 10.1098/rspb.1978.0075; VANEY DI, 1991, PROG RETIN RES, V9, P1; VARDI N, 1989, J COMP NEUROL, V288, P601, DOI 10.1002/cne.902880407; YANG G, 1994, J NEUROSCI, V14, P5267	29	118	123	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					378	382		10.1038/38723	http://dx.doi.org/10.1038/38723			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311778				2022-12-01	WOS:A1997XX67500051
J	Parker, L				Parker, L			Causes of testicular cancer	LANCET			English	Editorial Material							TRAUMA				Parker, L (corresponding author), UNIV NEWCASTLE UPON TYNE,SIR JAMES SPENCE INST CHILD HLTH,DEPT EPIDEMIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.			PARKER, LOUISE/0000-0002-5188-8113				Buetow SA, 1995, EPIDEMIOL REV, V17, P433, DOI 10.1093/oxfordjournals.epirev.a036202; Greaves MF, 1996, LEUKEMIA, V10, P372; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JENSEN TK, 1995, CLIN CHEM, V41, P1896; STONE JM, 1991, CANCER, V68, P211, DOI 10.1002/1097-0142(19910701)68:1<211::AID-CNCR2820680139>3.0.CO;2-Q; SWERDLOW AJ, 1988, BRIT J UROL, V61, P518, DOI 10.1111/j.1464-410X.1988.tb05094.x; Swerdlow AJ, 1997, BRIT MED J, V314, P1507, DOI 10.1136/bmj.314.7093.1507; WEISS L, 1990, J FORENSIC SCI, V35, P614	8	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					827	828		10.1016/S0140-6736(05)62028-4	http://dx.doi.org/10.1016/S0140-6736(05)62028-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310598				2022-12-01	WOS:A1997XX40100006
J	Krasnopolsky, VA; Mumma, MJ; Abbott, M; Flynn, BC; Meech, KJ; Yeomans, BK; Feldman, PD; Cosmovici, CB				Krasnopolsky, VA; Mumma, MJ; Abbott, M; Flynn, BC; Meech, KJ; Yeomans, BK; Feldman, PD; Cosmovici, CB			Detection of soft x-rays and a sensitive search for noble gases in comet Hale-Bopp (C/1995 O1)	SCIENCE			English	Article							ONE-ELECTRON CAPTURE; CROSS-SECTIONS; B2 HYAKUTAKE; P/HALLEY; COLLISIONS; IONS; EVOLUTION; HELIUM; SOLAR; EUVE	An image of comet Hale-Bopp (C/1995 O1) in soft x-rays reveals a central emission offset from the nucleus, as well as an extended emission feature that does not correlate with the dust jets seen at optical wavelengths, Neon was found to be depleted in the cometary ice by more than a factor of 25 relative to solar abundance, which suggests that ices in Hale-Bopp formed at (or later experienced) temperatures higher than 25 kelvin, A helium line emission at a wavelength of 584 angstroms was detected and may be attributable to charge transfer of solar wind alpha particles in the cometary coma, Ionized oxygen and another helium line contribute to an emission observed at 538 angstroms.	NASA, GODDARD SPACE FLIGHT CTR, GREENBELT, MD 20771 USA; UNIV CALIF BERKELEY, CTR EXTREME ULTRAVIOLET ASTROPHYS, BERKELEY, CA 94720 USA; UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD 21218 USA; CNR, IST FIS SPAZIO INTERPLANETARIO, I-00044 FRASCATI, ITALY	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of California System; University of California Berkeley; University of Hawaii System; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Johns Hopkins University; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF)	Krasnopolsky, VA (corresponding author), CATHOLIC UNIV AMER, WASHINGTON, DC 20064 USA.		Krasnopolsky, Vladimir/L-5085-2013; mumma, michael j/I-2764-2013; Meech, Karen/CAH-1412-2022; Flynn, Brigid/ABC-2003-2021	mumma, michael j/0000-0003-4627-750X; Flynn, Brigid/0000-0002-9329-724X				Abbott MJ, 1996, ASTROPHYS J SUPPL S, V107, P451, DOI 10.1086/192371; AHearn MF, 1995, ICARUS, V118, P223, DOI 10.1006/icar.1995.1190; AHEARN MF, 1984, ASTRON J, V89, P579, DOI 10.1086/113552; ALTWEGG K, 1993, ASTRON ASTROPHYS, V279, P260; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BARNUN A, 1988, ASTROPHYS J, V324, pL31, DOI 10.1086/185084; Bingham R, 1997, SCIENCE, V275, P49, DOI 10.1126/science.275.5296.49; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; Bowyer S., 1991, EXTREME ULTRAVIOLET, P397; BREKKE P, 1993, ASTROPHYS J, V408, P735, DOI 10.1086/172633; CHAKRABARTI S, 1983, J GEOPHYS RES-SPACE, V88, P4898, DOI 10.1029/JA088iA06p04898; Cravens TE, 1997, GEOPHYS RES LETT, V24, P105, DOI 10.1029/96GL03780; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; DIJKKAMP D, 1985, J PHYS B-AT MOL OPT, V18, P737, DOI 10.1088/0022-3700/18/4/018; FELDMAN PD, 1991, ASTROPHYS J, V379, pL37, DOI 10.1086/186148; FELDMAN PD, 1987, ASTRON ASTROPHYS, V187, P325; GLADSTONE GR, 1994, GEOPHYS RES LETT, V21, P461, DOI 10.1029/93GL03290; GLADSTONE GR, 1995, SCIENCE, V268, P1595, DOI 10.1126/science.268.5217.1595; GOLDSTEIN BE, 1987, ASTRON ASTROPHYS, V187, P174; GRINGAUZ KI, 1990, COMET HALLEY INVESTI, P147; Haberli RM, 1997, SCIENCE, V276, P939, DOI 10.1126/science.276.5314.939; HODGKINSON JM, 1995, J PHYS B-AT MOL OPT, V28, pL393, DOI 10.1088/0953-4075/28/12/001; JANEV RK, 1988, ATOM DATA NUCL DATA, V40, P249, DOI 10.1016/0092-640X(88)90008-3; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; KELLY RL, 1987, J PHYS CHEM REF DATA, V16, P1; Krasnopolsky V, 1997, ICARUS, V128, P368, DOI 10.1006/icar.1997.5722; Krasnopolsky V, 1997, PHYS WORLD, V10, P21; KRASNOPOLSKY VA, 1991, ASTRON ASTROPHYS, V245, P662; KRASNOPOLSKY VA, 1994, ICARUS, V109, P337, DOI 10.1006/icar.1994.1098; Krasnopolsky VA, 1996, J GEOPHYS RES-SPACE, V101, P15765, DOI 10.1029/96JA01080; KRASNOPOLSKY VA, 1996, B AM ASTRON SOC, V28, P1095; LIDE DR, 1995, CRC HDB CHEM PHYSICS; Lisse CM, 1996, SCIENCE, V274, P205, DOI 10.1126/science.274.5285.205; MCCULLOUGH RW, 1992, J PHYS B-AT MOL OPT, V25, pL193, DOI 10.1088/0953-4075/25/7/007; MCDONALD K, 1994, ASTRON J, V108, P1843, DOI 10.1086/117197; MEIER RR, 1991, SPACE SCI REV, V58, P1, DOI 10.1007/BF01206000; Millis R.L., 1996, B AM ASTRON SOC, V28, P1095; Mumma MJ, 1996, SCIENCE, V272, P1310, DOI 10.1126/science.272.5266.1310; MUMMA MJ, 1993, PROTOSTARS PLANETS, V3, P1172; MUMMA MJ, 1997, 6696 IAU; Northrop TG, 1997, ICARUS, V127, P246, DOI 10.1006/icar.1997.5694; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; Rauer H, 1997, SCIENCE, V275, P1909, DOI 10.1126/science.275.5308.1909; RICHARDS PG, 1994, J GEOPHYS RES-SPACE, V99, P8981, DOI 10.1029/94JA00518; RYUFUKU H, 1980, PHYS REV A, V21, P745, DOI 10.1103/PhysRevA.21.745; Safronov V. S., 1969, EVOLUTION PROTOPLANE; Safronov V.S., 1972, EVOLUTION PROTOPLANE; Schleicher DG, 1997, SCIENCE, V275, P1913, DOI 10.1126/science.275.5308.1913; SHAH MB, 1974, J PHYS B-AT MOL OPT, V7, P256, DOI 10.1088/0022-3700/7/2/011; STERN SA, 1992, ICARUS, V95, P157, DOI 10.1016/0019-1035(92)90198-G; STEWART AIF, 1987, ASTRON ASTROPHYS, V187, P369; VEMAZZA JE, 1978, ASTROPHYS J SUPPL SE, V37, P485; Weaver HA, 1997, SCIENCE, V275, P1900, DOI 10.1126/science.275.5308.1900; WEAVER HA, 1987, ASTRON ASTROPHYS, V187, P411; Wickramasinghe NC, 1996, ASTROPHYS SPACE SCI, V239, P121, DOI 10.1007/BF00653772	55	93	93	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1488	1491		10.1126/science.277.5331.1488	http://dx.doi.org/10.1126/science.277.5331.1488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278508	Green Submitted			2022-12-01	WOS:A1997XV42900035
J	Fan, QR; Mosyak, L; Winter, CC; Wagtmann, N; Long, EO; Wiley, DC				Fan, QR; Mosyak, L; Winter, CC; Wagtmann, N; Long, EO; Wiley, DC			Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors	NATURE			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; HUMAN GROWTH-HORMONE; HUMAN TISSUE FACTOR; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; HUMAN CD4; COMPLEX; BINDING; 2.8-ANGSTROM; MOLECULE	Abnormal cells deficient in class I major histocompatibility complex (MHC) expression are lysed by a class of lymphocytes called natural killer (NK) cells(1). This lysis provides a defence against pathogens and tumour cells that downregulate MHC expression to avoid an MHC-restricted, T-cell immune response. Normal cells escape lysis because their MHC molecules are recognized by NK-cell inhibitory receptors, which inhibit lysis(2). Several such inhibitory receptor families have been described in humans and mice (reviewed in Ief. 2). In the human killer-cell inhibitory receptor family, individual p58 members are specific for a subset of class I human leukocyte antigen (HLA)-C molecules. The human p58 natural killer-cell inhibitory receptor done 42 recognizes HLA-Cw4, -Cw2 and -Cw6, but not HLA-Cw3, -Cw2, -Cw7 or -Cw8, which are recognized by p58 killer-cell inhibitor receptor clone 43 (ref. 3). We have determined the X-ray structure of the p58 NK-cell inhibitory receptor clone 42 at 1.7-Angstrom resolution. The structure has tandem immunoglobulin-like domains positioned at an acute, 60-degree angle. Loops on the outside of the elbow between the domains form a binding site projected away from the NK-cell surface. The topology of the domains and their arrangement relative to each other reveal a relationship to the haematopoietic receptor family, with implications for the signalling mechanism in NK cells.	NIAID, IMMUNOGENET LAB, NIH, ROCKVILLE, MD 20852 USA; HARVARD UNIV, HOWARD HUGHES MED INST, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Howard Hughes Medical Institute			Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Fan QR, 1996, P NATL ACAD SCI USA, V93, P7178, DOI 10.1073/pnas.93.14.7178; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LJUGGREN HG, 1990, IMMUNOL TODAY, V11, P237; Long EO, 1997, IMMUNOL REV, V155, P135, DOI 10.1111/j.1600-065X.1997.tb00946.x; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; Pende D, 1996, J EXP MED, V184, P505, DOI 10.1084/jem.184.2.505; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Winter CC, 1997, J IMMUNOL, V158, P4026	31	148	153	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					96	100		10.1038/38028	http://dx.doi.org/10.1038/38028			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288975				2022-12-01	WOS:A1997XU59600053
J	Tarasow, TM; Tarasow, SL; Eaton, BE				Tarasow, TM; Tarasow, SL; Eaton, BE			RNA-catalysed carbon-carbon bond formation	NATURE			English	Article							LEWIS-ACID CATALYSIS; DIELS-ALDER REACTION; PORPHYRIN METALATION; RIBOZYMES; WORLD; EVOLUTION; WATER	The 'RNA world' hypothesis(1-3), which assumes that the chemical processes that led to the appearance of life were carried out by RNA molecules, has stimulated interest in catalytic reactions involving oligonucleotides such as catalytic RNA (ribozymes)(4). Naturally occurring ribozymes have, for example, been shown to efficiently catalyse the formation and cleavage of nucleic-acid phosphodiester bonds(4-8), and this narrow range of RNA-catalysed reactions has been subsequently expanded by in vitro selection methods to include ester(9) and amide(10,24) bond formation S(N)2 reactions and porphyrin metallations(11,12). Carbon-carbon bond formation and the creation of asymmetric centres are both of great importance biochemically, but have not yet been accomplished by RNA catalysis, A widely used reaction that creates two new carbon-carbon bonds and up to four stereo-centres is the Diels-Alder cycloaddition, which occurs between a 1,3-butadiene and an alkene. Here we report the successful application of in vitro selection to isolate pyridine-modified RNA molecules that catalyse a Diels-Alder cycloaddition, We find that the RNA molecules accelerate the reaction rate by a factor of up to 800 relative to the uncatalysed reaction.	NEXSTAR PHARMACEUT INC,BOULDER,CO 80301									BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; Conn MM, 1996, J AM CHEM SOC, V118, P7012, DOI 10.1021/ja961249c; Cotton F.A., 1988, ADV INORG CHEM; Dewey TM, 1996, NUCLEOS NUCLEOT, V15, P1611, DOI 10.1080/07328319608002461; ILLANGASEKARE M, 1995, SCIENCE, V267, P643, DOI 10.1126/science.7530860; JENCKS WP, 1987, CATALYSIS CHEM ENZYM, P644; Joyce GF, 1996, CURR BIOL, V6, P965, DOI 10.1016/S0960-9822(02)00640-1; JOYCE GF, 1991, NEW BIOL, V3, P399; JOYCE GF, 1996, CHEM BIOL, V3, P405; KAZAKOV SA, 1996, T BIOORG BIOL CHEM, P244; KUMAR PKR, 1995, FASEB J, V9, P1183, DOI 10.1096/fasebj.9.12.7672511; Li YF, 1996, NAT STRUCT BIOL, V3, P743, DOI 10.1038/nsb0996-743; Lohse PA, 1996, NATURE, V381, P442, DOI 10.1038/381442a0; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MORRIS KN, 1994, P NATL ACAD SCI USA, V91, P13028, DOI 10.1073/pnas.91.26.13028; Ni JS, 1996, ANAL CHEM, V68, P1989, DOI 10.1021/ac960270t; OTTO S, 1995, TETRAHEDRON LETT, V36, P2645, DOI 10.1016/0040-4039(95)00304-U; Otto S, 1996, J AM CHEM SOC, V118, P7702, DOI 10.1021/ja960318k; Pomerantz SC, 1997, J AM CHEM SOC, V119, P3861, DOI 10.1021/ja963875f; Tarasow TM, 1997, BIOCONJUGATE CHEM, V8, P89, DOI 10.1021/bc960082+; WIEGAND TW, IN PRESS CHEM BIOL; Williams J W, 1979, Methods Enzymol, V63, P437	24	300	322	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					54	57		10.1038/37950	http://dx.doi.org/10.1038/37950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288965				2022-12-01	WOS:A1997XU59600041
J	Cornwall, J				Cornwall, J			Tuberculosis: a clinical problem of international importance	LANCET			English	Article																			0	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 30	1997	350	9078					660	661		10.1016/S0140-6736(96)12039-0	http://dx.doi.org/10.1016/S0140-6736(96)12039-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288062				2022-12-01	WOS:A1997XU28300044
J	Raviglione, MC; Dye, C; Schmidt, S; Kochi, A				Raviglione, MC; Dye, C; Schmidt, S; Kochi, A			Assessment of worldwide tuberculosis control	LANCET			English	Article							UNITED-STATES; EPIDEMIOLOGY; TRENDS; EUROPE	Background Because worldwide tuberculosis (TB) control had never been assessed, WHO set up a surveillance and monitoring project in 1995. The objectives were to assess the performance of national TB programmes; to assess the extent of implementation of the WHO strategy of TB control; and to attempt a comparison between regions that had adopted the WHO strategy and those that had not. Methods In June, 1996, we sent data-collection forms requesting information on national TB programmes' control policies, 1995 case treatment results to 216 territories. We assessed the performance of national TB programmes by comparing case notifications with estimated incidence and by outcome of treatment in cohorts of patients. We also investigated worldwide treatment success and case detection among sputum-smear-positive patients. Findings 180 (83%) of the 216 countries, areas, and replied to WHO (98% of the In 1995, the WHO control strategy had been implemented in 75 countries, and in 39 of these implementation was countrywide. Up to 23% of the worldwide population lived in regions where the strategy was available. In 1995, 3 297 688 cases of TB (all types) were reported, of which 1 161 411 (35%) were sputum-smear positive. 54% of all reported cases in countries that used the WHO strategy were sputum-smear positive, compared with 30% in other countries. The worldwide case-detection rate of new sputum-smear-positive cases was 35%. 92% of cases registered for treatment in 1994 in regions that used WHO strategy were assessed for outcome and 76% were treated successfully, compared with 54% and 42%, respectively, in regions that had not implemented the WHO strategy. Among cases reported worldwide in 1994, the documented treatment-success rate was 43%. Interpretation National TB programmes that have control adopted the WHO TB strategy achieve higher cure rates, but their impact on TB is modest on a worldwide scale. Wider continuous coverage with the WHO strategy is needed for effective worldwide TB control.			Raviglione, MC (corresponding author), WHO, GLOBAL TB PROGRAMME, 20 AVE APPIA, CH-1211 GENEVA 27, SWITZERLAND.		Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793; RAVIGLIONE, Mario/0000-0002-9331-2067				CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; Enarson D A, 1991, Bull Int Union Tuberc Lung Dis, V66, P195; Harries AD, 1996, LANCET, V347, P807, DOI 10.1016/S0140-6736(96)90874-0; Jain NK, 1992, IND J TUBERC, V92, P145; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; *NAT TUB I, 1974, B WORLD HEALTH ORGAN, V51, P473; RAVIGLIONE MC, 1994, TUBERCLE LUNG DIS, V75, P400, DOI 10.1016/0962-8479(94)90113-9; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; SPRINGETT V H, 1971, Tubercle, V52, P73, DOI 10.1016/0041-3879(71)90015-8; SRYBLO K, 1989, REV INFECT DIS S2, V11, pS339; Styblo K, 1985, B INT UNION TUBERC L, V60, P117; UPLEKAR MW, 1993, TUBERCLE LUNG DIS, V74, P332, DOI 10.1016/0962-8479(93)90108-A; *WHO, 1997, WHOTB97225; *WHO, 1991, 44WORLD HLTH ASS GEN; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2; World Health Organization, 1994, WHOTB94179; Yanai H, 1996, AIDS, V10, P527, DOI 10.1097/00002030-199605000-00012; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1	22	153	158	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	1997	350	9078					624	629		10.1016/S0140-6736(97)04146-9	http://dx.doi.org/10.1016/S0140-6736(97)04146-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU283	9288045				2022-12-01	WOS:A1997XU28300010
J	Lodmell, JS; Dahlberg, AE				Lodmell, JS; Dahlberg, AE			A conformational switch in Escherichia coli 16S ribosomal RNA during decoding of messenger RNA	SCIENCE			English	Article							DIRECTED CROSS-LINKING; AFFECT TRANSLATIONAL FIDELITY; HIGHER-ORDER STRUCTURE; SECONDARY STRUCTURE; 30S SUBUNIT; A-SITE; P-SITE; REGION; BINDING; INITIATION	Direct evidence is presented for a conformational switch in 16S ribosomal RNA (rRNA) that affects tRNA binding to the ribosome and decoding of messenger RNA (mRNA). These data support the hypothesis that dynamic changes in rRNA structure occur during translation. The switch involves two alternating base-paired arrangements apparently facilitated by ribosomal proteins S5 and S12, and produces significant changes in the rRNA structure, Chemical probing shows reciprocal enhancements or protections at sites in 16S rRNA that are at or very near sites that were previously crosslinked to mRNA. These data indicate that the switch affects codon-anticodon arrangement acid proper selection of tRNA at the ribosomal A site, and that the switch is a fundamental mechanism in all ribosomes.	BROWN UNIV, DEPT MOL & CELL BIOL & BIOCHEM, PROVIDENCE, RI 02912 USA	Brown University					NIGMS NIH HHS [GM19756, GM07601] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAD JP, 1994, J MOL BIOL, V235, P1251, DOI 10.1006/jmbi.1994.1078; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; ANDERSSON DI, 1982, MOL GEN GENET, V187, P467, DOI 10.1007/BF00332630; ANDERSSON DI, 1986, BIOCHIMIE, V68, P705, DOI 10.1016/S0300-9084(86)80164-X; BILGIN N, 1990, EMBO J, V9, P735, DOI 10.1002/j.1460-2075.1990.tb08167.x; BOHMAN K, 1984, MOL GEN GENET, V198, P90, DOI 10.1007/BF00328706; BRAKIERGINGRAS L, COMMUNICATION; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; BRINK MF, 1993, EMBO J, V12, P3987, DOI 10.1002/j.1460-2075.1993.tb06076.x; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x; CURRAN JF, 1989, J MOL BIOL, V209, P65, DOI 10.1016/0022-2836(89)90170-8; DAMMEL CS, 1993, GENE DEV, V7, P660, DOI 10.1101/gad.7.4.660; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; Ehrenberg M, 1995, BIOCHEM CELL BIOL, V73, P1049, DOI 10.1139/o95-112; EHRESMANN C, 1986, NUCLEIC ACIDS RES, V14, P4803, DOI 10.1093/nar/14.12.4803; ERICSON G, 1995, J MOL BIOL, V250, P407, DOI 10.1006/jmbi.1995.0386; GESTELAND RF, 1993, RNA WORLD; GLOTZ C, 1980, NUCLEIC ACIDS RES, V8, P2377, DOI 10.1093/nar/8.11.2377; Gorini L., 1974, RIBOSOMES; GRAVEL M, 1987, BIOCHEMISTRY-US, V26, P6227, DOI 10.1021/bi00393a041; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; Heilek GM, 1996, SCIENCE, V272, P1659, DOI 10.1126/science.272.5268.1659; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HUI A, 1987, P NATL ACAD SCI USA, V84, P4762, DOI 10.1073/pnas.84.14.4762; JACOB WF, 1987, P NATL ACAD SCI USA, V84, P4757, DOI 10.1073/pnas.84.14.4757; Karimi R, 1996, EMBO J, V15, P1149, DOI 10.1002/j.1460-2075.1996.tb00453.x; KURLAND CG, 1990, RIBOSOME, P513; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; LATEANA A, 1995, RNA, V1, P772; LAUGHREA M, 1992, BIOCHEMISTRY-US, V31, P12035, DOI 10.1021/bi00163a011; Liebman Stuart., COMMUNICATION; LODMELL JS, 1995, P NATL ACAD SCI USA, V92, P10555, DOI 10.1073/pnas.92.23.10555; LODMELL JS, 1993, BIOCHEMISTRY-US, V32, P4067, DOI 10.1021/bi00066a030; LODMELL JS, UNPUB; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V191, P483, DOI 10.1016/0022-2836(86)90143-9; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1996, RIBOSOMAL RNA STRUCT, P239; OCONNOR M, 1992, NUCLEIC ACIDS RES, V20, P4221, DOI 10.1093/nar/20.16.4221; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; POWERS T, 1995, RNA, V1, P194; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; RHEINBERGER HJ, 1983, EUR J BIOCHEM, V134, P421, DOI 10.1111/j.1432-1033.1983.tb07584.x; RINKEAPPEL J, 1994, NUCLEIC ACIDS RES, V22, P3018, DOI 10.1093/nar/22.15.3018; RINKEAPPEL J, 1993, NUCLEIC ACIDS RES, V21, P2853, DOI 10.1093/nar/21.12.2853; Rodnina MV, 1995, BIOCHEM CELL BIOL, V73, P1221, DOI 10.1139/o95-132; Sergiev PV, 1997, RNA, V3, P464; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SIPLEY J, 1993, P NATL ACAD SCI USA, V90, P2315, DOI 10.1073/pnas.90.6.2315; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TRIMAN K, 1989, J MOL BIOL, V209, P645, DOI 10.1016/0022-2836(89)92000-7; VandePeer Y, 1996, NUCLEIC ACIDS RES, V24, P86, DOI 10.1093/nar/24.1.86; VANRYK DI, 1995, NUCLEIC ACIDS RES, V23, P3563, DOI 10.1093/nar/23.17.3563; VILA A, 1994, P NATL ACAD SCI USA, V91, P11148, DOI 10.1073/pnas.91.23.11148; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WATANABE S, 1972, J MOL BIOL, V67, P443, DOI 10.1016/0022-2836(72)90462-7; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; ZAMIR A, 1971, J MOL BIOL, V60, P347, DOI 10.1016/0022-2836(71)90299-3; ZIMMERMANN RA, 1996, RIBOSOMAL RNA STRUCT, P277	67	183	192	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	1997	277	5330					1262	1267		10.1126/science.277.5330.1262	http://dx.doi.org/10.1126/science.277.5330.1262			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271564				2022-12-01	WOS:A1997XT82700043
J	Cabral, JHM; Jackson, AP; Smith, CV; Shikotra, N; Maxwell, A; Liddington, RC				Cabral, JHM; Jackson, AP; Smith, CV; Shikotra, N; Maxwell, A; Liddington, RC			Crystal structure of the breakage-reunion domain of DNA gyrase	NATURE			English	Article							A PROTEIN; COMPLEX; TOPOISOMERASE; TRANSPORT; GRAPHICS; PROGRAM	DNA gyrase is a type II DNA topoisomerase from bacteria that introduces supercoils into DNA(1,2). It catalyses the breakage of a DNA duplex (the G segment), the passage of another segment (the T segment) through the break, and then the reunification of the break. This activity involves the opening and dosing of a series of molecular 'gates' which is coupled to ATP hydrolysis. Here we present the crystal structure of the 'breakage-reunion' domain of the gyrase at 2.8 Angstrom resolution. Comparison of the structure of this 59K (relative molecular mass, 59,000) domain with that of a 92K fragment of yeast topoisomerase II (ref. 3) reveals a very different quaternary organization, and we propose that the two structures represent two principal conformations that participate in the enzymatic pathway. The gyrase structure reveals a new dimer contact with a grooved concave surface for binding the G segment and a duster of conserved charged residues surrounding the active-site tyrosines. It also shows how breakage of the G segment can occur and, together with the topoisomerase II structure, suggests a pathway by which the T segment can be released through the second gate of the enzyme. Mutations that confer resistance to the quinolone antibacterial agents cluster at the new dimer interface, indicating how these drugs might interact with the gyrase-DNA complex.	UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND	University of Leicester			Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716; Maxwell, Anthony/0000-0002-5756-6430				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Caron P R, 1994, Adv Pharmacol, V29B, P271; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Wigley D.B., 1995, NUCL ACIDS MOL BIOL, P165; WILLMOTT CJR, 1993, ANTIMICROB AGENTS CH, V37, P126, DOI 10.1128/AAC.37.1.126	22	382	388	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					903	906		10.1038/42294	http://dx.doi.org/10.1038/42294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278055	Bronze			2022-12-01	WOS:A1997XT75400056
J	Severin, FF; Sorger, PK; Hyman, AA				Severin, FF; Sorger, PK; Hyman, AA			Kinetochores distinguish GTP from GDP forms of the microtubule lattice	NATURE			English	Article							SLOWLY HYDROLYZABLE ANALOG; NEWT LUNG-CELLS; DYNAMIC INSTABILITY; BUDDING YEAST; MITOTIC SPINDLE; PROTEIN COMPLEX; LIVING CELLS; IN-VITRO; CENTROMERE; HYDROLYSIS	During prometaphase in mitotic cell division, chromosomes attach to the walls of microtubules and subsequently move to microtubule ends, where they stay throughout mitosis(1,2). This end-attachment seems to be essential for correct chromosome segregating. However, the mechanism by which kinetochores, the multiprotein complexes that link chromosomes to the microtubules of the mitotic spindle(3,4), recognize and stay attached to microtubule ends is not understood. One due comes from the hydrolysis of GTP that occurs during microtubule polymerization. Although tubulin dimers must contain GTP to polymerize, this GTP is rapidly hydrolysed following the addition of dimers to a growing polymer. This creates a microtubule consisting largely of GDP-tubulin, with a small cap of GTP-tubulin at the ends. It is possible that kinetochores distinguish the different structural states of a GTP-versus a GDP-microtubule lattice, We have examined this question in vitro using reconstituted kinetochores from the yeast Saccharomyces cerevisiae. We found that kinetochores in vitro bind preferentially to GTP-rather than GDP-microtubules, and to the plus-end preferentially over the lattice. Our results could explain how kinetochores stay at microtubule ends and thus segregate chromosomes correctly during mitosis in vivo. This result demonstrates that proteins exist that can distinguish the GTP conformation of the microtubule lattice.	EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	European Molecular Biology Laboratory (EMBL); Massachusetts Institute of Technology (MIT)			Hyman, Anthony A/B-3917-2017; Severin, Fedor/AAD-5444-2019; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Sorger, Peter/0000-0002-3364-1838; Severin, Fedor/0000-0001-6703-1256				ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; BAILEY NTJ, 1995, STATISTICAL METHODS; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; EARNSHAW W C, 1992, Current Opinion in Cell Biology, V4, P86, DOI 10.1016/0955-0674(92)90063-I; HUITOREL P, 1988, J CELL BIOL, V106, P151, DOI 10.1083/jcb.106.1.151; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; KINGSBURY J, 1991, CELL, V66, P483, DOI 10.1016/0092-8674(81)90012-X; KINGSBURY J, 1993, MOL BIOL CELL, V4, P859, DOI 10.1091/mbc.4.8.859; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; MILLER JM, 1990, J CELL BIOL, V110, P703, DOI 10.1083/jcb.110.3.703; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SCHILSTRA MJ, 1987, BIOCHEM BIOPH RES CO, V147, P588, DOI 10.1016/0006-291X(87)90971-5; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WANG W, 1993, J BIOL CHEM, V268, P24796	31	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					888	891		10.1038/42270	http://dx.doi.org/10.1038/42270			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278051	Bronze			2022-12-01	WOS:A1997XT75400052
J	Kerneis, S; Bogdanova, A; Kraehenbuhl, JP; Pringault, E				Kerneis, S; Bogdanova, A; Kraehenbuhl, JP; Pringault, E			Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria	SCIENCE			English	Article							VIBRIO-CHOLERAE; EXPRESSION; BINDING; CACO-2; VILLIN; MODEL; LINE	The epithelium that lines the gut is impermeable to macromolecules and microorganisms, except in Peyer's patches (PPs), where the lymphoid follicle-associated epithelium (FAE) contains M cells that transport antigens and microorganisms. A cultured system that reproduces the main characteristics of FAE and M cells was established by cultivation of PP lymphocytes with the differentiated human intestinal cell line Caco-2. Lymphocytes settled into the epithelial monolayer, inducing reorganization of the brush border and a temperature-dependent transport of particles and Vibrio cholerae. This model system could prove useful for intestinal physiology, vaccine research, and drug delivery studies.	UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, SWISS INST EXPT CANC RES, CH-1066 EPALINGES, SWITZERLAND	University of Lausanne; Swiss Institute Experimental Cancer Research; University of Lausanne								Bens M, 1996, AM J PHYSIOL-CELL PH, V270, pC1666, DOI 10.1152/ajpcell.1996.270.6.C1666; Bienenstock J., 1994, HDB MUCOSAL IMMUNOLO, P403; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DANIELSEN EM, 1994, BIOCHEMISTRY-US, V33, P1599, DOI 10.1021/bi00172a041; DEBEAUREGARD MAC, 1995, EMBO J, V14, P409, DOI 10.1002/j.1460-2075.1995.tb07017.x; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; FREEMAN TC, 1995, PFLUG ARCH EUR J PHY, V430, P394, DOI 10.1007/BF00373915; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; KAOUTZANI P, 1994, J CLIN INVEST, V94, P788, DOI 10.1172/JCI117398; KEMEIS S, UNPUB; Kerneis S, 1996, GASTROENTEROLOGY, V110, P515, DOI 10.1053/gast.1996.v110.pm8566599; KRAEHENBUHL JP, UNPUB; MACDONALD TT, 1982, IMMUNOLOGY, V45, P769; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; OWEN RL, 1983, AM J ANAT, V168, P199, DOI 10.1002/aja.1001680207; OWEN RL, 1986, J INFECT DIS, V153, P1108, DOI 10.1093/infdis/153.6.1108; PANIGRAHI P, 1990, INFECT IMMUN, V58, P3415, DOI 10.1128/IAI.58.10.3415-3424.1990; PAPPO J, 1989, CLIN EXP IMMUNOL, V76, P144; PINTO M, 1983, BIOL CELL, V47, P323; SAVIDGE TC, 1994, PFLUG ARCH EUR J PHY, V428, P391, DOI 10.1007/BF00724523; SAVIDGE TC, 1995, ADV EXP MED BIOL, V371, P239; Siebers A, 1996, TRENDS MICROBIOL, V4, P22, DOI 10.1016/0966-842X(96)81501-0; SMITH MW, 1985, J CELL PHYSIOL, V124, P219, DOI 10.1002/jcp.1041240208	24	490	509	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					949	952		10.1126/science.277.5328.949	http://dx.doi.org/10.1126/science.277.5328.949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252325				2022-12-01	WOS:A1997XQ98500040
J	CourtoisCoutry, N; Roush, D; Rajendran, V; McCarthy, JB; Geibel, J; Kashgarian, M; Caplan, MJ				CourtoisCoutry, N; Roush, D; Rajendran, V; McCarthy, JB; Geibel, J; Kashgarian, M; Caplan, MJ			A tyrosine-based signal targets H/K-ATPase to a regulated compartment and is required for the cessation of gastric acid secretion	CELL			English	Article							HELICOBACTER-PYLORI; MENETRIERS DISEASE; HYPERTROPHIC GASTROPATHY; PARIETAL-CELLS; TRANSFERRIN RECEPTOR; NATURAL-HISTORY; TRANSGENIC MICE; ENDOCYTOSIS; INTERNALIZATION; IDENTIFICATION	Gastric acid secretion is mediated by the H/K-ATPase of parietal cells. Activation of acid secretion involves insertion of H/K-ATPase into the parietal cell plasmalemma, while its cessation is associated with reinternalization of the H/K-ATPase into an intracellular storage compartment The cytoplasmic tail of the H/K-ATPase beta subunit includes a four residue sequence homologous to tyrosine-based endocytosis signals. We generated transgenic mice expressing H/K-ATPase beta subunit in which this motif's tyrosine residue is mutated to alanine. Gastric glands from animals expressing mutant beta subunit constitutively secrete acid and continuously express H/K-ATPase at their cell surfaces. Thus, the beta subunit's tyrosine-based signal is required for the internalization of H/K-ATPase and for the termination of acid secretion. As a consequence of chronic hyperacidity, the mice develop gastric ulcers and a hypertrophic gastropathy resembling Menetrier's disease.	YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT SURG,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University			COUTRY, Nathalie/O-9352-2017	COUTRY, Nathalie/0000-0001-5830-4013; Caplan, Michael/0000-0001-5768-4405				[Anonymous], 1993, Gut, V34, P1672; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BAYERDORFFER E, 1993, NEW ENGL J MED, V329, P60, DOI 10.1056/NEJM199307013290116; BAYERDORFFER E, 1994, GUT, V35, P701, DOI 10.1136/gut.35.5.701; BERGLINDH T, 1980, AM J PHYSIOL, V238, pG165, DOI 10.1152/ajpgi.1980.238.3.G165; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; BLASER MJ, 1987, GASTROENTEROLOGY, V93, P371, DOI 10.1016/0016-5085(87)91028-6; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CHEW CS, 1986, AM J PHYSIOL, V250, pG814, DOI 10.1152/ajpgi.1986.250.6.G814; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS JM, 1977, ANN SURG, V185, P456, DOI 10.1097/00000658-197704000-00015; FORTE TM, 1977, GASTROENTEROLOGY, V73, P941; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; FRANK BW, 1967, GASTROENTEROLOGY, V53, P953; GEIBEL J, 1995, GASTROENTEROLOGY, V109, P1060, DOI 10.1016/0016-5085(95)90563-4; GIRONES N, 1991, J BIOL CHEM, V266, P19006; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; Hogan B., 1986, MANIPULATING MOUSE E; KIRKPATRICK PM, 1980, GASTROENTEROLOGY, V79, P4; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; LENCER WI, 1990, J CELL BIOL, V111, P379, DOI 10.1083/jcb.111.2.379; Menetrier P, 1888, ARCH PHYSL NORM PATH, V1, P32; MENETRIER P, 1888, ARCH PHYSL NORM PATH, V1, P236; MERCIER F, 1989, J CELL BIOL, V108, P441, DOI 10.1083/jcb.108.2.441; Murer H, 1996, ANNU REV PHYSIOL, V58, P607, DOI 10.1146/annurev.physiol.58.1.607; PETTITT JM, 1995, J CELL SCI, V108, P1127; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SCHARSCHMIDT BF, 1977, AM J MED, V63, P644, DOI 10.1016/0002-9343(77)90210-8; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; SCHOFIELD GC, 1979, J ANAT, V128, P669; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; STOLTE M, 1993, Z GASTROENTEROL, V31, P289; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; VERHEY KJ, 1995, J CELL BIOL, V130, P1071, DOI 10.1083/jcb.130.5.1071; Wang L, 1996, AM J PHYSIOL-GASTR L, V271, pG613, DOI 10.1152/ajpgi.1996.271.4.G613; WOLFSEN HC, 1993, GASTROENTEROLOGY, V104, P1310, DOI 10.1016/0016-5085(93)90339-E; ZOLLINGER RM, 1955, ANN SURG, V142, P709, DOI 10.1097/00000658-195510000-00015	44	94	98	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					501	510		10.1016/S0092-8674(00)80510-3	http://dx.doi.org/10.1016/S0092-8674(00)80510-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267030	hybrid			2022-12-01	WOS:A1997XQ06300014
J	Domian, IJ; Quon, KC; Shapiro, L				Domian, IJ; Quon, KC; Shapiro, L			Cell type-specific phosphorylation and proteolysis of a transcriptional regulator controls the G1-to-S transition in a bacterial cell cycle	CELL			English	Article							HISTIDINE PROTEIN-KINASE; CAULOBACTER-CRESCENTUS; ESCHERICHIA-COLI; CHROMOSOMAL ORIGIN; DNA-REPLICATION; GENE-EXPRESSION; ACTIVATOR; DIVISION; SITE; DIFFERENTIATION	The global transcriptional regulator CtrA controls multiple events in the Caulobacter cell cycle, including the initiation of DNA replication, DNA methylation, cell division, and flagellar biogenesis. CtrA is a member of the response regulator family of two component signal transduction systems and is activated by phosphorylation. We report here that this phosphorylation signal enters the cell cycle at mid S phase. In addition, CtrA function is modulated by temporally and spatially controlled proteolysis. When an active CtrA protein is present at the wrong time in the cell cycle, owing to expression of a mutant CtrA derivative that is active in the absence of phosphorylation and is not turned over during the cell cycle, the G1-to-S transition is blocked and the cell cycle aborts. Thus, both phosphorylation and proteolysis are critical determinants of bacterial cell cycle control in a manner that is analogous to the control of the eukaryotic cell cycle.			Domian, IJ (corresponding author), STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NIGMS NIH HHS [GM51426, GM32506/5120MZ] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032506, R01GM032506] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; ALLEY MRK, 1993, SCIENCE, V259, P1754, DOI 10.1126/science.8456303; BENSON AK, 1994, P NATL ACAD SCI USA, V91, P4989, DOI 10.1073/pnas.91.11.4989; BROWN JL, 1994, EMBO J, V13, P5186, DOI 10.1002/j.1460-2075.1994.tb06849.x; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Creighton TE, 1993, PROTEINS STRUCTURES; DEGNEN ST, 1972, J BACTERIOL, V110, P852, DOI 10.1128/JB.110.3.852-856.1972; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; DINGWALL A, 1992, J BACTERIOL, V174, P1760, DOI 10.1128/jb.174.6.1760-1768.1992; ELY B, 1991, METHOD ENZYMOL, V204, P372; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; Hendrix R.W., 1983, LAMBDA, VII; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARCZYNSKI GT, 1992, J MOL BIOL, V226, P959, DOI 10.1016/0022-2836(92)91045-Q; MARCZYNSKI GT, 1995, GENE DEV, V9, P1543, DOI 10.1101/gad.9.12.1543; Meisenzahl AC, 1997, J BACTERIOL, V179, P592, DOI 10.1128/jb.179.3.592-600.1997; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; NAYSMITH K, 1993, CURR OPIN CELL BIOL, V5, P166; OHTA N, 1992, P NATL ACAD SCI USA, V89, P10297, DOI 10.1073/pnas.89.21.10297; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Pogliano K, 1997, J BACTERIOL, V179, P3331, DOI 10.1128/jb.179.10.3331-3341.1997; Quardokus E, 1996, P NATL ACAD SCI USA, V93, P6314, DOI 10.1073/pnas.93.13.6314; Quon KC, 1996, CELL, V84, P83, DOI 10.1016/S0092-8674(00)80995-2; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Stephens C, 1996, P NATL ACAD SCI USA, V93, P1210, DOI 10.1073/pnas.93.3.1210; STEPHENS CM, 1993, MOL MICROBIOL, V9, P1169, DOI 10.1111/j.1365-2958.1993.tb01246.x; WANG SP, 1993, P NATL ACAD SCI USA, V90, P630, DOI 10.1073/pnas.90.2.630; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; WINGROVE JA, 1993, GENE DEV, V7, P1979, DOI 10.1101/gad.7.10.1979; Wingrove JA, 1996, SCIENCE, V274, P597, DOI 10.1126/science.274.5287.597; WINZELER E, 1995, J MOL BIOL, V251, P346, DOI 10.1006/jmbi.1995.0439; Wright R, 1996, GENE DEV, V10, P1532, DOI 10.1101/gad.10.12.1532; YU J, 1992, J BACTERIOL, V174, P3327, DOI 10.1128/jb.174.10.3327-3338.1992; ZWEIGER G, 1994, J MOL BIOL, V235, P472, DOI 10.1006/jmbi.1994.1007	43	328	329	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					415	424		10.1016/S0092-8674(00)80502-4	http://dx.doi.org/10.1016/S0092-8674(00)80502-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267022	Bronze			2022-12-01	WOS:A1997XQ06300006
J	PalBhadra, M; Bhadra, U; Birchler, JA				PalBhadra, M; Bhadra, U; Birchler, JA			Cosuppression in Drosophila: Gene silencing of Alcohol dehydrogenase by white-Adh transgenes is Polycomb dependent	CELL			English	Article							MELANOGASTER; EXPRESSION; COMPLEX; ZESTE; CHROMATIN; POSITION; ELEMENT; STATE; LOCUS	When two to six copies of a white promoter-Alcohol dehydrogenase (Adh) reporter fusion gene are introduced into the genome, the expression is progressively reduced both in larvae and adults rather than the expected gene dosage effect. In addition, multiple transgenes reduce endogenous Adh transcripts, a result that is strongly analogous to ''cosuppression'' phenomena described in many plant species but which has not been previously observed in animals. Silencing of the Adh gene is not influenced by zeste-dependent transvection but strongly affected by the Polycomb and Polycomblike mutations. Polycomb and polyhomeotic proteins are bound to the chromatin at the sites of the repressed w-Adh transgenes.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BABU P, 1980, DEV NEUROBIOLOGY DRO, P35; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BENYAJATI C, 1982, NUCLEIC ACIDS RES, V10, P7261, DOI 10.1093/nar/10.22.7261; BIALOJAN S, 1984, EMBO J, V3, P2543, DOI 10.1002/j.1460-2075.1984.tb02170.x; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; Depicker A., 1996, MECH APPL GENE SILEN, P71; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; FJOSE A, 1984, EMBO J, V3, P2087, DOI 10.1002/j.1460-2075.1984.tb02095.x; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GELBART WM, 1985, COLD SPRING HARB SYM, V50, P119, DOI 10.1101/SQB.1985.050.01.017; GREEN MM, 1959, HEREDITY, V13, P302; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; JACK JW, 1979, P NATL ACAD SCI USA, V76, P1368, DOI 10.1073/pnas.76.3.1368; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; KAUFMAN TC, 1973, GENETICS, V75, P299; LAURIE CC, 1994, GENETICS, V138, P379; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; RABINOW L, 1991, GENETICS, V129, P463; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; ROBERTSON HM, 1988, GENETICS, V118, P461; SCHMIDT ER, 1988, CHROMOSOMA, V96, P353, DOI 10.1007/BF00330701; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; Ursprnng H, 1970, Wilhelm Roux Arch. EntwMech. Org., V164, P201, DOI 10.1007/BF00582032; VANBLOKLAND R, 1994, PLANT J, V6, P861, DOI 10.1046/j.1365-313X.1994.6060861.x	31	190	202	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					479	490		10.1016/S0092-8674(00)80508-5	http://dx.doi.org/10.1016/S0092-8674(00)80508-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267028	Bronze			2022-12-01	WOS:A1997XQ06300012
J	vanSlegtenhorst, M; deHoogt, R; Hermans, C; Nellist, M; Janssen, B; Verhoef, S; Lindhout, D; vandenOuweland, A; Halley, D; Young, J; Burley, M; Jeremiah, S; Woodward, K; Nahmias, J; Fox, M; Ekong, R; Osborne, J; Wolfe, J; Povey, S; Snell, RG; Cheadle, JP; Jones, AC; Tachataki, M; Ravine, D; Sampson, JR; Reeve, MP; Richardson, P; Wilmer, F; Munro, C; Hawkins, TL; Sepp, T; Ali, JBM; Ward, S; Green, AJ; Yates, JRW; Kwiatkowska, J; Henske, EP; Short, MP; Haines, JH; Jozwiak, S; Kwiatkowski, DJ				vanSlegtenhorst, M; deHoogt, R; Hermans, C; Nellist, M; Janssen, B; Verhoef, S; Lindhout, D; vandenOuweland, A; Halley, D; Young, J; Burley, M; Jeremiah, S; Woodward, K; Nahmias, J; Fox, M; Ekong, R; Osborne, J; Wolfe, J; Povey, S; Snell, RG; Cheadle, JP; Jones, AC; Tachataki, M; Ravine, D; Sampson, JR; Reeve, MP; Richardson, P; Wilmer, F; Munro, C; Hawkins, TL; Sepp, T; Ali, JBM; Ward, S; Green, AJ; Yates, JRW; Kwiatkowska, J; Henske, EP; Short, MP; Haines, JH; Jozwiak, S; Kwiatkowski, DJ			Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34	SCIENCE			English	Article							POLYCYSTIC KIDNEY-DISEASE; ABO BLOOD-GROUP; DIAGNOSTIC-CRITERIA; HETEROGENEITY; LINKAGE; LOCUS; LOCALIZATION; MUTATION; AUTISM; 16P13	Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the widespread development of distinctive tumors termed hamartomas. TSC-determining loci have been mapped to chromosomes 9q34 (TSC1) and 16p13 (TSC2). The TSC1 gene was identified from a 900-kilobase region containing at least 30 genes. The 8.6-kilobase TSC1 transcript is widely expressed and encodes a protein of 130 kilodaltons (hamartin) that has homology to a putative yeast protein of unknown function. Thirty-two distinct mutations were identified in TSC1, 30 of which were truncating, and a single mutation (2105delAAAG) was seen in six apparently unrelated patients. In one of these six, a somatic mutation in the wild-type allele was found in a TSC-assaciated renal carcinoma, which suggests that hamartin acts as a tumor suppressor.	BRIGHAM & WOMENS HOSP, DIV EXPT MED & MED ONCOL, BOSTON, MA 02115 USA; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, NL-3000 DR ROTTERDAM, NETHERLANDS; UNIV ROTTERDAM HOSP, ROTTERDAM, NETHERLANDS; UNIV LONDON UNIV COLL, MRC, HUMAN BIOCHEM GENET UNIT, LONDON NW1 2HE, ENGLAND; UNIV LONDON UNIV COLL, GALTON LAB, LONDON NW1 2HE, ENGLAND; UNIV BATH, BATH BA2 7AY, AVON, ENGLAND; UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES; MIT, WHITEHEAD INST BIOMED RES, CTR GENOME RES, CAMBRIDGE, MA 02139 USA; UNIV CAMBRIDGE, ADDENBROOKES NHS TRUST, DEPT PATHOL, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CAMBRIDGE, ADDENBROOKES NHS TRUST, DEPT MED GENET, CAMBRIDGE CB2 2QQ, ENGLAND; UNIV CHICAGO, SCH MED, DEPT CHILD NEUROL, CHICAGO, IL 60637 USA; MASSACHUSETTS GEN HOSP, MOL NEUROGENET UNIT, BOSTON, MA 02129 USA; CHILDRENS HLTH CTR, DIV CHILD NEUROL, PL-04736 WARSAW, POLAND	Harvard University; Brigham & Women's Hospital; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; University of London; University College London; University of London; University College London; University of Bath; Cardiff University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Chicago; Harvard University; Massachusetts General Hospital; Children's Memorial Health Institute			Ali, Johari Mohd/B-5259-2010; Lindhout, Dick/AAH-5765-2019; Jura, Jolanta/F-8889-2015; Ravine, David/A-6797-2008; Hermans, Cedric/AAK-9433-2020; Green, Andrew/AAJ-7592-2020; Haines, Jonathan/C-3374-2012	Ali, Johari Mohd/0000-0002-6884-4280; Jura, Jolanta/0000-0002-0816-3475; Haines, Jonathan/0000-0002-4351-4728; Lindhout, Dick/0000-0001-9580-624X; Ekong, Rosemary/0000-0002-5984-7893; Snell, Russell/0000-0002-8166-4014; Jozwiak, Sergiusz/0000-0003-3350-6326; Green, Andrew/0000-0002-1077-7417				Au KS, 1996, J MED GENET, V33, P559, DOI 10.1136/jmg.33.7.559; Bjornsson J, 1996, AM J PATHOL, V149, P1201; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; BROOKES AJ, 1984, HUM MOL GENET, V3, P2011; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; Cook JA, 1996, J MED GENET, V33, P480, DOI 10.1136/jmg.33.6.480; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; FRYER AE, 1987, LANCET, V1, P659; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; HAINES JL, 1991, AM J HUM GENET, V49, P764; Hawkins TL, 1997, SCIENCE, V276, P1887, DOI 10.1126/science.276.5320.1887; HAWKINS TL, 1994, NUCLEIC ACIDS RES, V22, P4543, DOI 10.1093/nar/22.21.4543; Henske EP, 1996, AM J HUM GENET, V59, P400; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; HUNT A, 1993, J AUTISM DEV DISORD, V23, P323, DOI 10.1007/BF01046223; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; JANSSEN LAJ, 1990, GENOMICS, V8, P237, DOI 10.1016/0888-7543(90)90277-2; JONES C, 1980, CYTOGENET CELL GENET, V28, P181, DOI 10.1159/000131529; KANDT RS, 1989, EXP NEUROL, V104, P223, DOI 10.1016/0014-4886(89)90033-2; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; KUMAR A, 1995, HUM MOL GENET, V4, P2295, DOI 10.1093/hmg/4.12.2295; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KUMAR A, 1997, IN PRESS HUM MUTAT, V9, P64; Kwiatkowski David J., 1993, Cytogenetics and Cell Genetics, V64, P93, DOI 10.1159/000133566; KWIATKOWSKI DJ, 1994, ARCH DERMATOL, V130, P348, DOI 10.1001/archderm.130.3.348; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NELLIST M, 1993, J MED GENET, V30, P224, DOI 10.1136/jmg.30.3.224; NELLIST M, 1993, CELL, V75, P1305; NORTHRUP H, 1987, LANCET, V2, P804; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; ROACH ES, 1992, J CHILD NEUROL, V7, P221, DOI 10.1177/088307389200700219; SAMPSON JR, 1989, J MED GENET, V26, P28, DOI 10.1136/jmg.26.1.28; SAMPSON JR, 1989, J MED GENET, V26, P511, DOI 10.1136/jmg.26.8.511; Sepp T, 1996, J MED GENET, V33, P962, DOI 10.1136/jmg.33.11.962; SMALLEY SL, 1992, J AUTISM DEV DISORD, V22, P339, DOI 10.1007/BF01048239; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Vrtel R, 1996, J MED GENET, V33, P47, DOI 10.1136/jmg.33.1.47; WANG Q, IN PRESS HUM MUTAT; WEBB DW, 1991, J MED GENET, V28, P417, DOI 10.1136/jmg.28.6.417; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Xu Y, 1994, Genet Eng (N Y), V16, P241; [No title captured]	54	1192	1210	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					805	808		10.1126/science.277.5327.805	http://dx.doi.org/10.1126/science.277.5327.805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242607				2022-12-01	WOS:A1997XQ24700040
J	Schreiner, CE; Langner, G				Schreiner, CE; Langner, G			Laminar fine structure of frequency organization in auditory midbrain	NATURE			English	Article							INFERIOR COLLICULUS; CENTRAL NUCLEUS; SPECTRAL INTEGRATION; COCHLEAR NUCLEUS; SINGLE UNITS; CAT; INHIBITION; NERVE; REPRESENTATION; RESOLUTION	The perception of sound is based on signal processing by a bank of frequency-selective auditory filters, the so-called critical bands(1-3). Here we investigate how the internal frequency organization of the main auditory midbrain station, the central nucleus of the inferior colliculus (ICC), might contribute to the generation of the critical-band behaviour of its neurons. We find a unique spatial arrangement of the frequency distribution in the ICC that correlates with psychophysical critical-band characteristics. Systematic frequency discontinuities along the main tonotopic axis, in combination with a smooth frequency gradient orthogonal to the main tonotopic organization of cat ICC, reflect a layering of the frequency organization paralleling its anatomical laminae. This layered frequency organization is characterized by constant frequency ratios of corresponding locations on neighboring laminae and may provide a spatial framework for the generation of critical bands and for signal processing within(4) and across' frequency bands for the analysis of sound.	TECH UNIV DARMSTADT,INST ZOOL,D-64287 DARMSTADT,GERMANY	Technical University of Darmstadt	Schreiner, CE (corresponding author), UNIV CALIF SAN FRANCISCO,SLOAN CTR THEORET NEUROSCI,WM KECK CTR INTEGRAT NEUROSCI,COLEMAN LAB,SAN FRANCISCO,CA 94143, USA.			Schreiner, Christoph/0000-0002-4571-4328	NIDCD NIH HHS [R01 DC002260] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002260] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		CHAN JL, 1982, SOC NEUR ABSTR, V8, P348; EHRET G, 1991, BRAIN RES, V567, P350, DOI 10.1016/0006-8993(91)90819-H; EHRET G, 1984, HEARING RES, V14, P45, DOI 10.1016/0378-5955(84)90068-6; EHRET G, 1976, BIOL CYBERN, V24, P35, DOI 10.1007/BF00365592; EHRET G, 1985, SCIENCE, V227, P1245, DOI 10.1126/science.3975613; EHRET G, 1988, BRAIN RES REV, V13, P139, DOI 10.1016/0165-0173(88)90018-5; Evans E. F., 1989, BRIT J AUDIOL, V23, P151; Fletcher H, 1940, REV MOD PHYS, V12, P0047, DOI 10.1103/RevModPhys.12.47; GREENWOOD D, 1961, J ACOUST SOC AM, V33, P1344, DOI 10.1121/1.1908437; MALMIERCA MS, 1993, J COMP NEUROL, V333, P1, DOI 10.1002/cne.903330102; MERZENICH MM, 1974, BRAIN RES, V77, P397, DOI 10.1016/0006-8993(74)90630-1; NIENHUYS TGW, 1979, ACTA OTO-LARYNGOL, V88, P350, DOI 10.3109/00016487909137179; OLIVER DL, 1984, J COMP NEUROL, V224, P155, DOI 10.1002/cne.902240202; OLIVER DL, 1984, J COMP NEUROL, V222, P237, DOI 10.1002/cne.902220207; Palombi PS, 1996, J NEUROPHYSIOL, V75, P2211, DOI 10.1152/jn.1996.75.6.2211; PICKLES JO, 1976, J ACOUST SOC AM, V60, P1151, DOI 10.1121/1.381217; PICKLES JO, 1975, ACTA OTO-LARYNGOL, V80, P245, DOI 10.3109/00016487509121325; PICKLES JO, 1979, J ACOUST SOC AM, V66, P1725, DOI 10.1121/1.383645; POLLAK GD, 1993, HEARING RES, V65, P99, DOI 10.1016/0378-5955(93)90205-F; ROCKEL AJ, 1973, J COMP NEUROL, V147, P11, DOI 10.1002/cne.901470103; ROTH GL, 1978, J COMP NEUROL, V182, P661, DOI 10.1002/cne.901820407; SCHREINER CE, 1988, J NEUROPHYSIOL, V60, P1823, DOI 10.1152/jn.1988.60.6.1823; SEMPLE MN, 1979, J NEUROPHYSIOL, V42, P1626, DOI 10.1152/jn.1979.42.6.1626; SERVIERE J, 1981, NEUROSCI LETT, V27, P113, DOI 10.1016/0304-3940(81)90253-6; SHNEIDERMAN A, 1987, J COMP NEUROL, V266, P519, DOI 10.1002/cne.902660406; SUGA N, 1985, J NEUROPHYSIOL, V53, P1109, DOI 10.1152/jn.1985.53.4.1109; SUGA N, 1995, NEUROSCI RES, V21, P287, DOI 10.1016/0168-0102(94)00868-G; WATSON CS, 1963, J ACOUST SOC AM, V62, P167; YOST WA, 1989, J ACOUST SOC AM, V85, P848, DOI 10.1121/1.397556; ZWICKER E, 1957, J ACOUST SOC AM, V29, P548, DOI 10.1121/1.1908963	30	161	166	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					383	386		10.1038/41106	http://dx.doi.org/10.1038/41106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237756				2022-12-01	WOS:A1997XM52800052
J	Zuber, PLF; McKenna, MT; Binkin, NJ; Onorato, IM; Castro, KG				Zuber, PLF; McKenna, MT; Binkin, NJ; Onorato, IM; Castro, KG			Long-term risk of tuberculosis among foreign-born persons in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTIVE THERAPY; EPIDEMIOLOGY; INFECTION; TRANSMISSION; IMMIGRANTS; CANADA; ADULTS	Context.-Cases of tuberculosis (TB) in the United States have declined for 4 consecutive years, but cases among foreign-born persons account for an increasing percentage. Objective.-To describe the risk of tuberculosis among foreign-born persons with respect to their length of residence in the United States. Design.-Cross-sectional analysis of national surveillance data. Setting.-The United States. Patients.-All verified TB cases reported to the Centers for Disease Control and Prevention between 1986 and 1994. Main Outcome Measure.-Stratum-specific incidence rates of TB by age, place of birth, length of residence, age at arrival in the United States, or combinations of these variables. Results.-Several groups of persons from countries with a high prevalence of TB had incidence rates higher than 20 per 100 000 person-years more than 20 years after arrival. Among long-term residents, those who arrived in the United Stales after their fifth birthday had incidence rates of TB 2 to 6 times higher than those of similar age who arrived before their fifth birthday. A total of 45% of the TB cases were among persons younger than 35 years and an additional 18% were among persons who arrived in the United States before their 35th birthday. Conclusions.-Imported Mycobacterium tuberculosis infection (active or latent) is responsible for most TB cases among foreign-born persons in the United States. Detection of active cases among recent arrivals is the main priority in these populations, but many cases were in persons who arrived in the United States before the age of 35 years that could potentially have been avoided with preventive therapy. Elimination of TB in the United States may not be feasible using available diagnostic and treatment modalities without increased efforts to address the global burden of this disease.			Zuber, PLF (corresponding author), CTR DIS CONTROL & PREVENT, DIV TB ELIMINAT, 1600 CLIFTON RD, MAILSTOP E-10, ATLANTA, GA 30333 USA.		Castro, Kenneth G/P-1882-2018	Castro, Kenneth G/0000-0001-7964-6354				*1990 CENS POP HOU, 1992, PUBL US MICR SAMPL T; AICKIN M, 1991, AM J PUBLIC HEALTH, V81, P918, DOI 10.2105/AJPH.81.7.918; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ASCH S, 1994, WESTERN J MED, V161, P373; BALLEW KA, 1995, SOUTHERN MED J, V88, P1025, DOI 10.1097/00007611-199510000-00005; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Binkin NJ, 1996, CLIN INFECT DIS, V23, P1226, DOI 10.1093/clinids/23.6.1226; BISGARD K, 1994, AM J RESP CRIT CARE, V149, pA703; *BUR CENS, 1993, 1990 CENS POP FOR BO; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P40; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P703; *CDCP, 1996, MMWR; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P8; Centers for Disease control and prevention: Update: Trends in total alcohol syndrome-United States, 1995, MMWR-MORBID MORTAL W, V44, p[1979, 13]; DERIEMER K, 1995, 123 M AM PUBL HLTH A; ENARSON D, 1979, AM REV RESPIR DIS, V119, P11; ENARSON DA, 1994, MAYO CLIN PROC, V69, P85, DOI 10.1016/S0025-6196(12)61618-8; ENARSON DA, 1980, EUR J RESPIR DIS, V61, P139; FEIN DJ, 1990, DEMOGRAPHY, V27, P285, DOI 10.2307/2061454; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845; GUERIN N, 1995, PEDIATR PULM, P18; HOPEWELL P, 1995, TUBER LUNG DIS S2, V76, P47; *IMM NAT SERV, 1996, STAT YB IMM NAT SERV; ISEMAN MD, 1995, NEW ENGL J MED, V332, P1094, DOI 10.1056/NEJM199504203321611; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; POWELL KE, 1983, JAMA-J AM MED ASSOC, V249, P1455, DOI 10.1001/jama.249.11.1455; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIDZON R, IN PRESS J PEDIAT; ROSE DN, 1988, AM J PREV MED, V4, P102, DOI 10.1016/S0749-3797(18)31204-2; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579; SPRINGETT V H, 1958, Br J Prev Soc Med, V12, P135; SPRINGETT VH, 1964, LANCET, V1, P1091; STARKE JR, 1995, JAMA-J AM MED ASSOC, V274, P652, DOI 10.1001/jama.274.8.652; STERLING TR, 1995, ARCH INTERN MED, V155, P1622, DOI 10.1001/archinte.155.15.1622; STEVENSON DK, 1962, BMJ-BRIT MED J, P1382, DOI 10.1136/bmj.1.5289.1382; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; WELLS CD, 1996, 45 ANN EP INT SERV C; WILLERT PD, 1996, MID YEAR M N AM REG; *WORLD BANK, 1993, WORLD DEV REP; Zuber PLF, 1996, TUBERCLE LUNG DIS, V77, P524, DOI 10.1016/S0962-8479(96)90050-7; Zuber PLF, 1996, AM J RESP CRIT CARE, V154, P151, DOI 10.1164/ajrccm.154.1.8680671	46	175	176	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 23	1997	278	4					304	307		10.1001/jama.278.4.304	http://dx.doi.org/10.1001/jama.278.4.304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL059	9228436				2022-12-01	WOS:A1997XL05900031
J	Grether, JK; Nelson, KB				Grether, JK; Nelson, KB			Maternal infection and cerebral palsy in infants of normal birth weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MECONIUM ASPIRATION SYNDROME; PRETERM PREMATURE RUPTURE; PERINATAL RISK-FACTORS; INTRAAMNIOTIC INFECTION; COMPLICATIONS; PREDICTORS; ASPHYXIA; SEPSIS; POPULATION; PREVALENCE	Context.-Exposure to maternal or placental infection is related to risk of preterm birth and, in premature infants, of brain lesions predictive of cerebral palsy (CP). Few studies have investigated whether maternal infection is associated with risk of CP in children of normal birth weight. Objective.-To investigate maternal infection during the admission for delivery as a possible risk factor for CP in infants born weighing 2500 g or more. Design.-Population-based case-control study. Setting.-All hospitals in 4 northern California counties, 1983 through 1985. Participants.-A total of 46 children with disabling spastic CP who had no recognized prenatal brain lesions and 378 randomly selected control children weighing 2500 g or more at birth and surviving to age 3 years. Main Outcome Measures.-Disabling spastic CP and signs of neonatal morbidity. Results.-Maternal fever exceeding 38 degrees C in labor was associated with increased risk of unexplained CP (odds ratio [OR], 9.3; 95% confidence interval [CI], 2.7-31.0), as was a clinical diagnosis of chorioamnionitis. One or more indicators of maternal infection were present in 2.9% of control children, 22% of children with CP (OR, 9.3; 95% CI, 3.7-23.0), and 35% of those with the spastic quadriplegic subtype of CP (OR, 19.0; 95% CI, 6.5-56.0). Newborns exposed to maternal infection, both cases and controls, had 5-minute Apgar scores below 6 more often than those unexposed. Among children with CP, those born to infected women were more often hypotensive, needed intubation, had neonatal seizures, and received a clinical diagnosis of hypoxic-ischemic encephalopathy. Conclusion.-Intrauterine exposure to maternal infection was associated with a marked increase in risk of CP in infants of normal birth weight. Maternal infection was also linked with low Apgar scores, other evidence of hypertension and need for resuscitation, and neonatal seizures-signs commonly attributed to birth asphyxia.	NINCDS,NEUROEPIDEMIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Grether, JK (corresponding author), CALIF DEPT HLTH SERV,CALIF BIRTH DEFECTS MONITORING PROGRAM,1900 POWELL ST,SUITE 1050,EMERYVILLE,CA 94608, USA.				PHS HHS [263-95-C0255] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; ADINOLFI M, 1993, DEV MED CHILD NEUROL, V35, P549; Beebe LA, 1996, OBSTET GYNECOL, V87, P771, DOI 10.1016/0029-7844(95)00483-1; BEJAR R, 1988, AM J OBSTET GYNECOL, V159, P357, DOI 10.1016/S0002-9378(88)80084-X; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; Bone RC, 1996, CRIT CARE MED, V24, P163, DOI 10.1097/00003246-199601000-00026; BRENNEMAN DE, 1995, INT J DEV NEUROSCI, V13, P187, DOI 10.1016/0736-5748(95)00014-8; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; COOKE RWI, 1990, ARCH DIS CHILD, V65, P201, DOI 10.1136/adc.65.2.201; COUGHREY H, 1991, AUST N Z J OBSTET GY, V31, P92; CUMMINS SK, 1993, J PEDIATR-US, V123, P230, DOI 10.1016/S0022-3476(05)81693-2; EASTMAN NJ, 1955, AM J OBSTET GYNECOL, V69, P950, DOI 10.1016/0002-9378(55)90094-6; FAIX RG, 1985, PEDIATRICS, V76, P415; GERDES JS, 1991, CLIN PERINATOL, V18, P361, DOI 10.1016/S0095-5108(18)30528-1; GOLDSTEIN I, 1988, AM J OBSTET GYNECOL, V159, P363, DOI 10.1016/S0002-9378(88)80085-1; GRAU AJ, 1995, STROKE, V26, P373, DOI 10.1161/01.STR.26.3.373; Grether J K, 1992, Paediatr Perinat Epidemiol, V6, P339, DOI 10.1111/j.1365-3016.1992.tb00774.x; HAGEMAN JR, 1995, CLIN PERINATOL, V22, P251; HANKINS GDV, 1991, AM J OBSTET GYNECOL, V164, P1261, DOI 10.1016/0002-9378(91)90696-O; HERNANDEZ C, 1993, AM J OBSTET GYNECOL, V169, P61, DOI 10.1016/0002-9378(93)90132-3; KNUDSEN FU, 1976, ACTA PAEDIATR SCAND, V65, P725, DOI 10.1111/j.1651-2227.1976.tb04961.x; KUBAN KCK, 1994, NEW ENGL J MED, V330, P188, DOI 10.1056/NEJM199401203300308; MABERRY MC, 1990, OBSTET GYNECOL, V76, P351; Magee JF, 1996, LAB INVEST, V74, P17; MANTEL N, 1959, J NATL CANCER I, V22, P719; Maseri A, 1996, BRIT MED J, V312, P1049; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MURPHY DJ, 1995, LANCET, V346, P1449, DOI 10.1016/S0140-6736(95)92471-X; NAEYE RL, 1979, BIOL NEONATE, V35, P150; NAULTY CM, 1994, AM J PERINAT, V11, P377, DOI 10.1055/s-2007-994601; NELSON KB, 1984, JAMA-J AM MED ASSOC, V251, P1843, DOI 10.1001/jama.251.14.1843; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; PEEVY KJ, 1983, AM J OBSTET GYNECOL, V146, P989, DOI 10.1016/0002-9378(83)90985-7; Perlman JM, 1996, PEDIATRICS, V97, P822; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROBERTS AB, 1991, ULTRASOUND OBST GYN, V1, P36, DOI 10.1046/j.1469-0705.1991.01010036.x; ROMERO R, 1993, J REPROD MED, V38, P543; *SAS I INC, 1989, SAS STAT US GUID VER, P2; Schlesselman J, 1982, CASE CONTROL STUDIES, P220; STANLEY FJ, 1993, DEV MED CHILD NEUROL, V35, P191; USTA IM, 1995, OBSTET GYNECOL, V86, P230, DOI 10.1016/0029-7844(95)00124-A; WAITZMAN NJ, 1995, MMWR-MORBID MORTAL W, V44, P695; WEGMAN ME, 1984, PEDIATRICS, V74, P981; Wong ML, 1996, NAT MED, V2, P581, DOI 10.1038/nm0596-581; YOUNG GB, 1995, NEUROL CLIN, V13, P645, DOI 10.1016/S0733-8619(18)30037-9; Zupan V, 1996, DEV MED CHILD NEUROL, V38, P1061	48	584	600	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					207	211		10.1001/jama.278.3.207	http://dx.doi.org/10.1001/jama.278.3.207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218666				2022-12-01	WOS:A1997XK10800025
J	Dietmeier, K; Honlinger, A; Bomer, U; Dekker, PJT; Eckerskorn, C; Loffspeich, F; Kubrich, M; Pfanner, N				Dietmeier, K; Honlinger, A; Bomer, U; Dekker, PJT; Eckerskorn, C; Loffspeich, F; Kubrich, M; Pfanner, N			Tom5 functionally links mitochondrial preprotein receptors to the general import pore	NATURE			English	Article							PROTEIN IMPORT; OUTER-MEMBRANE; INSERTION PORE; COMPLEX; TRANSLOCATION; SUBUNIT; MOM22; COMPONENT; ATP	Most mitochondrial proteins are synthesized as preproteins on cytosolic polysomes and are subsequently imported into the organelle(1-3). The mitochondrial outer membrane contains a multisubunit preprotein translocase (Tom) which has receptors on the cytosolic side and a general import pore (GIP) in the membrane. Tom20-Tom22 and Tom70-Tom37 function as import receptors(4-7) with a preference for preproteins that have amino-terminal presequences or internal targeting information, respectively. Tom40 is an essential constituent of the GIP(8,9), whereas Tom6 and Tom7 modulate the assembly and dissociation of the Tom machinery(10,11). Here we report the identification of Tom5, a small subunit that has a crucial role importing preproteins destined for all four mitochondrial subcompartments. Tom5 has a single membrane anchor and a cytosolic segment with a negative net charge, and accepts preproteins from the receptors and mediates their insertion into the GIP. We conclude that Tom5 represents a functional link between surface receptors and GIP, and is part of an 'acid chain'(5) that guides the stepwise transport of positively charged mitochondrial targeting sequences.	UNIV FREIBURG,INST BIOCHEM & MOL BIOL,D-79104 FREIBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-92152 MARTINSRIED,GERMANY	University of Freiburg; Max Planck Society			Pfanner, Nikolaus/AAV-7878-2021	Dekker, Peter/0000-0002-8197-8822				ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; Dekker PJT, 1996, BIOL CHEM, V377, P535; ECKERSKORN C, 1988, EUR J BIOCHEM, V176, P509, DOI 10.1111/j.1432-1033.1988.tb14308.x; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; PFALLER R, 1989, J BIOL CHEM, V264, P34; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	30	223	227	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					195	200		10.1038/40663	http://dx.doi.org/10.1038/40663			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217162	Bronze			2022-12-01	WOS:A1997XK10900055
J	Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, F; Kemp, K; Sibert, J				Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, F; Kemp, K; Sibert, J			Safety of surfaces and equipment for children in playgrounds	LANCET			English	Article								Background The safety of playgrounds is important to protect children from injury, hut studies are mostly done mainly under laboratory conditions without epidemiological data. We investigated the safety of different playground surfaces, and types and heights of equipment in public playgrounds in the City of Cardiff, UK. Methods We did a correlational study of 330 children aged between 0 and 14 years. All children were hurt when playing in playgrounds in Cardiff and presented to the Accident and Emergency Department in Cardiff Royal Infirmary during summer (April to September) 1992 and 1993, and the whole of 1994. We studied the children's hospital records to establish the type of injury and interviewed their parents to find out the playground and type of equipment involved. The main outcome measures were the number of children injured whilst playing, and injury rates per observed number of children on different surfaces, types, and heights of equipment. Findings Children sustained significantly more injuries in playgrounds with concrete surfaces than in those with bark or rubberised surfaces (p<0.001). Playgrounds with rubber surfaces had the lowest rare of injury, with a risk half that of bark and a fifth of that of concrete. Bark surfaces were not significantly more protective against arm fractures than concrete. Most injuries were equipment related. Injury risk due to falls from monkey bars (suspended parallel bars or rings between which children swing) was twice that far climbing-frames and seven times that for swings or slides. The height of the equipment correlated significantly with the number of fractures (p=0.005) from falls. Interpretation Rubber or bath surfacing is associated with a low rate of injuries and we support their use in all public playgrounds. Bark alone is insufficient, however, to prevent all injuries, particularly arm fractures. Rubberised impact-absorbing surfaces are safer than bark. We believe that playing on monkey bars increases the risk of injury in playgrounds and that they should generally not he installed. Safety standards should be based on physical and epidemiological data. Our data suggest that the proposed raising of the maximum fall height from 2.5 m to 3.0 m in Europe is worrying.	UNIV WALES,COLL MED,ACAD CTR,LLANDOUGH HOSP,DEPT CHILD HLTH,PENARTH CF64 2XX,S GLAM,WALES; CARDIFF CTY COUNCIL,SPORTS & LEISURE DEPT,CARDIFF,S GLAM,WALES; CARDIFF ROYAL INFIRM,DEPT ACCID & EMERGENCY,CARDIFF,S GLAM,WALES	Cardiff Royal Infirmary								Altman DG, 1991, PRACTICAL STAT MED R; ATKEN M, 1989, STAT MODELLING GLIM; BALL DJ, 1991, J ROY SOC HEALTH, V111, P134, DOI 10.1177/146642409111100405; Chalmers D J, 1996, Inj Prev, V2, P98, DOI 10.1136/ip.2.2.98; *CIT CARD LEIS AM, 1993, PLAYGR STRAT; HESELTINE P, 1989, PLAYGROUND MANAGEMEN; HESLETINE P, 1987, PLAYGROUNDS PLANNING, P20; HESLETINE P, 1989, PLAYGROUND MANAGEMEN; *HLTH PROM WAL, 1996, SAF AR YOUR PLAYGR P; LEWIS LM, 1993, J TRAUMA, V35, P932, DOI 10.1097/00005373-199312000-00020; MOTT A, 1974, ARCH DIS CHILD, V71, P328; SACKS JJ, 1990, AM J PUBLIC HEALTH, V80, P986, DOI 10.2105/AJPH.80.8.986	12	79	80	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1874	1876		10.1016/S0140-6736(96)10343-3	http://dx.doi.org/10.1016/S0140-6736(96)10343-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217759				2022-12-01	WOS:A1997XG41700010
J	Bence, K; Ma, W; Kozasa, T; Huang, XY				Bence, K; Ma, W; Kozasa, T; Huang, XY			Direct stimulation of Bruton's tyrosine kinase by G(q)-protein alpha-subunit	NATURE			English	Article							ACTIVATED PROTEIN-KINASE; COLI EXPRESSION SYSTEM; BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C; ESCHERICHIA-COLI; MAP KINASE; CYTOPLASMIC DOMAIN; PURIFICATION; RECEPTOR; CELLS	Heterotrimeric guanine-nucleotide-binding regulatory proteins (G proteins) transduce signals from a wide variety of cell-surface receptors to generate physiological responses(1). Protein-tyrosine kinases are another group of critical cellular signal transducers and their malfunction often leads to cancer(2). Although activation of G-protein-coupled receptors can elicit rapid stimulation cellular protein-tyrosine phosphorylation(3), the mechanism used by G proteins to activate protein-tyrosine kinases is unclear. Here we show that the purified alpha-subunit of the G(q) class of G proteins (G alpha q) directly stimulates the activity of a purified non-receptor kinase, Bruton's tyrosine kinase (Btk)(4), whereas purified alpha-subunits from G(i1), G(0) or G(z) proteins do not, G alpha q can also activate Btk in vivo, Furthermore, in Btk-deficient cells, stimulation of another kinase, a p38 MAP kinase, by Gq-coupled receptors is blocked. Our results demonstrate that certain protein-tyrosine kinases can be direct effecters of G proteins.	CORNELL UNIV, COLL MED, DEPT PHYSIOL, NEW YORK, NY 10021 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BOYER JL, 1994, J BIOL CHEM, V269, P2814; FLINT NA, 1994, J CELL BIOCHEM, V55, P389, DOI 10.1002/jcb.240550317; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEE CW, 1994, J BIOL CHEM, V269, P25335; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; PRICE DJ, 1995, BBA-MOL CELL RES, V1265, P133, DOI 10.1016/0167-4889(94)00213-X; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; Satterthwaite A, 1996, ANNU REV IMMUNOL, V14, P131, DOI 10.1146/annurev.immunol.14.1.131; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913	28	161	163	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					296	299		10.1038/38520	http://dx.doi.org/10.1038/38520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305846				2022-12-01	WOS:A1997XW77200051
J	Winter, MC; Welsh, MJ				Winter, MC; Welsh, MJ			Stimulation of CFTR activity by its phosphorylated R domain	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; CYSTIC-FIBROSIS; CHLORIDE CHANNEL; CL CHANNELS; ATP HYDROLYSIS; PYROPHOSPHATE; INACTIVATION	Phosphorylation controls the activity of ion channels in many tissues. In epithelia, the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel is activated by phosphorylation of serine residues in its regulatory (R) domain and then gated by binding and hydrolysis of ATP by the nucleotide-binding domains(1-3). Current models propose that the unphosphorylated R domain serves as an inhibitory particle that occludes the pore(1,2,4-6), much like the inhibitory 'ball' in Shaker K+ channels(7,8); presumably, phosphorylation relieves this inhibition. Here we test this by adding an R-domain peptide to a CFTR variant in which much of the R domain had been deleted (CFTR-Delta R/S660A): in contrast to predictions, we found that adding an unphosphorylated R domain to CFTR-Delta R/S660A did not inhibit activity, whereas a phosphorylated R-domain peptide stimulated activity. To investigate how phosphorylation controls activity, we studied channel gating and found that phosphorylation of the R domain increases the rate of channel opening by enhancing the sensitivity to ATP. Our results indicate that CFTR is regulated by a new mechanism in which phosphorylation of one domain stimulates the interaction of ATP with another domain, thereby increasing activity.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa				Welsh, Michael/0000-0002-1646-6206				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; CARSON MR, 1995, J BIOL CHEM, V270, P20466, DOI 10.1074/jbc.270.35.20466; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LI C, 1996, J BIOL CHEM, V45, P28463; LIN K, 1995, J BIOL CHEM, V270, P26833, DOI 10.1074/jbc.270.45.26833; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; MALLER JL, 1978, P NATL ACAD SCI USA, V75, P248, DOI 10.1073/pnas.75.1.248; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Welsh M, 1995, METABOLIC MOL BASIS, V7, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	116	118	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					294	296		10.1038/38514	http://dx.doi.org/10.1038/38514			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305845				2022-12-01	WOS:A1997XW77200050
J	Niki, H; Hiraga, S				Niki, H; Hiraga, S			Subcellular distribution of actively partitioning F plasmid during the cell division cycle in E-coli	CELL			English	Article							ESCHERICHIA-COLI; BACTERIAL PLASMIDS; BACILLUS-SUBTILIS; ESSENTIAL PROTEIN; ATPASE ACTIVITY; DAUGHTER CELLS; PARB PROTEIN; P1 PLASMID; CHROMOSOME; GENES	F plasmid is partitioned with fidelity to daughter cells during cell division cycle owing to two trans-acting genes, sopA and sops, and a cis-acting site, sopC. We visualized the subcellular distribution of mini-F-plasmid molecules by fluorescence in situ hybridization. Mini-F-plasmid molecules having the sopABC segment were localized at midcell in newborn cells. Replicated plasmid molecules migrated to cell positions 1/4 and 3/4 without coupling with cell elongation and were tethered to these positions until completion of cell division. In contrast, molecules of a mini F plasmid lacking the sopABC segment were distributed randomly in spaces not occupied by nucleoids. The sopABC system caused replicated plasmid molecules to be positioned and tethered at the cell quarter sites.			Niki, H (corresponding author), KUMAMOTO UNIV,SCH MED,INST MED EMBRYOL & GENET,DEPT MOL CELL BIOL,4-24-1 KUHONJI,KUMAMOTO 862,JAPAN.			Niki, Hironori/0000-0002-5391-6595				AUSTIN S, 1990, CELL, V60, P351, DOI 10.1016/0092-8674(90)90584-2; AUSTIN S, 1983, J MOL BIOL, V169, P373, DOI 10.1016/S0022-2836(83)80056-4; Davis MA, 1996, MOL MICROBIOL, V21, P1029, DOI 10.1046/j.1365-2958.1996.721423.x; DAVIS MA, 1992, MOL MICROBIOL, V6, P1141, DOI 10.1111/j.1365-2958.1992.tb01552.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1990, ANNU REV GENET, V24, P249, DOI 10.1146/annurev.genet.24.1.249; ELLASSON A, 1992, MOL MICROBIOL, V6, P165; EZAKI B, 1991, J BACTERIOL, V173, P6643, DOI 10.1128/jb.173.20.6643-6646.1991; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; FUNNELL BE, 1995, J BACTERIOL, V177, P2381, DOI 10.1128/jb.177.9.2381-2386.1995; Hanai R, 1996, J BIOL CHEM, V271, P17469, DOI 10.1074/jbc.271.29.17469; Helmstetter CE, 1997, J BACTERIOL, V179, P1393, DOI 10.1128/jb.179.4.1393-1399.1997; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRAGA S, 1991, RES MICROBIOL, V142, P189, DOI 10.1016/0923-2508(91)90029-A; HOGAN JE, 1982, PLASMID, V8, P36, DOI 10.1016/0147-619X(82)90039-7; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JAFFE A, 1985, J BACTERIOL, V163, P841; KLINE BC, 1985, PLASMID, V14, P1, DOI 10.1016/0147-619X(85)90027-7; KUSUKAWA N, 1987, MOL GEN GENET, V208, P365, DOI 10.1007/BF00328125; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Miller JH., 1972, EXPT MOL GENETICS; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; MORI H, 1989, J BIOL CHEM, V264, P15535; MORI H, 1986, J MOL BIOL, V192, P1, DOI 10.1016/0022-2836(86)90459-6; MOTALLEBIVESHAREH M, 1990, MOL MICROBIOL, V4, P1455, DOI 10.1111/j.1365-2958.1990.tb02056.x; MYSLIWIEC TH, 1991, J BACTERIOL, V173, P1911, DOI 10.1128/jb.173.6.1911-1919.1991; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; NIKI H, 1988, J BACTERIOL, V170, P5272, DOI 10.1128/jb.170.11.5272-5278.1988; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; OGURA T, 1983, CELL, V32, P351, DOI 10.1016/0092-8674(83)90454-3; SCOTT JR, 1984, MICROBIOL REV, V48, P1; WATANABE E, 1989, MOL GEN GENET, V218, P431, DOI 10.1007/BF00332406; WATANABE E, 1992, MOL GEN GENET, V234, P346, DOI 10.1007/BF00538693; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Yamanaka K, 1996, MOL GEN GENET, V250, P241	39	162	162	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					951	957		10.1016/S0092-8674(00)80359-1	http://dx.doi.org/10.1016/S0092-8674(00)80359-1			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298906	Bronze			2022-12-01	WOS:A1997XV56300015
J	Paech, K; Webb, P; Kuiper, GGJM; Nilsson, S; Gustafsson, JA; Kushner, PJ; Scanlan, TS				Paech, K; Webb, P; Kuiper, GGJM; Nilsson, S; Gustafsson, JA; Kushner, PJ; Scanlan, TS			Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites	SCIENCE			English	Article							OVARIECTOMIZED RATS; RALOXIFENE; TAMOXIFEN; GENE; IDENTIFICATION; TRANSCRIPTION; ANTIESTROGENS; BONE	The transactivation properties of the two estrogen receptors, ER alpha and ER beta, were examined with different ligands in the context of an estrogen response element and an AP1 element. ER alpha and ER beta were shown to signal in opposite ways when complexed with the natural hormone estradiol from an AP1 site: with ER alpha, 17 beta-estradiol activated transcription, whereas with ER beta, 17 beta-estradiol inhibited transcription, Moreover, the antiestrogens tamoxifen, raloxifene, and imperial Chemical industries 164384 were potent transcriptional activators with ER beta at an AP1 site. Thus, the two ERs signal in different ways depending on ligand and response element, This suggests that ER alpha and ER beta may play different roles in gene regulation.	UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143; KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,NOVUM,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN; KARO BIO AB,NOVUM,S-14157 HUDDINGE,SWEDEN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet					NIGMS NIH HHS [GM 50672] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; GRANDIEN K, UNPUB; JONES CD, 1984, J MED CHEM, V27, P1057, DOI 10.1021/jm00374a021; Katzenellenbogen JA, 1996, CHEM BIOL, V3, P529, DOI 10.1016/S1074-5521(96)90143-X; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KULPER GGJ, 1996, P NATL ACAD SCI USA, V93, P5925; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; PAECH K, UNPUB; RYLANDER T, UNPUB; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222	22	1926	2012	2	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1508	1510		10.1126/science.277.5331.1508	http://dx.doi.org/10.1126/science.277.5331.1508			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278514				2022-12-01	WOS:A1997XV42900041
J	Guo, F; Gopaul, DN; VanDuyne, GD				Guo, F; Gopaul, DN; VanDuyne, GD			Structure of Cre recombinase complexed with DNA in a site-specific recombination synapse	NATURE			English	Article							HOLLIDAY JUNCTION; INTEGRASE FAMILY; ESCHERICHIA-COLI; PROTEIN; LOXP; BINDING; MICE; TYROSINE; HOMOLOGY; STRANDS	During site-specific DMA recombination, which brings about genetic rearrangement in processes such as viral integration and excision and chromosomal segregation, recombinase enzymes recognize specific DNA sequences and catalyse the reciprocal exchange of DNA strands between these sites. The bacteriophage recombinase Cre catalyses site-specific recombination between two 34-base-pair loxP sites. The crystal structure at 2.4 Angstrom resolution of Cre bound to aloxP substrate reveals an intermediate in the recombination reaction, fin which a Cre molecule has cleaved the substrate to form a covalent 3'-phosphotyrosine linkage with the DNA. Four recombinases and two loxP sites form a synapsed structure in which the DNA resembles models of four-way Holliday-junction intermediates. The Cre-loxP complex challenges models of site-specific recombination that require large changes in quaternary structure. Subtle allosteric changes at the carboxy termini of the Cre subunits may instead coordinate the cleavage and strand-exchange reactions.	UNIV PENN,SCH MED,JOHNSON RES FDN,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				GOPAUL, Deshmukh/0000-0003-1631-3303				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ABREMSKI K, 1984, J BIOL CHEM, V259, P1509; ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Arciszewska L, 1997, EMBO J, V16, P3731, DOI 10.1093/emboj/16.12.3731; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Azaro MA, 1997, EMBO J, V16, P3744, DOI 10.1093/emboj/16.12.3744; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; BLAKELY GW, 1996, MOL MICROBIOL, V20, P233; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOESS RH, 1984, P NATL ACAD SCI-BIOL, V81, P1026, DOI 10.1073/pnas.81.4.1026; HOESS RH, 1986, NUCLEIC ACIDS RES, V14, P2287, DOI 10.1093/nar/14.5.2287; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KILBY NJ, 1993, TRENDS GENET, V9, P413, DOI 10.1016/0168-9525(93)90104-P; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P93; Leslie A. G. W., 1991, CCP4 STUDY WEEKEND, P80; METZGER D, 1995, P NATL ACAD SCI USA, V92, P6991, DOI 10.1073/pnas.92.15.6991; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; QIAN XH, 1990, J BIOL CHEM, V265, P21779; QIN MM, 1994, P NATL ACAD SCI USA, V91, P1706, DOI 10.1073/pnas.91.5.1706; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SIGAL N, 1972, J MOL BIOL, V71, P789, DOI 10.1016/S0022-2836(72)80039-1; STARK WM, 1995, TRENDS GENET, V11, P121; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; STERNBERG N, 1981, COLD SPRING HARB SYM, V1, P297; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tsurushita N, 1996, GENE, V172, P59, DOI 10.1016/0378-1119(96)00170-9; VanDuyne GD, 1996, J MOL BIOL, V256, P377, DOI 10.1006/jmbi.1996.0093; ZOU YR, 1994, CURR BIOL, V4, P1099, DOI 10.1016/S0960-9822(00)00248-7	50	459	518	2	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					40	46		10.1038/37925	http://dx.doi.org/10.1038/37925			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288963				2022-12-01	WOS:A1997XU59600037
J	Takizawa, PA; Sil, A; Swedlow, JR; Herskowitz, I; Vale, RD				Takizawa, PA; Sil, A; Swedlow, JR; Herskowitz, I; Vale, RD			Actin-dependent localization of an RNA encoding a cell-fate determinant in yeast	NATURE			English	Article							MESSENGER-RNA; MICROFILAMENTS; MICROTUBULES; OOCYTES; MYOSIN; ASH1P; MOVE	The cytoplasmic localization of messenger RNA creates an asymmetric distribution of proteins that specify cell fate during development in multicellular eukaryotes(1,2). The protein Ash1 is a cell-fate determinant in budding yeast which localizes preferentially to the presumptive daughter nucleus, where it inhibits mating-type switching(3'4). Here we show that Ash1 mRNA is localized to the distal tip of daughter buds in post-anaphase cells. Three-dimensional imaging reveals that Ash1 mRNA is assembled into particles that associate with the cell cortex, To achieve this localization, Ash1 mRNA must have its 3' untranslated region and the actin cytoskeleton must be intact, Ash1 mRNA is not localized correctly in the absence of a myosin (Myo4) and is mislocalized to the mother-bud neck in the absence of a regulator of the actin cytoskeleton known as Bni1. We propose that Ash1 mRNA particles are transported into the daughter bud along actin filaments and are anchored at the distal tip. Thus, as in higher eukaryotes, Saccharomyces cerevisiae employs RNA localization to generate an asymmetric distribution of proteins and hence to determine cell fate.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOL PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Swedlow, Jason/0000-0002-2198-1958				ADAMS A E M, 1991, P729; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; [Anonymous], 1997, DECONVOLUTION IMAGES; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	17	310	314	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	1997	389	6646					90	93		10.1038/38015	http://dx.doi.org/10.1038/38015			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288973				2022-12-01	WOS:A1997XU59600051
J	Li, SH; Li, Y; Carthew, RW; Lai, ZC				Li, SH; Li, Y; Carthew, RW; Lai, ZC			Photoreceptor cell differentiation requires regulated proteolysis of the transcriptional repressor Tramtrack	CELL			English	Article							DROSOPHILA EYE DEVELOPMENT; ZINC-FINGER PROTEINS; ETS DOMAIN PROTEIN; FATE DETERMINATION; GENE; PATHWAY; ACTIVATION; BINDING; KINASE; SINA	The transcription repressor Tramtrack (TTK) is found in cone cells but not photoreceptor cells of the Drosophila eye. We show that down-regulation of TTK expression occurs in photoreceptor cells and is required for their fate determination. Down-regulation requires the presence of Phyllopod (PHYL), which is induced by the RAS pathway, and Seven In Absentia (SINA). Loss of either gene causes accumulation of TTK in photoreceptor cells, and TTK does not accumulate in cone cells if both PHYL and SINA are present. We report that SINA and PHYL promote ubiquitination and rapid degradation of TTK by the proteasome pathway in cell culture, and both SINA and PHYL bind to the N-terminal domain of TTK. These results argue that photoreceptor differentiation is regulated by the RAS pathway through targeted proteolysis of the TTK repressor.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260; PENN STATE UNIV,DEPT BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Li, Songhui/AAI-2919-2021		NEI NIH HHS [EY10111] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010111] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Boddy MN, 1996, ONCOGENE, V13, P971; BROWN JL, 1991, EMBO J, V10, P665, DOI 10.1002/j.1460-2075.1991.tb07995.x; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTHEW RW, 1994, P NATL ACAD SCI USA, V91, P11689, DOI 10.1073/pnas.91.24.11689; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DELLA NG, 1993, DEVELOPMENT, V117, P1333; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON BJ, 1995, CELL, V80, P543; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Kauffmann RC, 1996, GENE DEV, V10, P2167, DOI 10.1101/gad.10.17.2167; Lai ZC, 1996, P NATL ACAD SCI USA, V93, P5025, DOI 10.1073/pnas.93.10.5025; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Maufroid JP, 1996, INT J DEV BIOL, V40, P609; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; READ D, 1992, EMBO J, V11, P1035, DOI 10.1002/j.1460-2075.1992.tb05142.x; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Seyfert VL, 1996, ONCOGENE, V12, P2331; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; Yamamoto D, 1996, ROUX ARCH DEV BIOL, V205, P215, DOI 10.1007/BF00365799; Zhu AH, 1996, DEVELOPMENT, V122, P1577; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	37	184	187	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					469	478		10.1016/S0092-8674(00)80507-3	http://dx.doi.org/10.1016/S0092-8674(00)80507-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267027	Bronze			2022-12-01	WOS:A1997XQ06300011
J	Scully, R; Chen, JJ; Ochs, RL; Keegan, K; Hoekstra, M; Feunteun, J; Livingston, DM				Scully, R; Chen, JJ; Ochs, RL; Keegan, K; Hoekstra, M; Feunteun, J; Livingston, DM			Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage	CELL			English	Article							ATAXIA-TELANGIECTASIA GENE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; FAMILIAL BREAST; CELL-CYCLE; RECOMBINATION; CHECKPOINTS; CANCER; YEAST; DIFFERENTIATION	BRCA1 localizes to discrete nuclear foci (dots) during S phase. Hydroxyurea-mediated DNA synthesis arrest of S phase MCF7 cells led to a loss of BRCA1 from these structures. Ultraviolet light, mitomycin C, or gamma irradiation produced a similar effect but with no concurrent arrest of DNA synthesis. BARD1 and Rad51, two proteins associated with the BRCA1 dots, behaved similarly. Loss of the BRCA1 foci was accompanied by a specific, dose-dependent change(s) in the state of BRCA1 phosphorylation. Three distinct DNA damaging agents preferentially induced this change in S phase. The S phase BRCA1 phosphorylation response to DNA damage occurred in cells lacking, respectively, two DNA damage-sensing protein kinases, DNA-PK and Atm, implying that neither plays a prime role in this process. Finally, after BRCA1 dot dispersal, BRCA1, BARD1, and Rad51 accumulated, focally, on PCNA(+) replication structures, implying an interaction of BRCA1/BARD1/Rad51 containing complexes with damaged, replicating DNA. Taken together, the data imply that the BRCA1 S phase foci are dynamic physiological elements, responsive to DNA damage, and that BRCA1-containing multiprotein complexes participate in a replication checkpoint response.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA; ICOS CORP, BOTHELL, WA 98021 USA; INST GUSTAVE ROUSSY, CNRS, F-94805 VILLEJUIF, FRANCE	Scripps Research Institute; Icos Corporation; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Scully, R (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.		Feunteun, Jean/AAZ-1267-2020; Scully, Ralph/F-5008-2013	Feunteun, Jean/0000-0003-1212-9189				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/s004120050088; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bhatia PK, 1996, CURR OPIN GENET DEV, V6, P146, DOI 10.1016/S0959-437X(96)80043-8; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feunteun J, 1996, BBA-REV CANCER, V1242, P177, DOI 10.1016/0304-419X(95)00016-9; FORNACE AJ, 1983, NATURE, V304, P552, DOI 10.1038/304552a0; FRIEDBERG EC, 1995, DNA REPAIR; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	55	787	810	2	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					425	435		10.1016/S0092-8674(00)80503-6	http://dx.doi.org/10.1016/S0092-8674(00)80503-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267023	Bronze			2022-12-01	WOS:A1997XQ06300007
J	Sheridan, JP; Marsters, SA; Pitti, RM; Gurney, A; Skubatch, M; Baldwin, D; Ramakrishnan, L; Gray, CL; Baker, K; Wood, WI; Goddard, AD; Godowski, P; Ashkenazi, A				Sheridan, JP; Marsters, SA; Pitti, RM; Gurney, A; Skubatch, M; Baldwin, D; Ramakrishnan, L; Gray, CL; Baker, K; Wood, WI; Goddard, AD; Godowski, P; Ashkenazi, A			Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors	SCIENCE			English	Article							TNF RECEPTOR; DEATH	TRAIL (also called Apo2L) belongs to the tumor necrosis factor family, activates rapid apoptosis in tumor cells, and binds to the death-signaling receptor DR4. Two additional TRAIL receptors were identified. The receptor designated death receptor 5 (DR5) contained a cytoplasmic death domain and induced apoptosis much like DR4. The receptor designated decoy receptor 1 (DcR1) displayed properties of a glycophospholipid-anchored cell surface protein. DcR1 acted as a decoy receptor that inhibited TRAIL signaling. Thus, a cell surface mechanism exists for the regulation of cellular responsiveness to pro-apoptotic stimuli.	GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				[Anonymous], UNPUB; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; Ashkenazi Avi, 1995, Methods (Orlando), V8, P104, DOI 10.1006/meth.1995.9996; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MARSTERS SA, UNPUB; MORAN P, 1991, J BIOL CHEM, V266, P1250; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PITTI RM, 1996, J BIOL CHEM, V271, P12697; PITTI RM, UNPUB; SHERIDAN JB, UNPUB; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	29	1502	1661	1	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					818	821		10.1126/science.277.5327.818	http://dx.doi.org/10.1126/science.277.5327.818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242611				2022-12-01	WOS:A1997XQ24700044
J	Tronchere, H; Wang, JW; Fu, XD				Tronchere, H; Wang, JW; Fu, XD			A protein related to splicing factor U2AF(35) that interacts with U2AF(65) and SR proteins in splicing of pre-mRNA	NATURE			English	Article							RIBONUCLEOPROTEIN AUXILIARY FACTOR; BIOCHEMICAL-CHARACTERIZATION; INTRACELLULAR-LOCALIZATION; SERINE-RICH; SNRNP; PURIFICATION; RECOGNITION; CLONING; GENE	Recognition of a functional 3' splice site in pre-mRNA splicing requires a heterodimer of the proteins U2AF(65)/U2AF(35). U2AF(65) binds to RNA at the polypyrimidine tract(1,2), whereas U2AF(35) is thought to interact through its arginine/serine-rich (RS) domain with other RS-domain-containing factors;bound at the 5' splice site, assembled in splicing enhancer complexes, or associated with the U4/U6 . U5 small nuclear ribonucleoprotein complex(3-7). It is unclear, however, how such network interactions can all be established through the small RS domain in U2AF(35). Here we describe the function of a U2AF(35)-related protein (Urp), which is the human homologue of a mouse imprinted gene. Nuclear extracts depleted of Urp are defective in splicing, but activity can be restored by addition of recombinant Urp. U2AF(35) could not replace Urp in complementation, indicating that their functions do not overlap. Co-immunodepletion showed that Urp is associated with the U2AF(65)/U2AF(35) heterodimer, Binding studies revealed that Urp specifically interacts with U2AF(65) through a U2AF(35)-homologous region and with SR proteins (a large family of RS-domain-containing proteins) through its RS domain. Therefore, Urp and U2AF(35) may independently position RS-domain-containing factors within spliceosomes.	UNIV CALIF SAN DIEGO, DEPT MED, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			TRONCHERE, Helene/M-5631-2014					Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; Fetzer S, 1997, RNA, V3, P344; FU XD, 1995, RNA, V1, P663; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; KITAGAWA K, 1995, GENOMICS, V30, P257, DOI 10.1006/geno.1995.9879; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Nabetani A, 1997, MOL CELL BIOL, V17, P789, DOI 10.1128/MCB.17.2.789; ROSCIGNO RF, 1995, RNA, V1, P692; Rudner DZ, 1996, P NATL ACAD SCI USA, V93, P10333, DOI 10.1073/pnas.93.19.10333; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YAMAOKA T, 1995, GENOMICS, V27, P337, DOI 10.1006/geno.1995.1051; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	23	85	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	1997	388	6640					397	400		10.1038/41137	http://dx.doi.org/10.1038/41137			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237760	Bronze			2022-12-01	WOS:A1997XM52800056
J	Polyansky, OL; Zobov, NF; Viti, S; Tennyson, J; Bernath, PF; Wallace, L				Polyansky, OL; Zobov, NF; Viti, S; Tennyson, J; Bernath, PF; Wallace, L			Water on the sun: Line assignments based on variational calculations	SCIENCE			English	Article							HYDROGEN FLAME SPECTRA; RO-VIBRATIONAL LEVELS; GROUND-STATE; (H2O)-O-16; CM-1; SPECTROSCOPY; MOLECULES; STRENGTHS; H2O-16; BANDS	The infrared spectrum of hot water observed in a sunspot has been assigned. The high temperature of the sunspot, (3200 K) gave rise to a highly congested pure rotational spectrum in the 10-micrometer region that involved energy levels at least halfway to dissociation, Traditional spectroscopy, based on perturbation theory, is inadequate for this problem. Instead, accurate variational solutions of the vibration-rotation Schrodinger equation were used to make assignments, revealing unexpected features, including rotational difference bands and fewer degeneracies than anticipated. These results indicate that a shift away from perturbation theory to first. principles calculations is necessary in order to assign spectra of hot polyatomic molecules such as water.	UCL, DEPT PHYS & ASTRON, LONDON WC1E 6BT, ENGLAND; UNIV WATERLOO, DEPT CHEM, WATERLOO, ON N2L 3G1, CANADA; UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA; NATL OPT OBSERV, TUCSON, AZ 85732 USA; RUSSIAN ACAD SCI, INST APPL PHYS, NIZHNII NOVGOROD 603600, RUSSIA	University of London; University College London; University of Waterloo; University of Arizona; National Optical Astronomy Observatory; Russian Academy of Sciences; Institute of Applied Physics of the Russian Academy of Sciences			Tennyson, Jonathan/I-2222-2012; Bernath, Peter F/B-6567-2012; Nikolay, Zobov/U-1709-2019	Tennyson, Jonathan/0000-0002-4994-5238; Bernath, Peter F/0000-0002-1255-396X; 				ALLARD F, 1994, ASTROPHYS J, V426, pL39, DOI 10.1086/187334; BACIC Z, 1989, ANNU REV PHYS CHEM, V40, P469, DOI 10.1146/annurev.pc.40.100189.002345; CAMYPEYRET C, 1980, J PHYS LETT-PARIS, V41, pL23, DOI 10.1051/jphyslet:0198000410202300; CAMYPEYRET C, 1977, MOL PHYS, V33, P1641, DOI 10.1080/00268977700101361; FLAUD JM, 1976, MOL PHYS, V32, P499, DOI 10.1080/00268977600103251; FLAUD JM, 1974, J MOL SPECTROSC, V51, P142, DOI 10.1016/0022-2852(74)90177-5; FLAUD JM, 1977, J MOL SPECTROSC, V65, P219, DOI 10.1016/0022-2852(77)90189-8; FLAUD JM, 1981, WATER VAPOUR LINE PA; GABRIEL W, 1993, J CHEM PHYS, V99, P897, DOI 10.1063/1.465354; Herzberg G., 1945, MOL SPECTRA MOL STRU; HINKLE KH, 1979, ASTROPHYS J, V227, P923, DOI 10.1086/156801; JENSEN P, 1997, ADV SERIES PHYSICAL, V9; OPPENHEIMER BR, 1995, SCIENCE, V270, P1478, DOI 10.1126/science.270.5241.1478; Partridge H, 1997, J CHEM PHYS, V106, P4618, DOI 10.1063/1.473987; Polyansky OL, 1996, J CHEM PHYS, V105, P6490, DOI 10.1063/1.472501; Polyansky OL, 1996, J MOL SPECTROSC, V176, P305, DOI 10.1006/jmsp.1996.0091; Polyansky OL, 1997, J MOL SPECTROSC, V184, P35, DOI 10.1006/jmsp.1997.7307; POLYANSKY OL, 1994, J CHEM PHYS, V101, P7651, DOI 10.1063/1.468258; POLYANSKY OL, 1985, J MOL SPECTROSC, V112, P79, DOI 10.1016/0022-2852(85)90193-6; Polyansky OL, 1997, J MOL SPECTROSC, V186, P213, DOI 10.1006/jmsp.1997.7443; *PROP EN PAN WORK, 1993, 287 NATO AGARD PROP; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; SAYKALLY RJ, 1993, SCIENCE, V259, P1570, DOI 10.1126/science.259.5101.1570; Schwenke D. W., COMMUNICATION; TENNYSON J, 1995, REP PROG PHYS, V58, P421, DOI 10.1088/0034-4885/58/4/002; TENNYSON J, 1995, COMPUT PHYS COMMUN, V86, P175, DOI 10.1016/0010-4655(94)00139-S; TENNYSON J, 1994, PHYS REV A, V50, P314, DOI 10.1103/PhysRevA.50.314; TOTH RA, 1994, APPL OPTICS, V33, P4851, DOI 10.1364/AO.33.004851; TOTH RA, 1993, J OPT SOC AM B, V10, P1526, DOI 10.1364/JOSAB.10.001526; TSUJI T, 1995, ELEMENTARY PROCESSES, P193; ULENIKOV ON, 1986, J MOL SPECTROSC, V117, P195, DOI 10.1016/0022-2852(86)90149-9; WALLACE L, 1995, SCIENCE, V268, P1155, DOI 10.1126/science.7761830; WALLACE L, 1994, 199401 NATL SOL OBS; Worden H, 1997, J GEOPHYS RES-ATMOS, V102, P1287, DOI 10.1029/96JD02982; Zobov NF, 1996, CHEM PHYS LETT, V260, P381, DOI 10.1016/0009-2614(96)00872-X	35	123	124	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					346	348		10.1126/science.277.5324.346	http://dx.doi.org/10.1126/science.277.5324.346			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219686				2022-12-01	WOS:A1997XL35800038
J	VarghaKhadem, F; Gadian, DG; Watkins, KE; Connelly, A; VanPaesschen, W; Mishkin, M				VarghaKhadem, F; Gadian, DG; Watkins, KE; Connelly, A; VanPaesschen, W; Mishkin, M			Differential effects of early hippocampal pathology on episodic and semantic memory	SCIENCE			English	Article							RHESUS-MONKEYS; ASSOCIATION; IMPAIRMENT; EPILEPSY; AMNESIA; CORTEX	Global anterograde amnesia is described in three patients with brain injuries that occurred in one case at birth, in another by age 4, and in the third at age 9. Magnetic resonance techniques revealed bilateral hippocampal pathology in ail three cases. Remarkably, despite their pronounced amnesia For the episodes of everyday life, all three patients attended mainstream schools and attained levels of speech and language competence, literacy, and factual knowledge that are within the low average to average range. The findings provide support for the view that the episodic and semantic components of cognitive memory are partly dissociable, with only the episodic component being fully dependent an the hippocampus.	UCL, SCH MED, INST CHILD HLTH, RADIOL & PHYS UNIT, LONDON WC1N 1EH, ENGLAND; INST NEUROL, LONDON WC1N 3BG, ENGLAND; NIMH, NEUROPSYCHOL LAB, BETHESDA, MD 20892 USA	University of London; University College London; UCL Medical School; University of London; University College London; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	VarghaKhadem, F (corresponding author), UCL, SCH MED,WOLFSON CTR,INST CHILD HLTH, COGNIT NEUROSCI UNIT, MECKLENBURGH SQ, LONDON WC1N 2AP, ENGLAND.		Watkins, Kate E/A-6559-2012; Gadian, David G/C-4961-2008; Vargha-Khadem, Faraneh/C-2558-2008; Van Paesschen, Wim/A-4540-2010; Fahimifar, Sepideh/M-5303-2019; Connelly, Alan/A-9065-2013	Watkins, Kate E/0000-0002-2621-482X; Van Paesschen, Wim/0000-0002-8535-1699; Connelly, Alan/0000-0001-7159-8079; vargha-khadem, faraneh/0000-0003-4890-8379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CONNELLY A, 1994, NEUROLOGY, V44, P1411, DOI 10.1212/WNL.44.8.1411; Cross JH, 1996, ANN NEUROL, V39, P107, DOI 10.1002/ana.410390116; Gadian DG, 1996, NEUROLOGY, V46, P974, DOI 10.1212/WNL.46.4.974; Goulet S., 1995, Society for Neuroscience Abstracts, V21, P1446; ISAACS EB, 1989, BRIT J DEV PSYCHOL, V7, P377, DOI 10.1111/j.2044-835X.1989.tb00814.x; JACK CR, 1990, RADIOLOGY, V175, P423, DOI 10.1148/radiology.175.2.2183282; JACKSON GD, 1993, NEUROLOGY, V43, P1793, DOI 10.1212/WNL.43.9.1793; LANG C, 1981, J NEUROL NEUROSUR PS, V44, P626, DOI 10.1136/jnnp.44.7.626; MEUNIER M, 1993, J NEUROSCI, V13, P5418, DOI 10.1523/JNEUROSCI.13-12-05418.1993; MUGLER JP, 1990, MAGNET RESON MED, V15, P152, DOI 10.1002/mrm.1910150117; Murray E. A., 1996, Society for Neuroscience Abstracts, V22, P281; Murray E. A., 1993, Society for Neuroscience Abstracts, V19, P438; MURRAY EA, 1993, J NEUROSCI, V13, P4549; MURRAY EA, 1985, SCIENCE, V228, P604, DOI 10.1126/science.3983648; NATHAN PW, 1950, J NEUROL NEUROSUR PS, V13, P191, DOI 10.1136/jnnp.13.3.191; OSTERGAARD AL, 1987, NEUROPSYCHOLOGIA, V25, P341, DOI 10.1016/0028-3932(87)90023-6; Osterrieth P, 1944, ARCH PSYCHOL, V30, P306; PARKINSON JK, 1988, J NEUROSCI, V8, P4159; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; Rempel-Clower N. L., 1994, Society for Neuroscience Abstracts, V20, P1075; Rust J, 1993, WECHSLER OBJECTIVE R; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SPIEGLER BJ, 1981, BEHAV BRAIN RES, V3, P303, DOI 10.1016/0166-4328(81)90002-4; SPIEGLER BJ, 1979, SOC NEUR ABSTR, V5, P323; Squire Larry R., 1995, P825; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; Suzuki WA, 1996, SEMIN NEUROSCI, V8, P3, DOI 10.1006/smns.1996.0002; Talley JL, 1993, CAVLT 2 CHILDRENS AU; Tulving Endel, 1995, P839; VanPaesschen W, 1997, ANN NEUROL, V41, P41, DOI 10.1002/ana.410410109; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wilson B, 1985, RIVERMEAD BEHAVIOURA; Wood F., 1982, HUMAN MEMORY AMNESIA, P167; WOOD FB, 1989, BRAIN COGNITION, V10, P76, DOI 10.1016/0278-2626(89)90076-6; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	36	1178	1196	3	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					376	380		10.1126/science.277.5324.376	http://dx.doi.org/10.1126/science.277.5324.376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219696				2022-12-01	WOS:A1997XL35800048
J	Brown, NJ; Snowden, M; Griffin, MR				Brown, NJ; Snowden, M; Griffin, MR			Recurrent angiotensin-converting enzyme inhibitor-associated angioedema	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Angiotensin-converting enzyme (ACE) inhibitors are associated with an increased risk of angioedema, but the risk of recurrent angioedema if treatment is continued is not known. Objective.-To test the hypothesis that the association between ACE inhibitor use and angioedema may not be recognized and to determine characteristics of angioedema associated with continued use of ACE inhibitors. Design.-Retrospective cohort study. Setting.-Tennessee Medicaid program. Patients.-Medicaid enrollees aged 15 years or older who used an ACE inhibitor and had a first documented episode of angioedema between 1986 and 1992 were followed up for recurrent episodes through June 1993. Measurements and Main Results.-We previously identified 82 patients with a first confirmed diagnosis of angioedema during 51 752 person-years of ACE inhibitor use in this population (1.6 per 1000 person-years). Among these 82 patients, there were 16 outpatient recurrences of angioedema among 13 patients during 189 patient-years of follow-up (8.5 per 100 patient-years). The rate of angioedema was much higher in users of ACE inhibitors with continued exposure (18.7 per 100 patient-years) than in those whose use of the drug was discontinued (1.8 per 100 patient-years) (P=.001). Review of the medical records for patients taking ACE inhibitors who had recurrent angioedema revealed that physicians attributed angioedema to a number of causes not related to ACE inhibitor use, even after multiple recurrences. Conclusion.-Continuing use of ACE inhibitors in spite of angioedema results in a markedly increased rate of angioedema recurrence with serious morbidity.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PREVENT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University	Brown, NJ (corresponding author), VANDERBILT UNIV,DEPT MED,560 MED RES BLDG 1,NASHVILLE,TN 37232, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER; NCRR NIH HHS [MOI-RR00095-533] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; *PHS US DEP HLTH H, 1988, INT CLASS DIS 9 REV; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153	4	116	120	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 16	1997	278	3					232	233		10.1001/jama.278.3.232	http://dx.doi.org/10.1001/jama.278.3.232			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK108	9218671				2022-12-01	WOS:A1997XK10800030
J	Altuvia, S; WeinsteinFischer, D; Zhang, AX; Postow, L; Storz, G				Altuvia, S; WeinsteinFischer, D; Zhang, AX; Postow, L; Storz, G			A small, stable RNA induced by oxidative stress: Role as a pleiotropic regulator and antimutator	CELL			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TRANSCRIPTIONAL ACTIVATOR; FORMATE HYDROGENLYASE; GENETIC-REGULATION; POSITIVE CONTROL; OPERON FUSIONS; ANTISENSE RNA; OMPF PROTEIN	Exposure of E. coli to hydrogen peroxide induces the transcription of a small RNA denoted oxyS. The oxyS RNA is stable, abundant, and does not encode a protein. oxyS activates and represses the expression of numerous genes in E. coli, and eight targets, including genes encoding the transcriptional regulators FhlA and sigma(s), were identified. oxyS expression also leads to a reduction in spontaneous and chemically-induced mutagenesis. Our results suggest that the oxyS RNA acts as a regulator that integrates adaptation to hydrogen peroxide with other cellular stress responses and helps to protect cells against oxidative damage.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOL GENET & BIOTECHNOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	Altuvia, S (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892, USA.			Storz, Gisela/0000-0001-6698-1241				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; ALTUVIA S, 1991, J MOL BIOL, V218, P723, DOI 10.1016/0022-2836(91)90261-4; ANDERSEN J, 1989, J BIOL CHEM, V264, P17961; BECKERHAPAK M, 1995, FEMS MICROBIOL LETT, V134, P39, DOI 10.1111/j.1574-6968.1995.tb07911.x; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, P1715; BREMER E, 1985, J BACTERIOL, V162, P1092, DOI 10.1128/JB.162.3.1092-1099.1985; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROWNLEE GG, 1971, NATURE-NEW BIOL, V229, P147, DOI 10.1038/newbio229147a0; CHOU JH, 1993, J BACTERIOL, V175, P1026, DOI 10.1128/JB.175.4.1026-1031.1993; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; DELIHAS N, 1995, MOL MICROBIOL, V15, P411, DOI 10.1111/j.1365-2958.1995.tb02254.x; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; ELASCO JG, 1993, CONTROL MESSENGER RN, P3; GILMAN MZ, 1983, CELL, V35, P285, DOI 10.1016/0092-8674(83)90231-3; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; GUSTAFSSON C, 1992, J BACTERIOL, V174, P7878, DOI 10.1128/JB.174.23.7878-7879.1992; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; IVANOVA A, 1994, MOL MICROBIOL, V12, P571, DOI 10.1111/j.1365-2958.1994.tb01043.x; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Korsa I, 1997, J BACTERIOL, V179, P41, DOI 10.1128/jb.179.1.41-45.1997; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; MAUPIN JA, 1990, J BACTERIOL, V172, P4798, DOI 10.1128/jb.172.9.4798-4806.1990; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; McKenney K, 1981, Gene Amplif Anal, V2, P383; Miller JH., 1972, EXPT MOL GENETICS; Reddy R, 1988, STRUCTURE FUNCTION M, P1, DOI [10.1007/978-3-642-73020-7_1, 10.1007/978-3-642-73020-7_1.]; SALSER W, 1967, NATURE, V215, P588, DOI 10.1038/215588a0; SCHLENSOG V, 1990, MOL MICROBIOL, V4, P1319, DOI 10.1111/j.1365-2958.1990.tb00711.x; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; Sledjeski DD, 1996, EMBO J, V15, P3993, DOI 10.1002/j.1460-2075.1996.tb00773.x; SMITH DK, 1992, J BACTERIOL, V174, P5820, DOI 10.1128/jb.174.18.5820-5826.1992; Springer AL, 1996, J BACTERIOL, V178, P2154, DOI 10.1128/jb.178.7.2154-2157.1996; STORZ G, 1994, METHOD ENZYMOL, V234, P217; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; Turlin E, 1996, BIOCHIMIE, V78, P822, DOI 10.1016/S0300-9084(97)84334-9; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	51	367	374	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					43	53		10.1016/S0092-8674(00)80312-8	http://dx.doi.org/10.1016/S0092-8674(00)80312-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230301	hybrid			2022-12-01	WOS:A1997XL36200007
J	Bershitsky, SY; Tsaturyan, AK; Bershitskaya, ON; Mashanov, GI; Brown, P; Burns, R; Ferenczi, MA				Bershitsky, SY; Tsaturyan, AK; Bershitskaya, ON; Mashanov, GI; Brown, P; Burns, R; Ferenczi, MA			Muscle force is generated by myosin heads stereospecifically attached to actin	NATURE			English	Article							X-RAY-DIFFRACTION; SKELETAL-MUSCLE; CROSS-BRIDGES; CONTRACTING MUSCLE; STRUCTURAL-CHANGES; STRIATED-MUSCLE; FIBERS; REFLECTIONS; MOVEMENTS; STATES	Muscle force is generated by myosin crossbridges interacting with actin. As estimated from stiffness(1,2) and equatorial X-ray diffraction(3) of muscle and muscle fibres, most myosin cross-bridges are attached to actin during isometric contraction, but a much smaller fraction is bound stereospecifically(4-7). To determine the fraction of crossbridges contributing to tension and the structural changes that attached crossbridges undergo when generating force, we monitored the X-ray diffraction pattern during temperature-induced tension rise in fully activated permeabilized frog muscle fibres. Temperature jumps(8) from 5-6 degrees C to 16-19 degrees C initiated a 1.7-fold increase in tension without significantly changing fibre stiffness or the intensities of the (1,1) equatorial and (14.5 nm)(-1) meridional X-ray reflections. However, tension rise was accompanied by a 20% decrease in the intensity of the (1,0) equatorial reflection and an increase in the intensity of the first actin layer line by similar to 13% of that in rigor. Our results show that muscle force is associated with a transition of the crossbridges from a state in which they are nonspecifically attached to actin to one in which stereospecifically bound myosin crossbridges label the actin helix.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; RUSSIAN ACAD SCI,INST PHYSIOL,URALS BRANCH,EKATERINBURG 620219,RUSSIA; MOSCOW MV LOMONOSOV STATE UNIV,INST MECH,MOSCOW 119899,RUSSIA	MRC National Institute for Medical Research; Russian Academy of Sciences; Lomonosov Moscow State University			Ferenczi, Michael/F-9510-2015; Bershitsky, Sergey/AAE-6814-2019; Bershitsky, Sergey/S-4829-2016; Tsaturyan, Andrey K/B-1037-2014; Tsaturyan, Andrey/GXF-8722-2022	Ferenczi, Michael/0000-0002-0349-331X; Bershitsky, Sergey/0000-0001-5342-1739; Tsaturyan, Andrey K/0000-0002-0447-7725; 				AMEMIYA Y, 1987, SCIENCE, V237, P164, DOI 10.1126/science.3496662; Bershitsky S, 1996, BIOPHYS J, V71, P1462, DOI 10.1016/S0006-3495(96)79347-5; BERSHITSKY SY, 1995, BIOPHYS J, V69, P1011, DOI 10.1016/S0006-3495(95)79976-3; BORDOGNA G, 1991, INFORM PROCESS MANAG, V27, P15, DOI 10.1016/0306-4573(91)90028-K; BRENNER B, 1993, P NATL ACAD SCI USA, V90, P5252, DOI 10.1073/pnas.90.11.5252; COOKE R, 1984, CONTRACTILE MECHANIS, P413; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; GOLDMAN YE, 1977, J PHYSIOL-LONDON, V269, pP55; HARFORD JJ, 1992, BIOPHYS J, V63, P387, DOI 10.1016/S0006-3495(92)81613-2; HASELGROVE JC, 1973, J MOL BIOL, V77, P549, DOI 10.1016/0022-2836(73)90222-2; HIGUCHI H, 1995, BIOPHYS J, V69, P1000, DOI 10.1016/S0006-3495(95)79975-1; HIROSE K, 1993, BIOPHYS J, V65, P397, DOI 10.1016/S0006-3495(93)81061-0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1982, J MOL BIOL, V158, P637, DOI 10.1016/0022-2836(82)90253-4; HUXLEY HE, 1967, J MOL BIOL, V30, P383, DOI 10.1016/S0022-2836(67)80046-9; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; Ling N, 1996, BIOPHYS J, V70, P1836, DOI 10.1016/S0006-3495(96)79749-7; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; MARTINFERNANDEZ ML, 1994, J MUSCLE RES CELL M, V15, P319; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; PIAZZESI G, 1995, BIOPHYS J, V68, pS92; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; VAINSHTEIN BK, 1963, DIFFRACTION XRAYS CH; Yagi N, 1991, Adv Biophys, V27, P35, DOI 10.1016/0065-227X(91)90006-Y	29	82	84	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					186	190		10.1038/40651	http://dx.doi.org/10.1038/40651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217160	Bronze			2022-12-01	WOS:A1997XK10900053
J	tenWolde, PR; Frenkel, D				tenWolde, PR; Frenkel, D			Enhancement of protein crystal nucleation by critical density fluctuations	SCIENCE			English	Article							PHASE-BEHAVIOR; CRYSTALLIZATION; POLYMER; SYSTEM; TRANSITIONS; ENERGY; GROWTH; LATEX	Numerical simulations of homogeneous crystal nucleation with a model for globular proteins with short-range attractive interactions showed that the presence of a metastable fluid-fluid critical point drastically changes the pathway for the formation of a crystal nucleus. Close to this critical point, the free-energy barrier for crystal nucleation is strongly reduced and hence, the crystal nucleation rate increases by many orders of magnitude. Because the location of the metastable critical point can be controlled by changing the composition of the solvent, the present work suggests a systematic approach to promote protein crystallization.	FOM,INST ATOM & MOL PHYS,NL-1098 SJ AMSTERDAM,NETHERLANDS	AMOLF			Wolde, Pieter Rein Ten/U-4433-2019; Frenkel, Daan/G-2580-2014	Wolde, Pieter Rein Ten/0000-0001-9933-4016; Frenkel, Daan/0000-0002-6362-2021				Asherie N, 1996, PHYS REV LETT, V77, P4832, DOI 10.1103/PhysRevLett.77.4832; Bennett C.H., 1975, DIFFUSION SOLIDS, P73, DOI [10.1016/B978-0-12-522660-8.50007-6, DOI 10.1016/B978-0-12-522660-8.50007-6]; BERLAND CR, 1992, P NATL ACAD SCI USA, V89, P1214, DOI 10.1073/pnas.89.4.1214; Broide ML, 1996, PHYS REV E, V53, P6325, DOI 10.1103/PhysRevE.53.6325; Durbin SD, 1996, ANNU REV PHYS CHEM, V47, P171, DOI 10.1146/annurev.physchem.47.1.171; GAST AP, 1983, J COLLOID INTERF SCI, V96, P251, DOI 10.1016/0021-9797(83)90027-9; GAST AP, 1986, J COLLOID INTERF SCI, V109, P161, DOI 10.1016/0021-9797(86)90291-2; GEORGE A, 1994, ACTA CRYSTALLOGR D, V50, P361, DOI 10.1107/S0907444994001216; HAAS C, 1995, J CRYST GROWTH, V154, P126, DOI 10.1016/0022-0248(95)00135-2; HAGEN MHJ, 1994, J CHEM PHYS, V101, P4093, DOI 10.1063/1.467526; HANSEN JP, 1969, PHYS REV, V184, P151, DOI 10.1103/PhysRev.184.151; HILL TL, 1986, INTRO STAT THERMODYN, pCH15; ILETT SM, 1995, PHYS REV E, V51, P1344, DOI 10.1103/PhysRevE.51.1344; KELTON KF, 1991, SOLID STATE PHYS, V45, P75; KOSE A, 1976, J COLLOID INTERF SCI, V55, P487, DOI 10.1016/0021-9797(76)90059-X; LEKKERKERKER HNW, 1992, EUROPHYS LETT, V20, P559, DOI 10.1209/0295-5075/20/6/015; MALKIN AJ, 1993, J CRYST GROWTH, V133, P29, DOI 10.1016/0022-0248(93)90100-B; MALKIN AJ, 1992, J CRYST GROWTH, V128, P1232; MCPHERSON A, 1976, J BIOL CHEM, V251, P6300; McPherson A, 1982, PREPARATION ANAL PRO; Muschol M, 1997, J CHEM PHYS, V107, P1953, DOI 10.1063/1.474547; Poon WCK, 1997, PHYS REV E, V55, P3762, DOI 10.1103/PhysRevE.55.3762; Poon WCK, 1995, FARADAY DISCUSS, V101, P65, DOI 10.1039/fd9950100065; RICHARDS EG, 1980, INTRO PHYSICAL PROPE; Rosenbaum D, 1996, PHYS REV LETT, V76, P150, DOI 10.1103/PhysRevLett.76.150; Rosenbaum DF, 1996, J CRYST GROWTH, V169, P752, DOI 10.1016/S0022-0248(96)00455-1; Rosenberger F, 1996, J CRYST GROWTH, V166, P40, DOI 10.1016/0022-0248(95)00921-3; SMITS C, 1990, PHASE TRANSIT, V21, P157, DOI 10.1080/01411599008206888; TENWOLDE PR, 1995, PHYS REV LETT, V75, P2714, DOI 10.1103/PhysRevLett.75.2714; tenWolde PR, 1996, J CHEM PHYS, V104, P9932, DOI 10.1063/1.471721; TORRIE GM, 1974, CHEM PHYS LETT, V28, P578, DOI 10.1016/0009-2614(74)80109-0	31	1070	1077	7	253	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1975	1978		10.1126/science.277.5334.1975	http://dx.doi.org/10.1126/science.277.5334.1975			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302288	Green Submitted			2022-12-01	WOS:A1997XX84900038
J	Kim, D; Jun, KS; Lee, SB; Kang, NG; Min, DS; Kim, YH; Ryu, SH; Suh, PG; Shin, HS				Kim, D; Jun, KS; Lee, SB; Kang, NG; Min, DS; Kim, YH; Ryu, SH; Suh, PG; Shin, HS			Phospholipase C isozymes selectively couple to specific neurotransmitter receptors	NATURE			English	Article							PHOSPHOINOSITIDE HYDROLYSIS; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; MESSENGER-RNAS; RAT-BRAIN; EPILEPSY; SEIZURES; MICE; LOCALIZATION; INTERNEURONS	A variety of extracellular signals are transduced across the cell membrane by the enzyme phosphoinositide-specific phospholipase C-beta (PLC-beta) coupled with guanine-nucleotide-binding G proteins'. There are four isoenzymes of PLC-beta, beta 1-beta 4, but their functions in vivo are not known. Here we investigate the role of PLC-beta 1 and PLC-beta 4 in the brain by generating-null mutations in mice: we found that PLC beta 1(-/-) mice developed epilepsy and PLC beta 4(-/-) mice showed ataxia. We determined the molecular basis of these phenotypes and show that PLC-beta 1 is involved in signal transduction in the cerebral cortex and hippocampus by coupling pre-dominantly to the muscarinic acetylcholine receptor, whereas PLC-beta 4 works through the metabotropic glutamate receptor in the cerebellum, illustrating how PLC-beta isoenzymes are used to generate different functions in the brain.	POHANG UNIV SCI & TECHNOL,DEPT LIFE SCI,POHANG 790784,SOUTH KOREA; INJE UNIV,INST NEUROSCI,PUSAN 614735,SOUTH KOREA	Pohang University of Science & Technology (POSTECH); Inje University			Suh, Pann-Ghill/F-3610-2010; Kim, Daesoo/C-1625-2011	Kim, Daesoo/0000-0001-9915-1463; KANG, NAE-GYU/0000-0002-3318-3873; Ryu, Sung Ho/0000-0003-0913-3048; Lee, Seong-Beom/0000-0002-2767-6188				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; BUZSAKI G, 1989, NEUROSCIENCE, V28, P527, DOI 10.1016/0306-4522(89)90002-X; CREWS FT, 1994, LIFE SCI, V55, P1993, DOI 10.1016/0024-3205(94)00379-3; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; FISHER SK, 1992, J NEUROCHEM, V58, P18, DOI 10.1111/j.1471-4159.1992.tb09273.x; FRANKEL WN, 1995, MAMM GENOME, V6, P839, DOI 10.1007/BF00292432; Hesdorffer DC, 1996, NEUROLOGY, V46, P727, DOI 10.1212/WNL.46.3.727; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; Kelly JF, 1996, P NATL ACAD SCI USA, V93, P6753, DOI 10.1073/pnas.93.13.6753; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; KIM MJ, 1993, BIOCHEM BIOPH RES CO, V194, P706, DOI 10.1006/bbrc.1993.1879; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Mendez M F, 1994, J Geriatr Psychiatry Neurol, V7, P230; PITLER TA, 1992, J PHYSIOL-LONDON, V450, P127, DOI 10.1113/jphysiol.1992.sp019119; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SCHOEPP DD, 1991, EUR J PHARM-MOLEC PH, V207, P351, DOI 10.1016/0922-4106(91)90010-F; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; STAFSTROM CE, 1992, DEV BRAIN RES, V65, P227, DOI 10.1016/0165-3806(92)90184-X; TANAKA O, 1994, NEUROSCI LETT, V182, P17, DOI 10.1016/0304-3940(94)90194-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0	26	240	251	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					290	293		10.1038/38508	http://dx.doi.org/10.1038/38508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305844				2022-12-01	WOS:A1997XW77200049
J	Jost, CA; Marin, MC; Kaelin, WG				Jost, CA; Marin, MC; Kaelin, WG			p73 is a human p53-related protein that can induce apoptosis	NATURE			English	Article							P53 GENE-MUTATIONS; TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; DNA-BINDING; NEUROBLASTOMA; IDENTIFICATION; DOMAIN	The protein p53 is the most frequently mutated tumour suppressor to be identified so far in human cancers(1,2). The ability of p53 to inhibit cell growth is due, at least in part, to its ability to bind to specific DNA sequences and activate the transcription of target genes such as that encoding the cell-cycle inhibitor p21(Waf1/Cip1) (ref. 3), A gene has recently been identified that is predicted to encode a protein with significant amino-acid sequence similarity to p53 (ref, 4), In particular, each of the p53 amino-acid residues implicated in direct sequence-specific DNA binding is conserved in this protein(5). This gene, called p73, maps to the short arm of chromosome 1, and is found in a region that is frequently deleted in neuroblastomas(6). Here we show that p73 can, at least when overproduced, activate the transcription of p53-responsive genes and inhibit cell growth in a p53-like manner by inducing apoptosis (programmed cell death).	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN XB, 1993, GENE DEV, V7, P2652; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DILLER L, 1995, CANCER RES, V55, P2910; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLEMINGTON EK, 1994, MOL CELL BIOL, V14, P3041, DOI 10.1128/MCB.14.5.3041; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; KAGHAD M, IN PRESS CELL; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; VOGAN K, 1993, CANCER RES, V53, P5269	25	869	905	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					191	194		10.1038/38298	http://dx.doi.org/10.1038/38298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296498				2022-12-01	WOS:A1997XV75700051
J	Blattler, T; Brandner, S; Raeber, AJ; Klein, MA; Voigtlander, T; Weissmann, C; Aguzzi, A				Blattler, T; Brandner, S; Raeber, AJ; Klein, MA; Voigtlander, T; Weissmann, C; Aguzzi, A			PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain	NATURE			English	Article							CREUTZFELDT-JAKOB DISEASE; CENTRAL-NERVOUS-SYSTEM; HOST PRION PROTEIN; MICE; MOUSE; PATHOGENESIS; REPLICATION; AGENT; SPREAD	Much available evidence points to a pathological isoform of the prion protein PrP being the infectious agent that causes transmissible spongiform encephalopathies, but the mechanisms controlling the neurotropism of prions are still unclear. We have previously shown that mice that do not express PrP (Prnp(o/o) mice) are resistant to infection by prions(1,2), and that if a Prnp(+/+) neurograft is introduced into such animals and these are infected intracerebrally with scrapie, the graft but not the surrounding tissue shows scrapie pathology(3). Here we show that PrP-expressing neurografts in Prnp(o/o) mice do not develop scrapie histopathology after intraperitoneal or intravenous inoculation with scrapie prions. Prion titres were undetectable in spleens of inoculated Prnp(o/o) mice, but were restored to wild-type levels upon reconstitution of the host lymphohaemopoietic system with PrP-expressing cells. Surprisingly, however, i.p. or i.v. inoculation failed to produce scrapie pathology in the neurografts of 27 out of 28 reconstituted animals, in contrast to intracerebral inoculation. We conclude that transfer of infectivity from the spleen to the central nervous system is crucially dependent on the expression of PrP in a tissue compartment that cannot be reconstituted by bone marrow transfer. Thus the requirement for the normal isoform of PrP in peripheral tissues represents a bottleneck for the spread of prions from peripheral sites to the central nervous system.	UNIV ZURICH,INST NEUROPATHOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST MOL BIOL,CH-8093 ZURICH,SWITZERLAND	University of Zurich; University of Zurich			Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Aguzzi, Adriano/0000-0002-0344-6708				Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown KL, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P159; BROWN P, 1990, NEUROLOGY, V40, P887, DOI 10.1212/WNL.40.6.887; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER HR, 1992, NATURE, V256, P577; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; FRASER H, 1978, J COMP PATHOL, V88, P563, DOI 10.1016/0021-9975(78)90010-5; Isenmann S, 1996, NEUROPATH APPL NEURO, V22, P118; KIMBERLIN RH, 1983, J NEUROL SCI, V61, P315, DOI 10.1016/0022-510X(83)90165-X; KIMBERLIN RH, 1989, VIRUS RES, V12, P201, DOI 10.1016/0168-1702(89)90039-7; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; Lasmezas CI, 1996, J VIROL, V70, P1292; OROURKE KI, 1994, J GEN VIROL, V75, P1511, DOI 10.1099/0022-1317-75-6-1511; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620	21	223	228	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 4	1997	389	6646					69	73		10.1038/37981	http://dx.doi.org/10.1038/37981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XU596	9288968				2022-12-01	WOS:A1997XU59600046
J	Plemper, RK; Bohmler, S; Bordallo, J; Sommer, T; Wolf, DH				Plemper, RK; Bohmler, S; Bordallo, J; Sommer, T; Wolf, DH			Mutant analysis links the translocon and BiP to retrograde protein transport for ER degradation	NATURE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; UBIQUITIN-PROTEASOME PATHWAY; SEC61P COMPLEX; YEAST; HOMOLOGS; ROUTE; KAR2; GENE	Proteins enter the secretory pathway through the endoplasmic reticulum(1), which delivers properly folded proteins to their site of action(2) and contains a quality-control system to monitor and prevent abnormal proteins from being delivered(3), Many of these proteins are degraded by the cytoplasmic proteasome(4-8), which requires their retrograde transport to the cytoplasm(5,6). Based on a co-immunoprecipitation of major histocompatibility complex (MHC) class I heavy-chain breakdown intermediates with the translocon subunit Sec61p (refs 9, 10), it was speculated that Sec61p maybe involved in retrograde transport(11), Here we present functional evidence from genetic studies that Sec61p mediates retrograde transport of a mutated lumenal yeast carboxypeptidase ycsY (CPY*) in vivo. The endoplasmic reticulum lumenal chaperone BiP (Kar2p) and Sec63p, which are also subunits of the import machinery(10,12), are involved in export of CPY* to the cytosol, Thus our results demonstrate that retrograde transport of proteins is mediated by a functional translocon. We consider the export of endoplasmic reticulum-localized proteins to the cytosol by the translocon for proteasome degradation to be a general process in eukaryotic cell biology.	UNIV STUTTGART,INST BIOCHEM,D-70569 STUTTGART,GERMANY; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY	University of Stuttgart; Helmholtz Association; Max Delbruck Center for Molecular Medicine			bordallo, javier/X-5360-2019	bordallo, javier/0000-0002-5786-3929				Ausubel FM, 1992, CURRENT PROTOCOLS MO; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; CYYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cellbio.10.1.87; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	29	451	454	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					891	895		10.1038/42276	http://dx.doi.org/10.1038/42276			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278052	Bronze			2022-12-01	WOS:A1997XT75400053
J	Branche, CM; Conn, JM; Annest, JL				Branche, CM; Conn, JM; Annest, JL			Personal watercraft-related injuries - A growing public health concern	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							JET-SKI ACCIDENT	Context.-An increase in the recreational use of personal watercraft (PWC) raises concern about an increase in associated injuries on a national level. Objective.-To estimate the relative frequency, types of injury, and demographic features of persons injured while using PWC in the United States. Design.-Case series. Setting.-Emergency department (ED) visits to hospitals participating a national probability sample. Participants.-All persons treated for PWC-related injury from January 1, 1990, through December 31, 1995. Results.-An estimated 32 954 persons (95% confidence interval [CI], 22919-42 989) with PWC-related injuries were treated in US hospital EDs, of which 3.5% were hospitalized. Personal watercraft-related injuries have increased significantly from an estimated 2860 in 1990 to more than 12 000 in 1995. During this period, the number of PWC in operation increased 3-fold from approximately 241 500 in 1990 to an estimated 760 000 in 1995. The most prevalent diagnoses were lacerations, contusions, and fractures. Main Outcome Measures.-The estimated number and percentage of patients treated in EDs for PWC-related injuries, by year, age, sex, and the number and rate per 1000 of PWC in operation by year. Conclusions.-Since 1990, there has been at least a 4-fold increase in injuries associated with an increase in the recreational use of PWC. The rate of ED-treated injuries related to PWC was about 8.5 times higher (95% CI, 8.2-8.8; 1992 data) than the rate of those from motorboats. Specific training and adult supervision is recommended for miners using PWC. Furthermore, medical practitioners should encourage personal flotation device use and other protection for their patients who are known water enthusiasts.			Branche, CM (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,PUBL HLTH SERV,US DEPT HHS,ATLANTA,GA 30341, USA.							Annest J, 1996, INVENTORY FEDERAL DA; ARMITAGE P, 1994, STAT METHODS MED RES, P408; BEVER DL, 1996, SAFETY PERSONAL FOCU, P391; BRANCHEDORSEY CM, 1993, STUDY BOAT BOAT PROP; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P331; Francis R A, 1994, Mo Med, V91, P241; HAEFNER HK, 1991, OBSTET GYNECOL, V78, P986; HAMMAN BL, 1993, J PEDIATR SURG, V28, P920, DOI 10.1016/0022-3468(93)90697-J; Jeffery R S, 1991, Br J Sports Med, V25, P232; MARKER D, 1988, NEISS SAMPLE UPDATE; Muller R J, 1993, J La State Med Soc, V145, P27; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; *US COAST GUARD, 1995, BOAT STAT 1994; *US CONS PROD SAF, 1994, NAT EL INJ SURV SYST; WEIN P, 1990, AUST NZ J OBSTET GYN, V30, P384, DOI 10.1111/j.1479-828X.1990.tb02038.x	15	40	40	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					663	665		10.1001/jama.278.8.663	http://dx.doi.org/10.1001/jama.278.8.663			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272899				2022-12-01	WOS:A1997XR54700040
J	Steinhubl, SR; Topol, EJ				Steinhubl, SR; Topol, EJ			Stenting for acute myocardial infarction	LANCET			English	Editorial Material							CORONARY		CLEVELAND CLIN FDN,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,CLEVELAND,OH 44195; OHIO STATE UNIV,DEPT MED,CLEVELAND,OH 44195	Cleveland Clinic Foundation; University System of Ohio; Ohio State University	Steinhubl, SR (corresponding author), CLEVELAND CLIN FDN,DEPT CARDIOL,CLEVELAND,OH 44195, USA.			Topol, Eric/0000-0002-1478-4729				Antoniucci D., 1997, Journal of the American College of Cardiology, V29, p456A; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Grines C. L., 1997, Journal of the American College of Cardiology, V29, p389A; *GUSTO 2B ANG SUBS, 1997, NEW ENGL J MED, V336, P1621; HOORNTJE JC, 1996, CIRCULATION S1, V94, P570; Horstkotte D., 1996, European Heart Journal, V17, P297; Monassier Jean Pierre, 1996, Journal of the American College of Cardiology, V27, p68A; Nakagawa Y, 1996, AM J CARDIOL, V78, P980, DOI 10.1016/S0002-9149(96)00520-6; NATH FC, 1993, J AM COLL CARDIOL, V21, P622, DOI 10.1016/0735-1097(93)90093-G; Rodriguez A., 1997, Journal of the American College of Cardiology, V29, p221A; Saito S., 1997, Journal of the American College of Cardiology, V29, p390A; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201	13	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					532	533		10.1016/S0140-6736(05)63135-2	http://dx.doi.org/10.1016/S0140-6736(05)63135-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284772				2022-12-01	WOS:A1997XT22100005
J	Schwab, M; Lutum, AS; Seufert, W				Schwab, M; Lutum, AS; Seufert, W			Yeast Hct1 is a regulator of Clb2 cyclin proteolysis	CELL			English	Article							MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; G1 CYCLINS; CDC20 GENE; S-PHASE; UBIQUITIN; DEGRADATION; MITOSIS	Stage-specific proteolysis of mitotic cyclins is fundamental to eukaryotic cell cycle regulation. We found that yeast Hct1, a conserved protein of eukaryotes, is a necessary and rate-limiting component of this proteolysis pathway. In hct1 mutants, the mitotic cyclin Clb2 is highly stabilized and inappropriately induces DNA replication, while G1 cyclins and other proteolytic substrates remain short-lived. Viability of hct1 mutants depends on SIC1. This and further results suggest that inhibition of cyclin-dependent kinases may compensate for defects in cyclin proteolysis. Remarkably, elevated levels of Hct1 ectopically activate destruction box-and Cdc23-dependent degradation of Clb2 and cause phenotypic effects characteristic for a depletion of M-phase cyclins. Hct1 and the related Cdc20 may function as substrate-specific regulators of proteolysis during mitosis.			Schwab, M (corresponding author), UNIV STUTTGART,INST IND GENET,ALLMANDRING 31,D-70569 STUTTGART,GERMANY.		Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; KAISER C, 1994, MEHTODS YEAST GENETI; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHWOB E, 1994, CELL, V79, P239; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	41	427	432	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					683	693		10.1016/S0092-8674(00)80529-2	http://dx.doi.org/10.1016/S0092-8674(00)80529-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288748	Bronze			2022-12-01	WOS:A1997XT06600012
J	Shimamura, M; Yasue, H; Ohshima, K; Abe, H; Kato, H; Kishiro, T; Goto, M; Munechika, I; Okada, N				Shimamura, M; Yasue, H; Ohshima, K; Abe, H; Kato, H; Kishiro, T; Goto, M; Munechika, I; Okada, N			Molecular evidence from retroposons that whales form a clade within even-toed ungulates	NATURE			English	Article							SEQUENCES; ELEMENTS; PHYLOGENY; SINES	The origin of whales and their transition from terrestrial life to a fully aquatic existence has been studied in depth. Palaeontological(1,2), morphological(3) and molecular studies(4-7) suggest that the order Cetacea (whales, dolphins and porpoises) is more closely related to the order Artiodactyla (even-toed ungulates, including cows, camels and pigs) than to other ungulate orders. The traditional view that the order Artiodactyla is monophyletic has been challenged by molecular analyses of variations in mitochondrial and nuclear DNA(5-7). We have characterized two families of short interspersed elements (SINEs) that were present exclusively in the genomes of whales, ruminants and hippopotamuses, but not in those of camels and pigs. We made an extensive survey of retropositional events that might have occurred during the divergence of whales and even-toed ungulates. We have characterized nine retropositional events of a SINE unit, each of which provides phylogenetic resolution of the relationships among whales, ruminants, hippopotamuses and pigs. Our data provide evidence that whales, ruminants and hippopotamuses form a monophyletic group.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,YOKOHAMA,KANAGAWA 226,JAPAN; NATL INST ANIM IND,ANIM GENOME RES GRP,KUKIZAKI,IBARAKI 305,JAPAN; NATL INST FAR SEAS FISHERIES,LARGE CETACEAN SECT,SHIMIZU,SHIZUOKA 424,JAPAN; INST CETACEAN RES,GENET ECOL SECT,CHUO KU,TOKYO 104,JAPAN; CHIBA ZOOL PK,WAKABA KU,CHIBA 264,JAPAN	Tokyo Institute of Technology; National Agriculture & Food Research Organization - Japan			Ohshima, Kazuhiko/AAJ-1347-2021	Ohshima, Kazuhiko/0000-0001-8437-4744; Abe, Hideaki/0000-0002-8965-8970; Okada, Norihiro/0000-0002-3655-8060				Adachi J, 1996, MOL PHYLOGENET EVOL, V6, P72, DOI 10.1006/mpev.1996.0059; FORDYCE RE, 1994, ANNU REV EARTH PL SC, V22, P419, DOI 10.1146/annurev.ea.22.050194.002223; Gatesy J, 1996, MOL BIOL EVOL, V13, P954, DOI 10.1093/oxfordjournals.molbev.a025663; Gentry AW, 1988, PHYLOGENY CLASSIFICA, V35B, P235; GINGERICH PD, 1990, SCIENCE, V249, P154, DOI 10.1126/science.249.4965.154; GOLZ DJ, 1976, NATURAL HIST MUSEUM, V26, P1; GRAUR D, 1994, MOL BIOL EVOL, V11, P357; Hasegawa M, 1996, MOL BIOL EVOL, V13, P710, DOI 10.1093/oxfordjournals.molbev.a025632; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Irwin David M., 1994, Journal of Mammalian Evolution, V2, P37, DOI 10.1007/BF01464349; LENSTRA JA, 1993, ANIM GENET, V24, P33, DOI 10.1111/j.1365-2052.1993.tb00916.x; MILINKOVITCH MC, 1993, NATURE, V361, P346, DOI 10.1038/361346a0; MURATA S, 1993, P NATL ACAD SCI USA, V90, P6995, DOI 10.1073/pnas.90.15.6995; Murata S, 1996, GENETICS, V142, P915; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; OKADA N, 1991, TRENDS ECOL EVOL, V6, P358, DOI 10.1016/0169-5347(91)90226-N; Okada N., 1995, IMPACT SHORT INTERSP, P61; Philippe Herve, 1994, Journal of Mammalian Evolution, V2, P133, DOI 10.1007/BF01464365; Prothero D., 1988, PHYLOGENY CLASSIFICA, P201; ROSE KD, 1982, SCIENCE, V216, P621, DOI 10.1126/science.216.4546.621; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; TAKAHASHI H, 1992, ANIM GENET, V23, P443, DOI 10.1111/j.1365-2052.1992.tb02164.x; Thewissen J. G. M., 1994, Journal of Mammalian Evolution, V2, P157, DOI 10.1007/BF01473527; THEWISSEN JGM, 1993, NATURE, V361, P444, DOI 10.1038/361444a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.biochem.55.1.631	25	313	324	2	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					666	670		10.1038/41759	http://dx.doi.org/10.1038/41759			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262399	Bronze			2022-12-01	WOS:A1997XQ86300047
J	Alm, JS; Lilja, G; Pershagen, G; Scheynius, A				Alm, JS; Lilja, G; Pershagen, G; Scheynius, A			Early BCG vaccination and development of atopy	LANCET			English	Article							CYTOKINE PRODUCTION; CHILDREN; TUBERCULOSIS; PREVALENCE; PREVENTION; INDUCTION	Background The increase in atopic diseases may be partly explicable by a decline of certain infectious diseases, dr changes in childhood Vaccination programmes, or both. We investigated whether BCG vaccination against tuberculosis influences the development of atopy. Methods We did a retrospective cohort study of 216 children with atopic heredity, born in Stockholm between 1989 and 1992, who received BCG vaccination when they were younger than 6 months, and 358 age-matched controls who had not been vaccinated. Both groups attended Sachs' Children's Hospital, Stockholm, Sweden, during 1995-96 for assessment of atopic history and clinical signs of atopic disease. All children also underwent skin-prick testing (SPT) and serum was analysed for allergen-specific IgE antibodies. Serum from parents was also analysed for IgE antibodies. Findings 77 (36%) children in the BCG group and 145 (41%) in the control group had a positive history or clinical signs of atopic disease, in the vaccinated group, 26 (12%) children had one or more positive SPT, and 61 (31%) had circulating allergen-specific IgE antibodies, whereas in the control group, the numbers were 35 (10%) and 84 (27%) respectively. Atopy was confirmed by serology in parents of almost two-thirds of the children in each group. Other risk factors for atopic disease were evenly distributed between the two groups. Interpretation early BCG vaccination in children with atopic heredity does not seem to affect the development of atopic disease before school age.	KAROLINSKA HOSP & INST, INST ENVIRONM MED, DIV ENVIRONM EPIDEMIOL, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA HOSP & INST, DEPT LAB MED, DIV CLIN IMMUNOL, S-17176 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Alm, JS (corresponding author), KAROLINSKA INST, SACHS CHILDRENS HOSP, S-17176 STOCKHOLM, SWEDEN.			Pershagen, Goran/0000-0002-9701-1130; Alm, Johan/0000-0002-9062-4479				ALKASSIMI FA, 1995, AM J RESP CRIT CARE, V152, P1575, DOI 10.1164/ajrccm.152.5.7582297; AURELIUS G, 1995, CHILD HLTH CARE STOC, P20; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; COLDITZ GA, 1995, PEDIATRICS, V96, P29; DELPRETE G, 1992, ALLERGY, V47, P450; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HARADA M, 1990, DIABETES RES CLIN PR, V8, P85, DOI 10.1016/0168-8227(90)90017-N; Kajosaari M, 1994, Pediatr Allergy Immunol, V5, P26, DOI 10.1111/j.1399-3038.1994.tb00344.x; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; LARSSON LO, 1991, SENSITIVITY SENSITIN, P6; Lilja G, 1996, CLIN EXP ALLERGY, V26, P1073; MEHRA VL, 1990, NEW GENERATION VACCI, P611; Pepys J., 1975, , Clinical aspects of immunology., P877; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMANUS V, 1992, TUBERCLE LUNG DIS, V73, P150, DOI 10.1016/0962-8479(92)90149-E; ROMANUS V, 1996, SWEDISH TUBERCULOSIS; RYLANDER E, 1993, EUR J EPIDEMIOL, V9, P517, DOI 10.1007/BF00209530; Sander B, 1995, IMMUNOLOGY, V86, P512; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; SHEHADEH N, 1994, LANCET, V343, P706, DOI 10.1016/S0140-6736(94)91583-0; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIGURS N, 1992, PEDIATRICS, V89, P735; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; WARD BJ, 1991, CLIN IMMUNOL IMMUNOP, V61, P236, DOI 10.1016/S0090-1229(05)80027-3; WARD BJ, 1993, CLIN IMMUNOL IMMUNOP, V67, P171, DOI 10.1006/clin.1993.1061; Wichmann HE, 1996, CLIN EXP ALLERGY, V26, P621, DOI 10.1111/j.1365-2222.1996.tb00587.x	28	213	218	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	1997	350	9075					400	403		10.1016/S0140-6736(97)02207-1	http://dx.doi.org/10.1016/S0140-6736(97)02207-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9259654				2022-12-01	WOS:A1997XQ24800010
J	Cambridge, SB; Davis, RL; Minden, JS				Cambridge, SB; Davis, RL; Minden, JS			Drosophila mitotic domain boundaries as cell fate boundaries	SCIENCE			English	Article							EMBRYOS; EXPRESSION; GAL4; GENE; MELANOGASTER; PRODUCTS; YEAST	Fate determination in Drosophila embryos is evidenced by the appearance of mitotic domains. To identify fate or fates of cells, individual cells in mitotic domains 2, 8, and 15 were marked and monitored through development. Comparison of the different fates indicated that domain boundaries are cell fate boundaries. Cells were marked by expression of GAL4-dependent transgenes after photoactivation of a caged GAL4VP16 analog that had its DNA binding activity inhibited with a photolabile blocking reagent. Caged GAL4VP16 was also used to induce gene expression in Xenopus embryos. Thus, photoactivated gene expression is a versatile tool for spatiotemporal control of gene expression.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL,PITTSBURGH,PA 15213; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Carnegie Mellon University; Carnegie Mellon University; Harvard University; Harvard Medical School			Cambridge, Sidney/GYQ-5764-2022					ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; AFANASEVA GB, 1974, CHEM HETEROCYCLIC CO, V10, P302; BOMZE HM, 1994, GENETICS, V136, P965; BOSSING T, 1994, DEVELOPMENT, V120, P1895; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; DAVIS I, 1995, DEV BIOL, V170, P726, DOI 10.1006/dbio.1995.1251; FOE VE, 1989, DEVELOPMENT, V107, P1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; Halfon MS, 1997, P NATL ACAD SCI USA, V94, P6255, DOI 10.1073/pnas.94.12.6255; Harris J, 1996, DEVELOPMENT, V122, P3117; HATCHARD CG, 1956, PROC R SOC LON SER-A, V235, P518, DOI 10.1098/rspa.1956.0102; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; Marriott G, 1996, BIOCHEMISTRY-US, V35, P3170, DOI 10.1021/bi952207o; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; Minden JS, 1996, BIOTECHNIQUES, V20, P122; Namba R, 1997, DEVELOPMENT, V124, P1393; STRINGHAM EG, 1993, J EXP ZOOL, V266, P227, DOI 10.1002/jez.1402660309; TECHNAU G M, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P196, DOI 10.1007/BF00848247; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B	24	53	53	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					825	828		10.1126/science.277.5327.825	http://dx.doi.org/10.1126/science.277.5327.825			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242613				2022-12-01	WOS:A1997XQ24700046
J	Roberts, I; Barker, M; Li, L				Roberts, I; Barker, M; Li, L			Analysis of trends in deaths from accidental drug poisoning in teenagers, 1985-95	BRITISH MEDICAL JOURNAL			English	Article											Roberts, I (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL,CHILD HLTH MONITORING UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.							FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; HENRY JA, 1992, BRIT MED J, V305, P5, DOI 10.1136/bmj.305.6844.5; WRIGHT JD, 1995, BRIT MED J, V310, P20, DOI 10.1136/bmj.310.6971.20	3	20	20	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					289	289		10.1136/bmj.315.7103.289	http://dx.doi.org/10.1136/bmj.315.7103.289			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274550	Green Published			2022-12-01	WOS:A1997XP75000024
J	Benefit, BR; McCrossin, ML				Benefit, BR; McCrossin, ML			Earliest known Old World monkey skull	NATURE			English	Article							MABOKO ISLAND; FACIAL MORPHOLOGY; KENYA; VICTORIAPITHECUS; MIOCENE; AEGYPTOPITHECUS; PRIMATES; AGE	Similarities of the skull are commonly used to support hypotheses of ancestor-descendant relationships between fossil and living ape genera, especially between the late Miocene apes Sivapithecus and Dryopithecus from Eurasia and the living orang-utan (Pongo) from Borneo and Sumatra(1-4). Yet determining whether cranio-facial traits shared by extant and Miocene apes are primitive or derived is severely hampered by the rarity of well-preserved fossil crania, particularly of early members of their closest outgroup, the Old World monkeys (Cercopithecoidea). The discovery of a complete and undistorted skull of Victorispithecus at middle Miocene deposits from Maboko Island, Kenya, provides evidence of intact cranial-vault and basicranial morphology, brain size and craniofacial hafting for a primate from between 32 and 7 million years ago. Victoriapithecus represents a branch of Old World monkey that is intermediate between extant cercopithecids (Colobinae and Cercopithecinae) and the common ancestor they shared with apes (Hominoidea)(5-8). The skull preserves traits widely thought to be derived for extant and fossil members of a proposed Sivapithecus/Pongo clade, but which now appear to be primitive features of ancestral Old World higher primates in general.			Benefit, BR (corresponding author), SO ILLINOIS UNIV,DEPT ANTHROPOL,CARBONDALE,IL 62901, USA.		Klein, Richard G/B-5910-2009					ANDREWS P, 1981, J HUM EVOL, V10, P35, DOI 10.1016/S0047-2484(81)80024-3; BENEFIT BR, 1994, AM J PHYS ANTHROPOL, V95, P277, DOI 10.1002/ajpa.1330950304; BENEFIT BR, 1993, AM J PHYS ANTHROPOL, V92, P329, DOI 10.1002/ajpa.1330920307; BENEFIT BR, 1991, P NATL ACAD SCI USA, V88, P5267, DOI 10.1073/pnas.88.12.5267; BENEFIT BR, 1993, J HUM EVOL, V25, P83, DOI 10.1006/jhev.1993.1041; Brown B., 1988, P247; Delson E., 1975, P405; FEIBEL CS, 1991, J HUM EVOL, V21, P221, DOI 10.1016/0047-2484(91)90063-2; HARRISON T, 1989, J HUM EVOL, V18, P3, DOI 10.1016/0047-2484(89)90022-5; HARRISON T, 1987, J HUM EVOL, V16, P41, DOI 10.1016/0047-2484(87)90060-1; LEAKEY E, 1986, NATURE, V342, P143; LEAKEY MG, 1991, FOLIA PRIMATOL, V56, P65, DOI 10.1159/000156531; Martin R.D., 1990, PRIMATE ORIGINS EVOL; Moya Sola Salvadoor, 1995, Journal of Human Evolution, V29, P101; MOYASOLA S, 1993, NATURE, V365, P543, DOI DOI 10.1038/365543A0; PILBEAM D, 1982, NATURE, V295, P232, DOI 10.1038/295232a0; RADINSKY L, 1974, AM J PHYS ANTHROPOL, V41, P15, DOI 10.1002/ajpa.1330410104; SIMONS EL, 1987, J HUM EVOL, V16, P273, DOI 10.1016/0047-2484(87)90003-0; SIMONS EL, 1967, SCI AM, V218, P28; STRASSER E, 1987, J HUM EVOL, V16, P81, DOI 10.1016/0047-2484(87)90061-3; STROMER E, 1913, Z DTSCH GEOL GES, V65, P349; VOGEL C, 1966, BIBLIOTHECA PRIMATOL, V4, P1; Von Koenigswald G. H. R., 1969, FOSSIL VERTEBRATES A, P39	23	43	43	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					368	371		10.1038/41078	http://dx.doi.org/10.1038/41078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	XM528	9237753				2022-12-01	WOS:A1997XM52800047
J	Jacobsen, JR; Hutchinson, CR; Cane, DE; Khosla, C				Jacobsen, JR; Hutchinson, CR; Cane, DE; Khosla, C			Precursor-directed biosynthesis of erythromycin analogs by an engineered polyketide synthase	SCIENCE			English	Article							CHAIN-ELONGATION INTERMEDIATE; MACROLIDE BIOSYNTHESIS; INTACT INCORPORATION; GENE-CLUSTER; ANTIBIOTICS; NARGENICIN; ORGANIZATION; DIKETIDE; HOST; RING	A genetic block was introduced in the first condensation step of the polyketide biosynthetic pathway that leads to the formation of 6-deoxyerythronolide B (6-dEB), the macrocyclic precursor of erythromycin. Exogenous addition of designed synthetic molecules to small-scale cultures of this null mutant resulted in highly selective multimilligram production of unnatural polyketides, including aromatic and ring-expanded variants of 6-dEB. Unexpected incorporation patterns were observed, illustrating the catalytic versatility of modular polyketide synthases. Further processing of some of these scaffolds by postpolyketide enzymes of the erythromycin pathway resulted in the generation of novel antibacterials with in vitro potency comparable to that of their natural counterparts.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; BROWN UNIV,DEPT CHEM,PROVIDENCE,RI 02912	Stanford University; Stanford University; Stanford University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Brown University				Khosla, Chaitan/0000-0001-6529-495X	NATIONAL CANCER INSTITUTE [R01CA066736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031925, R01GM022172] Funding Source: NIH RePORTER; NCI NIH HHS [CA66736] Funding Source: Medline; NIGMS NIH HHS [GM31925, GM22172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abiko A, 1997, J AM CHEM SOC, V119, P2586, DOI 10.1021/ja963754f; ADACHI T, 1988, J ANTIBIOT, V41, P966, DOI 10.7164/antibiotics.41.966; BAKER WR, 1988, J ORG CHEM, V53, P2340, DOI 10.1021/jo00245a038; Bedford D, 1996, CHEM BIOL, V3, P827, DOI 10.1016/S1074-5521(96)90068-X; CANE DE, 1993, J AM CHEM SOC, V115, P527, DOI 10.1021/ja00055a024; CANE DE, 1995, J ANTIBIOT, V48, P647, DOI 10.7164/antibiotics.48.647; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CANE DE, 1988, J AM CHEM SOC, V110, P4840, DOI 10.1021/ja00222a059; CANE DE, 1993, J AM CHEM SOC, V115, P522, DOI 10.1021/ja00055a023; CANE DE, 1995, J AM CHEM SOC, V117, P6633, DOI 10.1021/ja00129a044; CORNISH VW, 1994, CURR OPIN STRUC BIOL, V4, P601, DOI 10.1016/S0959-440X(94)90224-0; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DAUM SJ, 1979, ANNU REV MICROBIOL, V533, P241; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DUTTON CJ, 1991, J ANTIBIOT, V44, P357, DOI 10.7164/antibiotics.44.357; DUTTON CJ, 1994, TETRAHEDRON LETT, V35, P327, DOI 10.1016/S0040-4039(00)76544-0; EVANS DA, 1981, J AM CHEM SOC, V103, P2127, DOI 10.1021/ja00398a058; Griesgraber G, 1996, J ANTIBIOT, V49, P465, DOI 10.7164/antibiotics.49.465; HAILES HC, 1994, TETRAHEDRON LETT, V35, P307, DOI 10.1016/S0040-4039(00)76539-7; HU ZH, 1994, MOL MICROBIOL, V14, P163, DOI 10.1111/j.1365-2958.1994.tb01276.x; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; Kao CM, 1996, BIOCHEMISTRY-US, V35, P12363, DOI 10.1021/bi9616312; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; Kao CM, 1996, J AM CHEM SOC, V118, P9184, DOI 10.1021/ja9617552; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Khosla C, 1996, TRENDS BIOTECHNOL, V14, P335, DOI 10.1016/0167-7799(96)10046-9; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; McDaniel R, 1997, J AM CHEM SOC, V119, P4309, DOI 10.1021/ja9702531; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MORIMOTO S, 1990, J ANTIBIOT, V43, P286, DOI 10.7164/antibiotics.43.286; O'Hagan D., 1991, POLYKETIDE METABOLIT; OLIYNYK M, 1996, GENE, V183, P231; PATERSON I, 1985, TETRAHEDRON, V41, P3569, DOI 10.1016/S0040-4020(01)91380-8; PATZELT H, 1993, J CHEM SOC CHEM COMM, P1258, DOI 10.1039/c39930001258; PIEPER R, 1995, NATURE, V378, P263, DOI 10.1038/378263a0; Pieper R, 1996, BIOCHEMISTRY-US, V35, P2054, DOI 10.1021/bi952860b; Pieper R, 1997, BIOCHEMISTRY-US, V36, P1846, DOI 10.1021/bi962324z; PIEPER R, 1995, J AM CHEM SOC, V117, P11373, DOI 10.1021/ja00150a049; SCHUPP T, 1995, J BACTERIOL, V177, P3673, DOI 10.1128/jb.177.13.3673-3679.1995; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; Seebach D., 1990, ORG SYNTH, VVII, P153; SWAN DG, 1994, MOL GEN GENET, V242, P358, DOI 10.1007/BF00280426; Vincent JG, 1944, P SOC EXP BIOL MED, V55, P162, DOI 10.3181/00379727-55-14502; WALKER MA, 1991, J ORG CHEM, V56, P5747, DOI 10.1021/jo00020a006; WEBER JM, 1985, J BACTERIOL, V164, P425, DOI 10.1128/JB.164.1.425-433.1985; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	49	252	270	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					367	369		10.1126/science.277.5324.367	http://dx.doi.org/10.1126/science.277.5324.367			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219693				2022-12-01	WOS:A1997XL35800045
J	vanThiel, GJMW; vanDelden, JJM; deHaan, K; Huibers, AK				vanThiel, GJMW; vanDelden, JJM; deHaan, K; Huibers, AK			Retrospective study of doctors' ''end of life decisions'' in caring for mentally handicapped people in institutions in the Netherlands	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To gain insight into the reasons behind and the prevalence of doctors' decisions at the end of life that might hasten a patient's death (''end of life decisions'') in institutions caring for mentally handicapped people in the Netherlands, and to describe important aspects of the decisions making process. Design: Survey of random sample of doctors caring for mentally handicapped people by means of self completed questionnaires and structured interviews. Subjects: 89 of the 101 selected doctors completed the questionnaire. 67 doctors had taken an end of life decision and were interviewed about their most recent case. Main outcome measures: Prevalence of end of life decisions; types of decisions; characteristics of patients; reasons why the decision was taken; and the decision making process. Results: The 89 doctors reported 222 deaths for 1995, An end of life decision was taken in 97 cases (44%); in 75 the decision was to withdraw or withhold treatment, and in 22 it was to relieve pain or symptoms with opiates in dosages that may have shortened life. In the 67 most recent cases with an end of life decision the patients were mostly incompetent (63) and under 65 years old (51). Only two patients explicitly asked to die, but in 23 cases there had been some communication with the patient In 60 cases the doctors discussed the decision with nursing staff and in 46 with a colleague. Conclusions: End of life decisions are an important aspect of the institutionalised care of mentally handicapped people. The proportion of such decisions in the total number of deaths is similar to that in other specialties. However, the discussion of such decisions is less open in the care of mental handicap than in other specialties. Because of distinctive features of care in this specialty an open debate about end of life decisions should not be postponed.	HEEREN LOO LOZENOORD,ERMELO,NETHERLANDS		vanThiel, GJMW (corresponding author), UNIV UTRECHT,CTR BIOETH & HLTH LAW,POB 80105,NL-3508 TC UTRECHT,NETHERLANDS.		Van Thiel, Ghislaine/R-8977-2019					DRANE JF, 1985, HASTINGS CENT REP, V15, P17, DOI 10.2307/3560639; Jonsen A. R., 1992, CLIN ETHICS; *MIN VOLSG WELZ SP, 1995, PERK BUIT MEERJ INT; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; VANDERMAAS PJ, 1992, EUTHANASIA MED DECIS; *VER GEH NED, 1996, JB VERST GEH DIC LRZ; *VER GEH NED, 1996, LAND REG ZORG DIENST	8	25	25	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 12	1997	315	7100					88	91		10.1136/bmj.315.7100.88	http://dx.doi.org/10.1136/bmj.315.7100.88			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL252	9240047	Green Published			2022-12-01	WOS:A1997XL25200020
J	Ericson, J; Rashbass, P; Schedl, A; BrennerMorton, S; Kawakami, A; vanHeyningen, V; Jessell, TM; Briscoe, J				Ericson, J; Rashbass, P; Schedl, A; BrennerMorton, S; Kawakami, A; vanHeyningen, V; Jessell, TM; Briscoe, J			Pax6 controls progenitor cell identity and neuronal fate in response to graded shh signaling	CELL			English	Article							SONIC HEDGEHOG; FLOOR PLATE; MOTOR-NEURONS; EXPRESSION PATTERN; NERVOUS-SYSTEM; CHICK-EMBRYO; NEURAL-TUBE; GENE; DIFFERENTIATION; INDUCTION	Distinct classes of motor neurons and ventral interneurons are generated by the graded signaling activity of Sonic hedgehog (Shh). Shh controls neuronal fate by establishing different progenitor cell populations in the ventral neural tube that are defined by the expression of Pax6 and Nkx2.2. Pax6 establishes distinct ventral progenitor cell populations and controls the identity of motor neurons and ventral interneurons, mediating graded Shh signaling in the ventral spinal cord and hindbrain.	COLUMBIA UNIV,DEPT BIOCHEM & MOL BIOPHYS,HOWARD HUGHES MED INST,NEW YORK,NY 10032; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; NAGOYA UNIV,DIV BIOL SCI,NAGOYA,AICHI 46401,JAPAN	Columbia University; Howard Hughes Medical Institute; University of Edinburgh; Nagoya University			Schedl, Andreas/GOP-3427-2022; van Heyningen, Veronica/B-8039-2008; Schedl, Andreas/F-8823-2015; Kawakami, Atsushi/D-3785-2019; VAN HEYNINGEN, Veronica/GYE-0531-2022	van Heyningen, Veronica/0000-0003-0359-0141; Schedl, Andreas/0000-0001-9380-7396; Kawakami, Atsushi/0000-0001-9461-6372; Briscoe, James/0000-0002-1020-5240; Ericson, Johan/0000-0002-8019-7127	MRC [MC_U127527199] Funding Source: UKRI; Medical Research Council [MC_U127527199] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARTH KA, 1995, DEVELOPMENT, V121, P1755; CALLISTER RJ, 1987, J COMP NEUROL, V255, P369, DOI 10.1002/cne.902550305; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; ERICSON J, 1992, SCIENCE, V256, P1550; Fan CM, 1996, MOL CELL NEUROSCI, V7, P1, DOI 10.1006/mcne.1996.0001; GOSHGARIAN HG, 1981, J COMP NEUROL, V201, P441, DOI 10.1002/cne.902010309; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KRAMMER EB, 1987, ADV ANAT EMBRYOL CEL, V103, P1; KURATANI S, 1990, ANAT EMBRYOL, V182, P435; KURATANI S, 1988, AM J ANAT, V182, P155, DOI 10.1002/aja.1001820206; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Liinamaa TL, 1997, J COMP NEUROL, V377, P298, DOI 10.1002/(SICI)1096-9861(19970113)377:2<298::AID-CNE10>3.0.CO;2-N; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; LU SW, 1994, MECH DEVELOP, V47, P187, DOI 10.1016/0925-4773(94)90089-2; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; OSUMI N, 1997, IN PRESS DEVELOPMENT; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; Quinn JC, 1996, GENE DEV, V10, P435, DOI 10.1101/gad.10.4.435; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; RYAN G, 1995, DEVELOPMENT, V121, P867; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Shoji H, 1996, MECH DEVELOP, V56, P25, DOI 10.1016/0925-4773(96)00509-6; SIMON H, 1994, J NEUROBIOL, V25, P1129, DOI 10.1002/neu.480250908; Stoykova A, 1996, DEVELOPMENT, V122, P3453; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VarelaEchavarria A, 1996, MOL CELL NEUROSCI, V8, P242, DOI 10.1006/mcne.1996.0061; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Warren N, 1997, DEVELOPMENT, V124, P1573; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	51	807	822	5	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					169	180		10.1016/S0092-8674(00)80323-2	http://dx.doi.org/10.1016/S0092-8674(00)80323-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230312	hybrid			2022-12-01	WOS:A1997XL36200018
J	Zou, H; Rothstein, R				Zou, H; Rothstein, R			Holliday junctions accumulate in replication mutants via a RecA homolog-independent mechanism	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; DNA-POLYMERASE-EPSILON; ESCHERICHIA-COLI; MEIOTIC RECOMBINATION; MISMATCH REPAIR; PRIMASE COMPLEX; RIBOSOMAL DNA; GENE-PRODUCT; PROTEIN; ALPHA	The Holliday junction recombination intermediate, an X-shaped DNA molecule (xDNA), was analyzed at rDNA in mitotically growing yeast. In wild-type cells, xDNA is only detected at S phase, suggesting that recombination is stimulated to repair replication-related lesions. A search for mutations that increase the level of xDNA uncovered a gene encoding a subunit of DNA polymerase alpha. Systematic examination of replication mutants revealed that defects in polymerase alpha and delta but not the epsilon complex stimulate the level of xDNA. These xDNAs are Holliday junctions and not replication intermediates. The level of Holliday junctions is greatly reduced in rad52 mutants, but surprisingly, not in mutants defective in the three known mitotically expressed yeast RecA homologs.	COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032	Columbia University				Rothstein, Rodney/0000-0002-4107-9654	NIGMS NIH HHS [GM50237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM050237, R01GM050237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; ASAI T, 1994, CELL, V78, P1051, DOI 10.1016/0092-8674(94)90279-8; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1990, GENETICS, V124, P573; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; CAMPBELL JL, 1993, J BIOL CHEM, V268, P25261; CAO Y, 1995, GENETICS, V139, P1483; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; FASULLO MT, 1987, P NATL ACAD SCI USA, V84, P6215, DOI 10.1073/pnas.84.17.6215; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; FRIEDBERG EC, 1995, DNA REPAIR; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GERRING S L, 1991, P57; GNAGLOFF S, 1996, EMBO J, V15, P1715; GORDENIN DA, 1992, P NATL ACAD SCI USA, V89, P3785, DOI 10.1073/pnas.89.9.3785; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KADYK LC, 1992, GENETICS, V132, P387; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; KAWASAKI I, 1994, MOL CELL BIOL, V14, P4173, DOI 10.1128/MCB.14.6.4173; KLEIN HL, 1995, BIOESSAYS, V17, P147, DOI 10.1002/bies.950170210; Kogoma T, 1997, P NATL ACAD SCI USA, V94, P3483, DOI 10.1073/pnas.94.8.3483; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KREUZER KN, 1994, MOL BIOL BACTERIOP T, V4, P28; KUNZ BA, 1989, GENETICS, V122, P535; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LIANG C, 1994, MOL CELL BIOL, V14, P1520, DOI 10.1128/MCB.14.2.1520; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MCDONALD JP, 1994, GENETICS, V137, P393; MONTELONE BA, 1981, J BACTERIOL, V147, P517, DOI 10.1128/JB.147.2.517-525.1981; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PETES TD, 1991, MOL CELLULAR BIOL YE; PLEVANI P, 1984, J BIOL CHEM, V259, P7532; RATTRAY AJ, 1995, GENETICS, V139, P45; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Rothstein R, 1995, GENOME RES, V5, P421, DOI 10.1101/gr.5.5.421; RUPP WD, 1971, J MOL BIOL, V61, P25, DOI 10.1016/0022-2836(71)90204-X; SAFFER LD, 1986, MOL CELL BIOL, V6, P1148, DOI 10.1128/MCB.6.4.1148; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; Sherman F., 1986, METHODS YEAST GENETI; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Skalka A., 1974, MECH RECOMBINATION, P421, DOI [10.1007/978-1-4684-2133-0_37, DOI 10.1007/978-1-4684-2133-0_37]; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1980, NATURE, V284, P426, DOI 10.1038/284426a0; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; WALMSLEY RM, 1984, MOL GEN GENET, V195, P260, DOI 10.1007/BF00332757; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; YOUNG CSH, 1984, J VIROL, V51, P571, DOI 10.1128/JVI.51.3.571-577.1984; ZGAGA Z, 1991, CURR GENET, V19, P329, DOI 10.1007/BF00355064	68	227	230	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					87	96		10.1016/S0092-8674(00)80316-5	http://dx.doi.org/10.1016/S0092-8674(00)80316-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230305	hybrid			2022-12-01	WOS:A1997XL36200011
J	Katritch, V; Olson, WK; Pieranski, P; Dubochet, J; Stasiak, A				Katritch, V; Olson, WK; Pieranski, P; Dubochet, J; Stasiak, A			Properties of ideal composite knots	NATURE			English	Article							NUMBER	The shortest tube of constant diameter that can form a given knot represents the 'ideal' form of the knot(1,2). Ideal knots provide an irreducible representation of the knot, and they have some intriguing mathematical and physical features, including a direct correspondence with the time-averaged shapes of knotted DNA molecules in solution(1,2). Here we describe the properties of ideal forms of composite knots-knots obtained by the sequential tying of two or more independent knots (called factor knots) on the same string. We find that the writhe (related to the handedness of crossing points) of composite knots is the sum of that of the ideal forms of the factor knots. By comparing ideal composite knots with simulated configurations of knotted, thermally fluctuating DNA, we conclude that the additivity of writhe applies also to randomly distorted configurations of composite knots and their corresponding factor knots. We show that composite knots with several factor knots may possess distinct structural isomers that can be interconverted only by loosening the knot.	UNIV LAUSANNE,LAB ANAL ULTRASTRUCT,CH-1015 LAUSANNE,SWITZERLAND; INST MOL PHYS,PL-60159 POZNAN,POLAND; POZNAN TECH UNIV,INST PHYS,PL-60965 POZNAN,POLAND; RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08903	University of Lausanne; Poznan University of Technology; Rutgers State University New Brunswick			Stasiak, Andrzej/E-5551-2010; Katritch, Vsevolod/Q-8357-2016; Pieranski, Piotr/H-7805-2014; Katritch, Vsevolod/Y-2721-2019	Stasiak, Andrzej/0000-0002-0398-1989; Katritch, Vsevolod/0000-0003-3883-4505; 				Calugareanu G., 1959, INTEGRALE GAUSS 1 AN, P5; FULLER FB, 1978, P NATL ACAD SCI USA, V75, P3557, DOI 10.1073/pnas.75.8.3557; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; Katritch V, 1996, NATURE, V384, P142, DOI 10.1038/384142a0; Pieranski P, 1996, PRODIALOG, V5, P111; Rolfsen D., 1976, MATH LECT SERIES, V7; Stasiak A, 1996, NATURE, V384, P122, DOI 10.1038/384122a0; VanRensburg EJJ, 1997, J KNOT THEOR RAMIF, V6, P31; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P	9	82	80	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					148	151		10.1038/40582	http://dx.doi.org/10.1038/40582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217153	Bronze			2022-12-01	WOS:A1997XK10900042
J	Zimmerman, RK; Medsger, AR; Ricci, EM; Raymund, M; Mieczkowski, TA; Grufferman, S				Zimmerman, RK; Medsger, AR; Ricci, EM; Raymund, M; Mieczkowski, TA; Grufferman, S			Impact of free vaccine and insurance status on physician referral of children to public vaccine clinics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	30th National Immunization Conference	APR 10-11, 1996	WASHINGTON, DC				IMMUNIZATION PRACTICES; PEDIATRICIANS; CARE	Context.-Concerns about financial barriers to vaccination led to the development of the Vaccines for Children (VFC) program, which provides free vaccines to states for children who are uninsured, Medicaid eligible, or Native American or Native Alaskan. Objective.-To understand the effect of economic factors on physician likelihood of referring children to public vaccine clinics for immunizations and to evaluate the VFC program. Design.-A standardized survey was conducted in 1995 by trained personnel using computer-assisted telephone interviewing. Setting and Participants.-A stratified random sample of family physicians, pediatricians, and general practitioners younger than 65 years who were in office-based practices across the United States. Main Outcome Measures.-Likelihood of referral of a child to a health department for vaccination by child's insurance status and by the physician's receipt of free vaccines. Results.-Of the 1769 physicians with whom an interviewer spoke, 1236 participated, Most respondents (66%) were likely to refer an uninsured child to the health department for vaccination, whereas only 8% were likely to refer a child who had insurance that covers vaccination, The majority (58%) of physicians reported differential referral based on insurance status. Among physicians who received free vaccine supplies from the VFC program or elsewhere, 44% were likely to refer an uninsured child whereas 90% of those not receiving free vaccine were likely to refer the same child (P<.001). In regression analysis, the receipt of free vaccine supplies accounted for 24% of the variance in the likelihood to refer an uninsured child for vaccination. Conclusions.-Physicians receiving free vaccine supplies report being less likely to refer children to public clinics for vaccinations.	UNIV PITTSBURGH,GRAD SCH PUBL HLTH,DEPT HLTH SERV ADM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zimmerman, RK (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT FAMILY MED & CLIN EPIDEMIOL,M-200 SCAIFE HALL,PITTSBURGH,PA 15261, USA.			Zimmerman, Richard/0000-0001-5941-6092; Santibanez, Tammy A./0000-0002-5784-7427	AHRQ HHS [HS08068] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY L, 1989, DESIGNING CONDUCTING; ARNOLD PJ, 1992, AM J DIS CHILD, V146, P728, DOI 10.1001/archpedi.1992.02160180088023; BORDLEY WC, 1994, PEDIATRICS, V94, P376; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P657; Cochran W.G., 1963, SAMPLING TECHNIQUES; FAIRBROTHER G, IN PRESS ARCH PEDIAT; Hamlin JS, 1996, AM J PUBLIC HEALTH, V86, P1812, DOI 10.2105/AJPH.86.12.1812; HOLTMANN AG, 1996, SUPPLYING VACCINE EC, P153; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; Murphy TV, 1997, PEDIATR INFECT DIS J, V16, P47, DOI 10.1097/00006454-199701000-00011; MURPHY TV, 1995, PEDIATR INFECT DIS J, V15, P561; *NAT VACC ADV COMM, 1991, JAMA-J AM MED ASSOC, V266, P1547; Public Health Service U.S. Department of Health and Human Services, 1991, HLTH PEOPL 2000 NAT; RUCHROSS HS, 1994, PEDIATRICS, V94, P508; *SAS I INC, 1996, SAS SYST WIND COMP P; SCHULTE JM, 1991, PEDIATRICS, V87, P204; Taylor JA, 1997, PEDIATRICS, V99, P209; *US GEN ACC OFF, 1995, VACC CHILDR REEX PRO; Wood DL, 1996, ARCH PEDIAT ADOL MED, V150, P577, DOI 10.1001/archpedi.1996.02170310011001; WRIGHT JA, 1992, AM J DIS CHILD, V146, P1033, DOI 10.1001/archpedi.1992.02160210035016; Zimmerman R K, 1993, Fam Pract Res J, V13, P213; Zimmerman R K, 1995, J Am Board Fam Pract, V8, P270; Zimmerman RK, 1997, AM J PREV MED, V13, P89, DOI 10.1016/S0749-3797(18)30204-6; Zimmerman RK, 1997, ARCH PEDIAT ADOL MED, V151, P657, DOI 10.1001/archpedi.1997.02170440019004	24	40	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	1997	278	12					996	1000		10.1001/jama.278.12.996	http://dx.doi.org/10.1001/jama.278.12.996			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX012	9307347				2022-12-01	WOS:A1997XX01200030
J	Kledal, TN; Rosenkilde, MM; Coulin, F; Simmons, G; Johnsen, AH; Alouani, S; Power, CA; Luttichau, HR; Gerstoft, J; Clapham, PR; ClarkLewis, I; Wells, TNC; Schwartz, TW				Kledal, TN; Rosenkilde, MM; Coulin, F; Simmons, G; Johnsen, AH; Alouani, S; Power, CA; Luttichau, HR; Gerstoft, J; Clapham, PR; ClarkLewis, I; Wells, TNC; Schwartz, TW			A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus	SCIENCE			English	Article							PROTEIN-COUPLED RECEPTOR; DNA-SEQUENCES; MOLECULAR MIMICRY; INTERLEUKIN-8; RANTES; GENES; CHEMOATTRACTANT; EXPRESSION; PATHWAYS; CLONING	Kaposi's sarcoma-associated herpesvirus encodes a chemokine called vMIP-II, This protein displayed a broader spectrum of receptor activities than any mammalian chemokine as it bound with high affinity to a number of both CC and CXC chemokine receptors, Binding of vMIP-II, however, was not associated with the normal, rapid mobilization of calcium from intracellular stores; instead, it blocked calcium mobilization induced by endogenous chemokines, In freshly isolated human monocytes the virally encoded vMIP-II acted as a potent and efficient antagonist of chemotaxis induced by chemokines. Because vMIP-II could inhibit cell entry of human immunodeficiency virus (HIV) mediated through CCR3 and CCR5 as well as CXCR4, this protein may serve as a lead for development of broad-spectrum anti-HIV agents.	GLAXO WELLCOME RES & DEV LTD,GENEVA BIOMED RES INST,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND; UNIV COPENHAGEN,PANUM INST,MOL PHARMACOL LAB,INST PHARMACOL,DK-2200 COPENHAGEN,DENMARK; RIGSHOSP,DEPT INFECT DIS,DK-2100 COPENHAGEN,DENMARK; INST CANC RES,CHESTER BEATTY LABS,SECT VIROL,LONDON SW3 6JB,ENGLAND; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA	GlaxoSmithKline; University of Copenhagen; Rigshospitalet; University of Copenhagen; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of British Columbia			Simmons, Graham/G-3523-2012	Simmons, Graham/0000-0002-9615-7023; Luttichau, Hans Rudolf/0000-0002-5428-4075; Schwartz, Thue W./0000-0002-0261-6904; Wells, Timothy/0000-0001-9796-847X; Rosenkilde, Mette Marie/0000-0001-9600-3254				AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; AKRANITAKIS L, 1997, NATURE, V385, P347; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P1043; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1989, J BIOL CHEM, V264, P18907; Damaj BB, 1996, J BIOL CHEM, V271, P20540, DOI 10.1074/jbc.271.34.20540; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DRAJIC T, 1996, NATURE, V381, P667; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FINCHAM NJ, 1988, J IMMUNOL, V140, P4294; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; JUNG YK, 1992, MOL ENDOCRINOL, V6, P2027, DOI 10.1210/me.6.12.2027; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; LustiNarasimhan M, 1996, J BIOL CHEM, V271, P3148, DOI 10.1074/jbc.271.6.3148; MacDonald MR, 1997, J VIROL, V71, P1671, DOI 10.1128/JVI.71.2.1671-1678.1997; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; Power CA, 1996, TRENDS PHARMACOL SCI, V17, P209, DOI 10.1016/0165-6147(96)10019-5; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Weiss RA, 1996, NAT MED, V2, P277, DOI 10.1038/nm0396-277; WULFF BS, 1993, MOL CELL ENDOCRINOL, V91, P135, DOI 10.1016/0303-7207(93)90265-L; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641	37	402	444	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1656	1659		10.1126/science.277.5332.1656	http://dx.doi.org/10.1126/science.277.5332.1656			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287217				2022-12-01	WOS:A1997XV68400048
J	Jeong, B; Bae, YH; Lee, DS; Kim, SW				Jeong, B; Bae, YH; Lee, DS; Kim, SW			Biodegradable block copolymers as injectable drug-delivery systems	NATURE			English	Article							CONTROLLED RELEASE; MEMBRANE; PH	Polymers that display a physicochemical response to stimuli are widely explored as potential drug-delivery systems(1-4), Stimuli studied to date include chemical substances and changes in temperature, pH and electric field, Homopolymers or copolymers of N-isopropylacrylamide(5,6) and poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (known as poloxamers)(7) are typical examples of thermosensitive polymers, but their use in drug delivery is problematic because they are toxic and nonbiodegradable, Biodegradable polymers used for drug delivery to date have mostly been in the form of injectable microspheres or implant systems, which require complicated fabrication processes using organic solvents(8). Such systems have the disadvantage that the use of organic solvents can cause denaturation when protein drugs are to be encapsulated. Furthermore, the solid form requires surgical insertion, which often results in tissue irritation and damage, Here we report the synthesis of a thermosensitive, biodegradable hydrogel consisting of blocks of poly(ethylene oxide) and poly(L-lactic acid), Aqueous solutions of these copolymers exhibit temperature-dependent reversible gel-sol transitions, The hydrogel can be loaded with bioactive molecules in an aqueous phase at an elevated temperature (around 45 degrees C), where they form a sol. In this form, the polymer is injectable. On subcutaneous injection and subsequent rapid cooling to body temperature, the loaded copolymer forms a gel that can act as a sustained-release matrix for drugs.	UNIV UTAH, CCCD PHARMACEUT, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah			Jeong, Byeongmoon/AAB-1570-2021; Kang, Bo Kyung/F-6726-2015; LEE, DOO SUNG/D-3363-2011	Jeong, Byeongmoon/0000-0001-9582-1343; 				ALEXANDRIDIS P, 1994, MACROMOLECULES, V27, P2414, DOI 10.1021/ma00087a009; BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; ISHIHARA K, 1984, J APPL POLYM SCI, V29, P211, DOI 10.1002/app.1984.070290119; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; MALSTOM M, 1992, MACROMOLECULES, V25, P5440; MORITZ AR, 1947, AM J PATHOL, V23, P695; Ronneberger B, 1996, J BIOMED MATER RES, V30, P31; THOMAS JL, 1995, J AM CHEM SOC, V117, P2949, DOI 10.1021/ja00115a039; Wout Z G, 1992, J Parenter Sci Technol, V46, P192; YOUXIN L, 1993, J CONTROL RELEASE, V27, P247; ZHU KJ, 1990, J APPL POLYM SCI, V39, P1, DOI 10.1002/app.1990.070390101	13	1741	1894	26	1247	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					860	862		10.1038/42218	http://dx.doi.org/10.1038/42218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278046				2022-12-01	WOS:A1997XT75400044
J	Weinstein, MR; Litt, M; Kertesz, DA; Wyper, P; Rose, D; Coulter, M; McGeer, A; Facklam, R; Ostach, C; Willey, BM; Borczyk, A; Low, DE				Weinstein, MR; Litt, M; Kertesz, DA; Wyper, P; Rose, D; Coulter, M; McGeer, A; Facklam, R; Ostach, C; Willey, BM; Borczyk, A; Low, DE			Invasive infections due to a fish pathogen, Streptococcus iniae	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 15-18, 1996	NEW ORLEANS, LA				ENTEROCOCCUS-SERIOLICIDA; SP-NOV; MENINGITIS; SUIS; MENINGOENCEPHALITIS; DIAGNOSIS; MASTITIS; CRITERIA; SYNONYM; STRAINS	Background Streptococcus iniae is a pathogen in fish, capable of causing invasive disease and outbreaks in aquaculture farms. During the winter of 1995-1996 in the greater Toronto area there was a cluster of four cases of invasive S. iniae infection in people who had recently handled fresh, whole fish from such farms. Methods We conducted a prospective and retrospective community-based surveillance for cases of S. iniae infection in humans. To obtain a large sample of isolates, we studied cultures obtained from the surface of fish from aquaculture farms. Additional isolates were obtained from the brains of infected tilapia (oreochromis species). All the isolates were characterized by pulsed-field gel electrophoresis (PFGE). Results During one year, our surveillance identified a total of nine patients with invasive S. iniae infection (cellulitis of the hand in eight and endocarditis in one). All the patients had handled live or freshly killed fish, and eight had percutaneous injuries. Six of the nine fish were tilapia, which are commonly used in Asian cooking. Thirteen additional S. iniae isolates (2 from humans and 11 from infected tilapia) were obtained from normally sterile sites. The isolates from the nine patients were indistinguishable by PFGE and were highly related to the other clinical isolates. There was substantial genetic diversity among the 42 surveillance isolates from the surface of fish, but in 10 isolates the PFGE patterns were identical to those from the patients with S. iniae infection. Conclusions S. iniae can produce invasive infection after skin injuries during the handling of fresh fish grown by aquaculture. We identified a clone of S. iniae that causes invasive disease in both humans and fish. (C) 1997, Massachusetts Medical Society.	MT SINAI HOSP,DEPT MICROBIOL,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; LAB CTR DIS CONTROL,OTTAWA,ON K1A 0L2,CANADA; SCARBOROUGH GRACE HOSP,SCARBOROUGH,ON,CANADA; PRINCESS MARGARET HOSPS,TORONTO,ON,CANADA; CITY SCARBOROUGH PUBL HLTH DEPT,SCARBOROUGH,ON,CANADA; PUBL HLTH LAB,TORONTO,ON,CANADA; CTR DIS CONTROL & PREVENT,ATLANTA,GA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Scarborough Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Centers for Disease Control & Prevention - USA			mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020; Low, Donald/B-1726-2012	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137; 				ARENDS JP, 1988, REV INFECT DIS, V10, P131; BAIRDPARKER AC, 1994, MICROBIOL-UK, V140, P687, DOI 10.1099/00221287-140-4-687; BARNHAM M, 1987, EPIDEMIOL INFECT, V99, P257, DOI 10.1017/S0950268800067728; CHAU PY, 1983, MED J AUSTRALIA, V1, P414, DOI 10.5694/j.1326-5377.1983.tb136138.x; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; ELDAR A, 1995, INT J SYST BACTERIOL, V45, P840, DOI 10.1099/00207713-45-4-840; ELDAR A, 1994, CURR MICROBIOL, V28, P139, DOI 10.1007/BF01571054; ELDAR A, 1995, VET MICROBIOL, V43, P33, DOI 10.1016/0378-1135(94)00052-X; HOOK EW, 1986, ARCH INTERN MED, V146, P295; KAIGE N, 1984, Fish Pathology, V19, P173; KITAO T, 1981, Fish Pathology, V15, P301; KUSUDA R, 1991, INT J SYST BACTERIOL, V41, P406, DOI 10.1099/00207713-41-3-406; Kusuda Riichi, 1992, Israeli Journal of Aquaculture Bamidgeh, V44, P140; LEE PC, 1985, J CLIN MICROBIOL, V22, P80, DOI 10.1128/JCM.22.1.80-83.1985; *METR TOR PLANN DE, 1995, MUN METR TOR KEY FAC; Michaud S, 1996, Can J Infect Dis, V7, P329; MOGOLLON JD, 1990, J CLIN MICROBIOL, V28, P2462, DOI 10.1128/JCM.28.11.2462-2466.1990; MURRAY BE, 1991, J INFECT DIS, V163, P780, DOI 10.1093/infdis/163.4.780; Musser JM, 1996, EMERG INFECT DIS, V2, P1, DOI 10.3201/eid0201.960101; *NAT COMM CLIN LAB, 1994, M7A3 NAT COMM CLIN L; Perera Ramesh P., 1994, Journal of Aquatic Animal Health, V6, P335, DOI 10.1577/1548-8667(1994)006&lt;0335:SIAWMO&gt;2.3.CO;2; PIER GB, 1976, INT J SYST BACTERIOL, V26, P545, DOI 10.1099/00207713-26-4-545; PIER GB, 1978, INT J SYST BACTERIOL, V28, P311, DOI 10.1099/00207713-28-2-311; ROBINSON JA, 1966, J BACTERIOL, V92, P512, DOI 10.1128/JB.92.2.512-512.1966; Ruoff Kathryn L., 1995, P299; SHARP MW, 1995, VET REC, V137, P128, DOI 10.1136/vr.137.5.128-b; Teixeira LM, 1996, INT J SYST BACTERIOL, V46, P664, DOI 10.1099/00207713-46-3-664; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Vandamme P, 1997, INT J SYST BACTERIOL, V47, P81, DOI 10.1099/00207713-47-1-81; Vidaver AK, 1996, ASM NEWS, V62, P583; Walsh B., 1992, Reviews in Medical Microbiology, V3, P65; WEINBERG AN, 1995, MANDELL DOUGLAS BENN, V2, P2790; Weinstein M, 1996, Can Commun Dis Rep, V22, P129; WINDSOR RS, 1975, J HYG-CAMBRIDGE, V75, P69, DOI 10.1017/S0022172400047070; 1996, MMWR-MORBID MORTAL W, V45, P650; 1975, LANCET, V1, P1286; 1994, C D R WKLY REP, V4, P241	37	217	239	2	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	1997	337	9					589	594		10.1056/NEJM199708283370902	http://dx.doi.org/10.1056/NEJM199708283370902			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT394	9271480	Green Published			2022-12-01	WOS:A1997XT39400002
J	PowellTuck, J				PowellTuck, J			Glutamine supplementation in artificial nutritional support	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; TOTAL PARENTERAL-NUTRITION; DOUBLE-BLIND				PowellTuck, J (corresponding author), ROYAL LONDON HOSP,ST BARTHOLOMEWS & ROYAL LONDON HOSP SCH MED,RANK DEPT HUMAN NUTR,LONDON E1 1BB,ENGLAND.							Bozzetti F, 1997, NUTRITION, V13, P748, DOI 10.1016/S0899-9007(97)83038-9; GRIFFITHS RD, 1997, NUTRITION, V13, P302; JEBB SA, 1995, CLIN NUTR, V14, P143; Jensen GL, 1996, AM J CLIN NUTR, V64, P615, DOI 10.1093/ajcn/64.4.615; MORLION BJ, 1996, CLIN NUTR S1, V15, P48; ORIORDAIN MG, 1994, ANN SURG, V220, P212, DOI 10.1097/00000658-199408000-00014; POWELLTUCK J, 1997, NUTRITION, V13, P725; SCHLOERB PR, 1993, JPEN-PARENTER ENTER, V17, P407, DOI 10.1177/0148607193017005407; VANDERHULST RRWJ, 1993, LANCET, V341, P1363, DOI 10.1016/0140-6736(93)90939-E; ZIEGLER TR, 1992, ANN INTERN MED, V116, P821, DOI 10.7326/0003-4819-116-10-821	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					534	534		10.1016/S0140-6736(05)63136-4	http://dx.doi.org/10.1016/S0140-6736(05)63136-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284773				2022-12-01	WOS:A1997XT22100006
J	Anzick, SL; Kononen, J; Walker, RL; Azorsa, DO; Tanner, MM; Guan, XY; Sauter, G; Kallioniemi, OP; Trent, JM; Meltzer, PS				Anzick, SL; Kononen, J; Walker, RL; Azorsa, DO; Tanner, MM; Guan, XY; Sauter, G; Kallioniemi, OP; Trent, JM; Meltzer, PS			AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer	SCIENCE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; AMPLIFICATION; SEQUENCE	Members of the recently recognized SRC-1 family of transcriptional coactivators interact with steroid hormone receptors to enhance ligand-dependent transcription. AIB1, a member of the SRC-1 family, was cloned during a search on the long arm of chromosome 20 for genes whose expression and copy number were elevated in human breast cancers. AIB1 amplification and overexpression were observed in four of five estrogen receptor-positive breast and ovarian cancer cell lines. Subsequent evaluation of 105 unselected specimens of primary breast cancer found AIB1 amplification in approximately 10 percent and high expression in 64 percent of the primary tumors analyzed. AIB1 protein interacted with estrogen receptors in a ligand-dependent fashion, and transfection of AIB1 resulted in enhancement of estrogen-dependent transcription, These observations identify AIB1 as a nuclear receptor coactivator whose altered expression may contribute to development of steroid-dependent cancers.	NATL HUMAN GENOME RES INST,CANC GENET LAB,NIH,BETHESDA,MD 20892; UNIV TAMPERE,INST MED TECHNOL,CANC GENET LAB,FIN-33101 TAMPERE,FINLAND; TAMPERE UNIV HOSP,FIN-33101 TAMPERE,FINLAND; UNIV BASEL,INST PATHOL,CH-4003 BASEL,SWITZERLAND	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Tampere University; Tampere University; Tampere University Hospital; University of Basel			Kallioniemi, Olli P/H-5111-2011; Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Kallioniemi, Olli P/0000-0002-3231-0332; Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805; Kononen, Juha/0000-0002-0157-2137; Walker, Robert/0000-0001-8235-4686				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; Guan XY, 1996, CANCER RES, V56, P3446; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; ISOLA JJ, 1995, AM J PATHOL, V147, P905; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; ONATE SA, 1995, SCIENCE, V270, P1354; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Sallinen P, 1997, AM J PATHOL, V150, P1159; Sambrook J., 1989, MOL CLONING LAB MANU; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1996, CANCER RES, V56, P3441; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	21	1356	1400	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					965	968		10.1126/science.277.5328.965	http://dx.doi.org/10.1126/science.277.5328.965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252329	Green Submitted			2022-12-01	WOS:A1997XQ98500044
J	Murata, T; Ushikubi, F; Matsuoka, T; Hirata, M; Yamasaki, A; Sugimoto, Y; Ichikawa, A; Aze, Y; Tanaka, T; Yoshida, N; Ueno, A; Ohishi, S; Narumiya, S				Murata, T; Ushikubi, F; Matsuoka, T; Hirata, M; Yamasaki, A; Sugimoto, Y; Ichikawa, A; Aze, Y; Tanaka, T; Yoshida, N; Ueno, A; Ohishi, S; Narumiya, S			Altered pain perception and inflammatory response in mice lacking prostacyclin receptor	NATURE			English	Article							MOUSE; HYPERALGESIA; RATS; EXPRESSION; INJECTION; MORPHINE; GENE	Prostanoids are a group of bioactive lipids working as local mediators' and include D, E, F and I types of prostaglandins (PGs) and thromboxanes. Prostacyclin (PGI(2)) acts on platelets and blood vessels to inhibit platelet aggregation and to cause vasodilatation, and is thought to be important for vascular homeostasis(2). Aspirin-like drugs, including indomethacin, which inhibit prostanoid biosynthesis, Suppress fever, inflammatory swelling and pain, and interfere with female reproduction, suggesting that prostanoids are involved in these processes(1,3), although it is not clear which prostanoid is the endogenous mediator of a particular process, Prostanoids act on seven-transmembrane-domain receptors which are selective for each type(4). Here we disrupt the gene for the prostacyclin receptor(5) in mice by using homologous recombination. The receptor-deficient mice are viable, reproductive and normotensive. However, their susceptibility to thrombosis is increased, and their inflammatory and pain responses are reduced to the levels observed in indomethacin-treated wild-type mice, Our results establish that prostacyclin is an antithrombotic agent in vivo and provide evidence for its role as a mediator of inflammation and pain.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 60601,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,KYOTO 60601,JAPAN; ONO PHARMACEUT CO,FUKUI INST SAFETY RES,MIKUNI,FUKUI 913,JAPAN; RES INST OSAKA MED CTR MATERNAL & CHILD HLTH,DIV MOL & CELLULAR IMMUNOL,IZUMI,OSAKA 59002,JAPAN; KITASATO UNIV,SCH PHARMACEUT SCI,DEPT PHARMACOL,SHIROGANEDAI,TOKYO 108,JAPAN	Kyoto University; Kyoto University; Ono Pharmaceutical Co Ltd; Kitasato University			Sugimoto, Yukihiko/AAV-6470-2021; Tanaka, Takashi/O-8254-2015	Sugimoto, Yukihiko/0000-0001-6973-932X; Murata, Takahiko/0000-0003-0132-5424				ARMSTRONG RA, 1989, BRIT J PHARMACOL, V97, P657, DOI 10.1111/j.1476-5381.1989.tb12001.x; BUNTING S, 1983, BR MED B, V39, P371; CAMPBELL WB, 1996, PHARMACOL BASIS THER, P601; DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.iy.02.040184.002003; DEJANA E, 1979, THROMB RES, V15, P191, DOI 10.1016/0049-3848(79)90064-1; DOHERTY NS, 1987, BRIT J PHARMACOL, V91, P39, DOI 10.1111/j.1476-5381.1987.tb08981.x; FERREIRA SH, 1981, TRENDS PHARMACOL SCI, V2, P183, DOI 10.1016/0165-6147(81)90306-0; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KOSTER R, 1959, FED PROC, V18, P412; KURZ KD, 1990, THROMB RES, V60, P269, DOI 10.1016/0049-3848(90)90106-M; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MILLAN MJ, 1991, J PHARMACOL EXP THER, V256, P983; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MURATA T, 1989, ARZNEIMITTEL-FORSCH, V39-2, P867; NAMBA T, 1994, J BIOL CHEM, V269, P9986; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; OKA T, 1993, BRAIN RES, V624, P61, DOI 10.1016/0006-8993(93)90060-Z; PIERCEY MF, 1981, EUR J PHARMACOL, V74, P135, DOI 10.1016/0014-2999(81)90523-9; RITTER JM, 1987, BRIT J PHARMACOL, V92, P857, DOI 10.1111/j.1476-5381.1987.tb11391.x; UENO A, 1995, EUR J PHARMACOL, V284, P211, DOI 10.1016/0014-2999(95)00439-R; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; UTSUNOMIYA I, 1994, EUR J PHARMACOL, V252, P213, DOI 10.1016/0014-2999(94)90599-1; VADAS P, 1981, NATURE, V293, P583, DOI 10.1038/293583a0; VANE JR, 1990, NEW ENGL J MED, V323, P27; WINTER CA, 1965, J PHARMACOL EXP THER, V150, P165	26	611	660	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					678	682		10.1038/41780	http://dx.doi.org/10.1038/41780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262402	Bronze			2022-12-01	WOS:A1997XQ86300050
J	Price, H				Price, H			Deaths from venous thromboembolism associated with combined oral contraceptives	LANCET			English	Letter											Price, H (corresponding author), HM CORONER,EASTERN DIST GREATER LONDON,CORONERS COURT,LONDON E17 8QP,ENGLAND.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 9	1997	350	9075					450	450		10.1016/S0140-6736(05)64187-6	http://dx.doi.org/10.1016/S0140-6736(05)64187-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ248	9289596				2022-12-01	WOS:A1997XQ24800074
J	Scherzinger, E; Lurz, R; Turmaine, M; Mangiarini, L; Hollenbach, B; Hasenbank, R; Bates, GP; Davies, SW; Lehrach, H; Wanker, EE				Scherzinger, E; Lurz, R; Turmaine, M; Mangiarini, L; Hollenbach, B; Hasenbank, R; Bates, GP; Davies, SW; Lehrach, H; Wanker, EE			Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo	CELL			English	Article							GLUTATHIONE-S-TRANSFERASE; NEURODEGENERATIVE DISEASES; GLUTAMINE REPEATS; LOCALIZATION; BRAIN; PRODUCT; SCRAPIE; EPITOPE	The mechanism by which an elongated polyglutamine sequence causes neurodegeneration in Huntington's disease (HD) is unknown. In this study, we show that the proteolytic cleavage of a GST-huntingtin fusion protein leads to the formation of insoluble high molecular weight protein aggregates only when the polyglutamine expansion is in the pathogenic range. Electron micrographs of these aggregates revealed a fibrillar or ribbon-like morphology, reminiscent of scrapie prions and beta-amyloid fibrils in Alzheimer's disease. Subcellular fractionation and ultrastructural techniques showed the in vivo presence of these structures in the brains of mice transgenic for the HD mutation. Our in vitro model will aid in an eventual understanding of the molecular pathology of HD and the development of preventative strategies.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,GUYS HOSP,DIV MED & MOL GENET,LONDON SE1 7EH,ENGLAND; MAX PLANCK INST MOL GENET,D-14195 BERLIN,DAHLEM,GERMANY; UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,LONDON WC1E 6BT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Max Planck Society; University of London; University College London			Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305; Wanker, Erich/0000-0001-8072-1630				[Anonymous], ADV NEUROL; BATES GP, 1997, IN PRESS HUM MOL GEN; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CAPUTO CB, 1992, ARCH BIOCHEM BIOPHYS, V292, P199, DOI 10.1016/0003-9861(92)90068-8; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Harper PS, 1991, HUNTINGTONS DIS; HOOGEVEEN AT, 1993, HUM MOL GENET, V2, P2069, DOI 10.1093/hmg/2.12.2069; *HUNT DIS COLL RES, 1993, CELL, V72, P971; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; KALCHMAN MA, 1997, NAT GENET, V16, P4; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LIM K, 1994, PROTEIN SCI, V3, P2233, DOI 10.1002/pro.5560031209; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Onodera O, 1996, FEBS LETT, V399, P135, DOI 10.1016/S0014-5793(96)01301-4; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; ROOS RAC, 1983, J NEUROL SCI, V61, P37, DOI 10.1016/0022-510X(83)90053-9; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Sathasivam K, 1997, HUM GENET, V99, P692, DOI 10.1007/s004390050432; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TELLEZNAGEL I, 1974, J NEUROCYTOL, V3, P308; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487	41	1037	1075	0	79	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					549	558		10.1016/S0092-8674(00)80514-0	http://dx.doi.org/10.1016/S0092-8674(00)80514-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267034	Bronze			2022-12-01	WOS:A1997XQ06300018
J	Nightingale, SL				Nightingale, SL			National conference on implementation of the waiver of informed consent in emergency situations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, JAMA-J AM MED ASSOC, V276, P1632	1	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-01	WOS:A1997XN51800010
J	vanderHeide, A; van der Maas, PJ; vanderWal, G; deGraaff, CLM; Kester, JGC; Kollee, LAA; deLeeuw, R; Holl, RA				vanderHeide, A; van der Maas, PJ; vanderWal, G; deGraaff, CLM; Kester, JGC; Kollee, LAA; deLeeuw, R; Holl, RA			Medical end-of-life decisions made for neonates and infants in the Netherlands	LANCET			English	Article							INTENSIVE-CARE; EUTHANASIA	Background Advances in neonatal intensive care have lowered the neonatal death rate. There are still some severely ill neonates and infants, however, for whom the application of all possible life-prolonging treatment modalities may be questioned. Methods We did two studies in the Netherlands. In the first we sent questionnaires to physicians who had attended 338 consecutive deaths (August-November, 1995) within the first year of life (death-certificate study), and in the second we interviewed 31 neonatologists or paediatric intensive-care specialists and 35 general paediatricians. The response rates were 88% and 99%, respectively. Findings in the death-certificate study, 57% of all deaths had been preceded by a decision to forgo life-sustaining treatment; this decision was accompanied by the administration of potentially life-shortening drugs to alleviate pain or other symptoms in 23%, and by the administration of drugs with the explicit aim of hastening death in 8%. A drug was given explicitly to hasten death to neonates not dependent on life-sustaining treatment in 1% of all death cases. No chance of survival was the main motive in 76% of all end-of-life decisions, and a poor prognosis was the main motive in 18%. The interview study showed that parents had been involved in making 79% of decisions, The physicians consulted colleagues about 88% of decisions, Most paediatricians favoured formal review of medical decisions by colleagues together with ethical or legal experts. Interpretation Death among neonates and infants is commonly preceded by medical end-of-life decisions. Most Dutch paediatricians seem to find prospects for survival and prognostic factors relevant in such decisions. Public control by a committee of physicians, paediatricians, ethicists, and legal experts is widely endorsed by paediatricians.	VRIJE UNIV AMSTERDAM, INST RES EXTRAMURAL MED, AMSTERDAM, NETHERLANDS; STAT NETHERLANDS, VOORBURG, NETHERLANDS	Vrije Universiteit Amsterdam	vanderHeide, A (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, NL-3000 DR ROTTERDAM, NETHERLANDS.							ANGELL M, 1986, NEW ENGL J MED, V314, P642, DOI 10.1056/NEJM198603063141010; BROUWERS HAA, 1995, OP GRENS LEVEN DOOD; CAMPBELL AGM, 1982, ARCH DIS CHILD, V57, P569, DOI 10.1136/adc.57.8.569; Cook L A, 1996, J Perinatol, V16, P133; de Kleine M J, 1993, Ned Tijdschr Geneeskd, V137, P496; deLeeuw R, 1996, J PEDIATR-US, V129, P661, DOI 10.1016/S0022-3476(96)70146-4; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; EGANDERSEN G, 1989, ACTA PAEDIATR SCAND, P56; Frader JE, 1996, PEDIATRICS, V98, P149; KOPELMAN LM, 1988, NEW ENGL J MED, V318, P677, DOI 10.1056/NEJM198803173181105; LEENEN HJJ, 1994, HDB GEZONDHEIDSREC 1; LUCE JM, 1995, CRIT CARE MED, V23, P760, DOI 10.1097/00003246-199504000-00027; Nederlandse Vereniging voor Kindergeneeskunde, 1992, DOEN LAT GRENZ MED H; Rivers RPA, 1996, BRIT MED BULL, V52, P238; RYAN CA, 1993, J PEDIATR-US, V123, P534, DOI 10.1016/S0022-3476(05)80946-1; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; VANDERWAL G, 1994, BRIT MED J, V308, P1346, DOI 10.1136/bmj.308.6940.1346; WHITELAW A, 1986, LANCET, V2, P328	20	87	88	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 26	1997	350	9073					251	255		10.1016/S0140-6736(97)02315-5	http://dx.doi.org/10.1016/S0140-6736(97)02315-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XM866	9242802	Green Submitted			2022-12-01	WOS:A1997XM86600012
J	Kim, J; Johnson, K; Chen, HJ; Carroll, S; Laughon, A				Kim, J; Johnson, K; Chen, HJ; Carroll, S; Laughon, A			Drosophila MAD binds to DNA and directly mediates activation of vestigial by decapentaplegic	NATURE			English	Article							HEDGEHOG; EXPRESSION; MELANOGASTER; ELEMENTS; PATTERN; PROTEIN; GENE; DPP	The TGF-beta (transforming growth factor-beta)-related signalling proteins, including Decapentaplegic (Dpp) in Drosophila and bone morphogenic proteins and activin in vertebrates, affect the growth and patterning of a great variety of structures. However, the mechanisms by which these ligands regulate gene expression are not understood. Activation of complexes of type I with type II receptors results in the phosphorylation and nuclear localization of members of the SMAD protein family(1-9), which are thought to act as co-activators of transcription, perhaps in conjunction with sequence-specific cofactors(10). Here we show that the aminoterminal domain of the Drosophila Mothers against dpp protein (Mad), a mediator of Dpp signalling(11-14), possesses a sequence-specific DNA-binding activity that becomes apparent when carboxy-terminal residues are removed. Mad binds to and is required for the activation of an enhancer within the vestigial wing-patterning gene in cells across the entire developing wing blade. Mad also binds to Dpp-response elements in other genes. These results suggest that Dpp signalling regulates gene expression by activating Mad binding to target gene enhancers.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV WISCONSIN,MOL BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,MCARDLE LAB CANC RES,DEPT ONCOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AUSUBEL EM, 1994, CURRENT PROTOCOLS S, V28, P1661; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR S, 1995, BIOESSAYS, V17, P229; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIU F, 1996, NATURE, V381, P622; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RAFTERY LA, 1995, GENETICS, V139, P241; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; TREMML G, 1992, DEVELOPMENT, V116, P447; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; ZECCA M, 1995, DEVELOPMENT, V121, P2265; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	31	450	464	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					304	308		10.1038/40906	http://dx.doi.org/10.1038/40906			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230443	Bronze			2022-12-01	WOS:A1997XL12100058
J	Kopp, JB; Miller, KD; Mican, JAM; Feuerstein, IM; Vaughan, E; Baker, C; Pannell, LK; Falloon, J				Kopp, JB; Miller, KD; Mican, JAM; Feuerstein, IM; Vaughan, E; Baker, C; Pannell, LK; Falloon, J			Crystalluria and urinary tract abnormalities associated with indinavir	ANNALS OF INTERNAL MEDICINE			English	Article						crystalluria; urinary tract; indinavir; human immunodeficiency virus infections; kidney calculi	PROTEASE INHIBITOR; PATHOGENESIS; L-735,524	Background: Indinavir, a protease inhibitor widely used to treat patients with HIV infection, has been associated with nephrolithiasis. Distinctive urinary crystals and a spectrum of urologic disorders were noted in patients receiving indinavir. Objective: To determine the composition of urinary crystals and the frequency of asymptomatic crystalluria and urinary tract symptoms in patients receiving indinavir. Patients: Patients with HIV infection who were enrolled in studies conducted at the National Institutes of Health. Measurements: Microscopic urinalysis, high-performance liquid chromatography (HPLC) and mass spectrometry of urinary crystals and stones, and clinical evaluation of patients with urologic symptoms. Results: Of 240 patients receiving indinavir, 142 provided urine specimens for analysis. Twenty-nine (20%) had crystals consisting of plate-like rectangles and fan-shaped or starburst forms. Mass spectrometry and HPLC confirmed that these crystals were composed of indinavir. OF 40 patients who were not receiving indinavir, none had similar crystals (P < 0.001). Nineteen of the 240 patients receiving indinavir (8%) developed urologic symptoms. Of these, 7 (3%) had nephrolithiasis and the other 12 (5%) had previously undescribed syndromes: crystalluria associated with dysuria and crystalluria associated with back or flank pain. Four of the patients with the latter syndrome had radiographic evidence of intrarenal sludging. Conclusions: Indinavir forms characteristic crystals in the urine. This crystalluria may be associated with dysuria and urinary frequency, with flank or back pain associated with intrarenal sludging, and with the classic syndrome of renal colic.	NIAID, NIH, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kopp, JB (corresponding author), NIDDK, WARREN GRANT MAGNUSON CLIN CTR, NIH, BLDG 10, ROOM 3N116, BETHESDA, MD 20892 USA.		Kopp, Jeffrey B/O-2681-2015	Kopp, Jeffrey B/0000-0001-9052-186X				BALANI SK, 1995, DRUG METAB DISPOS, V23, P266; Bartlett JG, 1996, ANN INTERN MED, V124, P1086, DOI 10.7326/0003-4819-124-12-199606150-00011; BIRCH DF, 1994, COLOR ATLAS URINE MI; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; Corey L, 1996, NEW ENGL J MED, V335, P1142, DOI 10.1056/NEJM199610103351509; Daudon M, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62506-8; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001; Farina Luis A., 1995, Archivos Espanoles de Urologia, V48, P418; GULICK R, 1996, 3 C RETR OPP INF WAS, pLB7; Haber MB, 1981, URINARY SEDIMENT TXB; LIN JH, 1995, DRUG METAB DISPOS, V23, P730; MCEVOY GK, 1996, DRUG INFORMATION; *MERCK CO, 1996, CRIX IND SULF US PAC; PATZELT WJ, 1974, POLARIZED LIGHT MICR; Piscitelli SC, 1996, CLIN INFECT DIS, V23, P685, DOI 10.1093/clinids/23.4.685; PREMINGER GM, 1992, SEMIN NEPHROL, V12, P200; Rapado A, 1987, Contrib Nephrol, V58, P25; SAWYER MH, 1988, AM J MED, V84, P1067, DOI 10.1016/0002-9343(88)90313-0; TANOUYE E, 1996, WALL STREET J   1105, pA6; Tanouye E, 1996, WALL STREET J   1106, pA1; Tashima KT, 1997, NEW ENGL J MED, V336, P138, DOI 10.1056/NEJM199701093360215	22	247	251	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					119	+		10.7326/0003-4819-127-2-199707150-00004	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230000				2022-12-01	WOS:A1997XK15800006
J	Slemenda, C; Brandt, KD; Heilman, DK; Mazzuca, S; Braunstein, EM; Katz, BP; Wolinsky, FD				Slemenda, C; Brandt, KD; Heilman, DK; Mazzuca, S; Braunstein, EM; Katz, BP; Wolinsky, FD			Quadriceps weakness and osteoarthritis of the knee	ANNALS OF INTERNAL MEDICINE			English	Article						muscle weakness; osteoarthritis; knee joint; quadriceps; disabled	X-RAY ABSORPTIOMETRY; OSTEO-ARTHRITIS; MUSCLE; ASSOCIATION; OUTCOMES; PROGRAM; THERAPY; HEALTH	Background: The quadriceps weakness commonly associated with osteoarthritis of the knee is widely believed to result from disuse atrophy secondary to pain in the in volved joint. However, quadriceps weakness may be an etiologic factor in the development of osteoarthritis. Objective: To explore the relation between lower-extremity weakness and osteoarthritis of the knee. Design: Cross-sectional prevalence study. Setting: Population-based, with recruitment by random-digit dialing. Participants: 462 volunteers 65 years of age or older. Measurements: Radiographs of the knee were graded for the presence of osteoarthritis. Knee pain and function were assessed with the Western Ontario and McMaster Universities Arthritis Index, the strength of leg flexors and extensors was assessed with isokinetic dynamometry, and lower-extremity lean tissue mass was assessed with dual-energy x-ray absorptiometry. Results: Among participants with osteoarthritis, quadriceps weakness, but not hamstring weakness, was common. The ratio of extensor strength to body weight was approximately 20% lower in those with than in those without radiographic osteoarthritis. Notably, among women with tibiofemoral osteoarthritis, extensor weakness was present in the absence of knee pain and was seen in participants with normal lower-extremity lean mass (extensor strength, 30.1 Ib-ft for those with osteoarthritis and 34.8 Ib-ft for those without osteoarthritis; P < 0.001). After adjustment for body weight, age, and sex, lesser quadriceps strength remained predictive of both radiographic and symptomatic osteoarthritis of the knee (odds ratio for prevalence of osteoarthritis per 10 Ib-ft loss of strength, 0.8 [95% CI, 0.71 to 0.90] for radiographic osteoarthritis and 0.71 [CI, 0.51 to 0.87] for symptomatic osteoarthritis). Conclusion: Quadriceps weakness may be present in patients who have osteoarthritis but do not have knee pain or muscle atrophy; this suggests that the weakness may be due to muscle dysfunction. The data are consistent with the possibility that quadriceps weakness is a primary risk factor for knee pain, disability, and progression of joint damage in persons with osteoarthritis of the knee.	INDIANA UNIV, SCH MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, MED CTR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis			Wolinsky, Fredric D/F-9231-2011	Wolinsky, Fredric/0000-0002-0916-4955	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020582] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00750] Funding Source: Medline; NIAMS NIH HHS [2P60AR20582-20] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Chamberlain M A, 1982, Int Rehabil Med, V4, P101; DAVIS MA, 1989, AM J EPIDEMIOL, V130, P278, DOI 10.1093/oxfordjournals.aje.a115334; FEINBERG J, 1992, ARTHRITIS RHEUM S5, V35, pR28; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FIATARONE MA, 1990, JAMA-J AM MED ASSOC, V263, P3029, DOI 10.1001/jama.263.22.3029; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P840, DOI 10.1016/0003-9993(93)90011-X; FISHER NM, 1994, AM J PHYS MED REHAB, V73, P413, DOI 10.1097/00002060-199411000-00006; FISHER NM, 1993, ARCH PHYS MED REHAB, V74, P1319, DOI 10.1016/0003-9993(93)90087-Q; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; FULLER NJ, 1992, CLIN PHYSIOL, V12, P253, DOI 10.1111/j.1475-097X.1992.tb00831.x; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; HAARBO J, 1990, J BONE MINER RES S2, V5, pS180; HADLER NM, 1992, ANN INTERN MED, V116, P598, DOI 10.7326/0003-4819-116-7-598; HURLEY MV, 1993, BRIT J RHEUMATOL, V32, P127; JEFFERSON RJ, 1990, ENG MED, V204, P21; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; Mazzuca S. A., 1995, Arthritis and Rheumatism, V38, pS227; MCALINDON TE, 1992, ANN RHEUM DIS, V51, P844, DOI 10.1136/ard.51.7.844; RUTHERFORD OM, 1986, J NEUROL NEUROSUR PS, V49, P1288, DOI 10.1136/jnnp.49.11.1288; Sharma L, 1996, J INVEST MED, V44, pA359; TATARANNI PA, 1995, AM J CLIN NUTR, V62, P730, DOI 10.1093/ajcn/62.4.730; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	27	639	673	2	51	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					97	+		10.7326/0003-4819-127-2-199707150-00001	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9230035				2022-12-01	WOS:A1997XK15800003
J	Nicoll, M; Akerib, CC; Meyer, BJ				Nicoll, M; Akerib, CC; Meyer, BJ			X-chromosome-counting mechanisms that determine nematode sex	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION; C-ELEGANS; GENE; IDENTIFICATION; XOL-1	Sex is determined in Caenorhabditis elegans by an X-chromosome-counting mechanism that reliably distinguishes the twofold difference in X-chromosome dose between males (1X) and hermaphrodites (2X)(1,2). This small quantitative difference is translated into the 'on/off' response of the target gene, xol-1, a switch that specifies the male fate when active and the hermaphrodite fate when inactive(3), Specific regions of X contain counted signal elements whose combined dose sets the activity of xol-1 (ref. 4). Here we ascribe the dose effects of one region to a discrete, protein-encoding gene, fox-1. We demonstrate that the dose-sensitive signal elements on chromosome X control xol-1 through two different molecular mechanisms. One involves the transcriptional repression of xol-1 in XX animals. The other uses the putative RNA-binding protein encoded by fox-1 to reduce the level of xol-1 protein, These two mechanisms of repression act together to ensure the fidelity of the X-chromosome counting process.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley				Meyer, Barbara/0000-0002-6530-4588	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM030702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERIB CC, 1994, GENETICS, V138, P1105; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BIRD CG, 1994, SCIENCE, V265, P615; Bridges CB, 1916, GENETICS, V1, P1; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HODGKIN J, 1994, DEVELOPMENT, V120, P3681; HODGKIN J, 1979, GENETICS, V91, P67; MADL JE, 1979, GENETICS, V93, P393; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; Nigon V., 1951, B BIOL FR BELG, V85, P187; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9	15	68	72	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					200	204		10.1038/40669	http://dx.doi.org/10.1038/40669			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217163	Bronze			2022-12-01	WOS:A1997XK10900056
J	Benbow, SJ; Walsh, A; Gill, GV				Benbow, SJ; Walsh, A; Gill, GV			Diabetes in institutionalised elderly people: A forgotten population?	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,CLIN DEPT AINTREE,FAZAKERLEY HOSP,DIABET & ENDOCRINOL CLIN RES GRP,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND	University of Liverpool	Benbow, SJ (corresponding author), WALTON HOSP,CTR DIABET,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND.							SINCLAIR AJ, 1993, BRIT MED J, V306, P1142, DOI 10.1136/bmj.306.6886.1142; Sinclair AJ, 1996, POSTGRAD MED J, V72, P334, DOI 10.1136/pgmj.72.848.334; TATTERSALL RB, 1984, DIABETOLOGIA, V27, P167	3	59	59	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1868	1869		10.1136/bmj.314.7098.1868	http://dx.doi.org/10.1136/bmj.314.7098.1868			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224129	Green Published			2022-12-01	WOS:A1997XH73800023
J	Sagoo, MS; Lagnado, L				Sagoo, MS; Lagnado, L			G-protein deactivation is rate-limiting for shut-off of the phototransduction cascade	NATURE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; LIGHT ADAPTATION; RETINAL RODS; SALAMANDER RODS; CALCIUM-CONCENTRATION; SATURATING FLASHES; RHODOPSIN; KINETICS; TRANSDUCTION	Photoreceptors detect light through a seven-helix receptor (rhodopsin) and heterotrimeric G protein (transducin) coupled to a cyclic GMP phosphodiesterase(1,2). Similar pathways are used to amplify responses to hormones, taste and smell(3-5). The amplification of phototransduction is reduced by a fall in cytoplasmic Ca2+ (refs 6-10), but it is not known how the deactivation of rhodopsin and transducin influence this response and hence the extent and duration of phosphodiesterase activity(11-14). Here we investigate this by recording the electrical response to flashes of light in truncated rod photoreceptors(10). By removing ATP to block the deactivation of rhodopsin by phosphorylation(15), we show that this reaction limits the amplitude of the response and begins within 3.2 s of a flash in a solution containing 1 mu M Ca2+, falling to 0.9 s in a zero-Ca2+ solution. In contrast, the activation and amplitude of the response were unaffected when transducin deactivation by GTP hydrolysis was blocked by replacing GTP with its nonhydrolysable analogue GTP-gamma S-11, demonstrating that there is little GTP hydrolysis occurring over the period in which photoexcited rhodopsin is quenched. The rapid deactivation of rhodopsin is therefore a Ca2+-sensitive step controlling the amplitude of the light response, whereas transducin deactivation is slower and controls recovery.	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology				Sagoo, Mandeep/0000-0003-1530-3824				CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CORSON DW, 1994, VISUAL NEUROSCI, V11, P91, DOI 10.1017/S0952523800011135; Detwiler PB, 1996, CURR OPIN NEUROBIOL, V6, P440, DOI 10.1016/S0959-4388(96)80047-X; Gold GH, 1997, NATURE, V385, P677, DOI 10.1038/385677a0; GrayKeller MP, 1996, NEURON, V17, P323, DOI 10.1016/S0896-6273(00)80163-4; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; JONES GJ, 1995, J PHYSIOL-LONDON, V487, P441, DOI 10.1113/jphysiol.1995.sp020891; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; LAGNADO L, 1992, J PHYSIOL-LONDON, V455, P111, DOI 10.1113/jphysiol.1992.sp019293; LAGNADO L, 1994, NATURE, V367, P273, DOI 10.1038/367273a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; Lyubarsky A, 1996, J GEN PHYSIOL, V107, P19, DOI 10.1085/jgp.107.1.19; Matthews HR, 1996, J PHYSIOL-LONDON, V490, P1; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; Murnick JG, 1996, J PHYSIOL-LONDON, V495, P1; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; Nikonov S. S., 1996, Investigative Ophthalmology and Visual Science, V37, pS5; PEPPERBERG DR, 1992, VISUAL NEUROSCI, V8, P9, DOI 10.1017/S0952523800006441; PEPPERBERG DR, 1994, VISUAL NEUROSCI, V11, P53, DOI 10.1017/S095252380001110X; Sagoo Mandeep S., 1997, Investigative Ophthalmology and Visual Science, V38, pS614; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YOUNGER JP, 1992, INVEST OPHTH VIS SCI, V33, P1104	30	69	69	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 25	1997	389	6649					392	395		10.1038/38750	http://dx.doi.org/10.1038/38750			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX675	9311782				2022-12-01	WOS:A1997XX67500055
J	Dokland, T; McKenna, R; Ilag, LL; Bowman, BR; Incardona, NL; Fane, BA; Rossmann, MG				Dokland, T; McKenna, R; Ilag, LL; Bowman, BR; Incardona, NL; Fane, BA; Rossmann, MG			Structure of a viral procapsid with molecular scaffolding	NATURE			English	Article							FUNCTIONAL IMPLICATIONS; ATOMIC-STRUCTURE; BACTERIOPHAGE-PHI-X174; PHI-X174; PROTEIN; VIRUS; PROHEAD; CAPSIDS	The assembly of a macromolecular structure proceeds along an ordered morphogenetic pathway, and is accomplished by the switching of proteins between discrete conformations as they are added to the nascent assembly(1-3). Scaffolding proteins often play a catalytic role in the assembly process(1,2,4), rather like molecular chaperones(5). Although macromolecular assembly processes are fundamental to all biological systems, they have been characterized most thoroughly in viral systems, such as the icosahedral Escherichia coli bacteriophage Phi X174 (refs 6, 7). The Phi X174 virion contains the proteins F, G, H and J(7,8). assembly, two scaffolding proteins B and D are required for formation of a 108S, 360-Angstrom-diameter procapsid from pentameric precursors containing the F, G and H protein(6,9). The procapsid contains 240 copies of protein D, forming an external scaffold, and 60 copies each of the internal scaffolding protein B, the capsid protein F, and the spike protein G(9,10). Maturation involves packaging of DNA and J proteins and loss of protein B, producing a 132S intermediate(6,7). Subsequent removal of the external scaffold yields the mature virion. Both the F and G proteins have the eight- stranded antiparallel beta-sandwich motifs(8,11) common to many plant and animal viruses(12,13). Here we describe the structure of a procapsid-like particle at 3.5-Angstrom resolution, showing how the scaffolding proteins coordinate assembly of the virus by interactions with the F and G proteins, and showing that the F protein undergoes conformational changes during capsid maturation.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA; UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, MEMPHIS, TN 38163 USA; UNIV ARKANSAS, DEPT BIOL SCI, FAYETTEVILLE, AR 72701 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Tennessee System; University of Tennessee Health Science Center; University of Arkansas System; University of Arkansas Fayetteville				Dokland, Terje/0000-0001-5655-4123				Asakura S., 1975, THERMODYNAMICS POLYM; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Casjens S, 1988, BACTERIOPHAGES, P15; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; DOKLAND T, 1993, J MOL BIOL, V233, P682, DOI 10.1006/jmbi.1993.1545; EKECHUKWU MC, 1995, GENETICS, V140, P1167; EKECHUKWU MC, 1995, J BACTERIOL, V177, P829, DOI 10.1128/jb.177.3.829-830.1995; FANE BA, 1993, GENETICS, V134, P1003; FARBER MB, 1976, J VIROL, V17, P1027, DOI 10.1128/JVI.17.3.1027-1037.1976; HARRISON SC, 1996, FIELDS VIROLOGY, V1, P59; HAYASHI M, 1978, SINGLE STRANDED DNA, P531; Hayashi M., 1988, BACTERIOPHAGES, V2, P1; ILAG LL, 1995, STRUCTURE, V3, P353, DOI 10.1016/S0969-2126(01)00167-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KING J, 1980, BIOL REGUL DEV, V2, P101; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; McKenna R, 1996, J MOL BIOL, V256, P736, DOI 10.1006/jmbi.1996.0121; MCKENNA R, 1994, J MOL BIOL, V237, P517, DOI 10.1006/jmbi.1994.1253; MUKAI R, 1979, P NATL ACAD SCI USA, V76, P4877, DOI 10.1073/pnas.76.10.4877; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRASAD BVV, 1993, J MOL BIOL, V231, P65, DOI 10.1006/jmbi.1993.1257; PRESTON VG, 1994, J GEN VIROL, V75, P2355, DOI 10.1099/0022-1317-75-9-2355; ROSSMANN MG, 1992, J APPL CRYSTALLOGR, V25, P166, DOI 10.1107/S002188989101141X; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530	29	118	125	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					308	313		10.1038/38537	http://dx.doi.org/10.1038/38537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305849				2022-12-01	WOS:A1997XW77200054
J	Stoddart, H; Noah, N				Stoddart, H; Noah, N			Usefulness of screening large numbers of contacts for tuberculosis: questionnaire based review	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT EPIDEMIOL & PUBL HLTH,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	Stoddart, H (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL BS8 2PR,AVON,ENGLAND.							CAPEWELL S, 1986, BRIT J DIS CHEST, V80, P37, DOI 10.1016/0007-0971(86)90007-0; *JOINT TUB COMM BR, 1994, THORAX, V49, P1193; SCOTT E, 1990, COMMUNICAB DIS REP, V34, P3; SELBY CD, 1989, RESP MED, V83, P353, DOI 10.1016/S0954-6111(89)80212-4; VEEN J, 1992, TUBERCLE LUNG DIS, V73, P73, DOI 10.1016/0962-8479(92)90058-R	5	5	5	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 13	1997	315	7109					651	651		10.1136/bmj.315.7109.651	http://dx.doi.org/10.1136/bmj.315.7109.651			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW694	9310568	Green Published			2022-12-01	WOS:A1997XW69400021
J	Offermanns, S; Toombs, CF; Hu, YH; Simon, MI				Offermanns, S; Toombs, CF; Hu, YH; Simon, MI			Defective platelet activation in G alpha(q)-deficient mice	NATURE			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOLIPASE-C ISOZYMES; G-PROTEINS; THROMBOXANE A(2); BLOOD-PLATELETS; RECEPTORS; EXPRESSION; C-BETA-2; FAMILY	Platelets are small disc-shaped cell fragments which undergo a rapid transformation when they encounter vascular damage. They become more spherical and extrude pseudopodia, their fibrinogen receptors are activated, causing them to aggregate, they release their granule contents, and eventually form a plug which is responsible for primary haemostasis(1). Activation of platelets is also implicated in the pathogenesis of unstable angina, myocardial infarction and stroke(2,3). Here we show that platelets from mice deficient in the alpha-subunit of the heterotrimeric guanine-nucleotide-binding protein G(q) are unresponsive to a variety of physiological platelet activators. As a result, G alpha(q)-deficient mice have increased bleeding times and are protected from collagen and adrenaline-induced thromboembolism. We conclude that G alpha(q), is essential for the signalling processes used by different platelet activators and that it cannot be replaced by G alpha(i) or the beta gamma subunits of the heterotrimeric G proteins. G alpha(q) may thus be a new target for drugs designed to block the activation of platelets.	CALTECH,DIV BIOL 147 75,PASADENA,CA 91125; AMGEN INC,DEPT PHARMACOL,THOUSAND OAKS,CA 91320	California Institute of Technology; Amgen			Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				Banno Y, 1996, J BIOL CHEM, V271, P14989, DOI 10.1074/jbc.271.25.14989; BEARER EL, 1995, CELL MOTIL CYTOSKEL, V30, P50, DOI 10.1002/cm.970300107; BUHL AM, 1995, J BIOL CHEM, V270, P24731; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; COLLER BS, 1992, HEART CARDIOVASCULAR, P219; DIMINNO G, 1983, J PHARMACOL EXP THER, V225, P57; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOURANI SMO, 1991, PHARMACOL REV, V43, P243; HOURANI SMO, 1994, TRENDS PHARMACOL SCI, V15, P103, DOI 10.1016/0165-6147(94)90045-0; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Johnson GJ, 1996, BIOCHEM J, V318, P1023, DOI 10.1042/bj3181023; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LAWRENCE WH, 1994, J PHARM SCI, V83, P222, DOI 10.1002/jps.2600830222; Lee SB, 1996, BLOOD, V88, P1684; MCMURRAY J, 1994, BMJ-BRIT MED J, V309, P1343, DOI 10.1136/bmj.309.6965.1343; MILLIGAN G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P208, DOI 10.1016/0167-4889(93)90143-D; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OFFERMANNS S, UNPUB NEURON; PACKHAM MA, 1994, CAN J PHYSIOL PHARM, V72, P278, DOI 10.1139/y94-043; PARK DG, 1993, J BIOL CHEM, V268, P4573; ROSENBLUM WI, 1983, THROMB RES, V30, P347, DOI 10.1016/0049-3848(83)90226-8; SAGE SO, 1995, PLATELETS PRACTICAL, P67; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808	30	449	459	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					183	186		10.1038/38284	http://dx.doi.org/10.1038/38284			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296496				2022-12-01	WOS:A1997XV75700049
J	Woo, KS; Robinson, JTC; Chook, P; Adams, MR; Yip, G; Mai, ZJ; Lam, CWK; Sorensen, KE; Deanfield, JE; Celermajer, DS				Woo, KS; Robinson, JTC; Chook, P; Adams, MR; Yip, G; Mai, ZJ; Lam, CWK; Sorensen, KE; Deanfield, JE; Celermajer, DS			Differences in the effect of cigarette smoking on endothelial function in Chinese and white adults	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTHY-YOUNG ADULTS; PASSIVE SMOKING; ATHEROSCLEROSIS; EPIDEMIOLOGY; DYSFUNCTION; DISEASE	Background: The prevalence of coronary artery disease in southern China is approximately one fifth that in ''westernized'' countries, even though approximately 70% of Chinese men smoke cigarettes and Chinese women have substantial passive exposure to cigarette smoke. Objectives: Endothelial dysfunction is an early event in atherosclerosis and occurs in young white active and passive smokers; we compared endothelial physiology in healthy young Chinese and white smokers and nonsmokers. Patients: 144 healthy adults who were 16 to 45 years of age: 72 Chinese persons in a village in southern China and 72 white persons in Australia and England who were matched for exposure to cigarette smoke. Each ethnic group comprised 36 controls (lifelong nonsmokers with no regular exposure to cigarette smoke; 16 men and 20 women) and 36 active or passive smokers (15 men and 21 women). Measurements: Arterial endothelial function was tested with high-resolution external vascular ultrasonography, and brachial artery diameter was measured at rest, after flow increase (which causes endothelium-dependent dilatation), and after administration of sublingual nitroglycerin (an endothelium-independent dilator). Results: Endothelium-dependent dilatation was similar in Chinese (7.9%) and white (8.4%) nonsmokers (P > 0.2). Among white persons, endothelium-dependent dilatation was lower in active or passive smokers (3.9%) than in nonsmokers (8.4%) (P < 0.001). Among Chinese persons, dilatation was not significantly lower in active or passive smokers (7.3%) than in nonsmokers (7.9%) (P > 0.2). Dilatation was higher in Chinese active or passive smokers (7.3%) than in white active or passive smokers (3.9%) (P < 0.001). Dilatation responses to nitroglycerin were similar in all groups (P = 0.17). Conclusion: Young Chinese adults have less evidence of arterial endothelial dysfunction than young white adults with similar direct or indirect exposure to cigarette smoke.	ROYAL PRINCE ALFRED HOSP, DEPT CARDIOL, CAMPERDOWN, NSW 2050, AUSTRALIA; PAN YU CTY HOSP, PAN YU, PEOPLES R CHINA; GREAT ORMOND ST HOSP CHILDREN, CARDIOTHORAC UNIT, LONDON WC1N 3JH, ENGLAND; HEART RES INST, SYDNEY, NSW, AUSTRALIA; CHINESE UNIV HONG KONG, HONG KONG, HONG KONG	University of Sydney; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Sydney; Heart Research Institute; Chinese University of Hong Kong			YIP, Gabriel/A-8837-2008; Deanfield, John E/C-5178-2008	YIP, Gabriel/0000-0002-3859-7194; Deanfield, John/0000-0001-8806-6052				Adams MR, 1996, J VASC INVEST, V2, P146; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; Cook NC, 1996, J NUTR BIOCHEM, V7, P66, DOI 10.1016/0955-2863(95)00168-9; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Heitzer T, 1996, CIRCULATION, V93, P1346, DOI 10.1161/01.CIR.93.7.1346; *HLTH BEN SMOK CES, 1990, 9084161917 DHHS CDC; HOLBROOK JH, 1984, CIRCULATION, V70, P1114; HONORE EK, 1995, CIRCULATION S1, V92, P1; PITTILO RM, 1984, BRIT J HAEMATOL, V58, P627, DOI 10.1111/j.1365-2141.1984.tb06109.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SORENSEN KE, 1995, BRIT HEART J, V74, P247; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; WENG XZ, 1988, CHINESE MED J-PEKING, V101, P371; WENG XZ, 1987, CHINESE MED J-PEKING, V100, P886; WOO KS, 1989, INT J CARDIOL, V24, P83, DOI 10.1016/0167-5273(89)90045-4	17	42	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					372	375		10.7326/0003-4819-127-5-199709010-00006	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273828				2022-12-01	WOS:A1997XU10000005
J	Fitzpatrick, DC; Batra, R; Stanford, TR; Kuwada, S				Fitzpatrick, DC; Batra, R; Stanford, TR; Kuwada, S			A neuronal population code for sound localization	NATURE			English	Article							INFERIOR COLLICULUS; UNANESTHETIZED RABBIT; BINAURAL INTERACTION; CHANGING FREQUENCY; INTERAURAL DELAYS; INFORMATION; DIRECTION; MOVEMENT	The accuracy with which listeners can locate sounds is much greater than the spatial sensitivity of single neurons(1-3). The broad spatial tuning of auditory neurons indicates that a code based on the responses of ensembles of neurons, a population code, must be used to determine the position of a sound in space, Here we show that the tuning of neurons to the most potent localization cue, the interaural time difference in low-frequency signals (< similar to 2 kHz; refs 4, 5), becomes sharper as the information ascends through the auditory system, We also show that this sharper tuning increases the efficiency of the population code, in the sense that fewer neurons are required to achieve a given acuity.			Fitzpatrick, DC (corresponding author), UNIV CONNECTICUT, CTR HLTH, DEPT ANAT, FARMINGTON, CT 06030 USA.		Fitzpatrick, Douglas/AFT-2814-2022	Fitzpatrick, Douglas/0000-0001-8099-7194; Stanford, Terrence/0000-0003-0759-5599				BATRA R, 1989, J NEUROPHYSIOL, V61, P257, DOI 10.1152/jn.1989.61.2.257; BATRA R, IN PRESS J NEUROPHYS; BLAUERT J, 1982, SPATIAL HEARING; BRUGGE JF, 1997, BINAURAL SPATIAL HEA, P447; CAPUANO U, 1981, J COMP NEUROL, V196, P13, DOI 10.1002/cne.901960103; DYE RH, 1990, J ACOUST SOC AM, V88, P2159, DOI 10.1121/1.400113; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Green DM, 1966, SIGNAL DETECTION THE, P1; HAFTER ER, 1975, J ACOUST SOC AM, V57, P181, DOI 10.1121/1.380412; HEFFNER H, 1980, J ACOUST SOC AM, V68, P1584, DOI 10.1121/1.385213; Heller LM, 1996, J ACOUST SOC AM, V99, P3632, DOI 10.1121/1.414961; Hinton GE, 1986, PARALLEL DISTRIBUTED; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KUWADA S, 1987, J NEUROPHYSIOL, V57, P1338, DOI 10.1152/jn.1987.57.5.1338; KUWADA S, 1997, BINAURAL SPATIAL HEA, P399; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; LI L, 1992, J NEUROSCI, V12, P4530; Mills A. W., 1958, J ACOUST SOC AM, V65, P991; PERROTT DR, 1984, J ACOUST SOC AM, V75, P1201, DOI 10.1121/1.390771; RUMMELHART DE, 1986, PARALLEL DISTRIBUTED, V2, P77; Salinas E, 1994, J Comput Neurosci, V1, P89, DOI 10.1007/BF00962720; STANFORD TR, 1992, J NEUROSCI, V12, P3200, DOI 10.1523/JNEUROSCI.12-08-03200.1992; STERN RM, 1992, ADV BIOSCI, V83, P547; STERN RM, 1978, J ACOUST SOC AM, V64, P127, DOI 10.1121/1.381978; THEUNISSEN FE, 1991, J NEUROPHYSIOL, V66, P1690, DOI 10.1152/jn.1991.66.5.1690; TRAHIOTIS C, 1990, J ACOUST SOC AM, V87, P810, DOI 10.1121/1.398892; VANGISBERGEN JAM, 1987, NEUROSCIENCE, V21, P541, DOI 10.1016/0306-4522(87)90140-0; WIGHTMAN FL, 1992, J ACOUST SOC AM, V91, P1648, DOI 10.1121/1.402445; YIN TCT, 1983, J NEUROPHYSIOL, V50, P1020, DOI 10.1152/jn.1983.50.4.1020	30	131	133	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					871	874		10.1038/42246	http://dx.doi.org/10.1038/42246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278047	Bronze			2022-12-01	WOS:A1997XT75400048
J	Gu, W; Roeder, RG				Gu, W; Roeder, RG			Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain	CELL			English	Article							NUCLEAR-PROTEIN CBP; TRANSCRIPTIONAL ACTIVATION; SUPPRESSION; COACTIVATOR; GROWTH; LOOP; SITE; TRANSFORMATION; EXPRESSION; INHIBITOR	The tumor suppressor p53 exerts antiproliferation effects through its ability to function as a sequence-specific DNA-binding transcription factor. Here, we demonstrate that p53 can be modified by acetylation both in vivo and in vitro. Remarkably, the site of p53 that is acetylated by its coactivator, p300, resides in a C-terminal domain known to be critical for the regulation of p53 DNA binding. Furthermore, the acetylation of p53 can dramatically stimulate its sequence-specific DNA-binding activity, possibly as a result of an acetylation-induced conformational change. These observations clearly indicate a novel pathway for p53 activation and, importantly, provide an example of an acetylation-mediated change in the function of a nonhistone regulatory protein. These results have significant implications regarding the molecular mechanisms of various acetyltransferase-containing transcriptional coactivators whose primary targets have been presumed to be histones.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University								Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Buckley AR, 1996, CELL GROWTH DIFFER, V7, P1713; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen WY, 1997, P NATL ACAD SCI USA, V94, P5798, DOI 10.1073/pnas.94.11.5798; CHIANG CM, 1993, PEPTIDE RES, V6, P62; Chresta CM, 1996, NAT MED, V2, P745, DOI 10.1038/nm0796-745; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; FISCELLA M, 1994, ONCOGENE, V9, P3249; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MIYASHITA T, 1995, CELL, V80, P293; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shaw P, 1996, ONCOGENE, V12, P921; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SOUSSI T, 1990, ONCOGENE, V5, P945; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/0092-8674(93)90673-E; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	83	2105	2189	0	127	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					595	606		10.1016/S0092-8674(00)80521-8	http://dx.doi.org/10.1016/S0092-8674(00)80521-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288740	Bronze			2022-12-01	WOS:A1997XT06600004
J	Averof, M; Patel, NH				Averof, M; Patel, NH			Crustacean appendage evolution associated with changes in Hox gene expression	NATURE			English	Article							BODY PLANS; ULTRABITHORAX; MORPHOLOGY; ANTIBODY; INSECT	Homeotic (Hox) genes specify the differential identity of segments along the body axis of insects. Changes in the segmental organization of arthropod bodies may therefore be driven by changes in the function of Hox genes(1-3), but so far this has been difficult to demonstrate. We shaw here that changes in the expression pattern of the Hox genes Ubx and AbdA in different crustaceans correlate well with the modification of their anterior thoracic limbs into feeding appendages (maxillipeds). Our observations provide direct evidence that major morphological changes in arthropod body plans are associated with changes in Hox gene regulation. They suggest that homeotic changes(1,4) may play a role in the normal process of adaptive evolutionary change.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND	Howard Hughes Medical Institute; University of Chicago				Patel, Nipam/0000-0003-4328-654X; Averof, Michalis/0000-0002-6803-7251	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAM M, 1995, PHILOS T R SOC B, V349, P313, DOI 10.1098/rstb.1995.0119; AKAM M, 1988, DEVELOPMENT, V104, P123; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; AVEROF M, 1995, NATURE, V376, P420, DOI 10.1038/376420a0; Averof M, 1996, SEMIN CELL DEV BIOL, V7, P539, DOI 10.1006/scdb.1996.0068; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BRIGGS DEG, 1978, PHILOS T ROY SOC B, V281, P439, DOI 10.1098/rstb.1978.0005; Brusca R.C., 1990, INVERTEBRATES, P1; BURKE AC, 1995, DEVELOPMENT, V121, P333; CALMAN WT, 1909, CRUSTACEA; CASTELLIGAIR J, 1995, DEVELOPMENT, V121, P2973; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; GAUNT SJ, 1994, INT J DEV BIOL, V38, P549; GIESBRECHT W, 1931, HANDWORTERBUCH NATUR, P800; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; LEWIS EB, 1978, NATURE, V276, P567; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MULLER KJ, 1988, FOSSILS STRATA, V23, P1; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PATEL NH, 1989, DEVELOPMENT, V107, P201; Raff R. A., 1991, EMBRYOS GENES EVOLUT; Salser SJ, 1996, DEVELOPMENT, V122, P1651; Schram F.R., 1986, CRUSTACEA; WAGNER GP, 1989, ANNU REV ECOL SYST, V20, P51, DOI 10.1146/annurev.es.20.110189.000411; Walossek Dieter, 1993, Fossils and Strata, V32, P1	26	268	273	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					682	686		10.1038/41786	http://dx.doi.org/10.1038/41786			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262403	Bronze			2022-12-01	WOS:A1997XQ86300051
J	Fass, D; Blacklow, S; Kim, PS; Berger, JM				Fass, D; Blacklow, S; Kim, PS; Berger, JM			Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module	NATURE			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CYSTEINE-RICH REPEAT; 3-DIMENSIONAL STRUCTURE; APOLIPOPROTEIN-E; BINDING DOMAIN; PROTEIN; MODELS; ERRORS; MAPS	The low-density lipoprotein receptor (LDLR) is responsible for the uptake of cholesterol-containing lipoprotein particles into cells(1,2). The amino-terminal region of LDLR, which consists of seven tandemly repeated, similar to 40-amino-acid, cysteine-rich modules (LDL-A modules), mediates binding to lipoproteins(3,4). LDL-A modules are biologically ubiquitous domains, found in over 100 proteins in the sequence database(5). The structure of ligand-binding repeat 5 (LR5) of the LDLR, determined to 1.7 Angstrom resolution by X-ray crystallography and presented here, contains a calcium ion coordinated by acidic residues that lie at the carboxy-terminal end of the domain and are conserved among LDL-A modules. Naturally occurring point mutations found in patients with the disease familial hypercholesterolaemia(6) alter residues that directly coordinate Ca2+ or that serve as scaffolding residues of LR5.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02142; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute								ABBADI A, 1991, J AM CHEM SOC, V113, P2729, DOI 10.1021/ja00007a056; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, X PLOR VERSION 3 1 S; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DALY NL, 1995, BIOCHEMISTRY-US, V34, P14474, DOI 10.1021/bi00044a025; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; ESSER V, 1988, J BIOL CHEM, V263, P13282; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; JI ZS, 1994, J BIOL CHEM, V269, P2764; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUSSELL DW, 1989, J BIOL CHEM, V264, P21782; *SERC DAR LAB, 1979, 4 SERC DAR LAB; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	27	296	307	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					691	693		10.1038/41798	http://dx.doi.org/10.1038/41798			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262405	Bronze			2022-12-01	WOS:A1997XQ86300053
J	Leger, J; LevyMarchal, C; Bloch, J; Pinet, A; Chevenne, D; Porquet, D; Collin, D; Czernichow, P				Leger, J; LevyMarchal, C; Bloch, J; Pinet, A; Chevenne, D; Porquet, D; Collin, D; Czernichow, P			Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; CORONARY HEART-DISEASE; LOW-BIRTH-WEIGHT; BLOOD-PRESSURE; ADULT LIFE; FETAL GROWTH; INFANT GROWTH; CARDIOVASCULAR-DISEASE; INTRAUTERINE GROWTH; CHILDREN	Objective: To investigate whether the association between low birth weight and increased risk of developing impaired glucose tolerance, insulin resistance, hypertriglyceridaemia, and hypertension in middle age is apparent by the age of 20 in people born small for gestational age, Design: Regional cohort study. Setting: Maternity registry, Haguenau, France, Subjects: 236 full term singleton babies born small for gestational age (birth weight or length, or both, below third centile) during 1971-8 and 281 with normal birth weight (between 25th and 75th centile). All subjects were contacted and evaluated at a mean (SD) age of 20.6 (2.1) years. Main outcome measures: Adult height; concentrations of glucose, insulin, and proinsulin during an oral glucose tolerance test; lipid and fibrinogen concentrations; and blood pressure, Results: After sex and target height were adjusted for, subjects who had been born small for gestational age were significantly shorter at age 20 than those with a normal birth weight (men 4.5 cm shorter (95% confidence interval 6.0 to 3.0 cm); women 3.94 cm shorter (5.2 to 2.7 cm)), After sex and body mass index were adjusted for, mean plasma glucose concentration 30 minutes after a glucose load, fasting insulin concentration (in women), and insulin and proinsulin concentrations 30 and 120 minutes after a glucose load were significantly higher in subjects who had been born small for gestational age than in those with a normal birth weight Mean lipid and fibrinogen concentrations and blood pressure were not different between the two groups. Conclusions: Intrauterine growth retardation has long term consequences such as reduced final height Raised insulin and proinsulin concentrations are present in young adults born small for gestational age and could be markers of early changes in insulin sensitivity.	HOP ROBERT DEBRE,INSERM,CJF 9313,F-75019 PARIS,FRANCE; HOP ROBERT DEBRE,DEPT BIOCHEM,F-75019 PARIS,FRANCE; CTR HOSP HAGUENAU,MATERN UNIT,HAGUENAU,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Leger, J (corresponding author), HOP ROBERT DEBRE,ENDOCRINOL & DIABET UNIT,F-75019 PARIS,FRANCE.							BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1989, BRIT MED J, V298, P567; CHEVENNE D, 1994, CLIN CHEM, V40, P754; CHEVENNE D, 1995, ANN BIOL CLIN-PARIS, V53, P3; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; deZegher F, 1996, J CLIN ENDOCR METAB, V81, P1887, DOI 10.1210/jc.81.5.1887; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HAFFNER SM, 1994, J CLIN ENDOCR METAB, V79, P1806, DOI 10.1210/jc.79.6.1806; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HOKKENKOELEGA ACS, 1995, PEDIATR RES, V38, P267, DOI 10.1203/00006450-199508000-00022; Job JC, 1996, PEDIATR RES, V39, P354, DOI 10.1203/00006450-199602000-00027; KARLBERG J, 1995, PEDIATR RES, V38, P733, DOI 10.1203/00006450-199511000-00017; KRAMER MS, 1990, PEDIATRICS, V86, P707; KRAMER MS, 1987, PEDIATRICS, V80, P502; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; LESAGE C, 1991, J PEDIATR-US, V119, P29, DOI 10.1016/S0022-3476(05)81034-0; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; MILLER HC, 1971, PEDIATRICS, V48, P511; NILSEN ST, 1984, ACTA PAEDIATR SCAND, V73, P168, DOI 10.1111/j.1651-2227.1984.tb09923.x; PAPIERNIK E, 1985, PEDIATRICS, V76, P154; PAZ I, 1993, AM J DIS CHILD, V47, P337; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P592; PHILLIPS DIW, 1994, DIABETIC MED, V11, P286, DOI 10.1111/j.1464-5491.1994.tb00273.x; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; Sheu W, 1996, J CLIN ENDOCR METAB, V81, P1156; TANNER JM, 1970, ARCH DIS CHILD, V45, P755, DOI 10.1136/adc.45.244.755; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/BF00403383; WALKER J, 1989, J CLIN ENDOCR METAB, V69, P253, DOI 10.1210/jcem-69-2-253; WESTWOOD M, 1983, PEDIATRICS, V71, P376; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	51	289	295	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					341	347						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270455				2022-12-01	WOS:A1997XQ86400020
J	VargaWeisz, PD; Wilm, M; Bonte, E; Dumas, K; Mann, M; Becker, PB				VargaWeisz, PD; Wilm, M; Bonte, E; Dumas, K; Mann, M; Becker, PB			Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II	NATURE			English	Article							PROMOTER IN-VITRO; CELL-FREE SYSTEM; TRANSCRIPTION FACTOR; DROSOPHILA EMBRYOS; ATP; IDENTIFICATION; INVOLVEMENT; DISRUPTION; MICROSCOPY; BINDING	Repressive chromatin structures need to be unravelled to allow DNA-binding proteins access to their target sequences. This de-repression constitutes an important point at which transcription and presumably other nuclear processes can be regulated(1,2). Energy-consuming enzyme complexes that facilitate the interaction of transcription factors with chromatin by modifying nucleosome structure are involved in this regulation(3-5). One such factor, nucleosome-remodelling factor (NURF), has been isolated from Drosophila embryo extracts(4,6,7), We have now identified a chromatin-accessibility complex (CHRAC) which uses energy to increase the general accessibility of DNA in chromatin. However, unlike other known chromatin remodelling factors, CHRAC can also function during chromatin assembly: it uses ATP to convert irregular chromatin into a regular array of nucleosomes with even spacing. CHRAC combines enzymes that modulate nucleosome structure and DNA topology. Using mass spectrometry, we identified two of the five CHRAC subunits as the ATPase ISWI, which is also part of NURF6,8, and topoisomerase II, The presence of ISWI in different contexts suggests that chromatin remodelling machines have a modular nature and that ISWI has a central role in different chromatin remodelling reactions.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013	Mann, Matthias/0000-0003-1292-4799; Becker, Peter/0000-0001-7186-0372; Varga-Weisz, Patrick/0000-0001-7409-8686; Wilm, Matthias/0000-0002-5461-6834				ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BUCHENAU P, 1993, J CELL SCI, V104, P1175; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHEN GL, 1984, J BIOL CHEM, V259, P3560; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; POLJAK L, 1995, TRENDS CELL BIOL, V5, P348, DOI 10.1016/S0962-8924(00)89068-6; SANDALTZOPOULOS R, 1995, NUCLEIC ACIDS RES, V23, P2479, DOI 10.1093/nar/23.13.2479; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	29	424	429	2	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					598	602		10.1038/41587	http://dx.doi.org/10.1038/41587			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252192	Bronze			2022-12-01	WOS:A1997XP72200053
J	Jones, AL; Hayes, PC; Proudfoot, AT; Vale, JA; Prescott, LF				Jones, AL; Hayes, PC; Proudfoot, AT; Vale, JA; Prescott, LF			Controversies in management - Should methionine be added to every paracetamol tablet? No: The risks are not well enough known	BRITISH MEDICAL JOURNAL			English	Article							SERUM TOTAL HOMOCYSTEINE; ORAL METHIONINE; ACETAMINOPHEN OVERDOSE; NITROGEN; DISEASE; INJURY; MEN		ROYAL INFIRM EDINBURGH NHS,SCOTTISH LIVER TRANSPLANT UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; CITY HOSP NHS TRUST,W MIDLANDS POISON UNIT,NATL POISONS INFORMAT SERV,BIRMINGHAM CTR,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND; WESTERN GEN HOSP,PHARMACOL UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,RES CTR,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Jones, AL (corresponding author), ROYAL INFIRM EDINBURGH NHS,SCOTTISH POISONS INFORMAT BUR,EDINBURGH CTR,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.		Vale, Allister/AAA-9216-2019					ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOND GR, 1995, PHARMACOECONOMICS, V8, P177, DOI 10.2165/00019053-199508030-00001; BREILLOT F, 1986, ANTICANCER RES, V76, P629; CHO ES, 1979, J NUTR, V109, P1086, DOI 10.1093/jn/109.6.1086; COHEN SM, 1974, BIOL PSYCHIAT, V8, P209; CONNOR H, 1978, POSTGRAD MED J, V54, P318, DOI 10.1136/pgmj.54.631.318; CROME P, 1976, LANCET, V2, P829; GATTONUMPHRESS TL, 1993, HOSP PRACT, V28, P83, DOI 10.1080/21548331.1993.11442926; GUO HY, 1993, CANCER RES, V53, P5676; HAMLYN AN, 1981, J INT MED RES, V9, P226, DOI 10.1177/030006058100900314; HARKER LA, 1974, NEW ENGL J MED, V291, P537, DOI 10.1056/NEJM197409122911101; HAWTON K, 1992, BRIT MED J, V304, P1409, DOI 10.1136/bmj.304.6839.1409; LEMANN J, 1956, J CLIN INVEST, V38, P2215; LITOVITZ TL, 1995, AM J EMERG MED, V13, P551, DOI 10.1016/0735-6757(95)90171-X; MACLEAN AEM, 1975, BIOCHEM PHARMACOL, V24, P37; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; MCLEAN AEM, 1974, LANCET, V1, P729; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; PHEAR EA, 1956, CLIN SCI, V15, P93; PRESCOTT LF, 1976, LANCET, V2, P109; PRINTEN KJ, 1979, AM J CLIN NUTR, V32, P1200, DOI 10.1093/ajcn/32.6.1200; SKOGLUND LA, 1992, GEN PHARMACOL, V23, P155, DOI 10.1016/0306-3623(92)90002-2; SPOONER JB, 1993, PHARM J, V250, P706; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; TAI J, 1994, P NATL ACAD SCI USA, V91, P6369; UELAND PM, 1992, ATHEROSCLEROTIC CARD, P1832; VALE JA, 1981, ARCH INTERN MED, V141, P394, DOI 10.1001/archinte.141.3.394; VALE JA, 1954, HUM TOXICOL, V3, P135; ZEZULKA AY, 1976, J NUTR, V106, P1286, DOI 10.1093/jn/106.9.1286	31	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 2	1997	315	7103					301	303		10.1136/bmj.315.7103.301	http://dx.doi.org/10.1136/bmj.315.7103.301			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP750	9274554	Green Published			2022-12-01	WOS:A1997XP75000029
J	Plummer, MA; Phillips, FM; FabrykaMartin, J; Turin, HJ; Wigand, PE; Sharma, P				Plummer, MA; Phillips, FM; FabrykaMartin, J; Turin, HJ; Wigand, PE; Sharma, P			Chlorine-36 in fossil rat urine: An archive of cosmogenic nuclide deposition during the past 40,000 years	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; ENVIRONMENTAL TRACERS; ATMOSPHERIC C-14/C-12; YOUNGER DRYAS; ICE CORE; BE-10; ISOTOPES; C-14; CLIMATE; AGES	Knowledge of the production history of cosmogenic nuclides, which is needed for geological and archaeological dating, has been uncertain. Measurements of chlorine-36/chlorine (Cl-36/Cl) ratios in fossil packrat middens from Nevada that are radiocarbon-dated between about 38 thousand years ago (ka) and the present showed that Cl-36/Cl ratios were higher by a factor of about 2 before similar to 11 ka. This raises the possibility that cosmogenic production rates just before the close of the Pleistocene were up to 50% higher than is suggested by carbon-14 calibration data. The discrepancy could be explained by addition of low-carbon-14 carbon dioxide to the atmosphere during that period, which would have depressed atmospheric radiocarbon activity. Alternatively, climatic effects on Cl-36 deposition may have enhanced the Cl-36/Cl ratios.	LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545; DESERT RES INST,RENO,NV 89512; PURDUE UNIV,DEPT PHYS,W LAFAYETTE,IN 47907	United States Department of Energy (DOE); Los Alamos National Laboratory; Nevada System of Higher Education (NSHE); Desert Research Institute NSHE; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Plummer, MA (corresponding author), NEW MEXICO INST MIN & TECHNOL,DEPT EARTH & ENVIRONM SCI,SOCORRO,NM 87801, USA.			Turin, H J/0000-0003-3861-692X				BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; BARNOLA JM, 1991, TELLUS B, V43, P83, DOI 10.1034/j.1600-0889.1991.t01-1-00002.x; BAUMGARTNER S, 1995, SOLID STATE RES LARG; BEER J, 1988, NATURE, V331, P675, DOI 10.1038/331675a0; BENSON L, 1995, PALAEOGEOGR PALAEOCL, V117, P1, DOI 10.1016/0031-0182(94)00103-F; Bentley H.W., 1986, HDB ENV GEOCHEMISTRY, P422; BENTLEY HW, 1986, WATER RESOUR RES, V22, P1991, DOI 10.1029/WR022i013p01991; Betancourt J.L., 1990, PACKRAT MIDDENS LAST; Bierman P, 1995, QUATERNARY RES, V44, P378, DOI 10.1006/qres.1995.1082; BROWN ET, 1995, EARTH PLANET SC LETT, V129, P193, DOI 10.1016/0012-821X(94)00249-X; CERLING TE, 1994, ANNU REV EARTH PL SC, V22, P273, DOI 10.1146/annurev.ea.22.050194.001421; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; FABRYKAMARTIN JT, 1993, DISTRIBUTION CHOLINE; FINKEL RC, IN PRESS J GEOPHYS R; FORESTER RM, 1997, 3GCA102M US GEOL SUR; FRIEDLINGSTEIN P, 1995, J GEOPHYS RES-ATMOS, V100, P7203, DOI 10.1029/94JD02948; GOSLAR T, 1995, NATURE, V377, P414, DOI 10.1038/377414a0; Guyodo Y, 1996, EARTH PLANET SC LETT, V143, P23, DOI 10.1016/0012-821X(96)00121-5; HAJDAS I, 1995, RADIOCARBON, V37, P75, DOI 10.1017/S0033822200014818; HOERING TC, 1961, GEOCHIM COSMOCHIM AC, V23, P186, DOI 10.1016/0016-7037(61)90043-6; HOUTERMA.J, 1966, Z PHYS, V193, P1, DOI 10.1007/BF01326455; HOUTERMANS JC, 1973, J GEOPHYS RES, V78, P1897, DOI 10.1029/JC078i012p01897; Huggle D, 1996, PLANET SPACE SCI, V44, P147, DOI 10.1016/0032-0633(95)00085-2; KAUFMANN R, 1984, NATURE, V309, P338, DOI 10.1038/309338a0; KUTZBACH JE, 1985, QUATERNARY SCI REV, V4, P147, DOI 10.1016/0277-3791(85)90024-1; KVENVOLDEN KA, 1993, REV GEOPHYS, V31, P173, DOI 10.1029/93RG00268; Laj C, 1996, GEOPHYS RES LETT, V23, P2045, DOI 10.1029/96GL02152; LAL D, 1987, GEOPHYS RES LETT, V14, P785, DOI 10.1029/GL014i008p00785; LAL D, 1988, SOLAR TERRESTRIAL RE, P216; LAL D, 1985, CARBON CYCLE ATMOSPH, P221; LAO Y, 1992, NATURE, V357, P576, DOI 10.1038/357576a0; LEHMANN BE, 1993, WATER RESOUR RES, V29, P2027, DOI 10.1029/93WR00543; Libby WF., 1952, RADIOCARBON DATING; MAZAUD A, 1991, GEOPHYS RES LETT, V18, P1885, DOI 10.1029/91GL02285; MCHARGUE LR, 1995, GEOPHYS RES LETT, V22, P659, DOI 10.1029/95GL00169; MIFFLIN MD, 1979, B NEVADA BUREAU MINE, V94; MORRIS JD, 1990, NATURE, V344, P31, DOI 10.1038/344031a0; NEWELL RE, 1971, SCI AM, V224, P32, DOI 10.1038/scientificamerican0171-32; OBRIEN K, 1979, J GEOPHYS RES-SPACE, V84, P423, DOI 10.1029/JA084iA02p00423; PAPKE KG, 1976, B NEVADA BUREAU MINE, V87; PHILLIPS FM, 1994, SOIL SCI SOC AM J, V58, P15, DOI 10.2136/sssaj1994.03615995005800010003x; PHILLIPS FM, 1995, REV GEOPHYS, V33, P1029, DOI 10.1029/95RG00247; PLUMMER MA, 1996, THESIS NEW MEXICO I; REHEIS MC, 1995, J GEOPHYS RES-ATMOS, V100, P8893, DOI 10.1029/94JD03245; Richards J. H., 1986, MINERAL EXPLORATION, P82; Robinson C, 1995, EARTH PLANET SC LETT, V136, P551, DOI 10.1016/0012-821X(95)00202-N; SARNTHEIN M, 1996, EOS S, V77, pF14; Schmidt-Nielsen K., 1964, DESERT ANIMALS PHYSL; STUIVER M, 1991, QUATERNARY RES, V35, P1, DOI 10.1016/0033-5894(91)90091-I; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; THOUVENY N, 1993, GLOBAL PLANET CHANGE, V7, P157, DOI 10.1016/0921-8181(93)90047-R; TYLER SW, 1994, SOIL SCI SOC AM J, V58, P25, DOI 10.2136/sssaj1994.03615995005800010004x; WELLS PV, 1976, QUATERNARY RES, V6, P223, DOI 10.1016/0033-5894(76)90052-1; Wood WW, 1995, WATER RESOUR RES, V31, P3121, DOI 10.1029/95WR02572; [No title captured]	55	49	51	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					538	541		10.1126/science.277.5325.538	http://dx.doi.org/10.1126/science.277.5325.538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9227999				2022-12-01	WOS:A1997XM86700044
J	Kim, TW; Pettingell, WH; Jung, YK; Kovacs, DM; Tanzi, RE				Kim, TW; Pettingell, WH; Jung, YK; Kovacs, DM; Tanzi, RE			Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease	SCIENCE			English	Article							DISEASE; NEURODEGENERATION; DEATH	Most cases of early-onset familiar Alzheimer's disease (FAD) are caused by mutations in the genes encoding the presenilin 1 (PS1) and PS2 proteins, both of which undergo regulated endoproteolytic processing. During apoptosis, PS1 and PS2 were shown to be cleaved at sites distal to their normal cleavage sites by a caspase-3 family protease. In cells expressing PS2 containing the asparagine-141 FAD mutant, the ratio of alternative to normal PS2 cleavage fragments was increased relative to wild-type PS2-expressing cells, suggesting a potential role for apoptosis-associated cleavage of presenilins in the pathogenesis of Alzheimer's disease.	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT NEUROL,GENET & AGING UNIT,CHARLESTOWN,MA 02129; KWANGJU INST SCI & TECHNOL,DEPT LIFE SCI,KWANGJU,SOUTH KOREA	Harvard University; Massachusetts General Hospital; Gwangju Institute of Science & Technology (GIST)			Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454; Jung, Yong-Keun/0000-0002-9686-3120				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUSH AI, 1992, ANN NEUROL, V32, P57, DOI 10.1002/ana.410320110; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; Guo Q, 1996, NEUROREPORT, V8, P379, DOI 10.1097/00001756-199612200-00074; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JOHNSON EM, 1994, NEUROBIOL AGING, V15, P5187; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim T. J., UNPUB; Kim TW, 1997, J BIOL CHEM, V272, P11006; KOVACS DG, UNPUB; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEBLANC A, 1996, MOL MECH DEMENTIA, P57; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NEAMATI N, 1994, J IMMUNOL, V154, P1693; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Paradis E, 1996, J NEUROSCI, V16, P7533; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; TANZI RE, 1997, TRENDS NEUROSCI, V20, P154; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; XIE W, 1997, J BIOL CHEM, V272, P7977	40	325	337	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					373	376		10.1126/science.277.5324.373	http://dx.doi.org/10.1126/science.277.5324.373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219695				2022-12-01	WOS:A1997XL35800047
J	Rowan, R; Knowlton, N; Baker, A; Jara, J				Rowan, R; Knowlton, N; Baker, A; Jara, J			Landscape ecology of algal symbionts creates variation in episodes of coral bleaching	NATURE			English	Article							ULTRAVIOLET-RADIATION; REEF CORALS; TEMPERATURE; ZOOXANTHELLAE	Reef-building corals are obligate, mutualistic symbioses of heterotrophic animals and phototrophic dinoflagellates (Symbiodinium spp.)(1). Contrary to the earlier, widely accepted belief that corals harbour only one symbiont, we found that the ecologically dominant Caribbean corals Montastraea annularis and M. faveolata can act as hosts to dynamic, multi-species communities of Symbiodinium. Composition of these communities follows gradients of environmental irradiance, implying that physiological acclimatization(2-4) is not the only mechanism by which corals cope with environmental heterogeneity. The importance of this diversity was underlined by analysis of a natural episode of coral bleaching. Patterns of bleaching could be explained by the preferential elimination of a symbiont associated with low irradiance from the brightest parts of its distribution. Comparative analyses of symbionts before and after bleaching from the same corals supported this interpretation, and suggested that some corals were protected from bleaching by hosting an additional symbiont that is more tolerant of high irradiance and temperature. This 'natural experiment' suggests that temporal and spatial variability can favour the coexistence of diverse symbionts within a host, despite the potential for destabilizing competition among them(5,6).	SMITHSONIAN TROP RES INST,BALBOA,PANAMA; UNIV MIAMI,ROSENSTIEL SCH MARINE & ATMOSPHER SCI,MIAMI,FL 33149	Smithsonian Institution; Smithsonian Tropical Research Institute; University of Miami	Rowan, R (corresponding author), UNIV GUAM,MARINE LAB,MANGILAO,GU 96923, USA.			Baker, Andrew/0000-0002-7866-2587				BROWN BE, IN PRESS CORAL REEFS; BUDDEMEIER RW, 1993, BIOSCIENCE, V43, P320, DOI 10.2307/1312064; DCROZ L, 1997, P 8 INT COR REEF S, V2, P203; DUNBAR RB, 1993, 10 CLIM GLOB CHANG P; EDMUNDS PJ, 1994, MAR BIOL, V121, P127; Falkowski P.G., 1990, P89; Fitt WK, 1995, BIOL BULL, V189, P298, DOI 10.2307/1542147; GATES RD, 1990, CORAL REEFS, V8, P193, DOI 10.1007/BF00265010; GLEASON DF, 1993, NATURE, V365, P836, DOI 10.1038/365836a0; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; GOREAU TF, 1959, ECOLOGY, V40, P67, DOI 10.2307/1929924; IGLESIASPRIETO R, 1994, MAR ECOL PROG SER, V113, P163, DOI 10.3354/meps113163; JEFFREY SW, 1968, BIOL BULL, V135, P149, DOI 10.2307/1539622; JOKIEL PL, 1990, CORAL REEFS, V8, P155, DOI 10.1007/BF00265006; LASKER HR, 1984, CORAL REEFS, V3, P183, DOI 10.1007/BF00288253; Leigh Egbert Giles Jr, 1995, Ecologie, V26, P131; LESSER MP, 1990, CORAL REEFS, V8, P225, DOI 10.1007/BF00265015; LESSIOS HA, 1997, P 8 INT COR REEF S, V1, P673; Maynard Smith J., 1995, MAJOR TRANSITIONS EV; PORTER JW, 1989, P NATL ACAD SCI USA, V86, P9342, DOI 10.1073/pnas.86.23.9342; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; ROWAN R, 1991, MAR ECOL PROG SER, V71, P65, DOI 10.3354/meps071065; ROWAN R, 1991, SCIENCE, V251, P1348, DOI 10.1126/science.251.4999.1348; ROWAN R, 1995, P NATL ACAD SCI USA, V92, P2850, DOI 10.1073/pnas.92.7.2850; SANDEMAN IM, 1988, MASS BLEACHING CORAL, P46; TRENCH RK, 1993, ENDOCYTOBIOSIS CELL, V9, P135; Ware JR, 1996, ECOL MODEL, V84, P199, DOI 10.1016/0304-3800(94)00132-4; WEIL E, 1994, B MAR SCI, V55, P151; Williams EH, 1990, ATOLL RES B, P330, DOI DOI 10.5479/SI.00775630.335.1; [No title captured]	30	580	599	2	258	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					265	269		10.1038/40843	http://dx.doi.org/10.1038/40843			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230434	Bronze			2022-12-01	WOS:A1997XL12100048
J	Epstein, Y				Epstein, Y			Predominance of type II fibres in exertional heat stroke	LANCET			English	Editorial Material							ENERGY				Epstein, Y (corresponding author), CHAIM SHEBA MED CTR,HELLER INST MED RES,IL-52621 TEL HASHOMER,ISRAEL.							ARMSTRONG RB, 1986, SPORTS MED, V3, P370, DOI 10.2165/00007256-198603050-00006; BALLBURNETT M, 1991, J PHYSIOL-LONDON, V437, P257, DOI 10.1113/jphysiol.1991.sp018594; EPSTEIN Y, 1983, J APPL PHYSIOL, V54, P831, DOI 10.1152/jappl.1983.54.3.831; Frank A, 1996, ENV ERGONOMICS RECEN, P194; Hsu YD, 1997, J NEUROL NEUROSUR PS, V62, P182, DOI 10.1136/jnnp.62.2.182; HUBBARD RW, 1990, MED SCI SPORT EXER, V22, P19; Siejo B K, 1985, BRIT J ANAESTH, V57, P47	7	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					83	84		10.1016/S0140-6736(05)61811-9	http://dx.doi.org/10.1016/S0140-6736(05)61811-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228957				2022-12-01	WOS:A1997XK11400005
J	Ito, T; Bulger, M; Pazin, MJ; Kobayashi, R; Kadonaga, JT				Ito, T; Bulger, M; Pazin, MJ; Kobayashi, R; Kadonaga, JT			ACF, an ISWI-containing and ATP-utilizing chromatin assembly and remodeling factor	CELL			English	Article							DNA-REPLICATION INVITRO; POLYMERASE-II TRANSCRIPTION; CELL-FREE SYSTEM; NUCLEOSOME; HISTONES; PURIFICATION; ACTIVATOR; BINDING; PROTEIN; GAL4-VP16	We describe the purification and characterization of ACF, an ATP-utilizing chromatin assembly and remodeling factor. ACF is a multisubunit factor that contains ISWI protein and is distinct from NURF, another ISWI-containing factor. In chromatin assembly, purified ACF and a core histone chaperone (such as NAP-1 or CAF-1) are sufficient for the ATP-dependent formation of periodic nucleosome arrays. In chromatin remodeling, ACF is able to modulate the internucleosomal spacing of chromatin by an ATP-dependent mechanism. Moreover, ACF can mediate promoter-specific nucleosome reconfiguration by Gal4-VP16 in an ATP-dependent manner. These results suggest that ACF acts catalytically both in chromatin assembly and in the remodeling of nucleosomes that occurs during transcriptional activation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of California System; University of California San Diego; Cold Spring Harbor Laboratory				Pazin, Michael/0000-0002-7561-3640	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BLANK TA, 1995, J MOL BIOL, V252, P305, DOI 10.1006/jmbi.1995.0498; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GERMOND JE, 1976, NUCLEIC ACIDS RES, V3, P3173, DOI 10.1093/nar/3.11.3173; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRUNSTEIN M, 1997, IN PRESS NATURE; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; JEONG SW, 1991, J MOL BIOL, V222, P1131, DOI 10.1016/0022-2836(91)90597-Y; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOGO JM, 1995, CHROMATIN STRUCTURE, P49; STEIN A, 1985, BIOCHEMISTRY-US, V24, P1783, DOI 10.1021/bi00328a032; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TREMETHICK DJ, 1992, J BIOL CHEM, V267, P15041; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; van Holde K.E., 1989, CHROMATIN; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; Wolffe A., 1995, CHROMATIN STRUCTURE; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735	51	513	523	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					145	155		10.1016/S0092-8674(00)80321-9	http://dx.doi.org/10.1016/S0092-8674(00)80321-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230310	Bronze			2022-12-01	WOS:A1997XL36200016
J	Bebb, G; Glickman, B; Gelmon, K; Gatti, R				Bebb, G; Glickman, B; Gelmon, K; Gatti, R			''AT risk'' for breast cancer	LANCET			English	Editorial Material							ATAXIA-TELANGIECTASIA		UNIV VICTORIA,CTR ENVIRONM HLTH,VICTORIA,BC,CANADA; UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90024	University of Victoria; University of California System; University of California Los Angeles	Bebb, G (corresponding author), BRITISH COLUMBIA CANC AGCY,DEPT ADV THERAPEUT,VANCOUVER,BC V5Z 4E6,CANADA.							Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bhatia S, 1996, NEW ENGL J MED, V334, P745, DOI 10.1056/NEJM199603213341201; EASTON DF, 1995, BRIT J CANCER, V72, P805; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; KASTAN MB, 1992, CELL, V74, P353; KIRSCH IR, 1994, INT J RADIAT BIOL, V66, pS97, DOI 10.1080/09553009414551921; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Telatar M, 1996, AM J HUM GENET, V59, P40; TOMLINSON IPM, 1995, J CLIN PATHOL, V48, P424, DOI 10.1136/jcp.48.5.424	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1784	1785		10.1016/S0140-6736(05)61687-X	http://dx.doi.org/10.1016/S0140-6736(05)61687-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269208				2022-12-01	WOS:A1997XF73500004
J	Hudson, LD; Martin, TR				Hudson, LD; Martin, TR			Predicting ARDS: Problems and prospects	LANCET			English	Editorial Material							RESPIRATORY-DISTRESS SYNDROME		UNIV WASHINGTON,SCH MED,SEATTLE,WA 98104	University of Washington; University of Washington Seattle	Hudson, LD (corresponding author), SEATTLE VA MED CTR,HARBORVIEW MED CTR,SECT PULM CRIT CARE MED,SEATTLE,WA 98104, USA.							Connelly KG, 1997, AM J RESP CRIT CARE, V155, P21, DOI 10.1164/ajrccm.155.1.9001283; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593; HAMMERSCHMIDT DE, 1980, LANCET, V1, P947; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; MOSS M, 1995, AM J RESP CRIT CARE, V151, P15, DOI 10.1164/ajrccm.151.1.7812545; PITTET JF, IN PRESS AM J RESP C; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1783	1783		10.1016/S0140-6736(05)61686-8	http://dx.doi.org/10.1016/S0140-6736(05)61686-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269207				2022-12-01	WOS:A1997XF73500003
J	Singleton, L; Turner, M; Haskal, R; Etkind, S; Tricarico, M; Nardell, E				Singleton, L; Turner, M; Haskal, R; Etkind, S; Tricarico, M; Nardell, E			Long-term hospitalization for tuberculosis control - Experience with a medical-psychosocial inpatient unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT; HEALTH; BABY	Context.-Patients with tuberculosis (TB) who are nonadherent to therapy or have complicated medical or social problems pose a threat to public health. In some cases, hospitalization may be a necessary component of a comprehensive TB control program. Objective.-To describe experience with a new inpatient program for TB control. Design.-Retrospective review. Setting.-Eighteen-bed, secure, TB treatment unit in a state public health hospital providing a spectrum of acute and chronic care services. Patients.-Patients with known or suspected TB who were unable to be treated as outpatients and were hospitalized from 1990 through 1995. Interventions.-voluntary or involuntary hospitalization, with medical, psychosocial, and legal services. Main Outcome Measures.-Admissions, treatment completion, and disposition. Results.-A total of 166 patients with a confirmed diagnosis of TB accounted for 214 hospitalizations for TB. The mean age was 42 years, 132 (79.5%) were men, 84 (50.6%) were nonwhite, and 45 (27.1%) were foreign born. At the time of admission, 58 patients (34.5%) were homeless, 116 (69.9%) had a history of abuse of alcohol or other drugs, and 46 (31.7%) were positive for human immunodeficiency virus. The mean length of stay was 119.7 days (median, 70 days; range, 7-656 days), and was higher among homeless patients than nonhomeless patients (168.8 vs 93.4 days). Of 48 patients (28.9%) who were admitted involuntarily, 21 required long-term confinement under court order. Admission indications (not mutually exclusive) changed over 5 years: nonadherence decreased (95% to 34%), medical complexity increased (14% to 77%), short-term isolation increased (19% to 39%), and involuntary admission decreased (54% to 13%). Of 157 patients with positive cultures for Mycobacterium tuberculosis, 36 (23.1%) were resistant to at least 1 drug, including 16 who were multidrug resistant. A total of 123 patients (74.7%) were discharged to an outpatient setting to complete therapy, 40 (24.1%) required inpatient care to complete therapy, and 3 died (1 from TB) before discharge. Conclusions.-A high proportion of patients with TB who failed outpatient therapy completed treatment in a combined medical and psychosocial inpatient unit. During the 5-year study period, involuntary admissions decreased and most patients completed therapy as outpatients. In Massachusetts, this program plays an important role in protecting public health and in providing specialized medical management for patients to complete therapy in a safe and supportive environment.	MASSACHUSETTS DEPT PUBL HLTH,LEMUEL SHATTUCK HOSP,BOSTON,MA 02130	Massachusetts Department of Public Health	Singleton, L (corresponding author), MASSACHUSETTS DEPT PUBL HLTH,DEPT PUBL HLTH,DIV TB PREVENT & CONTROL,305 S ST,BOSTON,MA 02130, USA.							ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; *AM LUNG ASS S CAR, 1989, US INC EN TUB CONTR; ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; Burman WJ, 1997, CHEST, V111, P1168, DOI 10.1378/chest.111.5.1168; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; EARNEST M, 1996, TUBERCULOSIS, P927; Etkind S, 1991, Semin Respir Infect, V6, P273; ETKIND SC, 1996, TUBERCULOSIS, P945; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; GUNDERSON JG, 1978, PSYCHIATRY, V41, P327, DOI 10.1080/00332747.1978.11023992; HARSCH HH, 1989, PSYCHOSOMATICS, V30, P313; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; POZIK CJ, 1993, MED CLIN N AM, V77, P1289; RUBEL AJ, 1992, PUBLIC HEALTH REP, V107, P626; SBARBARO JA, 1986, CHEST, V90, P754, DOI 10.1378/chest.90.5.754; STOUDEMIRE A, 1986, PSYCHOSOMATICS, V27, P341, DOI 10.1016/S0033-3182(86)72685-6; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; TURNER M, 1995, AM J RESP CRIT CAR 2, V151, pA554; TURNER M, 1994, AM J RESP CRIT CAR 2, V149, pA257; *US DEP HHS, 1994, IMPR PAT ADH TUB TRE; YEAGER H, 1986, CHEST, V90, P752, DOI 10.1378/chest.90.5.752	22	40	46	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					838	842		10.1001/jama.278.10.838	http://dx.doi.org/10.1001/jama.278.10.838			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XU552	9293992				2022-12-01	WOS:A1997XU55200039
J	Ortmann, B; Copeman, J; Lehner, PJ; Sadasivan, B; Herberg, JA; Grandea, AG; Riddell, SR; Tampe, R; Spies, T; Trowsdale, J; Cresswell, P				Ortmann, B; Copeman, J; Lehner, PJ; Sadasivan, B; Herberg, JA; Grandea, AG; Riddell, SR; Tampe, R; Spies, T; Trowsdale, J; Cresswell, P			A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes	SCIENCE			English	Article							HLA CLASS-I; PEPTIDE-BINDING; ANTIGEN PRESENTATION; CELL LINE; MOLECULES; TRANSPORTERS; EXPRESSION; RETENTION; PATHWAY; CHARGE	Newly assembled major histocompatibility complex (MHC) class I molecules, together with the endoplasmic reticulum chaperone calreticulin, interact with the transporter associated with antigen processing (TAP) through a molecule called tapasin, The molecular cloning of tapasin revealed it to be a transmembrane glycoprotein encoded by an MHC-linked gene. It is a member of the immunoglobulin superfamily with a probable cytoplasmic endoplasmic reticulum retention signal. Up to four MHC class I-tapasin complexes were found to bind to each TAP molecule. Expression of tapasin in a negative mutant human cell line (220) restored class I-TAP association and normal class I cell surface expression. Tapasin expression also corrected the defective recognition of virus-infected 220 cells by class I-restricted cytotoxic T cells, establishing a critical functional role for tapasin in MHC class I-restricted antigen processing.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; IMPERIAL CANC RES FUND, HUMAN IMMUNOGENET LAB, LONDON WC2A 3PX, ENGLAND; FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Howard Hughes Medical Institute; Yale University; Cancer Research UK; Fred Hutchinson Cancer Center; Max Planck Society			Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160; Lehner, Paul Joseph/0000-0001-9383-1054; Herberg, Jethro/0000-0001-6941-6491	NIAID NIH HHS [AI30581] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030581, R01AI030581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BUSCH R, 1996, EMBO J, V15, P412; COLLINS JF, 1990, METHOD ENZYMOL, V183, P474; COLLINS JF, 1987, NUCLEIC ACID PROTEIN, P323; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; Denzin LK, 1996, J EXP MED, V184, P2153, DOI 10.1084/jem.184.6.2153; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; GRANDEA AG, IN PRESS IMMUNOGENET; GREEN NM, 1991, NATURE, V351, P349, DOI 10.1038/351349a0; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JONES T, 1997, GENOMICS, V40, P189; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; LUTZ PM, 1987, IMMUNOGENETICS, V25, P228, DOI 10.1007/BF00404692; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Neisig A, 1996, J IMMUNOL, V156, P3196; Nelson K, 1989, IMMUNOBIOLOGY HLA, P292; Noessner Elfriede, 1995, Journal of Experimental Medicine, V181, P327; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; ORTMANN B, UNPUB; Riddell SR, 1996, NAT MED, V2, P216, DOI 10.1038/nm0296-216; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SENGER G, 1993, CYTOGENET CELL GENET, V64, P49, DOI 10.1159/000133559; Solheim JC, 1997, J IMMUNOL, V158, P2236; Suh WK, 1996, J EXP MED, V184, P337, DOI 10.1084/jem.184.2.337; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLISON K, 1987, EMBO J, V6, P1967, DOI 10.1002/j.1460-2075.1987.tb02459.x	38	427	434	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	1997	277	5330					1306	1309		10.1126/science.277.5330.1306	http://dx.doi.org/10.1126/science.277.5330.1306			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271576				2022-12-01	WOS:A1997XT82700055
J	Goodrich, LV; Milenkovic, L; Higgins, KM; Scott, MP				Goodrich, LV; Milenkovic, L; Higgins, KM; Scott, MP			Altered neural cell fates and medulloblastoma in mouse patched mutants	SCIENCE			English	Article							SONIC-HEDGEHOG; FLOOR PLATE; INDUCTION; GENE; EXPRESSION; ECTODERM; MICE; CNS	The PATCHED (PTC) gene encodes a Sonic hedgehog (Shh) receptor and a tumor suppressor protein that is defective in basal cell nevus syndrome (BCNS). Functions of PTC were investigated by inactivating the mouse gene. Mice homozygous for the ptc mutation died during embryogenesis and were found to have open and overgrown neural tubes. Two Shh target genes, ptc itself and Gli, were derepressed in the ectoderm and mesoderm but not in the endoderm. Shh targets that are, under normal conditions, transcribed ventrally were aberrantly expressed in dorsal and lateral neural tube cells. Thus Ptc appears to be essential for repression of genes that are locally activated by Shh. Mice heterozygous for the ptc mutation were larger than normal, and a subset of them developed hindlimb defects or cerebellar medulloblastomas, abnormalities also seen in BCNS patients.	STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University								AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BONNEROT C, 1993, GUIDE TECHNIQUES MOU, P463; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Concordet JP, 1996, DEVELOPMENT, V122, P2835; DICKINSON ME, 1995, DEVELOPMENT, V121, P2099; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GREEN MARGARET C., 1952, OHIO JOUR SCI, V52, P31; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hepker J, 1997, DEVELOPMENT, V124, P549; HOGAN B, 1994, MANIPULATING MOUSE E, P196; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JOYNER AL, 1993, GENE TARGETING PRACT, P33; KADIN ME, 1970, J NEUROPATH EXP NEUR, V29, P583, DOI 10.1097/00005072-197010000-00005; LACOMBE D, 1990, Genetic Counseling, V1, P273; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marigo V, 1996, DEVELOPMENT, V122, P1225; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Provias JP, 1996, J NEURO-ONCOL, V29, P35, DOI 10.1007/BF00165516; Raffel C, 1997, CANCER RES, V57, P842; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RORKE LB, 1994, AM J PATHOL, V144, P444; Shimamura K, 1995, DEVELOPMENT, V121, P3923; Stevenson L, 1934, ARCH NEURO PSYCHIATR, V31, P93, DOI 10.1001/archneurpsyc.1934.02250010105005; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; Xie JW, 1997, CANCER RES, V57, P2369	45	1357	1404	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	1997	277	5329					1109	1113		10.1126/science.277.5329.1109	http://dx.doi.org/10.1126/science.277.5329.1109			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262482				2022-12-01	WOS:A1997XT03300039
J	Meyerson, M; Counter, CM; Eaton, EN; Ellisen, LW; Steiner, P; Caddle, SD; Ziaugra, L; Beijersbergen, RL; Davidoff, MJ; Liu, QY; Bacchetti, S; Haber, DA; Weinberg, RA				Meyerson, M; Counter, CM; Eaton, EN; Ellisen, LW; Steiner, P; Caddle, SD; Ziaugra, L; Beijersbergen, RL; Davidoff, MJ; Liu, QY; Bacchetti, S; Haber, DA; Weinberg, RA			hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization	CELL			English	Article							TETRAHYMENA-TELOMERASE; EPITHELIAL-CELLS; HUMAN GENOME; HUMAN FIBROBLASTS; RNA COMPONENT; MAP; IDENTIFICATION; LYMPHOCYTES; SENESCENCE; CARCINOMA	Telomerase, the ribonucleoprotein enzyme that elongates telomeres, is repressed in normal human somatic cells but is reactivated during tumor progression. We report the cloning of a human gene, hEST2, that shares significant sequence similarity with the telomerase catalytic subunit genes of lower eukaryotes. hEST2 is expressed at high levels in primary tumors, cancer cell lines, and telomerase-positive tissues but is undetectable in telomerase-negative cell lines and differentiated telomerase-negative tissues. Moreover, the message is up-regulated concomitant with the activation of telomerase during the immortalization of cultured cells and down-regulated during in vitro cellular differentiation. Taken together, these observations suggest that the induction of hEST2 mRNA expression is required for the telomerase activation that occurs during cellular immortalization and tumor progression.	MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CTR CANC,CHARLESTOWN,MA 02129; MERCK RES LABS,DEPT HUMAN GENET,W POINT,PA 19486; MCMASTER UNIV,DEPT PATHOL,CANC RES GRP,HAMILTON,ON L8N 3Z5,CANADA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Merck & Company; McMaster University	Meyerson, M (corresponding author), MIT,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142, USA.		Ellisen, Leif W/AAA-6572-2022; Meyerson, Matthew L/E-7123-2012	Ellisen, Leif W/0000-0003-0444-7910; Beijersbergen, Roderick/0000-0003-0116-4130; Counter, Christopher M/0000-0003-0748-3079	NCI NIH HHS [CA 39826, CA 58596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA058596, R35CA039826, R01CA058596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avilion AA, 1996, CANCER RES, V56, P645; Balsara BR, 1997, CANCER RES, V57, P2116; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; CHUMAKOV IM, 1995, NATURE, V377, P175; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Gollahon LS, 1996, ONCOGENE, V12, P715; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GREIDER CW, 1995, TELOMERES, P35; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Petersen I, 1997, CANCER RES, V57, P2331; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; SACK GH, 1981, IN VITRO CELL DEV B, V17, P1; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Wright WE, 1996, DEV GENET, V18, P173; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Xu D, 1996, LEUKEMIA, V10, P1354; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	65	1590	1802	2	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					785	795		10.1016/S0092-8674(00)80538-3	http://dx.doi.org/10.1016/S0092-8674(00)80538-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288757	Bronze			2022-12-01	WOS:A1997XT06600021
J	Stella, N; Schweitzer, P; Piomelli, D				Stella, N; Schweitzer, P; Piomelli, D			A second endogenous cannabinoid that modulates long-term potentiation	NATURE			English	Article							ARACHIDONIC-ACID; BRAIN; ANANDAMIDE; RECEPTOR; NEURONS; IDENTIFICATION; INHIBITION; SLICES; BINDS	Cannabinoid receptors are molecular targets for marijuana and hashish, the widespread drugs of abuse. These receptors are expressed in areas of the central nervous system that contribute in important ways to the control of memory, cognition, movement and pain perception(1). Indeed, such functions can be strongly influenced by cannabinoid drugs, with consequences that include euphoria, analgesia, sedation and memory impairment(2). Although the pharmacology of cannabinoid drugs is now beginning to be understood, we still lack essential information on the endogenous signalling system(s) by which cannabinoid receptors are normally engaged. An endogenous ligand for cannabinoid receptors, anandamide, has been described(3). Here we report that sn-2 arachidonylglycerol (2-AG), a cannabinoid ligand isolated from intestinal tissue(4), is present in brain in amounts 170 times greater than anandamide. 2-AG is produced in hippocampal slices by stimulation of the Schaffer collaterals, an excitatory fibre tract that projects from CA3 to CA1 neurons. Formation of 2-AG is calcium dependent and is mediated by the enzymes phospholipase C and diacylglycerol lipase. 2-AG activates neuronal cannabinoid receptors as a full agonist, and prevents the induction of long-term potentiation at CA3-CA1 synapses. Our results indicate that 2-AG is a second endogenous cannabinoid ligand in the central nervous system.	INST NEUROSCI, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BELTRAMO M, IN PRESS SCIENCE; BRINDLEY DN, 1985, BIOCH LIPIDS MEMBRAN, P213; Cadas H, 1996, J NEUROSCI, V16, P3934; Cadas H, 1997, J NEUROSCI, V17, P1226; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; EVANS DM, 1994, J PHARMACOL EXP THER, V268, P1271; FAROOQUI AA, 1986, INT J BIOCHEM, V18, P991, DOI 10.1016/0020-711X(86)90244-2; Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014-5793(96)00891-5; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HEYSER CJ, 1993, J PHARMACOL EXP THER, V264, P294; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; Jung M, 1997, J NEUROCHEM, V68, P402; Mallet PE, 1996, BEHAV PHARMACOL, V7, P276; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; NOWICKY AV, 1987, BRAIN RES BULL, V19, P663, DOI 10.1016/0361-9230(87)90052-9; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; Schmid HHO, 1996, CHEM PHYS LIPIDS, V80, P133, DOI 10.1016/0009-3084(96)02554-6; Schmid PC, 1996, FEBS LETT, V385, P125; SCHWEITZER P, 1993, J NEUROSCI, V13, P2033; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; STELLA N, 1995, J NEUROSCI, V15, P3307; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; TERRANOVA JP, 1995, N-S ARCH PHARMACOL, V352, P576, DOI 10.1007/BF00169393; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823; WEISS S, 1986, P NATL ACAD SCI USA, V83, P2238, DOI 10.1073/pnas.83.7.2238	30	1157	1187	0	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					773	778		10.1038/42015	http://dx.doi.org/10.1038/42015			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285589	Bronze, Green Submitted			2022-12-01	WOS:A1997XR66700051
J	Weinstein, LB; Jones, BCNM; Cosstick, R; Cech, TR				Weinstein, LB; Jones, BCNM; Cosstick, R; Cech, TR			A second catalytic metal ion in a group I ribozyme	NATURE			English	Article							TETRAHYMENA RIBOZYME; ENDORIBONUCLEASE ACTIVITY; GUANOSINE BINDING; RNA; SUBSTRATE; SITE; MECHANISM; COMPLEXES; CLEAVAGE; STEP	Although only a subset of protein enzymes depend on the presence of a metal ion for their catalytic function, all naturally occurring RNA enzymes require metal ions to stabilize their structure and for catalytic competence(1). In the self-splicing group I intron from Tetrahymena thermophila(2), several divalent metals can serve structural roles, but only Mg2+ and Mn2+ promote splice-site cleavage and exon ligation(3,4). A study of a ribozyme reaction analogous to 5'-splice-site cleavage by guanosine uncovered the first metal ion with a definitive role in catalysis. Substitution of the 3'-oxygen of the leaving group with sulphur resulted in a metal-specificity switch, indicating an interaction between the leaving group and the metal ion(5). Here we use 3'-(thioinosylyl)-(3' --> 5')-uridine(6), IspU, as a substrate in a reaction that emulates exon ligation. Activity requires the addition of a thiophilic metal ion (Cd2+ or Mn2+), providing evidence for stabilization of the leaving group by a metal ion in that step of splicing. Based on the principle of microscopic reversibility, this metal ion activates the nucleophilic 3'-hydroxyl of guanosine in the first step of splicing, supporting the model of a two-metal-ion active site(7).	UNIV COLORADO,DEPT CHEM & BIOCHEM,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV LIVERPOOL,DEPT CHEM,ROBERT ROBINSON LABS,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Liverpool								BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P648, DOI 10.1021/bi951962z; BHAT V, 1992, SYNTHETIC COMMUN, V22, P1481, DOI 10.1080/00397919208021616; Cech T.R., 1993, RA WELCH FDN C CHEM, VXXXVII, P91; CECH TR, 1996, NUCL ACIDS MOL BIOL, P1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1994, BIOCHEMISTRY-US, V33, P5291, DOI 10.1021/bi00183a036; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; Kuimelis RG, 1995, NUCLEIC ACIDS RES, V23, P4753, DOI 10.1093/nar/23.23.4753; MCCONNELL TS, 1995, BIOCHEMISTRY-US, V34, P4056, DOI 10.1021/bi00012a024; McConnell TS, 1997, BIOCHEMISTRY-US, V36, P8293, DOI 10.1021/bi9700678; MCCONNELL TS, 1994, THESIS U COLORADO; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; Pyle AM, 1996, MET IONS BIOL SYST, V32, P479; Sjogren AS, 1997, NUCLEIC ACIDS RES, V25, P648, DOI 10.1093/nar/25.3.648; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Thomson JB, 1996, J ORG CHEM, V61, P6273, DOI 10.1021/jo960795l; Weinstein LB, 1996, J AM CHEM SOC, V118, P10341, DOI 10.1021/ja9616903; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	26	153	157	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					805	808		10.1038/42076	http://dx.doi.org/10.1038/42076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285596	Bronze			2022-12-01	WOS:A1997XR66700058
J	Lo, YMD; Corbetta, N; Chamberlain, PF; Rai, V; Sargent, IL; Redman, CWG; Wainscoat, JS				Lo, YMD; Corbetta, N; Chamberlain, PF; Rai, V; Sargent, IL; Redman, CWG; Wainscoat, JS			Presence of fetal DNA in maternal plasma and serum	LANCET			English	Article							PRENATAL-DIAGNOSIS; PERIPHERAL-BLOOD; AMPLIFICATION; DISEASE; CELLS	Background The potential use of plasma and serum for molecular diagnosis has generated interest. Tumour DNA has been found in the plasma and serum of cancer patients, and molecular analysis has been done on this material. We investigated the equivalent condition in pregnancy-that is, whether fetal DNA is present in maternal plasma and serum. Methods We used a rapid-boiling method to extract DNA from plasma and serum. DNA from plasma, serum, and nucleated blood cells from 43 pregnant women underwent a sensitive Y-PCR assay to detect circulating male fetal DNA from women bearing male fetuses. Findings Fetus-derived Y sequences were detected in 24 (80%) of the 30 maternal plasma samples, and in 21 (70%) of the 30 maternal serum samples, from women bearing male fetuses. These results were obtained with only 10 mu L of the samples. When DNA from nucleated blood cells extracted from a similar volume of blood was used, only five (17%) of the 30 samples gave a positive Y signal. None of the 13 women bearing female fetuses, and none of the ten non-pregnant control women, had positive results for plasma, serum or nucleated blood cells. Interpretation Our finding of circulating fetal DNA in maternal plasma may have implications for non-invasive prenatal diagnosis, and for improving our understanding of the fetomaternal relationship.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN BIOCHEM,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT HAEMATOL,OXFORD OX3 9DU,ENGLAND; OSPED MAGGIORE,IRCCS,IST MED INTERNA & FISIOPATOL MED,MILAN,ITALY	University of Oxford; University of Oxford; University of Oxford; IRCCS Ca Granda Ospedale Maggiore Policlinico			Lo, Yuk Ming Dennis/D-4468-2011	Lo, Yuk Ming Dennis/0000-0001-8746-0293	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIANCHI DW, 1996, PEDIATR RES, V39, P142; CAMASCHELLA C, 1990, BLOOD, V75, P2102; Chen XQ, 1996, NAT MED, V2, P1033; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; EMANUEL SL, 1993, GENET ANAL-BIOMOL E, V10, P144, DOI 10.1016/1050-3862(93)90009-8; Lo YMD, 1996, BLOOD, V88, P4390; LO YMD, 1993, LANCET, V341, P1147, DOI 10.1016/0140-6736(93)93161-S; LO YMD, 1990, LANCET, V335, P1463, DOI 10.1016/0140-6736(90)91491-R; LO YMD, 1989, LANCET, V2, P1363; Mulcahy HE, 1996, LANCET, V348, P628, DOI 10.1016/S0140-6736(05)65067-2; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; REBELLO MT, 1991, PRENATAL DIAG, V11, P41, DOI 10.1002/pd.1970110108; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIMPSON JL, 1993, JAMA-J AM MED ASSOC, V270, P2357, DOI 10.1001/jama.270.19.2357; STROUN M, 1989, ONCOLOGY, V46, P318	15	1984	2409	10	189	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					485	487		10.1016/S0140-6736(97)02174-0	http://dx.doi.org/10.1016/S0140-6736(97)02174-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274585				2022-12-01	WOS:A1997XR13500011
J	Shapiro, RL; Hatheway, C; Becher, J; Swerdlow, DL				Shapiro, RL; Hatheway, C; Becher, J; Swerdlow, DL			Botulism surveillance and emergency response - A public health strategy for a global challenge	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Shapiro, RL (corresponding author), CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333, USA.							Aureli P, 1996, LANCET, V348, P1594, DOI 10.1016/S0140-6736(05)66220-4; CARDELLA MA, 1964, PHS PUBLICATION; COLE LA, 1996, SCI AM           DEC, P60; DANZIG R, 1996, STRATEGIC FORUM  JAN; FRANZ DR, 1997, JAMA-J AM MED ASSOC, V278, P3990; MCNALLY RE, 1994, EFFECTIVENESS MED DE; Siegel LS, 1993, CLOSTRIDIUM BOTULINU, P323; Smith L. D. S., 1988, BOTULISM ORGANISM IT; TACKET CO, 1984, AM J MED, V76, P794, DOI 10.1016/0002-9343(84)90988-4; WANNEMACHER RW, 9120 US ARM BIOM RES; WEBER JT, 1993, J INFECT DIS, V167, P451, DOI 10.1093/infdis/167.2.451	11	65	72	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					433	435		10.1001/jama.278.5.433	http://dx.doi.org/10.1001/jama.278.5.433			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244338				2022-12-01	WOS:A1997XN51800038
J	Conrad, B; Weissmahr, RN; Boni, J; Arcari, R; Schupbach, J; Mach, B				Conrad, B; Weissmahr, RN; Boni, J; Arcari, R; Schupbach, J; Mach, B			A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes	CELL			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; MYELIN BASIC-PROTEIN; T-CELLS; RHEUMATOID-ARTHRITIS; NUCLEOTIDE-SEQUENCE; CLONAL DELETION; B RETROVIRUS; STIMULATION; TRANSCRIPTION	Microbial superantigens (SAGs) have been implicated in the pathogenesis of human autoimmune diseases. Preferential expansion of the V beta 7 T cell receptor positive T cell subset in patients suffering from acute-onset type I diabetes has indicated the presence of a surface membrane-bound SAG. Here, we have isolated a novel mouse mammary tumor virus-related human endogenous retrovirus. We further show that the N-terminal moiety of the envelope gene encodes an MHC class II-dependent SAG. We propose that expression of this SAG, induced in extrapancreatic and professional antigen-presenting cells, leads to beta-cell destruction via the systemic activation of autoreactive T cells. The SAG encoded by this novel retrovirus thus constitutes a candidate autoimmune gene in type I diabetes.	UNIV ZURICH,SWISS NATL CTR RETROVIRUSES,CH-8028 ZURICH,SWITZERLAND; UNIV TURIN,SCH MED,DEPT INTERNAL MED,I-10126 TURIN,ITALY	University of Zurich; University of Turin	Conrad, B (corresponding author), UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND.		Schüpbach, Jörg/G-4209-2016; Boeni, Juerg/B-8386-2015	Schüpbach, Jörg/0000-0002-8074-5891; 				ACHAORBEA H, 1995, ANNU REV IMMUNOL, V13, P459, DOI 10.1146/annurev.iy.13.040195.002331; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; Badenhoop K, 1996, HUM IMMUNOL, V50, P103, DOI 10.1016/0198-8859(96)00146-2; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; BRUNO G, 1993, DIABETES CARE, V16, P133, DOI 10.2337/diacare.16.1.133; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COLE BC, 1993, ARTHRITIS RHEUM-US, V36, P994, DOI 10.1002/art.1780360717; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; DOBRESCU D, 1995, CELL, V82, P753, DOI 10.1016/0092-8674(95)90472-7; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; HOWELL MD, 1991, P NATL ACAD SCI USA, V88, P10921, DOI 10.1073/pnas.88.23.10921; *INT UN BIOCH NOM, 1985, EUR J BIOCHEM, V150, P1; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; LO D, 1993, EUR J IMMUNOL, V23, P1693, DOI 10.1002/eji.1830230744; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MCCLURE MA, 1988, P NATL ACAD SCI USA, V85, P2469, DOI 10.1073/pnas.85.8.2469; MEDSTRAND P, 1993, J VIROL, V67, P6778, DOI 10.1128/JVI.67.11.6778-6787.1993; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; ONO M, 1987, J VIROL, V61, P2059, DOI 10.1128/JVI.61.6.2059-2062.1987; ONO M, 1986, J VIROL, V58, P937, DOI 10.1128/JVI.58.3.937-944.1986; ONO M, 1986, J VIROL, V60, P589, DOI 10.1128/JVI.60.2.589-598.1986; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PETTE M, 1990, P NATL ACAD SCI USA, V87, P7968, DOI 10.1073/pnas.87.20.7968; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; Roizman B, 1996, FIELDS VIROLOGY, P2221; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Stegall MD, 1996, TRANSPLANTATION, V61, P1272, DOI 10.1097/00007890-199604270-00027; STEINMAN L, 1995, CELL, V80, P7, DOI 10.1016/0092-8674(95)90443-3; Sutkowski N, 1996, J EXP MED, V184, P971, DOI 10.1084/jem.184.3.971; TASSABEHJI M, 1994, NUCLEIC ACIDS RES, V22, P5211, DOI 10.1093/nar/22.24.5211; TEMIN HM, 1981, CELL, V27, P1, DOI 10.1016/0092-8674(81)90353-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; Tonjes RR, 1996, J ACQ IMMUN DEF SYND, V1, P261; Tyden G, 1996, NEW ENGL J MED, V335, P860, DOI 10.1056/NEJM199609193351205; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WainHobson S, 1996, TRENDS MICROBIOL, V4, P135, DOI 10.1016/0966-842X(96)10023-8; Weissmahr RN, 1997, J VIROL, V71, P3005, DOI 10.1128/JVI.71.4.3005-3012.1997; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WILKINSON DA, 1994, RETROVIRIDAE, V3, P465; WINSLOW GM, 1992, CELL, V71, P719, DOI 10.1016/0092-8674(92)90549-R; WUCHERPFENNIG KW, 1995, J EXP MED, V181, P1597, DOI 10.1084/jem.181.5.1597; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YORK DF, 1992, J VIROL, V66, P4930, DOI 10.1128/JVI.66.8.4930-4939.1992	52	344	354	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					303	313		10.1016/S0092-8674(00)80338-4	http://dx.doi.org/10.1016/S0092-8674(00)80338-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244304	Green Accepted, Bronze			2022-12-01	WOS:A1997XN24900014
J	McDonald, TV; Yu, ZH; Ming, Z; Palma, E; Meyers, MB; Wang, KW; Goldstein, SAN; Fishman, GI				McDonald, TV; Yu, ZH; Ming, Z; Palma, E; Meyers, MB; Wang, KW; Goldstein, SAN; Fishman, GI			A minK-HERG complex regulates the cardiac potassium current I-Kr	NATURE			English	Article							RECTIFIER K+ CURRENT; XENOPUS-OOCYTES; CHANNEL; EXPRESSION; PROTEIN; CELLS; LOCALIZATION; ARRHYTHMIA; MUTATIONS; MEMBRANE	MinK is a widely expressed protein of relative molecular mass similar to 15K that forms potassium channels by aggregation with other membrane proteins(1-3) MinK: governs :ion channel activiation(4) regulation by second messengers(5,6), and the function and structure of the ion conduction pathway(7,8). Association of minK with a channel protein known as KvLQT1 produces a voltage-gated outward K+ current (I-sK) resembling the slow cardiac repolarization current (I-Ks)(9,10). HERG, a human homologue of the ether-a-go-go gene of the fruitfly Drosophila melanogaster, encodes a protein that produces the rapidly activating cardiac delayed rectifier (I-Kr)(11,12). These two potassium currents, I-Kc, and I-Kr, provide the principal repolarizing currents in cardiac myocytes for the termination of action potentials(13,14). Although heterologously expressed HERG channels are largely indistinguishable from native cardiac I-Kr, a role for minK in this current is suggested by the diminished I-Kr in an atrial tumour line subjected to minK antisense suppression(15). Here we show that HERG and minK form a stable complex, and that this heteromultimerization regulates I-Kr activity. MinK, through the formation of heteromeric channel complexes, is thus central to the control of the heart rate and rhythm.	YALE UNIV,SCH MED,BOYER CTR MOL MED,DEPT PEDIAT,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,BOYER CTR MOL MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06536	Yale University; Yale University	McDonald, TV (corresponding author), ALBERT EINSTEIN COLL MED,SECT MOL CARDIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		; Goldstein, Steven A./E-9817-2015	Fishman, Glenn/0000-0002-2366-8527; Goldstein, Steven A./0000-0001-5207-5061				ATTALI B, 1992, J BIOL CHEM, V267, P8650; BARHANIN J, 1996, NATURE, V384, P80; BLUMENTHAL EM, 1992, J NEUROSCI, V12, P290; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; Brahmajothi MV, 1996, CIRC RES, V78, P1083, DOI 10.1161/01.RES.78.6.1083; BUSCH AE, 1992, J PHYSIOL-LONDON, V450, P491, DOI 10.1113/jphysiol.1992.sp019138; CHOY AMJ, 1996, CIRCULATION, V94, P164; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; MARGIOTTA JF, 1987, P NATL ACAD SCI USA, V84, P8155, DOI 10.1073/pnas.84.22.8155; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; POND AL, UNPUB CIRC RES; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; SAKAGAMI M, 1991, HEARING RES, V56, P168, DOI 10.1016/0378-5955(91)90166-7; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; SUGIMOTO T, 1990, J MEMBRANE BIOL, V113, P39, DOI 10.1007/BF01869604; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WANG W, 1996, NEURON, V16, P571; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246	30	296	306	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					289	292		10.1038/40882	http://dx.doi.org/10.1038/40882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230439	Green Submitted			2022-12-01	WOS:A1997XL12100054
J	Rizzolatti, G; Fadiga, L; Fogassi, L; Gallese, V				Rizzolatti, G; Fadiga, L; Fogassi, L; Gallese, V			The space around us	SCIENCE			English	Editorial Material							INFERIOR AREA-6; MACAQUE MONKEY; FUNCTIONAL-ORGANIZATION; VISUAL RESPONSES; PROJECTIONS; NEURONS; MOVEMENTS; AFFERENT; CORTEX				Rizzolatti, G (corresponding author), UNIV PARMA, IST FISIOL UMANA, VIA GRAMSCI 14, I-43100 PARMA, ITALY.		Gallese, Vittorio/ABD-5097-2021; Galantucci, Bruno/E-5770-2010; Fadiga, Luciano/AAC-7404-2022; FOGASSI, Leonardo/K-3541-2018	Gallese, Vittorio/0000-0003-4815-3607; FOGASSI, Leonardo/0000-0003-3348-039X; fadiga, luciano/0000-0001-5691-5080				Arbib M. A., 2011, HDB PHYSL NERVOUS SY, P1449, DOI [10.1002/cphy.cp010233, DOI 10.1016/J.JPHYSPARIS.2008.03.001]; Colby CL, 1996, COGNITIVE BRAIN RES, V5, P105, DOI 10.1016/S0926-6410(96)00046-8; COLBY CL, 1993, J NEUROPHYSIOL, V69, P902, DOI 10.1152/jn.1993.69.3.902; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; Fogassi L, 1996, NATO ADV SCI I D-BEH, V85, P99; GENTILUCCI M, 1983, EXP BRAIN RES, V50, P464; GENTILUCCI M, 1988, EXP BRAIN RES, V71, P475, DOI 10.1007/BF00248741; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; Graziano MSA, 1997, SCIENCE, V277, P239, DOI 10.1126/science.277.5323.239; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; GRAZIANO MSA, 1994, COGNITIVE NEUROSCIEN, P1021; Gross C.G., 1995, NEUROSCIENTIST, V1, P43, DOI [10.1177/107385849500100107, DOI 10.1177/107385849500100107]; HE SQ, 1993, J NEUROSCI, V13, P952; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; LEINONEN L, 1979, EXP BRAIN RES, V34, P299; MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302; Matelli M, 1994, SOC NEUR ABSTR, V20; Merleau-Ponty M., 1962, PHENOMENOLOGY PERCEP; MURATA A, IN PRESS J NEUROPHYS; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; RIZZOLATTI G, 1988, EXP BRAIN RES, V71, P491, DOI 10.1007/BF00248742; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X	23	471	471	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 11	1997	277	5323					190	191		10.1126/science.277.5323.190	http://dx.doi.org/10.1126/science.277.5323.190			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK418	9235632				2022-12-01	WOS:A1997XK41800028
J	Honour, JW				Honour, JW			Misuse of natural hormones in sport	LANCET			English	Editorial Material											Honour, JW (corresponding author), UCL, DEPT MOL PATHOL, MORTIMER ST, LONDON W1N 8AA, ENGLAND.							BILTON RF, 1995, LANCET, V345, P1186, DOI 10.1016/S0140-6736(95)91022-0; DONIKE M, 1996, RECENT ADV DOPING AN, V3, P95; DONIKE M, 1993, SPORT LEISTUNG GESUN, P293; Honour JW, 1996, LANCET, V348, P41, DOI 10.1016/S0140-6736(96)05336-6; KICMAN AT, 1992, BRIT MED BULL, V48, P496, DOI 10.1093/oxfordjournals.bmb.a072559; SCHANZER W, 1997, RECENT ADV DOPING AN, V4	6	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1786	1786		10.1016/S0140-6736(05)61689-3	http://dx.doi.org/10.1016/S0140-6736(05)61689-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269210				2022-12-01	WOS:A1997XF73500006
J	Mumford, DM				Mumford, DM			Thank God I have cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	1997	278	11					956	956						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XV640	9302252				2022-12-01	WOS:A1997XV64000040
J	Liu, D; Diorio, J; Tannenbaum, B; Caldji, C; Francis, D; Freedman, A; Sharma, S; Pearson, D; Plotsky, PM; Meaney, MJ				Liu, D; Diorio, J; Tannenbaum, B; Caldji, C; Francis, D; Freedman, A; Sharma, S; Pearson, D; Plotsky, PM; Meaney, MJ			Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; MEDIAN-EMINENCE; MESSENGER-RNA; ADULT-RATS; SECRETION; BEHAVIOR; ALTERS; FEEDBACK; NEUROENDOCRINE; CORTICOSTERONE	Variations in maternal care affect the development of individual differences in neuroen-docrine responses to stress in rats. As adults, the offspring of mothers that exhibited more licking and grooming of pups during the first 10 days of life showed reduced plasma adrenocorticotropic hormone and corticosterone responses to acute stress, increased hippocampal glucocorticoid receptor messenger RNA expression, enhanced glucocorticoid feedback sensitivity, and decreased levels of hypothalamic corticotropin-releasing hormone messenger RNA. Each measure was significantly correlated with the frequency of maternal licking and grooming (all r's > -0.6). These findings suggest that maternal behavior serves to ''program'' hypothalamic-pituitary-adrenal responses to stress in the offspring.	MCGILL UNIV, FAC MED,DEPT PSYCHIAT,DEV NEUROENDOCRINOL LAB, DOUGLAS HOSP,RES CTR, MONTREAL, PQ H4H 1R3, CANADA; MCGILL UNIV, FAC MED,DEPT NEUROL & NEUROSURG, DEV NEUROENDOCRINOL LAB,DOUGLAS HOSP, RES CTR, MONTREAL, PQ H4H 1R3, CANADA; EMORY UNIV, DEPT PSYCHIAT & BEHAV SCI, ATLANTA, GA 30322 USA	McGill University; McGill University; Emory University			Meaney, Michael/N-5931-2019					ALBERTS JR, 1989, HDB BEHAV NEUROBIOLO, V9, P1; BARNETT SA, 1967, NATURE, V213, P150, DOI 10.1038/213150a0; BELL R W, 1971, Developmental Psychobiology, V4, P181, DOI 10.1002/dev.420040209; BELL RW, 1980, MATERNAL INFLUENCES, P201; BHATNAGAR S, 1995, J NEUROENDOCRINOL, V7, P97, DOI 10.1111/j.1365-2826.1995.tb00672.x; BUTLER SR, 1978, SCIENCE, V199, P445; DALY M, 1973, BRIT J PSYCHOL, V64, P435, DOI 10.1111/j.2044-8295.1973.tb01370.x; DEKLOET ER, 1991, FRONT NEUROENDOCRIN, V12, P95; FLEMING AS, 1974, J COMP PHYSIOL PSYCH, V86, P221, DOI 10.1037/h0035937; Francis D, 1996, ANN NY ACAD SCI, V794, P136, DOI 10.1111/j.1749-6632.1996.tb32517.x; HALTMEYE.GC, 1967, PHYSIOL BEHAV, V2, P61, DOI 10.1016/0031-9384(67)90012-1; HESS JL, 1969, PHYSIOL BEHAV, V4, P109, DOI 10.1016/0031-9384(69)90023-7; Hofer M. A., 1983, SYMBIOSIS PARENT OFF, P61; IMAKI T, 1991, J NEUROSCI, V11, P585; JACOBSON L, 1991, ENDOCR REV, V12, P118, DOI 10.1210/edrv-12-2-118; JANS JE, 1990, DEV PSYCHOBIOL, V23, P519, DOI 10.1002/dev.420230607; KELLERWOOD ME, 1984, ENDOCR REV, V5, P1, DOI 10.1210/edrv-5-1-1; KREY LC, 1975, ENDOCRINOLOGY, V96, P1088, DOI 10.1210/endo-96-5-1088; KUHN CM, 1978, SCIENCE, V201, P1034, DOI 10.1126/science.684424; LEE MHS, 1974, ANIM BEHAV, V22, P679, DOI 10.1016/S0003-3472(74)80016-3; LEON M, 1978, PHYSIOL BEHAV, V21, P793, DOI 10.1016/0031-9384(78)90021-5; LEVINE S, 1959, SCIENCE, V129, P42, DOI 10.1126/science.129.3340.42; LEVINE S, 1957, SCIENCE, V126, P405, DOI 10.1126/science.126.3270.405; LEVINE S, 1962, SCIENCE, V135, P795, DOI 10.1126/science.135.3506.795-a; Levine S., 1975, SOC STRESS DIS, P43; Levine S, 1994, ANN NY ACAD SCI, V746, P260; LIU D, UNPUB; MEANEY MJ, 1991, NEUROBIOL AGING, V12, P31, DOI 10.1016/0197-4580(91)90036-J; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; MEANEY MJ, 1985, DEV BRAIN RES, V22, P301, DOI 10.1016/0165-3806(85)90183-X; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; MEANEY MJ, 1985, BEHAV NEUROSCI, V99, P765, DOI 10.1037/0735-7044.99.4.765; MOORE CL, 1984, DEV PSYCHOBIOL, V17, P347, DOI 10.1002/dev.420170403; MYERS MM, 1992, EXPERIENTIA, V48, P322, DOI 10.1007/BF01923426; MYERS MM, 1989, DEV PSYCHOBIOL, V22, P55, DOI 10.1002/dev.420220105; ODONNELL D, 1994, MOL BRAIN RES, V26, P242, DOI 10.1016/0169-328X(94)90096-5; PLOTSKY PM, 1986, ENDOCRINOLOGY, V119, P1126, DOI 10.1210/endo-119-3-1126; PLOTSKY PM, 1987, ENDOCRINOLOGY, V120, P1361, DOI 10.1210/endo-120-4-1361; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; PLOTSKY PM, 1993, MOL BRAIN RES, V18, P195, DOI 10.1016/0169-328X(93)90189-V; SAPOLSKY RM, 1984, P NATL ACAD SCI-BIOL, V81, P6174, DOI 10.1073/pnas.81.19.6174; SAPOLSKY RM, 1995, NEUROSCIENCE, V66, P571; SARRIEAU A, 1988, DEV BRAIN RES, V43, P158, DOI 10.1016/0165-3806(88)90162-9; SAWCHENKO PE, 1987, J NEUROSCI, V7, P1093; SCHANBERG SM, 1987, CHILD DEV, V58, P1431, DOI 10.2307/1130683; SECKL JR, 1990, J NEUROENDOCRINOL, V2, P911, DOI 10.1111/j.1365-2826.1990.tb00659.x; SHANKS N, 1995, J NEUROSCI, V15, P376, DOI 10.1523/jneurosci.15-01-00376.1995; Vallee M, 1997, J NEUROSCI, V17, P2626; VIAU V, 1991, ENDOCRINOLOGY, V129, P2503, DOI 10.1210/endo-129-5-2503; VIAU V, 1993, J NEUROSCI, V13, P1097; WALKER CD, 1990, ENDOCRINOLOGY, V127, P832, DOI 10.1210/endo-127-2-832; WHITNALL MH, 1993, PROG NEUROBIOL, V40, P573, DOI 10.1016/0301-0082(93)90035-Q; WOODSIDE BC, UNPUB; ZARROW MX, 1972, P SOC EXP BIOL MED, V356, P141	54	2284	2332	6	253	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	1997	277	5332					1659	1662		10.1126/science.277.5332.1659	http://dx.doi.org/10.1126/science.277.5332.1659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287218				2022-12-01	WOS:A1997XV68400049
J	Michelotti, EF; Sanford, S; Levens, D				Michelotti, EF; Sanford, S; Levens, D			Marking of active genes on mitotic chromosomes	NATURE			English	Article							PROMOTER; DISPLACEMENT; PROPAGATION; REPLICATION; CHROMATIN; INVIVO	During development and differentiation, cellular phenotypes are stably propagated through numerous cell divisions(1). This epigenetic 'cell memory' helps to maintain stable patterns of gene expression(2). DNA methylation(3) and the propagation of specific chromatin structures may both contribute to cell memory(4). There are two impediments during the cell cycle that can hinder the inheritance of specific chromatin configurations: first, the pertinent structures must endure the passage of DNA-replication forks in S phase(5); second, the chromatin state must survive mitosis, when chromatin condenses, transcription is turned off, and almost all double-stranded DNA-binding proteins are displaced(6,7). After mitosis, the previous pattern of expressed and silent genes must be restored. This restoration might be governed by mass action, determined by the binding affinities and concentrations of individual components, Alternatively, a subset of factors might remain bound to mitotic chromosomes, providing a molecular bookmark to direct proper chromatin reassembly, Here we analyse DNA at transcription start sites during mitosis in vivo and find that it is conformationally distorted in genes scheduled for reactivation but is undistorted in repressed genes. These protein-dependent conformational perturbations could help to re-establish transcription after mitosis by 'marking' genes for re-expression.	NCI,PATHOL LAB,GENE REGULAT SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Levens, David/C-9216-2009	Levens, David/0000-0002-7616-922X				ALBERTS B, 1994, MOL BIOLCELL; BHAUMIK D, 1994, J BIOL CHEM, V269, P15861; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; CASTANO IB, 1996, GENE DEV, V10, P2546; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GROUDINE M, 1982, CELL, V30, P131, DOI 10.1016/0092-8674(82)90019-8; Juan G, 1996, EXP CELL RES, V227, P197, DOI 10.1006/excr.1996.0267; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KOIWAI O, 1988, BIOCHEM BIOPH RES CO, V154, P91, DOI 10.1016/0006-291X(88)90654-7; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; MARTIENSSEN RA, 1995, CURR OPIN GENET DEV, V5, P234, DOI 10.1016/0959-437X(95)80014-X; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; SCHWEIZER D, 1994, CHROMOSOME ANAL PROT; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3	21	135	138	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					895	899		10.1038/42282	http://dx.doi.org/10.1038/42282			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278053	Bronze			2022-12-01	WOS:A1997XT75400054
J	Burtnick, LD; Koepf, EK; Grimes, J; Jones, EY; Stuart, DI; McLaughlin, PJ; Robinson, RC				Burtnick, LD; Koepf, EK; Grimes, J; Jones, EY; Stuart, DI; McLaughlin, PJ; Robinson, RC			The crystal structure of plasma gelsolin: Implications for actin severing, capping, and nucleation	CELL			English	Article							BINDING DOMAIN; F-ACTIN; PROTEIN; SEQUENCE; FILAMENT; IDENTIFICATION; CALCIUM; VILLIN; AMYLOIDOSIS; DEFINITION	The structure of gelsolin has been determined by crystallography and comprises six structurally related domains that, in a Ca2+-free environment, pack together to form a compact globular structure in which the putative actin-binding sequences are not sufficiently exposed to enable binding to occur. We propose that binding Ca2+ can release the connections that join the N- and C-terminal halves of gelsolin, enabling each half to bind actin relatively independently. Domain shifts are proposed in response to Ca2+ as bases for models of how gelsolin acts to sever, cap, or nucleate F-actin filaments. The structure also invites discussion of polyphosphoinositide binding to segment 2 and suggests how mutation at Asp-187 could initiate a series of events that lead to deposition of amyloid plaques, as observed in victims of familial amyloidosis (Finnish type).	UNIV OXFORD,DEPT BIOCHEM,LAB MOL BIOPHYS,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD CTR MOL SCI,OXFORD OX1 3QU,ENGLAND; UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z1,CANADA; UNIV EDINBURGH,DEPT BIOCHEM,EDINBURGH EH8 9XD,MIDLOTHIAN,SCOTLAND	University of Oxford; University of Oxford; University of British Columbia; University of Edinburgh			Robinson, Robert/G-9702-2011; Jones, Yvonne/J-2293-2016; Jones, Yvonne/N-8111-2019	Robinson, Robert/0000-0001-6367-6903; Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210; Grimes, Jonathan Mark/0000-0001-9698-0389	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDRE E, 1988, J BIOL CHEM, V263, P722; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRYAN J, 1986, J CELL BIOL, V102, P1439, DOI 10.1083/jcb.102.4.1439; CHAPONNIER C, 1986, J CELL BIOL, V103, P1473, DOI 10.1083/jcb.103.4.1473; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; FEINBERG J, 1995, BIOCHEM BIOPH RES CO, V209, P426, DOI 10.1006/bbrc.1995.1520; HADDAD JG, 1990, P NATL ACAD SCI USA, V87, P1381, DOI 10.1073/pnas.87.4.1381; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HELLWEG T, 1993, BIOPHYS J, V65, P799, DOI 10.1016/S0006-3495(93)81121-4; HERRMANNSDOERFER AJ, 1993, AM J PHYSIOL, V265, pG1071, DOI 10.1152/ajpgi.1993.265.6.G1071; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P508; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARKUS MA, 1994, PROTEIN SCI, V3, P70; MAURY CPJ, 1990, FEBS LETT, V260, P85, DOI 10.1016/0014-5793(90)80072-Q; MCGOUGH A, 1995, J STRUCT BIOL, V115, P144, DOI 10.1006/jsbi.1995.1038; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; POPE B, 1991, FEBS LETT, V280, P70, DOI 10.1016/0014-5793(91)80206-I; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; REID SW, 1993, ARCH BIOCHEM BIOPHYS, V302, P31, DOI 10.1006/abbi.1993.1176; SCHNUCHEL A, 1995, J MOL BIOL, V247, P21, DOI 10.1006/jmbi.1994.0118; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; SUN HQ, 1994, J BIOL CHEM, V269, P9473; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VanTroys M, 1996, FEBS LETT, V397, P191, DOI 10.1016/S0014-5793(96)01086-1; VASCONCELLOS CA, 1993, BLOOD, V82, P3648; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEEDS AG, 1995, FEBS LETT, V360, P227, DOI 10.1016/0014-5793(95)00109-M; WEEDS AG, 1993, FEBS LETT, V335, P119, DOI 10.1016/0014-5793(93)80452-Z; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; Wen DY, 1996, BIOCHEMISTRY-US, V35, P9700, DOI 10.1021/bi960920n; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409; YU FX, 1992, J BIOL CHEM, V267, P14616	50	238	243	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					661	670		10.1016/S0092-8674(00)80527-9	http://dx.doi.org/10.1016/S0092-8674(00)80527-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288746	Bronze			2022-12-01	WOS:A1997XT06600010
J	Sontheimer, EJ; Sun, SG; Piccirilli, JA				Sontheimer, EJ; Sun, SG; Piccirilli, JA			Metal ion catalysis during splicing of premessenger RNA	NATURE			English	Article							PRE-MESSENGER-RNA; SITE; SPLICEOSOME; DNA; 3'-THIOTHYMIDINE; STEREOCHEMISTRY; HEXOKINASE; PRECURSORS; COMPLEXES; SUBSTRATE	The removal of intervening sequences from premessenger RNA is essential for the expression of most eukaryotic genes. The spliceosome ribonucleoprotein complex catalyses intron removal by two sequential phosphotransesterification reactions', but the catalytic mechanisms are unknown. It has been proposed that two divalent metal ions may mediate catalysis of both reaction steps, activating the 2'-or 3'-hydroxyl groups for nucleophilic attack and stabilizing the 3'-oxyanion leaving groups by direct coordination(2). Here we show that in splicing reactions with a precursor RNA containing a 3'-sulphur substitution at the 5' splice site, interaction between metal ion and leaving group is essential for catalysis of the first reaction step. This establishes that the spliceosome is a metalloenzyme and demonstrates a direct parallel with the catalytic strategy used by the self-splicing group I intron from Tetrahymena(3). In contrast, 3'-sulphur substitution at the 3' splice site provides no evidence for a metal ion-leaving group interaction in the second reaction step, suggesting that the two steps of splicing proceed by different catalytic mechanisms and therefore in distinct active sites.	UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago; University of Chicago				Sontheimer, Erik/0000-0002-0881-0310				ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; Anderegg G., 1987, COMPLEXONES, V2, P777; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; COSSTICK R, 1990, NUCLEIC ACIDS RES, V18, P829, DOI 10.1093/nar/18.4.829; Dantzman CL, 1996, J AM CHEM SOC, V118, P11715, DOI 10.1021/ja962265c; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; JAFFE EK, 1979, J BIOL CHEM, V254, P839; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Kramer A., 1995, PREMRNA PROCESSING, P35; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NARLIKAR GJ, 1995, P NATL ACAD SCI USA, V92, P3668, DOI 10.1073/pnas.92.9.3668; PEARSON RG, 1966, SCIENCE, V151, P172, DOI 10.1126/science.151.3707.172; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; Reyes J, 1996, RNA, V2, P213; SEIWERT SD, 1993, MOL CELL BIOL, V13, P3135, DOI 10.1128/MCB.13.6.3135; Sigel RKO, 1997, J AM CHEM SOC, V119, P744, DOI 10.1021/ja962970l; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TARN WY, IN PRESS BIOCHIMIE; VYLE JS, 1992, BIOCHEMISTRY-US, V31, P3012, DOI 10.1021/bi00126a024; Weinstein LB, 1996, J AM CHEM SOC, V118, P10341, DOI 10.1021/ja9616903	28	145	151	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					801	805		10.1038/42068	http://dx.doi.org/10.1038/42068			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285595	Bronze			2022-12-01	WOS:A1997XR66700057
J	Maisel, WH; Kuntz, KM; Reimold, SC; Lee, TH; Antman, EM; Friedman, PL; Stevenson, WG				Maisel, WH; Kuntz, KM; Reimold, SC; Lee, TH; Antman, EM; Friedman, PL; Stevenson, WG			Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital	ANNALS OF INTERNAL MEDICINE			English	Article							ARRHYTHMIA SUPPRESSION TRIAL; CARDIOVERSION; QUINIDINE; EFFICACY; MORTALITY; AGE	Background: The risks of antiarrhythmic therapy are increasingly recognized, but the risks associated with the initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation are poorly defined. Objective: To determine the incidence, time course, and predictors of adverse cardiac events that require intervention during initiation of antiarrhythmic drug therapy for atrial fibrillation. Design: Retrospective chart review. Setting: University hospital. Participants: 417 consecutive patients who underwent a total of 597 drug trials during a total of 550 hospitalizations for atrial fibrillation. Intervention: Initiation of therapy with antiarrhythmic drugs: procainamide (189 trials), quinidine (179 trials), disopyramide (20 trials), propafenone (110 trials), flecainide (2 trials), sotalol (72 trials), and amiodarone (25 trials). Electrical conversion was performed during 247 trials. Measurements: Incidence of adverse events and daily hazard rate were measured. Logistic regression was done to identify risk factors. Results: During the 597 drug trials, 80 (13.4%) cardiac adverse events occurred in 73 patients. The risk was greatest during the first 24 hours of therapy. Bradyarrhythmias were the most common adverse event, occurring in 47 trials (7.9%); prolongation of the QT interval warranting discontinuation of drug therapy (9 trials; 1.5%) and ventricular arrhythmias (8 trials; 1.3%) were less frequent. In multivariate analysis, previous myocardial infarction was associated with increased risk (odds ratio, 1.90 [95% CI, 1.05 to 3.43]) and the association between older age and increased risk (odds ratio, 1.29 per decade [CI, 0.97 to 1.72]) was of borderline statistical significance. Conclusions: A significant risk for cardiac adverse events exists during initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation. Observation with electrocardiographic monitoring seems advisable for 24 to 48 hours during initiation of antiarrhythmic therapy, particularly for elderly patients and patients who have previously had myocardial infarction.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital								AKIYAMA T, 1992, J AM GERIATR SOC, V40, P666, DOI 10.1111/j.1532-5415.1992.tb01957.x; COLLETT D, 1994, MODELLING SURVIVAL D, P27; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; HILL JD, 1987, J ROY COLL GEN PRACT, V37, P172; HOHNLOSER SH, 1995, J AM COLL CARDIOL, V26, P852, DOI 10.1016/0735-1097(95)00286-5; MANCINI GBJ, 1982, AM HEART J, V104, P617; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; RODEN DM, 1994, NEW ENGL J MED, V331, P785; RUSKIN JN, 1989, NEW ENGL J MED, V321, P386, DOI 10.1056/NEJM198908103210608; STRATMANN HG, 1987, AM HEART J, V113, P1470, DOI 10.1016/0002-8703(87)90664-8; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	16	75	78	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1997	127	4					281	+		10.7326/0003-4819-127-4-199708150-00004	http://dx.doi.org/10.7326/0003-4819-127-4-199708150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR266	9265427				2022-12-01	WOS:A1997XR26600006
J	Robbins, DJ; Nybakken, KE; Kobayashi, R; Sisson, JC; Bishop, JM; Therond, PP				Robbins, DJ; Nybakken, KE; Kobayashi, R; Sisson, JC; Bishop, JM; Therond, PP			Hedgehog elicits signal transduction by means of a large complex containing the kinesin-related protein costal2	CELL			English	Article							POLARITY GENE; DROSOPHILA-MELANOGASTER; SEGMENTAL POLARITY; SONIC-HEDGEHOG; FUSED GENE; PATTERN; FAMILY; TRANSCRIPTION; EXPRESSION; SUPPRESSOR	The hedgehog gene of Drosophila melanogaster encodes a secreted protein (HH) that plays a vital role in cell fate and patterning. Here we describe a protein complex that mediates signal transduction from HH. The complex includes the products of at least three genes:fused (a protein-serine/threonine kinase), cubitus interruptus (a transcription factor), and costal2 (a kinesin-like protein). The complex binds with great affinity to microtubules in the absence of HH, but binding is reversed by HH. Mutations in the extracatalytic domain of FU abolish both the biological function of the protein and its association with COS2. We conclude that the complex may facilitate signaling from HH by governing access of the cubitus interruptus protein to the nucleus.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Robbins, DJ (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Therond, pascal/AAE-4811-2019		NCI NIH HHS [CA44338, CA45508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044338, P30CA045508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BUSSON D, 1988, ROUX ARCH DEV BIOL, V197, P221, DOI 10.1007/BF02439429; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COLE DG, 1994, J BIOL CHEM, V269, P22913; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FORBES AJ, 1993, DEVELOPMENT S, V119, P115; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; Johnson RL, 1995, DEVELOPMENT, V121, P4161; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KELLOGG DR, 1989, J CELL BIOL, V109, P2977, DOI 10.1083/jcb.109.6.2977; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; MOHLER J, 1988, GENETICS, V120, P1061; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PHAM A, 1995, GENETICS, V140, P587; PREAT T, 1993, GENETICS, V135, P1047; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; Therond P, 1996, GENETICS, V142, P1181; THEROND P, 1993, MECH DEVELOP, V44, P65, DOI 10.1016/0925-4773(93)90017-R; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; ZECCA M, 1995, DEVELOPMENT, V121, P2265	56	305	314	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					225	234		10.1016/S0092-8674(00)80331-1	http://dx.doi.org/10.1016/S0092-8674(00)80331-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244297	Bronze			2022-12-01	WOS:A1997XN24900007
J	Dickson, RM; Cubitt, AB; Tsien, RY; Moerner, WE				Dickson, RM; Cubitt, AB; Tsien, RY; Moerner, WE			On/off blinking and switching behaviour of single molecules of green fluorescent protein	NATURE			English	Article							OPTICAL MICROSCOPY	Optical studies of individual molecules at low and room temperature can provide information about the dynamics of local environments in solids, liquids and biological systems unobscured by ensemble averaging(1-14). Here we present a study of the photophysical behaviour of single molecules of the green fluorescent protein (GFP) derived from the jellfish Aequorea victoria. Wild-type GFP and its mutant have attracted interest as fluorescent biological labels because the fluorophore may be formed in vivo(15,16). GFP mutants immobilized in aereated aqueous polymer gels and excited by 488-nm light undergo repeated cycles of fluorescent emission ('blinking') on a timescale of several seconds-behaviour that would be unobservable in bulk studies. Eventually the individual GFP molecules reach a long-lasting dark state, from which they can be switched back to the original emissive state by irradiation at 405 nm. This suggests the possibility of using these GFPs as fluorescent markers for time-dependent cell processes, and as molecular photonic switches or optical storage elements, addressable on the single-molecule level.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM 0340, LA JOLLA, CA 92093 USA; AURORA BIOSCI, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST 0647, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Moerner, William E/C-3260-2008; Wood, David W/B-2992-2012	Moerner, William E/0000-0002-2830-209X; 				AMBROSE WP, 1994, SCIENCE, V265, P364, DOI 10.1126/science.265.5170.364; BARBARA PF, 1996, ACC CHEM RES, V29; Basche T., 1997, SINGLE MOL OPTICAL D; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306; Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; Fawcett J. S., 1966, SEP SCI, V1, P9; FOX GEP, 1970, TIME SERIES ANAL FOR; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; IRIE M, 1994, PHOTOREACTIVE MAT UL, P1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lu HP, 1997, NATURE, V385, P143, DOI 10.1038/385143a0; MOERNER WE, 1989, PHYS REV LETT, V62, P2535, DOI 10.1103/PhysRevLett.62.2535; MOERNER WE, 1994, SCIENCE, V265, P46, DOI 10.1126/science.265.5168.46; MOERNER WE, 1994, J PHYS CHEM-US, V98, P7382, DOI 10.1021/j100081a025; NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; ORRIT M, 1990, PHYS REV LETT, V65, P2716, DOI 10.1103/PhysRevLett.65.2716; PARTHENOPOULOS DA, 1989, SCIENCE, V245, P843, DOI 10.1126/science.245.4920.843; REILLY PD, 1993, PHYS REV LETT, V71, P4257, DOI 10.1103/PhysRevLett.71.4257; Sakmann B., 1995, SINGLE CHANNEL RECOR; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; STUART JA, 1996, 6 BIENN IEEE INT NON, P35; Trautman JK, 1996, CHEM PHYS, V205, P221, DOI 10.1016/0301-0104(95)00391-6; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	30	1071	1111	9	425	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	1997	388	6640					355	358		10.1038/41048	http://dx.doi.org/10.1038/41048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237752	Bronze			2022-12-01	WOS:A1997XM52800043
J	Kaplan, SL				Kaplan, SL			Prevention of hearing loss from meningitis	LANCET			English	Editorial Material									TEXAS CHILDRENS HOSP,HOUSTON,TX 77030	Baylor College of Medicine	Kaplan, SL (corresponding author), BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030, USA.							Dodds A, 1997, ARCH DIS CHILD, V76, P139, DOI 10.1136/adc.76.2.139; FORTNUM HM, 1992, ARCH DIS CHILD, V67, P1128, DOI 10.1136/adc.67.9.1128; Kaplan S L, 1995, Adv Pediatr Infect Dis, V10, P167; Merchant SN, 1996, AM J OTOL, V17, P375; Richardson MP, 1997, ARCH DIS CHILD, V76, P134, DOI 10.1136/adc.76.2.134; Winter A, 1996, ACTA OTO-LARYNGOL, V116, P401, DOI 10.3109/00016489609137864; WOLFF AB, 1987, AM ANN DEAF, V131, P26	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 19	1997	350	9072					158	159		10.1016/S0140-6736(05)62346-X	http://dx.doi.org/10.1016/S0140-6736(05)62346-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250179				2022-12-01	WOS:A1997XL72200005
J	Sharpe, M; Hawton, K; Clements, A; Cowen, PJ				Sharpe, M; Hawton, K; Clements, A; Cowen, PJ			Increased brain serotonin function in men with chronic fatigue syndrome	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,LITTLEMORE HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND; UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND	University of Oxford; University of Oxford				Cowen, Philip/0000-0001-5518-6138; sharpe, michael/0000-0002-6474-9980				BAKHEIT AMO, 1992, BRIT MED J, V304, P1010, DOI 10.1136/bmj.304.6833.1010; BEARN J, 1995, BIOL PSYCHIAT, V37, P245, DOI 10.1016/0006-3223(94)00121-I; CLEARE AJ, 1995, J AFFECT DISORDERS, V35, P283; Sharpe M, 1996, PSYCHIAT CLIN N AM, V19, P549, DOI 10.1016/S0193-953X(05)70305-1; YATHAM LN, 1995, CAN J PSYCHIAT, V40, P3	5	50	50	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 19	1997	315	7101					164	165		10.1136/bmj.315.7101.164	http://dx.doi.org/10.1136/bmj.315.7101.164			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XM321	9251547	Green Published			2022-12-01	WOS:A1997XM32100021
J	Rand, JH; Wu, XX; Andree, HAM; Lockwood, CJ; Guller, S; Scher, J; Harpel, PC				Rand, JH; Wu, XX; Andree, HAM; Lockwood, CJ; Guller, S; Scher, J; Harpel, PC			Pregnancy loss in the antiphospholipid-antibody syndrome - A possible thrombogenic mechanism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACENTAL ANTICOAGULANT PROTEIN; PHOSPHOLIPID-BINDING; ANNEXIN-V; LIPOCORTIN FAMILY; FETAL LOSS; LINES; CELLS; MICE	Background The mechanisms of vascular thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome are unknown. Levels of annexin V, a phospholipid-binding protein with potent anticoagulant activity, are markedly reduced on placental villi from women with this syndrome. Hypercoagulability in such women may therefore be due to the reduction of surface-bound annexin V by antiphospholipid antibodies. To test this idea, we studied how antiphospholipid antibodies affect levels of annexin V on cultured trophoblasts and human umbilical vein endothelial cells and how they affect the procoagulant activity of these cells. Methods We isolated IgG fractions from three patients with the antiphospholipid-antibody syndrome and from normal controls. These antibodies were incubated with cultured BeWo cells (a placental-trophoblast cell line), primary cultured trophoblasts, and human umbilical-vein endothelial cells. Annexin V on the cell surfaces was measured by an enzyme-linked immunosorbent assay. The coagulation times of plasma overlaid on the cells were also determined. Results Trophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG as compared with control IgG had reduced levels of annexin V (trophoblasts, 0.37+/-0.02 vs. 0.85+/-0.12 ng per well, P=0.02; endothelial cells, 1.6+/-0.04 vs. 2.1+/-0.05 ng per well, P=0.001). Also, trophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG had faster mean (+/-SE) plasma coagulation times than cells exposed to control IgG (trophoblasts, 8.7+/-2.0 vs. 21.3+/-2.9 minutes, P=0.02; endothelial cells, 9.8+/-0.8 vs. 14.2+/-1.2 minutes, P=0.04). Conclusions Antiphospholipid antibodies reduce the levels of annexin V and accelerate the coagulation of plasma on cultured trophoblasts and endothelial cells. The reduction of annexin V levels on vascular cells may be an important mechanism of thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome. (C)1997, Massachusetts Medical Society.	MT SINAI SCH MED,DEPT MED,DIV THROMBOSIS,NEW YORK,NY; MT SINAI SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,NEW YORK,NY; NYU,SCH MED,DEPT OBSTET & GYNECOL,NEW YORK,NY	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; New York University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029019, R01HL032200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024671] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32200, HL-29019] Funding Source: Medline; NIAID NIH HHS [AI-24671] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREE HAM, 1992, J BIOL CHEM, V267, P17907; ANDREE HAM, 1992, PHOSPHOLIPID BINDING, P73; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BLANK M, 1994, J AUTOIMMUN, V7, P441, DOI 10.1006/jaut.1994.1032; BRANCH DW, 1990, AM J OBSTET GYNECOL, V163, P210, DOI 10.1016/S0002-9378(11)90700-5; DOUGLAS GC, 1989, J IMMUNOL METHODS, V119, P259, DOI 10.1016/0022-1759(89)90405-5; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HASEGAWA I, 1994, THROMB RES, V74, P77, DOI 10.1016/0049-3848(94)90037-X; HINEGARDNER RT, 1971, ANAL BIOCHEM, V39, P197, DOI 10.1016/0003-2697(71)90476-3; HUBER R, 1994, ANNEXINS, P105; JAFFE EA, 1973, J CLIN INVEST, V52, P2757, DOI 10.1172/JCI107471; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KRAUSE I, 1993, AM J REPROD IMMUNOL, V29, P155, DOI 10.1111/j.1600-0897.1993.tb00581.x; KRIKUN G, 1994, PLACENTA, V15, P601, DOI 10.1016/S0143-4004(05)80407-2; LOCKSHIN M D, 1991, Current Opinion in Rheumatology, V3, P797, DOI 10.1097/00002281-199110000-00008; Lockwood C J, 1994, Obstet Gynecol Surv, V49, P432, DOI 10.1097/00006254-199406000-00026; MESSMORE H, 1994, SEMIN THROMB HEMOST, V20, P79, DOI 10.1055/s-2007-1001892; ORNSTEIN MH, 1994, J RHEUMATOL, V21, P1360; Pierangeli SS, 1996, LUPUS, V5, P451, DOI 10.1177/096120339600500524; RAND JH, 1994, AM J OBSTET GYNECOL, V171, P1566, DOI 10.1016/0002-9378(94)90403-0; ROUBEY RAS, 1994, BLOOD, V84, P2854; SAMMARITANO LR, 1990, SEMIN ARTHRITIS RHEU, V20, P81, DOI 10.1016/0049-0172(90)90021-7; SAMMARITANO LR, 1992, J CLIN IMMUNOL, V12, P27, DOI 10.1007/BF00918270; Shapiro SS, 1996, ANNU REV MED, V47, P533; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TRIPLETT DA, 1995, THROMB HAEMOSTASIS, V74, P329	29	376	390	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	1997	337	3					154	160		10.1056/NEJM199707173370303	http://dx.doi.org/10.1056/NEJM199707173370303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK818	9219701				2022-12-01	WOS:A1997XK81800003
J	Rowe, JA; Moulds, JM; Newbold, CI; Miller, LH				Rowe, JA; Moulds, JM; Newbold, CI; Miller, LH			P-falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1	NATURE			English	Article							PLASMODIUM-FALCIPARUM; INFECTED ERYTHROCYTES; SWAIN-LANGLEY; MALARIA; EXPRESSION; PHENOTYPES; CYTOADHERENCE; ANTIGENS; SURFACE; DOMAINS	The factors determining disease severity in malaria are complex and include host polymorphisms, acquired immunity and parasite virulence(1). Studies in Africa have shown that severe malaria is associated with the ability of erythrocytes infected with the parasite Plasmodium falciparum to bind uninfected erythrocytes and form rosettes(2-5). The molecular basis of resetting is not well understood, although a group of low-molecular-mass proteins called rosettins have been described as potential parasite ligands(6). Infected erythrocytes also bind to endothelial cells, and this interaction is mediated by the parasite-derived variant erythrocyte membrane protein PfEMP1 (refs 7, 8), which is encoded by the var gene family(9-11). Here we report that the parasite ligand for resetting in a P. falciparum done is PfEMP1, encoded by a specific var gene, We also report that Complement-receptor 1 (CR1) on erythrocytes plays a role in the formation of rosettes and that erythrocytes with a common African CR1 polymorphism (Sl(a(-)))(12) have reduced adhesion to the domain of PfEMP1 that binds normal erythrocytes. Thus we describe a new adhesive function for PfEMP1 and raise the possibility that CR1 polymorphisms in Africans that influence the interaction between erythrocytes and PfEMP1 may protect against severe malaria.	JOHN RADCLIFFE HOSP,INST MOL MED,MOL PARASITOL GRP,OXFORD OX3 9DU,ENGLAND; UNIV TEXAS,HOUSTON MED SCH,DIV RHEUMATOL & CLIN IMMUNOGENET,HOUSTON,TX 77030	University of Oxford; University of Texas System; University of Texas Health Science Center Houston	Rowe, JA (corresponding author), NIAID,PARASIT DIS LAB,NIH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Newbold, Chris/0000-0002-9274-3789; Rowe, Alexandra/0000-0002-7702-1892	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arnold C, 1991, PCR Methods Appl, V1, P39; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; CARLSON J, 1992, J EXP MED, V176, P1311, DOI 10.1084/jem.176.5.1311; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; HANDUNNETTI SM, 1992, AM J TROP MED HYG, V46, P371, DOI 10.4269/ajtmh.1992.46.371; HANDUNNETTI SM, 1992, BLOOD, V80, P2097; HELMBY H, 1993, INFECT IMMUN, V61, P284, DOI 10.1128/IAI.61.1.284-288.1993; HILL AVS, 1992, T ROY SOC TROP MED H, V86, P225, DOI 10.1016/0035-9203(92)90282-H; MILLER LH, 1994, P NATL ACAD SCI USA, V91, P2415, DOI 10.1073/pnas.91.7.2415; MOULDS JM, 1992, VOX SANG, V62, P230, DOI 10.1111/j.1423-0410.1992.tb01204.x; MOULDS JM, 1991, J EXP MED, V173, P1159, DOI 10.1084/jem.173.5.1159; MOULDS MK, 1981, AM J MED TECHNOL, V47, P789; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; RINGWALD P, 1993, INFECT IMMUN, V61, P5198, DOI 10.1128/IAI.61.12.5198-5204.1993; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; ROWE A, 1994, EXP PARASITOL, V79, P506, DOI 10.1006/expr.1994.1111; ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995; Scholander C, 1996, NAT MED, V2, P204, DOI 10.1038/nm0296-204; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503, DOI 10.4269/ajtmh.1992.46.503; VENGELENTYLER V, 1996, AABB TECHNICAL MANUA; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; Yadava A, 1996, P NATL ACAD SCI USA, V93, P4595, DOI 10.1073/pnas.93.10.4595	29	451	460	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 17	1997	388	6639					292	295		10.1038/40888	http://dx.doi.org/10.1038/40888			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL121	9230440	Bronze			2022-12-01	WOS:A1997XL12100055
J	Freeman, G; Hjortdahl, P				Freeman, G; Hjortdahl, P			What future for continuity of care in general practice?	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; PRACTITIONERS KNOWLEDGE; PATIENT SATISFACTION; PERSONAL CONTINUITY; DOCTOR; CONSULTATIONS; QUALITY; VIEWS; KEY		UNIV OSLO,DEPT GEN PRACTICE & COMMUNITY MED,N-0317 OSLO,NORWAY	University of Oslo	Freeman, G (corresponding author), UNIV LONDON,CHARING CROSS & WESTMINSTER MED SCH,DEPT PUBL HLTH & PRIMARY CARE,LONDON SW10 9NH,ENGLAND.							BAKER R, 1995, BRIT J GEN PRACT, V45, P654; Baker R, 1996, BRIT J GEN PRACT, V46, P601; BANAHAN BF, 1981, J FAM PRACTICE, V12, P767; BECKER MH, 1974, AM J PUBLIC HEALTH, V64, P1062, DOI 10.2105/AJPH.64.11.1062; BRESLAU N, 1982, MED CARE, V20, P347, DOI 10.1097/00005650-198204000-00001; CHACKO MR, 1987, J ADOLESCENT HEALTH, V8, P261, DOI 10.1016/0197-0070(87)90429-3; DIETRICH AJ, 1982, J FAM PRACTICE, V15, P929; ETTLINGER PRA, 1981, BRIT MED J, V282, P1192, DOI 10.1136/bmj.282.6271.1192; FLYNN SP, 1985, J FAM PRACTICE, V21, P375; FREEDMAN R, 1987, ALCOHOL, V4, P249, DOI 10.1016/0741-8329(87)90019-X; FREEMAN G, 1984, FAM PRACT, V1, P245, DOI 10.1093/fampra/1.4.245; Freeman G., 1985, J ROYAL COLL GEN PRA, V5, P423; FREEMAN GK, 1994, BRIT J GEN PRACT, V44, P395; FREEMAN GK, 1989, J ROY COLL GEN PRACT, V39, P145; FREEMAN GK, 1993, BRIT J GEN PRACT, V43, P493; Freidson E., 1970, PROFESSION MED STUDY; *GEN MED SERV COMM, 1995, COR GEN MED SERV CLA; GORLIN R, 1983, NEW ENGL J MED, V308, P1059, DOI 10.1056/NEJM198305053081804; GROL R, 1985, FAM PRACT, V2, P128, DOI 10.1093/fampra/2.3.128; Haig-Smith C, 1989, BRIT MED J, V299, P494; Harris MF, 1996, MED J AUSTRALIA, V164, P456, DOI 10.5694/j.1326-5377.1996.tb122119.x; Heath I., 1995, MYSTERY GEN PRACTICE; Hennen B K, 1975, J Fam Pract, V2, P371; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; Hjortdahl P, 1990, Fam Med, V22, P361; HJORTDAHL P, 1992, FAM PRACT, V9, P3, DOI 10.1093/fampra/9.1.3; LEWIS JR, 1994, SOC SCI MED, V39, P655, DOI 10.1016/0277-9536(94)90022-1; MCWHINNEY IR, 1989, TXB FAMILY MED, P12; MILLER MH, 1973, J HEALTH SOC BEHAV, V14, P176, DOI 10.2307/2137067; MOREHEAD MA, 1974, MED CARE, V12, P301, DOI 10.1097/00005650-197404000-00002; PENDLETON DA, 1996, OXFORD GEN PRACTICE, V37; PHILLIPS DM, 1984, J FAM PRACTICE, V19, P793; PRATT J, 1995, PRACTITIONERS PRACTI, P60; ROOS LL, 1980, MED CARE, V18, P174, DOI 10.1097/00005650-198002000-00004; *ROYAL COLL GEN PR, 1985, EV ROYAL COMM NAT HL, P1; Schon Donald A., 1988, ED REFLECTIVE PRACTI; SMITH WG, 1985, EVAL HEALTH PROF, V8, P339, DOI 10.1177/016327878500800305; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; STARFIELD B, 1980, AM J PUBLIC HEALTH, V70, P117, DOI 10.2105/AJPH.70.2.117; VANDULMEN AM, 1995, PSYCHOL MED, V25, P1011, DOI 10.1017/S0033291700037508; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WILLIAMS SJ, 1991, FAM PRACT, V8, P237, DOI 10.1093/fampra/8.3.237; WILSON M, 1996, MED WORKFORCE	44	105	107	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 28	1997	314	7098					1870	1873		10.1136/bmj.314.7098.1870	http://dx.doi.org/10.1136/bmj.314.7098.1870			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XH738	9224130	Green Published			2022-12-01	WOS:A1997XH73800025
J	Sallusto, F; Mackay, CR; Lanzavecchia, A				Sallusto, F; Mackay, CR; Lanzavecchia, A			Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells	SCIENCE			English	Article							EOSINOPHIL CHEMOATTRACTANT; FUNCTIONAL-PROPERTIES; MOLECULAR-CLONING; PHENOTYPE; ASTHMA; INTERLEUKIN-4; INFLAMMATION; ACTIVATION; MECHANISM; ANTIGEN	There is growing evidence that T helper cell subsets (T(H)1 and T(H)2) can be differentially recruited to promote different types of inflammatory reactions. Murine T(H)1 but not T(H)2 cells are recruited through P-and E-selectin into inflamed tissues, where they induce delayed-type hypersensitivity reactions. The human eotaxin-receptor CCR3, originally described on eosinophils and basophils, was also found to be expressed by T(H)2 cells. An antibody to CCR3 was used to isolate T cells from peripheral blood that give rise to T(H)2-polarized cell lines and to identify T(H)2 cells derived from naive T cells in vitro. Eotaxin stimulated increases in intracellular calcium and chemotaxis of CCR3(+) T cells. The attraction of T(H)2 cells by eotaxin could represent a key mechanism in allergic reactions, because it promotes the allergen-driven production of interleukin-4 and interleukin-5 necessary to activate basophils and eosinophils.	LEUKOSITE INC,CAMBRIDGE,MA 02142		Sallusto, F (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340				Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; FORRSMANN U, 1997, J EXP MED, V185, P2171; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GERBER BO, UNPUB; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Lichtman AH, 1997, CURR BIOL, V7, P242; MACKAY CR, UNPUB; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SAD S, 1994, J IMMUNOL, V153, P3514; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SALLUSTO F, UNPUB; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; SOMASSE T, 1996, J EXP MED, V184, P473; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; UGUCCIONI MG, IN PRESS J CLIN INVE; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577	36	889	919	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					2005	2007		10.1126/science.277.5334.2005	http://dx.doi.org/10.1126/science.277.5334.2005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302298				2022-12-01	WOS:A1997XX84900048
J	Lesburg, CA; Zhai, GZ; Cane, DE; Christianson, DW				Lesburg, CA; Zhai, GZ; Cane, DE; Christianson, DW			Crystal structure of pentalenene synthase: Mechanistic insights on terpenoid cyclization reactions in biology	SCIENCE			English	Article							SESQUITERPENE CYCLASES; FARNESYL PYROPHOSPHATE; ENZYMATIC CYCLIZATION; BIOSYNTHESIS; STEREOCHEMISTRY; PURIFICATION; DIPHOSPHATE; STRATEGY; PROTEINS; PATHWAY	The crystal structure of pentalenene synthase at 2.6 angstrom resolution reveals critical active site features responsible for the cyclization of farnesyl diphosphate into the tricyclic hydrocarbon pentalenene. Metal-triggered substrate ionization initiates catalysis, and the alpha-barrel active site serves as a template to channel and stabilize the conformations of reactive carbocation intermediates through a complex cyclization cascade. The core active site structure of the enzyme may be preserved among the greater family of terpenoid synthases, possibly implying divergence from a common ancestral synthase to satisfy biological requirements for increasingly diverse natural products.	UNIV PENN, DEPT CHEM, ROY & DIANA VAGELOS LABS, PHILADELPHIA, PA 19104 USA; BROWN UNIV, DEPT CHEM, PROVIDENCE, RI 02912 USA	University of Pennsylvania; Brown University								ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; Back KW, 1996, P NATL ACAD SCI USA, V93, P6841, DOI 10.1073/pnas.93.13.6841; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1991, PHILOS T ROY SOC B, V332, P123, DOI 10.1098/rstb.1991.0040; CANE DE, 1984, BIOORG CHEM, V12, P312, DOI 10.1016/0045-2068(84)90013-0; CANE DE, 1994, CAN J CHEM, V72, P118, DOI 10.1139/v94-019; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CANE DE, 1985, ACCOUNTS CHEM RES, V18, P220, DOI 10.1021/ar00115a005; Cane DE, 1996, J AM CHEM SOC, V118, P1563, DOI 10.1021/ja953751n; CANE DE, 1990, J AM CHEM SOC, V112, P4513, DOI 10.1021/ja00167a059; CHAYET L, 1984, BIOORG CHEM, V12, P329, DOI 10.1016/0045-2068(84)90014-2; Corey EJ, 1997, J AM CHEM SOC, V119, P1277, DOI 10.1021/ja963227w; Corey EJ, 1997, J AM CHEM SOC, V119, P1289, DOI 10.1021/ja963228o; Corey EJ, 1996, J AM CHEM SOC, V118, P11982, DOI 10.1021/ja9632926; COREY EJ, 1995, J AM CHEM SOC, V117, P11819, DOI 10.1021/ja00152a030; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; DEHAL SS, 1988, ARCH BIOCHEM BIOPHYS, V261, P346, DOI 10.1016/0003-9861(88)90350-5; Dolara P, 1996, NATURE, V379, P29, DOI 10.1038/379029a0; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESBURG CA, 1995, PROTEIN SCI, V4, P2436, DOI 10.1002/pro.5560041124; LESBURG CA, UNPUB; Lin XY, 1996, BIOCHEMISTRY-US, V35, P2968, DOI 10.1021/bi9526239; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MICHIE CA, 1991, J ROY SOC MED, V84, P602; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nyborg J., 1977, ROTATION METHOD CRYS, P139; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLINY, 1969, NATURALIS HIST; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; RUZICKA L., 1963, PURE AND APPL CHEM, V6, P493, DOI 10.1351/pac196306040493; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018	44	335	353	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1820	1824		10.1126/science.277.5333.1820	http://dx.doi.org/10.1126/science.277.5333.1820			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295272				2022-12-01	WOS:A1997XX29800046
J	Masson, GS; Busettini, C; Miles, FA				Masson, GS; Busettini, C; Miles, FA			Vergence eye movements in response to binocular disparity without depth perception	NATURE			English	Article							VIEWING DISTANCE; VISUAL-CORTEX; MONKEY; DEPENDENCE; MECHANISMS; STEREOPSIS; MOTION	Primates use vergence eye movements to align their two eyes on the same object and can correct misalignments by sensing the difference in the positions of the two retinal images of the object (binocular disparity). When large random-dot patterns are viewed dichoptically and small binocular misalignments are suddenly imposed (disparity steps), corrective vergence eye movements are elicited at ultrashort latencies(1,2). Here we show that the same steps applied to dense anticorrelated patterns, in which each black dot in one eye is matched to a white dot in the other eye, initiate vergence responses that are very similar, except that they are in the opposite direction. This sensitivity to the disparity of anticorrelated patterns is shared by many disparity-selective neurons in cortical area V1 (ref. 3), despite the fact that human subjects fail to perceive depth in such stimuli(4,5). These data indicate that the vergence eye movements initiated at ultrashort latencies result solely from locally matched binocular features, and derive their visual input from an early stage of cortical processing before the level at which depth percepts are elaborated.	NEI,SENSORIMOTOR RES LAB,NIH,BETHESDA,MD 20892; CNRS,CTR RECH NEUROSCI COGNIT,F-13402 MARSEILLE,FRANCE	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Centre National de la Recherche Scientifique (CNRS)			MASSON, Guillaume S/G-4615-2012	MASSON, Guillaume S/0000-0001-9227-0777				BISHOP PO, 1986, VISION RES, V26, P1587, DOI 10.1016/0042-6989(86)90177-X; Busettini C, 1996, J NEUROPHYSIOL, V75, P1392, DOI 10.1152/jn.1996.75.4.1392; BUSETTINI C, 1994, EXP BRAIN RES, V100, P484, DOI 10.1007/BF02738407; Busettini C., 1994, Society for Neuroscience Abstracts, V20, P1403; COGAN AI, 1993, VISION RES, V33, P1959, DOI 10.1016/0042-6989(93)90021-N; Collewijn H, 1990, Rev Oculomot Res, V4, P213; Cumming BG, 1997, NATURE, V389, P280, DOI 10.1038/38487; CUMMING BG, 1986, J NEUROPHYSIOL, V55, P896, DOI 10.1152/jn.1986.55.5.896; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; JUDGE SJ, 1991, VISION VISUAL DYSFUN, V8, P157; JULESZ B, 1960, AT&T TECH J, V39, P1125, DOI 10.1002/j.1538-7305.1960.tb03954.x; MITCHELL DE, 1970, VISION RES, V10, P145, DOI 10.1016/0042-6989(70)90112-4; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; Parker A. J., 1996, Investigative Ophthalmology and Visual Science, V37, pS424; POGGIO GF, 1995, CEREB CORTEX, V5, P193, DOI 10.1093/cercor/5.3.193; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; QIAN N, 1994, NEURAL COMPUT, V6, P390, DOI 10.1162/neco.1994.6.3.390; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P339, DOI 10.1113/jphysiol.1961.sp006812; REGAN D, 1986, INVEST OPHTH VIS SCI, V27, P584; Trotter Y, 1996, J NEUROPHYSIOL, V76, P2872, DOI 10.1152/jn.1996.76.5.2872; WESTHEIMER G, 1969, VISION RES, V9, P749, DOI 10.1016/0042-6989(69)90012-1	21	175	178	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					283	286		10.1038/38496	http://dx.doi.org/10.1038/38496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305842				2022-12-01	WOS:A1997XW77200047
J	Somasundaram, K; Zhang, HB; Zeng, YX; Houvras, Y; Peng, Y; Zhang, HX; Wu, GS; Licht, JD; Weber, BL; ElDeiry, WS				Somasundaram, K; Zhang, HB; Zeng, YX; Houvras, Y; Peng, Y; Zhang, HX; Wu, GS; Licht, JD; Weber, BL; ElDeiry, WS			Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21(WAF1/CiP1)	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; CANCER-CELLS; HUMAN BREAST; GENE BRCA1; EXPRESSION; MOUSE	Much of the predisposition to hereditary breast and ovarian cancer has been attributed to inherited defects in the BRCA1 tumour-suppressor gene(1-3). The nuclear protein BRCA1 has the properties of a transcription factor(4-7), and can interact with the recombination and repair protein pAD51 (ref. 8), Young women with germline alterations in BRCA1 develop breast cancer at rates 100-fold higher than the general population(3), and BRCA1-null mice die before day 8 of development(9,10). However, the mechanisms of BRCA1-mediated growth regulation and tumour suppression remain unknown, Here we show that BRCA1 transactivates expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in a p53-independent manner, and that BRCA1 inhibits cell-cycle progression into the S-phase following its transfection into human cancer cells, BRCA1 does not inhibit S-phase progression in p21(-/-) cells, unlike p21(+/+) cells, and tumour-associated, transactivation-deficient mutants of BRCA1 are defective in both transactivation of p21 and cell-cycle inhibition, These data suggest that one mechanism by which BRCA1 contributes to cell-cycle arrest and growth suppression is through the induction of p21.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,LAB MOL ONCOL & CELL CYCLE REGULAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR CANC,PHILADELPHIA,PA 19104; CUNY MT SINAI SCH MED,BROOKDALE CTR DEV & MOL BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			El-Deiry, Wafik/AAJ-6080-2020; Licht, Jonathan/L-4239-2019	El-Deiry, Wafik/0000-0002-9577-8266; Houvras, Yariv/0000-0003-0751-3215; Licht, Jonathan/0000-0002-3942-1369				Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WALDMAN T, 1995, CANCER RES, V55, P5187; Zeng YX, 1997, BIOTECHNIQUES, V23, P88, DOI 10.2144/97231bm19; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZHANG W, 1995, CANCER RES, V55, P668	25	461	484	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					187	190		10.1038/38291	http://dx.doi.org/10.1038/38291			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296497				2022-12-01	WOS:A1997XV75700050
J	Canagarajah, BJ; Khokhlatchev, A; Cobb, MH; Goldsmith, EJ				Canagarajah, BJ; Khokhlatchev, A; Cobb, MH; Goldsmith, EJ			Activation mechanism of the MAP kinase ERK2 by dual phosphorylation	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; GROWTH-FACTOR; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; DOMAIN; IDENTIFICATION; SPECIFICITY; INSULIN	The structure of the active form of the MAP kinase ERK2 has been solved, phosphorylated on a threonine and a tyrosine residue within the phosphorylation lip. The lip is refolded, bringing the phosphothreonine and phosphotyrosine into alignment with surface arginine-rich binding sites. Conformational changes occur in the lip and neighboring structures, including the P+1 site, the MAP kinase insertion, the C-terminal extension, and helix C. Domain rotation and remodeling of the proline-directed P+1 specificity pocket account for the activation. The conformation of the P+1 pocket is similar to a second proline-directed kinase, CDK2-CyclinA, thus permitting the origin of this specificity to be defined. Conformational changes outside the lip provide loci at which the state of phosphorylation can be felt by other cellular components.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046993] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46993] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENG P, 1992, SCIENCE, V257, P1404; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Goldsmith EJ, 1996, FASEB J, V10, P702, DOI 10.1096/fasebj.10.7.8635687; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1993, O VERSION 5 9; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Wilson KP, 1996, J BIOL CHEM, V271, P27696, DOI 10.1074/jbc.271.44.27696; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	75	605	620	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					859	869		10.1016/S0092-8674(00)80351-7	http://dx.doi.org/10.1016/S0092-8674(00)80351-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298898	Bronze			2022-12-01	WOS:A1997XV56300007
J	Sinclair, DA; Mills, K; Guarente, L				Sinclair, DA; Mills, K; Guarente, L			Accelerated aging and nucleolar fragmentation yeast sgs1 mutants	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CLONING; GENE; DNA; HELICASE; HOMOLOG; RECQ; TRANSCRIPTION; INTERACTS; TELOMERES	The SGS1 gene of yeast encodes a DNA helicase with homology to the human WRN gene. Mutations in WRN result in Werner's syndrome, a disease with symptoms resembling premature aging. Mutation of SGS1 is shown to cause premature aging in yeast mother cells on the basis of a shortened life-span and the aging-induced phenotypes of sterility and redistribution of the Sir3 silencing protein from telomeres to the nucleolus. Further, in old sgs1 cells the nucleolus is enlarged and fragmented-changes that also occur in old wild-type cells. These findings suggest a conserved mechanism of cellular aging that may be related to nucleolar structure.			Sinclair, DA (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sinclair, David/0000-0002-9936-436X	NATIONAL INSTITUTE ON AGING [R37AG011119, R01AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMSTONE FB, 1979, J MORPHOL, V154, P459; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FOREMAN PK, 1994, GENE, V144, P63, DOI 10.1016/0378-1119(94)90204-6; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HALLE J, IN PRESS EUR J CELL; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kim S, 1996, BIOCHEM BIOPH RES CO, V219, P370, DOI 10.1006/bbrc.1996.0240; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; MARTIN GM, 1985, ADV EXP MED BIOL, V190, P161; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; PUVIONDUTILLEUL F, 1983, EXP CELL RES, V138, P423; RINE J, 1987, GENETICS, V116, P9; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEINSTEIN ME, 1988, MECH AGEING DEV, V42, P215, DOI 10.1016/0047-6374(88)90048-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	36	309	316	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 29	1997	277	5330					1313	1316		10.1126/science.277.5330.1313	http://dx.doi.org/10.1126/science.277.5330.1313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT827	9271578				2022-12-01	WOS:A1997XT82700057
J	Kimura, K; Hirano, T				Kimura, K; Hirano, T			ATP-dependent positive supercoiling of DNA by 13S condensin: A biochemical implication for chromosome condensation	CELL			English	Article							UBIQUITOUS PROTEIN FAMILY; ESCHERICHIA-COLI; DOSAGE COMPENSATION; CRUCIFORM DNA; SMC FAMILY; GENE; TOPOISOMERASE; TEMPLATE; DOMAINS; DEFINES	13S condensin is a five-subunit protein complex that plays a central role in mitotic chromosome condensation in Xenopus egg extracts. Two core subunits of this complex, XCAP-C and XCAP-E, belong to an emerging family of putative ATPases, the SMC family. We report here that 13S condensin has a DNA-stimulated ATPase activity and exhibits a high affinity for structured DNAs such as cruciform DNA. 13S condensin is able to introduce positive supercoils into a closed circular DNA in the presence of bacterial or eukaryotic topoisomerase I. The supercoiling reaction is ATP-dependent. We propose that 13S condensin wraps DNA in a right-handed direction by utilizing the energy of ATP hydrolysis. This reaction may represent a key mechanism underlying the compaction of chromatin fibers during mitosis.			Kimura, K (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NIGMS NIH HHS [GM53926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; Earnshaw WC, 1991, CURR OPIN STRUC BIOL, V1, P237, DOI 10.1016/0959-440X(91)90068-5; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; MULLINGER AM, 1980, J CELL SCI, V46, P61; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; NAKASU S, 1985, EMBO J, V4, P2705, DOI 10.1002/j.1460-2075.1985.tb03990.x; Oguro A, 1995, DNA Res, V2, P95, DOI 10.1093/dnares/2.2.95; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SEDAT J, 1977, COLD SPRING HARB SYM, V42, P331, DOI 10.1101/SQB.1978.042.01.035; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; TANABE K, 1991, CANCER RES, V51, P4903; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YANG L, 1989, P NATL ACAD SCI USA, V86, P6121, DOI 10.1073/pnas.86.16.6121; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	48	310	318	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					625	634		10.1016/S0092-8674(00)80524-3	http://dx.doi.org/10.1016/S0092-8674(00)80524-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288743	Bronze			2022-12-01	WOS:A1997XT06600007
J	Pierre, P; Turley, SJ; Gatti, E; Hull, M; Meltzer, J; Mirza, A; Inaba, K; Steinman, RM; Mellman, I				Pierre, P; Turley, SJ; Gatti, E; Hull, M; Meltzer, J; Mirza, A; Inaba, K; Steinman, RM; Mellman, I			Developmental regulation of MHC class II transport in mouse dendritic cells	NATURE			English	Article							LANGERHANS CELLS; COMPARTMENTS; MOLECULES; COMPLEX; EXPRESSION; ENDOSOMES; LYSOSOMES; MEMBRANE; PEPTIDE	Dendritic cells (DCs) have the unique capacity to initiate primary and secondary immune responses(1-3). They acquire antigens in peripheral tissues and migrate to lymphoid organs where they present processed peptides to T cells. DCs must therefore exist in distinct functional states, an idea that is supported by observations that they downregulate endocytosis and upregulate surface molecules of the class II major histocompatibility complex (MHC) upon maturation(4-7). Here we investigate the features of DC maturation by reconstituting the terminal differentiation of mouse DCs in vitro and in situ. We find that early DCs, corresponding to those found in peripheral tissues, exhibit a phenotype in which most class II molecules are intracellular and localized to lysosomes. Upon maturation, these cells give rise to a new intermediate phenotype in which intracellular class II molecules are found in peripheral non-lysosomal vesicles, similar to the specialized CIIV population seen in B cells. The intermediate cells then differentiate into late DCs which express almost all of their class II molecules on the plasma membrane. These variations in class II compartmentalization are accompanied by dramatic alterations in the intracellular transport of the ne iv class II molecules and in antigen presentation. We found that although early DCs could not present antigen immediately after uptake, efficient presentation of the previously internalized antigen occurred after maturation, 24-48 hours later. By regulating class II transport and compartmentalization, DCs are able to delay antigen display, a property crucial to their role in immune surveillance.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520; ROCKEFELLER UNIV,NEW YORK,NY 10021	Yale University; Rockefeller University			Steinman, Ralph/F-7729-2012; Mellman, Ira/ABG-5896-2020; Gatti, Evelina/B-7941-2012	Gatti, Evelina/0000-0002-0667-0799; pierre, philippe/0000-0003-0863-8255				AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; Austyn JM, 1996, J EXP MED, V183, P1287, DOI 10.1084/jem.183.4.1287; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; CAUX C, 1996, BLOOD CELL BIOCH, P263; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KLEIJMEER MJ, 1995, J IMMUNOL, V154, P5715; LARSEN CP, 1994, J IMMUNOL, V152, P5208; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; THOMAS R, 1997, IMMUNOL TODAY, V17, P559; WILLIAMS LA, 1994, INT REV CYTOL, V153, P41, DOI 10.1016/S0074-7696(08)62188-9	26	631	640	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					787	792		10.1038/42039	http://dx.doi.org/10.1038/42039			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285592	Bronze			2022-12-01	WOS:A1997XR66700054
J	Cousens, SN; Zeidler, M; Esmonde, TF; DeSilva, R; Wilesmith, JW; Smith, PG; Will, RG				Cousens, SN; Zeidler, M; Esmonde, TF; DeSilva, R; Wilesmith, JW; Smith, PG; Will, RG			Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96	BRITISH MEDICAL JOURNAL			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; ENGLAND; BSE	Objective: To identify changes in the occurrence of Creutzfeldt-Jakob disease that might be related to the epidemic of bovine spongiform encephalopathy. Design: Epidemiological surveillance of the United Kingdom population for Creutzfeldt-Jakob disease based on (a) referral of suspected cases by neurologists, neuropathologists, and neurophysiologists and (b) death certificates. Setting: England and Wales during 1970-84, and whole of the United Kingdom during 1985-96. Subjects: AU 662 patients identified as sporadic cases of Creutzfeldt-Jakob disease. Main outcome measures: Age distribution of patients, age specific time trends of disease, occupational exposure to cattle, potential exposure to causative agent of bovine spongiform encephalopathy. Results: During 1970-96 there was an increase in the number of sporadic cases of Creutzfeldt-Jakob disease recorded yearly in England and Wales. The greatest increase was among people aged over 70. There was a statistically significant excess of cases among dairy farm workers and their spouses and among people at increased risk of contact with live cattle infected with bovine spongiform encephalopathy. During 1994-6 there were six deaths from sporadic Creutzfeldt-Jakob disease in the United Kingdom in patients aged under 30. Conclusions: The increase in the incidence of sporadic Creutzfeldt-Jakob disease and the high incidence in dairy farmers in the United Kingdom may be unrelated to bovine spongiform encephalopathy. The most striking change in the pattern of Creutzfeldt-Jakob disease in the United Kingdom after the epidemic of bovine spongiform encephalopathy is provided by the incidence in a group of exceptionally young patients with a consistent and unusual neuropathological profile. The outcome of mouse transmission studies and the future incidence of the disease in the United Kingdom and elsewhere, will be important in judging whether the agent causing bovine spongiform encephalopathy has infected humans.	WESTERN GEN HOSP,NATL CREUTZFELDT JAKOB DIS SURVEILLANCE UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; CENT VET LAB,ADDLESTONE KT15 3NB,SURREY,ENGLAND	University of Edinburgh	Cousens, SN (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT INFECT & TROP DIS,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560				AYLIN P, 1996, POPUL TRENDS, V85, P34; BELL JE, 1993, BRIT MED BULL, V49, P738, DOI 10.1093/oxfordjournals.bmb.a072645; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Bruton CJ, 1995, NEURODEGENERATION, V4, P357, DOI 10.1006/neur.1995.0043; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COUSENS SN, 1990, J NEUROL NEUROSUR PS, V53, P459, DOI 10.1136/jnnp.53.6.459; DAVIES PTG, 1993, LANCET, V342, P680, DOI 10.1016/0140-6736(93)91787-M; HARRIESJONES R, 1988, J NEUROL NEUROSUR PS, V51, P113; Hill AF, 1997, LANCET, V350, P188, DOI 10.1016/S0140-6736(05)62356-2; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MEYER LA, 1996, THESIS; *NAT CJD SURV UN, 1995, 4 ANN REP DEP HLTH; SAWCER SJ, 1993, LANCET, V341, P642, DOI 10.1016/0140-6736(93)90414-C; SMITH PEM, 1995, LANCET, V346, P898, DOI 10.1016/S0140-6736(95)92734-4; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; Wickham A, 1996, BRIT MED J, V312, P1038; WILESMITH JW, 1988, VET REC, V123, P638; WILESMITH JW, 1994, SEMIN VIROL, V5, P179, DOI 10.1006/smvy.1994.1018; WILL RG, 1986, J NEUROL NEUROSUR PS, V49, P749, DOI 10.1136/jnnp.49.7.749; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1984, J NEUROL NEUROSUR PS, V47, P134, DOI 10.1136/jnnp.47.2.134; Will Robert G., 1996, P119; Young GR, 1996, LANCET, V348, P610, DOI 10.1016/S0140-6736(05)64822-2	24	90	91	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					389	395		10.1136/bmj.315.7105.389	http://dx.doi.org/10.1136/bmj.315.7105.389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR549	9277601	Green Published			2022-12-01	WOS:A1997XR54900017
J	Sultan, AA; Thathy, V; Frevert, U; Robson, KJH; Crisanti, A; Nussenzweig, V; Nussenzweig, RS; Menard, R				Sultan, AA; Thathy, V; Frevert, U; Robson, KJH; Crisanti, A; Nussenzweig, V; Nussenzweig, RS; Menard, R			TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites	CELL			English	Article							MALARIA CIRCUMSPOROZOITE PROTEIN; HOST-CELL INVASION; FALCIPARUM SPOROZOITES; PROTECTIVE ANTIGEN; ANONYMOUS PROTEIN; SURFACE PROTEIN-2; EIMERIA-TENELLA; SALIVARY-GLAND; BLOOD STAGES; REGION-II	Many protozoans of the phylum Apicomplexa are invasive parasites that exhibit a substrate-dependent gliding motility. Plasmodium (malaria) sporozoites, the stage of the parasite that invades the salivary glands of the mosquito vector and the liver of the vertebrate host, express a surface protein called thrombospondin-related anonymous protein (TRAP) that has homologs in other Apicomplexa. By gene targeting in a rodent Plasmodium, we demonstrate that TRAP is critical for sporozoite infection of the mosquito salivary glands and the rat liver, and is essential for sporozoite gliding motility in vitro. This suggests that in Plasmodium sporozoites, and likely in other Apicomplexa, gliding locomotion and cell invasion have a common molecular basis.	NYU, MED CTR,MICHAEL HEIDELBERGER DIV IMMUNOL, DEPT PATHOL,KAPLAN CANC CTR, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT MED & MOL PARASITOL, NEW YORK, NY 10016 USA; JOHN RADCLIFFE HOSP, INST MOL MED, MRC, MOL HAEMATOL UNIT, OXFORD OX3 9DU, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND	New York University; New York University; University of Oxford; Imperial College London				Frevert, Ute/0000-0001-9556-7330; Thathy, Vandana/0000-0001-7797-8638				AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; ARROWOOD MJ, 1991, J PARASITOL, V77, P315, DOI 10.2307/3283104; BALL GH, 1961, J PARASITOL, V47, P787, DOI 10.2307/3275472; BELER JC, 1993, PARASITOL TODAY, V9, P210; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CERAMI C, 1992, MOL BIOCHEM PARASIT, V54, P1, DOI 10.1016/0166-6851(92)90089-3; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Dobrowolski JM, 1996, CELL, V84, P933, DOI 10.1016/S0092-8674(00)81071-5; DUBREMETZ JF, 1978, J ULTRA MOL STRUCT R, V62, P94, DOI 10.1016/S0022-5320(78)90012-6; DUBREMETZ JF, 1985, EXP PARASITOL, V59, P24, DOI 10.1016/0014-4894(85)90053-0; ENTZEROTH R, 1989, PARASITOL RES, V76, P174, DOI 10.1007/BF00930842; FINE E, 1984, AM J TROP MED HYG, V33, P220, DOI 10.4269/ajtmh.1984.33.220; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; HOLLINGDALE MR, 1982, J IMMUNOL, V128, P1929; JENSEN JB, 1978, J PROTOZOOL, V25, P169, DOI 10.1111/j.1550-7408.1978.tb04391.x; KING CA, 1988, PARASITOL TODAY, V4, P315, DOI 10.1016/0169-4758(88)90113-5; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; NAGASAWA H, 1988, EXP PARASITOL, V66, P27, DOI 10.1016/0014-4894(88)90047-1; Nussenzweig RS, 1997, NEW ENGL J MED, V336, P128, DOI 10.1056/NEJM199701093360210; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; PIMENTA PF, 1994, J EUKARYOT MICROBIOL, V41, P608, DOI 10.1111/j.1550-7408.1994.tb01523.x; Robson KJH, 1997, MOL BIOCHEM PARASIT, V84, P1, DOI 10.1016/S0166-6851(96)02774-0; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, MOL BIOCHEM PARASIT, V53, P45, DOI 10.1016/0166-6851(92)90005-5; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; RUSSELL DG, 1983, PARASITOLOGY, V87, P199, DOI 10.1017/S0031182000052562; RUSSELL DG, 1981, J CELL SCI, V50, P345; RYNING FW, 1978, INFECT IMMUN, V20, P739, DOI 10.1128/IAI.20.3.739-743.1978; Shakibaei M, 1996, J EXP MED, V184, P1699, DOI 10.1084/jem.184.5.1699; Sinnis P, 1996, J EXP MED, V184, P945, DOI 10.1084/jem.184.3.945; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Sinnis P, 1996, INFECT AGENT DIS, V5, P182; Sinnis Photini, 1996, P15; SPEER CA, 1985, J PARASITOL, V71, P33, DOI 10.2307/3281974; STEWART MJ, 1986, INFECT IMMUN, V51, P859, DOI 10.1128/IAI.51.3.859-864.1986; STEWART MJ, 1988, J PROTOZOOL, V35, P389, DOI 10.1111/j.1550-7408.1988.tb04115.x; STEWART MJ, 1991, J PROTOZOOL, V38, P411, DOI 10.1111/j.1550-7408.1991.tb01379.x; STEWART MJ, 1992, J PROTOZOOL, V39, P663, DOI 10.1111/j.1550-7408.1992.tb04446.x; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Templeton TJ, 1997, MOL BIOCHEM PARASIT, V84, P13, DOI 10.1016/S0166-6851(96)02775-2; TOMLEY FM, 1991, MOL BIOCHEM PARASIT, V49, P277, DOI 10.1016/0166-6851(91)90071-D; VANDERBERG J, 1967, J PROTOZOOL, V14, P82, DOI 10.1111/j.1550-7408.1967.tb01452.x; VANDERBERG JP, 1975, J PARASITOL, V61, P43, DOI 10.2307/3279102; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; VANDERBERG JP, 1990, J PROTOZOOL, V37, P528, DOI 10.1111/j.1550-7408.1990.tb01260.x; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; vanDijk MR, 1996, SCIENCE, V271, P662, DOI 10.1126/science.271.5249.662; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X; WARBURG A, 1992, EXP PARASITOL, V75, P303, DOI 10.1016/0014-4894(92)90215-V; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745	60	469	491	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	1997	90	3					511	522		10.1016/S0092-8674(00)80511-5	http://dx.doi.org/10.1016/S0092-8674(00)80511-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267031	hybrid			2022-12-01	WOS:A1997XQ06300015
J	Maldonado, R; Saiardi, A; Valverde, O; Samad, TA; Roques, BP; Borrelli, E				Maldonado, R; Saiardi, A; Valverde, O; Samad, TA; Roques, BP; Borrelli, E			Absence of opiate rewarding effects in mice lacking dopamine D2 receptors	NATURE			English	Article							VENTRAL TEGMENTAL AREA; MORPHINE-WITHDRAWAL SYNDROME; NUCLEUS-ACCUMBENS; MESOLIMBIC SYSTEM; RATS; HEROIN; INVOLVEMENT; STIMULATION; INCREASE; COCAINE	Dopamine receptors have been implicated in the behavioural response to drugs of abuse. These responses are mediated particularly by the mesolimbic dopaminergic pathway arising in the ventral tegmental area and projecting to the limbic system, The rewarding properties of opiates(1) and the somatic expression of morphine abstinence(2) have been related to changes in mesolimbic dopaminergic activity that could constitute the neural substrate for opioid addiction(3), These adaptive responses to repeated morphine administration have been investigated in mice with a genetic disruption of the dopaminergic D2 receptors(4). Although the behavioural expression of morphine withdrawal was unchanged in these mice, a total suppression of morphine rewarding properties was observed in a place-preference test. This effect is specific to the drug, as mice lacking D2 receptors behaved the same as wild-type mice when food is used as reward, We conclude that the D2 receptor plays a crucial role in the motivational component of drug addiction.	UNIV STRASBOURG 1, INST GENET & BIOL MOL & CELLULAIRE, CNRS, INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV PARIS 05, DEPT PHARMACOCHIM MOL & STRUCT,CNRS,URA D1500, INSERM,U266, F-75270 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Borrelli, Emiliana/M-8994-2018; Valverde, Olga/D-8654-2012; Maldonado, Rafael/F-5657-2014	Valverde, Olga/0000-0003-2264-7852; Maldonado, Rafael/0000-0002-4359-8773				BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; BORG PJ, 1994, PHARMACOL BIOCHEM BE, V47, P633, DOI 10.1016/0091-3057(94)90169-4; BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X; BOZARTH MA, 1994, NEUROSCI BIOBEHAV R, V18, P373, DOI 10.1016/0149-7634(94)90050-7; BROEKKAMP CL, 1979, PHARMACOL BIOCHEM BE, V11, P289, DOI 10.1016/0091-3057(79)90137-0; DAUGE V, 1989, PSYCHOPHARMACOLOGY, V99, P168, DOI 10.1007/BF00442803; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; ELMER GI, 1995, PSYCHOPHARMACOLOGY, V117, P23, DOI 10.1007/BF02245094; ETTENBERG A, 1982, PSYCHOPHARMACOLOGY, V78, P204, DOI 10.1007/BF00428151; FOURNIEZALUSKI MC, 1992, J MED CHEM, V35, P2473, DOI 10.1021/jm00091a016; HARRIS GC, 1994, NATURE, V371, P155, DOI 10.1038/371155a0; JOYCE EM, 1979, NEUROSCI LETT, V14, P207, DOI 10.1016/0304-3940(79)96149-4; KALIVAS PW, 1986, AM J PHYSIOL, V251, pR243, DOI 10.1152/ajpregu.1986.251.2.R243; KALIVAS PW, 1983, J PHARMACOL EXP THER, V227, P229; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LONGONI R, 1987, PSYCHOPHARMACOLOGY, V93, P401, DOI 10.1007/BF00187265; MACKEY WB, 1985, PHARMACOL BIOCHEM BE, V22, P101, DOI 10.1016/0091-3057(85)90492-7; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MALDONADO R, 1992, J PHARMACOL EXP THER, V261, P669; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; PETTIT HO, 1984, PSYCHOPHARMACOLOGY, V84, P167, DOI 10.1007/BF00427441; PHILLIPS AG, 1980, PHARMACOL BIOCHEM BE, V12, P965, DOI 10.1016/0091-3057(80)90460-8; Salamone JD, 1996, J NEUROSCI METH, V64, P137, DOI 10.1016/0165-0270(95)00125-5; SALAMONE JD, 1994, BEHAV BRAIN RES, V61, P117, DOI 10.1016/0166-4328(94)90153-8; SMITH JE, 1985, PHARMACOL BIOCHEM BE, V23, P843, DOI 10.1016/0091-3057(85)90080-2; SPYRAKI C, 1983, PSYCHOPHARMACOLOGY, V79, P278, DOI 10.1007/BF00427827; STINUS L, 1989, BIOL PSYCHIAT, V26, P363, DOI 10.1016/0006-3223(89)90052-8; Valverde O, 1996, PSYCHOPHARMACOLOGY, V123, P119, DOI 10.1007/BF02246168; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469	30	358	391	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 7	1997	388	6642					586	589		10.1038/41567	http://dx.doi.org/10.1038/41567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252189	Bronze			2022-12-01	WOS:A1997XP72200050
J	Adams, JS; Lee, G				Adams, JS; Lee, G			Gains in bone mineral density with resolution of vitamin D intoxication	ANNALS OF INTERNAL MEDICINE			English	Article							WOMEN; OSTEOPOROSIS; PREVENTION; MILK	Background: Vitamin D intoxication is associated with the mobilization of skeletal calcium. Objective: To ascertain how the resolution of vitamin D intoxication affects bone density. Design: Case series. Setting: Referral service for metabolic bone disease in a tertiary care teaching hospital. Patients: Four patients with osteoporosis who were each using several nonprescription dietary supplements and were found to have fasting hypercalciuria. Intervention: Discontinuation of use of dietary supplements. Measurements: Serial measurement of serum levels of 25-hydroxyvitamin D, ratio of fasting urinary calcium to creatinine, and bone mineral density for 3 years. Results: Discontinuation of use of dietary supplements resulted in the normalization of serum levels of 25-hydroxyvitamin D, the normalization of the ratio of urinary calcium to creatinine, and a mean annual increase in bone mineral density (+/-SD) of 1.9% +/- 0.6%. Conclusions: Occult vitamin D intoxication was detected in patients who were using dietary supplements that contained an unadvertised high level of vitamin D. Resolution of vitamin D intoxication was associated with a rebound in bone mineral density.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Adams, JS (corresponding author), CEDARS SINAI MED CTR, B131, 8700 BEVERLY BLVD, LOS ANGELES, CA 94309 USA.		Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00425-28] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1956, BRIT MED J, V2, P149; BERTHJONES J, 1993, BRIT J DERMATOL, V129, P411, DOI 10.1111/j.1365-2133.1993.tb03168.x; CLEMENS TL, 1990, PRINCIPLES PRACTICE, P417; DIAMOND T, 1994, ANN INTERN MED, V120, P8, DOI 10.7326/0003-4819-120-1-199401010-00002; FRASER DR, 1995, LANCET, V345, P104, DOI 10.1016/S0140-6736(95)90067-5; HENNEY JE, 1993, NEW YORK STATE J MED, V93, P86; HOLICK MF, 1992, NEW ENGL J MED, V326, P1178, DOI 10.1056/NEJM199204303261802; JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052; Parfitt AM, 1996, ANN INTERN MED, V125, P413, DOI 10.7326/0003-4819-125-5-199609010-00009; POUILLES JM, 1992, CLIN RHEUMATOL, V11, P492, DOI 10.1007/BF02283104; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; VANDERSCHUEREN D, 1991, CALCIFIED TISSUE INT, V49, P84, DOI 10.1007/BF02565126; ZERWEKH JE, 1992, OSTEOPOROSIS INT, V2, P128, DOI 10.1007/BF01623819	16	77	81	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					203	206		10.7326/0003-4819-127-3-199708010-00004	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245225				2022-12-01	WOS:A1997XN12900004
J	Meier, DE; Morrison, RS; Cassel, CK				Meier, DE; Morrison, RS; Cassel, CK			Improving palliative care	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CANCER PAIN MANAGEMENT; TERMINALLY ILL PATIENTS; PHYSICIAN ATTITUDES; MEDICAL-EDUCATION; ADVANCE DIRECTIVES; DYING PATIENT; UNITED-STATES; DEATH; HOSPICE; LIFE	Although most deaths in the United States occur in hospitals, data suggest that hospitals and physicians are not equipped to handle the medical and psychosocial problems of dying patients. In this article, we review the barriers to achieving a peaceful death, including inadequate medical professional education on palliative care, and public and professional uncertainty about the difference between forgoing life-sustaining treatment and active euthanasia, and health professionals' difficulty recognizing when patients are dying and the associated sense that death is a professional failure. Other barriers include fiscal constraints on the length of stay, the number of nurses available to care for dying patients, legal and regulatory constraints on obtaining opioid prescriptions, and a segregated system of hospice care that requires patients to be separated from familiar health care providers and settings in order to receive palliative care at the end of life. Identifying the opportunities that can improve the delivery of palliative care at the end of life is the first step toward developing corrective approaches. Strategies that enhance these opportunities are proposed.			Meier, DE (corresponding author), MT SINAI MED CTR, BOX 1070, NEW YORK, NY 10029 USA.							Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; *AM MED ASS, 1993, ANN MED SCH QUEST 2; *AM SOC CLIN ONC A, 1992, J CLIN ONCOL, V10, P1976; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; ANGAROLO R, 1994, APS B, V4, P9; [Anonymous], 1994, AHCPR PUBL, V94-0592; ASCH DA, 1995, AM J RESP CRIT CARE, V151, P288, DOI 10.1164/ajrccm.151.2.7842181; Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BERRY ZS, 1993, JAMA-J AM MED ASSOC, V270, P221, DOI 10.1001/jama.270.2.221; BLANK LL, 1995, WESTERN J MED, V163, P297; Byock I R, 1993, J Palliat Care, V9, P25; Byock I R, 1994, J Palliat Care, V10, P8; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CASSEL C, 1996, ACP OBSERVER     JUL, P2; CASSEL C, 1994, I MED WORKSH EX FEAS; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; CHERNY NI, 1995, CANCER-AM CANCER SOC, V76, P2181, DOI 10.1002/1097-0142(19951201)76:11<2181::AID-CNCR2820761102>3.0.CO;2-F; CHERNY NI, 1994, P AMSLC CLIN ONCOL, V12, pA434; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Christakis NA, 1996, J GEN INTERN MED, V11, P422, DOI 10.1007/BF02600190; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; DICKINSON GE, 1985, J MED EDUC, V60, P942; DIDICH J, 1989, CLEV CLIN J MED, V56, P762, DOI 10.3949/ccjm.56.8.762; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; FORD G, 1993, OXFORD TXB PALLIATIV, P43; GIANELLI D, 1996, AM MED NEWS     0916, P5; Gilligan T, 1996, ANN INTERN MED, V125, P137, DOI 10.7326/0003-4819-125-2-199607150-00010; GRAY D, 1987, J CHRON DIS, V40, P801, DOI 10.1016/0021-9681(87)90132-9; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HAFFERTY FW, 1994, ACAD MED, V69, P861, DOI 10.1097/00001888-199411000-00001; *HAST CTR, 1987, GUID TERM LIF SUST T; HERMAN TA, 1980, NEW YORK STATE J MED, V80, P200; HILL CS, 1995, JAMA-J AM MED ASSOC, V274, P1881, DOI 10.1001/jama.274.23.1881; HILL TP, 1995, ARCH INTERN MED, V155, P1265, DOI 10.1001/archinte.155.12.1265; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; JORANSON DE, 1994, J PAIN SYMPTOM MANAG, V9, P244, DOI 10.1016/0885-3924(94)90101-5; JORANSON DE, 1995, AM PAIN SOC B, V5, P1; KANE AC, 1986, OMEGA, V16, P11; Kane RS, 1996, J AM GERIATR SOC, V44, P321, DOI 10.1111/j.1532-5415.1996.tb00923.x; KIDDER D, 1992, HEALTH SERV RES, V27, P195; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lewin Tamar, 1996, N Y Times Web, pD20; LO B, 1995, JAMA-J AM MED ASSOC, V274, P1634, DOI 10.1001/jama.274.20.1634; LYNN J, 1995, WESTERN J MED, V163, P250; MacDonald N, 1993, J Cancer Educ, V8, P197; MACDONALD N, 1991, CANCER DETECT PREV, V15, P253; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; Meier DE, 1996, ARCH INTERN MED, V156, P1227, DOI 10.1001/archinte.156.11.1227; MEIER DE, 1993, PHYSICIAN ASSISTED D; MERMANN AC, 1991, ACAD MED, V66, P35, DOI 10.1097/00001888-199101000-00010; Miller FG, 1996, NEW ENGL J MED, V334, P1740, DOI 10.1056/NEJM199606273342612; Morrison R S, 1995, Trends Health Care Law Ethics, V10, P91; MORRISON RS, 1995, JAMA-J AM MED ASSOC, V274, P478, DOI 10.1001/jama.274.6.478; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MORRISON RS, 1994, GENERATIONS, V18, P48; NARKIEWICZ R, 1986, AM J HOSP CARE, P12; *NAT CTR HLTH STAT, 1993, VIT STAT US, V2; *NAT HOSP ORG, 1995, NAT HOSP ORG FACT SH; *NEW YORK STAT TAS, 1994, DEATH IS SOUGHT; OJIMCNAIR K, 1984, HLTH MARKETING Q, V2, P119; PERRONE C, 1995, 712901 NAT HOSP ORG; Plumb J D, 1992, Am J Hosp Palliat Care, V9, P32, DOI 10.1177/104990919200900311; Portenoy R K, 1990, J Pain Symptom Manage, V5, pS46; PORTENOY RK, 1992, CANCER-AM CANCER SOC, V70, P1616, DOI 10.1002/1097-0142(19920915)70:6<1616::AID-CNCR2820700630>3.0.CO;2-7; RAPPAPORT W, 1993, SURGERY, V113, P163; SACHS GA, 1995, J AM GERIATR SOC, V43, P553, DOI 10.1111/j.1532-5415.1995.tb06106.x; SCOTT J, 1993, OXFORD TXB PALLIATIV; SCOTT RA, 1995, MILBANK Q, V73, P77, DOI 10.2307/3350314; SERAVALLI EP, 1988, NEW ENGL J MED, V319, P1728, DOI 10.1056/NEJM198812293192609; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; The Joint Commission on Accreditation of Healthcare Organizations, 1996, COMPR ACCR MAN HOSP; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; TULSKY JA, 1996, J GEN INTERN MED, V156, P1285; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V274, P449, DOI 10.1001/jama.274.6.449; vonGunten CF, 1996, NEW ENGL J MED, V335, P1766; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WALSH D, 1994, J PAIN SYMPTOM MANAG, V9, P109, DOI 10.1016/0885-3924(94)90163-5; WEISSMAN DE, 1993, J PAIN SYMPTOM MANAG, V8, P29, DOI 10.1016/0885-3924(93)90117-E; *WHO EXP COMM, 1990, TECHN REP SER WHO, V804; 1995, MED ETHICS ADVIS NOV, P143; 1996, UPDATE UPDATE CHOICE, P1	85	113	117	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					225	230		10.7326/0003-4819-127-3-199708010-00008	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245229				2022-12-01	WOS:A1997XN12900008
J	Wilson, TE; Grawunder, U; Lieber, MR				Wilson, TE; Grawunder, U; Lieber, MR			Yeast DNA ligase IV mediates non-homologous DNA end joining	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; GENE; REPAIR; CDC9	The discovery of homologues from the yeast Saccharomyces cerevisiae of the human Ku DNA-end-binding proteins (HDF1 and KU80) has established that this organism is capable of non-homologous double-strand end joining (NHET)(1-5), a form of DNA double-strand break repair (DSBR) active in mammalian V(D)J recombination(6-8). Identification of the DNA ligase that mediates NHEJ in yeast will help elucidate the function of the four mammalian DNA ligases in DSBR, V(D)J recombination and other reactions(9,10). Here we show that S. cerevisiae has two typical DNA ligases, the known DNA ligase I homologue CDC9 (refs 11-14) and the previously unknown DNA ligase IV homologue DNL4. dnl4 mutants are deficient in precise and end-processed NHEJ. DNL4 and HDF1 are epistatic in this regard, with the mutation of each having equivalent effects. dn14 mutants are complemented by overexpression of Dn14 but not of Cdc9, and deficiency of Dn14 alone does not impair either cell growth or the Cdc9-mediated responses to ionizing and ultraviolet radiation. Thus, S. cerevisiae has two distinct and separate Ligation pathways.	WASHINGTON UNIV, SCH MED, DIV LAB MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, DIV MOL ONCOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)				Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Lieber M, 1996, CURR BIOL, V6, P134, DOI 10.1016/S0960-9822(02)00443-8; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; Lindahl T, 1995, J CELL SCI, P73; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MOORE CW, 1982, J BACTERIOL, V150, P1227, DOI 10.1128/JB.150.3.1227-1233.1982; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Siede W, 1996, GENETICS, V142, P91; TOMKINSON AE, 1992, BIOCHEMISTRY-US, V31, P11762, DOI 10.1021/bi00162a013; Weaver D, 1995, ANN NY ACAD SCI, V764, P99; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	24	335	335	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 31	1997	388	6641					495	498		10.1038/41365	http://dx.doi.org/10.1038/41365			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242411	Bronze			2022-12-01	WOS:A1997XN55300054
J	Edwardson, JM; An, S; Jahn, R				Edwardson, JM; An, S; Jahn, R			The secretory granule protein syncollin binds to syntaxin in a Ca2+-sensitive manner	CELL			English	Article							PANCREATIC ZYMOGEN GRANULES; NEUROTRANSMITTER RELEASE; MEMBRANE-FUSION; PLASMA-MEMBRANES; VESICLE FUSION; REGULATED EXOCYTOSIS; VESICULAR TRANSPORT; CALCIUM-DEPENDENCE; EXOCRINE PANCREAS; AMYLASE RELEASE	The membrane proteins synaptobrevin, syntaxin, and SNAP-25 form the core of a ubiquitous fusion machine that interacts with the soluble proteins NSF and alpha-SNAP. During regulated exocytosis, membrane fusion is usually strictly controlled by Ca2+ ions. However, the mechanism by which Ca2+ regulates exocytosis is still unclear. Here we show that the membranes of exocrine secretory granules contain an 18-kDa protein, syncollin, that binds to syntaxin at tow Ca2+ concentrations and dissociates at concentrations known to stimulate exocytosis. Syncollin has a single hydrophobic domain at its N-terminus and shows no significant homology with any known protein. Recombinant syncollin inhibits fusion in vitro between zymogen granules and pancreatic plasma membranes, and its potency falls as Ca2+ concentration rises. We suggest that syncollin acts as a Ca2+-sensitive regulator of exocytosis in exocrine tissues.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University	Edwardson, JM (corresponding author), UNIV CAMBRIDGE,DEPT PHARMACOL,TENNIS COURT RD,CAMBRIDGE CB2 1QJ,ENGLAND.			Jahn, Reinhard/0000-0003-1542-3498				ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; EDWARDSON JM, 1993, FEBS LETT, V320, P52, DOI 10.1016/0014-5793(93)81656-K; EDWARDSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1053, P32, DOI 10.1016/0167-4889(90)90022-6; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FOHR KJ, 1993, METHOD ENZYMOL, V221, P149, DOI 10.1016/0076-6879(93)21014-Y; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; IWATSUKI N, 1980, NATURE, V283, P492, DOI 10.1038/283492a0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; LEE EG, 1994, BIOCHEM J, V298, P599, DOI 10.1042/bj2980599; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MACLEAN CM, 1992, BIOCHEM J, V286, P747, DOI 10.1042/bj2860747; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; NADIN CY, 1989, J CELL BIOL, V109, P2801, DOI 10.1083/jcb.109.6.2801; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P536, DOI 10.1016/0006-291X(91)91450-Q; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; THOM P, 1993, CELL, V74, P661; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	57	70	74	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					325	333		10.1016/S0092-8674(00)80340-2	http://dx.doi.org/10.1016/S0092-8674(00)80340-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244306	Bronze			2022-12-01	WOS:A1997XN24900016
J	Stamos, JK; Shulman, S				Stamos, JK; Shulman, S			Abandoning empirical antibiotics for febrile children	LANCET			English	Editorial Material							OCCULT BACTEREMIA				Stamos, JK (corresponding author), NORTHWESTERN UNIV,SCH MED,CHILDRENS MEM HOSP,DEPT PEDIAT,CHICAGO,IL 60614, USA.							BARAFF LJ, 1993, PEDIATRICS, V82, P1; BASS JW, 1993, PEDIATR INFECT DIS J, V12, P466, DOI 10.1097/00006454-199306000-00003; Browne GJ, 1997, ARCH DIS CHILD, V76, P129, DOI 10.1136/adc.76.2.129; JAFFE DM, 1987, NEW ENGL J MED, V317, P1175, DOI 10.1056/NEJM198711053171902; LONG SS, 1994, J PEDIATR-US, V124, P585, DOI 10.1016/S0022-3476(05)83137-3; MCGOWAN JE, 1973, NEW ENGL J MED, V288, P1309, DOI 10.1056/NEJM197306212882501	6	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 12	1997	350	9071					84	84		10.1016/S0140-6736(05)61812-0	http://dx.doi.org/10.1016/S0140-6736(05)61812-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK114	9228958				2022-12-01	WOS:A1997XK11400006
J	Saitoh, S; Takahashi, K; Yanagida, M				Saitoh, S; Takahashi, K; Yanagida, M			Mis6, a fission yeast inner centromere protein, acts during G1/S and forms specialized chromatin required for equal segregation	CELL			English	Article							SPINDLE POLE BODY; DNA TOPOISOMERASE-II; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; S-POMBE; FUNCTIONAL-ANALYSIS; GENE DISRUPTION; CHROMOSOME; MITOSIS	Disorder in sister chromatid separation can lead to genome instability and cancer. A temperature-sensitive S. pombe mis6-302 frequently loses a minichromosome at 26 degrees C and abolishes equal segregation of regular chromosomes at 36 degrees C. The mis6(+) gene is essential for viability, and its deletion results in missegregation identical to mis6-302. Miss acts before or at the onset of S phase, and mitotic missegregation defects are produced only after the passage of G1/S at 36 degrees C. Mise locates at the centromeres throughout the cell cycle. In the mutant, positioning of the centromeres becomes abnormal, and specialized chromatin in the inner centromeres, which give the smear micrococcal nuclease pattern in wild type, is disrupted. The ability to establish correct biorientation of sister centromeres in metaphase cells requires the Mis6-containing chromatin and originates during the passage of G1/S.			Saitoh, S (corresponding author), KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN.			Saitoh, Shigeaki/0000-0001-5408-296X				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARKE L, 1986, P NATL ACAD SCI USA, V83, P8253, DOI 10.1073/pnas.83.21.8253; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; FANKHAUSER C, 1993, EMBO J, V12, P2697, DOI 10.1002/j.1460-2075.1993.tb05931.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Gutz H., 1974, HDB GENETICS, V1, P395; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HAGAN IM, 1988, J CELL SCI, V89, P343; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KOSHLAND D, 1994, CELL, V77, P951, DOI 10.1016/0092-8674(94)90432-4; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; MATSUMOTO T, 1990, CURR GENET, V18, P323, DOI 10.1007/BF00318213; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURAKAMI S, 1995, MOL GEN GENET, V246, P671, DOI 10.1007/BF00290712; MURAKAMI S, 1991, CHROMOSOMA, V101, P214, DOI 10.1007/BF00365153; NABESHIMA K, 1995, GENE DEV, V9, P1572, DOI 10.1101/gad.9.13.1572; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; NIWA O, 1989, EMBO J, V8, P3045, DOI 10.1002/j.1460-2075.1989.tb08455.x; NIWA O, 1986, MOL GEN GENET, V203, P397, DOI 10.1007/BF00422063; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAMEJIMA I, 1994, J CELL BIOL, V127, P1665; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SPENCER F, 1990, GENETICS, V124, P237; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; STEINER NC, 1993, MOL CELL BIOL, V13, P457; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UZAWA S, 1992, J CELL SCI, V101, P267; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WOODS A, 1989, J CELL SCI, V93, P491	62	195	198	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 11	1997	90	1					131	143		10.1016/S0092-8674(00)80320-7	http://dx.doi.org/10.1016/S0092-8674(00)80320-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XL362	9230309	Bronze			2022-12-01	WOS:A1997XL36200015
J	Miyawaki, A; Llopis, J; Heim, R; McCaffery, JM; Adams, JA; Ikura, M; Tsien, RY				Miyawaki, A; Llopis, J; Heim, R; McCaffery, JM; Adams, JA; Ikura, M; Tsien, RY			Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin	NATURE			English	Article							ENDOPLASMIC-RETICULUM; POINT MUTATIONS; INTACT-CELLS; 2 SERIES; BINDING; AEQUORIN; SITES	Important Ca2+ signals in the cytosol and organelles are often extremely localized and hard to measure. To overcome this problem we have constructed new fluorescent indicators for Ca2+ that are genetically encoded without cofactors and are targetable to specific intracellular locations. We have dubbed these fluorescent indicators 'cameleons', They consist of tandem fusions of a blue-or cyan-emitting mutant of the green fluorescent protein (GFP)(1,2), calmodulin(3-5), the calmodulin-binding peptide M13 (ref, 6), and an enhanced green-or yellow-emitting GFP(7-9). Binding of Ca2+ makes calmodulin wrap around the M13 domain, increasing the fluorescence resonance energy transfer (FRET) between the flanking GFPs(2), Calmodulin mutations can tune the Ca2+ affinities to measure free Ca2+ concentrations in the range 10(-8) to 10(-2) M, We have visualized free Ca2+ dynamics in the cytosol, nucleus and endoplasmic reticulum of single HeLa cells transfected with complementary DNAs encoding chimaeras bearing appropriate localization signals, Ca2+ concentration in the endoplasmic reticulum of individual cells ranged from 60 to 400 mu M at rest, and 1 to 50 mu M after Ca2+ mobilization, FRET is also an indicator of the reversible intermolecular association of cyan-GFP-labelled calmodulin with yellow-GFP-labelled M13, Thus FRET between GFP mutants can monitor localized Ca2+ signals and protein heterodimerization in individual live cells.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; SAN DIEGO STATE UNIV, DEPT CHEM, SAN DIEGO, CA 92182 USA; UNIV TORONTO, ONTARIO CANC INST, DIV MOL & STRUCT BIOL, TORONTO, ON M5G 2M9, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5G 2M9, CANADA; UNIV TSUKUBA, CTR TSUKUBA ADV RES ALLIANCE, TSUKUBA, IBARAKI 305, JAPAN	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; California State University System; San Diego State University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba			Wood, David W/B-2992-2012; Llopis, Juan/I-2622-2012; Miyawaki, Atsushi/K-3569-2014	Llopis, Juan/0000-0002-9460-0642; Miyawaki, Atsushi/0000-0002-2329-3235; Ikura, Mitsuhiko/0000-0002-9524-1303				Adams S.R., 1993, FLUORESCENT PROBES B, P133; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; BRINI M, 1994, CELL CALCIUM, V16, P259, DOI 10.1016/0143-4160(94)90089-2; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; Bygrave FL, 1996, CELL CALCIUM, V19, P547, DOI 10.1016/S0143-4160(96)90064-0; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; GAO ZH, 1993, J BIOL CHEM, V268, P20096; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; Kendall JM, 1996, BIOCHEM J, V318, P383, DOI 10.1042/bj3180383; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Martin SR, 1996, BIOCHEMISTRY-US, V35, P3508, DOI 10.1021/bi952522a; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PORUMB T, 1994, PROTEIN ENG, V7, P109, DOI 10.1093/protein/7.1.109; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; SMIT MJ, 1993, EUR J PHARM-MOLEC PH, V247, P223, DOI 10.1016/0922-4106(93)90082-K; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	30	2408	2594	20	786	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	1997	388	6645					882	887		10.1038/42264	http://dx.doi.org/10.1038/42264			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278050	Bronze			2022-12-01	WOS:A1997XT75400051
J	Walker, SS; Shen, WC; Reese, JC; Apone, LM; Green, MR				Walker, SS; Shen, WC; Reese, JC; Apone, LM; Green, MR			Yeast TAF(II)145 required for transcription of G1/S cyclin genes and regulated by the cellular growth state	CELL			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; ACTIVATION; COMPLEX; KINASE; CELLS; TRANSITION; MITOSIS; TARGETS	TFIID comprises the TATA box-binding protein and a set of highly conserved associated factors (TAF(II)s). yTAF(II)145, the core subunit of the yeast TAF(II) complex, is dispensable for transcription of most yeast genes but specifically required for progression through G1/S. Here we show that transcription of G1 and certain B-type cyclin genes is dependent upon yTAF(II)145. At high cell density or following nutrient deprivation, yeast cells cease division, enter a G(0)-like state, and terminate transcription of most genes. In this stationary phase, we find that the levels of yTAF(II)145, several other yTAF(II)s, and TBP are drastically reduced. Collectively, our results indicate that yTAF(II)145 and other TFIID components have a specialized role in transcriptional regulation of cell cycle progression and growth control.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Ausubel F.M., 1995, CURRENT PROTOCOLS MO; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIA LL, 1979, MOL GEN GENET, V170, P137, DOI 10.1007/BF00337788; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Guthrie C, 1991, GUIDE YEAST GENETICS; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; Hung DT, 1996, CHEM BIOL, V3, P623, DOI 10.1016/S1074-5521(96)90129-5; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLENK HP, 1994, CURR BIOL, V4, P920, DOI 10.1016/S0960-9822(00)00206-2; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LIU HT, 1985, J BIOL CHEM, V260, P3269; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; POON D, 1993, J BIOL CHEM, V268, P15325; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; Sauer F, 1996, CELL, V87, P1271, DOI 10.1016/S0092-8674(00)81822-X; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SIKORSKI RS, 1989, GENETICS, V122, P19; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	46	125	125	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					607	614		10.1016/S0092-8674(00)80522-X	http://dx.doi.org/10.1016/S0092-8674(00)80522-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288741	Bronze			2022-12-01	WOS:A1997XT06600005
J	Wilson, PWF; Hoeg, JM; DAgostino, RB; Silbershatz, H; Belanger, AM; Poehlmann, H; OLeary, D; Wolf, PA				Wilson, PWF; Hoeg, JM; DAgostino, RB; Silbershatz, H; Belanger, AM; Poehlmann, H; OLeary, D; Wolf, PA			Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ARTERY WALL THICKNESS; ELEVATED SERUM-CHOLESTEROL; RISK FACTOR; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR HEALTH; ATHEROSCLEROSIS RISK; OLDER PERSONS; FRAMINGHAM; LIPOPROTEIN	Background Single measurements of cardiovascular risk factors may not accurately reflect a person's past exposure to those risk factors. We therefore studied the long-term associations of cardiovascular risk factors such as high serum cholesterol levels, high blood pressure, and cigarette smoking with the prevalence of carotid stenosis. Methods We studied cross-sectional and longitudinal information from a sample of 429 men and 661 women in the Framingham Heart Study who underwent B-mode ultrasound measurements of the carotid artery. Their mean age was 75 years, and each had attended most of the biennial clinic examinations over the 34 years before the carotid ultrasound study. We used time-integrated measurements to assess the associations between various cardiovascular risk factors and the degree of carotid stenosis. Results Moderate carotid stenosis (greater than or equal to 25 percent) was present in 189 men and 226 women. We assessed the odds ratios for this degree of stenosis as compared with minimal stenosis (<25 percent) according to increases in risk factors. In the men, the odds ratio for moderate carotid stenosis associated with an increase of 20 mm Hg in systolic blood pressure was 2.11 (95 percent confidence interval, 1.51 to 2.97). The odds ratio for an increase of 10 mg per deciliter (0.26 mmol per liter) in the cholesterol level was 1.10 (95 percent confidence interval, 1.03 to 1.16), and for an increase of five pack-years of smoking it was 1.03 (95 percent confidence interval, 1.03 to 1.13). The results were similar in the women. Time-integrated measurements of diastolic blood pressure showed significant associations with carotid stenosis in men and insignificant associations in women. Conclusions Over the long term, high systolic blood pressure, high cholesterol levels, and smoking were associated with an increased risk of carotid stenosis in this elderly population. (C) 1997, Massachusetts Medical Society.	NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, DEPT MATH, BOSTON, MA 02215 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; TUFTS UNIV, MED CTR, DEPT RADIOL, MEDFORD, MA 02155 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Tufts University	Wilson, PWF (corresponding author), NHLBI, FRAMINGHAM HEART STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA.		Wilson, Peter W.F./J-2455-2016	Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [5R01-NS17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELL LL, 1952, J BIOL CHEM, V195, P357; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1995, Lancet, V345, P209; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BROWN SA, 1993, ARTERIOSCLER THROMB, V13, P1558, DOI 10.1161/01.ATV.13.11.1558; COOPER GR, 1992, JAMA-J AM MED ASSOC, V267, P1652, DOI 10.1001/jama.267.12.1652; COOPER GR, 1994, CLIN CHEM, V40, P227; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; CROUSE JR, 1995, AM J CARDIOL, V75, P862; FABRIS F, 1994, STROKE, V25, P1133, DOI 10.1161/01.STR.25.6.1133; FOLSOM AR, 1994, STROKE, V25, P66, DOI 10.1161/01.STR.25.1.66; GORDON T, 1977, JAMA-J AM MED ASSOC, V238, P497, DOI 10.1001/jama.238.6.497; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; HOEG JM, 1994, ARTERIOSCLER THROMB, V14, P1066, DOI 10.1161/01.ATV.14.7.1066; HOEG JM, 1994, JAMA-J AM MED ASSOC, V271, P543, DOI 10.1001/jama.271.7.543; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; KANNEL WB, 1981, JAMA-J AM MED ASSOC, V245, P1225, DOI 10.1001/jama.245.12.1225; KANNEL WB, 1979, LANCET, V2, P950; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P124; KRITCHEVSKY SB, 1995, CIRCULATION, V92, P2142, DOI 10.1161/01.CIR.92.8.2142; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; *NAT CHOL ED PROGR, 1988, CLIN CHEM, V34, P193; O'Leary D H, 1992, Ann Epidemiol, V2, P147, DOI 10.1016/1047-2797(92)90049-V; OLeary DH, 1996, STROKE, V27, P224, DOI 10.1161/01.STR.27.2.224; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; PERSSON J, 1994, ARTERIOSCLER THROMB, V14, P261, DOI 10.1161/01.ATV.14.2.261; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; Schmidt HHJ, 1996, AM J CARDIOL, V77, P575, DOI 10.1016/S0002-9149(97)89309-5; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; Sidhu P S, 1996, J Cardiovasc Risk, V3, P61, DOI 10.1097/00043798-199602000-00009; Stamler J, 1989, Hypertension, V13, pI2; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TELL GS, 1994, CIRCULATION, V90, P2905, DOI 10.1161/01.CIR.90.6.2905; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WILSON PWF, 1994, J GERONTOL, V49, pM252, DOI 10.1093/geronj/49.6.M252; WILSON PWF, 1995, ARCH INTERN MED, V155, P2146; WILSON PWF, 1993, AM J GERIATR CARDIOL, V2, P52	46	201	209	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	1997	337	8					516	522		10.1056/NEJM199708213370802	http://dx.doi.org/10.1056/NEJM199708213370802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR548	9262494				2022-12-01	WOS:A1997XR54800002
J	Ray, P; Black, S; Shinefield, H; Dillon, A; Schwalbe, J; Holmes, S; Hadler, S; Chen, R; Cochi, S; Wassilak, S				Ray, P; Black, S; Shinefield, H; Dillon, A; Schwalbe, J; Holmes, S; Hadler, S; Chen, R; Cochi, S; Wassilak, S			Risk of chronic arthropathy among women after rubella vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RHEUMATOID-ARTHRITIS; PROLONGED ARTHRITIS; JOINT REACTIONS; PREGNANCY; IMMUNIZATION; ASSOCIATION; VIREMIA	Context.-A review by the institute of Medicine found a possible relationship between rubella vaccination and chronic arthritis among women. Objective.-To evaluate the risk of persistent joint and neurologic symptoms in rubella seronegative women subsequently vaccinated with RA 27/3 rubella vaccine. Design.-Retrospective cohort study based on computerized laboratory data and medical record review. Records were reviewed for symptoms occurring within 2 years before and after the date of serological testing and to identify vaccinees. Possible cases were evaluated by a rheumatologist blinded to serological findings and vaccination status. Setting.-Large health maintenance organization in northern California. Patients.-Women aged 15 to 59 years serotested for rubella during 1990 with continuous health plan membership for 2 years before and after the date of their serological test. Seronegative women immunized within 1 year of serotesting (n=971) were defined as exposed. Primary comparison groups included all unvaccinated, seronegative women (n=924) and randomly selected, seropositive, unvaccinated women (n=2421) matched to exposed subjects on serological test date and age (+/-3 years). Main Outcome Measures.-Prevalence and incidence of chronic joint and neurologic symptoms during 1-year follow-up period stratified by age and serological findings, immunization, and postpartum status. Results.-No significantly increased risk was associated with receipt of rubella vaccine for any outcome except for prevalence of carpal tunnel syndrome in vaccinated women at least 30 years old compared with seropositive, unvaccinated women (2.9% vs 1.4%; P=.03), A total of 34 women had onset of conditions within the 1-year follow-up period; 9 of these were in the group of seronegative, immunized women, of whom 6 had onset of symptoms within 6 weeks of vaccination. Among these 6 women, symptoms included transient arthritis or arthralgias (6 weeks duration) in 4 women, arthralgia of indeterminate chronicity in 1 woman, and carpal tunnel syndrome in 1 woman. Postpartum women across all groups were less likely to be seen for nontraumatic arthropathies than nonpostpartum women (4.5% vs 7.2%, P=.08 in vaccinated women; 4.8% vs 8.1%, P=.09 in seronegative controls; and 4.8% vs 10.0%, P=.01 in seropositive controls). Conclusions.-In this large retrospective cohort analysis there was no evidence of any increased risk of new onset chronic arthropathies or neurologic conditions in women receiving the RA 27/3 rubella vaccine. These data support the continued vaccination of rubella-susceptible women to reduce the risk of congenital rubella syndrome.	NO CALIF KAISER PERMANENTE VACCINE STUDY CTR, OAKLAND, CA USA; EASTERN VIRGINIA MED SCH, CTR PEDIAT RES, NORFOLK, VA 23501 USA; CTR DIS CONTROL & PREVENT, NATL IMMUNIZAT PROGRAM, ATLANTA, GA 30333 USA	Kaiser Permanente; Eastern Virginia Medical School; Centers for Disease Control & Prevention - USA								*CDC, 1990, MMWR-MORBID MORTAL W, V39, P10; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P329; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; DASILVA JAP, 1992, CLIN RHEUMATOL, V11, P189, DOI 10.1007/BF02207955; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; FREY T, 1994, J INFECT DIS, V170, P507; HOWSON CP, 1992, CLIN INFECT DIS, V15, P307, DOI 10.1093/clinids/15.2.307; *I MED, 1991, ADV EFF PERT RUB VAC; KAPLAN KM, 1990, AM J DIS CHILD, V144, P118, DOI 10.1001/archpedi.1990.02150250130050; LANSINK M, 1993, CLIN EXP RHEUMATOL, V11, P171; LERMAN SJ, 1971, ANN INTERN MED, V74, P67, DOI 10.7326/0003-4819-74-1-67; LINOS A, 1980, AM J EPIDEMIOL, V111, P87, DOI 10.1093/oxfordjournals.aje.a112878; MITCHELL LA, 1993, ARCH INTERN MED, V153, P2268, DOI 10.1001/archinte.153.19.2268; MORTONKUTE L, 1985, ANN INTERN MED, V102, P563, DOI 10.7326/0003-4819-102-4-563_3; NEELY NT, 1977, TEX MED, V73, P59; OSTENSEN M, 1983, SCAND J RHEUMATOL, V12, P69, DOI 10.3109/03009748309102886; OSTENSEN M, 1983, ARTHRITIS RHEUM, V26, P1155, DOI 10.1002/art.1780260915; PELTOLA H, 1986, LANCET, V1, P939; Persellin R H, 1976, Bull Rheum Dis, V27, P922; POLK BF, 1982, AM J EPIDEMIOL, V115, P19, DOI 10.1093/oxfordjournals.aje.a113276; SCHUMACHER HR, 1993, PRIMER RHEUMATIC DIS, P328; SILMAN AJ, 1986, ANN RHEUM DIS, V45, P1031, DOI 10.1136/ard.45.12.1031; SLATER PE, 1995, VACCINE, V13, P1529, DOI 10.1016/0264-410X(95)00096-J; SPRUANCE SL, 1977, ARTHRITIS RHEUM, V20, P741, DOI 10.1002/art.1780200216; THOMPSON GR, 1971, ARTHRITIS RHEUM, V14, P19, DOI 10.1002/art.1780140104; THOMPSON GR, 1973, AM J DIS CHILD, V125, P526, DOI 10.1001/archpedi.1973.04160040040008; TINGLE AJ, 1983, INFECT IMMUN, V40, P22, DOI 10.1128/IAI.40.1.22-28.1983; TINGLE AJ, 1985, J INFECT DIS, V152, P606, DOI 10.1093/infdis/152.3.606; TINGLE AJ, 1986, ANN RHEUM DIS, V45, P110, DOI 10.1136/ard.45.2.110; TINGLE AJ, 1984, LANCET, V1, P1475; VALENSIN PE, 1987, VACCINE, V5, P289, DOI 10.1016/0264-410X(87)90154-X	31	57	60	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					551	556		10.1001/jama.278.7.551	http://dx.doi.org/10.1001/jama.278.7.551			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268275				2022-12-01	WOS:A1997XQ98600028
J	Bottaci, L; Drew, PJ; Hartley, JE; Hadfield, MB; Farouk, R; Lee, PWR; Macintyre, IMC; Duthie, GS; Monson, JRT				Bottaci, L; Drew, PJ; Hartley, JE; Hadfield, MB; Farouk, R; Lee, PWR; Macintyre, IMC; Duthie, GS; Monson, JRT			Artificial neural networks applied to outcome prediction for colorectal cancer patients in separate institutions	LANCET			English	Article							MYOCARDIAL-INFARCTION; SURVIVAL ANALYSIS; CENSORED-DATA; CLASSIFICATION; BREAST	Background Artificial neural networks are computer programs that can be used to discover complex relations within data sets. They permit the recognition of patterns in complex biological data sets that cannot be detected with conventional linear statistical analysis. One such complex problem is the prediction of outcome for individual patients treated for colorectal cancer. Predictions of outcome in such patients have traditionally been based on population statistics. However, these predictions have little meaning for the individual patient. We report the training of neural networks to predict outcome for individual patients from one institution and their predictive performance on data from a different institution in another region. Methods 5-year follow-up data from 334 patients treated for colorectal cancer were used to train and validate six neural networks designed for the prediction of death within 9, 12, 15, 18, 21, and 24 months. The previously trained 12-month neural network was then applied to 2-year followup data from patients from a second institution; outcome was concealed. No further training of the neural network was undertaken. The network's predictions were compared with those of two consultant colorectal surgeons supplied with the same data. Findings All six neural networks were able to achieve overall accuracy greater than 80% for the prediction of death for individual patients al institution I within 9, 12, 15, 18, 21, and 24 months. The mean sensitivity and specificity were 60% and 88%. When the neural network trained to predict death within 12 months was applied to data from the second institution, overall accuracy of 90% (95% CI 84-96) was achieved, compared with the overall accuracy of the colorectal surgeons of 79% (71-87) and 75% (66-84). Interpretation The neural networks were able to predict outcome for individual patients with colorectal cancer much more accurately than the currently available clinicopathological methods. Once trained on data from one institution, the neural networks were able to predict outcome for patients from an unrelated institution.	UNIV HULL, ACAD SURG UNIT, CASTLE HILL HOSP, KINGSTON UPON HULL HU16 5JQ, N HUMBERSIDE, ENGLAND; UNIV HULL, KINGSTON UPON HULL HU6 7RX, N HUMBERSIDE, ENGLAND; WESTERN GEN HOSP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Hull; University of Hull; University of Edinburgh			Farouk, Ridzuan/T-5968-2017	Farouk, Ridzuan/0000-0002-7644-4682; Macintyre, Iain/0000-0003-2716-8500				ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BAXT WG, 1994, MED DECIS MAKING, V14, P217, DOI 10.1177/0272989X9401400303; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; Bishop CM, 1995, NEURAL NETWORKS PATT; CARPENTER GA, 1993, P WORLD C NEURAL NET, V1, P501; CLARK GM, 1994, BREAST CANCER RES TR, V32, P105, DOI 10.1007/BF00666211; CROFT DJ, 1974, ANN BIOMED ENG, V2, P69, DOI 10.1007/BF02368087; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; DELAURENTIIS M, 1994, BREAST CANCER RES TR, V32, P113, DOI 10.1007/BF00666212; DELAURENTIIS M, 1994, CANCER LETT, V77, P127, DOI 10.1016/0304-3835(94)90095-7; Downs J, 1996, ARTIF INTELL MED, V8, P403, DOI 10.1016/0933-3657(95)00044-5; DOYE HR, 1994, ANN SURG, V219, P408; Engle Ralph L., 1963, ARCH INTERN MED, V112, P108; ENGLE RL, 1963, ARCH INTERN MED, V112, P512, DOI 10.1001/archinte.1963.03860040108009; FISHER ER, 1989, CANCER, V64, P2354, DOI 10.1002/1097-0142(19891201)64:11<2354::AID-CNCR2820641127>3.0.CO;2-#; Hartman EJ, 1990, NEURAL COMPUT, V2, P210, DOI 10.1162/neco.1990.2.2.210; HORROCKS JC, 1972, BMJ-BRIT MED J, V2, P5, DOI 10.1136/bmj.2.5804.5; JASS JR, 1987, LANCET, V1, P1303; KAPLAN D, 1995, UNDERSTANDING NONLIN; MA Z, 1996, EXPLANATION GEN RULE; Mackay D., 1994, MODELS NEURAL NETWOR; MCGUIRE WL, 1992, J NATL CANCER I MONO, V11, P173; NEWLAND RC, 1994, CANCER, V73, P2076, DOI 10.1002/1097-0142(19940415)73:8<2076::AID-CNCR2820730811>3.0.CO;2-6; RAVDIN PM, 1992, BREAST CANCER RES TR, V22, P285, DOI 10.1007/BF01840841; RAYDIN PM, 1992, BREAST CANCER RES TR, V21, P47, DOI 10.1007/BF01811963; Rumelhart D., 1986, PARALLEL DISTRIBUTED; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Shortliffe, 1984, READINGS MED ARTIFIC; *U STUTTG, STUTTG NEUR NETW SIM	30	138	142	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	1997	350	9076					469	472		10.1016/S0140-6736(96)11196-X	http://dx.doi.org/10.1016/S0140-6736(96)11196-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274582				2022-12-01	WOS:A1997XR13500008
J	Brown, JP; Wei, WY; Sedivy, JM				Brown, JP; Wei, WY; Sedivy, JM			Bypass of senescence after disruption of p21(CIP1/WAF1) gene in normal diploid human fibroblasts	SCIENCE			English	Article							REPLICATIVE SENESCENCE; TELOMERASE ACTIVITY; IMMORTAL CELLS; P53; EXPRESSION; MECHANISMS; P16(INK4); DIVISION; CULTURE; CANCER	Most somatic cells die after a finite number of cell divisions, a phenomenon described as senescence. The p21(CIP1/WAF1) gene encodes an inhibitor of cyclin-dependent kinases. Inactivation: of p21 by two sequential rounds of targeted homologous recombination was sufficient to bypass senescence in normal diploid human fibroblasts. At the checkpoint between the prereplicative phase of growth and the phase of chromosome replication, cells lacking p21 failed to arrest the cell cycle in response to DNA damage, but their apoptotic response and genomic stability were unaltered. These results establish the feasibility of using gene targeting for genetic studies of normal human cells.			Brown, JP (corresponding author), BROWN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, PROVIDENCE, RI 02912 USA.				NIGMS NIH HHS [GM41690] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bond J, 1996, ONCOGENE, V13, P2097; BROWN JP, UNPUYB; Campisi Judith, 1996, P121; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREENE AE, 1973, TISSUE CULTURE METHO, P69; HANSON KD, 1995, MOL CELL BIOL, V15, P45, DOI 10.1128/MCB.15.1.45; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TAHARA H, 1995, ONCOGENE, V10, P835; TROTT DA, 1995, CARCINOGENESIS, V16, P193, DOI 10.1093/carcin/16.2.193; VARIZI H, 1996, EXP GERONTOL, V31, P295; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WEI W, UNPUB; WHITAKER NJ, 1995, ONCOGENE, V11, P971; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9	36	659	685	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					831	834		10.1126/science.277.5327.831	http://dx.doi.org/10.1126/science.277.5327.831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242615				2022-12-01	WOS:A1997XQ24700048
J	Li, P; Yang, XH; Wasser, M; Cai, Y; Chia, W				Li, P; Yang, XH; Wasser, M; Cai, Y; Chia, W			Inscuteable and staufen mediate asymmetric localization and segregation of prospero RNA during Drosophila neuroblast cell divisions	CELL			English	Article							OSKAR MESSENGER-RNA; POSTERIOR DETERMINANT; PROTEIN; GENE; OOCYTE; EMBRYO; NANOS; NUMB; SPECIFICATION; ORIENTATION	When neuroblasts divide, inscuteable acts to coordinate protein localization and mitotic spindle orientation, ensuring that asymmetrically localized determinants like Prospero partition into one progeny. staufen encodes a dsRNA-binding protein implicated in mRNA transport in oocytes. We demonstrate that prospero RNA is also asymmetrically localized and partitioned during neuroblast cell divisions, a process requiring both inscuteable and staufen. Inscuteable and Staufen interact and colocalize with prospero RNA on the apical cortex of interphase neuroblasts. Staufen binds prospero RNA in its 3'UTR. Our findings suggest that Inscuteable nucleates an apical complex and is required for protein localization, spindle orientation, and RNA localization. Stau, as one component of this complex, is required only for RNA localization. Hence staufen also acts zygotically, downstream of inscuteable, to effect aspects of neuroblast asymmetry.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,DEV NEUROBIOL LAB,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Cai, Yu/R-7737-2019	Cai, Yu/0000-0003-2044-3290; Wasser, Martin/0000-0002-8753-2346				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; Bossing T, 1996, DEV BIOL, V179, P41, DOI 10.1006/dbio.1996.0240; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; DAVIS I, 1993, COLD SPRING HARB SYM, V58, P793, DOI 10.1101/SQB.1993.058.01.086; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1995, NEURON, V15, P991, DOI 10.1016/0896-6273(95)90088-8; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; FERRANDON D, 1994, CELL, V79, P1121; FINLEY RL, 1994, GENE PROBES PRACTICA; FrancisLang H, 1996, EMBO J, V15, P640, DOI 10.1002/j.1460-2075.1996.tb00396.x; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JAN YN, 1995, NEURON, V14, P1; KarlinMcginness M, 1996, DEV GENET, V19, P238, DOI 10.1002/(SICI)1520-6408(1996)19:3<238::AID-DVG7>3.0.CO;2-A; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LUNDELL MJ, 1994, BIOTECHNIQUES, V16, P434; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; STERNBERG PW, 1984, ANNU REV GENET, V18, P489, DOI 10.1146/annurev.ge.18.120184.002421; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; TAUTZ D, 1989, DROSOPHILA LAB MANUA, P194; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; UEMERA T, 1989, CELL, V5, P349; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K	44	194	199	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					437	447		10.1016/S0092-8674(00)80504-8	http://dx.doi.org/10.1016/S0092-8674(00)80504-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267024	Bronze			2022-12-01	WOS:A1997XQ06300008
J	Annas, GJ				Annas, GJ			'Reefer Madness' - The Federal response to California's medical-marijuana law	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Annas George J, 1989, Villanova Law Rev, V34, P771; ANNAS GJ, 1991, NEW ENGL J MED, V325, P362, DOI 10.1056/NEJM199108013250519; DOBLIN RE, 1991, J CLIN ONCOL, V9, P1314, DOI 10.1200/JCO.1991.9.7.1314; GOLDEN T, 1997, NY TIMES        0417, pA14; Golden Tim, 1997, N Y Times Web, P7; GOODMAN E, 1997, BOSTON GLOBE    0202, pC7; GOULD SJ, 1993, TIMES           0504; Grinspoon L, 1995, MARIHUANA FORBIDDEN; Kassirer JP, 1997, NEW ENGL J MED, V336, P366, DOI 10.1056/NEJM199701303360509; LEARY WE, 1997, NY TIMES        0221, pA27; Sidney S, 1997, AM J PUBLIC HEALTH, V87, P585, DOI 10.2105/AJPH.87.4.585; STAPLETON S, 1997, AM MED NEWS     0317, P1; STAPLETON S, 1997, AM MED NEWS     0317, P33; WREN C, 1997, NY TIMES        0420, pE4	14	37	37	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					435	439		10.1056/NEJM199708073370621	http://dx.doi.org/10.1056/NEJM199708073370621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241134	Green Published			2022-12-01	WOS:A1997XP40700029
J	Bender, JB; Hedberg, CW; Besser, JM; Boxrud, DJ; MacDonald, KL; Osterholm, MT				Bender, JB; Hedberg, CW; Besser, JM; Boxrud, DJ; MacDonald, KL; Osterholm, MT			Surveillance for Escherichia coli O157:H7 infections in Minnesota by molecular subtyping	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIELD GEL-ELECTROPHORESIS; HEMOLYTIC UREMIC SYNDROME; OUTBREAK; EPIDEMIOLOGY	Background Escherichia coli O157:H7 is a leading cause of diarrhea and the hemolytic-uremic syndrome. Current public health surveillance for E. coli O157:H7 requires considerable resources; traditional methods lack the sensitivity and specificity to detect outbreaks effectively. Methods During 1994 and 1995, the Minnesota Department of Health requested that all clinical isolates of E. coli O157:H7 be submitted to our laboratory. Isolates were subtyped by pulsed-field gel electrophoresis (PFGE), and patients were interviewed about potential sources of infection. Results In 1994 and 1995, 344 cases of E. coli O157:H7 infection were reported to the Minnesota Department of Health; 317 (92 percent) were subtyped by PFGE, and 143 distinct PFGE patterns were identified. Ten outbreaks of E. coli O157:H7 were identified; these accounted for 56 (18 percent) of the 317 subtyped cases, Four outbreaks were detected solely as a result of subtype-specific surveillance. In 11 two-week periods, the number of reported cases of E. coli O157:H7 doubled from the previous two weeks. In eight of these instances, the patterns identified were dissimilar and there were no outbreaks. Two of the remaining three increases resulted from multiple simultaneous outbreaks. Conclusions Subtype-specific surveillance for E. coli O157:H7 can identify outbreaks that are not detected by traditional methods and can ascertain whether sudden increases in reported cases are due to sporadic isolated cases or to one or more outbreaks. (C) 1997, Massachusetts Medical Society.	MINNESOTA DEPT HLTH,DIV PUBL HLTH LABS,MINNEAPOLIS,MN 55440	Minnesota Department of Health (MHD)	Bender, JB (corresponding author), MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 DELAWARE ST SE,MINNEAPOLIS,MN 55440, USA.			Bender, Jeffrey/0000-0003-4645-9936	PHS HHS [U50/CCU511190] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Banatvala N, 1996, J INFECT DIS, V173, P480, DOI 10.1093/infdis/173.2.480; BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013, DOI 10.1128/JCM.32.12.3013-3017.1994; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; Krause U, 1996, J CLIN MICROBIOL, V34, P959, DOI 10.1128/JCM.34.4.959-961.1996; *MN DEP HLTH, 1996, MINN HLTH STAT 1994; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; RODRIGUE DC, 1995, J INFECT DIS, V172, P1122, DOI 10.1093/infdis/172.4.1122; Shefer AM, 1996, WESTERN J MED, V165, P15; SWAMINATHAN B, 1995, DIAGNOSTIC MOL MICRO, P26; TARR PI, 1995, CLIN INFECT DIS, V20, P1, DOI 10.1093/clinids/20.1.1; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; 1996, MMWR-MORBID MORTAL W, V45, P437; 1995, MMWR-MORBID MORTAL W, V44, P417; 1995, MMWR-MORBID MORTAL W, V44, P157	17	118	126	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 7	1997	337	6					388	394		10.1056/NEJM199708073370604	http://dx.doi.org/10.1056/NEJM199708073370604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP407	9241128				2022-12-01	WOS:A1997XP40700004
J	Mannings, V; Koerner, DW; Sargent, AI				Mannings, V; Koerner, DW; Sargent, AI			A rotating disk of gas and dust around a young counterpart to beta Pictoris	NATURE			English	Article							T-TAURI STARS; CIRCUMSTELLAR DISKS; GRAINS; ABSORPTION	beta Pictoris is the best known example of a main-sequence star encircled by a tenuous disk(1), Optical(2,3) and infrared(4) images of beta Pic suggest that the disk is composed of dust grains which have been interpreted(1) as the debris generated by the disruption of the asteroid-sized remnants of planet-formation processes(5), The star itself is relatively old, with an age in excess of 100 Myr, Here we present high-resolution millimetre-wave images of continuum and molecular-line emission from dust and gas surrounding a much younger star, MWC480: the stellar properties of MWC480 are similar to those of beta Pic, but its age is just 6 Myr, The morphology of the circumstellar material and a comparison with the predictions of kinematic modelling indicate the presence of a rotating disk, gravitationally bound to the star, Moreover, the mass of the disk is greater than the minimum required to form a planetary system like our own(5), We therefore suggest that the disk around the young star MWC480 could be a progenitor of debris disks of the type associated with older stars such as beta Pic, and so holds much promise for the study of both the origin of debris disks and the early stages of the formation of planetary systems.	CALTECH,JET PROP LAB,PASADENA,CA 91109	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Mannings, V (corresponding author), CALTECH,DIV PHYS MATH & ASTRON,MS 105-24,PASADENA,CA 91125, USA.							AUMANN HH, 1984, ASTROPHYS J, V278, pL23, DOI 10.1086/184214; Backman D. E., 1993, PROTOSTARS PLANETS, P1253; Beckwith SVW, 1996, NATURE, V383, P139, DOI 10.1038/383139a0; BECKWITH SVW, 1990, ASTRON J, V99, P924, DOI 10.1086/115385; BECKWITH SVW, 1991, ASTROPHYS J, V381, P250, DOI 10.1086/170646; BEUST H, 1994, ASTRON ASTROPHYS, V282, P804; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; DENT WRF, 1995, MON NOT R ASTRON SOC, V277, pL25; DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480; DUTREY A, 1994, ASTRON ASTROPHYS, V286, P149; GOLIMOWSKI DA, 1993, ASTROPHYS J, V411, pL41, DOI 10.1086/186907; Herbig G.H., 1960, ASTROPHYS J SUPPL S, V4, P337, DOI [10.1086/190050, DOI 10.1086/190050]; HILDEBRAND RH, 1983, Q J ROY ASTRON SOC, V24, P267; KOERNER DW, 1993, ICARUS, V106, P2, DOI 10.1006/icar.1993.1154; KOERNER DW, 1997, 25 YEARS MILLIMETER, V170, P162; LAGAGE PO, 1994, NATURE, V369, P628, DOI 10.1038/369628a0; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; MANNINGS V, 1994, MON NOT R ASTRON SOC, V267, P361, DOI 10.1093/mnras/267.2.361; MANNINGS V, IN PRESS ASTROPHYS J; MIYAKE K, 1993, ICARUS, V106, P20, DOI 10.1006/icar.1993.1156; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; SARGENT AI, 1996, DISKS OUTFLOWS YOUNG, P1; SCOVILLE NZ, 1986, ASTROPHYS J, V303, P416, DOI 10.1086/164086; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; Sylvester RJ, 1996, MON NOT R ASTRON SOC, V279, P915, DOI 10.1093/mnras/279.3.915; WEIDENSCHILLING S, IN PRESS ICARUS; WRIGHT EL, 1987, ASTROPHYS J, V320, P818, DOI 10.1086/165597	27	90	90	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					555	557		10.1038/41505	http://dx.doi.org/10.1038/41505			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252187				2022-12-01	WOS:A1997XP72200040
J	Preti, HA; Cabanillas, F; Talpaz, M; Tucker, SL; Seymour, JF; Kurzrock, R				Preti, HA; Cabanillas, F; Talpaz, M; Tucker, SL; Seymour, JF; Kurzrock, R			Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma	ANNALS OF INTERNAL MEDICINE			English	Article						interleukin-6; lymphoma, large-cell, diffuse; outcome assessment (health care); disease-free survival; survival rate	NON-HODGKINS-LYMPHOMA; MULTIPLE-MYELOMA; MONOCLONAL-ANTIBODY; LEVELS CORRELATE; B CELLS; DISEASE; EXPRESSION; CANCER; PARAMETERS; SURVIVAL	Background: Interleukin-6 has important lymphoid bioregulatory effects, and serum levels of interleukin-6 are often elevated in patients with lymphoma. Objective: To determine the relation between serum levels of interleukin-6 before treatment and outcome in patients with diffuse large-cell lymphoma. Design: Retrospective cohort analysis with multivariate analysis. Setting: Tertiary referral center. Participants: 118 untreated patients with diffuse large-cell lymphoma who were enrolled in frontline chemotherapy protocols and 45 healthy controls. Measurements: Serum levels of interleukin-6 were measured by using a sensitive enzyme-linked immunosorbent assay. Levels below the upper limit of the range for controls were considered normal. Outcomes were complete response, failure-free survival, and overall survival. Results: Serum levels of interleukin-6 were higher in patients with lymphoma (median, 4.6 pg/mL [range, undetectable to 224 pg/mL]) than in controls (median, undetectable [range, undetectable to 4.3 pg/mL]) (P = 0.009). The complete response rate was 95% for persons with normal interleukin-6 levels and 66% for persons with high interleukin-6 levels (P = 0.001). Patients with high interleukin-6 levels had inferior failure-free and overall survival rates (P < 0.001 for both comparisons). The actuarial 4-year failure-free and overall survival rates were 72% and 85%, respectively, for persons with normal interleukin-6 levels and 37% and 46%, respectively, for persons with high interleukin-6 levels. In multivariate analysis, interleukin-6 was selected as the most significant predictor of complete response and failure-free survival. Failure-free and overall survival of patients stratified according to International Prognostic Index score could be further stratified by interleukin-6 level (P less than or equal to 0.03 for all comparisons). Conclusion: In patients with diffuse large-cell lymphoma, serum interleukin-6 levels are an independent prognostic factor for complete response and failure-free survival.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOIMMUNOTHERAPY, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOMATH, HOUSTON, TX 77030 USA; ROYAL MELBOURNE HOSP, DEPT CLIN HAEMATOL & MED ONCOL, PARKVILLE, VIC 3050, AUSTRALIA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Royal Melbourne Hospital			Kurzrock, Razelle/AAU-9782-2020; Seymour, John/K-7326-2019	Seymour, John/0000-0003-2188-6835; Cabanillas, Fernando/0000-0001-9234-7893; Talpaz, Moshe/0000-0003-3361-3981				Altman DG., 1991, PRACTICAL STAT MED R; BEREK JS, 1991, AM J OBSTET GYNECOL, V164, P1038, DOI 10.1016/0002-9378(91)90582-C; BLAY JY, 1992, CANCER RES, V52, P3317; CABANILLAS F, 1990, SEMIN ONCOL, V17, P28; COX DR, 1972, J R STAT SOC B, V34, P187; EMILIE D, 1994, BLOOD, V84, P2472; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; FREEMAN GJ, 1989, J CLIN INVEST, V83, P1512, DOI 10.1172/JCI114046; GAUSE A, 1991, HEMATOL ONCOL, V9, P307; GROGAN TM, 1988, BLOOD, V71, P1157; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HONG C, 1992, LEUKEMIA LYMPHOMA, V8, P97, DOI 10.3109/10428199209049823; HORST E, 1990, LEUKEMIA, V4, P595; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KURZROCK R, 1993, CANCER RES, V53, P2118; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; LU ZY, 1995, BLOOD, V86, P3123; LUDWIG H, 1991, BLOOD, V77, P2794; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; NACHBAUR DM, 1991, ANN HEMATOL, V62, P54, DOI 10.1007/BF01714900; PLUDA JM, 1993, J CLIN ONCOL, V11, P1099, DOI 10.1200/JCO.1993.11.6.1099; ROSENBERG SA, 1982, CANCER, V49, P2112; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; Seymour JF, 1997, AM J MED, V102, P21; SEYMOUR JF, 1995, J CLIN ONCOL, V13, P575, DOI 10.1200/JCO.1995.13.3.575; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SHIPP MA, 1994, BLOOD, V83, P1165; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518; TOSATO G, 1993, J CLIN INVEST, V91, P2806, DOI 10.1172/JCI116523; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; UCHIYAMA H, 1993, BLOOD, V82, P3712; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.iy.08.040190.001345; VELASQUEZ WS, 1989, BLOOD, V74, P551; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; YEE C, 1989, BLOOD, V74, P798; YOSHIZAKI K, 1989, BLOOD, V74, P1360	40	93	94	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					186	+		10.7326/0003-4819-127-3-199708010-00002	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245223				2022-12-01	WOS:A1997XN12900002
J	Levine, RL; Wayne, MA; Miller, CC				Levine, RL; Wayne, MA; Miller, CC			End-tidal carbon dioxide and outcome of out-of-hospital cardiac arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE COMPRESSION-DECOMPRESSION; CARDIOPULMONARY-RESUSCITATION; PROGNOSTIC INDICATOR; SURVIVAL; PRESSURE; EPINEPHRINE; PREDICTION; EMERGENCY; INDEX; PCO2	Background Survival after cardiac arrest occurring outside the hospital averages less than 3 percent, Unfortunately, the outcome of prolonged resuscitative attempts cannot be predicted. End-tidal carbon dioxide levels reflect cardiac output during cardiopulmonary resuscitation. We prospectively determined whether death could be predicted by monitoring end-tidal carbon dioxide during resuscitation after cardiac arrest. Methods We performed a prospective observational study in 150 consecutive victims of cardiac arrest outside the hospital who had electrical activity but no pulse. The patients were intubated and evaluated by mainstream end-tidal carbon dioxide monitoring. Our hypothesis was that an end-tidal carbon dioxide level of 10 mm Hg or less after 20 minutes of standard advanced cardiac life support would predict death. Results There was no difference in the mean age or initial end-tidal carbon dioxide level between patients who survived to hospital admission (survivors) and those who did not (nonsurvivors). After 20 minutes of advanced cardiac life support, end-tidal carbon dioxide (+/-SD) averaged 4.4+/-2.9 mm Hg in nonsurvivors and 32.8+/-7.4 mm Hg in survivors (P<0.001). A 20-minute end-tidal carbon dioxide value of 10 mm Hg or less successfully discriminated between the 35 patients who survived to hospital admission and the 115 nonsurvivors. When a 20-minute end-tidal carbon dioxide value of 10 mm Hg or less was used as a screening test to predict death, the sensitivity, specificity, positive predictive value, and negative predictive value were all 100 percent. Conclusions An end-tidal carbon dioxide level of 10 mm Hg or less measured 20 minutes after the initiation of advanced cardiac life support accurately predicts death in patients with cardiac arrest associated with electrical activity but no pulse. Cardiopulmonary resuscitation may reasonably be terminated in such patients. (C) 1997, Massachusetts Medical Society.	CITY BELLINGHAM EMERGENCY MED SERV,BELLINGHAM,WA 98225; BAYLOR COLL MED,DEPT MED,DIV PULM CRIT CARE,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,DIV EMERGENCY MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT SURG,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine								ASPLIN BR, 1995, ANN EMERG MED, V25, P756, DOI 10.1016/S0196-0644(95)70203-2; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; Bhende MS, 1995, PEDIATR EMERG CARE, V11, P365, DOI 10.1097/00006565-199512000-00008; CALLAHAM M, 1992, CRIT CARE MED, V20, P337, DOI 10.1097/00003246-199203000-00008; CALLAHAM M, 1990, CRIT CARE MED, V18, P358, DOI 10.1097/00003246-199004000-00002; Cantineau JP, 1996, CRIT CARE MED, V24, P791, DOI 10.1097/00003246-199605000-00011; CANTINEAU JP, 1994, AM J EMERG MED, V12, P267, DOI 10.1016/0735-6757(94)90136-8; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; CUMMINS RO, 1994, TXB ADV CARDIAC LIFE; DOHI S, 1987, CRIT CARE MED, V15, P944, DOI 10.1097/00003246-198710000-00010; EISENBERG M, 1979, AM J PUBLIC HEALTH, V69, P30, DOI 10.2105/AJPH.69.1.30; FALK JL, 1988, NEW ENGL J MED, V318, P607, DOI 10.1056/NEJM198803103181005; GARNETT AR, 1987, JAMA-J AM MED ASSOC, V257, P512, DOI 10.1001/jama.257.4.512; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GRAY WA, 1993, JAMA-J AM MED ASSOC, V270, P1471, DOI 10.1001/jama.270.12.1471; GULY UM, 1995, BRIT HEART J, V73, P372; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P333; IDRIS AH, 1994, ANN EMERG MED, V23, P568, DOI 10.1016/S0196-0644(94)70080-X; ISSERLES SA, 1991, ANESTH ANALG, V73, P808; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; KERN KB, 1992, ARCH INTERN MED, V152, P145, DOI 10.1001/archinte.152.1.145; KERN KB, 1989, J AM COLL CARDIOL, V13, P1184, DOI 10.1016/0735-1097(89)90282-9; LAMBERT Y, 1992, ANESTHESIOLOGY S, V77, pA1081; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; MARWICK TH, 1991, RESUSCITATION, V22, P129, DOI 10.1016/0300-9572(91)90003-H; ORNATO JP, 1988, CRIT CARE MED, V16, P241, DOI 10.1097/00003246-198803000-00007; PANTRIDG.JF, 1967, LANCET, V2, P271; PEPE PE, 1993, CRIT CARE MED, V21, P1838, DOI 10.1097/00003246-199312000-00009; SANDERS AB, 1989, JAMA-J AM MED ASSOC, V262, P1347, DOI 10.1001/jama.262.10.1347; SANDERS AB, 1985, AM J EMERG MED, V3, P147, DOI 10.1016/0735-6757(85)90039-7; SANDERS AB, 1985, ANN EMERG MED, V14, P948, DOI 10.1016/S0196-0644(85)80235-3; SAS Institute, 1988, SAS STAT US GUID VER; SCHWAB TM, 1995, JAMA-J AM MED ASSOC, V273, P1261, DOI 10.1001/jama.273.16.1261; SHIBUTANI K, 1994, ANESTH ANALG, V79, P829; VARON AJ, 1991, J CLIN MONITOR, V7, P289, DOI 10.1007/BF01619347; WAYNE MA, 1995, ANN EMERG MED, V25, P762, DOI 10.1016/S0196-0644(95)70204-0; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011; WEST JB, 1977, AM REV RESPIR DIS, V116, P919; WRIGHT D, 1990, BRIT MED J, V301, P600, DOI 10.1136/bmj.301.6752.600	39	276	282	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 31	1997	337	5					301	306		10.1056/NEJM199707313370503	http://dx.doi.org/10.1056/NEJM199707313370503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN119	9233867				2022-12-01	WOS:A1997XN11900003
J	Dale, JK; Vesque, C; Lints, TJ; Sampath, TK; Furley, A; Dodd, J; Placzek, M				Dale, JK; Vesque, C; Lints, TJ; Sampath, TK; Furley, A; Dodd, J; Placzek, M			Cooperation of BMP7 and SHH in the induction of forebrain ventral midline cells by prechordal mesoderm	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-7; FLOOR PLATE DIFFERENTIATION; MOTOR-NEURON INDUCTION; CENTRAL-NERVOUS-SYSTEM; SONIC-HEDGEHOG; SPINAL-CORD; EXPRESSION; SIGNALS; BRAIN; EYE	Ventral midline cells at different rostrocaudal levels of the central nervous system exhibit distinct properties but share the ability to pattern the dorsoventral axis of the neural tube. We show here that ventral midline cells acquire distinct identities in response to the different signaling activities of underlying mesoderm. Signals from prechordal mesoderm control the differentiation of rostral diencephalic ventral midline cells, whereas notochord induces floor plate cells caudally. Sonic hedgehog (SHH) is expressed throughout axial mesoderm and is required for the induction of both rostral diencephalic ventral midline cells and floor plate. However, prechordal mesoderm also expresses BMP7 whose function is required coordinately with SHH to induce rostral diencephalic ventral midline eels. BMP7 acts directly on neural cells, modifying their response to SHH so that they differentiate into rostral diencephalic Ventral midline cells rather than floor prate cells. Our results suggest a model whereby axial mesoderm both induces the differentiation of overlying neural cells and controls the rostrocaudal character of the ventral midline of the neural tube.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; COLUMBIA UNIV,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; CREAT BIOMOL,HOPKINTON,MA 01748	MRC National Institute for Medical Research; Columbia University; Columbia University			Furley, Andrew JW/B-7316-2012; Furley, Andrew J. W./D-4798-2013; Lints, Thierry/K-4408-2012; Dale, Kim J/A-4480-2016; Vesque, Christine/Q-8461-2019; Vesque, Christine/L-9839-2017; Placzek, Marysia/E-6172-2010	Furley, Andrew JW/0000-0001-5549-8668; Dale, Kim J/0000-0002-9294-947X; Vesque, Christine/0000-0001-7983-4953; Placzek, Marysia/0000-0002-4106-9229	NINDS NIH HHS [NS 30532] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030532] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Adelmann H. B., 1922, American Journal of Anatomy, V31, P55, DOI 10.1002/aja.1000310104; Adelmann HB, 1932, J MORPHOL, V54, P1, DOI 10.1002/jmor.1050540102; Adelmann HB, 1930, J EXP ZOOL, V57, P223, DOI 10.1002/jez.1400570204; ANG SL, 1994, DEVELOPMENT, V120, P2979; BARTH KA, 1995, DEVELOPMENT, V121, P1755; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; HARLAND RM, 1997, IN PRESS NEURONAL DE; HATTA K, 1994, P NATL ACAD SCI USA, V91, P2061, DOI 10.1073/pnas.91.6.2061; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEATH MJS, 1995, J PHYSIOL-LONDON, V486, P139, DOI 10.1113/jphysiol.1995.sp020798; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MARTI E, 1995, DEVELOPMENT, V121, P2537; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1990, COLD SPRING HARB SYM, V55, P279; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SEIFERT R, 1993, J ANAT, V183, P75; Solursh M, 1996, BIOCHEM BIOPH RES CO, V218, P438, DOI 10.1006/bbrc.1996.0078; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Varlet I, 1997, DEVELOPMENT, V124, P1033; VUKICEVIC S, 1994, BIOCHEM BIOPH RES CO, V198, P693, DOI 10.1006/bbrc.1994.1100; ZECCA M, 1995, DEVELOPMENT, V121, P2265	49	245	251	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					257	269		10.1016/S0092-8674(00)80334-7	http://dx.doi.org/10.1016/S0092-8674(00)80334-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244300	hybrid			2022-12-01	WOS:A1997XN24900010
J	Hua, W; Young, EC; Fleming, ML; Gelles, J				Hua, W; Young, EC; Fleming, ML; Gelles, J			Coupling of kinesin steps to ATP hydrolysis	NATURE			English	Article							MICROTUBULE MOVEMENT; HEAVY-CHAIN; DERIVATIVES; MOLECULES	A key goal in the study of the function of ATP-driven motor enzymes is to quantify the movement produced from consumption of one ATP molecule(1-3). Discrete displacements of the processive motor kinesin along a microtubule have been reported as 5 and/or 8 mn (refs 4, 5). However, analysis of nanometre-scale movements is hindered by superimposed brownian motion, Moreover, because kinesin is processive and turns over stochastically, some observed displacements must arise from summation of smaller movements that are too closely spaced in time to be resolved, To address both of these problems, we used light microscopy instrumentation(6) with low positional drift (<39 pm s(-1)) to observe single molecules of a kinesin derivative moving slowly (similar to 2.5 nm s(-1)) at very low (150 nM) ATP concentration, so that ATP-induced displacements were widely spaced in time, This allowed increased time-averaging to suppress brownian noise (without application of external force(4,5)), permitting objective measurement of the distribution of all observed displacement sizes, The distribution was analysed with a statistics-based method which explicitly takes into account the occurrence of unresolved movements, and determines both the underlying step size and the coupling of steps to ATP hydrolytic events, Our data support a fundamental enzymatic cycle for kinesin in which hydrolysis of a single ATP molecule is coupled to a step distance of the microtubule protofilament lattice spacing of 8.12 nm (ref. 7). Step distances other than 8 nm are excluded, as is the coupling of each step to two or more consecutive ATP hydrolysis reactions with similar rates, or the coupling of two 8-nm steps to a single hydrolysis. The measured ratio of ATP consumption rate to stepping rate is invariant over a wide range of ATP concentration, suggesting that the 1 ATP to 8 nm coupling inferred from behaviour at low ATP can be generalized to high ATP.	BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOCHEM,BIOPHYS & STRUCT BIOL GRAD PROGRAM,WALTHAM,MA 02254	Brandeis University; Brandeis University				Young, Edgar C./0000-0002-8453-088X				Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, 1995, THESIS BRANDEIS U WA; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; GALLAGHER NC, 1981, IEEE T ACOUST SPEECH, V29, P1136, DOI 10.1109/TASSP.1981.1163708; GELLES J, 1995, BIOPHYS J, V68, pS276; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; Segel I. H, 1993, ENZYME KINETICS; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TAYLOR EW, 1993, NATURE, V361, P115, DOI 10.1038/361115a0; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; YOUNG EC, 1995, J BIOL CHEM, V270, P3926, DOI 10.1074/jbc.270.8.3926	29	270	274	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					390	393		10.1038/41118	http://dx.doi.org/10.1038/41118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237758				2022-12-01	WOS:A1997XM52800054
J	Paushkin, SV; Kushnirov, VV; Smirnov, VN; TerAvanesyan, MD				Paushkin, SV; Kushnirov, VV; Smirnov, VN; TerAvanesyan, MD			In vitro propagation of the prion-like state of yeast Sup35 protein	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; BIOLOGY; GENE; DISEASES; URE3	The yeast cytoplasmically inherited genetic determinant [PSI+] is presumed to be a manifestation of the prion-like properties of the Sup35 protein (Sup35p). Here, cell-free conversion of Sup35p from [psi(-)] cells (Sup35(psi-)) to the prion-like [PSI+]-specific form (Sup35p(PSI+)) was observed. The conversion reaction could be repeated for several consecutive cycles, thus modeling in vitro continuous [PSI+] propagation. Size fractionation of lysates of [PSI+] cells demonstrated that the converting activity was associated solely with Sup35p(PSI+) aggregates, which agrees with the nucleation model for [PSI+] propagation. Sup35p(PSI+) was purified and showed high conversion activity, thus confirming the prion hypothesis for Sup35p.	CARDIOL RES CTR,INST EXPT CARDIOL,MOSCOW 121552,RUSSIA	National Medical Research Center of Cardiology			Vitaly, Kushnirov/AAU-6003-2021	Kushnirov, Vitaly/0000-0003-0316-0766				AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Frolova L, 1996, RNA, V2, P334; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, MOL CELL BIOL, V17, P2798, DOI 10.1128/MCB.17.5.2798; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; PAUSHKIN SV, UNPUB; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; TUITE MF, 1987, FEBS LETT, V225, P205, DOI 10.1016/0014-5793(87)81158-4; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	22	196	201	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					381	383		10.1126/science.277.5324.381	http://dx.doi.org/10.1126/science.277.5324.381			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219697				2022-12-01	WOS:A1997XL35800049
J	Bellis, MA; Weild, AR; Beeching, NJ; Mutton, KJ; Syed, Q				Bellis, MA; Weild, AR; Beeching, NJ; Mutton, KJ; Syed, Q			Prevalence of HIV and injecting drug use in men entering Liverpool prison	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL LIVERPOOL SCH TROP MED,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND; LIVERPOOL PUBL HLTH LAB,COMMUNICABLE DIS SURVEILLANCE CTR NW,LIVERPOOL L9 7AL,MERSEYSIDE,ENGLAND	Liverpool School of Tropical Medicine	Bellis, MA (corresponding author), UNIV LIVERPOOL,DEPT PUBL HLTH,SEXUAL HLTH & ENVIRONM EPIDEMIOL UNIT,LIVERPOOL L69 3GB,MERSEYSIDE,ENGLAND.		Bellis, Mark A./HGA-2019-2022; Beeching, Nicholas J/L-5363-2017	Beeching, Nicholas/0000-0002-7019-8791				Curtis SP, 1995, INT J STD AIDS, V6, P387, DOI 10.1177/095646249500600602; FORD BT, 1992, AIDS, V6, P623; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; MORRISON CL, 1995, POSTGRAD MED J, V71, P593, DOI 10.1136/pgmj.71.840.593; Yirrell DI, 1997, BRIT MED J, V314, P1446, DOI 10.1136/bmj.314.7092.1446	5	37	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					30	31		10.1136/bmj.315.7099.30	http://dx.doi.org/10.1136/bmj.315.7099.30			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233323	Green Published			2022-12-01	WOS:A1997XJ94700024
J	Chuang, LSH; Ian, HI; Koh, TW; Ng, HH; Xu, GL; Li, BFL				Chuang, LSH; Ian, HI; Koh, TW; Ng, HH; Xu, GL; Li, BFL			Human DNA (cytosine-5) methyltransferase PCNA complex as a target for p21(WAF1)	SCIENCE			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; CYCLIN-DEPENDENT KINASES; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; TUMOR SUPPRESSION; BINDING DOMAINS; POLYMERASE-III; HISTONE H1; REPLICATION; METHYLATION	DNA-(cytosine-5) methyltransferase (MCMT) methylates newly replicated mammalian DNA, but the factors regulating this activity are unknown. Here, MCMT is shown to bind proliferating cell nuclear antigen (PCNA), an auxiliary factor for DNA replication and repair. Binding of PCNA requires amino acids 163 to 174 of MCMT, occurs in intact cells at fool of newly replicated DNA, and does not alter MCMT activity. A peptide derived from the cell cycle regulator p21(WAF1) disrupt the MCMT-PCNA interaction, which suggests that p21(WAF1) may regulate methylation by blocking access of MCMT to PCNA, MCMT and p21(WAF1) may be linked in a regulatory pathway, because the extents of their expression are inversely related in both SV40-transformed and nontransformed cells.	NATL UNIV SINGAPORE,INST MOL & CELL BIOL,CHEM CARCINOGENESIS LAB,SINGAPORE 119260,SINGAPORE; NATL UNIV SINGAPORE,BIOSCI CTR,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore			Ng, Huck Hui/A-1135-2009; Koh, Tong-Wey/M-3774-2013	Koh, Tong-Wey/0000-0001-9136-3189				AYI TC, 1992, CANCER RES, V52, P6423; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Carotti D, 1996, BIOCHEMISTRY-US, V35, P11660, DOI 10.1021/bi9606051; CHEN YQ, 1995, CANCER RES, V55, P4536; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gasser R, 1996, J MOL BIOL, V258, P224, DOI 10.1006/jmbi.1996.0245; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Herendeen DR, 1996, CELL, V84, P5, DOI 10.1016/S0092-8674(00)80069-0; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1996, CANCER RES, V56, P2463; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Lim A, 1996, EMBO J, V15, P4050, DOI 10.1002/j.1460-2075.1996.tb00778.x; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Oh HK, 1996, BIOCHEMISTRY-US, V35, P12259, DOI 10.1021/bi9603635; PETERSON SR, 1995, CANCER RES, V55, P4651; Sambrook J., 1989, MOL CLONING LAB MANU; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TAN NW, 1990, BIOCHEMISTRY-US, V29, P9234, DOI 10.1021/bi00491a018; TEO AKC, UNPUB; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996	43	707	733	8	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 26	1997	277	5334					1996	2000		10.1126/science.277.5334.1996	http://dx.doi.org/10.1126/science.277.5334.1996			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302295				2022-12-01	WOS:A1997XX84900045
J	Coyne, KJ; Qin, XX; Waite, JH				Coyne, KJ; Qin, XX; Waite, JH			Extensible collagen in mussel byssus: A natural block copolymer	SCIENCE			English	Article							DRAGLINE SILK; PROTEINS; ELASTIN; CDNA; GENE; IDENTIFICATION; EVOLUTION; SEQUENCE; THREADS; FIBROIN	To adhere to solid surfaces, marine mussels produce byssal threads, each of which is a stiff tether at one end and a shock absorber with 160 percent extensibility at the other end. The elastic extensibility of proximal byssus is extraordinary given its construction of collagen and the limited extension (less than 10 percent) of most collagenous materials. From the complementary DNA, we deduced that the primary structure of a collagenous protein (preCol-P) predominating in the extensible proximal portion of the threads encodes an unprecedented natural block copolymer with three major domain types: a central collagen domain, flanking elastic domains, and histidine-rich terminal domains. The elastic domains have sequence motifs that strongly resemble those of elastin and the amorphous glycine-rich regions of spider silk fibroins. Byssal thread extensibility may be imparted by the elastic domains of preCol-P.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware	Coyne, KJ (corresponding author), UNIV DELAWARE,COLL MARINE STUDIES,NEWARK,DE 19716, USA.			Coyne, Kathryn/0000-0001-8846-531X				BAIRATI A, 1991, FORM FUNCTION ZOOLOG, P163; Bell EC, 1996, J EXP BIOL, V199, P1005; BELL EJ, UNPUB; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; BRYAN GW, 1979, J MAR BIOL ASSOC UK, V59, P969, DOI 10.1017/S0025315400036961; COOMBS TL, 1981, AQUAT TOXICOL, V1, P291, DOI 10.1016/0166-445X(81)90023-0; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; Denny M. W., 1988, BIOL MECH WAVE SWEPT; Guerette PA, 1996, SCIENCE, V272, P112, DOI 10.1126/science.272.5258.112; Hall, 1981, POLYM MAT, DOI 10.1007/978-1-349-10187-0_4; HINMAN MB, 1992, J BIOL CHEM, V267, P19320; HUANG X, 1991, GENOMICS, V14, P18; JOHNSON KS, 1987, MOL BIOCHEM PARASIT, V22, P89, DOI 10.1016/0166-6851(87)90072-7; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; LILIUS G, 1991, EUR J BIOCHEM, V198, P499, DOI 10.1111/j.1432-1033.1991.tb16042.x; LION T, 1990, ANAL BIOCHEM, V188, P335, DOI 10.1016/0003-2697(90)90616-H; MELNICK SC, 1958, NATURE, V181, P1483, DOI 10.1038/1811483a0; Patwary MU, 1996, J SHELLFISH RES, V15, P265; PIKKARAINEN J, 1968, EUR J BIOCHEM, V4, P555, DOI 10.1111/j.1432-1033.1968.tb00248.x; Qin X., UNPUB; QIN XX, 1995, J EXP BIOL, V198, P633; RAJU K, 1987, J BIOL CHEM, V262, P5755; ROBSON P, 1993, J BIOL CHEM, V268, P1440; ROSE JR, 1993, FASEB J, V7, pA1208, DOI 10.1096/fasebj.7.13.8405806; Rudall KM, 1955, S SOC EXP BIOL, V9, P49; SAGE H, 1979, COMP BIOCHEM PHYS B, V64, P313, DOI 10.1016/0305-0491(79)90277-3; Simmons AH, 1996, SCIENCE, V271, P84, DOI 10.1126/science.271.5245.84; SMEATHERS JE, 1979, J MOLLUS STUD, V49, P219; SMITH MC, 1987, INORG CHEM, V26, P1965, DOI 10.1021/ic00259a030; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; THIEL BL, 1995, MRS BULL, V20, P52, DOI 10.1557/S0883769400034941; URRY DW, 1984, J PROTEIN CHEM, V3, P403, DOI 10.1007/BF01025061; VITELLAROZUCCARELLO L, 1983, TISSUE CELL, V15, P547, DOI 10.1016/0040-8166(83)90006-X; Waite J.H., 1992, Results and Problems in Cell Differentiation, V19, P27; WAITE JH, 1989, BIOCHEMISTRY-US, V28, P6104, DOI 10.1021/bi00440a056; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; [No title captured]	38	209	220	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 19	1997	277	5333					1830	1832		10.1126/science.277.5333.1830	http://dx.doi.org/10.1126/science.277.5333.1830			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295275				2022-12-01	WOS:A1997XX29800049
J	Debanne, D; Guerineau, NC; Gahwiler, BH; Thompson, SM				Debanne, D; Guerineau, NC; Gahwiler, BH; Thompson, SM			Action-potential propagation gated by an axonal I-A-like K+ conductance in hippocampus	NATURE			English	Article							SLICE CULTURES; POTASSIUM CURRENTS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; CELLS; CA3; MECHANISM; FREQUENCY; RELEASE	Integration of membrane-potential changes is traditionally reserved for neuronal somatodendritic compartments. Axons are typically considered to transmit reliably the result of this integration, the action potential(1), to nerve terminals(2,3). By recording from pairs of pyramidal cells in hippocampal slice cultures(4-6), we show here that the propagation of action potentials to nerve terminals is impaired if presynaptic action potentials are preceded by brief or tonic hyperpolarization. Action-potential propagation fails only when the presynaptic action potential is triggered within the first 15-20 ms of a depolarizing step from hyperpolarized potentials; action-potential propagation failures are blocked when presynaptic cells are impaled with electrodes containing 4-aminopyridine, indicating that a fast-inactivating, A-type K+ conductance is involved. Propagation failed between some, but not all, of the postsynaptic cells contacted by a single presynaptic cell, suggesting that the presynaptic action potentials failed at axonal branch points. We conclude that the physiological activation of an I-A-like potassium conductance can locally block propagation of presynaptic action potentials in axons of the central nervous system, Thus axons do not always behave as simple electrical cables: their capacity to transmit action potentials is determined by a time-dependent integration of recent membrane-potential changes.	UNIV ZURICH, BRAIN RES INST, CH-8029 ZURICH, SWITZERLAND	University of Zurich			Debanne, Dominique/O-4673-2016; Thompson, Scott M/K-8921-2015	Debanne, Dominique/0000-0001-8581-5695; Guerineau, Nathalie/0000-0003-2517-4210				Bossu JL, 1996, J PHYSIOL-LONDON, V495, P367, DOI 10.1113/jphysiol.1996.sp021600; Colbert CM, 1996, J NEUROSCI, V16, P6676; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282, DOI 10.1152/jn.1995.73.3.1282; Debanne D, 1996, J PHYSIOL-LONDON, V491, P163, DOI 10.1113/jphysiol.1996.sp021204; Eccles, 2013, PHYSL SYNAPSES; FROTSCHER M, 1988, NEUROSCIENCE, V24, P541, DOI 10.1016/0306-4522(88)90348-X; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; KOCSIS JD, 1986, BRAIN RES, V383, P357, DOI 10.1016/0006-8993(86)90040-5; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; LUSCHER C, 1994, J NEUROPHYSIOL, V72, P622, DOI 10.1152/jn.1994.72.2.622; MacKenzie PJ, 1996, NEURON, V16, P783, DOI 10.1016/S0896-6273(00)80098-7; PARNAS I, 1972, J NEUROPHYSIOL, V35, P903, DOI 10.1152/jn.1972.35.6.903; PARNAS I, 1976, J NEUROPHYSIOL, V39, P909, DOI 10.1152/jn.1976.39.4.909; SEGEV I, 1990, J NEUROPHYSIOL, V63, P987, DOI 10.1152/jn.1990.63.5.987; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; STEPHENS GJ, 1994, J PHYSIOL-LONDON, V477, P187, DOI 10.1113/jphysiol.1994.sp020183; Storm J. F., 1994, Society for Neuroscience Abstracts, V20, P1339; STORM JF, 1990, PROG BRAIN RES, V83, P161; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; Vincent P, 1996, J PHYSIOL-LONDON, V494, P183, DOI 10.1113/jphysiol.1996.sp021484; WALL PD, 1995, TRENDS NEUROSCI, V18, P99, DOI 10.1016/0166-2236(95)93883-Y	21	221	221	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					286	289		10.1038/38502	http://dx.doi.org/10.1038/38502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305843				2022-12-01	WOS:A1997XW77200048
J	Nedelec, FJ; Surrey, T; Maggs, AC; Leibler, S				Nedelec, FJ; Surrey, T; Maggs, AC; Leibler, S			Self-organization of microtubules and motors	NATURE			English	Article							CHROMOSOME SEGREGATION; KINESIN; EXTRACTS; INVITRO; FORCE	Cellular structures are established and maintained through a dynamic interplay between assembly and regulatory processes. Self-organization of molecular components provides a variety of possible spatial structures: the regulatory machinery chooses the most appropriate to express a given cellular function(1). Here we study the extent and the characteristics of self-organization using microtubules and molecular motors(2) as a model system. These components are known to participate in the formation of many cellular structures, such as the dynamic asters found in mitotic and meiotic spindles(3,4). Purified motors and microtubules have previously been observed to form asters in vitro(5). We have reproduced this result with a simple system consisting solely of multi-headed constructs of the motor protein kinesin(6) and stabilized microtubules. We show that dynamic asters can also be obtained from a homogeneous solution of tubulin and motors. By varying the relative concentrations of the components, we obtain a variety of self-organized structures. Further, by studying this process in a constrained geometry of micro-fabricated glass chambers(7), we demonstrate that the same final structure can be reached through different assembly 'pathways'.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544; ECOLE SUPER PHYS & CHIM IND VILLE PARIS,LAB PHYSICOCHIM THEOR,F-75231 PARIS,FRANCE	Princeton University; Princeton University; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)			Nedelec, Francois/AAC-1673-2019; Nedelec, Francois J/H-3317-2011; Surrey, Thomas/AAC-4608-2021	Nedelec, Francois/0000-0002-8141-5288; Nedelec, Francois J/0000-0002-8141-5288; Surrey, Thomas/0000-0001-9082-1870				ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BAYER E, 1990, METHOD ENZYMOL, V184, P51; BERLINER E, 1994, J BIOL CHEM, V269, P8610; DOGTEROM M, 1993, PHYS REV LETT, V70, P1347, DOI 10.1103/PhysRevLett.70.1347; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.biophys.21.1.145; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Holy TE, 1997, P NATL ACAD SCI USA, V94, P6228, DOI 10.1073/pnas.94.12.6228; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; MAYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; Rodionov VI, 1997, NATURE, V386, P170, DOI 10.1038/386170a0; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TABONY J, 1994, SCIENCE, V264, P245, DOI 10.1126/science.8146654; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X; YOUNG EC, 1995, J BIOL CHEM, V270, P3926, DOI 10.1074/jbc.270.8.3926; [No title captured]	29	613	622	2	99	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 18	1997	389	6648					305	308		10.1038/38532	http://dx.doi.org/10.1038/38532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305848				2022-12-01	WOS:A1997XW77200053
J	Feuchtgruber, H; Lellouch, E; deGraauw, T; Bezard, B; Encrenaz, T; Griffin, M				Feuchtgruber, H; Lellouch, E; deGraauw, T; Bezard, B; Encrenaz, T; Griffin, M			External supply of oxygen to the atmospheres of the giant planets	NATURE			English	Article							SHORT-PERIOD COMETS; MIXING RATIOS; NEPTUNE; SATURN; RINGS; URANUS; DUST; MODEL; CO; SPECTROMETER	The atmospheres of the giant planets are reducing, being mainly composed of hydrogen, helium and methane. But the rings and icy satellites that surround these planets, together with the flux of interplanetary dust, could act as important sources of oxygen, which would be delivered to the atmospheres mainly in the form of water ice or silicate dust(1-7). Here we report the detection, by infrared spectroscopy, of gaseous H2O in the upper atmospheres of Saturn, Uranus and Neptune. The implied H2O column densities are 1.5 x 10(15), 9 x 10(13) and 3 x 10(14) molecules cm(-2) respectively, CO2 in comparable amounts was also detected in the atmospheres of Saturn and Neptune, These observations can be accounted for by external fluxes of 10(5)-10(7) H2O molecules cm(-2) s(-1) and subsequent chemical processing in the atmospheres, The presence of gaseous water and infalling dust will affect the photochemistry, energy budget and ionospheric properties of these atmospheres. Moreover, our findings may help to constrain the injection rate and possible activity of distant icy objects in the Solar System.	OBSERV PARIS,DESPA,F-92195 MEUDON,FRANCE; MAX PLANCK INST EXTRATERR PHYS,D-85748 GARCHING,GERMANY; ESA,ISO,SCI OPERAT CTR,VILLAFRANCA 28080,SPAIN; SRON,NL-9700 AV GRONINGEN,NETHERLANDS; UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON E1 4NS,ENGLAND	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Max Planck Society; University of London; Queen Mary University London				Bezard, Bruno/0000-0002-5433-5661				ATNEYA SK, 1990, URANUS, P110; Atreya S. K., 1984, SATURN, P239; BISHOP J, 1992, J GEOPHYS RES-PLANET, V97, P11681, DOI 10.1029/92JE00959; BISHOP J, 1990, ICARUS, V88, P448, DOI 10.1016/0019-1035(90)90094-P; BROADFOOT AL, 1986, SCIENCE, V233, P74, DOI 10.1126/science.233.4759.74; COLWELL JE, 1992, J GEOPHYS RES-PLANET, V97, P10227, DOI 10.1029/92JE00788; COLWELL JE, 1990, GEOPHYS RES LETT, V17, P1741, DOI 10.1029/GL017i010p01741; COLWELL JE, 1990, ICARUS, V86, P530, DOI 10.1016/0019-1035(90)90232-X; CONNERNEY JEP, 1984, NATURE, V312, P136, DOI 10.1038/312136a0; CROVISIER J, 1993, ASTEROIDS COMETS MET, P313; CUZZI JN, 1990, ICARUS, V84, P467, DOI 10.1016/0019-1035(90)90049-F; deGraauw T, 1997, ASTRON ASTROPHYS, V321, pL13; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; FERNANDEZ JA, 1985, ICARUS, V64, P308; Foryta DW, 1996, ICARUS, V123, P129, DOI 10.1006/icar.1996.0146; FOUCHET T, 1996, B AM ASTRON SOC, V28, P1129; GRUN E, 1994, ASTRON ASTROPHYS, V286, P915; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; HUBBARD WB, UNPUB ICARUS; HUMES DH, 1980, J GEOPHYS RES-SPACE, V85, P5841, DOI 10.1029/JA085iA11p05841; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; Lara LM, 1996, J GEOPHYS RES-PLANET, V101, P23261, DOI 10.1029/96JE02036; LELLOUCH E, 1996, COLLISION COMET SHOE, P213; MAJEED T, 1991, PLANET SPACE SCI, V39, P1715, DOI 10.1016/0032-0633(91)90031-5; MARTEN A, 1993, ASTROPHYS J, V406, P285, DOI 10.1086/172440; MORFILL GE, 1983, ICARUS, V55, P439, DOI 10.1016/0019-1035(83)90114-8; MOSES JI, 1992, ICARUS, V99, P368, DOI 10.1016/0019-1035(92)90153-X; NOLL KS, 1990, ICARUS, V89, P168; NORTHROP TG, 1993, J GEOPHYS RES, V88, P6102; PRATHER MJ, 1978, ASTROPHYS J, V223, P1072, DOI 10.1086/156340; QUINN T, 1990, ASTROPHYS J, V355, P667, DOI 10.1086/168800; RIZK B, 1990, ICARUS, V88, P429, DOI 10.1016/0019-1035(90)90093-O; ROMANI PN, 1993, ICARUS, V106, P442, DOI 10.1006/icar.1993.1184; ROSENQVIST J, 1992, ASTROPHYS J, V392, pL99, DOI 10.1086/186435; SAMUELSON RE, 1983, J GEOPHYS RES-SPACE, V88, P8709, DOI 10.1029/JA088iA11p08709; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SMITH GR, 1983, J GEOPHYS RES-SPACE, V88, P8667, DOI 10.1029/JA088iA11p08667; STROBEL DF, 1979, ICARUS, V37, P256, DOI 10.1016/0019-1035(79)90130-1; STROBEL DF, 1990, URANUS, P65; WINKELSTEIN P, 1983, ICARUS, V54, P309, DOI 10.1016/0019-1035(83)90200-2	40	162	162	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					159	162		10.1038/38236	http://dx.doi.org/10.1038/38236			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296492				2022-12-01	WOS:A1997XV75700041
J	Schnell, MJ; Johnson, JE; Buonocore, L; Rose, JK				Schnell, MJ; Johnson, JE; Buonocore, L; Rose, JK			Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; G-PROTEIN; RECEPTOR; EXPRESSION; GENE; GLYCOPROTEIN; FUSION; SYSTEM; ENTRY	We describe a recombinant vesicular stomatitis virus lacking its glycoprotein gene and expressing instead the HIV-1 receptor CD4 and a coreceptor, CXCR4. This virus was unable to infect normal cells but did infect, propagate on, and kill cells that were first infected with HIV-1 and therefore had the HIV membrane fusion protein on their surface. Killing of HIV-l-infected cells controlled HIV infection in a T cell line and reduced titers of infectious HIV-1 in the culture by as much as 10(4)-fold. Such a targeted virus could have therapeutic value in reducing HIV viral load. Our results also demonstrate a general strategy of targeting one virus to the envelope protein of another virus to control infection.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University				Schnell, Matthias/0000-0001-9040-9405	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024345, R01AI049235, R56AI049235, R01AI024345] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49235, AI24345] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Berson JF, 1996, J VIROL, V70, P6288, DOI 10.1128/JVI.70.9.6288-6295.1996; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FLORKIEWICZ RZ, 1984, SCIENCE, V225, P721, DOI 10.1126/science.6087454; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Johnson JE, 1997, J VIROL, V71, P5060, DOI 10.1128/JVI.71.7.5060-5068.1997; KNIPE DM, 1977, J VIROL, V21, P1149, DOI 10.1128/JVI.21.3.1149-1158.1977; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LAWSON ND, 1995, P NATL ACAD SCI USA, V92, P4477, DOI 10.1073/pnas.92.10.4477; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Mebatsion T, 1996, CELL, V84, P941, DOI 10.1016/S0092-8674(00)81072-7; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; REED L. J., 1938, AMER JOUR HYG, V27, P493; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; RIEDEL H, 1984, EMBO J, V3, P1477, DOI 10.1002/j.1460-2075.1984.tb01999.x; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; Schnell MJ, 1996, J VIROL, V70, P2318, DOI 10.1128/JVI.70.4.2318-2323.1996; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; Schuitemaker H, 1996, AIDS, V10 Suppl A, pS25, DOI 10.1097/00002030-199601001-00004; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; TILL MA, 1988, SCIENCE, V242, P1166, DOI 10.1126/science.2847316; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wagner RR., 1996, FIELDS VIROLOGY, V1, P1121; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	34	184	206	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					849	857		10.1016/S0092-8674(00)80350-5	http://dx.doi.org/10.1016/S0092-8674(00)80350-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298897	hybrid			2022-12-01	WOS:A1997XV56300006
J	Adami, J; Nyren, O; Bergstrom, R; Ekbom, A; McLaughlin, JK; Hogman, C; Fraumeni, JF; Glimelius, B				Adami, J; Nyren, O; Bergstrom, R; Ekbom, A; McLaughlin, JK; Hogman, C; Fraumeni, JF; Glimelius, B			Blood transfusion and non-Hodgkin lymphoma: Lack of association	ANNALS OF INTERNAL MEDICINE			English	Article						blood transfusion; lymphoma, non-Hodgkin's; case-control studies; leukemia, lymphocytic, chronic; immunosuppression	C VIRUS-INFECTION; POSTOPERATIVE INFECTIONS; CANCER RISK; SELECTION; INCREASE; SURGERY; SWEDEN; WOMEN	Background: Non-Hodgkin lymphoma is the seventh most commonly diagnosed malignant condition worldwide, and its incidence has increased markedly in recent decades. Blood transfusions have been implicated as a possible risk factor for non-Hodgkin lymphoma. Objective: To determine whether blood transfusions are associated with an elevated risk for non-Hodgkin lymphoma. Design: Population-based, nested case-control study. Setting: Nationwide cohort in Sweden. Patients: 361 patients with non-Hodgkin lymphoma and 705 matched controls, nested within a population-based cohort of 96 795 patients at risk for blood transfusion between 1970 and 1983. Prospectively collected information on exposure was retrieved from computerized transfusion registries. Measurements: Odds ratios obtained from conditional logistic regression models were used as measures of relative risks. Results: No association was found between blood transfusions and the risk for non-Hodgkin lymphoma when patients who had received transfusions were compared with patients who had not received transfusions (odds ratio, 0.93 [95% Cf, 0.71 to 1.23]). A reduction in risk was seen among persons who received transfusion of blood without leukocyte depletion (odds ratio, 0.72 [CI, 0.53 to 0.97]). Risk was not related to number of transfusions, and no interaction was seen with latency after transfusion. Conclusion: The findings in this study do not support previous observations of an association between blood transfusions and the risk for non-Hodgkin lymphoma.	INT EPIDEMIOL INST LTD, ROCKVILLE, MD 20850 USA; UPPSALA UNIV, UPPSALA, SWEDEN; NCI, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Uppsala University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	Adami, J (corresponding author), KAROLINSKA INST, DEPT MED EPIDEMIOL, BOX 281, S-17177 STOCKHOLM, SWEDEN.		Adami, Johanna/AAA-3312-2021					Biggar Robert J., 1992, Current Opinion in Oncology, V4, P883, DOI 10.1097/00001622-199210000-00011; BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; BLUMBERG N, 1994, SCI BASIS TRANSFUSIO, P580; Brandt L, 1996, BRIT J CANCER, V73, P1148, DOI 10.1038/bjc.1996.220; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; CARLI PM, 1994, BRIT J CANCER, V70, P713, DOI 10.1038/bjc.1994.380; CARTWRIGHT RA, 1992, CANCER RES, V52, pS5441; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; DAVIS W, 1980, STAT METHODS CANC RE, V1; DEVESA SS, 1992, CANCER RES, V52, pS5432; FERRI C, 1994, BRIT J HAEMATOL, V88, P392, DOI 10.1111/j.1365-2141.1994.tb05036.x; FILIPOVICH AH, 1990, NONHODGKINS LYMPHOMA, P135; Hakulinen T, 1986, Acta Pathol Microbiol Immunol Scand Suppl, V288, P1; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; HARRIS NL, 1994, BLOOD, V84, P1361; Hjalgrim H, 1996, BRIT J CANCER, V73, P951, DOI 10.1038/bjc.1996.170; HOGMAN CF, 1970, TRANSFUSION, V10, P121; Izumi T, 1996, BLOOD, V87, P5380, DOI 10.1182/blood.V87.12.5380.bloodjournal87125380; KINLEN L, 1982, CANCER SURV, V1, P565; MARTINSSON U, 1992, ACTA ONCOL, V31, P275, DOI 10.3109/02841869209108173; MEMON A, 1994, INT J CANCER, V58, P366, DOI 10.1002/ijc.2910580310; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MUELLER BU, 1995, J PEDIATR-US, V126, P1, DOI 10.1016/S0022-3476(95)70491-4; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; Nilsson A C, 1994, Lakartidningen, V91, P603; Nilsson AC, 1994, LAKARTIDNINGEN, V91, P603; NYREN O, 1995, JNCI-J NATL CANCER I, V87, P28, DOI 10.1093/jnci/87.1.28; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; PENN I, 1988, CANCER DETECT PREV, V12, P39; Pioltelli P, 1996, LANCET, V347, P624, DOI 10.1016/S0140-6736(96)91328-8; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; *SWED CANC REG, 1996, CANC INC SWED; TARTTER PI, 1988, BRIT J SURG, V75, P789, DOI 10.1002/bjs.1800750822; TARTTER PI, 1989, TRANSFUSION, V29, P456, DOI 10.1046/j.1537-2995.1989.29589284149.x; TARTTER PI, 1993, BEITR INFUS, V31, P52; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; TRIULZI DJ, 1990, TRANSFUSION MEDICINE IN THE 1990S, P1; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1042, DOI 10.1093/oxfordjournals.aje.a116398; ZHENG TZ, 1992, CANCER, V70, P840, DOI 10.1002/1097-0142(19920815)70:4&lt;840::AID-CNCR2820700420&gt;3.0.CO;2-I	41	31	32	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1997	127	5					365	+		10.7326/0003-4819-127-5-199709010-00004	http://dx.doi.org/10.7326/0003-4819-127-5-199709010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU100	9273827				2022-12-01	WOS:A1997XU10000004
J	Laor, A; Stevenson, DK; Shemer, J; Gale, R; Seidman, DS				Laor, A; Stevenson, DK; Shemer, J; Gale, R; Seidman, DS			Size at birth, maternal nutritional status in pregnancy, and blood pressure at age 17: population based analysis	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; FETAL INFLUENCES; WEIGHT; HYPERTENSION; CHILDHOOD; GROWTH; ADOLESCENCE; CHILDREN; INFANTS; WOMEN	Objective: To assess the effect of size at birth, maternal nutrition, and body mass index on blood pressure in late adolescence. Design: Population based analysis of birth weight corrected for gestational age, mother's weight before pregnancy and weight gain in pregnancy, obtained from the Jerusalem perinatal study, and blood pressure and body mass index at age 17, available from military draft records. Setting: Jerusalem, Israel. Subjects: 10 883 subjects (6684 men and 4199 women) born in Jerusalem during 1974-6 and subsequently drafted to the army. Main outcome measures: Systolic and diastolic blood pressures measured at age 17 and their correlation with birth weight, size at birth, mother's body mass index and weight gain during pregnancy, and height and weight at age 17. Results: Systolic and diastolic blood pressures were significantly and positively correlated with body weight, height, body mass index at age 17, and with mother's body weight and body mass index before pregnancy, but not with birth weight or mother's weight gain in pregnancy. Conclusion: Variables reflecting poor intrauterine nutrition, including low maternal body mass index before pregnancy, poor maternal weight gain in pregnancy, and being born small for gestational age, were not associated with a higher blood pressure in late adolescence.	CHAIM SHEBA MED CTR,DEPT OBSTET & GYNECOL,IL-52621 TEL HASHOMER,ISRAEL; CARMEL HOSP,DEPT INTERNAL MED,HAIFA,ISRAEL; STANFORD UNIV,SCH MED,DEPT PEDIAT,STANFORD,CA 94305; TEL AVIV UNIV,SACKLER SCH MED,CHAIM SHEBA MED CTR,DEPT INTERNAL MED,TEL HASHOMER,ISRAEL; BIKUR CHOLIM HOSP,DEPT NEONATOL,JERUSALEM,ISRAEL	Chaim Sheba Medical Center; Clalit Health Services; Carmel Medical Center; Stanford University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine								BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; CAMBELL DM, 1996, BRIT J OBSTET GYNAEC, V103, P273; DANN PM, 1985, ACTA PAEDIATR SC   S, V319, P7; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; Forrester TE, 1996, BRIT MED J, V312, P156; GODFREY KM, 1994, BRIT J OBSTET GYNAEC, V101, P398, DOI 10.1111/j.1471-0528.1994.tb11911.x; HARLAP S, 1979, NEW ENGL J MED, V300, P1445, DOI 10.1056/NEJM197906283002601; HARLAP S, 1977, ISRAEL J MED SCI, V13, P1073; HARLAP S, 1978, PILLS BIRTHS JERUSAL; JONES DW, 1994, J HYPERTENS, V12, P1433, DOI 10.1097/00004872-199412000-00018; KARK JD, 1986, ISRAEL J MED SCI, V12, P318; LAUNER LJ, 1993, BMJ-BRIT MED J, V307, P1451, DOI 10.1136/bmj.307.6917.1451; LAW C, 1995, J HUM HYPERTENS, V9, P649; LAW CM, 1994, J HYPERTENS, V12, P1329; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Lindsay CA, 1997, OBSTET GYNECOL, V89, P377, DOI 10.1016/S0029-7844(96)00517-0; LUCAS A, 1994, BRIT MED J, V309, P302; MACINTYRE S, 1991, J EPIDEMIOL COMMUN H, V45, P143, DOI 10.1136/jech.45.2.143; MATTHES JWA, 1994, BMJ-BRIT MED J, V308, P1074, DOI 10.1136/bmj.308.6936.1074; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; SEIDMAN DS, 1989, OBSTET GYNECOL, V74, P240; WHINCUP P, 1995, BRIT MED J, V311, P773, DOI 10.1136/bmj.311.7008.773; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	26	88	94	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					449	453		10.1136/bmj.315.7106.449	http://dx.doi.org/10.1136/bmj.315.7106.449			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284660	Green Published			2022-12-01	WOS:A1997XT71400014
J	Pearlman, M; Faix, R				Pearlman, M; Faix, R			No rush to obliterate genital tract colonisation in pregnant women	LANCET			English	Editorial Material							INFECTIONS; BIRTH		UNIV MICHIGAN,CTR MED,DEPT PAEDIAT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Pearlman, M (corresponding author), UNIV MICHIGAN,CTR MED,DEPT OBSTET & GYNAECOL,ANN ARBOR,MI 48109, USA.							BARTLETT JG, 1977, J INFECT DIS, V136, P271, DOI 10.1093/infdis/136.2.271; ESCHENBACH DA, 1991, AM J OBSTET GYNECOL, V164, P734, DOI 10.1016/0002-9378(91)90506-M; HALL RT, 1976, AM J OBSTET GYNECOL, V124, P630, DOI 10.1016/0002-9378(76)90065-X; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; Krohn MA, 1997, J INFECT DIS, V175, P606, DOI 10.1093/infdis/175.3.606; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; MEIS PJ, 1995, AM J OBSTET GYNECOL, V173, P1231, DOI 10.1016/0002-9378(95)91360-2; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8	8	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 23	1997	350	9077					531	532		10.1016/S0140-6736(05)63133-9	http://dx.doi.org/10.1016/S0140-6736(05)63133-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284770				2022-12-01	WOS:A1997XT22100003
J	Sorensen, HT; Sabroe, S; Olsen, J; Rothman, KJ; Gillman, MW; Fischer, P				Sorensen, HT; Sabroe, S; Olsen, J; Rothman, KJ; Gillman, MW; Fischer, P			Birth weight and cognitive function in young adult life: historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							INFANTS	Objective: To examine the relation between birth weight and cognitive function in young adult life. Design: Retrospective cohort study based on birth registry data and cognitive function measured during evaluation for military service. Subjects: 4300 Danish conscripts born between 1973 and 1975. Main outcome measures: Mean score in the Boerge Prien test of cognitive function; score is the number of correct answers to 78 questions and correlates with full scale intelligence quotient (IQ). Results: Mean score in the Boerge Prien test increased from 39.9 at a birth weight of less than or equal to 2500 g to 44.6 at a birth weight of 4200 g even after adjustment for gestational age and length at birth, maternal age and parity and other variables. Above a birth weight of 4200 g the test score decreased slightly. Conclusion: Birth weight is associated with cognitive performance in young adult life, Interference with fetal growth may influence adult cognitive performance.	AARHUS UNIV HOSP,DEPT INTERNAL MED 5,DK-8000 AARHUS C,DENMARK; BOSTON UNIV,SCH MED,DEPT EPIDEMIOL & PREVENT MED,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02215; HARVARD PILGRIM HLTH CARE,BOSTON,MA 02215; CONSCRIPT ADM,COUNTY N JUTLAND,DK-9000 AALBORG,DENMARK	Aarhus University; Boston University; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care			Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Rothman, Kenneth/0000-0003-2398-1705				Barker D. J. P., 1994, MOTHERS BABIES DIS L; ELARDO R, 1975, CHILD DEV, V46, P71; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; LANTING CI, 1994, LANCET, V344, P1319, DOI 10.1016/S0140-6736(94)90692-0; Martyn CN, 1996, BRIT MED J, V312, P1393; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; Mortensen EL, 1989, SCAND J PSYCHOL, V30, P3115; OLSEN J, 1994, SCAND J SOC MED, V22, P213, DOI 10.1177/140349489402200310; Osofsky H J, 1975, Obstet Gynecol Surv, V30, P227, DOI 10.1097/00006254-197504000-00001; TEMBOURY MC, 1994, J PEDIATR GASTR NUTR, V18, P32, DOI 10.1097/00005176-199401000-00005	10	164	168	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 16	1997	315	7105					401	403		10.1136/bmj.315.7105.401	http://dx.doi.org/10.1136/bmj.315.7105.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XR549	9277604	Green Published			2022-12-01	WOS:A1997XR54900020
J	Nakamura, TM; Morin, GB; Chapman, KB; Weinrich, SL; Andrews, WH; Lingner, J; Harley, CB; Cech, TR				Nakamura, TM; Morin, GB; Chapman, KB; Weinrich, SL; Andrews, WH; Lingner, J; Harley, CB; Cech, TR			Telomerase catalytic subunit homologs from fission yeast and human	SCIENCE			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; TETRAHYMENA TELOMERASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; IMMORTAL CELLS; DNA; RNA; SEQUENCES; CANCER; GENES	Catalytic protein subunits of telomerase from the ciliate Euplotes aediculatus and the yeast Saccharomyces cerevisiae contain reverse transcriptase motifs. Here the homologous genes from the fission yeast Schizosaccharomyces pombe and human are identified. Disruption of the S. pombe gene resulted in telomere shortening and senescence, and expression of mRNA from the human gene correlated with telomerase activity in cell lines. Sequence comparisons placed the telomerase proteins in the reverse transcriptase family but revealed hallmarks that distinguish them from retroviral and retrotransposon relatives. Thus, the proposed telomerase catalytic subunits are phylogenetically conserved and represent a deep branch in the evolution of reverse transcriptases.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; GERON CORP,MENLO PK,CA 94025	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Geron Corporation			Morin, Gregg B/E-9123-2012; Nakamura, Toru M/B-2055-2008	Morin, Gregg B/0000-0001-8949-4374; Nakamura, Toru M/0000-0001-5752-0814; Lingner, Joachim/0000-0002-2853-5803	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028039, R01GM028039] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28039] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C., 1993, EXPT FISSION YEAST; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, IN PRESS P NATL ACAD; Eickbush Thomas H., 1994, P121; Feisenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P4673; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1996, DNA REPLICATION EUKA, P619; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Javerzat JP, 1996, NUCLEIC ACIDS RES, V24, P4676, DOI 10.1093/nar/24.23.4676; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lendvay TS, 1996, GENETICS, V144, P1399; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEVIS RW, 1993, CELL, V75, P1; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Pardue ML, 1996, TRENDS GENET, V12, P48, DOI 10.1016/0168-9525(96)81399-0; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; Ricchetti M, 1996, BIOCHEMISTRY-US, V35, P14970, DOI 10.1021/bi961274v; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZHANG MQ, 1994, NUCLEIC ACIDS RES, V22, P1750, DOI 10.1093/nar/22.9.1750	41	2004	2183	3	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 15	1997	277	5328					955	959		10.1126/science.277.5328.955	http://dx.doi.org/10.1126/science.277.5328.955			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252327				2022-12-01	WOS:A1997XQ98500042
J	Hedtke, B; Borner, T; Weihe, A				Hedtke, B; Borner, T; Weihe, A			Mitochondrial and chloroplast phage-type RNA polymerases in Arabidopsis	SCIENCE			English	Article							PROTEIN-TRANSPORT; BACTERIOPHAGE-T7; SUBUNIT	In addition to the RNA polymerases (RNAPs) transcribing the nuclear genes, eukaryotic cells also require RNAPs to transcribe the genes of the mitochondrial genome and, in plants, of the chloroplast genome, The plant Arabidopsis thaliana was found to contain two nuclear genes similar to genes encoding the mitochondrial RNAP from yeast and RNAPs of bacteriophages T7, T3, and SP6. The putative transit peptides of the two polymerases were capable of targeting fusion proteins to mitochondria and chloroplasts, respectively, in vitro. The results indicate that the mitochondrial RNAP in plants is a bacteriophage-type enzyme. A gene duplication event may have generated the second RNAP, which along with the plastid-encoded eubacteria-like RNAP could transcribe the chloroplast genome.	HUMBOLDT UNIV BERLIN,INST BIOL,D-10115 BERLIN,GERMANY	Humboldt University of Berlin				Borner, Thomas/0000-0001-9548-3348				Allison LA, 1996, EMBO J, V15, P2802, DOI 10.1002/j.1460-2075.1996.tb00640.x; BOGORAD L, 1990, MOL BIOL PLASTIDS, P93; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; Cermakian N, 1996, NUCLEIC ACIDS RES, V24, P648, DOI 10.1093/nar/24.4.648; CHAUMONT F, 1994, PLANT MOL BIOL, V24, P631, DOI 10.1007/BF00023559; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; Chen B, 1996, J BIOL CHEM, V271, P6537, DOI 10.1074/jbc.271.11.6537; Ems SC, 1995, PLANT MOL BIOL, V29, P721, DOI 10.1007/BF00041163; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KELLY JL, 1986, J BIOL CHEM, V261, P348; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LERBSMACHE S, 1993, P NATL ACAD SCI USA, V90, P5509, DOI 10.1073/pnas.90.12.5509; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Weihe A, 1997, NUCLEIC ACIDS RES, V25, P2319, DOI 10.1093/nar/25.12.2319	21	302	320	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					809	811		10.1126/science.277.5327.809	http://dx.doi.org/10.1126/science.277.5327.809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242608				2022-12-01	WOS:A1997XQ24700041
J	DiDonato, JA; Hayakawa, M; Rothwarf, DM; Zandi, E; Karin, M				DiDonato, JA; Hayakawa, M; Rothwarf, DM; Zandi, E; Karin, M			A cytokine-responsive I kappa B kinase that activates the transcription factor NF-kappa B	NATURE			English	Article							ALPHA PROTEOLYSIS; PHOSPHORYLATION; FAMILY; DISSOCIATION; DEGRADATION; SUFFICIENT; PROTEINS; RECEPTOR; DOMAIN	Nuclear transcription factors of the NF-kappa B/Rel family are inhibited by I kappa B proteins, which inactivate NF-kappa B by trapping it in the cell cytoplasm. Phosphorylation of I kappa Bs marks them out for destruction, thereby relieving their inhibitory effect on NF-kappa B. A cytokine-activated protein kinase complex, IKK (for I kappa B kinase), has now been purified that phosphorylates I kappa Bs on the sites that trigger their degradation. A component of IKK was molecularly cloned and identified as a serine kinase. IKK turns out to be the long-sought-after protein kinase that mediates the critical regulatory step In NF-kappa B activation.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LAB GENE REGULAT & SIGNAL TRANSDUCT,LA JOLLA,CA 92093	University of California System; University of California San Diego			Hazen, Stanley L/ABD-5845-2021					ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CAO Z, 1996, SCIENCE, V383, P443; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	31	1843	1944	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					548	554		10.1038/41493	http://dx.doi.org/10.1038/41493			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252186	Bronze			2022-12-01	WOS:A1997XP72200039
J	Kolavic, SA; Kimura, A; Simons, SL; Slutsker, L; Barth, S				Kolavic, SA; Kimura, A; Simons, SL; Slutsker, L; Barth, S			An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIELD GEL-ELECTROPHORESIS; SONNEI	Context.-Shigella dysenteriae type 2 is rare in the United States, and outbreaks associated with this pathogen are uncommon. Objective.-To determine the magnitude and source of an outbreak of S dysenteriae type 2. Design.-Retrospective cohort. Setting.-Laboratory of a large medical center. Patients.-Case patients were identified as laboratory workers who had diarrhea on or after October 28 and a positive stool culture or temperature greater than 37.8 degrees C. Laboratory workers with diarrhea only were probable case patients. Main Outcome Measures.-We interviewed laboratory staff and performed identification, serotyping, and pulsed-field gel electrophoresis on isolates from case patients, implicated food, and laboratory stock culture. Results.-From October 29 through November 1, a total of 12 (27%) of 45 laboratory staff developed severe, acute diarrheal illness; 8 had S dysenteriae isolated from stool and 4 were hospitalized. All case patients reported having eaten muffins or doughnuts placed in the staff break room on October 29. Pulsed-field gel electrophoresis showed stool isolates from 9 case patients were indistinguishable from S dysenteriae type 2 recovered from an uneaten muffin and from the laboratory's stock strain, a portion of which was missing. Conclusions.-The source of the outbreak was most likely the laboratory's stock culture, which was used to contaminate the pastries. Results of this investigation underscore the need for adequate precautions to prevent inadvertent or intentional contamination from highly pathogenic laboratory specimens.	CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,FOODBORNE & DIARRHEAL DIS BRANCH,ATLANTA,GA 30333; TEXAS DEPT HLTH,BUR LABS,AUSTIN,TX 78756; TEXAS DEPT HLTH,BUR CHRON DIS PREVENT & CONTROL,AUSTIN,TX 78756; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,STATE BRANCH,ATLANTA,GA 30333; DALLAS CTY HLTH & HUMAN SERV,DALLAS,TX	Centers for Disease Control & Prevention - USA; Texas Department of State Health Services; Texas Department of State Health Services; Centers for Disease Control & Prevention - USA								[Anonymous], 1995, CONTROL COMMUNICABLE; *ASS OFF AN CHEM, 1992, BACT AN MAN; BLASER MJ, 1983, J INFECT DIS, V147, P771, DOI 10.1093/infdis/147.4.771; BRIAN MJ, 1993, J CLIN MICROBIOL, V31, P2152, DOI 10.1128/JCM.31.8.2152-2156.1993; *CDC, 1983, MMWR-MORBID MORTAL W, V32, P250; Dean A.G., 1994, EPI INFO VERSION 6 W; Evans AC, 1938, LANCET, V2, P187; LIU PYF, 1995, J CLIN MICROBIOL, V33, P1779, DOI 10.1128/JCM.33.7.1779-1783.1995; NASTASI A, 1991, MICROBIOLOGICA, V14, P219; *OR HLTH DIV, 1984, COMM DIS SUMM, V33, P1; PARKER MT, 1983, TOPLEY WILSONS PRINC, V3, P434; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; ROWE B, 1983, TOPLEY WILSONS PRINC, V2, P320; SCHMITZ K. E. F., 1917, Zeitschrift fur Hygiene und Infektionskrankheiten, V84, P449, DOI 10.1007/BF02284440; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; 1966, SCIENCE J, V2, P11; 1988, UPI             1214	18	110	115	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					396	398		10.1001/jama.278.5.396	http://dx.doi.org/10.1001/jama.278.5.396			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244331				2022-12-01	WOS:A1997XN51800031
J	Rybenkov, VV; Ullsperger, C; Vologodskii, AV; Cozzarelli, NR				Rybenkov, VV; Ullsperger, C; Vologodskii, AV; Cozzarelli, NR			Simplification of DNA topology below equilibrium values by type II topoisomerases	SCIENCE			English	Article							ESCHERICHIA-COLI; PURIFICATION; MECHANISM; TRANSPORT; ENZYME; HELIX; IV	Type II DNA topoisomerases catalyze the interconversion of DNA topoisomers by transporting one DNA segment through another. The steady-state fraction of knotted or catenated DNA molecules produced by prokaryotic and eukaryotic type II topoisomerases was found to be as much as 80 times lower than at thermodynamic equilibrium. These enzymes also yielded a tighter distribution of linking number topoisomers than at equilibrium. Thus, topoisomerases do not merely catalyze passage of randomly juxtaposed DNA segments but control a global property of DNA, its topology. The results imply that type II topoisomerases use the energy of adenosine triphosphate hydrolysis to preferentially remove the topological links that provide barriers to DNA segregation.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; NYU,DEPT CHEM,NEW YORK,NY 10003	University of California System; University of California Berkeley; New York University			Vologodskii, Alexander V/A-6994-2009; Vologodskii, Alexander V/I-6201-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031657, R01GM054215, R37GM031657] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31657, GM54215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATES AD, 1993, DNA TOPOLOGY; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; KATO J, 1992, J BIOL CHEM, V267, P25676; KELLENBERGER E, 1987, TRENDS BIOCHEM SCI, V12, P105, DOI 10.1016/0968-0004(87)90049-1; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PENG H, 1993, J BIOL CHEM, V268, P24481; POHL WF, 1978, J MATH BIOL, V6, P383, DOI 10.1007/BF02463003; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; Roca J, 1996, GENES CELLS, V1, P17, DOI 10.1046/j.1365-2443.1996.01001.x; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; Rybenkov VV, 1997, J MOL BIOL, V267, P312, DOI 10.1006/jmbi.1996.0877; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SHORE D, 1983, J MOL BIOL, V170, P983, DOI 10.1016/S0022-2836(83)80199-5; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; Vologodskii A, 1996, BIOPHYS J, V70, P2548, DOI 10.1016/S0006-3495(96)79826-0; WANG JC, 1966, J MOL BIOL, V15, P111, DOI 10.1016/S0022-2836(66)80213-9; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	25	230	231	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					690	693		10.1126/science.277.5326.690	http://dx.doi.org/10.1126/science.277.5326.690			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235892				2022-12-01	WOS:A1997XN90700042
J	Gillum, RF; Mussolino, ME; Madans, JH				Gillum, RF; Mussolino, ME; Madans, JH			Coronary heart disease incidence and survival in African-American women and men - The NHANES I epidemiologic follow-up study	ANNALS OF INTERNAL MEDICINE			English	Article						coronary disease; blacks; follow-up studies; myocardial infarction; sex factors	RISK-FACTORS; UNITED-STATES; MYOCARDIAL-INFARCTION; BLACK POPULATIONS; CIGARETTE-SMOKING; EVANS COUNTY; WHITE MEN; MORTALITY; INFORMATION; CHOLESTEROL	Background: Relatively few data are available on risk for or survival with cor Objective: To determine whether incidence of coronary heart disease, rate of survival with the disease. and rate of coronary surgery differ between ethnic groups. Design: Prospective cohort study. Setting: United States. Participants: Persons who responded to the National Health and Nutrition Examination Survey (NHANES) I Epidemiologic Follow-up Study. Included in this analysis were 11 406 white persons and African-American persons aged 25 to 74 years who had no history of coronary heart disease. Average follow-up for survivors was 19 years (maximum, 22 years). Measurements: Incident coronary heart disease. Results: Compared with that in white persons, the age-adjusted risk for coronary heart disease was higher in African-American women aged 25 to 54 years (relative risk. 1.76 [95% CI, 1.36 to 2.29]) but was lower in African-American men within each age subgroup. The age-adjusted risk was lower in African-American men for all ages combined (25 to 74 years) (relative risk, 0.78 [CI, 0.65 to 0.93] for coronary heart disease and 0.62 [CI, 0.42 to 0.92] for acute myocardial infarction). The higher rate in African-American women aged 25 to 54 years could be explained statistically by the higher risk factor levels iri these women. Ethnic groups did not significantly differ in survival after the first hospitalization for coronary heart disease. However, the incidence of coronary procedures after hospitalization for coronary heart disease was markedly lower in African-American persons than in white persons (age- and sex-adjusted relative risk, 0.40 [CI, 0.16 to 0.991). Conclusions: Total incidence of coronary heart disease is higher in African-American women aged 25 to 54 years than in white women of the same ages and is lower in African-American men aged 25 to 74 years than in white men of the same ages.	CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, OFF CTR DIRECTOR, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Gillum, RF (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, OFF ANAL EPIDEMIOL & HLTH PROMOT, 6525 BELCREST RD, HYATTSVILLE, MD 20782 USA.							Cohen B B, 1987, Vital Health Stat 1, P1; COOPER R, 1991, CARDIOVASCULAR DISEA, P205; Cooper R S, 1992, Ann Epidemiol, V2, P637; Cox C S, 1992, Vital Health Stat 1, P1; Engel A, 1978, Vital Health Stat 1, P1; Finucane F F, 1990, Vital Health Stat 1, P1; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; GILLUM RF, 1982, AM HEART J, V104, P839, DOI 10.1016/0002-8703(82)90021-7; GILLUM RF, 1982, AM HEART J, V104, P852, DOI 10.1016/0002-8703(82)90022-9; GILLUM RF, 1987, AM HEART J, V113, P804, DOI 10.1016/0002-8703(87)90723-X; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GILLUM RF, 1984, AM HEART J, V108, P727, DOI 10.1016/0002-8703(84)90664-1; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; INGRAM DD, 1989, STAT MED, V8, P525, DOI 10.1002/sim.4780080502; INGRAM DD, 1994, SERIES VITAL HLTH ST, V2, P1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KEIL JE, 1995, ARCH INTERN MED, V155, P1521, DOI 10.1001/archinte.155.14.1521; KEIL JE, 1984, AM HEART J, V108, P779, DOI 10.1016/0002-8703(84)90671-9; KLAG MJ, 1989, CIRCULATION S1, V80, P300; Kumanyika S, 1996, NEW ENGL J MED, V335, P738, DOI 10.1056/NEJM199609053351011; LEAVERTON PE, 1990, HLTH STATUS WELL BEI, P53; Lee Marshall H., 1990, Annals of Epidemiology, V1, P1; LIAO YL, 1992, JAMA-J AM MED ASSOC, V268, P1867, DOI 10.1001/jama.268.14.1867; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P474; MADANS JH, 1986, PUBLIC HEALTH REP, V101, P465; MADANS JH, 1995, STAT MED, V14, P643, DOI 10.1002/sim.4780140521; MAYNARD C, 1987, AM J CARDIOL, V60, P513, DOI 10.1016/0002-9149(87)90296-7; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MILLER HERBERT S., 1978, PLAN OPERATION HLTH, P1; *NAT CTR HLTH STAT, 1979, HANES 1 HEM CLIN CHE; National Heart Lung and Blood Institute, 1994, REP WORK GROUP RES C, P1; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; Popkin BM, 1996, NEW ENGL J MED, V335, P716, DOI 10.1056/NEJM199609053351006; *RES TRIANGL I, 1992, SOFTW SURV DES AN SU; *SAS I INC, 1991, P217 SAS I INC, P1; *SAS I INC, 1985, SAS US GUID STAT, P529; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; Traven ND, 1996, ANN EPIDEMIOL, V6, P130, DOI 10.1016/1047-2797(95)00131-X; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; WATKINS LO, 1986, AM J CARDIOL, V57, P538, DOI 10.1016/0002-9149(86)90831-3; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0	45	124	124	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1997	127	2					111	+		10.7326/0003-4819-127-2-199707150-00003	http://dx.doi.org/10.7326/0003-4819-127-2-199707150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XK158	9229999				2022-12-01	WOS:A1997XK15800005
J	Bird, AG; Gore, SM; Hutchinson, SJ; Lewis, SC; Cameron, S; Burns, S				Bird, AG; Gore, SM; Hutchinson, SJ; Lewis, SC; Cameron, S; Burns, S			Harm reduction measures and injecting inside prison versus mandatory drugs testing: Results of a cross sectional anonymous questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							HIV SURVEILLANCE	Objectives: (a) To determine both the frequency of injecting inside prison and use of sterilising tablets to clean needles in the previous four weeks; (b) to assess the efficiency of random mandatory drugs testing at detecting prisoners who inject heroin inside prison; (c) to determine the percentage of prisoners who had been offered vaccination against hepatitis B. Design: Cross sectional willing anonymous salivary HIV surveillance linked to a self completion risk factor questionnaire. Setting: Lowmoss prison, Glasgow, and Aberdeen prison on 11 and 30 October 1996. Subjects: 293 (94%) of all 312 inmates at Lowmoss and 146 (93%) of all 157 at Aberdeen, resulting in 286 and 143 valid questionnaires. Main outcome measures: Frequency of injecting inside prison in the precious four weeks by injector inmates who had been in prison for at least four weeks. Results: 116 (41%) Lowmoss and 53 (37%) Aberdeen prisoners had a history of injecting drug use but only 4% of inmates (17/395; 95% confidence interval 2% to 6%) had ever been offered vaccination against hepatitis B. 42 Lowmoss prisoners (estimated 207 injections and 258 uses of sterilising tablets) and 31 Aberdeen prisoners (229 injections, 221 uses) had injected inside prison in the previous four weeks. The prisons together held 112 injector inmates who had been in prison for more than four weeks, of whom 57 (51%; 42% to 60%) had injected in prison in the past four weeks; their estimated mean number of injections was 6.0 (SD 5.7). Prisoners injecting heroin six times in four weeks will test positive in random mandatory drugs testing on at most 18 days out of 28. Conclusions: Sterilising tablets and hepatitis B vaccination should be offered to all prisoners. Random mandatory drugs testing seriously underestimates injector inmates' harm reduction needs.	REG VIRUS LAB,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND; CHURCHILL HOSP,OXFORD OX3 7LJ,ENGLAND; MRC BIAS,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND; REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND	MRC Biostatistics Unit; University of Oxford								Acheson D, 1997, BRIT MED J, V314, P302; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1995, AIDS, V9, P801, DOI 10.1097/00002030-199507000-00019; BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; BIRD AG, 1996, HERALD          0122, P12; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; FREEMAN J, 1996, HERALD          1012, P4; GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293; GORE SM, 1995, BRIT MED J, V310, P595, DOI 10.1136/bmj.310.6979.595; GORE SM, IN PRESS INT J STD A; GORE SM, 1995, ANSWER, V39, P1; Her Majesty's Inspectorate of Prisons, 1996, PAT PRIS NEW STRAT H; *HM PRIS SERV, 1995, DRUG MIS PRIS POL ST, P7; JURGENS R, 1996, HIV AIDS PRISONS; MANGTANI P, 1995, BRIT MED J, V311, P1500, DOI 10.1136/bmj.311.7018.1500; Nelles J., 1995, DRUG HIV PREVENTION; PAYNEJAMES JJ, 1994, J ROY SOC MED, V87, P13; *TASK FORC REV SER, 1996, IND REV DRUG TREATM; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; *WHO, 1993, GLOB PROGR AIDS WHO; WOODS J, 1997, SCOTSMAN        0114, P13	21	55	55	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 5	1997	315	7099					21	24		10.1136/bmj.315.7099.21	http://dx.doi.org/10.1136/bmj.315.7099.21			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XJ947	9233321	Green Published			2022-12-01	WOS:A1997XJ94700022
J	Ahmed, A; Kilby, MD				Ahmed, A; Kilby, MD			Hypoxia or hyperoxia in placental insufficiency?	LANCET			English	Editorial Material							PREGNANCIES; VILLI; FORMS				Ahmed, A (corresponding author), UNIV BIRMINGHAM,DEPT OBSTET & GYNAECOL,REPROD PHYSIOL GRP,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND.		Ahmed, Asif/A-7268-2010; FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Ahmed, Asif/ABE-9544-2020	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Ahmed, Asif/0000-0002-8755-8546; Goswami, Kaushal/0000-0002-7052-4358				Ahmed A, 1997, LAB INVEST, V76, P779; AHMED A, 1997, TROPHOBLAST RES, V10, P215; Burton GJ, 1996, PLACENTA, V17, P49, DOI 10.1016/S0143-4004(05)80643-5; Genbacev O, 1996, J CLIN INVEST, V97, P540, DOI 10.1172/JCI118447; Krebs C, 1996, AM J OBSTET GYNECOL, V175, P1534, DOI 10.1016/S0002-9378(96)70103-5; LYALL F, 1977, PLACENTA, V18, P269; Macara L, 1996, PLACENTA, V17, P37, DOI 10.1016/S0143-4004(05)80642-3; PANIGEL M, 1972, ACTA ANAT, V81, P481; PARDI G, 1992, AM J OBSTET GYNECOL, V166, P699, DOI 10.1016/0002-9378(92)91700-K	9	41	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 20	1997	350	9081					826	827		10.1016/S0140-6736(05)62027-2	http://dx.doi.org/10.1016/S0140-6736(05)62027-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XX401	9310597				2022-12-01	WOS:A1997XX40100005
J	Oscherwitz, T; Peterson, J; Roger, S; Sciortino, S; Alpers, A; Royce, S; Lo, B				Oscherwitz, T; Peterson, J; Roger, S; Sciortino, S; Alpers, A; Royce, S; Lo, B			Detention of persistently nonadherent patients with tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Patients with tuberculosis (TB) who are persistently nonadherent to treatment present a public health risk. In 1993, California created a new civil detention process and allowed detention of noninfectious but persistently nonadherent patients. Objectives.-To determine (1) which patients TB controllers attempt to detain, (2) how often and where patients are detained, and (3) how many or these patients complete TB treatment. Design.-Case series with cross-sectional comparison to other adult TB patients in the study counties. Setting-Twelve California counties with the largest number of new TB cases reported in 1994. Subjects.-All patients whom TB controllers sought to detain during 1994 and 1995 because of persistent nonadherence to treatment. Data Sources.-Public health records, interviews with county TB officials, and Reports of Verified Cases of Tuberculosis to the California Tuberculosis Control Branch. Results.-Tuberculosis controllers sought the civil detention or arrest of 67 patients during the study period (1.3% of adult TB patients with the same disease sites). Forty-six percent of these patients were homeless, 81% had drug or alcohol abuse, and 28% had mental illness. Tuberculosis controllers sought civil detention of 15 patients. Fourteen patients were detained (median length of detention, 14.5 days). Tuberculosis controllers sought to arrest 62 patients during the study period. Fifty-three patients were arrested (median time in jail, 83 days). In 10 cases, both civil and criminal detention were attempted. We analyzed completion of therapy after excluding patients who were not detained or who died or moved. Overall, 41 (84%) of the remaining 49 detained patients completed therapy. Of the patients who completed therapy, only 17 were detained until treatment was completed. Compared with other TB patients in these counties, detained patients had 4 times the proportion lost to follow-up and half the proportion completing therapy within 12 months. Conclusion.-Further improvements in the care of persistently nonadherent patients may require more psychosocial services, appropriate facilities for civil detention, and detaining patients long enough to assure completion of treatment.	UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; CALIF DEPT HLTH SERV,BERKELEY,CA 94704	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Department of Health Care Services				Sciortino, Stanley/0000-0002-6191-8179	NIMH NIH HHS [2 P50 MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ball C. A., 1994, YALE LAW POLICY REV, V12, P38; BAYER R, 1995, ANNU REV PUBL HEALTH, V16, P307; Bayer Ronald, 1992, TUBERCULOSIS REVIVAL; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GASNER R, 1996, TB TIMES, V10, P4; Gostin Lawrence O, 1995, MD Law Rev, V54, P1; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; Herrera J. L., 1993, Morbidity and Mortality Weekly Report, V42, P1	8	33	33	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	1997	278	10					843	846		10.1001/jama.278.10.843	http://dx.doi.org/10.1001/jama.278.10.843			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XU552	9293993				2022-12-01	WOS:A1997XU55200040
J	Irie, M; Hata, Y; Takeuchi, M; Ichtchenko, K; Toyoda, A; Hirao, K; Takai, Y; Rosahl, TW; Sudhof, TC				Irie, M; Hata, Y; Takeuchi, M; Ichtchenko, K; Toyoda, A; Hirao, K; Takai, Y; Rosahl, TW; Sudhof, TC			Binding of neuroligins to PSD-95	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; POSTSYNAPTIC DENSITY; SEPTATE JUNCTIONS; GUANYLATE KINASES; MEMBRANE PROTEIN; NEUREXINS; INTERACTS; HOMOLOG; FAMILY	PSD-95 is a component of postsynaptic densities in central synapses, It contains three PDZ domains that localize N-methyl-D-aspartate receptor subunit 2 (NMDA2 receptor) and K+ channels to synapses. In mouse forebrain, PSD-95 bound to the cytoplasmic COOH-termini of neuroligins, which are neuronal cell adhesion molecules that interact with beta-neurexins and form intercellular junctions. Neuroligins bind to the third PDZ domain of PSD-95, whereas NMDA2 receptors and K+ channels interact with the first and second PDZ domains. Thus different PDZ domains of PSD-95 are specialized for distinct functions. PSD-95 may recruit ion channels and neurotransmitter receptors to intercellular junctions formed between neurons by neuroligins and beta-neurexins.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; JAPAN SCI & TECHNOL CORP,ERATO,TAKAI BIOTIMER PROJECT,NISHI KU,KOBE,HYOGO 65122,JAPAN; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Japan Science & Technology Agency (JST); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Osaka University			Toyoda, Atsushi/AAA-5885-2020	Toyoda, Atsushi/0000-0002-0245-3244	NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; Hata Y, 1996, J NEUROSCI, V16, P2488; Hunt CA, 1996, J NEUROSCI, V16, P1380; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOEHNSSON U, 1991, EIOTECHNIQUES, V11, P520; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NGUYEN T, IN PRESS J BIOL CHEM; Niethammer M, 1996, J NEUROSCI, V16, P2157; ROSE MD, 1990, METHODS YEAST GENETI; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Russell AB, 1997, J NEUROSCI, V17, P4734; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Woods D F, 1993, J Cell Sci Suppl, V17, P171; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	30	569	590	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1511	1515		10.1126/science.277.5331.1511	http://dx.doi.org/10.1126/science.277.5331.1511			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278515				2022-12-01	WOS:A1997XV42900042
J	Li, JM; Chory, J				Li, JM; Chory, J			A putative leucine-rich repeat receptor kinase involved in brassinosteroid signal transduction	CELL			English	Article							ARABIDOPSIS-THALIANA; PROTEIN-KINASE; CELL-SURFACE; HUMAN SPERM; TRANSMEMBRANE PROTEIN; TYROSINE KINASE; BINDING SITES; GENE; PHOSPHATASE; RESISTANCE	Brassinosteroids are a class of growth-promoting regulators that play a key role throughout plant development. Despite their importance, nothing is known of the mechanism of action of these steroid hormones. We describe the identification of 18 Arabidopsis dwarf mutants that are unable to respond to exogenously added brassinosteroid, a phenotype that might be expected for brassinosteroid signaling mutants. All 18 mutations define alleles of a single previously described gene, BRI1. We cloned BRI1 and examined its expression pattern. It encodes a ubiquitously expressed putative receptor kinase. The extracellular domain contains 25 tandem leucine-rich repeats that resemble repeats found in animal hormone receptors, plant disease resistance genes, and genes involved in unknown signaling pathways controlling plant development.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA	Salk Institute			Li, Jianming/O-1772-2014	Li, Jianming/0000-0003-3231-0778				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BarbierBrygoo H, 1997, TRENDS PLANT SCI, V2, P214, DOI 10.1016/S1360-1385(97)89548-9; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Bishop GJ, 1996, PLANT CELL, V8, P959, DOI 10.1105/tpc.8.6.959; BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHOI S, 1995, WEEDS WORLD, V2, P17; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671; Dixon MS, 1996, CELL, V84, P451, DOI 10.1016/S0092-8674(00)81290-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1973, DOI 10.1271/bbb.59.1973; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hong SW, 1997, PLANT PHYSIOL, V113, P1203, DOI 10.1104/pp.113.4.1203; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; Kauschmann A, 1996, PLANT J, V9, P701, DOI 10.1046/j.1365-313X.1996.9050701.x; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KWON HB, 1986, DEV BIOL, V117, P354, DOI 10.1016/0012-1606(86)90305-2; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LEWIN DI, 1996, J NIH RES, V8, P29; Li JM, 1997, P NATL ACAD SCI USA, V94, P3554, DOI 10.1073/pnas.94.8.3554; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.pp.39.060188.000323; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MENDOZA C, 1995, BIOCHEM BIOPH RES CO, V210, P518, DOI 10.1006/bbrc.1995.1690; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Nakhla AM, 1997, J BIOL CHEM, V272, P6838, DOI 10.1074/jbc.272.11.6838; Nomura T, 1997, PLANT PHYSIOL, V113, P31, DOI 10.1104/pp.113.1.31; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHULZ B, 1995, PLANT MOL BIOL MANUA; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; TAKAHASHI T, 1995, GENE DEV, V9, P97, DOI 10.1101/gad.9.1.97; TESARIK J, 1993, ENDOCRINOLOGY, V133, P328, DOI 10.1210/en.133.1.328; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERKNAAP E, 1996, PLANT PHYSIOL, V112, P1397; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WISTROM CA, 1993, DEV BIOL, V159, P679	61	1169	1263	6	188	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	1997	90	5					929	938		10.1016/S0092-8674(00)80357-8	http://dx.doi.org/10.1016/S0092-8674(00)80357-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298904	Bronze			2022-12-01	WOS:A1997XV56300013
J	Mebatsion, T; Finke, S; Weiland, F; Conzelmann, KK				Mebatsion, T; Finke, S; Weiland, F; Conzelmann, KK			A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells	CELL			English	Article							RABIES VIRUS GLYCOPROTEIN; HUMAN CD4; RECEPTOR; FUSION; PARTICLES; COFACTOR; ENTRY; CCR5; RETROVIRUS; CLONING	We show that a cellular virus receptor functions in the envelope of a virus, allowing selective infection of cells displaying the receptor ligand. A G-deficient rabies virus (RV) pseudotyped with CD4- and CXCR4-derived proteins selectively infected cells expressing HIV-1 envelope protein. Envelope protein or CD4 antibodies blocked virus entry. Pseudotype virus formation was most efficient with chimeric receptor proteins possessing the cytoplasmic tail of the RV G spike protein (CXCR4-RV and CD4-RV). While CXCR4-RV was incorporated when expressed alone, CD4-RV incorporation required CXCR4-RV as a carrier protein, indicating a mechanism by which oligomeric surface proteins are sorted into the RV envelope. Viral vectors bearing virus receptors in their envelope may be useful reagents for targeting virus-infected cells in vivo.	FED RES CTR VIRUS DIS ANIM,DEPT CLIN VIROL,D-72076 TUBINGEN,GERMANY				Conzelmann, Karl-Klaus/L-7239-2013	Finke, Stefan/0000-0001-8716-2341; Conzelmann, Karl-Klaus/0000-0002-8614-3656				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Conzelmann KK, 1996, TRENDS MICROBIOL, V4, P386, DOI 10.1016/0966-842X(96)10062-7; CONZELMANN KK, 1994, J VIROL, V68, P713, DOI 10.1128/JVI.68.2.713-719.1994; CONZELMANN KK, 1990, VIROLOGY, V175, P485, DOI 10.1016/0042-6822(90)90433-R; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Franci C, 1996, J IMMUNOL, V157, P5606; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Mebatsion T, 1996, P NATL ACAD SCI USA, V93, P7310, DOI 10.1073/pnas.93.14.7310; Mebatsion T, 1996, P NATL ACAD SCI USA, V93, P11366, DOI 10.1073/pnas.93.21.11366; Mebatsion T, 1996, CELL, V84, P941, DOI 10.1016/S0092-8674(00)81072-7; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; PRINCE AM, 1991, AIDS RES HUM RETROV, V7, P971, DOI 10.1089/aid.1991.7.971; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Schnell MJ, 1996, J VIROL, V70, P2318, DOI 10.1128/JVI.70.4.2318-2323.1996; SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; SCHUBERT M, 1992, J VIROL, V66, P1579, DOI 10.1128/JVI.66.3.1579-1589.1992; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wagner RR., 1996, FIELDS VIROLOGY, V1, P1121; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHITT MA, 1991, VIROLOGY, V185, P681, DOI 10.1016/0042-6822(91)90539-N; WIMMER E, 1994, CELLULAR RECEPTORS A; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; YOUNG JAT, 1990, SCIENCE, V250, P1421, DOI 10.1126/science.2175047	39	114	122	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					841	847		10.1016/S0092-8674(00)80349-9	http://dx.doi.org/10.1016/S0092-8674(00)80349-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298896	Bronze			2022-12-01	WOS:A1997XV56300005
J	Barger, SW; Harmon, AD				Barger, SW; Harmon, AD			Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E	NATURE			English	Article							CEREBROSPINAL-FLUID; SENILE PLAQUES; HEAD-INJURY; DISEASE; IMMUNOREACTIVITY; EXPRESSION; DOMAIN; CELLS; ONSET; BRAIN	A role for beta-amyloid precursor protein (beta-APP) in the development of Alzheimer's disease has been indicated by genetics', and many conditions in which beta-APP is raised have been associated with an increased risk of Alzheimer's disease or an Alzheimer's-like pathology(2-4). Inflammatory events may also contribute to Alzheimer's disease(5), Here we investigate whether a secreted derivative of beta-APP (sAPP-alpha) can induce inflammatory reactions in microglia, which are brain cells of monocytic lineage. We found that treatment with sAPP-alpha increased markers of activation in microglia and enhanced their production of neurotoxins. The ability of sAPP-alpha to activate microglia was blocked by prior incubation of the protein with apolipoprotein E3 but not apolipoprotein E4, a variant associated with an increased risk for Alzheimer's(6). A product of amyloidogenic beta-APP processing (sAPP-beta) also activated microglia. Because sAPP-beta is deficient in the neuroprotective activity shown by sAPP-alpha, our results indicate that increased amyloidogenic processing could adversely affect the balance of sAPP activities that determine neuronal viability.	UNIV ARKANSAS MED SCI,DEPT ANAT CELL BIOL & NEUROBIOL,LITTLE ROCK,AR 72205; JOHN L MCCLELLAN MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center	Barger, SW (corresponding author), UNIV ARKANSAS MED SCI,DONALD W REYNOLDS DEPT GERIATR,LITTLE ROCK,AR 72205, USA.			Barger, Steven/0000-0001-6049-6480				Barger SW, 1997, J NEUROCHEM, V69, P60; Barger SW, 1996, MOL BRAIN RES, V40, P116; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; CLAY MA, 1995, BIOCHEMISTRY-US, V34, P11142, DOI 10.1021/bi00035a020; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Hardy J, 1996, ANN MED, V28, P255, DOI 10.3109/07853899609033127; LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24; MARTIN LJ, 1994, AM J PATHOL, V145, P1358; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NORDSTEDT C, 1991, P NATL ACAD SCI USA, V88, P8910, DOI 10.1073/pnas.88.20.8910; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PALMERT MR, 1990, NEUROLOGY, V40, P1028, DOI 10.1212/WNL.40.7.1028; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Rossi F, 1996, BIOCHEM BIOPH RES CO, V225, P474, DOI 10.1006/bbrc.1996.1197; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SHENG JG, 1994, J NEUROCHEM, V63, P1872; VANNOSTRAND WE, 1992, P NATL ACAD SCI USA, V89, P2551, DOI 10.1073/pnas.89.7.2551; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	29	513	547	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					878	881		10.1038/42257	http://dx.doi.org/10.1038/42257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278049				2022-12-01	WOS:A1997XT75400050
J	Tsukamoto, Y; Kato, J; Ikeda, H				Tsukamoto, Y; Kato, J; Ikeda, H			Silencing factors participate in DNA repair and recombination in Saccharomyces cerevisiae	NATURE			English	Article							2-HYBRID SYSTEM; YEAST; PROTEINS; TELOMERES; RAP1	DNA double-strand breaks are repaired by homologous recombination or DNA end-joining, but the latter process often causes illegitimate recombination and chromosome rearrangements. One of the factors involved in the end-joining process is Hdf1, a yeast homologue of Ku protein(1-4). We used the yeast two-hybrid assay to show that Hdf1 interacts with Sir4, which is involved in transcriptional silencing at telomeres and HM loci(5,6). Analyses of sir4 mutants showed that Sir4 is required for deletion by illegitimate recombination and DNA end-joining in the pathway involving Hdf1. Sir2 and Sir3, but not Sir1, were also found to participate in these processes. Furthermore, mutations of the SIR2, SIR3 and SIR4 genes conferred increased sensitivity to gamma-radiation in a genetic background with a mutation of the RAD52 gene, which is essential for double-strand break repair mediated by homologous recombination. These results indicate that Sir proteins are involved in double-strand break repair mediated by end-joining. We propose that Sir proteins act with Hdf1 to alter broken DNA ends to create an inactivated chromatin structure that is essential for the rejoining of DNA ends.	UNIV TOKYO,INST MED SCI,DEPT MOL BIOL,TOKYO 108,JAPAN	University of Tokyo								APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lea D, 1948, J GENET, V49, P264; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Luria SE, 1943, GENETICS, V28, P491; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PILUS L, 1989, CELL, V59, P637; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; ROSE MD, 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHORE D, 1995, TELOMERES, P139; Siede W, 1996, GENETICS, V142, P91; SIKORSKI RS, 1989, GENETICS, V122, P19; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TSKAMOTO Y, IN PRESS MOL GEN GEN; Tsukamoto Y, 1996, GENETICS, V142, P383; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; [No title captured]	30	293	304	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					900	903		10.1038/42288	http://dx.doi.org/10.1038/42288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278054	Bronze			2022-12-01	WOS:A1997XT75400055
J	Hurwitz, A; Brady, DA; Schaal, E; Samloff, IM; Dedon, J; Ruhl, CE				Hurwitz, A; Brady, DA; Schaal, E; Samloff, IM; Dedon, J; Ruhl, CE			Gastric acidity in older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUODENAL-ULCER PATIENTS; SERUM PEPSINOGEN-I; BACTERIAL OVERGROWTH; INTRAGASTRIC ACIDITY; ATROPHIC GASTRITIS; SMALL-INTESTINE; HEALTHY-MEN; SECRETION; AGE; PH	Context.-Early studies suggested that gastric acidity declines as people age. However, sequelae of achlorhydria are uncommon in older people, making this conventional wisdom unlikely. Objective.-To ascertain the prevalence of basal gastric acidity and atrophic gastritis (indicated by serum pepsinogen ratio) in older adults. Design.-Cross-sectional study in a volunteer sample. Setting.-Retirement communities in suburbs of Kansas City, Mo. Subjects.-A total of 248 white male and female volunteers aged 65 years or older living independently. Main Outcome Measures.-Presence of basal unstimulated gastric acid was evaluated noninvasively by having subjects swallow quininium resin. Gastric acid with a pH lower than 3.5 releases quinine, which is then absorbed and excreted into urine, Atrophic gastritis was defined as a ratio of serum pepsinogen I/pepsinogen II of less than 2.9. Results.-Basal unstimulated gastric content was acidic (pH <3.5) in 208 (84%) of 248 elderly subjects. On retesting 66 subjects (35 normals and 31 hyposecretors), 28 (80%) of 35 had pH less than 3.5 both times, and 22 (71%) of 31 had pH of 3.5 or higher twice; in the remaining 16 subjects, low vs high gastric pH changed between tests, Weighted population prevalence estimates in this sample were 67% for consistent acid secretion, 22% for intermittent secretion, and 11% for consistent gastric pH higher than 3.5. Whereas 14 (67%) of 21 consistent hyposecretors had serum pepsinogen ratios of less than 2.9, indicating atrophic gastritis, only 2 (5%) of 44 consistent or intermittent secretors of acid had ratios in this range (P<.001). Conclusions.-In contrast to what is commonly stated, nearly 90% of elderly people in this study were able to acidity gastric contents, even in the basal, unstimulated state. Of those who were consistent hyposecretors of acid, most had serum markers of atrophic gastritis.	UNIV KANSAS,MED CTR,CTR AGING,KANSAS CITY,KS 66160; VET AFFAIRS MED CTR,SEPULVEDA,CA; TRUMAN MED CTR,DEPT COMMUNITY MED & FAMILY PRACTICE,KANSAS CITY,MO	University of Kansas; University of Kansas Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Hurwitz, A (corresponding author), UNIV KANSAS,MED CTR,DEPT MED,3901 RAINBOW BLVD,KANSAS CITY,KS 66160, USA.				NIA NIH HHS [R01AG02780] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREWS GR, 1967, AUSTRALAS ANN MED, V16, P230; BARON JH, 1963, GUT, V4, P136, DOI 10.1136/gut.4.2.136; BIEMOND I, 1994, SCAND J GASTROENTERO, V29, P238, DOI 10.3109/00365529409090470; BLAIR AJ, 1987, J CLIN INVEST, V79, P582, DOI 10.1172/JCI112850; BORCH K, 1989, SCAND J GASTROENTERO, V24, P870, DOI 10.3109/00365528909089228; COLLEN MJ, 1994, AM J GASTROENTEROL, V89, P712; CONNELL AM, 1973, CLIN TESTS GASTRIC F, P20; CORAZZA GR, 1990, GASTROENTEROLOGY, V98, P302, DOI 10.1016/0016-5085(90)90818-L; CRAMER G, 1963, SCAND J CLIN LAB INV, V15, P553, DOI 10.3109/00365516309079786; DRESSMAN JB, 1990, PHARMACEUT RES, V7, P756, DOI 10.1023/A:1015827908309; FELDMAN M, 1991, DIGEST DIS SCI, V36, P866, DOI 10.1007/BF01297133; Feldman M, 1996, GASTROENTEROLOGY, V110, P1043, DOI 10.1053/gast.1996.v110.pm8612992; GOLDSCHMIEDT M, 1991, GASTROENTEROLOGY, V101, P977, DOI 10.1016/0016-5085(91)90724-Y; GOLDSCHMIEDT M, 1993, CHRONIC GASTRITIS HY, P13; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; HIRSCHOWITZ BI, 1992, GASTROENTEROLOGY, V103, pA83; HOLT PR, 1989, DIGEST DIS SCI, V34, P933, DOI 10.1007/BF01540281; HOLT PT, 1993, CHRONIC GASTRITIS HY; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; HUSEBYE E, 1992, GUT, V33, P1331, DOI 10.1136/gut.33.10.1331; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; KEKKI M, 1991, SCAND J GASTROENTERO, V26, P109, DOI 10.3109/00365529109103997; KERLIN P, 1988, GASTROENTEROLOGY, V95, P982, DOI 10.1016/0016-5085(88)90173-4; KING CE, 1986, GASTROENTEROLOGY, V91, P1447, DOI 10.1016/0016-5085(86)90199-X; KIRSNER JB, 1956, GASTROENTEROLOGY, V30, P779; KRASINSKI SD, 1986, J AM GERIATR SOC, V34, P800, DOI 10.1111/j.1532-5415.1986.tb03985.x; KUNA S., 1964, ARCH INT PHARMACODYN THERAP, V151, P79; MERKI HS, 1988, GASTROENTEROLOGY, V94, P887, DOI 10.1016/0016-5085(88)90543-4; MODLIN IM, 1994, AM J GASTROENTEROL, V89, P308; OCHS HR, 1978, AM J CARDIOL, V42, P481, DOI 10.1016/0002-9149(78)90944-X; POUNDER RE, 1993, BAILLIERE CLIN GASTR, V7, P55, DOI 10.1016/0950-3528(93)90031-M; RUSSELL TL, 1993, PHARMACEUT RES, V10, P187, DOI 10.1023/A:1018970323716; SALTZMAN JR, 1994, GASTROENTEROLOGY, V106, P615, DOI 10.1016/0016-5085(94)90693-9; SAMLOFF IM, 1982, GASTROENTEROLOGY, V83, P204; SAMLOFF IM, 1982, GASTROENTEROLOGY, V82, P26; SAVARINO V, 1988, DIGEST DIS SCI, V33, P1077, DOI 10.1007/BF01535781; SEGAL HL, 1953, ANN NY ACAD SCI, V57, P308, DOI 10.1111/j.1749-6632.1953.tb36405.x; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; ZAR JH, 1984, BIOSTAT ANAL, P380	40	113	122	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	1997	278	8					659	662		10.1001/jama.278.8.659	http://dx.doi.org/10.1001/jama.278.8.659			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR547	9272898				2022-12-01	WOS:A1997XR54700039
J	Foster, GR; Goldin, RD; Main, J; MurrayLyon, I; Hargreaves, S; Thomas, HC				Foster, GR; Goldin, RD; Main, J; MurrayLyon, I; Hargreaves, S; Thomas, HC			Management of chronic hepatitis C: clinical audit of biopsy based management algorithm	BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT INTERFERON-ALFA; CONTROLLED TRIAL; VIRUS-INFECTION; ALPHA	Objective: To assess the attendance, outcome, compliance with treatment, and response to interferon alfa in patients with chronic hepatitis C who attended during 1995 and were treated according to a biopsy based algorithm. Design: Retrospective audit of all patients with chronic hepatitis C attending outpatient clinics over one year. Setting: The liver unit at a London teaching hospital. Subjects: 255 patients with chronic hepatitis C. Main outcome measures: Patient survival, attendance, and compliance with diagnostic and therapeutic regimens. Response to interferon alfa treatment, based on loss of viraemia three months after cessation of treatment. Results: A large proportion of patients (39%) with newly diagnosed chronic hepatitis C infection do not want to undergo further investigation. Of those patients who do attend for further treatment, a large proportion with severe hepatic fibrosis (42%) do not want to undergo currently available treatment. The response rate to interferon (21%) in treated patients was similar to that previously reported in a trial setting. There was no significant difference in response rates in patients with or without severe fibrosis not amounting to cirrhosis. In patients with cirrhosis there was a high incidence of hepatocellular carcinoma (18%) over a follow up period of 20 months. Conclusion: Current strategies aimed at investigating and treating patients with chronic hepatitis C are not acceptable to a large proportion of patients. Many patients with cirrhosis related to hepatitis C infection develop hepatic neoplasms, and management strategies to deal with this problem are urgently required.	ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT HISTOPATHOL,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT MED,LONDON W2 1PG,ENGLAND; CHELSEA & WESTMINSTER HOSP,LONDON SW10 9NH,ENGLAND; KENSINGTON & CHELSEA & WESTMINSTER HLTH AUTHOR,LONDON W2 6LX,ENGLAND	Imperial College London; Imperial College London; Imperial College London	Foster, GR (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,LIVER UNIT,PRAED ST,LONDON W2 1PG,ENGLAND.		Thomas, Howard C/A-3152-2009	Hargreaves, Sally/0000-0003-2974-4348; Foster, Graham/0000-0002-3704-386X; Goldin, Robert/0000-0001-5184-4519				BOOTH JCL, 1995, GUT, V36, P427, DOI 10.1136/gut.36.3.427; BOOTH JCL, 1995, GUT, V37, P449, DOI 10.1136/gut.37.4.449; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; Davis G L, 1994, J Viral Hepat, V1, P55, DOI 10.1111/j.1365-2893.1994.tb00062.x; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Dusheiko GM, 1996, BMJ-BRIT MED J, V312, P357, DOI 10.1136/bmj.312.7027.357; Fattovich G, 1996, J HEPATOL, V24, P38, DOI 10.1016/S0168-8278(96)80184-X; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; MALAGUARNERA M, 1995, CLIN DRUG INVEST, V9, P141, DOI 10.2165/00044011-199509030-00002; MUTIMER DJ, 1995, J VIRAL HEPATITIS, V2, P47, DOI 10.1111/j.1365-2893.1995.tb00071.x; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; SCHALM SW, 1996, DIGEST DIS SCI, V41, P1315; TIBBS CJ, 1995, J VIRAL HEPATITIS, V2, P113, DOI 10.1111/j.1365-2893.1995.tb00016.x; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607	16	72	75	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 23	1997	315	7106					453	458		10.1136/bmj.315.7106.453	http://dx.doi.org/10.1136/bmj.315.7106.453			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT714	9284661	Green Published			2022-12-01	WOS:A1997XT71400015
J	He, ZG; TessierLavigne, M				He, ZG; TessierLavigne, M			Neuropilin is a receptor for the axonal chemorepellent Semaphorin III	CELL			English	Article							GROWTH CONE GUIDANCE; NEURONAL RECOGNITION MOLECULE; CELL-SURFACE MOLECULE; CHICK NERVOUS-SYSTEM; SPINAL-CORD; C-ELEGANS; COLORECTAL-CANCER; NEURITE OUTGROWTH; VISUAL CENTERS; PROTEIN	Extending axons in the developing nervous system are guided to their targets through the coordinate actions of attractive and repulsive guidance cues. The semaphorin family of guidance cues comprises several members that can function as diffusible axonal chemorepellents. To begin to elucidate the mechanisms that mediate the repulsive actions of Collapsin-1/Semaphorin III/D (Sema III), we searched for Sema III-binding proteins in embryonic rat sensory neurons by expression cloning. We report that Sema III binds with high affinity to the transmembrane protein neuropilin, and that antibodies to neuropilin block the ability of Sema III to repel sensory axons and to induce collapse of their growth cones. These results provide evidence that neuropilin is a receptor or a component of a receptor complex that mediates the effects of Sema III on these axons.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	He, ZG (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, SAN FRANCISCO, CA 94143 USA.							Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BUSBY TF, 1990, BIOCHEMISTRY-US, V29, P4613, DOI 10.1021/bi00471a016; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJISAWA H, 1989, DEV BIOL, V135, P231, DOI 10.1016/0012-1606(89)90175-9; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; HIRATA T, 1993, NEUROSCI RES, V17, P159, DOI 10.1016/0168-0102(93)90092-5; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KINDT RM, 1995, NEURON, V15, P79, DOI 10.1016/0896-6273(95)90066-7; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LI W, 1992, GENETICS, V132, P675; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; Shepherd IT, 1997, DEVELOPMENT, V124, P1377; Shirasaki R, 1996, NEURON, V17, P1079, DOI 10.1016/S0896-6273(00)80241-X; SNIDER WD, 1992, J NEUROSCI, V12, P3494; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	51	925	977	0	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					739	751		10.1016/S0092-8674(00)80534-6	http://dx.doi.org/10.1016/S0092-8674(00)80534-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288753	Bronze			2022-12-01	WOS:A1997XT06600017
J	Cella, M; Engering, A; Pinet, V; Pieters, J; Lanzavecchia, A				Cella, M; Engering, A; Pinet, V; Pieters, J; Lanzavecchia, A			Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells	NATURE			English	Article							ANTIGEN PROCESSING CAPACITY; EPIDERMAL LANGERHANS CELLS; TUMOR-NECROSIS-FACTOR; INVARIANT CHAIN; MOLECULES; COMPARTMENT; LYMPHOCYTES; EXPRESSION; PEPTIDES; CULTURE	Dendritic cells have the remarkable property of presenting any incoming antigen(1). To do so they must not only capture antigens with high efficiency and broad specificity, but must also maximize their capacity to load class II molecules of the major histocompatibility complex (MHC) with antigenic peptides in order to present a large array of epitopes from different proteins, each at a sufficient copy number. Here we show that formation of peptide-MHC class II complexes is boosted by inflammatory stimuli that induce maturation of dendritic cells. In immature dendritic cells, class II molecules are rapidly internalized and recycled, turning over with a half-life of about 10 hours. Inflammatory stimuli induce a rapid and transient boost of class II synthesis, while the half-life of dass II molecules increases to over 100 hours. These coordinated changes result in the rapid accumulation of a large number of long-lived peptide-loaded MHC dass II molecules capable of stimulating T cells even after several days, The capacity of dendritic cells to load many antigenic peptides over a short period of initial exposure to inflammatory stimuli could favour presentation of infectious antigens.	HOP ST ELOI,IMMUNOL LAB,INSERM,U291,F-34295 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Cella, M (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Cella, Marina/ABA-8564-2020; PINET, Valérie/G-6085-2012; Cella, Marina/G-8850-2011	PINET, Valérie/0000-0002-4044-6440; Pieters, Jean/0000-0002-5284-9757; Cella, Marina/0000-0003-1230-1313				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; KAMPGEN E, 1991, P NATL ACAD SCI USA, V88, P3014, DOI 10.1073/pnas.88.8.3014; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NELSON CA, 1994, NATURE, V371, P250, DOI 10.1038/371250a0; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; PINET V, 1994, J IMMUNOL, V152, P4852; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; ROOSNEK E, 1988, J IMMUNOL, V140, P4079; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; STOSSEL H, 1990, J EXP MED, V172, P1471, DOI 10.1084/jem.172.5.1471; Zhong GM, 1997, J EXP MED, V185, P429, DOI 10.1084/jem.185.3.429	19	907	931	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					782	787		10.1038/42030	http://dx.doi.org/10.1038/42030			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285591	Bronze			2022-12-01	WOS:A1997XR66700053
J	Barquet, N; Domingo, P; Cayla, JA; Gonzalez, J; Rodrigo, C; FernandezViladrich, P; MoragaLlop, FA; Marco, F; Vazquez, J; SaezNieto, JA; Casal, J; Canela, J; Foz, M				Barquet, N; Domingo, P; Cayla, JA; Gonzalez, J; Rodrigo, C; FernandezViladrich, P; MoragaLlop, FA; Marco, F; Vazquez, J; SaezNieto, JA; Casal, J; Canela, J; Foz, M			Prognostic factors in meningococcal disease - Development of a bedside predictive model and scoring system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEPTICEMIA; INFECTIONS; PENICILLIN; THERAPY; SCALE; COMA	Context.-Meningococcal disease is associated with significant morbidity and mortality. Development of a prognostic model based on clinical findings may be useful for identification and management of patients with meningococcal infection. Objectives.-To construct and validate a bedside model and scoring system for prognosis in meningococcal disease. Design.-Prospective, population-based study. Setting.-Twenty-four hospitals in the metropolitan area of Barcelona, Spain. Patients.-A total of 907 patients with microbiologically proven meningococcal disease. Patients diagnosed with meningococcal disease from 1987 through 1990 were used to develop the prognostic model, and those diagnosed in 1991. and 1992 were used to validate it. Outcome Measures.-Clinical independent prognostic factors for mortality in meningococcal disease. The association between outcome and independent prognostic factors was determined by logistic regression analysis. A scoring system was constructed and tested using receiver operating characteristic curves. Results.-Among 624 patients in the derivation set, 287 (46%) were male, the mean age was 12.4 years, and 34 patients (5.4%) died. Among 283 patients in the validation set, 124 (43.8%) were male, the mean age was 12.7 years, and 17 patients (6.0%) died. In multivariate analysis, independent predictors of death were hemorrhagic diathesis (odds ratio [OR], 101; 95% confidence interval [CI], 30-333), focal neurologic signs (OR, 25; 95% CI, 7-83), and age 60 years or older (OR, 10; 95% CI, 3-34), whereas receipt of adequate antibiotic therapy prior to admission was associated with reduced likelihood of death (OR, 0.09; 95% CI, 0.02-0.4). Hemorrhagic diathesis was scored with 2 points, presence of focal neurologic signs with 1 point, age of 60 years or older with 1 point, and preadmission antibiotic therapy was scored as -1. The clinical scores of -1, 0, 1, 2, and 3 or more points were associated with a probability of death of 0%, 2.3%, 27.3%, 73.3%, and 100%, respectively. Conclusions.-Hemorrhagic diathesis, focal neurologic signs, and age of 60 years or older were independent predictors of death in meningococcal disease, whereas receipt of adequate antibiotic therapy was associated with a more favorable prognosis. The scoring system presented is simple, is based on findings readily ;available at the bedside, and may be useful to help guide aggressive therapy.	INST CATALA SALUT, CAP GRACIA, BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, E-08025 BARCELONA, SPAIN; INST MUNICIPAL SALUT, BARCELONA, SPAIN; HOSP CLIN BARCELONA, BARCELONA, SPAIN; HOSP INFANTIL VALL HEBRON, BARCELONA, SPAIN; DEPT SALUT PUBL & LEGISLACIO SANITARIA, BARCELONA, SPAIN; HOSP GERMANS TRIAS & PUJOL, BADALONA, SPAIN; BELLVITGE HOSP, LHOSPITALET DE LLOBREGAT, SPAIN; CTR NACL MICROBIOL VIROL & INMUNOL SANITARIAS, LAB REFERENCIA MENINGOCOCOS, MADRID, SPAIN	University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitari Vall d'Hebron; Hospital Germans Trias i Pujol; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital			Marco, Francesc D/K-2900-2017; Domingo, Pere/AAP-7571-2021; Domingo, Pere/CAF-3577-2022; Rodrigo, Carlos/F-7602-2017; Moraga Llop, Fernando/E-2316-2016	Marco, Francesc D/0000-0002-1863-6379; Domingo, Pere/0000-0003-1138-5770; Rodrigo, Carlos/0000-0003-1140-2585; Vazquez, Julio A/0000-0003-3326-8831; Cayla, Joan A./0000-0003-3891-111X; Moraga Llop, Fernando/0000-0001-7449-2632				BJORVATN B, 1984, BRIT MED J, V288, P439, DOI 10.1136/bmj.288.6415.439; BOHR V, 1983, J INFECTION, V7, P193, DOI 10.1016/S0163-4453(83)96980-3; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRANDTZEAG P, 1987, LANCET, V2, P862; BUSUND R, 1993, CRIT CARE MED, V21, P1699, DOI 10.1097/00003246-199311000-00019; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; DOMINGO P, 1995, LANCET, V345, P460, DOI 10.1016/S0140-6736(95)90446-8; DRAPER WH, 1864, AM MED TIMES, V9, P114; DRAPER WH, 1864, AM MED TIMES, V9, P99; DRAPER WH, 1864, AM MED TIMES, V9, P101; EMPARANZA JI, 1988, CRIT CARE MED, V16, P168, DOI 10.1097/00003246-198802000-00015; Flexner S, 1913, J EXP MED, V17, P553, DOI 10.1084/jem.17.5.553; GARDLUND B, 1986, INTENS CARE MED, V12, P302, DOI 10.1007/BF00261740; GEDDEDAHL TW, 1990, REV INFECT DIS, V12, P973; GIRAUD T, 1991, ARCH INTERN MED, V151, P310, DOI 10.1001/archinte.151.2.310; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; KAHN A, 1978, CLIN PEDIATR, V17, P680, DOI 10.1177/000992287801700902; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LEWIS LS, 1979, ARCH DIS CHILD, V54, P44, DOI 10.1136/adc.54.1.44; MORELLO JA, 1991, MANUAL CLIN MICROBIO, P258; NIKLASSON P-M, 1971, Scandinavian Journal of Infectious Diseases, V3, P17, DOI 10.3109/inf.1971.3.issue-1.03; Norusis M. J., 1986, SPSS PC IBM PC XT AT; SAUKKONEN K, 1988, J INFECT DIS, V158, P209, DOI 10.1093/infdis/158.1.209; SIMPSON D, 1982, LANCET, V2, P450; SINCLAIR JF, 1987, LANCET, V2, P38; *STAT EP RES CORP, 1990, EP GRAPH EST TEST PA; STIEHM ER, 1966, J PEDIATR-US, V68, P457, DOI 10.1016/S0022-3476(66)80250-0; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; STRONG N, 1811, MED PHILOS REG, V1, P12; STRONG N, 1811, MED PHILOS REG, V1, P57; STRONG N, 1811, MED PHILOS REG, V1, P96; TEASDALE G, 1974, LANCET, V2, P81; TESORO LJ, 1991, AM J DIS CHILD, V145, P218, DOI 10.1001/archpedi.1991.02160020112029; THOMSON APJ, 1991, CRIT CARE MED, V19, P26, DOI 10.1097/00003246-199101000-00010; THOMSON APJ, 1991, PEDIATRIC REV COMMUN, V5, P199; TUYSUZ B, 1993, ACTA PAEDIATR, V82, P1053, DOI 10.1111/j.1651-2227.1993.tb12809.x; Vieusseux G, 1806, J MED CHIR PHARMACOL, V11, P163; VIKMO H, 1978, SCAND J INFECT DIS, V10, P187, DOI 10.3109/inf.1978.10.issue-3.06; WONG VK, 1989, PEDIATR INFECT DIS J, V8, P224	42	62	63	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	1997	278	6					491	496		10.1001/jama.278.6.491	http://dx.doi.org/10.1001/jama.278.6.491			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP243	9256224				2022-12-01	WOS:A1997XP24300031
J	Bannerman, E; Reilly, JJ; MacLennan, WJ; Kirk, T; Pender, F				Bannerman, E; Reilly, JJ; MacLennan, WJ; Kirk, T; Pender, F			Evaluation of validity of British anthropometric reference data for assessing nutritional state of elderly people in Edinburgh: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							SKELETAL SIZE; MALNUTRITION; INDEXES; VALUES	Objectives: To evaluate the appropriateness of two sets of commonly used anthropometric reference data for nutritional assessment of elderly people. Design: Cross sectional study. Setting: Two general practices in Edinburgh. Subjects: 200 independently living men and women aged 75 or over randomly recruited from the age and sex register of the practices. Main outcome measures: Weight (kg), knee height (cm), demispan (cm), mid-upper arm circumference (cm), triceps skinfold thickness (mm), arm muscle circumference (cm) body mass index (kg/m(2)), and demiquet (kg/m(2)) in men and minder (kg/m) in women. Results: Men and women in Edinburgh were significantly shorter than those in measured for the Nottingham reference data (demispan 0.79 v 0.80 (P < 0.05) for men and 0.72 v 0.73 (P < 0.01) for women). Comparison with data from South Wales showed that men and women from Edinburgh had significantly greater mid-upper arm circumference, triceps skinfold thickness, and arm muscle circumference. No one fell below the 10th centile of the South Wales data (the commonly used cut off point for determining malnutrition) for these measures. Conclusions: Both sets of reference data commonly used in Britain may be inappropriate for nutritional screening of elderly people in Edinburgh. Contemporary reference data appropriate for the whole of Britain need to be developed, and in the longer term biologically or clinically defined criteria for undernutrition should be established.	QUEEN MARGARET COLL,DEPT NUTR & DIETET,EDINBURGH EH12 8TS,MIDLOTHIAN,SCOTLAND; YORKHILL HOSP,DEPT HUMAN NUTR,GLASGOW G3 8SJ,LANARK,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM EDINBURGH,GERIATR MED UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Queen Margaret University; Royal Infirmary of Edinburgh; University of Edinburgh								Bannerman E, 1997, P NUTR SOC, V55, p249A; BASSEY EJ, 1986, ANN HUM BIOL, V13, P499, DOI 10.1080/03014468600008661; BURR ML, 1984, BRIT J NUTR, V51, P165, DOI 10.1079/BJN19840020; CHUMLEA WC, 1985, J AM GERIATR SOC, V33, P116, DOI 10.1111/j.1532-5415.1985.tb02276.x; CHUMLEA WC, 1989, AM J CLIN NUTR, V50, P1158, DOI 10.1093/ajcn/50.5.1158; COCKRAM DB, 1990, AM J CLIN NUTR, V52, P397, DOI 10.1093/ajcn/52.2.397; DELARUE J, 1994, BRIT J NUTR, V71, P295, DOI 10.1079/BJN19940135; Department of Health, 1992, 43 DEP HLTH; FRIEDMAN PJ, 1985, AGE AGEING, V14, P149, DOI 10.1093/ageing/14.3.149; Gibson R.S., 1990, PRINCIPLES NUTR ASSE; Gregory J., 1990, DIETARY NUTR SURVEY; LEHMANN AB, 1991, CLIN NUTR, V10, P18, DOI 10.1016/0261-5614(91)90076-O; Lennard-Jones J E, 1992, POSITIVE APPROACH NU; Lohman T, 1991, ANTHROPOMETRIC STAND; LOHMAN TG, 1993, ADV BODY COMPOSITION, V3; MCWHIRTER JP, 1994, BRIT MED J, V308, P945, DOI 10.1136/bmj.308.6934.945; MORGAN DB, 1986, AGE AGEING, V15, P65, DOI 10.1093/ageing/15.2.65; POTTER J, 1995, AGE AGEING, V24, P131, DOI 10.1093/ageing/24.2.131; SAVAGE SA, 1997, P NUTR SOC, V55, pA81; Thuluvath PJ, 1995, NUTRITION, V11, P731; Wright CM, 1996, BMJ-BRIT MED J, V313, P513, DOI 10.1136/bmj.313.7056.513	21	31	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					338	341						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270454	Green Published			2022-12-01	WOS:A1997XQ86400019
J	Carlezon, WA; Boundy, VA; Haile, CN; Lane, SB; Kalb, RG; Neve, RL; Nestler, EJ				Carlezon, WA; Boundy, VA; Haile, CN; Lane, SB; Kalb, RG; Neve, RL; Nestler, EJ			Sensitization to morphine induced by viral-mediated gene transfer	SCIENCE			English	Article							GLUTAMATE-RECEPTOR CHANNELS; VENTRAL TEGMENTAL AREA; TYROSINE-HYDROXYLASE; BEHAVIORAL SENSITIZATION; INDIVIDUAL-DIFFERENCES; AMPHETAMINE; COCAINE; NEURONS; RATS; EXPRESSION	Repeated administration of morphine sensitizes animals to the stimulant and rewarding properties of the drug. It also selectively increases expression of GluR1 (an AMPA glutamate receptor subunit) in the ventral tegmental area, a midbrain region implicated in morphine action, By viral-mediated gene transfer, a causal relation is shown between these behavioral and biochemical adaptations: Morphine's stimulant and rewarding properties are intensified after microinjections of a viral vector expressing GluR1 into the ventral tegmental area, These results confirm the importance of AMPA receptors in morphine action and demonstrate specific locomotor and motivational adaptations resulting from altered expression of a single localized gene product.	YALE UNIV, SCH MED, CONNECTICUT MENTAL HLTH CTR, DEPT PSYCHIAT, NEW HAVEN, CT 06508 USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA; HARVARD UNIV, MCLEAN HOSP, SCH MED, DEPT GENET, BELMONT, MA 02178 USA	Yale University; Yale University; Yale University; Harvard University; McLean Hospital				/0000-0002-4162-3947; Haile, Colin/0000-0001-8293-7291				Berhow MT, 1996, J NEUROSCI, V16, P4707; Berhow MT, 1996, J NEUROSCI, V16, P8019; BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X; CARLEZON WA, UNPUB; DEROCHE V, 1993, BRAIN RES, V623, P341, DOI 10.1016/0006-8993(93)91451-W; DURING MJ, 1994, SCIENCE, V266, P1399, DOI 10.1126/science.266.5189.1399; Fink DJ, 1996, ANNU REV NEUROSCI, V19, P265; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; GALEY D, 1977, BRAIN RES, V124, P83, DOI 10.1016/0006-8993(77)90865-4; HENRY DJ, 1995, J NEUROSCI, V15, P6287; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; ISACSON O, 1995, SCIENCE, V269, P856, DOI 10.1126/science.7638605; JAKOWEC MW, 1995, NEUROSCIENCE, V67, P909, DOI 10.1016/0306-4522(95)00094-Y; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KARIER R, 1991, BRAIN RES, V552, P295; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LETT BT, 1989, PSYCHOPHARMACOLOGY, V98, P357, DOI 10.1007/BF00451687; LI Y, IN PRESS PSYCHOPHARM; Lim F, 1996, BIOTECHNIQUES, V20, P460; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; MISERENDINO MJD, 1993, MOL CELL NEUROSCI, V4, P440, DOI 10.1006/mcne.1993.1055; Neve RL, 1997, NEUROSCIENCE, V79, P435, DOI 10.1016/S0306-4522(96)00645-8; Neve RL, 1996, CLIN NEUROSCI, V3, P262; ORTIZ J, 1995, SYNAPSE, V21, P289, DOI 10.1002/syn.890210403; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; PRUSS RM, 1991, NEURON, V7, P509, DOI 10.1016/0896-6273(91)90302-G; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SEGAL DS, 1992, BRAIN RES, V577, P351, DOI 10.1016/0006-8993(92)90297-M; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.ne.18.030195.002335; SklairTavron L, 1996, P NATL ACAD SCI USA, V93, P11202, DOI 10.1073/pnas.93.20.11202; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VEZINA P, 1989, BRAIN RES, V499, P108, DOI 10.1016/0006-8993(89)91140-2; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; WISE RA, 1989, NEUROPHARMACOLOGICAL; Zhang XF, 1997, J PHARMACOL EXP THER, V281, P699	36	232	238	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 8	1997	277	5327					812	814		10.1126/science.277.5327.812	http://dx.doi.org/10.1126/science.277.5327.812			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242609				2022-12-01	WOS:A1997XQ24700042
J	Lewis, FD; Wu, TF; Zhang, YF; Letsinger, RL; Greenfield, SR; Wasielewski, MR				Lewis, FD; Wu, TF; Zhang, YF; Letsinger, RL; Greenfield, SR; Wasielewski, MR			Distance-dependent electron transfer in DNA hairpins	SCIENCE			English	Article							OLIGONUCLEOTIDES; FLUORESCENCE; DYNAMICS	The distance dependence of photoinduced electron transfer in duplex DNA was determined for a family of synthetic DNA hairpins in which a stilbene dicarboxamide forms a bridge connecting two oligonucleotide arms. Investigation of the fluorescence and transient absorption spectra of these hairpins established that no photoinduced electron transfer occurs for a hairpin that has six deoxyadenosine-deoxythymidine base pairs. However, the introduction of a single deoxyguanosine-deoxycytidine base pair resulted in distance-dependent fluorescence quenching and the formation of the stilbene anion radical. Kinetic analysis suggests that duplex DNA is somewhat more effective than proteins as a medium for electron transfer but that it does not function as a molecular wire.	ARGONNE NATL LAB,DIV CHEM,ARGONNE,IL 60439	United States Department of Energy (DOE); Argonne National Laboratory	Lewis, FD (corresponding author), NORTHWESTERN UNIV,DEPT CHEM,2145 SHERIDAN RD,EVANSTON,IL 60208, USA.		Greenfield, Scott/GOE-6006-2022					[Anonymous], 1988, ELECT ABSORPTION SPE; Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Beratan DN, 1997, CHEM BIOL, V4, P3, DOI 10.1016/S1074-5521(97)90230-1; BIRKS JB, 1970, PHOTOPHYSICS AROMATI, P128; BRUN AM, 1992, J AM CHEM SOC, V114, P3656, DOI 10.1021/ja00036a013; CANDEIAS LP, 1989, J AM CHEM SOC, V111, P1094, DOI 10.1021/ja00185a046; Dandliker PJ, 1997, SCIENCE, V275, P1465, DOI 10.1126/science.275.5305.1465; GREENFIELD SR, 1995, OPT LETT, V20, P1394, DOI 10.1364/OL.20.001394; Greenfield SR, 1996, J AM CHEM SOC, V118, P6767, DOI 10.1021/ja9600789; Guckian KM, 1996, J AM CHEM SOC, V118, P8182, DOI 10.1021/ja961733f; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; LETSINGER RL, 1995, J AM CHEM SOC, V117, P7323, DOI 10.1021/ja00133a005; LEWIS FD, 1995, J AM CHEM SOC, V117, P8785, DOI 10.1021/ja00139a011; Lincoln P, 1997, J AM CHEM SOC, V119, P1454, DOI 10.1021/ja9631965; MATAGA N, 1990, J PHYS CHEM-US, V94, P1443, DOI 10.1021/j100367a045; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; Olson EJC, 1997, J PHYS CHEM B, V101, P299, DOI 10.1021/jp963109v; Priyadarshy S, 1996, J PHYS CHEM-US, V100, P17678, DOI 10.1021/jp961731h; REHM D, 1970, ISRAEL J CHEM, V8, P259; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Taubes G, 1997, SCIENCE, V275, P1420, DOI 10.1126/science.275.5305.1420; WALDECK DH, 1991, CHEM REV, V91, P415, DOI 10.1021/cr00003a007; WILSON EK, 1997, CHEM ENG NEWS, P33	23	553	566	4	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					673	676		10.1126/science.277.5326.673	http://dx.doi.org/10.1126/science.277.5326.673			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235887				2022-12-01	WOS:A1997XN90700037
J	Moll, S; Ortel, TL				Moll, S; Ortel, TL			Monitoring warfarin therapy in patients with lupus anticoagulants	ANNALS OF INTERNAL MEDICINE			English	Article						warfarin; lupus coagulation inhibitor; anticoagulants; prothrombin time; thromboembolism	DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; PROTHROMBIN TIME; ANTIBODIES; THROMBOPLASTIN; ERYTHEMATOSUS; POPULATION; INHIBITION; DIAGNOSIS; PLASMA	Background: Recommended therapeutic international normalized ratios (INRs) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event are controversial. Patients with lupus anticoagulants often have a prolonged prothrombin time, which may complicate management of anticoagulant therapy. Objectives: To determine the validity of the INR as a monitor for warfarin therapy in patients with lupus anticoagulants and to investigate alternate approaches to monitoring warfarin therapy in these patients. Design: Prospective case series. Setting: Tertiary care hospital. Patients: 34 patients with lupus anticoagulants. Measurements: Prothrombin times were determined by using several thromboplastins, and INRs were calculated for the patients receiving warfarin. Factor II levels, chromogenic factor X levels, and prothrombin-proconvertin times were determined for patients receiving warfarin. Results: For patients with lupus anticoagulants who were not receiving warfarin, prothrombin times were often elevated and varied significantly with different thromboplastins. individual thromboplastins differed in sensitivity to the presence of a lupus anticoagulant. For patients receiving warfarin, INRs obtained by using different thromboplastins greatly varied and often overestimated the extent of anticoagulation. Chromogenic factor X levels and prothrombin-proconvertin times correlated well with each other and with established therapeutic ranges. Conclusions: Lupus anticoagulants can influence prothrombin times and lead to INRs that do not accurately reflect the true level of anticoagulation. Use of the INR to standardize prothrombin times is invalid for some patients with lupus anticoagulants. To prevent supratherapeutic or subtherapeutic anticoagulation, these patients must be individually monitored with a test that is insensitive to lupus anticoagulants.	DUKE UNIV, DEPT MED, DIV HEMATOL, MED CTR, DURHAM, NC 27710 USA; FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, FRANZ VOLHARD KLIN, D-13122 BERLIN, GERMANY	Duke University; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin					NCRR NIH HHS [MO1-RR-30] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; BAJAJ SP, 1983, BLOOD, V61, P684; BICK RL, 1994, MED CLIN N AM, V78, P667, DOI 10.1016/S0025-7125(16)30152-3; BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; BRANDT JT, 1991, THROMB HAEMOSTASIS, V66, P453; CIAVARELLA N, 1980, THROMB RES, V19, P493, DOI 10.1016/0049-3848(80)90022-5; COON WW, 1973, CIRCULATION, V48, P839, DOI 10.1161/01.CIR.48.4.839; EGBERG N, 1982, THROMB RES, V25, P437, DOI 10.1016/0049-3848(82)90134-7; FLECK RA, 1988, BLOOD, V72, P512; GALLI M, 1989, BRIT J HAEMATOL, V72, P549, DOI 10.1111/j.1365-2141.1989.tb04322.x; GINSBERG JS, 1995, BLOOD, V86, P3685, DOI 10.1182/blood.V86.10.3685.bloodjournal86103685; GINSBERG JS, 1993, BLOOD, V81, P2958; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HORELLOU MH, 1987, J MED, V18, P199; Khamashta MA, 1996, LUPUS, V5, P463, DOI 10.1177/096120339600500527; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KHAMASHTA MA, 1995, NEW ENGL J MED, V333, P666; KOVACS MJ, 1994, THROMB HAEMOSTASIS, V71, P727; LE DT, 1994, ANN INTERN MED, V120, P552, DOI 10.7326/0003-4819-120-7-199404010-00004; Lind SE, 1997, BLOOD COAGUL FIBRIN, V8, P48, DOI 10.1097/00001721-199701000-00008; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MANNUCCI PM, 1979, SCAND J HAEMATOL, V22, P423; NASR SZ, 1995, NEW ENGL J MED, V333, P666; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; OUT HJ, 1989, ANN RHEUM DIS, V48, P1023, DOI 10.1136/ard.48.12.1023; OWREN PA, 1951, SCAND J CLIN LAB INV, V3, P201, DOI 10.3109/00365515109060600; RAPAPORT SI, 1995, NEW ENGL J MED, V333, P665; RAPAPORT SI, 1960, BLOOD, V15, P212, DOI 10.1182/blood.V15.2.212.212; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; ROUBEY RAS, 1994, BLOOD, V84, P2854; Shapiro SS, 1996, ANNU REV MED, V47, P533; Simioni P, 1996, THROMB HAEMOSTASIS, V76, P187; SKOGEN WF, 1983, BIOCHEM BIOPH RES CO, V111, P14, DOI 10.1016/S0006-291X(83)80110-7; SLIVKA A, 1995, NEW ENGL J MED, V333, P665; The Committee of Stratigraphy of China, 1996, CPMPBWP21496, P1; TRIPLETT DA, 1983, AM J CLIN PATHOL, V79, P678, DOI 10.1093/ajcp/79.6.678; VANDENBESSELAAR AMHP, 1993, THROMB HAEMOSTASIS, V69, P85	38	156	171	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1997	127	3					177	+		10.7326/0003-4819-127-3-199708010-00001	http://dx.doi.org/10.7326/0003-4819-127-3-199708010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN129	9245222				2022-12-01	WOS:A1997XN12900001
J	Stokoe, D; Stephens, LR; Copeland, T; Gaffney, PRJ; Reese, CB; Painter, GF; Holmes, AB; McCormick, F; Hawkins, PT				Stokoe, D; Stephens, LR; Copeland, T; Gaffney, PRJ; Reese, CB; Painter, GF; Holmes, AB; McCormick, F; Hawkins, PT			Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B	SCIENCE			English	Article							C-AKT; V-AKT	Protein kinase B (PKB) is a proto-oncogene that is activated in signaling pathways initiated by phosphoinositide 3-kinase. Chromatographic separation of brain cytosol revealed a kinase activity that phosphorylated and activated PKB only in the presence of phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P-3]. Phosphorylation occurred exclusively on threonine-308, a residue implicated in activation of PKB in vivo. PtdIns(3,4,5)P-3 was determined to have a dual role: its binding to the pleckstrin homology domain of PKB was required to allow phosphorylation by the upstream kinase and it directly activated the upstream kinase.	ONYX PHARMACEUT,RICHMOND,CA 94806; BABRAHAM INST,CAMBRIDGE CB2 4AT,ENGLAND; NCI,ABL BASIC RES PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; UNIV LONDON KINGS COLL,DEPT CHEM,LONDON WC2R 2LS,ENGLAND; UNIV CAMBRIDGE,DEPT CHEM,CAMBRIDGE CB2 3RA,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of London; King's College London; University of Cambridge				stephens, len/0000-0002-2771-3487; Hawkins, Phillip/0000-0002-6979-0464				AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1993, ONCOGENE, V8, P745; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOKOE D, UNPUB	23	1030	1077	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 25	1997	277	5325					567	570		10.1126/science.277.5325.567	http://dx.doi.org/10.1126/science.277.5325.567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM867	9228007				2022-12-01	WOS:A1997XM86700052
J	Impicciatore, P; Pandolfini, C; Casella, N; Bonati, M				Impicciatore, P; Pandolfini, C; Casella, N; Bonati, M			Reliability of health information for the public on the world wide web: Systematic survey of advice on managing fever in children at home	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECTAL TEMPERATURE; PARENTS; INFANTS	Objective: To assess the reliability of healthcare information on the world wide web and therefore how it may help lay people cope with common health problems. Methods: Systematic search by means of two search engines, Yahoo and Excite, of parent oriented web pages relating to home management of feverish children. Reliability of information on the web sites was checked by comparison with published guidelines. Main outcome measures: Minimum temperature of child that should be considered as fever, optimal sites for measuring temperature, pharmacological and physical treatment of fever, conditions that may warrant a doctor's visit. Results: 41 web pages were retrieved and considered. 28 web pages gave a temperature above which a child is feverish; 26 pages indicated the optimal site for taking temperature, most recommending rectal measurement; 31 of the 34 pages that mentioned drug treatment recommended paracetamol as an antipyretic; 38 pages recommended non-drug measures, most commonly tepid sponging, dressing lightly, and increasing fluid intake; and 36 pages gave some indication of when a doctor should be called. Only four web pages adhered closely to the main recommendations in the guidelines. The largest deviations were in sponging procedures and how to take a child's temperature, whereas there was a general agreement in the use of paracetamol. Conclusions: Only a few web sites provided complete and accurate information for this common and widely discussed condition. This suggests an urgent need to check public oriented healthcare information on the internet for accuracy, completeness, and consistency.	MARIO NEGRI INST PHARMACOL RES, LAB MOTHER & CHILD HLTH, I-20157 MILAN, ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Pandolfini, Chiara/K-5693-2016; Bonati, Maurizio/K-8980-2016	Pandolfini, Chiara/0000-0001-9809-2991; Bonati, Maurizio/0000-0003-3997-3726				ADAM D, 1994, EUR J PEDIATR, V153, P394; CASEY R, 1984, PEDIATRICS, V73, P600; Coeira E., 1996, BRIT MED J, V312, P3; DEAN AG, 1994, EPI INFO VERSION 6; ELRADHI AS, 1994, FEVER PAEDIAT PRACTI, P229; Fagan E, 1996, BRIT MED J, V313, P1417, DOI 10.1136/bmj.313.7070.1417; GRIBETZ B, 1987, PEDIATRICS, V80, P630; Impicciatore P, 1997, BRIT MED J, V314, P373, DOI 10.1136/bmj.314.7077.373a; KAI J, 1993, BRIT MED J, V307, P660, DOI 10.1136/bmj.307.6905.660; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KEELEY D, 1992, BRIT MED J, V304, P931, DOI 10.1136/bmj.304.6832.931; KINMONTH AL, 1992, BRIT MED J, V305, P1134, DOI 10.1136/bmj.305.6862.1134; KLUGER MJ, 1992, PEDIATRICS, V90, P846; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; KRAMER MS, 1991, LANCET, V337, P591, DOI 10.1016/0140-6736(91)91648-E; KRAMER MS, 1985, PEDIATRICS, V75, P1110; KRESCH MJ, 1984, J PEDIATR-US, V104, P596, DOI 10.1016/S0022-3476(84)80558-2; LAPORTE RE, 1994, BRIT MED J, V308, P1651, DOI 10.1136/bmj.308.6945.1651; LaPorte RE, 1996, ANN EPIDEMIOL, V6, P162, DOI 10.1016/1047-2797(95)00133-6; LESKO SM, 1995, JAMA-J AM MED ASSOC, V273, P929, DOI 10.1001/jama.273.12.929; McIntyre J, 1996, ARCH DIS CHILD, V74, P164, DOI 10.1136/adc.74.2.164; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MOSS MH, 1970, PEDIATRICS, V46, P445; PALLEN M, 1995, BRIT MED J, V311, P1552, DOI 10.1136/bmj.311.7019.1552; PENNA A, 1991, BRIT J CLIN PHARMACO, V32, P143, DOI 10.1111/j.1365-2125.1991.tb03873.x; ROBINSON JS, 1989, AM J DIS CHILD, V143, P698, DOI 10.1001/archpedi.1989.02150180076024; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Spooner SA, 1996, PEDIATRICS, V98, P1185; TARLOW M, 1986, BRIT MED J, V292, P1543, DOI 10.1136/bmj.292.6535.1543; The International Agranulocytosis and Aplastic Anemia Study, 1986, JAMA-J AM MED ASSOC, V256, P1749; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209; 1991, LANCET, V338, P1049	33	414	421	1	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	1997	314	7098					1875	1879		10.1136/bmj.314.7098.1875	http://dx.doi.org/10.1136/bmj.314.7098.1875			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH738	9224132	Green Published			2022-12-01	WOS:A1997XH73800028
J	Veronesi, U; Paganelli, G; Galimberti, V; Viale, G; Zurrida, S; Bedoni, M; Costa, A; deCicco, C; Geraghty, JG; Luini, A; Sacchini, V; Veronesi, P				Veronesi, U; Paganelli, G; Galimberti, V; Viale, G; Zurrida, S; Bedoni, M; Costa, A; deCicco, C; Geraghty, JG; Luini, A; Sacchini, V; Veronesi, P			Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes	LANCET			English	Article							GAMMA-PROBE; LYMPHADENECTOMY; MELANOMA	Background Axillary lymph-node dissection is an important staging procedure in the surgical treatment of breast cancer. However, early diagnosis has led to increasing numbers of dissections in which axillary nodes are free of disease. This raises questions about the need for the procedure. We carried out a study to assess, first, whether a single axillary lymph node (sentinel node) initially receives malignant cells from a breast carcinoma and, second, whether a clear sentinel node reliably forecasts a disease-free axilla. Methods In a consecutive series of 163 women with operable breast carcinoma, we injected microcolloidal human serum albumin labelled with technetium-99m. This tracer was injected subdermally, close to the tumour site, on the day before surgery, and scintigraphic images of the axilla and breast were taken 10 min, 30 min, and 3 h later. A mark was placed on the skin over the site of the radioactive node (sentinel node). During breast surgery, a hand-held gamma-ray detector probe was used to locate the sentinel node, and make possible its separate removal via a small axillary incision. Complete axillary lymphadenectomy was then done. The sentinel node was tagged separately from other nodes. Permanent sections of all removed nodes were prepared for pathological examination. Findings From the sentinel node, we could accurately predict axillary lymph-node status in 156 (97.5%) of the 160 patients in whom a sentinel node was identified, and in all cases (45 patients) with tumours less than 1.5 cm in diameter. In 32 (38%) of the 85 cases with metastatic axillary nodes, the only positive node was the sentinel node. Interpretation in the large majority of patients with breast cancer, lymphoscintigraphy and gamma-probe-guided surgery can be used to locate the sentinel node in the axilla, and thereby provide important information about the status of axillary nodes. Patients without clinical involvement of the axilla should undergo sentinel-node biopsy routinely, and may be spared complete axillary dissection when the sentinel node is disease-free.	EUROPEAN INST ONCOL,DIV NUCL MED,I-20141 MILAN,ITALY; EUROPEAN INST ONCOL,DEPT PATHOL,I-20141 MILAN,ITALY; EUROPEAN INST ONCOL,DEPT ANAESTHESIOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO)	Veronesi, U (corresponding author), EUROPEAN INST ONCOL,DIV SURG,VIA RIPAMONTI 435,I-20141 MILAN,ITALY.		paganelli, giovanni/AAC-5267-2022; Luini, Alberto/AAS-4322-2020; GALIMBERTI, Viviana Enrica/AAS-3963-2020; Viale, Giuseppe/AAE-8921-2019; VERONESI, PAOLO/AAS-4132-2020	GALIMBERTI, Viviana Enrica/0000-0002-5036-7439; VERONESI, PAOLO/0000-0001-8926-4106; Paganelli, Giovanni/0000-0002-2631-4652				Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; [Anonymous], 1992, SURG ONCOLOGY CLIN; CHILOSI M, 1994, BIOTECH HISTOCHEM, V69, P235, DOI 10.3109/10520299409106292; *CONS C, 1985, JAMA-J AM MED ASSOC, V254, P461; Doglioni C, 1996, AM J SURG PATHOL, V20, P1037, DOI 10.1097/00000478-199609000-00001; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FISHER B, 1981, SURG GYNECOL OBSTET, V152, P765; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; Giuliano AE, 1996, J SURG ONCOL, V62, P75, DOI 10.1002/(SICI)1096-9098(199606)62:2<75::AID-JSO1>3.0.CO;2-N; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; Greco M, 1996, ANTICANCER RES, V16, P3913; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; MOFFAT FL, 1992, J SURG ONCOL, V51, P8, DOI 10.1002/jso.2930510105; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Rosen PP, 1993, TUMORS MAMMARY GLAND; VANDERVEEN H, 1994, BRIT J SURG, V81, P1769, DOI 10.1002/bjs.1800811220; VERONESI U, 1990, EUR J SURG ONCOL, V16, P127; VERONESI U, 1987, CANCER, V59, P682, DOI 10.1002/1097-0142(19870215)59:4<682::AID-CNCR2820590403>3.0.CO;2-Z; *WHO, 1981, 2 WHO INT HIST CLASS	20	1540	1594	1	85	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1864	1867		10.1016/S0140-6736(97)01004-0	http://dx.doi.org/10.1016/S0140-6736(97)01004-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217757				2022-12-01	WOS:A1997XG41700008
J	Harris, TB; Launer, LJ; Madans, J; Feldman, JJ				Harris, TB; Launer, LJ; Madans, J; Feldman, JJ			Cohort study of effect of being overweight and change in weight on risk of coronary heart disease in old age	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NUTRITION EXAMINATION SURVEY; BODY-WEIGHT; FOLLOW-UP; NATIONAL-HEALTH; BLOOD-PRESSURE; OBESITY; MORTALITY; HAZARDS; CHOLESTEROL; PROGRAM	Objective: To evaluate risk of late life coronary heart disease associated with being overweight in late middle or old age and to assess whether weight change modifies this risk. Design: Longitudinal study of subjects in the epidemiological follow up study of the national health and nutrition examination survey I. Setting: United States. Subjects: 621 men and 960 women free of coronary heart disease in 1982-84 (mean age 77 years). Main outcome measure: Incidence of coronary heart disease. Results: Body mass index of 27 or more in late middle age nas associated with increased risk of coronary heart disease in late life (relative risk = 1.7 (95% confidence interval 1.3 to 2.1)) while body mass index of 27 or more in old age was not (1.1 (0.8 to 1.5)). This difference in risk was due largely to weight loss between middle and old age. Exclusion of those with weight loss of 10% or more increased risk associated with heavier weight in old age (1.4 (1.0 to 1.9)). Thinner older people who lost weight and heavier people who had gained weight showed increased risk of coronary heart disease compared with thinner people with stable weight. Conclusions: Heavier weight in late middle age was a risk factor for coronary heart disease in late life. Heavier weight in old age was associated with an increased risk once those with substantial weight loss were excluded. The contribution of weight to risk of coronary heart disease in older people may be underestimated if weight history is neglected.	NATL INST PUBL HLTH & ENVIRONM PROTECT, DEPT CHRON DIS & ENVIRONM EPIDEMIOL, BILTHOVEN, NETHERLANDS; NATL CTR HLTH STAT, HYATTSVILLE, MD 20782 USA	Netherlands National Institute for Public Health & the Environment; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Harris, TB (corresponding author), NIA, EPIDEMIOL DEMOG & BIOMETRY PROGRAM, BETHESDA, MD 20892 USA.							ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BLAIR SN, 1993, ANN INTERN MED, V119, P749, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00024; BURACK RC, 1985, J CHRON DIS, V38, P865, DOI 10.1016/0021-9681(85)90111-0; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; COX DR, 1972, J R STAT SOC B, V34, P187; GURWITZ JH, 1994, J AM GERIATR SOC, V42, P1235, DOI 10.1111/j.1532-5415.1994.tb06503.x; HARRIS T, 1988, J AM GERIATR SOC, V36, P1023, DOI 10.1111/j.1532-5415.1988.tb04370.x; HARRIS TB, 1993, AM J EPIDEMIOL, V137, P1318, DOI 10.1093/oxfordjournals.aje.a116641; HIGGINS M, 1993, ANN INTERN MED, V119, P758, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00025; INGRAM DD, 1994, VITAL HLTH STAT, V1, P121; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; LEAN MEJ, 1990, DIABETIC MED, V44, P133; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MUST A, 1993, AM J EPIDEMIOL, V138, P56, DOI 10.1093/oxfordjournals.aje.a116777; *NAT CTR HLTH STAT, 1983, VIT HLTH STAT, V11, P230; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; PEKKANEN J, 1994, AM J EPIDEMIOL, V139, P155, DOI 10.1093/oxfordjournals.aje.a116977; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; SHINTON R, 1995, J EPIDEMIOL COMMUN H, V49, P259, DOI 10.1136/jech.49.3.259; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; YANO K, 1989, ARCH INTERN MED, V149, P1528, DOI 10.1001/archinte.149.7.1528; 1987, VITAL HLTH STAT, V1, P22; 1979, VITAL HLTH STAT, V1, pA10	28	87	88	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	1997	314	7097					1791	1794		10.1136/bmj.314.7097.1791	http://dx.doi.org/10.1136/bmj.314.7097.1791			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG166	9224080	Green Published			2022-12-01	WOS:A1997XG16600021
J	Koljak, R; Boutaud, O; Shieh, BH; Samel, N; Brash, AR				Koljak, R; Boutaud, O; Shieh, BH; Samel, N; Brash, AR			Identification of a naturally occurring peroxidase-lipoxygenase fusion protein	SCIENCE			English	Article							CORAL PLEXAURA-HOMOMALLA; ALLENE OXIDE SYNTHASE; MOLECULAR-CLONING; ACID; BIOSYNTHESIS; PURIFICATION; EICOSANOIDS; PROSTANOIDS; CATALASE; PATHWAY	A distant relative of catalase that is specialized for metabolism of a fatty acid hydroperoxide was identified. This heme peroxidase occurs in coral as part of a fusion protein, the other component of which is a lipoxygenase that forms the hydroperoxide substrate, The end product is an unstable epoxide (an allene oxide) that is a potential precursor of prostaglandin-like molecules. These results extend the known chemistry of catalase-like proteins and reveal a distinct type of enzymatic construct involved in the metabolism of polyunsaturated fatty acids.	VANDERBILT UNIV, MED CTR, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; INST CHEM, DEPT BIOORGAN CHEM, EE-0026 TALLINN, ESTONIA	Vanderbilt University			Samel, Nigulas/A-1420-2019		FIC NIH HHS [TW00404] Funding Source: Medline; NIGMS NIH HHS [GM49502] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049502] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BJ, 1985, J AM CHEM SOC, V107, P2976, DOI 10.1021/ja00296a026; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1996, J BIOL CHEM, V271, P20949, DOI 10.1074/jbc.271.34.20949; BRASH AR, 1989, J AM CHEM SOC, V111, P1891, DOI 10.1021/ja00187a060; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRASH AR, 1991, J BIOL CHEM, V266, P22926; BUNDY GL, 1985, ADV PROSTAG THROMB L, V14, P229; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; Crombie L, 1991, J CHEM SOC P1, V1, P581; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; Gerwick WH, 1996, LIPIDS, V31, P1215, DOI 10.1007/BF02587906; GRIFFIN BW, 1991, PEROXIDASES CHEM BIO, V2, P85; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; Hamberg M, 1996, ACTA CHEM SCAND, V50, P219, DOI 10.3891/acta.chem.scand.50-0219; HAMBERG M, 1989, J AM OIL CHEM SOC, V66, P1445, DOI 10.1007/BF02661968; KIKUCHI H, 1982, TETRAHEDRON LETT, V23, P5171, DOI 10.1016/S0040-4039(00)85788-3; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; OHTA H, 1992, EUR J BIOCHEM, V206, P331, DOI 10.1111/j.1432-1033.1992.tb16931.x; Peterson Julian A., 1995, P151; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; VALNSHTEIN BK, 1981, NATURE, V293, P411; Wang Y, 1995, Adv Pharmacol, V34, P71; WEINHEIMER AJ, 1969, TETRAHEDRON LETT, P5185; WEINHEIMER AJ, 1974, PROSTAGLANDINS PLEXA, P17	29	100	102	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					1994	1996		10.1126/science.277.5334.1994	http://dx.doi.org/10.1126/science.277.5334.1994			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302294				2022-12-01	WOS:A1997XX84900044
J	Kovall, R; Matthews, BW				Kovall, R; Matthews, BW			Toroidal structure of lambda-exonuclease	SCIENCE			English	Article							BREAK REPAIR MODEL; CRYSTAL-STRUCTURE; PHAGE-LAMBDA; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; GENETIC RECOMBINATION; ECORV ENDONUCLEASE; PVUII ENDONUCLEASE; BETA PROTEIN; RED PATHWAY	Structure determination at 2.4 angstrom resolution shows that lambda-exonuclease consists of three subunits that form a toroid. The central channel is funnel shaped, tapering from an inner diameter of about 30 angstroms at the wider end to 15 angstroms at the narrow end. This is adequate to accommodate the DNA substrate and thus provides a structural basis for the ability of the enzyme to sequentially hydrolyze thousands of nucleotides in a highly processive manner, The results also suggest the locations of the active sites and the constraints that limit cleavage to a single strand.	UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	University of Oregon	Kovall, R (corresponding author), UNIV OREGON, HOWARD HUGHES MED INST, INST MOL BIOL, EUGENE, OR 97403 USA.		Kovall, Rhett/A-3106-2008		NIGMS NIH HHS [GM20066] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020066, R01GM020066] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CARTER DM, 1971, J BIOL CHEM, V246, P2502; CASSUTO E, 1971, P NATL ACAD SCI USA, V68, P1639, DOI 10.1073/pnas.68.7.1639; CASSUTO E, 1971, NATURE-NEW BIOL, V229, P13, DOI 10.1038/newbio229013a0; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; COLMAN PM, 1972, J MOL BIOL, V70, P701, DOI 10.1016/0022-2836(72)90569-4; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; HABER JE, 1995, BIOESSAYS, V17, P609, DOI 10.1002/bies.950170707; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KLEE CB, 1968, J BIOL CHEM, V243, P923; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; Linn S.M., 1993, NUCLEASES; LITTLE JW, 1967, J BIOL CHEM, V242, P672; LITTLE JW, 1967, J BIOL CHEM, V242, P679; MARYON E, 1991, MOL CELL BIOL, V11, P3278, DOI 10.1128/MCB.11.6.3278; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OTWINOWSKI Z, 1991, DARESBURY STUDY WEEK, P80; RADDING CM, 1966, J MOL BIOL, V18, P235, DOI 10.1016/S0022-2836(66)80243-7; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; STAHL FW, 1985, J MOL BIOL, V181, P199, DOI 10.1016/0022-2836(85)90085-3; STAHL FW, 1985, J GENET, V64, P31; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TAKAHASHI N, 1990, P NATL ACAD SCI USA, V87, P2790, DOI 10.1073/pnas.87.7.2790; THALER DS, 1987, J MOL BIOL, V195, P75, DOI 10.1016/0022-2836(87)90328-7; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANOOSTRUM J, 1985, ARCH BIOCHEM BIOPHYS, V243, P332, DOI 10.1016/0003-9861(85)90510-7; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	46	174	219	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1824	1827		10.1126/science.277.5333.1824	http://dx.doi.org/10.1126/science.277.5333.1824			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295273				2022-12-01	WOS:A1997XX29800047
J	Takeyama, K; Kitanaka, S; Sato, T; Kobori, M; Yanagisawa, J; Kato, S				Takeyama, K; Kitanaka, S; Sato, T; Kobori, M; Yanagisawa, J; Kato, S			25-hydroxyvitamin D-3 1 alpha-hydroxylase and vitamin D synthesis	SCIENCE			English	Article							D ENDOCRINE SYSTEM; GENE-EXPRESSION; D METABOLISM; CALCIFEROL METABOLISM; PARATHYROID-HORMONE; MESSENGER-RNA; RAT; KIDNEY; 24-HYDROXYLASE; 1,25-DIHYDROXYVITAMIN-D3	Renal 25-hydroxyvitamin D-3 1 alpha-hydroxylase [1 alpha(OH)ase] catalyzes metabolic activation of 25-hydroxyvitamin D-3 into 1 alpha,25-dihydroxyvitamin D-3 [1 alpha,25(OH)(2)D-3], an active form of vitamin D, and is inhibited by 1 alpha,25(OH)(2)D-3. 1 alpha(OH)ase, which was cloned from the kidney of mice lacking the vitamin D receptor (VDR-/- mice), is a member of the P450 family of enzymes (P450(VD1 alpha)). Expression of 1 alpha(OH)ase was suppressed by 1 alpha,25(OH)(2)D-3 in VDR+/+ and VDR+/- mice but not in VDR-/- mice. These results indicate that the negative feedback regulation of active vitamin D synthesis is mediated by 1 alpha(OH)ase through liganded VDR.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN; JAPAN SCI & TECHNOL, CREST, KAWAGUCHI, SAITAMA 332, JAPAN; YAMANOUCHI PHARMACEUT CO LTD, INST DRUG DISCOVERY RES, MOL MED LABS, TSUKUBA, IBARAKI 305, JAPAN	University of Tokyo; Japan Science & Technology Agency (JST); Astellas Pharmaceuticals								ADAMS JS, 1985, J CLIN ENDOCR METAB, V60, P960, DOI 10.1210/jcem-60-5-960; AXEN E, 1995, FEBS LETT, V375, P277, DOI 10.1016/0014-5793(95)01226-5; BALSAN S, 1991, NESTLE NUTR WORKS SE, V21, P155; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BECKMAN MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P535, DOI 10.1006/abbi.1995.1328; BIKLE DD, 1993, ENDOCR REV, V14, P3, DOI 10.1210/er.14.1.3; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BURGOSTRINIDAD M, 1992, J BIOL CHEM, V267, P3498; COLSTON KW, 1973, BIOCHEM J, V134, P817, DOI 10.1042/bj1340817; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DeLuca H F, 1986, Adv Exp Med Biol, V196, P361; DILWORTH FJ, 1995, J BIOL CHEM, V270, P16766, DOI 10.1074/jbc.270.28.16766; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; FRASER D, 1973, NEW ENGL J MED, V289, P817, DOI 10.1056/NEJM197310182891601; FRASER DR, 1973, NATURE-NEW BIOL, V241, P163, DOI 10.1038/newbio241163a0; FREDERICK MA, 1995, CURRENT PROTOCOLS MO; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; GRAY TK, 1979, SCIENCE, V204, P1311, DOI 10.1126/science.451538; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARADA H, 1995, ENDOCRINOLOGY, V136, P5329, DOI 10.1210/en.136.12.5329; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HENRY HL, 1974, J BIOL CHEM, V249, P7584; HENRY HL, 1992, J CELL BIOCHEM, V49, P4, DOI 10.1002/jcb.240490103; HENRY HL, 1974, J BIOL CHEM, V249, P7529; HOWARD GA, 1981, J BIOL CHEM, V256, P7738; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; Imai T, 1997, BIOCHEM BIOPH RES CO, V233, P765, DOI 10.1006/bbrc.1997.6531; ITOH S, 1995, BBA-GENE STRUCT EXPR, V1264, P26, DOI 10.1016/0167-4781(95)00147-9; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KAWASHIMA H, 1981, NATURE, V291, P327, DOI 10.1038/291327a0; KAWASHIMA H, 1981, P NATL ACAD SCI-BIOL, V78, P1199, DOI 10.1073/pnas.78.2.1199; KOBORI M, 1993, NUCLEIC ACIDS RES, V21, P2782, DOI 10.1093/nar/21.11.2782; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; MALLOY PJ, 1990, J CLIN INVEST, V86, P2071, DOI 10.1172/JCI114944; MANO H, 1994, J BIOL CHEM, V269, P1591; MATKOVITS T, 1995, ENDOCRINOLOGY, V136, P3971, DOI 10.1210/en.136.9.3971; MAWER EB, 1994, J CLIN ENDOCR METAB, V79, P554, DOI 10.1210/jc.79.2.554; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; PICADOLEONARD J, 1988, MOL ENDOCRINOL, V2, P1145, DOI 10.1210/mend-2-11-1145; Sakaki T, 1996, J BIOL CHEM, V271, P26209, DOI 10.1074/jbc.271.42.26209; SASAKI H, 1995, BIOCHEMISTRY-US, V34, P370, DOI 10.1021/bi00001a045; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Takeyama K, 1996, BIOCHEM BIOPH RES CO, V222, P395, DOI 10.1006/bbrc.1996.0755; TANAKA Y, 1974, SCIENCE, V183, P1198, DOI 10.1126/science.183.4130.1198; TONG HS, 1994, J BONE MINER RES, V9, P577; TURNER RT, 1980, P NATL ACAD SCI-BIOL, V77, P5720, DOI 10.1073/pnas.77.10.5720; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; Wakino S, 1996, GERONTOLOGY, V42, P67; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; WARNER M, 1982, J BIOL CHEM, V257, P2995; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	55	406	426	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1827	1830		10.1126/science.277.5333.1827	http://dx.doi.org/10.1126/science.277.5333.1827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295274				2022-12-01	WOS:A1997XX29800048
J	Ulrich, HD; Mundroff, E; Santarsiero, BD; Driggers, EM; Stevens, RC; Schultz, PG				Ulrich, HD; Mundroff, E; Santarsiero, BD; Driggers, EM; Stevens, RC; Schultz, PG			The interplay between binding energy and catalysis in the evolution of a catalytic antibody	NATURE			English	Article							OXY-COPE REARRANGEMENT; IMMUNE-RESPONSE; GERM-LINE; DIVERSITY; MECHANISM; GENES; VL; VH	Antibody catalysis(1) provides an opportunity to examine the evolution of binding energy and its relation to catalytic function in a system that has many parallels with natural enzymes. Here we report such a study involving an antibody AZ-28 that catalyses an oxy-Cope rearrangement, a pericyclic reaction that belongs to a well studied and widely used class of reactions in organic chemistry(2). Immunization with transition state analogue 1 results in a germline-encoded antibody that catalyses the rearrangement of hexadiene 2 to aldehyde 3 with a rate approaching that of a related pericyclic reaction catalysed by the enzyme chorismate mutase(3). Affinity maturation gives antibody AZ-28, which has six amino acid substitutions, one of which results in a decrease in catalytic rate. To understand the relationship between binding and catalytic rate in this system we characterized a series of active-site mutants and determined the three-dimensional crystal structure of the complex of AZ-28 with the transition state analogue. This analysis indicates that the activation energy depends on a complex balance of several, stereoelectronic effects which are controlled by an extensive network of binding interactions in the active site, Thus in this instance the combinatorial diversity of the immune system provided both an efficient catalyst far a reaction where no enzyme is known, as well as an opportunity to explore the mechanisms and evolution of biological catalysis.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV MAT SCI, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley			Santarsiero, Bernard D/N-9249-2018; Stevens, Raymond/K-7272-2015	Santarsiero, Bernard D/0000-0002-9032-9699; Stevens, Raymond/0000-0002-4522-8725; Ulrich, Helle D./0000-0003-0431-2223				AKOLKAR PN, 1987, J IMMUNOL, V138, P4472; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BRAISTED AC, 1994, J AM CHEM SOC, V116, P2211, DOI 10.1021/ja00084a098; BRUNGER AT, 1996, X PLOR VERSION 3 851; DEWAR MJS, 1977, J AM CHEM SOC, V99, P4417, DOI 10.1021/ja00455a034; DOERING WVE, 1962, TETRAHEDRON, V18, P67; DRIGGERS EM, UNPUB J AM CHEM SOC; GAJEWSKI JJ, 1991, J AM CHEM SOC, V113, P967, DOI 10.1021/ja00003a033; GAJEWSKI JJ, 1980, ACCOUNTS CHEM RES, V13, P142, DOI 10.1021/ar50149a003; Haldane J.B.S., 1930, ENZYMES; JANDA KD, 1994, P NATL ACAD SCI USA, V91, P2532, DOI 10.1073/pnas.91.7.2532; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KUROSAWA Y, 1982, J EXP MED, V155, P201, DOI 10.1084/jem.155.1.201; NAHMIAS C, 1988, J IMMUNOL, V140, P1304; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI DOI 10.1021/CEN-V024N010.P1375; PECH M, 1981, NATURE, V291, P668, DOI 10.1038/291668a0; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; STEIGERWALD ML, 1979, J AM CHEM SOC, V101, P1994, DOI 10.1021/ja00502a011; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; STRONG RK, 1991, BIOCHEMISTRY-US, V30, P3739, DOI 10.1021/bi00229a022; TAWFIK DS, 1993, P NATL ACAD SCI USA, V90, P373, DOI 10.1073/pnas.90.2.373; ULRICH H, 1996, THESIS U CALIFORNIA; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; Ulrich HD, 1996, ACTA CHEM SCAND, V50, P328, DOI 10.3891/acta.chem.scand.50-0328; ULRICH HD, UNPUB J MOL BIOL; Woodward R. B., 1970, CONSERVATION ORBITAL	33	76	77	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	1997	389	6648					271	275		10.1038/38470	http://dx.doi.org/10.1038/38470			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XW772	9305839				2022-12-01	WOS:A1997XW77200043
J	PebayPeyroula, E; Rummel, G; Rosenbusch, JP; Landau, EM				PebayPeyroula, E; Rummel, G; Rosenbusch, JP; Landau, EM			X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases	SCIENCE			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; DRIVEN PROTON PUMP; HALOBACTERIUM-HALOBIUM; PURPLE MEMBRANE; 3-DIMENSIONAL CRYSTALS; ELECTRON-MICROSCOPY; NEUTRON-DIFFRACTION; MOLECULAR-DYNAMICS; TRANSLOCATION; LIGHT	Lipidic cubic phases provide a continuous three-dimensional bilayer matrix that facilitates nucleation and growth of bacteriorhodopsin microcrystals. The crystals diffract x-rays isotropically to 2.0 angstroms. The structure of this light-driven proton pump was solved at a resolution of 2.5 angstroms by molecular replacement, using previous results from electron crystallographic studies as a model, The earlier structure was generally confirmed, but several differences were found, including loop conformations and side chain residues, Eight water molecules are now identified experimentally in the proton pathway. These findings reveal the constituents of the proton translocation pathway in the ground state.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel	PebayPeyroula, E (corresponding author), UNIV GRENOBLE 1,CNRS,INST BIOL STRUCT,CEA,41 AVE MARTYRS,F-38027 GRENOBLE 1,FRANCE.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BLAUROCK AE, 1975, J MOL BIOL, V93, P139, DOI 10.1016/0022-2836(75)90124-2; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BROWN LS, 1995, J BIOL CHEM, V270, P27122, DOI 10.1074/jbc.270.45.27122; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; DENCHER NA, 1989, P NATL ACAD SCI USA, V86, P7876, DOI 10.1073/pnas.86.20.7876; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2023, DOI 10.1073/pnas.77.4.2023; FERRAND M, 1993, FEBS LETT, V327, P256, DOI 10.1016/0014-5793(93)80999-B; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HEBERLE J, UNPUB; HENDERSON R, 1975, J MOL BIOL, V93, P123, DOI 10.1016/0022-2836(75)90123-0; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1980, J MOL BIOL, V139, P99, DOI 10.1016/0022-2836(80)90298-3; HUMPHREY W, 1994, BIOCHEMISTRY-US, V33, P3668, DOI 10.1021/bi00178a025; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHORANA HG, 1979, P NATL ACAD SCI USA, V76, P5046, DOI 10.1073/pnas.76.10.5046; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KREBS MP, 1991, P NATL ACAD SCI USA, V88, P859, DOI 10.1073/pnas.88.3.859; Landau EM, 1997, J PHYS CHEM B, V101, P1935, DOI 10.1021/jp963347q; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; leCoutre J, 1996, FEBS LETT, V398, P333, DOI 10.1016/S0014-5793(96)01254-9; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; MICHEL H, 1980, P NATL ACAD SCI-BIOL, V77, P1283, DOI 10.1073/pnas.77.3.1283; MICHEL H, 1982, EMBO J, V1, P1267, DOI 10.1002/j.1460-2075.1982.tb00023.x; NI B, 1990, GENE, V90, P169, DOI 10.1016/0378-1119(90)90456-2; OESTERHELT D, 1992, J BIOENERG BIOMEMBR, V24, P181, DOI 10.1007/BF00762676; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P66; OVCHINNIKOV YA, 1979, FEBS LETT, V100, P219, DOI 10.1016/0014-5793(79)80338-5; PAPADOPOULOS G, 1990, J MOL BIOL, V214, P15, DOI 10.1016/0022-2836(90)90140-H; Riesle J, 1996, BIOCHEMISTRY-US, V35, P6635, DOI 10.1021/bi9600456; Russell VA, 1997, SCIENCE, V276, P575, DOI 10.1126/science.276.5312.575; SASAKI J, 1992, J BIOL CHEM, V267, P20782; SCHARNAGL C, 1995, J PHYS CHEM-US, V99, P7787, DOI 10.1021/j100019a068; SCHERTLER GFX, 1993, J MOL BIOL, V234, P156, DOI 10.1006/jmbi.1993.1570; SCHULTEN K, 1978, NATURE, V272, P85, DOI 10.1038/272085a0; SZARAZ S, 1994, BIOPHYS J, V67, P1706, DOI 10.1016/S0006-3495(94)80644-7; TAKEI H, 1994, J BIOL CHEM, V269, P7387; TITTOR J, 1994, BIOPHYS J, V67, P1682, DOI 10.1016/S0006-3495(94)80642-3; ULRICH AS, 1994, BIOCHEMISTRY-US, V33, P5370, DOI 10.1021/bi00184a003; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; WEISSBUCH I, 1995, ACTA CRYSTALLOGR B, V51, P115, DOI 10.1107/S0108768194012061; WILKINS MHF, 1971, NATURE-NEW BIOL, V230, P72, DOI 10.1038/newbio230072a0; Xu D, 1995, BIOPHYS J, V69, P2745, DOI 10.1016/S0006-3495(95)80146-3	48	800	815	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 12	1997	277	5332					1676	1681		10.1126/science.277.5332.1676	http://dx.doi.org/10.1126/science.277.5332.1676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV684	9287223				2022-12-01	WOS:A1997XV68400054
J	Leirs, H; Stenseth, NC; Nichols, JD; Hines, JE; Verhagen, R; Verheyen, W				Leirs, H; Stenseth, NC; Nichols, JD; Hines, JE; Verhagen, R; Verheyen, W			Stochastic seasonality and nonlinear density-dependent factors regulate population size in an African rodent	NATURE			English	Article							CAPTURE-RECAPTURE; TANZANIA; SURVIVAL; CYCLES; MODELS; RATS	Ecology has long been troubled by the controversy over how populations are regulated(1,2). Some ecologists focus on the role of environmental effects, whereas others argue that density-dependent feedback mechanisms are central(3-6). The relative importance of both processes is still hotly debated, but clear examples of both processes acting in the same population are rare(7,8). Key-factor analysis (regression of population changes on possible causal factors) and time-series analysis are often used to investigate the presence of density dependence, but such approaches may be biased and provide no information on actual demographic rates(9,10). Here we report on both density-dependent and density-independent effects in a murid rodent pest species, the multimammute rat Mastomys natalensis (Smith, 1834), using statistical capture-recapture models, Both effects occur simultaneously, but we also demonstrate that they do not affect all demographic rates in the same way. We have incorporated the obtained estimates of demographic rates in a population dynamics model and show that the observed dynamics are affected by stabilizing nonlinear density-dependent components coupled with strong deterministic and stochastic seasonal components.	UNIV OSLO,DEPT BIOL,DIV ZOOL,N-0316 OSLO,NORWAY; NATL BIOL SERV,PATUXENT WILDLIFE RES CTR,LAUREL,MD 20708; UNIV ANTWERP,RIJKSUNIV CTR ANTWERP,DEPT BIOL,B-2020 ANTWERP,BELGIUM	University of Oslo; University of Antwerp	Leirs, H (corresponding author), DANISH PEST INFESTAT LAB,SKOVBRYNET 14,DK-2800 LYNGBY,DENMARK.		Leirs, Herwig/B-8197-2008; Stenseth, Nils Chr./G-5212-2016	Leirs, Herwig/0000-0002-7612-5024; Stenseth, Nils Chr./0000-0002-1591-5399				Andrewartha H.G., 1954, DISTRIBUTION ABUNDAN; BROWNIE C, 1993, BIOMETRICS, V49, P1173, DOI 10.2307/2532259; COHEN JE, 1995, NATURE, V378, P610, DOI 10.1038/378610a0; Ebenman B., 1988, SIZE STRUCTURED POPU; GRANJON L, 1994, POL ECOL STUD, V30, P343; GRENFELL BT, 1992, NATURE, V355, P823, DOI 10.1038/355823a0; HINES JE, 1994, MSSURVTV USERS MANUA; HORNFELDT B, 1994, ECOLOGY, V75, P791, DOI 10.2307/1941735; HUBERT B, 1982, REV ECOL, V35, P73; ITO Y, 1972, OECOLOGIA, V10, P347, DOI 10.1007/BF00345737; KENDALL WL, 1992, WILDLIFE 2001 : POPULATIONS, P31; Krebs C.J., 1989, ECOLOGICAL METHODOLO; Kuno E., 1971, Researches Popul Ecol Kyoto Univ, V13, P28, DOI 10.1007/BF02522011; Lebreton J.-D., 1991, BIRD POPULATION STUD, P105; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; LEIRS H, 1994, J TROP ECOL, V10, P55, DOI 10.1017/S0266467400007719; Leirs H, 1996, J APPL ECOL, V33, P937, DOI 10.2307/2404675; LEIRS H, 1993, OIKOS, V68, P53, DOI 10.2307/3545308; NICHOLS JD, 1984, ACTA THERIOL, V29, P357, DOI 10.4098/AT.arch.84-35; Nicholson AJ, 1933, J ANIM ECOL, V2, P132, DOI 10.2307/954; OSTFELD RS, 1995, ECOLOGY, V76, P521, DOI 10.2307/1941210; OSTFELD RS, 1993, NATURE, V366, P259, DOI 10.1038/366259a0; Pollock K. H., 1982, J WILDLIFE MANAGE, V46, P757, DOI DOI 10.2307/3808568; POLLOCK KH, 1981, BIOMETRICS, V37, P521, DOI 10.2307/2530565; Putman RJ, 1996, MAMMAL REV, V26, P81, DOI 10.1111/j.1365-2907.1996.tb00148.x; Saitoh T, 1997, J ANIM ECOL, V66, P14, DOI 10.2307/5960; SUGIHARA G, 1995, NATURE, V378, P559, DOI 10.1038/378559a0; White A, 1996, P ROY SOC B-BIOL SCI, V263, P1731, DOI 10.1098/rspb.1996.0253; WOLDA H, 1993, OECOLOGIA, V95, P581, DOI 10.1007/BF00317444; [No title captured]	30	244	249	0	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					176	180		10.1038/38271	http://dx.doi.org/10.1038/38271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296494				2022-12-01	WOS:A1997XV75700047
J	Case, RB; Pierce, DW; HomBooher, N; Hart, CL; Vale, RD				Case, RB; Pierce, DW; HomBooher, N; Hart, CL; Vale, RD			The directional preference of kinesin motors is specified by an element outside of the motor catalytic domain	CELL			English	Article							DIRECTED MICROTUBULE MOTOR; STIMULATED ATP HYDROLYSIS; CRYSTAL-STRUCTURE; DIMERIC KINESIN; NCD PROTEIN; HEAVY-CHAIN; MOVEMENT; DROSOPHILA; MOLECULES; SEGREGATION	Members of the kinesin superfamily share a similar motor catalytic domain yet move either toward the plus end (e.g., conventional kinesin) or the minus end (e.g., Ncd) of microtubules. The structural features that determine the polarity of movement have remained enigmatic. Here, we show that kinesin's catalytic domain (316 residues) in a dimeric construct (560 residues) can be replaced with the catalytic domain of Ncd and that the resultant motor moves in the kinesin direction. We also demonstrate that this chimera does not move processively over many tubulin subunits, which is similar to Ncd but differs from the highly processive motion of conventional kinesin. These findings reveal that the catalytic domain contributes to motor processivity but does not control the polarity of movement. We propose that a region adjacent to the catalytic domain serves as a mechanical transducer that determines directionality.										Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G, 1995, PROTEIN PROFILE, V2, P1112; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GIBBONS IR, 1979, J BIOL CHEM, V254, P187; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; HYMAN AA, 1991, J CELL SCI S, V14, P125; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; LOCKHART A, 1994, EMBO J, V13, P751, DOI 10.1002/j.1460-2075.1994.tb06317.x; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; Morii H, 1997, BIOCHEMISTRY-US, V36, P1933, DOI 10.1021/bi962392l; MORRIS RL, 1997, IN PRESS J CELL BIOL; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; Pierce DW, 1997, NATURE, V388, P338, DOI 10.1038/41009; PIERCE DW, 1997, IN PRESS METH ENZYMO; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TAYLOR EW, 1993, NATURE, V361, P115, DOI 10.1038/361115a0; Tripet B, 1997, J BIOL CHEM, V272, P8946; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Vernos I, 1996, CURR OPIN CELL BIOL, V8, P4, DOI 10.1016/S0955-0674(96)80041-X; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	46	282	285	2	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					959	966		10.1016/S0092-8674(00)80360-8	http://dx.doi.org/10.1016/S0092-8674(00)80360-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298907	Bronze			2022-12-01	WOS:A1997XV56300016
J	Sewankambo, N; Gray, RH; Wawer, MJ; Paxton, L; McNairn, D; WabwireMangen, F; Serwadda, D; Li, CJ; Kiwanuka, N; Hillier, SL; Rabe, L; Gaydos, CA; Quinn, TC; KondeLule, J				Sewankambo, N; Gray, RH; Wawer, MJ; Paxton, L; McNairn, D; WabwireMangen, F; Serwadda, D; Li, CJ; Kiwanuka, N; Hillier, SL; Rabe, L; Gaydos, CA; Quinn, TC; KondeLule, J			HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; SEXUALLY-TRANSMITTED DISEASES; PELVIC INFLAMMATORY DISEASE; PREGNANT-WOMEN; GRAM STAIN; SEROPREVALENCE; TYPE-1; SYSTEM; HEALTH; COHORT	Background In-vitro research has suggested that bacterial vaginosis may increase the survival of HIV-1 in the genital tract. Therefore, we investigated the association of HIV-1 infection with vaginal flora abnormalities, including bacterial vaginosis and depletion of lactobacilli, after adjustment for sexual activity and the presence of other sexually transmitted diseases(STDs). Methods During the initial survey round of our community-based trial of STD control for HIV-1 prevention in rural Rakai District, southwestern Uganda, we selected 4718 women aged 15-59 years. They provided interview information, blood for HIV-1 and syphilis serology, urine for detection of Chlamydia trachomatis and Neisseria gonorrhoeae, and two self-administered vaginal swabs for culture of Trichomonas vaginalis and gram-stain detection of vaginal flora, classified by standardised, quantitative, morphological scoring. Scores 0-3 were normal vaginal flora (predominant lactobacilli). Higher scores suggested replacement of lactobacilli by gram-negative, anaerobic microorganisms (4-6 intermediate; 7-8 and 9-10 moderate and severe bacterial vaginosis). Findings HIV-1 frequency was 14.2% among women with normal vaginal flora and 26.7% among those with severe bacterial vaginosis (p<0.001). We found an association between bacterial vaginosis and increased HIV-1 infection among younger women, but not among women older than 40 years; the association could not be explained by differences in sexual activity or concurrent infection with other STDs. The frequency of bacterial vaginosis was similar among HIV-l-infected women with symptoms (55.0%) and without symptoms (55.7%). The adjusted odds ratio of HIV-1 infection associated with any vaginal flora abnormality (scores 4-10) was 1.52 (95% CI 1.22-1.90), for moderate bacterial vagniosis (scores 7-8) it was 1.50 (1.18-1.89), and for severe bacterial vaginosis (scores 9-10) it was 2.08 (1.48-2.94). Interpretation This cross-sectional study cannot show whether disturbed vaginal flora increases susceptibility to HIV-1 infection. Nevertheless, the increased frequency of HIV-1 associated with abnormal flora among younger women, for whom HIV-1 acquisition is likely to be recent, but not among older women, in whom HIV-1 is likely to have been acquired earlier, suggests that loss of lactobacilli or presence of bacterial vaginosis may increase susceptibility to HIV-1 acquisition. If this inference is correct, control of bacterial vaginosis could reduce HIV-1 transmission.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21205 USA; MAKERERE UNIV, KAMPALA, UGANDA; COLUMBIA UNIV, NEW YORK, NY USA; UGANDA VIRUS RES INST, RAKAI PROJECT, ENTEBBE, UGANDA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA	Johns Hopkins University; Makerere University; Columbia University; Uganda Virus Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Quinn, Thomas/A-2494-2010; Gaydos, Charlotte A./E-9937-2010	Sewankambo, Nelson/0000-0001-9362-053X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034826] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34826-03] Funding Source: Medline; NICHD NIH HHS [5P30HD06268] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		COHEN CR, 1995, AIDS, V9, P1093, DOI 10.1097/00002030-199509000-00017; DRAPER D, 1993, J CLIN MICROBIOL, V31, P1016, DOI 10.1128/JCM.31.4.1016-1018.1993; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HILL JA, 1992, AM J OBSTET GYNECOL, V166, P720, DOI 10.1016/0002-9378(92)91703-D; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; HILLIER SL, 1993, AM J OBSTET GYNECOL, V169, P455, DOI 10.1016/0002-9378(93)90340-O; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; KAMENGA MC, 1995, AM J OBSTET GYNECOL, V172, P919, DOI 10.1016/0002-9378(95)90022-5; KLEBANOFF SJ, 1991, J EXP MED, V174, P289, DOI 10.1084/jem.174.1.289; KORN AP, 1995, OBSTET GYNECOL, V85, P387, DOI 10.1016/0029-7844(94)00400-8; KORN AP, 1995, J ACQ IMMUN DEF SYND, V9, P361; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MARTIN HL, 1996, 11 INT C AIDS JUL, P7; MONTANER JSG, 1992, AIDS, V6, P719, DOI 10.1097/00002030-199207000-00016; MULDER D, 1995, BRIT MED J, V311, P833, DOI 10.1136/bmj.311.7009.833; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; PAAVONEN J, 1987, BRIT J OBSTET GYNAEC, V94, P454, DOI 10.1111/j.1471-0528.1987.tb03125.x; SMITH KR, 1995, J CLIN MICROBIOL, V33, P455, DOI 10.1128/JCM.33.2.455-457.1995; SWEET RL, 1993, AM J OBSTET GYNECOL, V169, P479, DOI 10.1016/0002-9378(93)90346-K; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303	23	444	461	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	1997	350	9077					546	550		10.1016/S0140-6736(97)01063-5	http://dx.doi.org/10.1016/S0140-6736(97)01063-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT221	9284776	hybrid			2022-12-01	WOS:A1997XT22100009
J	Thorpe, CJ; Schlesinger, A; Carter, JC; Bowerman, B				Thorpe, CJ; Schlesinger, A; Carter, JC; Bowerman, B			Wnt signaling polarizes an early C-elegans blastomere to distinguish endoderm from mesoderm	CELL			English	Article							ASYMMETRIC CELL DIVISIONS; CAENORHABDITIS-ELEGANS; MATERNAL GENES; EMBRYOS; GLP-1; PROTEIN; AXES; GUT; IDENTIFICATION; ESTABLISHMENT	A polarizing signal induces endoderm production by a 4-cell stage blastomere in C. elegans called EMS. We identified 16 mutations in five genes, mom-1 through mom-5, required for EMS to produce endoderm. mom-1, mom-2, and mom-3 are required in the signaling cell, P-2, while mom-4 is required in EMS. P-2 signaling downregulates an HMG domain protein, POP-1, in one EMS daughter. The sequence of mom-2 predicts that it encodes a member of the Wnt family of secreted glycoproteins, which in other systems activate HMG domain proteins. Defective mitotic spindle orientations in mom mutant embryos indicate that Wnt signaling influences cytoskeletal polarity in blastomeres throughout the early embryo.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NICHD NIH HHS [HD07348] Funding Source: Medline; NIGMS NIH HHS [GM07413, GM49869] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BRENNER S, 1974, GENETICS, V77, P71; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; DU SJ, 1995, MOL CELL BIOL, V15, P2625; EDGAR LG, 1995, CAENORHABDITIS ELEGA, P303; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1995, J CELL BIOL, V129, P1071, DOI 10.1083/jcb.129.4.1071; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1227; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; Gonczy P, 1996, TRENDS CELL BIOL, V6, P382, DOI 10.1016/0962-8924(96)10035-0; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Hird SN, 1996, DEVELOPMENT, V122, P1303; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HUTTER H, 1994, DEVELOPMENT, V120, P2051; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MANGO SE, 1994, DEVELOPMENT, V120, P3019; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Merriam JM, 1997, DEV BIOL, V185, P67, DOI 10.1006/dbio.1997.8550; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; Shelton CA, 1996, DEVELOPMENT, V122, P2043; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	43	409	425	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					695	705		10.1016/S0092-8674(00)80530-9	http://dx.doi.org/10.1016/S0092-8674(00)80530-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288749	Bronze			2022-12-01	WOS:A1997XT06600013
J	Lakshmi, BB; Martin, CR				Lakshmi, BB; Martin, CR			Enantioseparation using apoenzymes immobilized in a porous polymeric membrane	NATURE			English	Article							ENZYME-FACILITATED TRANSPORT; ALPHA-AMINO-ACID; OPTICAL RESOLUTION; ORGANIC-ACIDS; SEPARATION; SURFACE	Chemical separations represent a large portion of the cost of bringing any new pharmaceutical product to the market. Membrane-based separation technologies(1,2), in which the target molecule is selectively extracted and transported across a membrane, are potentially more economical and easier to implement than competing separations methods; but membranes with higher transport selectivities are required, Here we describe an approach for preparing highly selective membranes which involves immobilizing apoenzymes within a microporous composite. The apoenzyme selectively recognizes its substrate molecule and transports it across the composite membrane, without effecting the unwanted chemical conversion of the substrate molecule to product, We demonstrate this approach using three different apoenzymes, Most importantly, it can be used to make enantioselective membranes for chiral separations, one of the most challenging and important problems in bioseparations technology, We are able to achieve a fivefold difference between the transport rates of D-and L-amino acids.	COLORADO STATE UNIV,DEPT CHEM,FT COLLINS,CO 80523	Colorado State University			Martin, Charles/AAA-1040-2019					[Anonymous], 1991, MEMBRANE SEPARATION; BORMAN S, 1990, CHEM ENG NEWS, V68, P9, DOI 10.1021/cen-v068n028.p009; BOYER PD, 1975, ENZYMES; Chen XS, 1996, B CHEM SOC JPN, V69, P255, DOI 10.1246/bcsj.69.255; Collins A.N., 1992, CHIRALITY IND; DIXON M, 1965, BIOCHIM BIOPHYS ACTA, V96, P368, DOI 10.1016/0005-2787(65)90557-5; DORDICK JS, 1989, BIOCATALYSTS IND, P311; HIGUCHI A, 1993, DESALINATION, V90, P127, DOI 10.1016/0011-9164(93)80170-R; HIGUCHI A, 1994, J MEMBRANE SCI, V93, P157, DOI 10.1016/0376-7388(94)80004-9; JENSEN RD, 1994, SCIENCE, V263, P1425; KAKUCHI T, 1990, POLYM J, V22, P199, DOI 10.1295/polymj.22.199; LAKSHMI B, UNPUB; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; Martin CR, 1996, CHEM MATER, V8, P1739, DOI 10.1021/cm960166s; MARUYAMA A, 1990, MACROMOLECULES, V23, P2748, DOI 10.1021/ma00212a027; MATSON SL, 1989, FRONTIERS BIOPROCESS; NISHIZAWA M, 1995, SCIENCE, V268, P700, DOI 10.1126/science.268.5211.700; NOBLE RD, 1989, CHEM ENG PROG, V85, P58; NOBLE RD, 1992, J MEMBRANE SCI, V75, P121, DOI 10.1016/0376-7388(92)80011-8; PARTHASARATHY A, 1994, J MEMBRANE SCI, V94, P249, DOI 10.1016/0376-7388(93)E0206-Y; PARTHASARATHY RV, 1994, NATURE, V369, P298, DOI 10.1038/369298a0; PENNER RM, 1988, J PHYS CHEM-US, V92, P5274, DOI 10.1021/j100329a042; RETHWISCH DG, 1994, J MEMBRANE SCI, V95, P83, DOI 10.1016/0376-7388(94)85031-3; RETHWISCH DG, 1990, J AM CHEM SOC, V112, P1649, DOI 10.1021/ja00160a065; SCHOLANDER PF, 1960, SCIENCE, V131, P585, DOI 10.1126/science.131.3400.585; STANLEY TJ, 1987, CHEM ENG SCI, V42, P2313, DOI 10.1016/0009-2509(87)80104-5; STEIN WD, 1967, MOVEMENT MOL ACROSS; STINSON SC, 1995, CHEM ENG NEWS, V73, P44, DOI 10.1021/cen-v073n041.p044; Winston W.S., 1992, MEMBRANE HDB; Worthington CC, 1988, WORTHINGTON MANUAL; YOSHIKAWA M, 1995, J MEMBRANE SCI, V108, P171, DOI 10.1016/0376-7388(95)00160-8	31	145	152	6	75	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					758	760		10.1038/41978	http://dx.doi.org/10.1038/41978			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285586				2022-12-01	WOS:A1997XR66700046
J	Speller, DCE; Johnson, AP; James, D; Marples, RR; Charlett, A; George, RC				Speller, DCE; Johnson, AP; James, D; Marples, RR; Charlett, A; George, RC			Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95	LANCET			English	Article							VIRULENCE	Background Methicillin-resistant Staphylococcus aureus (MRSA) strains are colonising hospital patients in most areas of England and Wales, UK. The extent to which they cause invasive infection can be gauged from their presence in isolates from blood or cerebrospinal fluid. Methods About 200 clinical laboratories reported the results of susceptibility testing of between 4501 and 6370 isolates of S aureus from blood or cerebrospinal fluid in each of the years 1989-95. We assessed the rate of resistance to methicillin and other antibiotics for each of these years. Findings Resistance to methicillin was stable at about 1.5% of isolates during 1989-91, but increased thereafter to 13.2% in 1995 (p<0.001). At the same time there was a significant increase in the percentage of isolates resistant to erythromycin, clindamycin, ciprofloxacin, gentamicin, trimethoprim, and rifampicin (p<0.001 for each)-resistance characteristics often seen in MRSA. Resistance to benzylpenicillin increased slightly but significantly (p>0.001); resistance to fusidic acid was stable (p>0.05); resistance to tetracycline decreased significantly (P<0.001). Interpretation Among cases of S aureus bacteraemia, the proportion due to MRSA has increased significantly. Bacteraemia due to MRSA has a poor prognosis, especially if not treated with suitable antibiotics. Therefore, these findings are important, especially for management of patients and the development of antibiotic policies.	CENT PUBL HLTH LAB,LAB HOSP INFECT,LONDON NW9 5HT,ENGLAND; CENT PUBL HLTH LAB,RESP & SYST INFECT LAB,LONDON NW9 5HT,ENGLAND; CENT PUBL HLTH LAB,STAT UNIT,LONDON NW9 5HT,ENGLAND	Public Health England; Public Health England; Public Health England			Johnson, Alan P/F-4420-2014					CASEWELL MW, 1995, J HOSP INFECT, V30, P465, DOI 10.1016/0195-6701(95)90050-0; FRENCH GL, 1990, J HOSP INFECT, V15, P117, DOI 10.1016/0195-6701(90)90120-D; HERSHOW RC, 1992, INFECT CONT HOSP EP, V13, P587, DOI 10.2307/30148461; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; LACEY RW, 1987, J HOSP INFECT, V9, P103, DOI 10.1016/0195-6701(87)90046-6; MACKINTOSH CA, 1991, J HOSP INFECT, V18, P279, DOI 10.1016/0195-6701(91)90185-B; Marples R R, 1992, Commun Dis Rep CDR Rev, V2, pR25; SNELL JJS, 1994, J ANTIMICROB CHEMOTH, V33, P1, DOI 10.1093/jac/33.1.1; WENZEL RP, 1991, AM J MED, V91, pS221, DOI 10.1016/0002-9343(91)90372-5; 1995, J HOSP INFECT, V31, P1; 1997, COMMUN DIS REP CDR W, V6, P191	11	133	138	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					323	325		10.1016/S0140-6736(97)12148-1	http://dx.doi.org/10.1016/S0140-6736(97)12148-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251636				2022-12-01	WOS:A1997XP24200009
J	Gunshin, H; Mackenzie, B; Berger, UV; Gunshin, Y; Romero, MF; Boron, WF; Nussberger, S; Gollan, JL; Hediger, MA				Gunshin, H; Mackenzie, B; Berger, UV; Gunshin, Y; Romero, MF; Boron, WF; Nussberger, S; Gollan, JL; Hediger, MA			Cloning and characterization of a mammalian proton-coupled metal-ion transporter	NATURE			English	Article							RAT SMALL-INTESTINE; INTRACELLULAR PARASITES; NATURAL-RESISTANCE; XENOPUS-OOCYTES; MESSENGER-RNA; IRON; CELLS; COTRANSPORTER; INFECTION; REDUCTION	Metal ions are essential cofactors for a wealth of biological processes, including oxidative phosphorylation, gene regulation and free-radical homeostasis. Failure to maintain appropriate levels of metal ions in humans is a feature of hereditary haemoduomatosis(1), disorders of metal-ion deficiency, and certain neurodegenerative diseases(2). Despite their pivotal physiological roles, however, there is no molecular information on how metal ions are actively absorbed by mammalian cells. We have now identified a new metal-ion transporter in the rat, DCT1, which has an unusually broad substrate range that includes Fe2+ Zn2+, Mn2+, Co2+, Cd2+, Cu2+, Ni2+, and Pb2+. DCT1 mediates active transport that is proton-coupled and depends on the cell membrane potential, It is a 561-amino-acid protein with 12 putative membrane-spanning domains and is ubiquitously expressed, most notably in the proximal duodenum. DCT1 is upregulated by dietary iron deficiency, and may represent a key mediator of intestinal iron absorption. DCT1 is a member of the 'natural-resistance-associated macrophage protein' (Nramp) family(3-5) and thus its properties provide insight into how these proteins confer resistance to pathogens.	YALE UNIV,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06510; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GASTROENTEROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Yale University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gunshin, H (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,77 AVE LOUIS PASTEUR,BOSTON,MA 02115, USA.		Boron, Walter/ABI-1564-2020	Romero, Michael F/0000-0002-1555-7835; Nussberger, Stephan/0000-0003-3619-4452; Boron, Walter/0000-0003-4741-7287; Mackenzie, Bryan/0000-0002-9661-8838; Hediger, Matthias/0000-0003-1946-027X	NIDDK NIH HHS [F32 DK009342-01, F32 DK009342-02, F32 DK009342, F32 DK009342-03] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009342] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOORER KJ, 1994, J BIOL CHEM, V269, P20417; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; Conrad ME, 1996, J CLIN INVEST, V98, P1449, DOI 10.1172/JCI118933; DOREY C, 1993, BRIT J NUTR, V70, P157, DOI 10.1079/BJN19930113; EIDE DJ, IN PRESS CURR OPIN C; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GRUENHEID S, 1995, GENOMICS, V25, P514, DOI 10.1016/0888-7543(95)80053-O; GUNSHIN H, 1991, AGR BIOL CHEM TOKYO, V55, P2813, DOI 10.1080/00021369.1991.10857152; HAN O, 1995, J NUTR, V125, P1291; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HIRSCH EC, 1997, MOL NEUROL, V94, P135; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; JORDAN I, 1994, BIOCHEM J, V302, P875, DOI 10.1042/bj3020875; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MACKENZIE B, UNPUB COUPLING STOIC; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MCEWAN GTA, 1988, PROC R SOC SER B-BIO, V234, P219, DOI 10.1098/rspb.1988.0045; NICHOLS GM, 1989, AM J GASTROENTEROL, V84, P851; Nussberger S, 1997, J BIOL CHEM, V272, P7777, DOI 10.1074/jbc.272.12.7777; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; RAJA KB, 1992, BIOCHIM BIOPHYS ACTA, V1135, P141, DOI 10.1016/0167-4889(92)90129-Y; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VIDAL S, 1995, J LEUKOCYTE BIOL, V58, P382, DOI 10.1002/jlb.58.4.382; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D	30	2507	2609	7	180	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					482	488		10.1038/41343	http://dx.doi.org/10.1038/41343			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242408				2022-12-01	WOS:A1997XN55300051
J	Killcross, S; Robbins, TW; Everitt, BJ				Killcross, S; Robbins, TW; Everitt, BJ			Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala	NATURE			English	Article							POTENTIATED STARTLE; MEMORY; ORGANIZATION; HIPPOCAMPUS; ANXIETY; EMOTION; LESIONS; SYSTEM; BRAIN	The amygdala has long been thought to be involved in emotional behaviour(1,2), and its role in anxiety and conditioned fear has been highlighted(3,4). Individual amygdaloid nuclei have been shown to project to various cortical and subcortical regions implicated in affective processing(5-7). Here we show that some of these nuclei have separate roles in distinct mechanisms underlying conditioned fear responses. Rats with lesions of the central nucleus exhibited reduction in the suppression of behaviour elicited by a conditioned fear stimulus, but were simultaneously able to direct their actions to avoid further presentations of this aversive stimulus. In contrast, animals with lesions of the basolateral amygdala were unable to avoid the conditioned aversive stimulus by their choice behaviour, but exhibited normal conditioned suppression to this stimulus. This double dissociation demonstrates that distinct neural systems involving separate amygdaloid nuclei mediate different types of conditioned fear behaviour. We suggest that theories of amygdala function should take into account the roles of discrete amygdala subsystems in controlling different components of integrated emotional responses.			Killcross, S (corresponding author), UNIV CAMBRIDGE, DEPT EXPT PSYCHOL, DOWNING ST, CAMBRIDGE CB2 3EB, ENGLAND.		anand, amit/A-7222-2009; Killcross, Simon/N-1426-2019; Robbins, Trevor W/A-7551-2008; Killcross, Simon/A-4113-2009	Killcross, Simon/0000-0002-5571-548X; Robbins, Trevor/0000-0003-0642-5977; Everitt, Barry/0000-0003-4431-6536				ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; AMARAL D G, 1992, P1; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; BOUTON ME, 1980, ANIM LEARN BEHAV, V8, P429, DOI 10.3758/BF03199629; Cahill L, 1996, P NATL ACAD SCI USA, V93, P8016, DOI 10.1073/pnas.93.15.8016; CAHILL L, 1995, NATURE, V377, P295, DOI 10.1038/377295a0; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; DAMASIO AR, 1994, DESCARTES ERROR; DAVIS M, 1987, PSYCHOL LEARN MOTIV, V21, P263; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; EVERITT B J, 1992, P401; EVERITT BJ, 1991, NEUROSCIENCE, V42, P1, DOI 10.1016/0306-4522(91)90145-E; Gallagher M, 1996, CURR OPIN NEUROBIOL, V6, P221, DOI 10.1016/S0959-4388(96)80076-6; GROENEWEGEN HJ, 1990, PROG BRAIN RES, V85, P95; Kapp BS, 1984, NEUROPSYCHOLOGY MEMO, P473; Kluver H, 1939, ARCH NEURO PSYCHIATR, V42, P979; LeDoux J.E., 1996, EMOTIONAL BRAIN; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; Maren S, 1996, BEHAV NEUROSCI, V110, P718, DOI 10.1037/0735-7044.110.4.718; Mowrer OH, 1947, HARVARD EDUC REV, V17, P102; MOWRER OH, 1954, AM J PSYCHOL, V67, P15, DOI 10.2307/1418068; PARENT MB, 1992, BEHAV NEUROSCI, V106, P789, DOI 10.1037/0735-7044.106.5.789; SANANES CB, 1992, BEHAV NEUROSCI, V106, P72, DOI 10.1037/0735-7044.106.1.72; Scott SK, 1997, NATURE, V385, P254, DOI 10.1038/385254a0; SELDEN NRW, 1991, NEUROSCIENCE, V42, P335, DOI 10.1016/0306-4522(91)90379-3; Swanson L. W, 1992, BRAIN MAPS STRUCTURE; THOMPSON RF, 1994, ANNU REV NEUROSCI, V17, P519, DOI 10.1146/annurev.neuro.17.1.519; Wan FJ, 1997, NEUROSCIENCE, V76, P715, DOI 10.1016/S0306-4522(96)00218-7; WEISKRANTZ L, 1956, J COMP PHYSIOL PSYCH, V49, P381, DOI 10.1037/h0088009	30	517	523	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 24	1997	388	6640					377	380		10.1038/41097	http://dx.doi.org/10.1038/41097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237754				2022-12-01	WOS:A1997XM52800050
J	Cohen, MS; Hoffman, IF; Royce, RA; Kazembe, P; Dyer, JR; Daly, CC; Zimba, D; Vernazza, PL; Maida, M; Fiscus, SA; Eron, JJ; Nkata, E; Kachenje, E; Banda, T; Mughogho, G; Koller, C; Schock, J; Chakraborty, H; Dallabetta, G; Gilliam, B				Cohen, MS; Hoffman, IF; Royce, RA; Kazembe, P; Dyer, JR; Daly, CC; Zimba, D; Vernazza, PL; Maida, M; Fiscus, SA; Eron, JJ; Nkata, E; Kachenje, E; Banda, T; Mughogho, G; Koller, C; Schock, J; Chakraborty, H; Dallabetta, G; Gilliam, B			Reduction of concentration of HIV-1, in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMITTED DISEASES; CHLAMYDIA-TRACHOMATIS; NEISSERIA-GONORRHOEAE; INFECTION; MEN; ASSOCIATION; THERAPY; SPREAD; MALAWI	Background transmission of HIV-1 is predominantly by heterosexual contact in sub-Saharan Africa, where sexually transmitted diseases (STDs) are also common. Epidemiological studies suggest that STDs facilitate transmission of HIV-1, but the biological mechanism remains unclear, We investigated the hypothesis that STDs increase the likelihood of transmission of HIV-1 through increased concentration of the virus in semen. Methods HIV-1 RNA concentrations were measured in seminal and blood plasma from 135 HIV-1-seropositive men in Malawi; 86 had urethritis and 49 controls did not have urethritis. Men with urethritis received antibiotic treatment according to the guidelines of the Malawian STD Advisory Committee. Samples were analysed at baseline and at week 1 and week 2 after antibiotic therapy in urethritis patients, and at baseline and week 2 in the control group. Findings HIV-1-seropositive men with urethritis had HIV-1 RNA concentrations in seminal plasma eight times higher than those in seropositive men without urethritis (12.4 vs 1.51x10(4) copies/mL, p=0.035), despite similar CD4 counts and concentrations of blood plasma viral RNA. Gonorrhoea was associated with the greatest concentration of HIV-1 in semen (15.8x10(4) copies/mL). After the urethritis patients received antimicrobial therapy directed against STDs, the concentration of HIV-1 RNA in semen decreased significantly (from 12.4x10(4) copies/mL to 8.91x10(4) copies/mL at 1 week [p=0.03] and 4.12x10(4) copies/mL at 2 weeks [p=0.0001]). Blood plasma viral RNA concentrations did not change. There was no significant change in seminal plasma HIV-1 RNA concentrations during the 2-week period in the control group (p=0.421). These results suggest that urethritis increases the infectiousness of men with HIV-1 infection. HIV-1-control programmes, which include detection and treatment of STDs in patients already infected with HIV-1, may help to curb the epidemic. Targeting of gonococcal urethritis may be a particularly effective strategy.	UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,AIDSCAP,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT EPIDEMIOL,CHAPEL HILL,NC 27599; LILONGWE CENT HOSP,LILONGWE,MALAWI; JOHN SNOW INC,MALAWI SUPPORT AIDS & FAMILY HLTH PROJECT,BOSTON,MA; KANTONSSPITAL,DEPT MED,ST GALLEN,SWITZERLAND	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	Cohen, MS (corresponding author), UNIV N CAROLINA,DEPT MED,CB 7030,547 BURNETT WOMACK BLDG,CHAPEL HILL,NC 27599, USA.		Royce, Rachel A/A-7964-2012		PHS HHS [UO31496, R0149381] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atkins MC, 1996, BRIT MED J, V313, P341, DOI 10.1136/bmj.313.7053.341; BEHETS FMT, 1995, J INFECT DIS, V171, P451, DOI 10.1093/infdis/171.2.451; Busch MP, 1996, J INFECT DIS, V174, P26, DOI 10.1093/infdis/174.1.26; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; Dickerson MC, 1996, SEX TRANSM DIS, V23, P429, DOI 10.1097/00007435-199609000-00015; Dyer JR, 1996, J VIROL METHODS, V60, P161, DOI 10.1016/0166-0934(96)02063-0; Eron JJ, 1996, JAMA-J AM MED ASSOC, V275, P36, DOI 10.1001/jama.275.1.36; ERON JJ, 1997, 4 C RETR OPP INF WAS; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; Fowke KR, 1996, LANCET, V348, P1347, DOI 10.1016/S0140-6736(95)12269-2; GARNETT GP, 1995, J ACQ IMMUN DEF SYND, V9, P500; GILLIAM BL, IN PRESS J ACQUIR IM; GOBBERS E, 1996, 11 INT C AIDS VANC J; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HAIZLIP J, 1995, SEX TRANSM DIS, V22, P145, DOI 10.1097/00007435-199505000-00002; HO JL, 1995, J EXP MED, V181, P1493, DOI 10.1084/jem.181.4.1493; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kissinger P, 1996, J GEN INTERN MED, V11, P750, DOI 10.1007/BF02598989; KIVIAT NB, 1990, HUM PATHOL, V21, P831, DOI 10.1016/0046-8177(90)90052-7; KREISS J, 1994, J INFECT DIS, V170, P1597, DOI 10.1093/infdis/170.6.1597; KRIEGER JN, 1995, J UROLOGY, V154, P1035, DOI 10.1016/S0022-5347(01)66969-6; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Lee TH, 1996, J ACQ IMMUN DEF SYND, V12, P427, DOI 10.1097/00042560-199608010-00015; LULE G, 1994, GENITOURIN MED, V70, P384; MERSON MH, 1993, SCIENCE, V260, P1266, DOI 10.1126/science.8493570; MOSS GB, 1995, J INFECT DIS, V172, P1469, DOI 10.1093/infdis/172.6.1469; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; RAMSEY KH, 1995, J INFECT DIS, V172, P186, DOI 10.1093/infdis/172.1.186; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; SPECK CE, 1996, 11 INT C AIDS VANC; VERNAZZA P, IN PRESS AIDS; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996	34	685	701	0	23	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1868	1873		10.1016/S0140-6736(97)02190-9	http://dx.doi.org/10.1016/S0140-6736(97)02190-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217758				2022-12-01	WOS:A1997XG41700009
J	Ames, JB; Ishima, R; Tanaka, T; Gordon, JI; Stryer, L; Ikura, M				Ames, JB; Ishima, R; Tanaka, T; Gordon, JI; Stryer, L; Ikura, M			Molecular mechanics of calcium-myristoyl switches	NATURE			English	Article							RHODOPSIN KINASE; RECOVERIN; PROTEIN; BINDING; SYSTEM; RESOLUTION; TERMINUS; FAMILY	Many eukaryotic cellular and viral proteins have a covalently attached myristoyl group at the amino terminus. One such protein is recovering a calcium sensor in retinal rod cells, which controls the lifetime of photoexited rhodopsin by inhibiting rhodopsin kinase(1-6). Recoverin has a relative molecular mass of 23,000 (M-r 23K), and contains an amino-terminal myristoyl group (or related acyl group) and four EF hands(7). The binding of two Ca2+ ions to rccoverin leads to its translocation from the cytosol to the disc membraned(8,9). In the Ca2+-free state, the myristoyl group is sequestered in a deep hydrophobic box, where it is clamped by multiple residues contributed by three of the EF hands(10). We have used nuclear magnetic resonance to show that Ca2+ induces the unclamping and extrusion of the myristoyl group, enabling it to interact with a lipid bilayer membrane. The transition is also accompanied by a 45-degree rotation of the amino-terminal domain relative to the carboxy-terminal domain, and many hydrophobic residues are exposed. The conservation of the myristoyl binding site and two swivels in recoverin homologues from yeast to humans indicates that calcium-myristoyl switches are ancient devices for controlling calcium-sensitive processes.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; UNIV TORONTO,ONTARIO CANC INST,DIV MOL & STRUCT BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	Stanford University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba; University of Tsukuba; Washington University (WUSTL)				Ikura, Mitsuhiko/0000-0002-9524-1303				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HUGHES RE, 1995, BIOCHEMISTRY-US, V34, P11410, DOI 10.1021/bi00036a013; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KELLER MPG, 1993, NEURON, V10, P523; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	29	411	416	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 11	1997	389	6647					198	202		10.1038/38310	http://dx.doi.org/10.1038/38310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV757	9296500				2022-12-01	WOS:A1997XV75700053
J	Lijam, N; Paylor, R; McDonald, MP; Crawley, JN; Deng, CX; Herrup, K; Stevens, KE; Maccaferri, G; McBain, CJ; Sussman, DJ; WynshawBoris, A				Lijam, N; Paylor, R; McDonald, MP; Crawley, JN; Deng, CX; Herrup, K; Stevens, KE; Maccaferri, G; McBain, CJ; Sussman, DJ; WynshawBoris, A			Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1	CELL			English	Article							SEGMENT-POLARITY GENE; PREPULSE INHIBITION; ACOUSTIC STARTLE; SCHIZOPHRENIC-PATIENTS; INBRED STRAINS; ANIMAL-MODEL; DROSOPHILA; STIMULATION; DEFICITS; HABITUATION	Mice completely deficient for Dvl1, one of three mouse homologs of the Drosophila segment polarity gene Dishevelled, were created by gene targeting. Dv1-deficient mice are viable, fertile, and structurally normal. Surprisingly, these mice exhibited reduced social interaction, including differences in whisker trimming, deficits in nest-building, less huddling contact during home cage sleeping, and subordinate responses in a social dominance test. Sensorimotor gating was abnormal, as measured by deficits in prepulse inhibition of acoustic and tactile startle. Thus, Dv1 mutants may provide a model for aspects of several human psychiatric disorders. These results are consistent with an interpretation that common genetic mechanisms underlie abnormal social behavior and sensorimotor gating deficits and implicate Dvl1 in processes underlying complex behaviors.	NIMH,SECT BEHAV NEUROPHARMACOL,EXPT THERAPEUT BRANCH,BETHESDA,MD 20892; NIDDK,BIOCHEM & METAB LAB,BETHESDA,MD 20892; NICHHD,LAB CELLULAR & MOL NEUROPHYSIOL,NATL INST HLTH,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; UNIV COLORADO,HLTH SCI CTR,DEPT PSYCHIAT,DENVER,CO 80262; UNIV MARYLAND,SCH MED,DIV HUMAN GENET,BALTIMORE,MD 21201	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University System of Maryland; University of Maryland Baltimore	Lijam, N (corresponding author), NATL HUMAN GENOME RES INST,LAB GENET DIS RES,BETHESDA,MD 20892, USA.		deng, chuxia/N-6713-2016; Herrup, Karl/C-5313-2014	McDonald, Michael P./0000-0002-9642-964X; Herrup, Karl/0000-0001-7786-5844	NATIONAL CANCER INSTITUTE [R55CA063929, R01CA063929] Funding Source: NIH RePORTER; NCI NIH HHS [CA63929] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKSHI VP, 1994, J PHARMACOL EXP THER, V271, P787; BEIER DR, 1992, P NATL ACAD SCI USA, V89, P9102, DOI 10.1073/pnas.89.19.9102; BRAFF D, 1978, PSYCHOPHYSIOLOGY, V15, P339, DOI 10.1111/j.1469-8986.1978.tb01390.x; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; CADENHEAD KS, 1993, AM J PSYCHIAT, V150, P1862; Castellanos FX, 1996, BIOL PSYCHIAT, V39, P33, DOI 10.1016/0006-3223(95)00101-8; CIARANELLO AL, 1995, ANNU REV NEUROSCI, V18, P101, DOI 10.1146/annurev.ne.18.030195.000533; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; DAVIS M, 1982, J NEUROSCI, V2, P791; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; GEYER MA, 1987, SCHIZOPHRENIA BULL, V13, P643, DOI 10.1093/schbul/13.4.643; GEYER MA, 1993, BIOL PSYCHIAT, V34, P361, DOI 10.1016/0006-3223(93)90180-L; GRAHAM FK, 1975, PSYCHOPHYSIOLOGY, V12, P238, DOI 10.1111/j.1469-8986.1975.tb01284.x; GRANT E. C, 1963, BEHAVIOUR, V21, P246, DOI 10.1163/156853963X00185; GRILLON C, 1992, BIOL PSYCHIAT, V32, P939, DOI 10.1016/0006-3223(92)90183-Z; Hahn ME, 1996, BEHAV GENET, V26, P463, DOI 10.1007/BF02359750; HARLOW E, 1988, J HERED, V43, P77; ISON JR, 1973, PHYSIOL BEHAV, V10, P1036; JOHANSSON C, 1995, PHARMACOL BIOCHEM BE, V52, P649, DOI 10.1016/0091-3057(95)00160-X; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; LIJAM N, 1996, GENOME RES, V5, P116; LINDZEY G, 1961, NATURE, V191, P474, DOI 10.1038/191474a0; LONG SY, 1972, ANIM BEHAV, V20, P10, DOI 10.1016/S0003-3472(72)80167-2; Luna L.G., 1992, HISTOPATHOLOGICAL ME; Maccaferri G, 1996, J NEUROSCI, V16, P5334; MANSBACH RS, 1988, PSYCHOPHARMACOLOGY, V94, P507, DOI 10.1007/BF00212846; MCDOWD JM, 1993, SCHIZOPHRENIA BULL, V19, P733, DOI 10.1093/schbul/19.4.733; MESSERI P, 1975, PHYSIOL BEHAV, V14, P53, DOI 10.1016/0031-9384(75)90141-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Murphy KC, 1996, J MOL NEUROSCI, V7, P147, DOI 10.1007/BF02736794; Paylor R, 1997, PSYCHOPHARMACOLOGY, V132, P169, DOI 10.1007/s002130050333; Paylor R, 1996, BEHAV NEUROSCI, V110, P1415, DOI 10.1037/0735-7044.110.6.1415; PICKAR D, 1995, LANCET, V345, P557, DOI 10.1016/S0140-6736(95)90469-7; Pizzuti A, 1996, AM J HUM GENET, V58, P722; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; Steitz SA, 1996, IN VITRO CELL DEV-AN, V32, P441, DOI 10.1007/BF02723007; STROZIK E, 1981, LAB ANIM, V15, P309, DOI 10.1258/002367781780953040; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; SWERDLOW NR, 1995, J NEUROL NEUROSUR PS, V58, P192, DOI 10.1136/jnnp.58.2.192; SWERDLOW NR, 1994, ARCH GEN PSYCHIAT, V51, P139; SWERDLOW NR, 1993, BIOL PSYCHIAT, V33, P298, DOI 10.1016/0006-3223(93)90300-3; THEISEN H, 1994, DEVELOPMENT, V120, P347; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; WILKINSON LS, 1994, NEUROPSYCHOPHARMACOL, V10, P61, DOI 10.1038/npp.1994.8; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	51	373	392	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					895	905		10.1016/S0092-8674(00)80354-2	http://dx.doi.org/10.1016/S0092-8674(00)80354-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298901	Bronze			2022-12-01	WOS:A1997XV56300010
J	Panning, B; Dausman, J; Jaenisch, R				Panning, B; Dausman, J; Jaenisch, R			X chromosome inactivation is mediated by Xist RNA stabilization	CELL			English	Article							MOUSE DEVELOPMENT; EMBRYONIC-CELLS; GENE-EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; METHYLATION; REQUIREMENT; BLASTOCYST; NUCLEUS; PROTEIN	Low level Xist expression can be detected from both active X chromosomes (Xa) in female embryonic stem cells prior to X inactivation. After differentiation, Xist is expressed at high levels only from the inactive X chromosome (Xi). Differentiating female cells increase Xist expression from the Xi prior to silencing low level Xist expression from the Xa. The transition from low level to high level expression is regulated by the stabilization of Xist transcripts at the Xi. We suggest that these developmentally modulated changes in Xist expression are regulated by several different mechanisms: factors that stabilize Xist transcripts at the Xi, an activity that blocks this stabilization at the Xa, and a mechanism that silences low level Xist expression from the Xa.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	Panning, B (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA44339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; ANDREWS GK, 1982, DEV BIOL, V89, P111, DOI 10.1016/0012-1606(82)90299-8; BARR ML, 1959, SCIENCE, V130, P679, DOI 10.1126/science.130.3377.679; BARR ML, 1962, ACTA CYTOL, V6, P34; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BURGOYNE PS, 1993, DEVELOPMENT, V117, P341; CATTANACH BM, 1975, ANNU REV GENET, V9, P1, DOI 10.1146/annurev.ge.09.120175.000245; CLEMSON CM, 1996, J CELL BIOL, V132, P1; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; CRUZ YP, 1993, IN VITRO CELL DEV, V29, P671; GARDNER RL, 1971, NATURE, V231, P385, DOI 10.1038/231385a0; HENDRICH BD, 1997, NUCLEIC ACIDS RES, V13, P2661; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; LOCK LF, 1986, MOL CELL BIOL, V6, P914, DOI 10.1128/MCB.6.3.914; Lyon MF, 1996, NATURE, V379, P116, DOI 10.1038/379116a0; LYON MF, 1961, NATURE, V190, P327; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MATTEI JF, 1981, HUM GENET, V56, P409, DOI 10.1007/BF00274703; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; MOORE MJ, 1993, RNA WORLD, P305; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PANNING B, 1993, MOL CELL BIOL, V13, P3231, DOI 10.1128/MCB.13.6.3231; PANNING B, 1996, GENE DEV, V10, P1191; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; TAKAGI N, 1974, EXP CELL RES, V86, P127, DOI 10.1016/0014-4827(74)90657-0; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219	48	248	257	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					907	916		10.1016/S0092-8674(00)80355-4	http://dx.doi.org/10.1016/S0092-8674(00)80355-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298902	Bronze			2022-12-01	WOS:A1997XV56300011
J	Elders, MJ; Scott, CR; Frindik, JP; Kemp, SF				Elders, MJ; Scott, CR; Frindik, JP; Kemp, SF			Clinical workup for precocious puberty	LANCET			English	Editorial Material							ADULT				Elders, MJ (corresponding author), UNIV ARKANSAS MED SCI,ARKANSAS CHILDRENS HOSP,LITTLE ROCK,AR 72202, USA.							*A GUTTM I, 1994, SEX AM TEEN; CUTLER GB, 1992, MED PRACTICING PHYSI, P577; Eckert KL, 1996, PEDIATRICS, V97, P517; HermanGiddens ME, 1997, PEDIATRICS, V99, P505, DOI 10.1542/peds.99.4.505; MALES MA, 1995, LANCET, V346, P64, DOI 10.1016/S0140-6736(95)92105-2; OERTER KE, 1991, J CLIN ENDOCR METAB, V73, P1235, DOI 10.1210/jcem-73-6-1235	6	13	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 16	1997	350	9076					457	458		10.1016/S0140-6736(05)63075-9	http://dx.doi.org/10.1016/S0140-6736(05)63075-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XR135	9274578				2022-12-01	WOS:A1997XR13500004
J	Kimura, KD; Tissenbaum, HA; Liu, YX; Ruvkun, G				Kimura, KD; Tissenbaum, HA; Liu, YX; Ruvkun, G			daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans	SCIENCE			English	Article							DAUER LARVA DEVELOPMENT; INTERMEDIARY METABOLISM; HORMONE; ENCODES; KINASE; MUTATIONS; PEPTIDE; FAMILY; CYCLE	A C. elegans neurosecretory signaling system regulates whether animals enter the reproductive life cycle or arrest development at the long-lived dauer diapause stage. daf-2, a key gene in the genetic pathway that mediates this endocrine signaling, encodes an insulin receptor family member. Decreases in DAF-2 signaling induce metabolic and developmental changes, as in mammalian metabolic control by the insulin receptor, Decreased DAF-2 signaling also causes an increase in life-span. Life-span regulation by insulin-like metabolic control is analogous to mammalian longevity enhancement induced by caloric restriction, suggesting a general link between metabolism, diapause, and longevity.	MASSACHUSETTS GEN HOSP, DEPT MOL BIOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Kimura, Koutarou D./T-9645-2019	Kimura, Koutarou D./0000-0002-3359-1578	NATIONAL INSTITUTE ON AGING [R01AG014161] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG14161] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARPAGAUS M, 1987, ROUX ARCH DEV BIOL, V196, P527, DOI 10.1007/BF00399877; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; COLEMAN DL, 1979, SCIENCE, V203, P663, DOI 10.1126/science.760211; DORMAN JB, 1995, GENETICS, V141, P1399; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Finch CE., 1990, LONGEVITY SENESCENCE; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOTTLIEB S, 1994, GENETICS, V137, P107; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HETRU C, 1991, EUR J BIOCHEM, V201, P495, DOI 10.1111/j.1432-1033.1991.tb16308.x; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jonas EA, 1997, NATURE, V385, P343, DOI 10.1038/385343a0; Kahn CR, 1996, ANNU REV MED, V47, P509; KAHN CR, 1994, JOSLINS DIABETES MEI; KAWAKAMI A, 1989, P NATL ACAD SCI USA, V86, P6843, DOI 10.1073/pnas.86.18.6843; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KENYON C, 1997, C ELEGANS, V2, P791; KIM H, 1992, DIABETOLOGIA, V35, P261, DOI 10.1007/BF00400927; Krause M, 1995, METHOD CELL BIOL, V48, P483; LARSEN PL, 1995, GENETICS, V139, P1567; MALONE EA, 1994, GENETICS, V136, P879; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; NAGASAWA H, 1984, SCIENCE, V226, P1344, DOI 10.1126/science.226.4680.1344; ORIORDAN VB, 1989, COMP BIOCHEM PHYS B, V92, P233, DOI 10.1016/0305-0491(89)90271-X; ORIORDAN VB, 1990, COMP BIOCHEM PHYS B, V95, P125, DOI 10.1016/0305-0491(90)90258-U; PATTERSON GI, UNPUB; POPHAM JD, 1979, CAN J ZOOL, V57, P794, DOI 10.1139/z79-098; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; Riddle DL, 1997, C ELEGANS, P739; ROOVERS E, 1995, GENE, V162, P181, DOI 10.1016/0378-1119(95)00323-X; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; SHIER P, 1989, J BIOL CHEM, V264, P14605; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Tauber M.J., 1986, SEASONAL ADAPTATIONS; THOMAS JH, 1993, GENETICS, V134, P1105; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOWELS JJ, 1992, GENETICS, V130, P105; WADSWORTH WG, 1989, DEV BIOL, V132, P167, DOI 10.1016/0012-1606(89)90214-5; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	1637	1702	6	250	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	1997	277	5328					942	946		10.1126/science.277.5328.942	http://dx.doi.org/10.1126/science.277.5328.942			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ985	9252323				2022-12-01	WOS:A1997XQ98500038
J	Miles, P; Everett, J; Murphy, J; Kerr, D				Miles, P; Everett, J; Murphy, J; Kerr, D			Comparison of blood or urine testing by patients with newly diagnosed non-insulin dependent diabetes: patient survey after randomised crossover trial	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BOURNEMOUTH HOSP,BOURNEMOUTH DIABET & ENDOCRINE CTR,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND									BRADLEY C, 1995, HDB PSYCHOL DIABETES, P92; *DCGT RES GROUP, 1993, NEW ENGL J MED, V329, P977; TATTERSALL R, 1992, BRIT MED J, V305, P1171, DOI 10.1136/bmj.305.6863.1171; WATKINS PJ, 1993, J ROY COLL PHYS LOND, V27, P259; WING RR, 1986, AM J MED, V81, P830, DOI 10.1016/0002-9343(86)90354-2	5	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 9	1997	315	7104					348	349						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ864	9270457				2022-12-01	WOS:A1997XQ86400022
J	Wang, Y; Okamoto, M; Schmitz, F; Hofmann, K; Sudhof, TC				Wang, Y; Okamoto, M; Schmitz, F; Hofmann, K; Sudhof, TC			Rim is a putative Rab3 effector in regulating synaptic-vesicle fusion	NATURE			English	Article							PROTEIN; EXOCYTOSIS; RABPHILIN-3A; CELLS	Rab3 is a neuronal GTP-binding protein that regulates fusion of synaptic vesicles and is essential for long-term potentiation of hippocampal messy fibre synapses(1-5). More than thirty Rab GTP-binding proteins are known to function in diverse membrane transport pathways, although their mechanisms of action are unclear. We have now identified a putative Rab3-effector protein called Rim. Rim is composed of an amino-terminal zinc-finger motif and carboxy-terminal PDZ and C-2 domains. It binds only to GTP (but not to GDP)-complexed Rab3, and interacts with no other Rab protein tested. There is enrichment of Rab3 and Rim in neurons, where they have complementary distributions. Rab3 is found only on synaptic vesicles, whereas Rim is localized to presynaptic active zones in conventional synapses, and to presynaptic ribbons in ribbon synapses. Transfection of PC12 cells with the amino-terminal domains of Rim greatly enhances regulated exocytosis in a Rab3-dependent manner. We propose that Rim serves as a Rab3-dependent regulator of synaptic-vesicle fusion by forming a GTP-dependent complex between synaptic plasma membranes and docked synaptic vesicles.	UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; MAX PLANCK INST EXPT MED,ABT 9,D-37075 GOTTINGEN,GERMANY; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society; Swiss Institute Experimental Cancer Research			Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083				Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Dowling J.E., 1987, RETINA APPROACHABLE; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMITZ F, 1996, J NEUROSCI, V15, P7109; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525	30	511	540	0	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					593	598		10.1038/41580	http://dx.doi.org/10.1038/41580			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252191	Bronze			2022-12-01	WOS:A1997XP72200052
J	Harris, WM; Combi, MR; Honeycutt, RK; Mueller, BEA; Scherb, F				Harris, WM; Combi, MR; Honeycutt, RK; Mueller, BEA; Scherb, F			Evidence for interacting gas flows and an extended volatile source distribution in the coma of comet C/1996 B2 (Hyakutake)	SCIENCE			English	Article							PHYSICO-CHEMICAL PHENOMENA; P/HALLEY; NUCLEUS; WEST	Images of comet C/1996 B2 (Hyakutake) taken during its close approach to Earth show differences in the distribution of gas and dust in the inner coma and reveal two are-shaped molecular resonant emission features. The morphology of these features, as well as the apparent decoupling gas from dust in the inner coma, suggest that an extended region of icy grains surrounds the nucleus of Hyakutake and contributes substantially to the production of volatiles. Model simulations suggest the same conclusion and indicate that the brighter are is explainable by the presence of a trailing condensation of ice-bearing granules with a rate of volatile production approximately 23 percent of that of the nucleus.	UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; INDIANA UNIV,DEPT ASTRON,BLOOMINGTON,IN 47405; NATL OPT ASTRON OBSERV,TUCSON,AZ 85719; UNIV WISCONSIN,DEPT PHYS,MADISON,WI 53706	University of Michigan System; University of Michigan; Indiana University System; Indiana University Bloomington; National Optical Astronomy Observatory; University of Wisconsin System; University of Wisconsin Madison	Harris, WM (corresponding author), UNIV WISCONSIN,SPACE ASTRON LAB,1150 UNIV AVE,MADISON,WI 53706, USA.		Combi, Michael R/J-1697-2012	Combi, Michael R/0000-0002-9805-0078				AHEARN MF, 1980, MOON PLANETS, V23, P41; AHEARN MF, 1977, ASTRON J, V82, P518, DOI 10.1086/112085; AHEARN MF, IN PRESS P 1996 AST; Combi MR, 1996, ICARUS, V123, P207, DOI 10.1006/icar.1996.0150; COMBI MR, 1980, ASTROPHYS J, V237, P1026; DELSEMME AH, 1970, PLANET SPACE SCI, V18, P709, DOI 10.1016/0032-0633(70)90052-8; DELSEMME AH, 1971, PLANET SPACE SCI, V19, P1259, DOI 10.1016/0032-0633(71)90181-4; FEHRENBACH C, 1973, CR ACAD SCI B PHYS, V277, P569; HAFFNER LM, COMMUNICATION; HANNER MS, 1981, ICARUS, V47, P342, DOI 10.1016/0019-1035(81)90182-2; Harmon J.K., 1996, BAAS, V28, P1195; HARRIS WM, 1996, B AM ASTRON SOC, V28, P1088; HUGGINS W, 1981, CR HEBD ACAD SCI, V10, P26; JEWITT DC, 1987, ASTROPHYS J, V317, P992, DOI 10.1086/165347; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; KITAMURA Y, 1986, ICARUS, V66, P241, DOI 10.1016/0019-1035(86)90155-7; KOROSMEZEY A, 1990, ICARUS, V84, P118, DOI 10.1016/0019-1035(90)90162-3; LAFFONT C, 1996, B AM ASTRON SOC, V28, P926; LARSON S, 1987, ASTRON ASTROPHYS, V187, P639; MAZETS EP, 1987, ASTRON ASTROPHYS, V187, P699; Mukai T., 1985, Advances in Space Research, V5, P339, DOI 10.1016/0273-1177(85)90107-3; NEWBURN RL, 1981, ASTRON J, V86, P469, DOI 10.1086/112906; SAITO K, 1981, ICARUS, V41, P351; SCHLEICHER DG, 1996, B AM ASTRON SOC, V28, P1089; TOZZI GP, COMMUNICATION; TOZZI GP, 1996, B AM ASTRON SOC, V28, P1089	26	39	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 1	1997	277	5326					676	681		10.1126/science.277.5326.676	http://dx.doi.org/10.1126/science.277.5326.676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN907	9235888				2022-12-01	WOS:A1997XN90700038
J	Cardone, MH; Salvesen, GS; Widmann, C; Johnson, G; Frisch, SM				Cardone, MH; Salvesen, GS; Widmann, C; Johnson, G; Frisch, SM			The regulation of anoikis: MEKK-1 activation requires cleavage by caspases	CELL			English	Article							EXTRACELLULAR-MATRIX; APOPTOSIS; SURVIVAL; KINASE; EXPRESSION; PROTEINASE; CELLS; RAF-1; ICE	Certain cell types undergo apoptosis when they lose integrin-mediated contacts with the extracellular matrix (''anoikis''). The Jun N-terminal kinase (JNK) pathway is activated in and promotes anoikis. This activation requires caspase activity. We presently report that a DEVD motif-specific caspase that cleaves MEKK-1 specifically is activated when cells lose matrix contact. This cleavage is required for the activation of the kinase activity. When overexpressed, the MEKK-1 cleavage product stimulates apoptosis; the wild-type, full-length MEKK-1 sensitizes cells to anoikis; and a cleavage-resistant mutant of MEKK-1 partially protects cells against anoikis. The cleavage-resistant or kinase-inactive mutants also prevent caspase-7 from being activated completely. Thus, caspases can induce apoptosis by activating MEKK-1, which in turn activates more caspase activity, comprising a positive feedback loop.	BURNHAM INST,LA JOLLA,CA 92037; UNIV COLORADO,SCH MED,DIV BASIC SCI,NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80206	Sanford Burnham Prebys Medical Discovery Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051452] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cahill MA, 1996, ONCOGENE, V13, P2087; CHINNAIYAN A, 1997, SCIENCE, V275, P1081; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Gilmore TD, 1996, ONCOGENE, V13, P1367; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAGATA S, 1997, J BIOL CHEM, V274, P20977; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIDMANN C, 1997, UNPUB SCIENCE; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	34	459	468	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 25	1997	90	2					315	323		10.1016/S0092-8674(00)80339-6	http://dx.doi.org/10.1016/S0092-8674(00)80339-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244305	Bronze			2022-12-01	WOS:A1997XN24900015
J	Hunt, JF; vanderVies, SM; Henry, L; Deisenhofer, J				Hunt, JF; vanderVies, SM; Henry, L; Deisenhofer, J			Structural adaptations in the specialized bacteriophage T4 co-chaperonin Gp31 expand the size of the Anfinsen cage	CELL			English	Article							BYPASS 31 MUTATIONS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE-PRODUCTS; PROTEIN; GROEL; BACTERIAL; LAMBDA; HEAD; MORPHOGENESIS	The Gp31 protein from bacteriophage T4 functionally substitutes for the bacterial co-chaperonin GroES in assisted protein folding reactions both in vitro and in vivo. But Gp31 is required for the folding and/or assembly of the T4 major capsid protein Gp23, and this requirement cannot be satisfied by GroES. The 2.3 Angstrom crystal structure of Gp31 shows that its tertiary and quaternary structures are similar to those of GroES despite the existence of only 14% sequence identity between the two proteins. However, Gp31 shows a series of structural adaptations which will increase the size and the hydrophilicity of the ''Anfinsen cage,'' the enclosed cavity within the GroEL/GroES complex that is the location of the chaperonin-assisted protein folding reaction.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV GENEVA, DEPT BIOCHIM MED, CH-1211 GENEVA 4, SWITZERLAND	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Geneva	Hunt, JF (corresponding author), UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA.							Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CASTILLO CJ, 1978, J BIOL CHEM, V253, P2132; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DOERMANN AH, 1984, J VIROL, V51, P315, DOI 10.1128/JVI.51.2.315-320.1984; Drenth J, 1994, PRINCIPLES PROTEIN X; ELLIS RJ, 1994, CURR BIOL, V4, P633; ELLIS RJ, 1996, CHAPERONINS; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P14, DOI 10.1016/S0968-0004(00)88941-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIVINSKAS R, 1988, GENE, V73, P251, DOI 10.1016/0378-1119(88)90332-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SIMON LD, 1984, J VIROL, V51, P321, DOI 10.1128/JVI.51.2.321-328.1984; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; Yifrach O, 1996, J MOL BIOL, V255, P356, DOI 10.1006/jmbi.1996.0028; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZeilstraRyalls J, 1996, FASEB J, V10, P148, DOI 10.1096/fasebj.10.1.8566535; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	71	87	90	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 25	1997	90	2					361	371		10.1016/S0092-8674(00)80343-8	http://dx.doi.org/10.1016/S0092-8674(00)80343-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XN249	9244309	Bronze			2022-12-01	WOS:A1997XN24900019
J	Festing, MFW				Festing, MFW			Fat rats and carcinogenesis screening	NATURE			English	Editorial Material							LABORATORY RODENTS; BODY-WEIGHT; PATHOLOGY; SURVIVAL; MICE				Festing, MFW (corresponding author), UNIV LEICESTER,MRC,TOXICOL UNIT,POB 138,LEICESTER LE1 9HN,LEICS,ENGLAND.							ABELSON PH, 1992, SCIENCE, V255, P141, DOI 10.1126/science.1553536; ARCOS JC, 1968, CHEM INDUCTION CANC; BRONSON RT, 1993, AGING-CLIN EXP RES, V5, P253, DOI 10.1007/BF03324169; FELTON RP, 1989, J TOXICOL ENV HEALTH, V26, P399, DOI 10.1080/15287398909531264; FESTING MFW, 1990, TOXICOL APPL PHARM, V102, P197, DOI 10.1016/0041-008X(90)90020-U; FESTING MFW, 1993, AGING-CLIN EXP RES, V5, P309, DOI 10.1007/BF03324180; FESTING MFW, 1995, ENVIRON HEALTH PERSP, V103, P44, DOI 10.2307/3432255; HASEMAN JK, 1979, J TOXICOL ENV HEALTH, V5, P89, DOI 10.1080/15287397909529728; HASEMAN JK, 1992, FUND APPL TOXICOL, V19, P207, DOI 10.1016/0272-0590(92)90153-9; MCAUSLANE JAN, 1991, HUM EXP TOXICOL, V10, P205, DOI 10.1177/096032719101000310; NOHYNEK GJ, 1993, HUM EXP TOXICOL, V12, P87, DOI 10.1177/096032719301200201; Nomura T., 1991, ILAR J, V33, P42; Popper K., 1972, OBJECTIVE KNOWLEDGE; RAO GN, 1989, LAB ANIM SCI, V39, P389; ROE FJC, 1994, LAB ANIM, V28, P148, DOI 10.1258/002367794780745236; SHELLABARGER CJ, 1978, JNCI-J NATL CANCER I, V61, P1505; SPROTT RL, 1993, AGING-CLIN EXP RES, V5, P249, DOI 10.1007/BF03324168; Tennant RW, 1996, MUTAT RES-REV GENET, V365, P119, DOI 10.1016/S0165-1110(96)90016-0	18	9	9	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 24	1997	388	6640					321	322		10.1038/40964	http://dx.doi.org/10.1038/40964			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XM528	9237745				2022-12-01	WOS:A1997XM52800020
J	Long, RM; Singer, RH; Meng, XH; Gonzalez, I; Nasmyth, K; Jansen, RP				Long, RM; Singer, RH; Meng, XH; Gonzalez, I; Nasmyth, K; Jansen, RP			Mating type switching in yeast controlled by asymmetric localization of ASH1 mRNA	SCIENCE			English	Article							CLASS-V MYOSIN; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; MUTATIONAL ANALYSIS; GENE; IDENTIFICATION; TROPOMYOSIN; REQUIREMENT; TRANSPORT; MYO2	Cell divisions that produce progeny differing in their patterns of gene expression are key to the development of multicellular organisms. In the budding yeast Saccharomyces cerevisiae, mother cells but not daughter cells can switch mating type because they selectively express the HO endonuclease gene. This asymmetry is due to the preferential accumulation of an unstable transcriptional repressor protein, Ash1p, in daughter cell nuclei. Here it is shown that ASH1 messenger RNA (mRNA) preferentially accumulates in daughter cells by a process that is dependent on actin and myosin. A cis-acting element in the 3'-untranslated region of ASH1 mRNA is sufficient to localize a chimeric RNA to daughter cells. These results suggest that localization of mRNA may have been an early property of the eukaryotic lineage.	RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Long, RM (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Calatrava, Isidro González/S-4410-2018	Calatrava, Isidro González/0000-0003-4784-2582; Nasmyth, Kim/0000-0001-7030-4403	NICHD NIH HHS [7 F32 HD08088-02] Funding Source: Medline; NIGMS NIH HHS [GM54887] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD008088] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ayscough KR, 1996, ANNU REV CELL DEV BI, V12, P129, DOI 10.1146/annurev.cellbio.12.1.129; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BOGUCKAGLOTZER J, 1996, SEMIN CELL DEV BIOL, V7, P357; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Govindan B, 1995, J EXP ZOOL, V273, P401, DOI 10.1002/jez.1402730505; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; HAARER BK, 1994, J CELL SCI, V107, P1055; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kislauskis Edward H., 1992, Current Opinion in Cell Biology, V4, P975, DOI 10.1016/0955-0674(92)90128-Y; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; Long RM, 1995, RNA, V1, P1071; Long Roy M., 1996, Molecular Biology of the Cell, V7, p104A; Manseau L, 1996, DEVELOPMENT, V122, P2109; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; Politz JC, 1995, NUCLEIC ACIDS RES, V23, P4946, DOI 10.1093/nar/23.24.4946; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; Roemer T, 1996, TRENDS CELL BIOL, V6, P434, DOI 10.1016/S0962-8924(96)10039-8; Sherman F, 1986, LAB COURSE MANUAL ME; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SINGER RH, 1993, CURR BIOL, V3, P719, DOI 10.1016/0960-9822(93)90079-4; St. Johnston D., 1995, CELL, V81, P161, DOI DOI 10.1016/0092-8674(95)90324-0; STEWARD O, 1997, MRNA METABOLISM POST; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; WERTMAN KF, 1992, GENETICS, V132, P337	39	390	396	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 18	1997	277	5324					383	387		10.1126/science.277.5324.383	http://dx.doi.org/10.1126/science.277.5324.383			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XL358	9219698				2022-12-01	WOS:A1997XL35800050
J	Rook, GAW; Zumla, A				Rook, GAW; Zumla, A			Gulf War syndrome: Is it due to a systemic shift in cytokine balance towards a Th2 profile?	LANCET			English	Article							MEASLES IMMUNIZATION; SUSCEPTIBLE MICE; IMMUNE-RESPONSE; T-CELLS; DEHYDROEPIANDROSTERONE; INTERLEUKIN-2; CORTICOTROPIN; INHIBITION; RESISTANT; CORTISOL	The symptoms of Gulf War syndrome are compatible with the hypothesis that the immune system of affected individuals is biased towards a Th2-cytokine pattern. Factors that could lead to a Th2 shift among Gulf War veterans include exposure to multiple Th2-inducing vaccinations under stressful circumstances and the way in which such vaccinations were administered, which would be expected to maximise Th2 immunogenicity. These factors may have led to a long-term systemic shift towards a Th2-cytokine balance and to mood changes related to the immunoendocrine state. Other vaccines that lead to similar long-term, non-specific shifts in cytokine balance are well-established. If our hypothesis is proven, treatment may be possible with regimens that induce a systemic Th1 bias.	UCL, SCH MED, DEPT MED, ACAD INFECT DIS UNIT, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School	Rook, GAW (corresponding author), UCL, SCH MED, DEPT BACTERIOL, LONDON W1P 6DB, ENGLAND.		ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735; Rook, Graham/0000-0002-8041-8110				AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; AABY P, 1995, SOC SCI MED, V41, P673, DOI 10.1016/0277-9536(95)00038-9; Bernton E, 1995, ANN NY ACAD SCI, V774, P217; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; BRINKMANN V, 1995, J IMMUNOL, V155, P3322; BROWN DH, 1993, INFECT IMMUN, V61, P4793, DOI 10.1128/IAI.61.11.4793-4800.1993; CASALE GP, 1993, IMMUNOPHARM IMMUNOT, V15, P199, DOI 10.3109/08923979309025994; David A, 1997, BRIT MED J, V314, P239, DOI 10.1136/bmj.314.7076.239; DAYNES RA, 1990, J EXP MED, V171, P979, DOI 10.1084/jem.171.4.979; DAYNES RA, 1995, J INVEST DERMATOL, V105, pS14, DOI 10.1111/1523-1747.ep12315187; DAYNES RA, 1993, J IMMUNOL, V150, P5319; FISCHER A, 1991, IMMUNOLOGY, V74, P228; GARG M, 1993, INFECT IMMUN, V61, P2238, DOI 10.1128/IAI.61.5.2238-2241.1993; GLASER R, 1993, BEHAV NEUROSCI, V107, P525, DOI 10.1037/0735-7044.107.3.525; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; HOLSBOER F, 1984, NEW ENGL J MED, V311, P1127; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; MU HH, 1993, INFECT IMMUN, V61, P2834, DOI 10.1128/IAI.61.7.2834-2840.1993; Nilsson L, 1996, JAMA-J AM MED ASSOC, V275, P760, DOI 10.1001/jama.275.10.760; ODENT MR, 1994, JAMA-J AM MED ASSOC, V272, P592, DOI 10.1001/jama.1994.03520080034035; Padgett DA, 1995, ANN NY ACAD SCI, V774, P323; Ramirez F, 1996, J IMMUNOL, V156, P2406; Ramiya VK, 1996, J AUTOIMMUN, V9, P349, DOI 10.1006/jaut.1996.0047; RAVEN PW, 1995, CLIN ENDOCRINOL, V43, P637, DOI 10.1111/j.1365-2265.1995.tb02930.x; RAVEN PW, 1996, PSYCHONEUROENDOCRINO, V20, P543; Rook GAW, 1996, QJM-INT J MED, V89, P333; Rook GAW, 1996, ANNU REV MICROBIOL, V50, P259, DOI 10.1146/annurev.micro.50.1.259; RUPPRECHT M, 1995, PSYCHONEUROENDOCRINO, V20, P543, DOI 10.1016/0306-4530(94)00082-L; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Smit JA, 1996, TRANSPLANT P, V28, P665; Strachan DP, 1996, ARCH DIS CHILD, V74, P422, DOI 10.1136/adc.74.5.422; STRAUS S, 1996, NIH PUBLICATION, P1; Suitters AJ, 1997, IMMUNOLOGY, V91, P314, DOI 10.1046/j.1365-2567.1997.00254.x; SUZUKI T, 1991, CLIN IMMUNOL IMMUNOP, V61, P202, DOI 10.1016/S0090-1229(05)80024-8; TOBACH E, 1956, AM J PHYSIOL, V187, P399, DOI 10.1152/ajplegacy.1956.187.2.399; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092; YOUNG MRI, 1995, CHRONOBIOL INT, V12, P19, DOI 10.3109/07420529509064496; Zwilling B, 1992, ASM NEWS, V58, P23; 1997, ECONOMIST       0111, P87	40	129	131	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 21	1997	349	9068					1831	1833		10.1016/S0140-6736(97)01164-1	http://dx.doi.org/10.1016/S0140-6736(97)01164-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269228				2022-12-01	WOS:A1997XF73500044
J	DiFiglia, M; Sapp, E; Chase, KO; Davies, SW; Bates, GP; Vonsattel, JP; Aronin, N				DiFiglia, M; Sapp, E; Chase, KO; Davies, SW; Bates, GP; Vonsattel, JP; Aronin, N			Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain	SCIENCE			English	Article							GLUTAMINE REPEATS; NEURODEGENERATIVE DISEASES; TRINUCLEOTIDE REPEAT; MUTANT HUNTINGTIN; CEREBRAL-CORTEX; EXPRESSION; EXPANSION; PATHOLOGY; VESICLES; LENGTH	The cause of neurodegeneration in Huntington's disease (HD) is unknown. Patients with HD have an expanded NH2-terminal polyglutamine region in huntingtin. An NH2-terminal fragment of mutant huntingtin was localized to neuronal intranuclear inclusions (NIIs) and dystrophic neurites (DNs) in the HD cortex and striatum, which are affected in HD, and polyglutamine length influenced the extent of huntingtin accumulation in these structures. Ubiquitin was also found in NIIs and DNs, which suggests that abnormal huntingtin is targeted for proteolysis but is resistant to removal. The aggregation of mutant huntingtin may be part of the pathogenic mechanism in HD.	UNIV LONDON UNIV COLL, DEPT ANAT & DEV BIOL, LONDON WC1E 6BT, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, LONDON SE1 7EH, ENGLAND; UNIV MASSACHUSETTS, MED CTR, DEPT MED & CELL BIOL, WORCESTER, MA 01655 USA	University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Massachusetts System; University of Massachusetts Worcester	DiFiglia, M (corresponding author), MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA.		Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031579, P50NS016367, P01NS016367] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16367, NS 31579] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], ADV NEUROL; ARONIN N, 1995, NEURON, V15, P1193, DOI 10.1016/0896-6273(95)90106-X; ARONIN N, 1991, NEUROSCIENCE, V44, P409, DOI 10.1016/0306-4522(91)90065-V; Bhide PG, 1996, J NEUROSCI, V16, P5523; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; BYERS RK, 1973, NEUROLOGY, V23, P561, DOI 10.1212/WNL.23.6.561; CAMMARATA S, 1993, NEUROSCI LETT, V156, P96, DOI 10.1016/0304-3940(93)90448-T; CUDKOWICZ M, 1990, ANN NEUROL, V27, P200, DOI 10.1002/ana.410270217; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DELAMONTE SM, 1988, J NEUROPATH EXP NEUR, V47, P516, DOI 10.1097/00005072-198809000-00003; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FOLSTEIN SE, 1989, HUNTINGTONS DISEASE, P1; FUNATA N, 1990, CLIN NEUROPATHOL, V9, P89; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; HALTIA M, 1984, ANN NEUROL, V15, P316, DOI 10.1002/ana.410150403; HEDREEN JC, 1991, NEUROSCI LETT, V133, P257, DOI 10.1016/0304-3940(91)90583-F; JACKSON M, 1995, NEUROPATH APPL NEURO, V21, P18, DOI 10.1111/j.1365-2990.1995.tb01024.x; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; PETERS JM, 1994, J BIOL CHEM, V269, P7709; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; Sapp E, 1997, ANN NEUROL, V42, P604, DOI 10.1002/ana.410420411; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003	37	2180	2244	2	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	1997	277	5334					1990	1993		10.1126/science.277.5334.1990	http://dx.doi.org/10.1126/science.277.5334.1990			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX849	9302293				2022-12-01	WOS:A1997XX84900043
J	Whitaker, RC; Wright, JA; Pepe, MS; Seidel, KD; Dietz, WH				Whitaker, RC; Wright, JA; Pepe, MS; Seidel, KD; Dietz, WH			Predicting obesity in young adulthood from childhood and parental obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	37th Annual Meeting of the Ambulatory-Pediatric-Association	MAY 02-06, 1997	WASHINGTON, D.C.	Ambulatory Pediat Assoc			BODY-MASS INDEX; NUTRITION EXAMINATION SURVEYS; FOLLOW-UP; NATIONAL-HEALTH; BLOOD-PRESSURE; CHILDREN; ADOLESCENTS; OVERWEIGHT; FATNESS; WEIGHT	Background Childhood obesity increases the risk of obesity in adulthood, but how parental obesity affects the chances of a child's becoming an obese adult is unknown. We investigated the risk of obesity in young adulthood associated with both obesity in childhood and obesity in one or both parents. Methods Height and weight measurements were abstracted from the records of 854 subjects born at a health maintenance organization in Washington State between 1965 and 1971. Their parents' medical records were also reviewed. Childhood obesity was defined as a body-mass index at or above the 85th percentile for age and sex, and obesity in adulthood as a mean body-mass index at or above 27.8 for men and 27.3 for women. Results In young adulthood (defined as 21 to 29 years of age), 135 subjects (16 percent) were obese. Among those who were obese during childhood, the chance of obesity in adulthood ranged from 8 percent for 1- or 2-year-olds without obese parents to 79 percent for 10-to-14-year-olds with at least one obese parent. After adjustment for parental obesity, the odds ratios for obesity in adulthood associated with childhood obesity ranged from 1.3 (95 percent confidence interval, 0.6 to 3.0) for obesity at 1 or 2 years of age to 17.5 (7.7 to 39.5) for obesity at 15 to 17 years of age. After adjustment for the child's obesity status, the odds ratios for obesity in adulthood associated with having one obese parent ranged from 2.2 (95 percent confidence interval, 1.1 to 4.3) at 15 to 17 years of age to 3.2 (1.8 to 5.7) at 1 or 2 years of age. Conclusions Obese children under three years of age without obese parents are at low risk for obesity in adulthood, but among older children, obesity is an increasingly important predictor of adult obesity, regardless of whether the parents are obese. Parental obesity more than doubles the risk of adult obesity among both obese and nonobese children under 10 years of age. (C) 1997, Massachusetts Medical Society.	UNIV CINCINNATI, COLL MED, CINCINNATI, OH USA; UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DIV PUBL HLTH SCI, BIOSTAT PROGRAM, SEATTLE, WA 98104 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	University System of Ohio; University of Cincinnati; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Tufts Medical Center	Whitaker, RC (corresponding author), CHILDRENS HOSP, MED CTR,DIV GEN & COMMUNITY PEDIAT,DEPT PEDIAT, CH-1 S, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.		Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793	NIDDK NIH HHS [P30DK46200] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM S, 1971, HEALTH SERV REP, V86, P273, DOI 10.2307/4594149; ABRAHAM S, 1960, PUBLIC HEALTH REP, V75, P263, DOI 10.2307/4590775; [Anonymous], 1985, Ann Intern Med, V103, P147; CLARKE WR, 1993, CRIT REV FOOD SCI, V33, P423, DOI 10.1080/10408399309527641; EPSTEIN LH, 1990, JAMA-J AM MED ASSOC, V264, P2519, DOI 10.1001/jama.264.19.2519; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; Folsom AR, 1996, AM J EPIDEMIOL, V144, P235, DOI 10.1093/oxfordjournals.aje.a008918; Frisancho AR., 1990, ANTHROPOMETRIC STAND; GARN SM, 1985, AM J DIS CHILD, V139, P181, DOI 10.1001/archpedi.1985.02140040083033; GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810; GUTIN B, 1990, JAMA-J AM MED ASSOC, V264, P1123, DOI 10.1001/jama.264.9.1123; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; KRAEMER H C, 1990, Annals of Behavioral Medicine, V12, P112, DOI 10.1207/s15324796abm1203_3; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LASKARZEWSKI P, 1980, AM J EPIDEMIOL, V111, P395, DOI 10.1093/oxfordjournals.aje.a112914; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Liu K, 1996, CIRCULATION, V93, P60, DOI 10.1161/01.CIR.93.1.60; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MOLL PP, 1991, AM J HUM GENET, V49, P1243; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; Perusse L, 1997, OBES RES, V5, P49, DOI 10.1002/j.1550-8528.1997.tb00283.x; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; ROBINSON TN, 1993, CRIT REV FOOD SCI, V33, P313, DOI 10.1080/10408399309527626; ROCHE AF, 1981, AM J CLIN NUTR, V34, P2831, DOI 10.1093/ajcn/34.12.2831; ROLLANDCACHERA MF, 1987, ANN HUM BIOL, V14, P219, DOI 10.1080/03014468700008991; ROLLANDCACHERA MF, 1982, AM J CLIN NUTR, V36, P178, DOI 10.1093/ajcn/36.1.178; RONNEMAA T, 1991, ANN MED, V23, P67, DOI 10.3109/07853899109147933; SCHAPPERT SM, 1996, DHHS PUBLICATION; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; STARK O, 1981, BMJ-BRIT MED J, V283, P13, DOI 10.1136/bmj.283.6283.13; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005	32	2868	2937	3	236	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	1997	337	13					869	873		10.1056/NEJM199709253371301	http://dx.doi.org/10.1056/NEJM199709253371301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	XX302	9302300	Bronze			2022-12-01	WOS:A1997XX30200001
J	Wendt, KU; Poralla, K; Schulz, GE				Wendt, KU; Poralla, K; Schulz, GE			Structure and function of a squalene cyclase	SCIENCE			English	Article							ENCODING LANOSTEROL SYNTHASE; RAT OXIDOSQUALENE CYCLASE; HOPENE CYCLASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; BACILLUS-ACIDOCALDARIUS; 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE; PARTIAL-PURIFICATION; CANDIDA-ALBICANS	The crystal structure of squalene-hopene cyclase from Alicyclobacillus acidocaldarius was determined at 2.9 angstrom resolution. The mechanism and sequence of this cyclase are closely related to those of 2,3-oxidosqualene cyclases that catalyze the cyclization step in cholesterol biosynthesis. The structure reveals a membrane protein with membrane-binding characteristics similar to those of prostaglandin-H-2 synthase, the only other reported protein of this type. The active site of the enzyme is located in a large central cavity that is of suitable size to bind squalene in its required conformation and that is lined by aromatic residues. The structure supports a mechanism in which the acid starting the reaction by protonating a carbon-carbon double bond is an aspartate that is coupled to a histidine. Numerous surface alpha helices are connected by characteristic QW-motifs (Q is glutamine and W is tryptophan) that tighten the protein structure, possibly for absorbing the reaction energy without structural damage.	UNIV FREIBURG, INST ORGAN CHEM & BIOCHEM, D-79104 FREIBURG, GERMANY; INST BIOL, D-72076 TUBINGEN, GERMANY	University of Freiburg								ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; ABE I, 1994, J BIOL CHEM, V269, P802; ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER CH, 1995, BIOCHEM BIOPH RES CO, V213, P154, DOI 10.1006/bbrc.1995.2110; BALLIANO G, 1992, ARCH BIOCHEM BIOPHYS, V293, P122, DOI 10.1016/0003-9861(92)90374-6; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOAR RB, 1984, J AM CHEM SOC, V106, P2476, DOI 10.1021/ja00320a064; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUNTEL CJ, 1992, J AM CHEM SOC, V114, P9711, DOI 10.1021/ja00050a090; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; COREY EJ, 1993, P NATL ACAD SCI USA, V90, P11628, DOI 10.1073/pnas.90.24.11628; Corey EJ, 1996, BIOCHEM BIOPH RES CO, V219, P327, DOI 10.1006/bbrc.1996.0232; Corey EJ, 1997, J AM CHEM SOC, V119, P1277, DOI 10.1021/ja963227w; COREY EJ, 1994, P NATL ACAD SCI USA, V91, P2211, DOI 10.1073/pnas.91.6.2211; Corey EJ, 1997, J AM CHEM SOC, V119, P1289, DOI 10.1021/ja963228o; CORNFORT.JW, 1965, J AM CHEM SOC, V87, P3224, DOI 10.1021/ja01092a038; ESCHENMOSER A, 1955, HELV CHIM ACTA, V38, P1890, DOI 10.1002/hlca.19550380728; Feil C, 1996, EUR J BIOCHEM, V242, P51, DOI 10.1111/j.1432-1033.1996.0051r.x; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; JOHNSON WS, 1987, J AM CHEM SOC, V109, P5852, DOI 10.1021/ja00253a048; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kaneko T, 1996, DNA Res, V3, P109; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NEUMANN S, 1986, BIOL CHEM H-S, V367, P723, DOI 10.1515/bchm3.1986.367.2.723; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OCHS D, 1990, EUR J BIOCHEM, V194, P75, DOI 10.1111/j.1432-1033.1990.tb19429.x; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; OURISSON G, 1992, ACCOUNTS CHEM RES, V25, P403, DOI 10.1021/ar00021a004; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; REIPEN IG, 1995, MICROBIOL-SGM, V141, P155, DOI 10.1099/00221287-141-1-155; ROESSNER CA, 1993, GENE, V127, P149, DOI 10.1016/0378-1119(93)90631-C; SECKLER B, 1986, BIOCHIM BIOPHYS ACTA, V881, P356, DOI 10.1016/0304-4165(86)90027-9; SHI Z, 1994, P NATL ACAD SCI USA, V91, P7370, DOI 10.1073/pnas.91.15.7370; SIMON SA, 1977, BIOPHYS J, V19, P83, DOI 10.1016/S0006-3495(77)85570-7; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; VANTAMELEN EE, 1982, J AM CHEM SOC, V104, P6480, DOI 10.1021/ja00387a070; Wendt KU, 1997, PROTEIN SCI, V6, P722; WOODWARD RB, 1953, J AM CHEM SOC, V75, P2023, DOI 10.1021/ja01104a535; ZHENG YF, 1995, J AM CHEM SOC, V117, P670, DOI 10.1021/ja00107a011	46	363	377	5	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	1997	277	5333					1811	1815		10.1126/science.277.5333.1811	http://dx.doi.org/10.1126/science.277.5333.1811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XX298	9295270				2022-12-01	WOS:A1997XX29800044
J	Jack, D				Jack, D			Hot shots inside the body	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 13	1997	350	9080					790	790		10.1016/S0140-6736(05)62583-4	http://dx.doi.org/10.1016/S0140-6736(05)62583-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XW282	9298011				2022-12-01	WOS:A1997XW28200035
J	Frank, SH; Stange, KC; Langa, D; Workings, M				Frank, SH; Stange, KC; Langa, D; Workings, M			Direct observation of community-based ambulatory encounters involving medical students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE; PRODUCTIVITY; ATTITUDES; COSTS	Context.-The current shift of predoctoral medical education from inpatient tertiary settings to community-based, ambulatory practice has raised questions about the effect of the medical student on the process of patient care. Objective.-To determine how the presence of a medical student during the ambulatory medical encounter affects the use of clinical time and patient satisfaction. Design.-Cross-sectional, multimethod study using direct observation of ambulatory care by research-trained nurses. Setting.-A total of 16 community-based family practice offices accepting family practice clerkship students. Patients.-A total of 452 outpatient visits with and without student involvement. Main Outcome Measures.-Clinical time use as measured by the Davis Observation Code; patient satisfaction was assessed with the Medical Outcomes Study 9-item visit rating scale. Results.-When students were involved, physicians spent more time discussing visit expectations (P=.03) and less time in history taking (P=.007), providing assessment (P=.01), and answering questions (P=.04), Despite these differences, patients were equally satisfied with explanations received, and there was no change in the rank order of the 5 most commonly observed physician behaviors. There was no difference in time spent in treatment planning, physical examination, health education, or social chatting. The physician spent equal time with the patient with (10.3 minutes) and without (9.9 minutes, P=.6) student involvement, There was no decrease in patient satisfaction when students were involved. Physicians were more likely to discuss another family member's problems when a student was present (P=.001). Students were directed to care for minority patients at a disproportionate rate (P=.001), controlling for confounding variables. Conclusions.-Medical student involvement alters the content but not the duration of the ambulatory medical encounter. Application of validated measures indicate that students did not impair patient satisfaction or hinder the physicians' ability to ensure that patient expectations for the visit were met.	CASE WESTERN RESERVE UNIV, DEPT SOCIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CTR CANC RES, CLEVELAND, OH 44106 USA; HENRY FORD HLTH SYST, DEPT FAMILY MED, DETROIT, MI USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Henry Ford Health System; Henry Ford Hospital	Frank, SH (corresponding author), CASE WESTERN RESERVE UNIV, DEPT FAMILY MED, 10900 EUCLID AVE, CLEVELAND, OH 44106 USA.		Frank, Scott/R-5727-2019	Frank, Scott/0000-0002-2303-5922	NCI NIH HHS [1R01 CA60862] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060862] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM AC FAM PHYS, 1994, FACTS FAM PRACT; [Anonymous], 1993, ACAD MED, V68, P1; Bertakis K D, 1992, Fam Med, V24, P307; Bertakis K D, 1993, Fam Med, V25, P530; Callahan E J, 1993, Fam Pract Res J, V13, P171; Callahan E J, 1996, Fam Med, V28, P346; Callahan E J, 1991, Fam Med, V23, P19; Crandall L A, 1986, J Rural Health, V2, P7, DOI 10.1111/j.1748-0361.1986.tb00142.x; Delbanco T L, 1988, J Gen Intern Med, V3, pS34, DOI 10.1007/BF02600250; Doyle G A, 1997, Fam Med, V29, P12; FIELDS SA, 1994, ACAD MED, V69, pS87, DOI 10.1097/00001888-199410000-00052; FLOCKE SA, IN PRESS J FAM PRACT; GARG ML, 1991, ACAD MED, V66, P348, DOI 10.1097/00001888-199106000-00009; KEARL GW, 1993, ACAD MED, V68, P166, DOI 10.1097/00001888-199302000-00017; KIRZ HL, 1986, JAMA-J AM MED ASSOC, V256, P734, DOI 10.1001/jama.256.6.734; PAWLSON LG, 1980, J FAM PRACTICE, V10, P847; PERKOFF GT, 1986, NEW ENGL J MED, V314, P27, DOI 10.1056/NEJM198601023140105; PETERSDORF RG, 1989, JAMA-J AM MED ASSOC, V262, P826, DOI 10.1001/jama.262.6.826; Robbins J A, 1993, Fam Med, V25, P17; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SCHAPPERT SM, 1996, ADV DATA, V273, P1; SIMONS RJ, 1995, J GEN INTERN MED, V10, P251, DOI 10.1007/BF02599880; SOSTOK MA, 1995, ACAD MED, V70, P949, DOI 10.1097/00001888-199511000-00003; STIMMEL B, 1992, JAMA-J AM MED ASSOC, V268, P2060, DOI 10.1001/jama.268.15.2060; VINSON DC, 1994, ACAD MED, V69, P237, DOI 10.1097/00001888-199403000-00020; Vinson DC, 1996, J FAM PRACTICE, V42, P243; WARE JE, 1992, MEASURING FUNCTIONIN, P291; YORK NL, 1995, AM J SURG, V169, P421, DOI 10.1016/S0002-9610(99)80189-5	28	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	1997	278	9					712	716		10.1001/jama.278.9.712	http://dx.doi.org/10.1001/jama.278.9.712			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XT709	9286829				2022-12-01	WOS:A1997XT70900022
J	Wada, T; Tachibana, T; Shimura, Y; Okada, K				Wada, T; Tachibana, T; Shimura, Y; Okada, K			Epidermal cell differentiation in Arabidopsis determined by a Myb homolog, CPC	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; REGULATORY GENE; ROOT; THALIANA; PROTEIN; DOMAIN; PLANT; ORGANIZATION; ENCODES	The roots of plants normally carry small hairs arranged in a regular pattern. Transfer DNA-tagged lines of Arabidopsis thaliana included a mutant with few, randomly distributed root hairs. The mutated gene CAPRICE (CPC) encoded a protein with a Myb-like DNA binding domain typical of transcription factors involved in animal and plant development. Analysis in combination with other root hair mutations showed that CPC may work together with the TTG gene and upstream of the GL2 gene, Transgenic plants overexpressing CPC had more root hairs and fewer trichomes than normal. Thus, the CPC gene determines the fate of epidermal cell differentiation in Arabidopsis.	KYOTO UNIV,GRAD SCH SCI,DEPT BOT,KYOTO 60601,JAPAN; NATL INST BASIC BIOL,DIV GENE EXPRESS & REGULAT 1,OKAZAKI,AICHI 444,JAPAN; KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University				Tachibana, Tatsuhiko/0000-0001-8339-3986				ANZAI H, 1990, NUCLEIC ACIDS RES, V18, P1890, DOI 10.1093/nar/18.7.1890; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1994, TRENDS GENET, V10, P84, DOI 10.1016/0168-9525(94)90230-5; CHANG SS, 1994, PLANT J, V5, P551, DOI 10.1046/j.1365-313X.1994.5040551.x; CONE KC, 1993, PLANT CELL, V5, P1795, DOI 10.1105/tpc.5.12.1795; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DOLAN L, 1994, DEVELOPMENT, V120, P2465; DOLAN L, 1993, DEVELOPMENT, V119, P71; GALWAY ME, 1994, DEV BIOL, V166, P710; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4687; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Massucci JD, 1996, DEVELOPMENT, V122, P1253; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; NODA K, 1994, NATURE, V369, P661, DOI 10.1038/369661a0; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OKADA K, 1990, SCIENCE, V250, P274, DOI 10.1126/science.250.4978.274; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3353; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; WADA T, UNPUB	24	439	479	6	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 22	1997	277	5329					1113	1116		10.1126/science.277.5329.1113	http://dx.doi.org/10.1126/science.277.5329.1113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262483				2022-12-01	WOS:A1997XT03300040
J	Portenoy, RK; Dole, V; Joseph, H; Lowinson, J; Rice, C; Segal, S; Richman, BL				Portenoy, RK; Dole, V; Joseph, H; Lowinson, J; Rice, C; Segal, S; Richman, BL			Pain management and chemical dependency - Evolving perspectives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ADDICTION; CANCER		MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,PAIN & PALLIAT CARE SERV,NEW YORK,NY 10021; ROCKEFELLER UNIV,NEW YORK,NY 10021; NEW YORK STATE OFF ALCOHOLISM & SUBST ABUSE SERV,NEW YORK,NY	Memorial Sloan Kettering Cancer Center; Rockefeller University	Portenoy, RK (corresponding author), BETH ISRAEL MED CTR,DEPT PAIN MED & PALLIAT CARE,1ST AVE & 16TH ST,NEW YORK,NY 10003, USA.							*AD HOC COMM CANC, 1992, J CLIN ONCOL, V10, P1976; ANGAROLA RT, 1989, ADV PAIN RES THER, V11, P213; [Anonymous], [No title captured]; BESSON JM, 1987, PHYSIOL REV, V67, P67, DOI 10.1152/physrev.1987.67.1.67; BREITBART W, 1996, PAIN, V65, P239; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; COOPER JR, 1992, JAMA-J AM MED ASSOC, V268, P1306, DOI 10.1001/jama.268.10.1306; ELLIOTT KJ, IN PRESS ANESTHESIA; Jacox A., 1994, AHCPR PUBLICATION; JORANSON DE, 1992, FED B, V4, P415; NESTLER EJ, 1994, NEUROPSYCHOPHARMACOL, V11, P77, DOI 10.1038/npp.1994.37; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; PORTENOY RK, 1997, SUBSTANCE ABUSE COMP, P563; SEES KL, 1993, J PAIN SYMPTOM MANAG, V8, P257, DOI 10.1016/0885-3924(93)90154-N; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L; World Health Organization, 1996, CANC PAIN REL GUID O, V2nd	16	53	55	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					592	593		10.1001/jama.278.7.592	http://dx.doi.org/10.1001/jama.278.7.592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ986	9268282				2022-12-01	WOS:A1997XQ98600035
J	Marafioti, T; Hummel, M; Anagnostopoulos, I; Foss, HD; Falini, B; Delsol, G; Isaacson, PG; Pileri, S; Stein, H				Marafioti, T; Hummel, M; Anagnostopoulos, I; Foss, HD; Falini, B; Delsol, G; Isaacson, PG; Pileri, S; Stein, H			Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REED-STERNBERG CELLS; GENE REARRANGEMENTS; SOMATIC MUTATIONS; CHAIN; NEOPLASMS; LYMPHOMAS; SUBTYPE; LINEAGE; MARKER; PCR	Background The atypical cells of nodular lymphocyte-predominant Hodgkin's disease, designated lymphocytic and histiocytic (L&H) cells, have a B-cell phenotype. To clarify the clonality of these cells, we studied rearranged immunoglobulin genes for the variable region of the heavy chain (V-H genes) in individual L&H cells from 11 patients with nodular lymphocyte-predominant Hodgkin's disease. We also studied the expression of immunoglobulin light chains by those cells in six of the same patients. Methods Single CD20+ L&H cells were isolated from frozen sections by a technique of micromanipulation. The rearranged V-H genes of these cells were amplified by the polymerase chain reaction (PCR), sequenced, and compared with germ-line V-H genes. Immunoglobulin light-chain messenger RNA (mRNA) was detected by in situ hybridization. Results Of 615 L&H cells isolated from all the frozen sections, 160 yielded PCR products. In each of the 11 patients, the L&H cells that could be evaluated had identically rearranged V-H genes, whether they were isolated from the same nodule, different nodules, or different blocks of tissue. All the V-H sequences derived from the L&H cells were highly mutated (7.5 to 27.2 percent). in two cases the coding capacity of the V-H genes was completely or partially disrupted by mutations. Intraclonal diversity was found in six cases, and monotypic immunoglobulin light-chain mRNA was found in six. Conclusions The L&H cells of nodular lymphocyte-predominant Hodgkin's disease represent a monoclonal expansion of B cells. The high load of V-H gene mutations and signs of intraclonal diversity suggest a relation between L&H cells and germinal-center B cells at the centroblastic stage of differentiation. (C) 1997, Massachusetts Medical Society.	FREE UNIV BERLIN, KLINIKUM BENJAMIN FRANKLIN, INST PATHOL, D-12200 BERLIN, GERMANY; CONSULTAT & REFERENCE CTR LYMPH NODE PATHOL & HAE, BERLIN, GERMANY; UNIV PERUGIA, INST HEMATOL, I-06100 PERUGIA, ITALY; CHU PURPAN, HOP TOULOUSE, LAB CENT ANAT PATHOL, TOULOUSE, FRANCE; UCL, SCH MED, DEPT HISTOPATHOL, LONDON, ENGLAND; UNIV BOLOGNA, SEZ EMOLINFOPATOL, SERV ANAT PATOL 2, BOLOGNA, ITALY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Perugia; CHU de Toulouse; University of London; University College London; UCL Medical School; University of Bologna			Marafioti, Teresa/B-4493-2009; Marafioti, Teresa/AAA-4652-2019; Pileri, Stefano/AAP-6337-2020	Marafioti, Teresa/0000-0003-1223-6275; Marafioti, Teresa/0000-0003-1223-6275; FALINI, Brunangelo/0000-0002-7198-5965				ANGEL CA, 1993, J CLIN PATHOL, V46, P337, DOI 10.1136/jcp.46.4.337; ANGEL CA, 1993, J CLIN PATHOL, V46, P940, DOI 10.1136/jcp.46.10.940; COLBY TV, 1982, CANCER, V49, P1848, DOI 10.1002/1097-0142(19820501)49:9<1848::AID-CNCR2820490918>3.0.CO;2-Y; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; DELABIE J, 1994, BLOOD, V84, P3291; Falini B, 1996, BLOOD, V87, P465, DOI 10.1182/blood.V87.2.465.bloodjournal872465; FOSS HD, 1993, BRIT J HAEMATOL, V84, P627, DOI 10.1111/j.1365-2141.1993.tb03138.x; Greiner TC, 1996, BLOOD, V88, P657, DOI 10.1182/blood.V88.2.657.bloodjournal882657; HANSMANN ML, 1990, AM J CLIN PATHOL, V93, P219, DOI 10.1093/ajcp/93.2.219; HARRIS NL, 1994, BLOOD, V84, P1361; Hell K, 1995, HISTOPATHOLOGY, V27, P491, DOI 10.1111/j.1365-2559.1995.tb00319.x; HUMMEL M, 1995, NEW ENGL J MED, V333, P901, DOI 10.1056/NEJM199510053331403; HUMMEL M, 1994, BLOOD, V84, P403; Jackson H, 1944, NEW ENGL J MED, V230, P1, DOI 10.1056/NEJM194401062300101; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; KORKOLOPOULOU P, 1994, HISTOPATHOLOGY, V24, P511; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; LUKES RJ, 1966, CANCER RES, V26, P1063; MARKS JD, 1991, EUR J IMMUNOL, V21, P985, DOI 10.1002/eji.1830210419; Pan LX, 1996, BLOOD, V87, P2428, DOI 10.1182/blood.V87.6.2428.bloodjournal8762428; PASCUAL V, 1994, J EXP MED, V180, P329, DOI 10.1084/jem.180.1.329; PINKUS GS, 1988, AM J PATHOL, V133, P211; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; REE HJ, 1989, CANCER, V63, P2030, DOI 10.1002/1097-0142(19890515)63:10<2030::AID-CNCR2820631027>3.0.CO;2-P; REGULA DP, 1988, NEW ENGL J MED, V318, P214, DOI 10.1056/NEJM198801283180404; ROTH J, 1994, INT J CANCER, V57, P799, DOI 10.1002/ijc.2910570607; SCHMID C, 1991, AM J PATHOL, V139, P1281; STEIN H, 1986, AM J CLIN PATHOL, V86, P292, DOI 10.1093/ajcp/86.3.292; STOLER MH, 1995, AM J PATHOL, V146, P812; SUNDEEN JT, 1988, AM J SURG PATHOL, V12, P599; TAMARU J, 1994, BLOOD, V84, P708; WICKERT RS, 1995, BLOOD, V86, P2312, DOI 10.1182/blood.V86.6.2312.bloodjournal8662312	34	240	246	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	1997	337	7					453	458		10.1056/NEJM199708143370703	http://dx.doi.org/10.1056/NEJM199708143370703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XQ499	9250847				2022-12-01	WOS:A1997XQ49900003
J	Price, CSC				Price, CSC			Conspecific sperm precedence in Drosophila	NATURE			English	Article							MELANOGASTER; DISPLACEMENT; HOMOGAMY; FEMALES; PROTEIN	Traits that influence the interactions between males and females can evolve very rapidly through sexual selection(1) or sexually antagonistic coevolution(2). Rapid change in the fertilization systems of independent populations can give rise to reproductive incompatibilities between populations(3,4), and may contribute to speciation(5). Here I provide evidence for cryptic reproductive divergence among three sibling species of Drosophila that leads to a form of postmating isolation. When a female mates with both a conspecific and a heterospecific male, the conspecific sperm fertilize the vast majority of the eggs, regardless of the order of the matings. Heterospecific sperm fertilize fewer eggs after these double matings than after single matings. Experiments using spermless males show that the seminal fluid of the conspecific male is largely responsible for this conspecific sperm precedence. Moreover, when two males of the same species mate sequentially with a female from a different species, a highly variable pattern of sperm precedence replaces the second-male sperm precedence that is consistently found within species. These results indicate that females mediate sperm competition, and that second-male sperm precedence is not an automatic consequence of the mechanics of sperm storage.			Price, CSC (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.							[Anonymous], [No title captured]; BELLA JL, 1992, HEREDITY, V68, P345, DOI 10.1038/hdy.1992.49; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CLARK AG, 1995, GENETICS, V139, P189; COYNE JA, 1993, EVOLUTION, V47, P778, DOI 10.1111/j.1558-5646.1993.tb01233.x; DAVID J, 1974, ANN GENET-PARIS, V17, P235; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; Fisher R.A., 1930, GENETICAL THEORY NAT; GREGORY PG, 1997, EVOLUTION, V48, P705; GROMKO MH, 1964, SPERM COMPETITION EV, P371; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; HERNDON LA, 1995, P NATL ACAD SCI USA, V92, P10114, DOI 10.1073/pnas.92.22.10114; HEWITT GM, 1989, HEREDITY, V62, P343, DOI 10.1038/hdy.1989.49; Hughes KA, 1997, GENETICS, V145, P139; INGMANBAKER J, 1980, BIOCHEM GENET, V18, P809, DOI 10.1007/BF00484595; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; PALUMBI SR, 1991, MOL BIOL EVOL, V8, P227; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; PYLE DW, 1978, EXPERIENTIA, V34, P449, DOI 10.1007/BF01935920; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; WADE MJ, 1994, HEREDITY, V72, P163, DOI 10.1038/hdy.1994.23	22	161	163	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 14	1997	388	6643					663	666		10.1038/41753	http://dx.doi.org/10.1038/41753			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ863	9262398	Bronze			2022-12-01	WOS:A1997XQ86300046
J	Shadmehr, R; Holcomb, HH				Shadmehr, R; Holcomb, HH			Neural correlates of motor memory consolidation	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; INITIATED HAND MOVEMENTS; PREMOTOR CORTEX; FUNCTIONAL-ANATOMY; NEURONAL-ACTIVITY; ELBOW MOVEMENTS; BLOOD-FLOW; CEREBELLUM; MONKEY; MODEL	Computational studies suggest that acquisition of a motor skill involves learning an internal model of the dynamics of the task, which enables the brain to predict and compensate for mechanical behavior. During the hours that follow completion of practice, representation of the internal model gradually changes, becoming less fragile with respect to behavioral interference. Here, functional imaging of the brain demonstrates that within 6 hours after completion of practice, while performance remains unchanged, the brain engages new regions to perform the task; there is a shift from prefrontal regions of the cortex to the premotor, posterior parietal, and cerebellar cortex structures. This shift is specific to recall of an established motor skill and suggests that with the passage of time, there is a change in the neural representation of the internal model and that this change may underlie its increased functional stability.	UNIV MARYLAND,MARYLAND PSYCHIAT RES CTR,BALTIMORE,MD 21228; JOHNS HOPKINS UNIV,DEPT RADIOL,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Shadmehr, R (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOMED ENGN,720 RUTLAND AVE,419 TRAYLOR,BALTIMORE,MD 21205, USA.							AIZAWA H, 1991, EXP BRAIN RES, V84, P668; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P7041, DOI 10.1073/pnas.91.15.7041; [Anonymous], 1993, BRAIN ACTIVATION; Bastian AJ, 1996, J NEUROPHYSIOL, V76, P492, DOI 10.1152/jn.1996.76.1.492; BOUSSAOUD D, 1993, EXP BRAIN RES, V95, P28; BrashersKrug T, 1996, NATURE, V382, P252, DOI 10.1038/382252a0; Brindley, 1964, INT BRAIN RES ORG B, V3, P80; Carelli RM, 1997, J NEUROSCI, V17, P1804; CHEN YC, 1995, EXP BRAIN RES, V102, P461; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; CONRAD B, 1974, BRAIN RES, V71, P507, DOI 10.1016/0006-8993(74)90994-9; DETTMERS C, 1995, J NEUROPHYSIOL, V74, P802, DOI 10.1152/jn.1995.74.2.802; Flanagan JR, 1997, J NEUROSCI, V17, P1519; FRISTON KJ, 1993, P ROY SOC B-BIOL SCI, V254, P47, DOI 10.1098/rspb.1993.0125; FRISTON KJ, 1992, P ROY SOC B-BIOL SCI, V248, P223, DOI 10.1098/rspb.1992.0065; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Fuster J.M., 1995, MEMORY CEREBRAL CORT; GERMAIN L, 1993, BRAIN RES, V611, P175, DOI 10.1016/0006-8993(93)91792-Q; GHEZ C, 1995, CAN J PHYSIOL PHARM, V73, P273, DOI 10.1139/y95-038; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; Goodkin H. P., 1993, Canadian Journal of Neurological Sciences, V20, pS93; GORDON AM, 1993, J NEUROPHYSIOL, V69, P1789, DOI 10.1152/jn.1993.69.6.1789; GOTTLIEB GL, 1994, EXP BRAIN RES, V97, P545; Grafton S T, 1994, Hum Brain Mapp, V1, P221, DOI 10.1002/hbm.460010307; GRAFTON ST, 1992, J NEUROSCI, V12, P2542; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; HALSBAND U, 1990, BRAIN, V113, P207, DOI 10.1093/brain/113.1.207; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; HRELJAC A, 1993, BIOL CYBERN, V68, P375, DOI 10.1007/BF00201862; ITO M, 1972, BRAIN RES, V40, P80; JENKINS IH, 1994, J NEUROSCI, V14, P3775; Johnson PB, 1996, CEREB CORTEX, V6, P102, DOI 10.1093/cercor/6.2.102; Jueptner M, 1997, J NEUROPHYSIOL, V77, P1313, DOI 10.1152/jn.1997.77.3.1313; KADEKARO M, 1985, P NATL ACAD SCI USA, V82, P6010, DOI 10.1073/pnas.82.17.6010; KARNI A, 1995, NATURE, V377, P155; KAWASHIMA R, 1995, CEREB CORTEX, V5, P111, DOI 10.1093/cercor/5.2.111; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KAWATO M, 1988, BIOL CYBERN, V59, P161, DOI 10.1007/BF00318008; KIM JJ, 1995, BEHAV NEUROSCI, V109, P195, DOI 10.1037/0735-7044.109.2.195; Kleim JA, 1997, J NEUROSCI, V17, P717; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; LACKNER JR, 1994, J NEUROPHYSIOL, V72, P299, DOI 10.1152/jn.1994.72.1.299; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; MATA M, 1980, J NEUROCHEM, V34, P213, DOI 10.1111/j.1471-4159.1980.tb04643.x; MILNER TE, 1993, EXP BRAIN RES, V94, P522; MITZ AR, 1991, J NEUROSCI, V11, P1855; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OJAKANGAS CL, 1992, J NEUROPHYSIOL, V68, P2222, DOI 10.1152/jn.1992.68.6.2222; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; PascualLeone A, 1996, EXP BRAIN RES, V107, P479; PASSINGHAM RE, 1988, EXP BRAIN RES, V70, P590; PASSINGHAM RE, 1989, BRAIN BEHAV EVOLUT, V33, P189, DOI 10.1159/000115927; PAVLIDES C, 1993, J NEUROPHYSIOL, V70, P733, DOI 10.1152/jn.1993.70.2.733; POIZNER H, 1995, BRAIN, V118, P227, DOI 10.1093/brain/118.1.227; QUINTANA J, 1992, NEUROREPORT, V3, P721, DOI 10.1097/00001756-199208000-00018; RAICHLE ME, 1983, J NUCL MED, V24, P790; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; SASAKI K, 1982, EXP BRAIN RES, V48, P429; SASAKI K, 1986, BRAIN RES, V374, P278, DOI 10.1016/0006-8993(86)90422-1; SCHLAUG G, 1994, EXP BRAIN RES, V98, P523; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Seitz R J, 1990, Neuroreport, V1, P57, DOI 10.1097/00001756-199009000-00016; SEITZ RJ, 1994, NEUROREPORT, V5, P2541, DOI 10.1097/00001756-199412000-00034; SEITZ RJ, 1992, EUR J NEUROSCI, V4, P154, DOI 10.1111/j.1460-9568.1992.tb00862.x; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; Shadmehr R, 1997, J NEUROSCI, V17, P409, DOI 10.1523/JNEUROSCI.17-01-00409.1997; SHADMEHR R, IN PRESS NEUROMECHAN; SHIDARA M, 1993, NATURE, V365, P50, DOI 10.1038/365050a0; SHINDY WW, 1994, CEREB CORTEX, V4, P443, DOI 10.1093/cercor/4.4.443; Sirigu A, 1996, SCIENCE, V273, P1564, DOI 10.1126/science.273.5281.1564; Tanne J, 1995, NEUROREPORT, V7, P267, DOI 10.1097/00001756-199512000-00064; Thach W. T., 1996, Behavioral and Brain Sciences, V19, P411; VILIS T, 1980, J NEUROPHYSIOL, V43, P279, DOI 10.1152/jn.1980.43.2.279; Wise SP, 1996, ACQUISITION OF MOTOR BEHAVIOR IN VERTEBRATES, P261; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; WOODS RP, 1992, J COMPUT ASSIST TOMO, V115, P665; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	78	730	738	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 8	1997	277	5327					821	825		10.1126/science.277.5327.821	http://dx.doi.org/10.1126/science.277.5327.821			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XQ247	9242612				2022-12-01	WOS:A1997XQ24700045
J	Shen, CP; Jan, LY; Jan, YN				Shen, CP; Jan, LY; Jan, YN			Miranda is required for the asymmetric localization of Prospero during mitosis in Drosophila	CELL			English	Article							C-ELEGANS EMBRYOS; PREDICTING COILED COILS; CAENORHABDITIS-ELEGANS; 2-HYBRID SYSTEM; CELL-DIVISION; GENE; PROTEIN; NUMB; SEGREGATION; FATES	Asymmetric division of Drosophila neuroblasts, sensory organ precursor cells, and cells in the procephalic neurogenic region involves the segregation of Numb and Prospero proteins into one of the two daughter cells. We have isolated a novel gene, miranda, based on the ability of its gene product to interact with the Prospero asymmetric localization domain. miranda expression coincides spatially and temporally with asymmetric cell divisions and asymmetric localization of Prospero. Miranda protein is localized asymmetrically, along with Prospero, to the basal cell membrane during mitosis. Loss of miranda gene function abolishes asymmetric Prospero localization during mitosis. The asymmetric localization of Miranda protein requires inscuteable. Our results suggest that miranda functions downstream of inscuteable and works as an adapter that connects Prospero to the basal cell membrane during asymmetric cell division.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shen, CP (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BARTEL PL, 1993, USING 2 HYBRID SYSTE; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)10052-9; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STAUGER C, 1993, CURR OPIN CELL BIOL, V5, P226; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P942; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	40	230	235	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 8	1997	90	3					449	458		10.1016/S0092-8674(00)80505-X	http://dx.doi.org/10.1016/S0092-8674(00)80505-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XQ063	9267025	Bronze			2022-12-01	WOS:A1997XQ06300009
J	Tomb, JF; White, O; Kerlavage, AR; Clayton, RA; Sutton, GG; Fleischmann, RD; Ketchum, KA; Klenk, HP; Gill, S; Dougherty, BA; Nelson, K; Quackenbush, J; Zhou, LX; Kirkness, EF; Peterson, S; Loftus, B; Richardson, D; Dodson, R; Khalak, HG; Glodek, A; McKenney, K; Fitzegerald, LM; Lee, N; Adams, MD; Hickey, EK; Berg, DE; Gocayne, JD; Utterback, TR; Peterson, JD; Kelley, JM; Cotton, MD; Weldman, JM; Fujii, C; Bowman, C; Watthey, L; Wallin, E; Hayes, WS; Weidman, JM; Fujii, C; Borodovsky, M; Karp, PD; Smith, HO; Fraser, CM; Venter, JC				Tomb, JF; White, O; Kerlavage, AR; Clayton, RA; Sutton, GG; Fleischmann, RD; Ketchum, KA; Klenk, HP; Gill, S; Dougherty, BA; Nelson, K; Quackenbush, J; Zhou, LX; Kirkness, EF; Peterson, S; Loftus, B; Richardson, D; Dodson, R; Khalak, HG; Glodek, A; McKenney, K; Fitzegerald, LM; Lee, N; Adams, MD; Hickey, EK; Berg, DE; Gocayne, JD; Utterback, TR; Peterson, JD; Kelley, JM; Cotton, MD; Weldman, JM; Fujii, C; Bowman, C; Watthey, L; Wallin, E; Hayes, WS; Weidman, JM; Fujii, C; Borodovsky, M; Karp, PD; Smith, HO; Fraser, CM; Venter, JC			The complete genome sequence of the gastric pathogen Helicobacter pylori	NATURE			English	Article							MYCOPLASMA-GENITALIUM; GENE; PROTEIN; IDENTIFICATION; EPITHELIUM; INFECTION; MUTATION	Helicobacter pylori, strain 26695, has a circular genome of 1,667,867 base pairs and 1,590 predicted coding sequences, Sequence analysis indicates that H. pylori has well-developed systems for motility, for scavenging iron, and for DNA restriction and modification, Many putative adhesins, lipoproteins and other outer membrane proteins were identified, underscoring the potential complexity of host-pathogen interaction, Based on the large number of sequence-related genes encoding outer membrane proteins and the presence of homopolymeric tracts and dinucleotide repeats in coding sequences, H. pylori, like several other mucosal pathogens, probably uses recombination and slipped-strand mispairing within repeats as mechanisms for antigenic variation and adaptive evolution, Consistent with its restricted niche, H. pylori has a few regulatory networks, and a limited metabolic repertoire and biosynthetic capacity, Its survival in acid conditions depends, in part, on its ability to establish a positive inside-membrane potential in low pH.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL,ST LOUIS,MO 63110; UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN; GEORGIA TECH RES INST,SCH BIOL,ATLANTA,GA 30332; SRI INT,CTR ARTIFICIAL INTELLIGENCE,MENLO PK,CA 94025; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	Washington University (WUSTL); Stockholm University; University System of Georgia; Georgia Institute of Technology; SRI International; Johns Hopkins University	Tomb, JF (corresponding author), INST GENOM RES,9712 MED CTR DR,ROCKVILLE,MD 20850, USA.		; Karp, Peter/C-3514-2012	Kerlavage, Anthony/0000-0002-3954-9653; Quackenbush, John/0000-0002-2702-5879; Fraser, Claire/0000-0003-1462-2428; loftus, brendan/0000-0001-8871-8356; Karp, Peter/0000-0002-5876-6418				Akopyants Natalia S., 1996, Gut, V39, pA67; AKOPYANTS NS, 1995, INFECT IMMUN, V63, P116, DOI 10.1128/IAI.63.1.116-121.1995; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; BAKER PJ, 1994, INFECT IMMUN, V62, P2257, DOI 10.1128/IAI.62.6.2257-2269.1994; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BORODOVSKY M, 1994, NUCLEIC ACIDS RES, V22, P4756, DOI 10.1093/nar/22.22.4756; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLEMENS J, 1995, J INFECT DIS, V171, P1653, DOI 10.1093/infdis/171.6.1653; Cover TL, 1996, ADV INTERNAL MED, V41, P85; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; DOIG P, 1995, J BACTERIOL, V177, P5447, DOI 10.1128/jb.177.19.5447-5452.1995; EARHART CF, 1996, CELLULAR MOL BIOL, P1075; EVANS DJ, 1995, GENE, V153, P123, DOI 10.1016/0378-1119(94)00774-M; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRAZIER BA, 1993, J BACTERIOL, V175, P966, DOI 10.1128/JB.175.4.966-972.1993; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GO MF, 1994, J GASTROENTROL HEP S, V9, P8; HUGHES NJ, 1995, J BACTERIOL, V177, P3953, DOI 10.1128/jb.177.14.3953-3959.1995; Ilver D., 1996, Gut, V39, pA55; Jones A. C., 1996, Gut, V39, pA62; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; Karp PD, 1997, NUCLEIC ACIDS RES, V25, P43, DOI 10.1093/nar/25.1.43; KORNBERG A, 1992, REPLICATION MECH OPE, P471; LINN S, 1996, CELLULAR MOL BIOL, P764; MACNAB RM, 1996, CELLULAR MOL BIOL, P123; MARCZYNSKI GT, 1993, CURR OPIN GENET DEV, V3, P775, DOI 10.1016/S0959-437X(05)80098-X; Matin A, 1996, INFECT IMMUN, V64, P1434, DOI 10.1128/IAI.64.4.1434-1436.1996; McGowan CC, 1996, GASTROENTEROLOGY, V110, P926, DOI 10.1053/gast.1996.v110.pm8608904; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Melchers K., 1996, Gut, V39, pA67; MENDZ GL, 1995, INT J BIOCHEM CELL B, V27, P1085, DOI 10.1016/1357-2725(95)00069-2; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; Moran AP, 1996, ALIMENT PHARM THER, V10, P39, DOI 10.1046/j.1365-2036.1996.22164004.x; MOXON ER, 1994, CURR BIOL, V4, P24, DOI 10.1016/S0960-9822(00)00005-1; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Odenbreit S, 1996, MOL MICROBIOL, V20, P361, DOI 10.1111/j.1365-2958.1996.tb02623.x; Peek R. M., 1996, Gut, V39, pA71; PETERSON SN, 1995, P NATL ACAD SCI USA, V92, P11829, DOI 10.1073/pnas.92.25.11829; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SONNHAMMER ELL, IN PRESS PROTEINS; STROM MS, 1994, METHOD ENZYMOL, V235, P527; SUERBAUM S, 1995, TRENDS MICROBIOL, V3, P168, DOI 10.1016/S0966-842X(00)88913-1; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x; WARREN JR, 1983, LANCET, V1, P1273; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7	50	2872	3663	5	194	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 7	1997	388	6642					539	547		10.1038/41483	http://dx.doi.org/10.1038/41483			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XP722	9252185	Bronze			2022-12-01	WOS:A1997XP72200038
J	Torok, TJ; Tauxe, RV; Wise, RP; Livengood, JR; Sokolow, R; Mauvais, S; Birkness, KA; Skeels, MR; Horan, JM; Foster, LR				Torok, TJ; Tauxe, RV; Wise, RP; Livengood, JR; Sokolow, R; Mauvais, S; Birkness, KA; Skeels, MR; Horan, JM; Foster, LR			A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-This large outbreak of foodborne disease highlights the challenge of investigating outbreaks caused by intentional contamination and demonstrates the vulnerability of self-service foods to intentional contamination. Objective.-To investigate a large community outbreak of Salmonella Typhimurium infections. Design.-Epidemiologic investigation of patients with Salmonella gastroenteritis and possible exposures in The Dalles, Oregon. Cohort and case-control investigations were conducted among groups of restaurant patrons and employees to identify exposures associated with illness. Setting.-A community in Oregon. Outbreak period was September and October 1984. Patients.-A total of 751 persons with Salmonella gastroenteritis associated with eating or working at area restaurants. Most patients were identified through passive surveillance; active surveillance was conducted for selected groups. A case was defined either by clinical criteria or by a stool culture yielding S Typhimurium. Results.-The outbreak occurred in 2 waves, September 9 through 18 and September 19 through October 10. Most cases were associated with 10 restaurants, and epidemiologic studies of customers at 4 restaurants and of employees at all 10 restaurants implicated eating from salad bars as the major risk factor for infection. Eight (80%) of 10 affected restaurants compared with only 3 (11%) of the 28 other restaurants in The Dalles operated salad bars (relative risk, 7.5; 95% confidence interval, 2.4-22.7; P<.001). The implicated food items on the salad bars differed from one restaurant to another. The investigation did not identify any water supply, food item, supplier, or distributor common to all affected restaurants, nor were employees exposed to any single common source. In some instances, infected employees may have contributed to the spread of illness by inadvertently contaminating foods. However, no evidence was found linking ill employees to initiation of the outbreak. Errors in food rotation and inadequate refrigeration on ice-chilled salad bars may have facilitated growth of the S Typhimurium but could not have caused the outbreak. A subsequent criminal investigation revealed that members of a religious commune had deliberately contaminated the salad bars. An S Typhimurium strain found in a laboratory at the commune was indistinguishable from the outbreak strain. Conclusions.-This outbreak of salmonellosis was caused by intentional contamination of restaurant salad bars by members of a religious commune.	CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30333; OREGON HLTH DIV,PORTLAND,OR	Centers for Disease Control & Prevention - USA; Oregon Health & Science University	Torok, TJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,MAILSTOP G-17,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.							BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLASER MJ, 1981, AM J EPIDEMIOL, V114, P663, DOI 10.1093/oxfordjournals.aje.a113237; BUCHWALD DS, 1984, REV INFECT DIS, V6, P345; CALLISTER S, 1985, OREGONIAN       1230, pB1; CALLISTER S, 1985, OREGONIAN          S, P36; DEAN A, 1995, EPI INFO VERSION 6 W; FITZGERALD F, 1986, CITIES HILL; JOSEPH PR, 1965, NEW ENGL J MED, V273, P188, DOI 10.1056/NEJM196507222730403; Kaplan David E., 1996, CULT END WORLD; LAATZ J, 1986, OREGONIAN       0320, pE6; LAATZ J, 1986, OREGONIAN       0320, pA1; LAATZ J, 1986, OREGONIAN       0723, pB2; MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V258, P1496, DOI 10.1001/jama.258.11.1496; MANIATIS T, 1982, MOL CLONING LABORATO, P150; MARTIN WJ, 1980, MANUAL CLIN MICROBIO, P207; PETHER JVS, 1982, J INFECTION, V5, P81, DOI 10.1016/S0163-4453(82)93365-5; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; ROBERTS D, 1982, J HYG-CAMBRIDGE, V89, P491, DOI 10.1017/S0022172400071059; RUBENSTEIN AD, 1953, NEW ENGL J MED, V248, P527, DOI 10.1056/NEJM195303262481301	20	369	384	2	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					389	395		10.1001/jama.278.5.389	http://dx.doi.org/10.1001/jama.278.5.389			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244330				2022-12-01	WOS:A1997XN51800030
J	Vogel, P; Fritz, DL; Kuehl, K; Davis, KJ; Geisbert, T				Vogel, P; Fritz, DL; Kuehl, K; Davis, KJ; Geisbert, T			The agents of biological warfare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Vogel, P (corresponding author), USA,MIL RES INST INFECT DIS,DIV PATHOL,1425 PORTER ST,FT DETRICK,MD 21702, USA.		Vogel, Peter/N-2490-2018	Vogel, Peter/0000-0002-7535-0545					0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					438	439		10.1001/jama.278.5.438	http://dx.doi.org/10.1001/jama.278.5.438			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244340				2022-12-01	WOS:A1997XN51800040
J	DeLaet, CEDH; vanHout, LB; Burger, H; Hofman, A; Pols, HAP				DeLaet, CEDH; vanHout, LB; Burger, H; Hofman, A; Pols, HAP			Bone density and risk of hip fracture in men and women: Cross sectional analysis	BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; ELDERLY MEN; OSTEOPOROSIS; EPIDEMIOLOGY; PREDICTION; MASS; AGE	Objective: To determine the relative contribution of decline in bone density to the increase in risk of hip fracture with age in men and women. Design: Incidence data of hip fracture from the general population were combined with the bone density distribution in a sample from the same population and with a risk estimate of low bone density known fi om literature. Setting: The Netherlands. Subjects: All people with a hospital admission for a hip fracture in 1993, and bone density measured in a sample of 5814 men and women aged 55 years and over in a district of Rotterdam. Main outcome measure: One year cumulative risk of hip fracture by age, sex, and bone density measured at the femoral neck. Results: A quarter of all hip fractures occurred in men. Men reached the same incidence as women at five years older. Controlled for age, the risk of hip fracture by bone density was similar in men and women. The risk of hip fracture increased 13-fold from age 60 to 80; decrease in bone density associated with age contributed 1.9 (95% confidence interval 1.5 to 2.4) in women and 1.6 (1.3 to 1.8) in men. Conclusions: The risk of hip fracture by age and bone density is similar in men and women. The decrease in bone density associated with age makes a limited contribution to the exponential increase of the risk of hip fracture with age.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT INTERNAL MED 3,NL-3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,NL-3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,INST MED TECHNOL ASSESSMENT,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam				De Laet, Chris/0000-0002-1951-2079				BLACK DM, 1992, J BONE MINER RES, V7, P639; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BOEREBOOM FTJ, 1992, OSTEOPOROSIS INT, V2, P279, DOI 10.1007/BF01623183; *CENTR BUR STAT, 1994, STAT JB 1994; *CONS DEV C, 1993, AM J MED, V94, P646; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JONES G, 1994, OSTEOPOROSIS INT, V4, P277, DOI 10.1007/BF01623352; Kanis JA, 1996, OSTEOPOROSIS INT, V6, P256, DOI 10.1007/BF01622743; KANIS JA, 1996, BONE S3, V18, P127; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; MELTON LJ, 1993, BONE, V14, pS1; NEVITT MC, 1994, OSTEOPOROSIS INT, V4, P325, DOI 10.1007/BF01622192; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; Nguyen TV, 1996, AM J EPIDEMIOL, V144, P255, DOI 10.1093/oxfordjournals.aje.a008920; PEARSON J, 1995, OSTEOPOROSIS INT, V5, P174, DOI 10.1007/BF02106097; *SPSS, 1995, STAT PACK SOC SCI RE; STEIGER P, 1992, J BONE MINER RES, V7, P625; TOSS G, 1992, J INTERN MED, V231, P181, DOI 10.1111/j.1365-2796.1992.tb00521.x; VANBURGER H, 1994, BONE MINER, V25, P1	24	255	257	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 26	1997	315	7102					221	225		10.1136/bmj.315.7102.221	http://dx.doi.org/10.1136/bmj.315.7102.221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN517	9253270	Green Published			2022-12-01	WOS:A1997XN51700024
J	Kim, KHS; Relkin, NR; Lee, KM; Hirsch, J				Kim, KHS; Relkin, NR; Lee, KM; Hirsch, J			Distinct cortical areas associated with native and second languages	NATURE			English	Article							BRAIN; SPEECH; REPRESENTATION; ORGANIZATION	The ability to acquire and use several languages selectively is a unique and essential human capacity. Here we investigate the fundamental question of how multiple languages are represented in a human brain. We applied functional magnetic resonance imaging (fMRI) to determine the spatial relationship between native and second languages in the human cortex, and show that within the frontal-lobe language-sensitive regions (Broca's area)(1-3), second languages acquired in adulthood ('late' bilingual subjects) are spatially separated from native languages. However, when acquired during the early language acquisition stage of development ('early' bilingual subjects), native and second languages tend to be represented in common frontal cortical areas. In both late and early bilingual subjects, the temporal-lobe language-sensitive regions (Wernicke's area)(1-3) also show effectively little or no separation of activity based on the age of language acquisition. This discovery of language-specific regions in Broca's area advances our understanding of the cortical representation that underlies multiple language functions.	MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021; CORNELL UNIV MED COLL,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Lee, Kyoung Min/J-2775-2012	Hirsch, Joy/0000-0002-1418-6489				BLACK PM, 1987, NEUROSURGERY, V20, P914, DOI 10.1227/00006123-198706000-00016; DAMASIO H, 1995, HUMAN BRAIN ANATOMY; Damasio H., 1989, LESION ANAL NEUROPSY; Demonet J. F., 1993, Human Brain Mapping, V1, P39, DOI 10.1002/hbm.460010105; GESCHWIND N, 1970, SCIENCE, V170, P640; GOMEZTORTOSA E, 1995, BRAIN LANG, V48, P320, DOI 10.1006/brln.1995.1014; HINKE RM, 1993, NEUROREPORT, V4, P675, DOI 10.1097/00001756-199306000-00018; HIRSCH J, 1995, P NATL ACAD SCI USA, V92, P6469, DOI 10.1073/pnas.92.14.6469; HIRSCH J, 1994, P SOC MAG RES, V2, P637; KLEIN D, 1995, P NATL ACAD SCI USA, V92, P2899, DOI 10.1073/pnas.92.7.2899; KRETSCHMANN HJ, 1992, CRANIAL NEUROIMAGING; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; Meyer KL, 1996, MAGNET RESON MED, V36, P606, DOI 10.1002/mrm.1910360416; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; OJEMANN GA, 1983, BEHAV BRAIN SCI, V6, P189, DOI 10.1017/S0140525X00015491; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PETSCHE H, 1993, ELECTROEN CLIN NEURO, V86, P385, DOI 10.1016/0013-4694(93)90134-H; SCHWARTZ MS, 1994, J NEUROL NEUROSUR PS, V57, P121, DOI 10.1136/jnnp.57.1.121; STEINMETZ H, 1991, NEUROPSYCHOLOGIA, V29, P1149, DOI 10.1016/0028-3932(91)90030-C; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; ZATORRE RJ, 1989, BRAIN LANG, V36, P127, DOI 10.1016/0093-934X(89)90056-4; Zatorre RJ, 1996, CEREB CORTEX, V6, P21, DOI 10.1093/cercor/6.1.21	24	642	667	4	157	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 10	1997	388	6638					171	174		10.1038/40623	http://dx.doi.org/10.1038/40623			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XK109	9217156	Bronze			2022-12-01	WOS:A1997XK10900049
J	Li, JH; Xu, M; Zhou, H; Ma, JY; Potter, H				Li, JH; Xu, M; Zhou, H; Ma, JY; Potter, H			Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation	CELL			English	Article							APOLIPOPROTEIN-E; DISEASE GENE; MISSENSE MUTATIONS; DOWNS-SYNDROME; BETA-PROTEIN; IN-VITRO; LAMIN-B; APOPTOSIS; EXPRESSION; SCLERODERMA	Mutations in two related genes, presenilin 1 and 2, account for most early-onset familial Alzheimer's disease. Although structural features indicate that the presenilins are membrane proteins, their function(s) is unknown. We have localized the presenilins to the nuclear membrane, its associated interphase kinetochores, and the centrosomes-all subcellular structures involved in cell cycle regulation and mitosis. The colocalization of the presenilins with kinetochores on the nucleoplasmic surface of the inner nuclear membrane, together with other results, suggests that they may play a role in chromosome organization and segregation, perhaps as kinetochore binding proteins/receptors. We discuss a pathogenic pathway for familial Alzheimer's disease in which defective presenilin function causes chromosome missegregation during mitosis, resulting in apoptosis and/or trisomy 21 mosaicism.	HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIA NIH HHS [AG08084, AG09665] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009665, R01AG008084] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; Deng GM, 1996, FEBS LETT, V397, P50, DOI 10.1016/S0014-5793(96)01142-8; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Dewji NN, 1996, SCIENCE, V271, P159, DOI 10.1126/science.271.5246.159; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Elder GA, 1996, J NEUROSCI RES, V45, P308; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LeBlanc A, 1995, J NEUROSCI, V15, P7837; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Ma JY, 1996, NEUROBIOL AGING, V17, P773; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Martins RH, 1995, NEUROREPORT, V7, P217, DOI 10.1097/00001756-199512290-00052; MCKEON FD, 1983, P NATL ACAD SCI-BIOL, V80, P4374, DOI 10.1073/pnas.80.14.4374; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Mitchell AR, 1996, MUTAT RES-FUND MOL M, V372, P153, DOI 10.1016/S0027-5107(96)00135-2; MOROI Y, 1981, J CELL BIOL, V90, P254, DOI 10.1083/jcb.90.1.254; Moussaoui S, 1996, FEBS LETT, V383, P219, DOI 10.1016/0014-5793(96)00250-5; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; POTTER H, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P643; POTTER H, 1991, AM J HUM GENET, V48, P1192; Potter H, 1996, LANCET, V348, P66, DOI 10.1016/S0140-6736(05)64399-1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHWEBER M, 1985, ANN NY ACAD SCI, V450, P223, DOI 10.1111/j.1749-6632.1985.tb21495.x; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STONE JF, 1995, MUTAT RES-DNAGING G, V338, P107, DOI 10.1016/0921-8734(95)00016-Y; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; Takashima A, 1996, BIOCHEM BIOPH RES CO, V227, P423, DOI 10.1006/bbrc.1996.1523; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; TUFFANELLI DL, 1983, ARCH DERMATOL, V119, P560, DOI 10.1001/archderm.119.7.560; Varmus H., 1993, GENES BIOL CANC; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; WINEY M, 1993, J CELL BIOL, V122, P743, DOI 10.1083/jcb.122.4.743; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; YE Q, 1994, J BIOL CHEM, V269, P11306; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	71	184	190	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 5	1997	90	5					917	927		10.1016/S0092-8674(00)80356-6	http://dx.doi.org/10.1016/S0092-8674(00)80356-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XV563	9298903	Bronze			2022-12-01	WOS:A1997XV56300012
J	Michalet, X; Ekong, R; Fougerousse, F; Rousseaux, S; Schurra, C; Hornigold, N; vanSlegtenhorst, M; Wolfe, J; Povey, S; Beckmann, JS; Bensimon, A				Michalet, X; Ekong, R; Fougerousse, F; Rousseaux, S; Schurra, C; Hornigold, N; vanSlegtenhorst, M; Wolfe, J; Povey, S; Beckmann, JS; Bensimon, A			Dynamic molecular combing: Stretching the whole human genome for high-resolution studies	SCIENCE			English	Article							IN-SITU HYBRIDIZATION; TUBEROUS-SCLEROSIS; PRENATAL-DIAGNOSIS; HUMAN-CHROMOSOMES; CANDIDATE REGION; COSMID CONTIGS; DNA; CHROMATIN; 9Q34; CELLS	DNA in amounts representative of hundreds of eukaryotic genomes was extended on silanized surfaces by dynamic molecular combing. The precise measurement of hybridized DNA probes was achieved directly without requiring normalization. This approach was validated with the high-resolution mapping of cosmid contigs on a yeast artificial chromosome (YAC) within yeast genomic DNA. It was extended to human genomic DNA for precise measurements ranging from T to 150 kilobases, of gaps within a contig, and of microdeletions in the tuberous sclerosis 2 gene on patients' DNA. The simplicity, reproducibility, and precision of this approach makes it a powerful tool for a variety of genomic studies.	INST PASTEUR, DEPT BIOTECHNOL, LAB BIOPHYS ADN, F-75724 PARIS 15, FRANCE; UCL, MRC, HUMAN BIOCHEM GENET UNIT, LONDON NW1 2HE, ENGLAND; GENETHON, URA 1922, F-91002 EVRY, FRANCE; UCL, DEPT BIOL, GALTON LAB, LONDON NW1 2HE, ENGLAND; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, NL-3015 GE ROTTERDAM, NETHERLANDS	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of London; University College London; University of London; University College London; Erasmus University Rotterdam			Beckmann, Jacques Simon/A-9772-2008; Michalet, Xavier/A-9704-2009; Rousseaux, Sophie/G-1697-2013	Beckmann, Jacques Simon/0000-0002-9741-1900; Michalet, Xavier/0000-0001-6602-7693; Rousseaux, Sophie/0000-0001-5246-5350; Ekong, Rosemary/0000-0002-5984-7893	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEMAND JF, IN PRESS BIOPHYS J; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON A, 1995, PHYS REV LETT, V76, P4754; BLANCATO JK, 1995, J REPROD MED, V40, P537; Boysen C, 1997, GENOME RES, V7, P330, DOI 10.1101/gr.7.4.330; BROOKCARTER PT, 1994, NAT GENET, V8, P328, DOI 10.1038/ng1294-328; Cheung MC, 1996, NAT GENET, V14, P264, DOI 10.1038/ng1196-264; CHUMAKOV IM, 1995, NATURE S, V373, P175; DAVIES KE, 1988, GENOME ANAL PRACTICA; EKONG R, UNPUB; EVANS IH, 1996, METHOD MOL BIOL, V53, P71; FIDLEROVA H, 1994, CYTOGENET CELL GENET, V65, P203, DOI 10.1159/000133632; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLORIJN RJ, 1995, HUM MOL GENET, V4, P831, DOI 10.1093/hmg/4.5.831; FOUGEROUSSE F, 1994, HUM MOL GENET, V3, P285, DOI 10.1093/hmg/3.2.285; GIBBS RA, 1995, NAT GENET, V11, P121, DOI 10.1038/ng1095-121; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; GROFFEAU A, 1996, SCIENCE, V274, P546; HAAF T, 1994, HUM MOL GENET, V3, P697, DOI 10.1093/hmg/3.5.697; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; HEISKANEN M, 1995, GENOMICS, V30, P31, DOI 10.1006/geno.1995.0005; Hornigold N, 1997, GENOMICS, V41, P385, DOI 10.1006/geno.1997.4681; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; MENG X, 1995, NAT GENET, V9, P432, DOI 10.1038/ng0495-432; MICHALET X, UNPUB; NAHMIAS J, 1995, EUR J HUM GENET, V3, P65; NELLIST M, 1993, CELL, V75, P1305; Niederacher D, 1997, GENE CHROMOSOME CANC, V18, P181, DOI 10.1002/(SICI)1098-2264(199703)18:3<181::AID-GCC5>3.0.CO;2-Y; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; PERTL B, 1994, LANCET, V343, P1197, DOI 10.1016/S0140-6736(94)92404-X; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; RICHARD I, 1995, MAMM GENOME, V6, P754, DOI 10.1007/BF00354303; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAMPSON J, COMMUNICATION; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; SENGER G, 1994, HUM MOL GENET, V3, P1275, DOI 10.1093/hmg/3.8.1275; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Tomizuka K, 1997, NAT GENET, V16, P133, DOI 10.1038/ng0697-133; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; VANSLEGTENHORST M, 1995, EUR J HUM GENET, V3, P78; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; WEIER HUG, 1995, HUM MOL GENET, V4, P1903; WIEGANT J, 1992, HUM MOL GENET, V1, P587, DOI 10.1093/hmg/1.8.587; Yokota H, 1997, NUCLEIC ACIDS RES, V25, P1064, DOI 10.1093/nar/25.5.1064	48	481	527	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	1997	277	5331					1518	1523		10.1126/science.277.5331.1518	http://dx.doi.org/10.1126/science.277.5331.1518			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XV429	9278517				2022-12-01	WOS:A1997XV42900044
J	Forti, L; Bossi, M; Bergamaschi, A; Villa, A; Malgaroli, A				Forti, L; Bossi, M; Bergamaschi, A; Villa, A; Malgaroli, A			Loose-patch recordings of single quanta at individual hippocampal synapses	NATURE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC CURRENTS; RAT HIPPOCAMPUS; NEURONS; SLICES; VARIABILITY; MINIATURE; CHANNELS; CLAMP; CA3	Synapses in the central nervous system are typically studied by recording electrical responses from the cell body of the postsynaptic cell. Because neurons are normally connected by multiple synaptic contacts, these postsynaptic responses reflect the combined activity of many thousands synapses, and it remains unclear to what extent the properties of individual synapses can be deduced from the population response(1-5). We have therefore developed a method for recording the activity of individual hippocampal synapses. By capturing an isolated presynaptic bouton inside a loose-patch pipette and recording from the associated patch of postsynaptic membrane, we were able to detect miniature excitatory postsynaptic currents ('minis') arising from spontaneous vesicle exocytosis at a single synaptic site, and to compare these with minis recorded simultaneously from the cell body. The average peak conductance at a single synapse was about 900 pS, corresponding roughly to the opening of 90 AMPA-type glutamate-receptor channels, The variability in this conductance was about 30%, matching the value reported for the neuromuscular junction(6). Given that our synapses displayed single postsynaptic densities (PSDs), this variability is larger than would be predicted from the random opening of receptor channels, suggesting that they are not saturated by the content of a single vesicle. Therefore the response to a quantum of neurotransmitter at these synapses is not limited by the number of available postsynaptic receptors.	SAN RAFFAELE SCI INST,DIBIT,DEPT BIOL & TECHNOL RES,I-20123 MILAN,ITALY; UNIV MILAN,CELLULAR & MOL PHARMACOL CTR,CNR,DEPT PHARMACOL,I-20123 MILAN,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); University of Milan			Villa, Antonello/B-4781-2012; Forti, Lia/AAU-8156-2020; Malgaroli, Antonio/I-5090-2013; Forti, Lia/E-9957-2018	Forti, Lia/0000-0003-3979-0284; Malgaroli, Antonio/0000-0003-3758-7477; Forti, Lia/0000-0003-3979-0284; Villa, Antonello/0000-0002-3820-8072	Telethon [D.044] Funding Source: Medline	Telethon(Fondazione Telethon)		Bauerfeind Rudol, 1994, Trends in Cell Biology, V4, P155, DOI 10.1016/0962-8924(94)90191-0; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EDWARDS FA, 1995, PHYSIOL REV, V75, P759, DOI 10.1152/physrev.1995.75.4.759; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FABER DS, 1992, SCIENCE, V258, P1494, DOI 10.1126/science.1279813; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; FERKING M, 1996, CURR OPIN NEUROBIOL, V6, P395; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JACK JJB, 1994, ADV SEC MESS PHOSPH, V29, P275; JACK JJB, 1983, ELECTRIC CURRENT FLO; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KORN H, 1994, ADV SEC MESS PHOSPH, V29, P301; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; Lewis CA, 1996, J NEUROPHYSIOL, V76, P461, DOI 10.1152/jn.1996.76.1.461; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; Stricker C, 1996, J PHYSIOL-LONDON, V490, P419, DOI 10.1113/jphysiol.1996.sp021155; STUEHMER W, 1983, SINGLE CHANNEL RECOR, P123	30	145	148	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 28	1997	388	6645					874	878		10.1038/42251	http://dx.doi.org/10.1038/42251			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT754	9278048	Bronze			2022-12-01	WOS:A1997XT75400049
J	Kolodkin, AL; Levengood, DV; Rowe, EG; Tai, YT; Giger, RJ; Ginty, DD				Kolodkin, AL; Levengood, DV; Rowe, EG; Tai, YT; Giger, RJ; Ginty, DD			Neuropilin is a Semaphorin III receptor	CELL			English	Article							GROWTH CONE GUIDANCE; NEURONAL RECOGNITION MOLECULE; COLLAPSIN-1 MESSENGER-RNA; CHICK NERVOUS-SYSTEM; SPINAL-CORD; DIFFERENTIAL EXPRESSION; NEURITE OUTGROWTH; AXON GUIDANCE; C-ELEGANS; PROTEIN	The semaphorin family contains a large number of phylogenetically conserved proteins and includes several members that have been shown to function in repulsive axon guidance. Semaphorin III (Sema III) is a secreted protein that in vitro causes neuronal growth cone collapse and chemorepulsion of neurites, and in vivo is required for correct sensory afferent innervation and other aspects of development. The mechanism of Sema III function, however, is unknown. Here, we report that neuropilin, a type I transmembrane protein implicated in aspects of neurodevelopment, is a Sema III receptor. We also describe the identification of neuropilin-2, a related neuropilin family member, and show that neuropilin and neuropilin-2 are expressed in overlapping, yet distinct, populations of neurons in the rat embryonic nervous system.			Kolodkin, AL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.							Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Adams RH, 1996, MECH DEVELOP, V57, P33, DOI 10.1016/0925-4773(96)00525-4; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HIRATA T, 1993, NEUROSCI RES, V17, P159, DOI 10.1016/0168-0102(93)90092-5; IVAINS JK, 1991, J NEUROSCI, V11, P1597; KAWAKAMI A, 1995, J NEUROBIOL, V29, P1; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KINDT RM, 1995, NEURON, V15, P79, DOI 10.1016/0896-6273(95)90066-7; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1996, TRENDS CELL BIOL, V6, P15, DOI 10.1016/0962-8924(96)81033-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4065; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; Puschel AW, 1996, EUR J NEUROSCI, V8, P1317, DOI 10.1111/j.1460-9568.1996.tb01593.x; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Sambrook J., 1989, MOL CLONING LAB MANU; SATODA M, 1995, J NEUROSCI, V15, P942; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHEPHERD, 1997, DEVELOPMENT, V124, P1377; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Wang LH, 1996, J NEUROSCI, V16, P6197; WRIGHT DE, 1995, J COMP NEUROL, V361, P321, DOI 10.1002/cne.903610209; Zhou L, 1997, MOL CELL NEUROSCI, V9, P26, DOI 10.1006/mcne.1997.0607	45	957	1004	0	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 22	1997	90	4					753	762		10.1016/S0092-8674(00)80535-8	http://dx.doi.org/10.1016/S0092-8674(00)80535-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288754	hybrid			2022-12-01	WOS:A1997XT06600018
J	Schorey, JS; Carroll, MC; Brown, EJ				Schorey, JS; Carroll, MC; Brown, EJ			A macrophage invasion mechanism of pathogenic mycobacteria	SCIENCE			English	Article							COMPLEMENT RECEPTORS; IMMUNE-COMPLEXES; HUMAN-MONOCYTES; TUBERCULOSIS; PHAGOCYTOSIS; ACTIVATION; ANTIBODIES; INFECTION; DEFICIENT; SECRETION	Tuberculosis is the leading cause of death due to an infectious organism, killing an estimated 3 million people annually, Mycobacterium tuberculosis, the causative agent of tuberculosis, and other pathogenic mycobacteria require entry into host macrophages to initiate infection, An invasion mechanism was defined that was shared among pathogenic mycobacteria including M. tuberculosis, M. leprae, and M. avium but not by nonpathogenic mycobacteria or nonmycobacterial intramacrophage pathogens. This pathway required the association of the complement cleavage product C2a with mycobacteria resulting in the formation of a C3 convertase. The mycobacteria-associated C2a cleaved C3, resulting in C3b opsonization of the mycobacteria and recognition by macrophages.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV INFECT DIS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOL MICROBIOL, ST LOUIS, MO 63110 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University; Harvard Medical School					NIAID NIH HHS [AI33348] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033348] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA KSSS, 1990, TUBERCLE, V71, P103, DOI 10.1016/0041-3879(90)90004-R; BROSTOFF J, 1981, TUBERCLE, V62, P169, DOI 10.1016/0041-3879(81)90002-7; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CARR RI, 1980, CLIN EXP IMMUNOL, V39, P562; COLE FS, 1980, J IMMUNOL, V125, P1120; ELLNER JJ, 1991, J INFECT DIS, V163, P1326, DOI 10.1093/infdis/163.6.1326; Fenton MJ, 1996, INFECT IMMUN, V64, P683, DOI 10.1128/IAI.64.3.683-690.1996; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; LAUNOIS P, 1992, INT J LEPROSY, V60, P225; LEPOW IH, 1963, J EXP MED, V117, P983, DOI 10.1084/jem.117.6.983; MULLEREBERHARD HJ, 1967, J EXP MED, V125, P359, DOI 10.1084/jem.125.2.359; POLLEY MJ, 1968, J EXP MED, V128, P533, DOI 10.1084/jem.128.3.533; ROACH TIA, 1993, J IMMUNOL, V150, P1886; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SCHORLEMMER HU, 1977, IMMUNOLOGY, V32, P929; SCHORLEMMER HU, 1976, IMMUNOLOGY, V31, P781; SITOMER G, 1966, IMMUNOCHEMISTRY, V3, P57, DOI 10.1016/0019-2791(66)90282-5; STOKES RW, 1993, J IMMUNOL, V151, P7067; STROUD RM, 1966, IMMUNOCHEMISTRY, V3, P163, DOI 10.1016/0019-2791(66)90182-0; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; WEISSLER JC, 1993, AM J MED SCI, V305, P52, DOI 10.1097/00000441-199301000-00009; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	28	134	142	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	1997	277	5329					1091	1093		10.1126/science.277.5329.1091	http://dx.doi.org/10.1126/science.277.5329.1091			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XT033	9262476				2022-12-01	WOS:A1997XT03300033
J	Shen, WC; Green, MR				Shen, WC; Green, MR			Yeast TAF(II)145 functions as a core promoter selectivity factor, not a general coactivator	CELL			English	Article							TATA-BINDING PROTEIN; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; BOX-BINDING; DNA; ELEMENTS; COMPLEX; DOWNSTREAM; SEQUENCES	In yeast, TATA box binding protein associated factors (TAF(II)s) are dispensable for transcription of most genes. Here we use differential display to identify a small subset of yeast genes whose transcription in vivo requires yTAF(II)145. Promoter-mapping studies reveal, unexpectedly, that the region of a gene that renders it yTAF(II)145-dependent is not the upstream activating sequence, which contains the activator-binding sites, but rather the core promoter. In fact, a core promoter requiring yTAF(II)145 retained that requirement when its transcription was directed by several unrelated upstream activating sequences and even in the absence of an activator. Taken together, our results indicate that yTAF(II)145 functions in recognition and selection of core promoters by a mechanism not involving upstream activators.			Shen, WC (corresponding author), UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOL MED, WORCESTER, MA 01605 USA.							Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Baker RT, 1996, J BIOL CHEM, V271, P13549, DOI 10.1074/jbc.271.23.13549; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CROSS FR, 1994, MOL CELL BIOL, V14, P4779, DOI 10.1128/MCB.14.7.4779; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; GE H, 1994, J BIOL CHEM, V269, P17136; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; Guthrie C, 1991, GUIDE YEAST GENETICS; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; IGNATOVICH O, 1995, NUCLEIC ACIDS RES, V23, P4616, DOI 10.1093/nar/23.22.4616; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INOSTROZA JA, 1992, CELL, V70, P477; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLAKOWSKI LF, 1988, NUCLEIC ACIDS RES, V16, P10441, DOI 10.1093/nar/16.22.10441; LEER RJ, 1982, NUCLEIC ACIDS RES, V10, P5869, DOI 10.1093/nar/10.19.5869; Lenfant F, 1996, EMBO J, V15, P3974, DOI 10.1002/j.1460-2075.1996.tb00771.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MARTINEZ E, 1995, P NATL ACAD SCI USA, V92, P11864, DOI 10.1073/pnas.92.25.11864; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Planta RJ, 1995, BIOCHEM CELL BIOL, V73, P825, DOI 10.1139/o95-090; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; STUART D, 1994, MOL CELL BIOL, V14, P4788, DOI 10.1128/MCB.14.7.4788; SYPES MA, 1994, NUCLEIC ACIDS RES, V22, P807, DOI 10.1093/nar/22.5.807; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TORNOW J, 1990, GENE, V90, P79, DOI 10.1016/0378-1119(90)90441-S; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; WOOLFORD JL, 1991, MOL CELLULAR BIOL YE, V1, P587; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	69	165	166	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	1997	90	4					615	624		10.1016/S0092-8674(00)80523-1	http://dx.doi.org/10.1016/S0092-8674(00)80523-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	XT066	9288742	Bronze			2022-12-01	WOS:A1997XT06600006
J	Sutani, T; Yanagida, M				Sutani, T; Yanagida, M			DNA renaturation activity of the SMC complex implicated in chromosome condensation	NATURE			English	Article							UBIQUITOUS PROTEIN FAMILY; DOSAGE COMPENSATION; FISSION YEAST; RECA PROTEIN; GENE; SEGREGATION; SCAFFOLD; DEFINES; STRANDS	Chromosome condensation occurs in mitosis before the separation of sister chromatids, and requires DNA topoisomerase II (refs 1, 2) and a group of proteins called SMCs3-5. The resulting condensed chromosomes in metaphase have a complex hierarchical structure(6,7). SMCs, the components of condensed chromosomes, are also required for the separation of sister chromatids and gene dosage compensation, and are found in a range of organisms from yeasts to mammals(8-13). However, the mechanisms by which the SMCs contribute to chromosome condensation are unknown. We have studied chromosomes in fission-yeast SMC mutants cut3-477 and cut14-208 (ref. 9), which remain largely non-condensed during mitosis at the restrictive temperature (36 degrees C)(9). To test their role in DNA condensation, we isolated the proteins Cut3 and Cut14 as an oligomeric complex, and tested their interactions with isolated DNA. The complex efficiently promoted the DNA renaturation reactions (the winding up of single-strand DNAs into double helical DNA) as much as similar to 70-fold more efficiently than RecA(14), which is a bacterial protein with similar activity. The activity of the mutant complex was heat sensitive. As DNA winding by renaturation is a potential cause of supercoiling, the SMC complex may be implicated in promoting the higher-order DNA coiling found in condensed chromosomes.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University				Sutani, Takashi/0000-0002-9959-9513				BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BRYANT FR, 1989, BIOCHEMISTRY-US, V28, P1062, DOI 10.1021/bi00429a021; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; FUNABIKI H, 1996, NATURE, V381, P468; GASSER SM, 1995, CURR BIOL, V5, P357, DOI 10.1016/S0960-9822(95)00071-6; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Swedlow JR, 1993, CURR OPIN CELL BIOL, V5, P412, DOI 10.1016/0955-0674(93)90005-B	23	111	112	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					798	801		10.1038/42062	http://dx.doi.org/10.1038/42062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285594				2022-12-01	WOS:A1997XR66700056
J	Zuo, J; DeJager, PL; Takahashi, KA; Jiang, WN; Linden, DJ; Heintz, N				Zuo, J; DeJager, PL; Takahashi, KA; Jiang, WN; Linden, DJ; Heintz, N			Neurodegeneration in Lurcher mice caused by mutation in delta 2 glutamate receptor gene	NATURE			English	Article							CEREBELLAR PURKINJE-CELLS; POLYMERASE CHAIN-REACTION; HUMPBACK-WHALES; SIMPLE SEQUENCES; DNA; MOUSE; POPULATION; EXPRESSION; SUBUNIT; MAINE	Lurcher (Lc) is a spontaneous, semidominant mouse neurological mutation(1). Heterozygous Lurcher mite (Lc/+) display ataxia as a result of a selective, coil-autonomous and apoptotic death of cerebellar Purkinje cells during postnatal develoment(2-4). Homozygous Lurcher mice (Lc/Lc) die shortly after birth because of a massive loss of mid-and hindbrain neurons during late embryogenesis(5). We have used positional cloning to identify the mutations responsible for neurodegeneration in two independent Lc alleles as G-to-A transitions that change a highly conserved alanine to a threonine residue in transmembrane domain III of the mouse delta 2 glutamate receptor gene (GluR delta 2). Lc/+ Purkinje cells have a very high membrane conductance and a depolarized resting potential, indicating the presence of a large, constitutive inward current. Expression of the mutant GluR delta 2(Lc) protein in Xenopus oocytes confirmed these results, demonstrating that Lc is inherited as a neurodegenerative disorder resulting from a gain-of-function mutation in a glutamate receptor gene. Thus the activation of apoptotic neuronal death in Lurcher mice may provide a physiologically relevant model for excitotoxic cell death.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOL BIOL LAB,NEW YORK,NY 10021; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Rockefeller University; Johns Hopkins University					NIMH NIH HHS [MH51106] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051106, R29MH051106, R37MH051106] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMOS B, 1993, SCIENCE, V260, P670, DOI 10.1126/science.8480176; ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; Barlow J, 1997, ECOLOGY, V78, P535; Berube M, 1996, MOL ECOL, V5, P283; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; CADDY KWT, 1979, PHILOS T ROY SOC B, V287, P167, DOI 10.1098/rstb.1979.0055; Cheng SSW, 1997, J NEUROSCI, V17, P2400, DOI 10.1523/jneurosci.17-07-02400.1997; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P1065, DOI 10.1139/z93-142; CLAPHAM PJ, 1993, MAR MAMMAL SCI, V9, P213, DOI 10.1111/j.1748-7692.1993.tb00448.x; Clapham PJ, 1997, P ROY SOC B-BIOL SCI, V264, P95, DOI 10.1098/rspb.1997.0014; CLAPHAM PJ, 1995, MAR MAMMAL SCI, V11, P227, DOI 10.1111/j.1748-7692.1995.tb00520.x; CLAPHAM PJ, 1993, CAN J ZOOL, V71, P440, DOI 10.1139/z93-063; CONSTABLE JJ, 1995, NATURE, V373, P393, DOI 10.1038/373393a0; DeJager PL, 1997, GENOME RES, V7, P736, DOI 10.1101/gr.7.7.736; DEJAGER PL, IN PRESS MAMM GENOME; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; GERLOFF U, 1995, MOL ECOL, V4, P515, DOI 10.1111/j.1365-294X.1995.tb00247.x; Hammond PS, 1990, REPORT INT WHALING C, P440; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KASHIWABUCHI N, 1995, CELL, V81, P245, DOI 10.1016/0092-8674(95)90334-8; Katona, 1990, REPORT INT WHALING C, V12, P295; Katona S.K., 1981, Polar Record, V20, P439; LAMBERTSEN RH, 1987, J MAMMAL, V68, P443, DOI 10.2307/1381495; Landsend AS, 1997, J NEUROSCI, V17, P834, DOI 10.1523/jneurosci.17-02-00834.1997; Larsen AH, 1996, P ROY SOC B-BIOL SCI, V263, P1611, DOI 10.1098/rspb.1996.0236; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; Maniatis T., 1982, MOL CLONING; MATTILA DK, 1989, CAN J ZOOL, V67, P251; MAYAT E, 1995, J NEUROSCI, V15, P2533, DOI 10.1523/JNEUROSCI.15-03-02533.1995; MORIN PA, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P63; NORMAN DJ, 1995, DEVELOPMENT, V121, P1183; PAETKAU D, 1994, MOL ECOL, V3, P489, DOI 10.1111/j.1365-294X.1994.tb00127.x; PALSBALL PJ, IN PRESS MOL ECOL; Palsboll P.J., 1991, Reports of the International Whaling Commission Special Issue, P71; PALSBOLL PJ, 1995, MAR ECOL PROG SER, V116, P1, DOI 10.3354/meps116001; PATEL N, 1995, NAT GENET, V11, P126; PHILLIPS RITA J. S., 1960, JOUR GENET, V57, P35, DOI 10.1007/BF02985337; QUICK MW, 1994, METH NEUROSCI, V19, P261; ROY MS, 1994, MOL BIOL EVOL, V11, P553; Seber GAF, 1982, ESTIMATION ANIMAL AB, V2; STEVICK PT, IN PRESS MAR MAMM SC; Takayama C, 1996, DEV BRAIN RES, V92, P147, DOI 10.1016/0165-3806(95)00212-X; TAKAYAMA C, 1995, NEUROSCI LETT, V188, P89, DOI 10.1016/0304-3940(95)11403-J; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; WEBER JL, 1989, AM J HUM GENET, V44, P388; WETTS R, 1982, J EMBRYOL EXP MORPH, V68, P87; ZUO J, 1995, GENOME RES, V5, P381, DOI 10.1101/gr.5.4.381	51	429	435	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 21	1997	388	6644					769	773		10.1038/42009	http://dx.doi.org/10.1038/42009			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XR667	9285588	Bronze			2022-12-01	WOS:A1997XR66700050
J	Rivara, FP; Mueller, BA; Somes, G; Mendoza, CT; Rushforth, NB; Kellermann, AL				Rivara, FP; Mueller, BA; Somes, G; Mendoza, CT; Rushforth, NB; Kellermann, AL			Alcohol and illicit drug abuse and the risk of violent death in the home	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN OWNERSHIP; SUICIDE; CONSUMPTION; SMOKING; DRINKING; BEHAVIOR; YOUTH	Context.-While acute alcohol and illicit drug use are common in homicide and suicide victims, the role of chronic substance use in violent death is unclear. Objective.-To measure the magnitude of risk of violent death in the home associated with alcohol use or chronic abuse and use of illicit drugs. Data Sources.-Data obtained from a case-control study of risk factors for homicide and suicide in 3 large metropolitan areas of the United States. Design.-Matched case-control study including 388 homicide cases, 438 suicide cases, and equal numbers of controls matched for age, sex, race, neighborhood, and county. Data were analyzed by means of conditional logistic regressions in which other potential risk factors for violent death were also considered. Outcome and Exposure Measures.-Homicide and suicide victims were identified from medical examiner reports in Shelby County, Tennessee; King County, Washington; and Cuyahoga County, Ohio. Structured interviews were conducted with proxy respondents close to the decedents to obtain information about alcohol or illicit drug use, and history of alcohol-related hospitalization or trouble at work because of drinking by the subject. Data about alcohol use by others living in the same house as the subject were also obtained. Results.-The risks of homicide and suicide associated with alcohol or illicit drug use were elevated, as were the risks of violent death associated with several indicators of chronic alcohol abuse. In addition, nondrinkers living in a home with alcohol users were at increased risk of homicide (odds ratio, 1.7; 95% confidence interval, 0.98-3.0), and non-drug-using individuals residing in homes with illicit drug users were at greatly increased risk of homicide (odds ratio, 11.3, 95% confidence interval, 4.4-28.8). Conclusions.-Alcohol and illicit drug use appear to be associated with an increased risk of violent death. The risk of homicide was increased for non-substance-abusing individuals living in households in which other members abused alcohol or drugs. The concept of the individual at risk of homicide should be broadened to include not only the abuser but also those who may be at risk because of their exposure to others.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV TENNESSEE,DEPT PREVENT MED,MEMPHIS,TN; CASE WESTERN RESERVE UNIV,DEPT BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CTR ADOLESCENT HLTH,CLEVELAND,OH 44106; EMORY UNIV,EMORY CTR INJURY CONTROL,ATLANTA,GA 30322	University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Health Science Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Emory University	Rivara, FP (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,HARBORVIEW INJURY PREVENT & RES CTR,325 9TH AVE,POB 359960,SEATTLE,WA 98104, USA.				PHS HHS [R49/CCR002570, CCR402424] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bailey JE, 1997, ARCH INTERN MED, V157, P777, DOI 10.1001/archinte.157.7.777; Biro M, 1991, Crisis, V12, P64; Blumstein A, 1995, J CRIM LAW CRIM, V86, P10, DOI 10.2307/1143998; BRENT DA, 1987, JAMA-J AM MED ASSOC, V257, P3369, DOI 10.1001/jama.257.24.3369; BRESLOW N. E., 1980, STATISTICAL METHODS; CHEREK DR, 1985, J STUD ALCOHOL, V46, P321, DOI 10.15288/jsa.1985.46.321; COLLINS JJ, 1988, J STUD ALCOHOL, V49, P516, DOI 10.15288/jsa.1988.49.516; Collins JJ, 1993, ALCOHOL HEALTH RES W, V17, P93; CORNELIUS JR, 1995, AM J PSYCHIAT, V152, P358; Farrington D. P., 1990, CRIMINALITY PERSONAL, P115, DOI DOI 10.1007/978-3-642-75418-0_9; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; GOODMAN RA, 1991, J STUD ALCOHOL, V52, P156, DOI 10.15288/jsa.1991.52.156; GREENBERG SW, 1981, DRINKING CRIME PERSP, P253; HOLDER HD, 1993, J STUD ALCOHOL, V54, P23, DOI 10.15288/jsa.1993.54.23; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; LI GH, 1994, AM J PUBLIC HEALTH, V84, P1402, DOI 10.2105/AJPH.84.9.1402; Lindqvist P, 1986, Int J Law Psychiatry, V8, P19, DOI 10.1016/0160-2527(86)90081-6; MACK TM, 1986, JNCI-J NATL CANCER I, V76, P49; MERRILL J, 1992, BRIT J ADDICT, V87, P83; MICZEK KA, 1994, UNDERSTANDING PREVEN, V3, P377; Miller B A, 1990, NIDA Res Monogr, V103, P177; MURDOCH D, 1990, INT J ADDICT, V25, P1065, DOI 10.3109/10826089009058873; Pernanen K., 1991, ALCOHOL HUMAN VIOLEN; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; PULKKINEN L, 1983, J YOUTH ADOLESCENCE, V12, P253, DOI 10.1007/BF02088726; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; RICHARDSON J, 1994, HEALTH ECON, V3, P73, DOI 10.1002/hec.4730030204; RIVARA FP, 1995, ANN EMERG MED, V26, P609, DOI 10.1016/S0196-0644(95)70013-7; ROSSOW I, 1995, ADDICTION, V90, P685, DOI 10.1111/j.1360-0443.1995.tb02206.x; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; STEPHENSCHERPIT.CJ, 1988, ALCOHOLISM CLIN EXP, V12, P105; Tinklenberg J. R., 1981, BIOBEHAVIORAL ASPECT, P121; Wagenaar A C, 1994, J Public Health Policy, V15, P37, DOI 10.2307/3342606; Wolfgang M. E., 1958, PATTERNS CRIMINAL HO; YU MC, 1983, CANCER RES, V43, P6077	37	84	85	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	1997	278	7					569	575		10.1001/jama.278.7.569	http://dx.doi.org/10.1001/jama.278.7.569			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XQ986	9268278				2022-12-01	WOS:A1997XQ98600031
J	Neal, DE				Neal, DE			Watchful waiting or drug therapy for benign prostatic hyperplasia?	LANCET			English	Editorial Material							PROSTATECTOMY; SYMPTOMS				Neal, DE (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT SURG,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Neal, David/0000-0002-6033-5086				Andersen JT, 1997, UROLOGY, V49, P839, DOI 10.1016/S0090-4295(97)00185-4; Barry MJ, 1997, J UROLOGY, V157, P10, DOI 10.1016/S0022-5347(01)65267-4; EMBERTON M, 1995, BRIT J UROL, V75, P301, DOI 10.1111/j.1464-410X.1995.tb07341.x; JACOBSEN SJ, 1997, J UROL S, V17, P191; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; NEAL DE, 1987, BRIT J UROL, V60, P554, DOI 10.1111/j.1464-410X.1987.tb05041.x; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202	7	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 2	1997	350	9074					305	306		10.1016/S0140-6736(05)63382-X	http://dx.doi.org/10.1016/S0140-6736(05)63382-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XP242	9251630				2022-12-01	WOS:A1997XP24200003
J	Fitzsimonds, RM; Song, HJ; Poo, MM				Fitzsimonds, RM; Song, HJ; Poo, MM			Propagation of activity-dependent synaptic depression in simple neural networks	NATURE			English	Article							LONG-TERM DEPRESSION; NEUROMUSCULAR SYNAPSES; HIPPOCAMPAL-NEURONS; AREA CA1; POTENTIATION; INDUCTION; TRANSMISSION; STIMULATION; MECHANISMS; PLASTICITY	Triple whole-cell recordings from simple networks of cultured hippocampal neurons show that induction of long-term depression at glutamatergic synapses is accompanied by a back propagation of depression to input synapses on the dendrite of the presynaptic neuron. The depression also propagates laterally to divergent outputs of the presynaptic neuron and to convergent inputs on the postsynaptic neuron. There is no forward propagation of depression to the output of the postsynaptic neuron and no presynaptic propagation accompanying long-term depression at GABAergic synapses. Activity-induced synaptic modification is therefore not restricted to the activated synapse, but selectively propagates throughout the neural network.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				Fitzsimonds, Reiko/0000-0002-0576-9885				ABRAHAM WC, 1983, NATURE, V305, P717, DOI 10.1038/305717a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BROCHER S, 1992, P NATL ACAD SCI USA, V89, P123, DOI 10.1073/pnas.89.1.123; Cash S, 1996, SCIENCE, V272, P998, DOI 10.1126/science.272.5264.998; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; CHRISTIE BR, 1992, SYNAPSE, V10, P1, DOI 10.1002/syn.890100102; CHURCHLAND PS, 1972, COMPUTATIONAL BRAIN; Clarke P.G.H., 1991, Concepts in Neuroscience, V2, P201; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; Dan Yang, 1994, Current Opinion in Neurobiology, V4, P95, DOI 10.1016/0959-4388(94)90037-X; DAVIS GW, 1994, J NEUROBIOL, V25, P740, DOI 10.1002/neu.480250612; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Engert F, 1997, NATURE, V388, P279, DOI 10.1038/40870; FITZSIMONDS RM, IN PRESS PHYSL REV; Goda Y, 1996, NEURON, V16, P103, DOI 10.1016/S0896-6273(00)80027-6; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Ito M, 1991, Curr Opin Neurobiol, V1, P616, DOI 10.1016/S0959-4388(05)80038-8; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kossel A, 1990, Neuroreport, V1, P115, DOI 10.1097/00001756-199010000-00008; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.neuro.18.1.319; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MATHEWS MR, 1975, J PHYSIOL-LONDON, V245, P91; MCMAHON LL, 1977, NEURON, V18, P737; MCMAHON LL, 1977, NEURON, V18, P266; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; OTANI S, 1995, LEARN MEMORY, V2, P101, DOI 10.1101/lm.2.2.101; PILAR G, 1972, SCIENCE, V177, P1116, DOI 10.1126/science.177.4054.1116; PURVES D, 1975, J PHYSIOL-LONDON, V252, P429, DOI 10.1113/jphysiol.1975.sp011151; PURVES D, 1985, PRINCIPLES NEURAL DE; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; RUMELHART DE, 1986, PARALLEL DISTRIBUTED, V1, P316; Scanziani M, 1996, NATURE, V380, P446, DOI 10.1038/380446a0; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; Tong G, 1996, NEURON, V16, P1147, DOI 10.1016/S0896-6273(00)80141-5; VINCENT P, 1993, NEURON, V11, P885, DOI 10.1016/0896-6273(93)90118-B; WILCOX KS, 1994, SYNAPSE, V18, P128, DOI 10.1002/syn.890180206; WOOD MR, 1986, J COMP NEUROL, V244, P43; XIAO MY, 1994, EUR J NEUROSCI, V6, P1055, DOI 10.1111/j.1460-9568.1994.tb00600.x; Zipser D., 1990, COMPUTATIONAL NEUROS, P192	51	141	143	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					439	448		10.1038/41267	http://dx.doi.org/10.1038/41267			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242402	Bronze			2022-12-01	WOS:A1997XN55300039
J	Ramsden, DA; Paull, TT; Gellert, M				Ramsden, DA; Paull, TT; Gellert, M			Cell-free V(D)J recombination	NATURE			English	Article							DNA-LIGASE-I; MOUSE THYMOCYTES; MAMMALIAN-CELLS; REARRANGEMENT; REPAIR	V(D)J recombination generates diversity in the immune system through the lymphoid-specific assembly of multiple gene segments into functional immunoglobulin and T-cell receptor genes (for reviews, see refs 1, 2). The first step in V(D)J recombination is cleavage of DNA at recombination signal sequences. Cleavage produces a blunt DNA end on each signal sequence and a hairpin end on adjacent coding gene segments(3,4), and can be reproduced in vitro by using purified RAG1 and RAG2 proteins(5,6). The later steps involve processing and joining of the cleaved DNA ends, and until now have been studied only in cells, Here we reconstitute the complete V(D)J recombination reaction in a cell-free system, We find that the RAG proteins are not only involved in cleavage, but are also needed in the later steps for efficient joining of coding ends. Joining is largely directed by short pieces of identical sequence in the coding flanks, but addition of human DNA ligase I results in greater diversity. Coding junctions contain short deletions as well as additions complementary to a coding flank (P nucleotides). Addition of non-templated nucleotides into coding junctions is mediated by terminal deoxyribonucleotidyl transferase. The cell-free reaction can therefore reproduce the complete set of processing events that occur in cells.	NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Paull, Tanya/0000-0002-2991-651X; Ramsden, Dale/0000-0003-1575-4748				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; ARRAND JE, 1986, J BIOL CHEM, V261, P9079; Cortes P, 1996, P NATL ACAD SCI USA, V93, P14008, DOI 10.1073/pnas.93.24.14008; ELDER RH, 1992, EUR J BIOCHEM, V203, P53, DOI 10.1111/j.1432-1033.1992.tb19826.x; GELLERT M, 1992, ANNU REV GENET, V22, P425; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; ROBBINS DJ, 1988, NUCLEIC ACIDS RES, V16, P2943, DOI 10.1093/nar/16.7.2943; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEI YF, 1995, MOL CELL BIOL, V15, P3206	22	111	112	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 31	1997	388	6641					488	491		10.1038/41351	http://dx.doi.org/10.1038/41351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242409	Bronze			2022-12-01	WOS:A1997XN55300052
J	Zeyl, C; Bell, G				Zeyl, C; Bell, G			The advantage of sex in evolving yeast populations	NATURE			English	Article							DELETERIOUS MUTATIONS; EVOLUTION; TY3	Sex is a general feature of the life cycle of eukaryotes. It is not universal, however, as many organisms seem to lack sex entirely(1). The widespread occurrence of sex is puzzling, both because meiotic recombination can disrupt co-adapted combinations of genes, and because it halves the potential rate of reproduction in organisms with strongly differentiated male and female gametes(2). Most attempts to explain the maintenance of sexuality invoke differences between parents and sexual offspring. These differences may be advantageous in novel or changing environments if new gene combinations are favoured from time to time(1). Sex would then serve to concentrate beneficial mutations that have arisen independently into the same line of descent. But in a stable environment sex might serve to concentrate deleterious mutations, so that they will be more effectively purged from the population by selection(3). We have studied the effect of sex on mean fitness in experimental populations of the budding yeast Saccharomyces cervisiae. Our results show that sex increases mean fitness in an environment to which the populations were well adapted, but not in an environment to which new adaptation occurred, supporting the hypothesis that the advantage of sexuality lay in the removal of deleterious mutations.	MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA; MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA; MCGILL UNIV, REDPATH MUSEUM, MONTREAL, PQ H3A 1B1, CANADA	Michigan State University; McGill University; McGill University								Bell G., 1982, MASTERPIECE NATURE; BILANCHONE VW, 1993, GENETICS, V134, P685; Birdsell J, 1996, P NATL ACAD SCI USA, V93, P908, DOI 10.1073/pnas.93.2.908; CHARLESWORTH D, 1993, GENET RES, V61, P39, DOI 10.1017/S0016672300031086; Crow J. F., 1988, EVOLUTION SEX EXAMIN, P56; deVisser JAGM, 1996, P ROY SOC B-BIOL SCI, V263, P193, DOI 10.1098/rspb.1996.0031; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KUNZ BA, 1981, MOL BIOL YEAST SACCH, V1, P371; MALMBERG RL, 1977, GENETICS, V86, P607; Maynard-Smith J., 1978, MODELS ECOLOGY; MCPHEE CP, 1970, GENET RES, V16, P1, DOI 10.1017/S0016672300002238; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; MORTIMER RK, 1981, MOL BIOL YEAST SACCH, V3, P341; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; PECK JR, 1994, GENETICS, V137, P597	17	112	118	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 31	1997	388	6641					465	468		10.1038/41312	http://dx.doi.org/10.1038/41312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	XN553	9242403	Bronze			2022-12-01	WOS:A1997XN55300046
J	Bowie, WR; King, AS; Werker, DH; IsaacRenton, JL; Bell, A; Eng, SB; Marion, SA				Bowie, WR; King, AS; Werker, DH; IsaacRenton, JL; Bell, A; Eng, SB; Marion, SA			Outbreak of toxoplasmosis associated with municipal drinking water	LANCET			English	Article							OOCYSTS; GONDII; OZONE; CATS	Background Outbreaks of toxoplasmosis are recognised infrequently. In March, 1995, a sudden increase of serologically diagnosed cases of acute toxoplasmosis was noted in the Greater Victoria area of British Columbia, Canada. Concurrently, but independently, seven cases of acute toxoplasma retinitis were diagnosed against a background of no cases in the previous 5 years. Methods Cases were defined by serological testing, clinical presentation, and residence in Greater Victoria. A screening programme for women who were or had been pregnant was started. Geographical mapping of cases, and case-control studies of symptomatic cases and of women enrolled in the screening programme were done. Findings 100 individuals aged 6 to 83 years met the definition for an acute, outbreak-related case. 94 resided in Greater Victoria and six had visited it; 19 had retinitis, 51 had lymphadenopathy, four others had symptoms consistent with toxoplasmosis, seven had other symptoms, 18 were symptom-free, and one would not provide information. 36 (0.9%) of 3812 screened pregnant and postnatal women were cases. Excess cases were not detected outside Greater Victoria and no conventional source of toxoplasmosis was implicated. Mapping studies of cases and of the screened women, and both case-control studies showed significant associations between acute infection and residence in the distribution system of one reservoir supplying water to Greater Victoria (ORs or RRs: 3.53, 3.05, 8.27, acid 5.42, respectively). The epidemic curve appeared bimodal, with peaks in December, 1994, and March, 1995, that were preceded by increased rainfall and turbidity in the implicated reservoir. Interpretation A municipal water system that uses unfiltered, chloraminated surface water was the likely source of this large community-wide outbreak of toxoplasmosis.	UNIV BRITISH COLUMBIA, DIV INFECT DIS, VANCOUVER, BC V5Z 1M9, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL & LAB MED, VANCOUVER, BC V5Z 1M9, CANADA; UNIV BRITISH COLUMBIA, DEPT HLTH CARE & EPIDEMIOL, VANCOUVER, BC V6T 1W5, CANADA; BC CTR DIS CONTROL, EPIDEMIOL SERV, VANCOUVER, BC, CANADA; BC CTR DIS CONTROL, PROV LAB, VANCOUVER, BC, CANADA; HLTH CANADA, LAB CTR DIS CONTROL, FIELD EPIDEMIOL TRAINING PROGRAM, OTTAWA, ON K1A 0L2, CANADA; CAPITAL REG DIST HLTH, VICTORIA, BC, CANADA	University of British Columbia; University of British Columbia; University of British Columbia; Health Canada								BEAMAN MH, 1995, PRINCIPLES PRACTICE, P2455; BENENSON MW, 1982, NEW ENGL J MED, V307, P666, DOI 10.1056/NEJM198209093071107; DANNEMANN BR, 1990, J CLIN MICROBIOL, V28, P1928, DOI 10.1128/JCM.28.9.1928-1933.1990; Dubey J.P., 1988, TOXOPLASMOSIS ANIMAL; Dubey JP, 1996, J PARASITOL, V82, P438, DOI 10.2307/3284082; DUBEY JP, 1970, J EXP MED, V132, P636, DOI 10.1084/jem.132.4.636; FINCH GR, 1993, APPL ENVIRON MICROB, V59, P3674, DOI 10.1128/AEM.59.11.3674-3680.1993; FRENKEL JK, 1975, AM J TROP MED HYG, V24, P439, DOI 10.4269/ajtmh.1975.24.439; FRENKEL JK, 1972, J INFECT DIS, V126, P664, DOI 10.1093/infdis/126.6.664; KEAN BH, 1969, J AMER MED ASSOC, V208, P1002; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; Magaldi C., 1969, Revista Latinoamericana de Microbiologia y Parasitologia, V11, P5; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; *MAP CORP, 1992, MAP WIND 3 0 US GUID; MILLER NL, 1972, J PARASITOL, V58, P928, DOI 10.2307/3286588; MONTOYA JG, 1995, CLIN INFECT DIS, V20, P781, DOI 10.1093/clinids/20.4.781; Remington JS., 1995, INFECT DIS FETUS NEW, V4, P140; SNOW J, 1965, SNOW CHOLERA; Stephen C, 1996, CAN VET J, V37, P241; TEUTSCH SM, 1979, NEW ENGL J MED, V300, P695, DOI 10.1056/NEJM197903293001302; WONG SY, 1994, CLIN INFECT DIS, V18, P853, DOI 10.1093/clinids/18.6.853; YILMAZ SM, 1972, J PARASITOL, V58, P938, DOI 10.2307/3286589	22	423	459	2	63	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 19	1997	350	9072					173	177		10.1016/S0140-6736(96)11105-3	http://dx.doi.org/10.1016/S0140-6736(96)11105-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XL722	9250185				2022-12-01	WOS:A1997XL72200012
J	Gardon, J; GardonWendel, N; DemangaNgangue, D; Kamgno, J; Chippaux, JP; Boussinesq, M				Gardon, J; GardonWendel, N; DemangaNgangue, D; Kamgno, J; Chippaux, JP; Boussinesq, M			Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection	LANCET			English	Article							LOIASIS; DISEASE	Background In 1995, the World Bank launched an African Programme for Onchocerciasis Control to eliminate Onchocerca volvulus disease from 19 African countries by means of community-based ivermectin treatment (CBIT). Several cases of encephalopathy have been reported after ivermectin in people heavily infected with microfilariae of Loa loa (loiasis). We assessed the incidence of serious events in an area where onchocerciasis and loiasis are both endemic. Methods Ivermectin (at 150 mu g/kg) was given to 17 877 people living in the Lekie area of Cameroon. 50 mu L samples of capillary blood were taken during the daytime before treatment from all adults (aged greater than or equal to 15 years), and the numbers of L loa and Mansonella perstans microfilariae in them were counted. Patients were monitored for 7 days after treatment. Adverse reactions were classified as mild, marked, or serious. Serious reactions were defined as those associated with a functional impairment that required at least a week of full-time assistance to undertake normal activities. We calculated the relative risk of developing marked or serious reactions for increasing L loa microfilarial loads, Risk factors for serious reactions were identified and assessed with a logistic regression model. Findings 20 patients (0.11%) developed serious reactions without neurological signs but associated with a functional impairment lasting more than a week. Two other patients were in coma for 2-3 days, associated with L loa microfilariae in cerebrospinal fluid. Occurrence of serious reactions was related to the intensity of pretreatment L loa microfilaraemia. The relative risk of developing marked or serious reactions was significantly higher when the L loa load exceeded 8000 microfilariae/mL; for serious reactions, the risk is very high (odds ratio >1000) for loads above 50 000 microfilariae/mL. Interpretation Epidemiological surveys aimed at assessing the intensity of infection with L loa microfilariae should be done before ivermectin is distributed for onchocerciasis control in areas where loiasis is endemic, In communities at risk, monitoring procedures should be established and adhered to during CBIT so that people developing serious reactions may receive appropriate treatment.	SECT DEPT SANTE PUBL MBAM,BAFIA,CAMEROON		Gardon, J (corresponding author), CTR PASTEUR,ANTENNE ORSTOM,BP 1274,YAOUNDE,CAMEROON.		Boussinesq, Michel/J-7256-2016; Gardon, Jacques/J-8022-2016; Gardon, Jacques/AAQ-8410-2020	Boussinesq, Michel/0000-0001-6312-0681; Gardon, Jacques/0000-0002-0570-634X; Gardon, Jacques/0000-0002-0570-634X; Chippaux, Jean-Philippe/0000-0002-1976-8568				ABIOSE A, 1993, LANCET, V341, P130, DOI 10.1016/0140-6736(93)90002-X; *ASS RECH METH PHA, 1992, AN INC PHARM; AZIZ MA, 1982, LANCET, V2, P171; BERTRANDFONTAIN, 1948, B MEM SOC MED HOP P, V64, P1092; BONNET R., 1943, Medecine Tropicale, V3, P273; BOUSSINESQ M, 1995, AM J TROP MED HYG, V53, P63; BRUNETIERE M, 1913, GAZ HEBDOM SCI MED B, V30, P351; CARME B, 1991, AM J TROP MED HYG, V44, P684, DOI 10.4269/ajtmh.1991.44.684; CARME B, 1991, ANN SOC BELG MED TR, V71, P47; Chippaux JP, 1996, PARASITOL TODAY, V12, P448, DOI 10.1016/0169-4758(96)40006-0; Ducorps M, 1995, B SOC PATHOL EXOT, V88, P105; FAIN A, 1978, B WORLD HEALTH ORGAN, V56, P155; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; KULZ H, 1908, ARCH SCHIFFS TROP, V12, P547; MARTINPREVEL Y, 1993, AM J TROP MED HYG, V48, P186, DOI 10.4269/ajtmh.1993.48.186; PACQUE M, 1991, AM J MED, V90, P590, DOI 10.1016/S0002-9343(05)80010-5; REMME JHF, 1995, PARASITOL TODAY, V11, P403, DOI 10.1016/0169-4758(95)80017-4; RICHARDLENOBLE D, 1988, AM J TROP MED HYG, V39, P480, DOI 10.4269/ajtmh.1988.39.480; TAYLOR HR, 1989, AM J TROP MED HYG, V41, P460, DOI 10.4269/ajtmh.1989.41.460; *WHO EXP COMM ONCH, 1995, TECHN REP SER WHO, V852, P27; 1991, WHO DRUG INFORMATION, V5, P127	21	388	392	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 5	1997	350	9070					18	22		10.1016/S0140-6736(96)11094-1	http://dx.doi.org/10.1016/S0140-6736(96)11094-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XH869	9217715				2022-12-01	WOS:A1997XH86900011
J	Collins, JJ; Brennan, FT				Collins, JJ; Brennan, FT			Euthanasia and the potential adverse effects for Northern Territory Aborigines	LANCET			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; PAIN		AUSTRALIAN NATL UNIV,RES SCH SOCIAL SCI,CANBERRA,ACT 2600,AUSTRALIA	Australian National University	Collins, JJ (corresponding author), MEM SLOAN KETTERING CANC CTR,PAIN & PALLIAT CARE SERV,1275 YORK AVE,NEW YORK,NY 10021, USA.							ALCORN G, 1996, SYDNEY MORNING  0823; AUSTIN N, 1996, LETS MEET HALF WAY P; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; *CANC PAIN REL PAL, 1990, WHO TECHN REP SER, V804; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; CHASSIN MR, 1994, WHEN DEATH IS SOUGHT; CORDNER S, 1995, LANCET, V346, P692, DOI 10.1016/S0140-6736(95)92295-4; Cunningham J, 1996, MED J AUSTRALIA, V165, P309, DOI 10.5694/j.1326-5377.1996.tb124987.x; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; FOLEY KM, 1995, PAIN FORUM, V4, P163; HARRISON B, 1994, DEMOGRAPHY NO TERRIT; Hoy WE, 1996, MED J AUSTRALIA, V165, P126, DOI 10.5694/j.1326-5377.1996.tb124882.x; Maguire GP, 1996, MED J AUSTRALIA, V164, P721, DOI 10.5694/j.1326-5377.1996.tb122270.x; MCLENNON W, 1994, DEATHS AUSTR; MOBBS R, 1994, HLTH ABORIGINAL AUST, P292; PORTENOY RK, IN PRESS PSYCHOSOMAT; REID J, 1994, HLTH ABORIGINAL AUST, pR11; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; 1997, SYDNEY MORNING  0116	19	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 28	1997	349	9069					1907	1908		10.1016/S0140-6736(96)12388-6	http://dx.doi.org/10.1016/S0140-6736(96)12388-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XG417	9217772				2022-12-01	WOS:A1997XG41700043
J	Hurley, SF; Jolley, DJ; Kaldor, JM				Hurley, SF; Jolley, DJ; Kaldor, JM			Effectiveness of needle-exchange programmes for prevention of HIV infection	LANCET			English	Article							INJECTING DRUG-USERS	Background Needle-exchange programmes (NEPs) are potentially a key strategy for containing the spread of HIV infection among injecting drug users, but their implementation has been limited by uncertainty about their effectiveness. We used an ecological study design to compare changes over time in HIV seroprevalence in injecting drug users worldwide, for cities with and without NEPs. Methods Published reports of HIV seroprevalence in injecting drug users were identified, and unpublished information on HIV seroprevalence for injecting drug users entering drug treatment in the USA between 1988 and 1993 was obtained from the Centers for Disease Control and Prevention. Details of the implementation of NEPs were obtained from published reports and experts. For each of the 81 cities with HIV seroprevalence data from more than 1 year and NEP implementation details, the rate of change of seroprevalence was estimated by regression analysis. The average difference in this rate for cities with and without NEPs was calculated. Findings On average, seroprevalence increased by 5.9% per year in the 52 cities without NEPs, and decreased by 5.8% per year in the 29 cities with NEPs. The average annual change in seroprevalence was 11% lower in cities with NEPs (95% CI - 17.6 to -3.9, p = 0.004). Interpretation A plausible explanation for this difference is that NEPs led to a reduction in HIV incidence among injecting drug users. Despite the possibility of confounding, our results, together with the clear theoretical mechanisms by which NEPs could reduce HIV incidence, strongly support the view that NEPs are effective.	UNIV MELBOURNE, DEPT PUBL HLTH & COMMUNITY MED, PARKVILLE, VIC 3052, AUSTRALIA; UNIV NEW S WALES, NATL CTR HIV EPIDEMIOL & CLIN RES, SYDNEY, NSW, AUSTRALIA	University of Melbourne; University of New South Wales Sydney; Kirby Institute			Kaldor, John M/D-4545-2011					Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; Clayton D., 1993, STAT MODELS EPIDEMIO; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; HAGAN H, 1995, AM J PUBLIC HEALTH, V85, P1531, DOI 10.2105/AJPH.85.11.1531; *I HLTH POL STUD, 1993, PUBL HLTH IMP NEEDL; Jarlais DCD, 1996, LANCET, V348, P987, DOI 10.1016/S0140-6736(96)02536-6; KAPLAN EH, 1994, AIDS, V8, P567, DOI 10.1097/00002030-199405000-00001; KAPLAN EH, 1994, STAT MED, V13, P2179, DOI 10.1002/sim.4780131923; NICOLOSI A, 1992, AM J EPIDEMIOL, V135, P225, DOI 10.1093/oxfordjournals.aje.a116275; *PAN NEEDL EXCH BL, 1995, PREV HIV TRANSM ROL; Prevots DR, 1996, AM J EPIDEMIOL, V143, P733, DOI 10.1093/oxfordjournals.aje.a008807; STIMSON GV, 1989, AIDS, V3, P253, DOI 10.1097/00002030-198905000-00001; *US GEN ACC OFF, 1993, NEEDL EXCH PROGR RES	14	254	256	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 21	1997	349	9068					1797	1800		10.1016/S0140-6736(96)11380-5	http://dx.doi.org/10.1016/S0140-6736(96)11380-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XF735	9269214				2022-12-01	WOS:A1997XF73500010
J	Nightingale, SL				Nightingale, SL			Workshop on thalidomide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-01	WOS:A1997XN51800011
J	Nightingale, SL				Nightingale, SL			Health advisory on concomitant fenfluramine and phentermine use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	1997	278	5					379	379		10.1001/jama.278.5.379	http://dx.doi.org/10.1001/jama.278.5.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XN518	9244318				2022-12-01	WOS:A1997XN51800008
